0001159036-20-000013.txt : 20200224 0001159036-20-000013.hdr.sgml : 20200224 20200224161638 ACCESSION NUMBER: 0001159036-20-000013 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 110 CONFORMED PERIOD OF REPORT: 20191231 FILED AS OF DATE: 20200224 DATE AS OF CHANGE: 20200224 FILER: COMPANY DATA: COMPANY CONFORMED NAME: HALOZYME THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001159036 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 880488686 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-32335 FILM NUMBER: 20644498 BUSINESS ADDRESS: STREET 1: 11388 SORRENTO VALLEY ROAD CITY: SAN DIEGO STATE: CA ZIP: 92121-1345 BUSINESS PHONE: (858) 794-8889 MAIL ADDRESS: STREET 1: 11388 SORRENTO VALLEY ROAD CITY: SAN DIEGO STATE: CA ZIP: 92121-1345 FORMER COMPANY: FORMER CONFORMED NAME: HALOZYME THERAPEUTICS INC DATE OF NAME CHANGE: 20040312 FORMER COMPANY: FORMER CONFORMED NAME: GLOBAL YACHT SERVICES INC DATE OF NAME CHANGE: 20010912 10-K 1 halo2019-10k.htm 10-K Document
false--12-31FY2019000115903610.0010.0012000000003000000001367124801447251641367124802050-12-310.340.210.2100000.0010.00120000000200000000000.02130.02960.02560.01730.02250.01320.71730.69810.70060.57180.56940.51560.250.250.250.0208P5Y6M0DP5Y6M0D144725164P3Y000 0001159036 2019-01-01 2019-12-31 0001159036 2020-02-14 0001159036 2019-06-30 0001159036 2019-12-31 0001159036 2018-12-31 0001159036 us-gaap:CommonStockMember 2018-12-31 0001159036 2018-01-01 2018-12-31 0001159036 2017-01-01 2017-12-31 0001159036 us-gaap:ProductMember 2018-01-01 2018-12-31 0001159036 us-gaap:ProductMember 2017-01-01 2017-12-31 0001159036 us-gaap:RoyaltyMember 2019-01-01 2019-12-31 0001159036 halo:CollaborativeAgreementsMember 2017-01-01 2017-12-31 0001159036 us-gaap:RoyaltyMember 2018-01-01 2018-12-31 0001159036 halo:CollaborativeAgreementsMember 2019-01-01 2019-12-31 0001159036 us-gaap:RoyaltyMember 2017-01-01 2017-12-31 0001159036 us-gaap:ProductMember 2019-01-01 2019-12-31 0001159036 halo:CollaborativeAgreementsMember 2018-01-01 2018-12-31 0001159036 2017-12-31 0001159036 2016-12-31 0001159036 us-gaap:RetainedEarningsMember 2018-01-01 2018-12-31 0001159036 us-gaap:CommonStockMember 2018-01-01 2018-12-31 0001159036 us-gaap:RetainedEarningsMember 2016-12-31 0001159036 us-gaap:CommonStockMember 2019-01-01 2019-12-31 0001159036 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0001159036 us-gaap:RetainedEarningsMember 2018-12-31 0001159036 us-gaap:AdditionalPaidInCapitalMember 2016-12-31 0001159036 us-gaap:CommonStockMember 2017-12-31 0001159036 us-gaap:CommonStockMember 2019-12-31 0001159036 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-12-31 0001159036 us-gaap:CommonStockMember 2017-01-01 2017-12-31 0001159036 us-gaap:RetainedEarningsMember 2019-01-01 2019-12-31 0001159036 us-gaap:AdditionalPaidInCapitalMember 2017-01-01 2017-12-31 0001159036 us-gaap:CommonStockMember 2016-12-31 0001159036 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001159036 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001159036 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001159036 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-12-31 0001159036 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-12-31 0001159036 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-12-31 0001159036 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-12-31 0001159036 us-gaap:RetainedEarningsMember 2019-12-31 0001159036 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-01-01 2017-12-31 0001159036 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0001159036 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-12-31 0001159036 us-gaap:RetainedEarningsMember 2017-12-31 0001159036 us-gaap:RetainedEarningsMember 2018-01-01 0001159036 2018-01-01 0001159036 halo:ArgenxMember us-gaap:SalesMember us-gaap:CustomerConcentrationRiskMember 2018-01-01 2018-12-31 0001159036 halo:RocheMember us-gaap:SalesMember us-gaap:CustomerConcentrationRiskMember 2017-01-01 2017-12-31 0001159036 halo:JanssenMember us-gaap:SalesMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-12-31 0001159036 halo:JanssenMember us-gaap:SalesMember us-gaap:CustomerConcentrationRiskMember 2017-01-01 2017-12-31 0001159036 halo:BMSMember us-gaap:SalesMember us-gaap:CustomerConcentrationRiskMember 2018-01-01 2018-12-31 0001159036 halo:BMSMember us-gaap:SalesMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-12-31 0001159036 halo:RocheMember us-gaap:SalesMember us-gaap:CustomerConcentrationRiskMember 2018-01-01 2018-12-31 0001159036 halo:AlexionMember us-gaap:SalesMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-12-31 0001159036 halo:JanssenMember us-gaap:SalesMember us-gaap:CustomerConcentrationRiskMember 2018-01-01 2018-12-31 0001159036 halo:ArgenxMember us-gaap:SalesMember us-gaap:CustomerConcentrationRiskMember 2017-01-01 2017-12-31 0001159036 halo:RocheMember us-gaap:SalesMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-12-31 0001159036 halo:AlexionMember us-gaap:SalesMember us-gaap:CustomerConcentrationRiskMember 2017-01-01 2017-12-31 0001159036 halo:ArgenxMember us-gaap:SalesMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-12-31 0001159036 halo:AlexionMember us-gaap:SalesMember us-gaap:CustomerConcentrationRiskMember 2018-01-01 2018-12-31 0001159036 halo:BMSMember us-gaap:SalesMember us-gaap:CustomerConcentrationRiskMember 2017-01-01 2017-12-31 0001159036 halo:HylenexRecombinantMember us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember 2019-12-31 0001159036 halo:RocheandBaxaltaMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2019-12-31 0001159036 srt:MaximumMember 2019-12-31 0001159036 halo:A1.25ConvertibleSeniorNotesdue2024Member us-gaap:ConvertibleDebtMember 2019-11-30 0001159036 srt:MinimumMember 2019-12-31 0001159036 halo:BulkFormulationMember us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember 2018-12-31 0001159036 srt:MinimumMember 2019-01-01 2019-12-31 0001159036 srt:MaximumMember 2019-01-01 2019-12-31 0001159036 halo:BulkFormulationMember us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember 2019-01-01 2019-12-31 0001159036 halo:HylenexRecombinantMember 2018-12-31 0001159036 halo:BulkrHuPH20Member 2019-12-31 0001159036 halo:A1.25ConvertibleSeniorNotesdue2024Member us-gaap:ConvertibleDebtMember 2019-01-01 2019-12-31 0001159036 halo:HylenexRecombinantMember 2019-12-31 0001159036 halo:BulkrHuPH20Member 2018-12-31 0001159036 halo:InlicensetechnologiesMember 2019-01-01 2019-12-31 0001159036 halo:BulkrHuPH20AndENHANZEMember 2019-01-01 2019-12-31 0001159036 halo:RocheandBaxaltaMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2018-12-31 0001159036 halo:BulkrHuPH20AndENHANZEMember 2019-10-01 2019-12-31 0001159036 halo:BulkFormulationMember us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember 2019-12-31 0001159036 halo:HylenexRecombinantMember us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember 2018-12-31 0001159036 us-gaap:SalesMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-12-31 0001159036 us-gaap:GeographicConcentrationRiskMember 2018-01-01 2018-12-31 0001159036 country:CH us-gaap:GeographicConcentrationRiskMember 2018-01-01 2018-12-31 0001159036 country:US us-gaap:GeographicConcentrationRiskMember 2017-01-01 2017-12-31 0001159036 us-gaap:GeographicDistributionForeignMember us-gaap:GeographicConcentrationRiskMember 2017-01-01 2017-12-31 0001159036 us-gaap:GeographicConcentrationRiskMember 2019-01-01 2019-12-31 0001159036 us-gaap:GeographicDistributionForeignMember us-gaap:GeographicConcentrationRiskMember 2019-01-01 2019-12-31 0001159036 country:CH us-gaap:GeographicConcentrationRiskMember 2017-01-01 2017-12-31 0001159036 country:US us-gaap:GeographicConcentrationRiskMember 2018-01-01 2018-12-31 0001159036 country:US us-gaap:GeographicConcentrationRiskMember 2019-01-01 2019-12-31 0001159036 us-gaap:GeographicDistributionForeignMember us-gaap:GeographicConcentrationRiskMember 2018-01-01 2018-12-31 0001159036 country:CH us-gaap:GeographicConcentrationRiskMember 2019-01-01 2019-12-31 0001159036 us-gaap:GeographicConcentrationRiskMember 2017-01-01 2017-12-31 0001159036 us-gaap:FairValueInputsLevel3Member 2018-12-31 0001159036 us-gaap:USTreasurySecuritiesMember 2019-12-31 0001159036 us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0001159036 us-gaap:AssetBackedSecuritiesMember 2019-12-31 0001159036 us-gaap:CommercialPaperMember 2019-12-31 0001159036 us-gaap:USTreasurySecuritiesMember 2018-12-31 0001159036 us-gaap:AssetBackedSecuritiesMember 2018-12-31 0001159036 us-gaap:CorporateDebtSecuritiesMember 2018-12-31 0001159036 us-gaap:CommercialPaperMember 2018-12-31 0001159036 us-gaap:FairValueInputsLevel3Member 2019-12-31 0001159036 us-gaap:FairValueInputsLevel2Member 2018-12-31 0001159036 us-gaap:FairValueInputsLevel1Member 2019-12-31 0001159036 us-gaap:FairValueInputsLevel1Member us-gaap:CorporateDebtSecuritiesMember 2018-12-31 0001159036 us-gaap:MoneyMarketFundsMember 2019-12-31 0001159036 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:USTreasurySecuritiesMember 2019-12-31 0001159036 us-gaap:CommercialPaperMember 2019-12-31 0001159036 us-gaap:USTreasurySecuritiesMember 2018-12-31 0001159036 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:USTreasurySecuritiesMember 2018-12-31 0001159036 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member 2019-12-31 0001159036 us-gaap:MoneyMarketFundsMember us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2018-12-31 0001159036 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:CorporateDebtSecuritiesMember 2018-12-31 0001159036 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member 2018-12-31 0001159036 us-gaap:FairValueInputsLevel1Member us-gaap:AssetBackedSecuritiesMember 2018-12-31 0001159036 us-gaap:USTreasurySecuritiesMember 2019-12-31 0001159036 us-gaap:FairValueInputsLevel2Member us-gaap:USTreasurySecuritiesMember 2018-12-31 0001159036 us-gaap:CorporateDebtSecuritiesMember 2018-12-31 0001159036 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0001159036 us-gaap:CommercialPaperMember 2018-12-31 0001159036 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel2Member us-gaap:CommercialPaperMember 2018-12-31 0001159036 us-gaap:FairValueInputsLevel2Member us-gaap:AssetBackedSecuritiesMember 2018-12-31 0001159036 us-gaap:FairValueInputsLevel1Member us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0001159036 us-gaap:FairValueInputsLevel1Member us-gaap:AssetBackedSecuritiesMember 2019-12-31 0001159036 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel2Member 2019-12-31 0001159036 us-gaap:MoneyMarketFundsMember 2018-12-31 0001159036 us-gaap:FairValueInputsLevel1Member us-gaap:CommercialPaperMember 2019-12-31 0001159036 us-gaap:FairValueInputsLevel1Member us-gaap:CommercialPaperMember 2018-12-31 0001159036 us-gaap:FairValueInputsLevel2Member us-gaap:AssetBackedSecuritiesMember 2019-12-31 0001159036 us-gaap:FairValueInputsLevel2Member 2019-12-31 0001159036 us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0001159036 us-gaap:FairValueInputsLevel2Member us-gaap:USTreasurySecuritiesMember 2019-12-31 0001159036 us-gaap:FairValueInputsLevel1Member 2018-12-31 0001159036 us-gaap:MoneyMarketFundsMember us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2019-12-31 0001159036 halo:ENHANZEdrugproductMemberDomain 2019-01-01 2019-12-31 0001159036 halo:DevelopmentFeesMember 2018-01-01 2018-12-31 0001159036 halo:BulkrHuPH20Member 2017-01-01 2017-12-31 0001159036 halo:ResearchandDevelopmentServicesMember 2017-01-01 2017-12-31 0001159036 halo:HylenexRecombinantMember 2017-01-01 2017-12-31 0001159036 halo:ENHANZEdrugproductMemberDomain 2018-01-01 2018-12-31 0001159036 halo:DevelopmentFeesMember 2019-01-01 2019-12-31 0001159036 halo:SalesbasedmilestoneMember 2017-01-01 2017-12-31 0001159036 halo:ResearchandDevelopmentServicesMember 2019-01-01 2019-12-31 0001159036 halo:HylenexRecombinantMember 2018-01-01 2018-12-31 0001159036 halo:ENHANZEdrugproductMemberDomain 2017-01-01 2017-12-31 0001159036 halo:ResearchandDevelopmentServicesMember 2018-01-01 2018-12-31 0001159036 halo:HylenexRecombinantMember 2019-01-01 2019-12-31 0001159036 halo:SalesbasedmilestoneMember 2019-01-01 2019-12-31 0001159036 halo:BulkrHuPH20Member 2019-01-01 2019-12-31 0001159036 halo:UpfrontfeesMember 2019-01-01 2019-12-31 0001159036 halo:BulkrHuPH20Member 2018-01-01 2018-12-31 0001159036 halo:UpfrontfeesMember 2017-01-01 2017-12-31 0001159036 halo:SalesbasedmilestoneMember 2018-01-01 2018-12-31 0001159036 halo:UpfrontfeesMember 2018-01-01 2018-12-31 0001159036 halo:DevelopmentFeesMember 2017-01-01 2017-12-31 0001159036 us-gaap:AccountingStandardsUpdate201409Member us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member 2018-01-01 2018-12-31 0001159036 halo:A2017RocheMember 2019-01-01 2019-12-31 0001159036 us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member 2018-12-31 0001159036 us-gaap:AccountingStandardsUpdate201409Member us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member 2018-12-31 0001159036 2019-07-01 2019-12-31 0001159036 us-gaap:ProductMember 2019-12-31 0001159036 halo:DevelopmentFeesMember halo:BMSMember 2019-12-31 0001159036 halo:UpfrontfeesMember halo:LillyMember 2019-12-31 0001159036 halo:JanssenMember 2019-01-01 2019-12-31 0001159036 halo:DevelopmentFeesMember halo:AlexionMember 2019-12-31 0001159036 halo:DevelopmentFeesMember halo:AbbVieMember 2019-12-31 0001159036 halo:UpfrontfeesMember halo:PfizerMember 2019-12-31 0001159036 halo:AbbVieMember 2019-01-01 2019-12-31 0001159036 halo:DevelopmentFeesMember halo:BaxaltaMember 2019-12-31 0001159036 halo:PfizerMember 2019-01-01 2019-12-31 0001159036 halo:DevelopmentFeesMember halo:ArgenxMember 2019-12-31 0001159036 us-gaap:RoyaltyMember 2019-12-31 0001159036 halo:RocheMember 2019-01-01 2019-12-31 0001159036 halo:UpfrontfeesMember halo:AlexionMember 2019-12-31 0001159036 halo:UpfrontfeesMember halo:JanssenMember 2019-12-31 0001159036 halo:UpfrontfeesMember halo:ArgenxMember 2019-12-31 0001159036 halo:SalesbasedmilestoneMember halo:RocheMember 2019-12-31 0001159036 halo:UpfrontfeesMember halo:BaxaltaMember 2019-12-31 0001159036 halo:LillyMember 2019-01-01 2019-12-31 0001159036 halo:SalesbasedmilestoneMember halo:BaxaltaMember 2019-12-31 0001159036 halo:UpfrontfeesMember halo:BMSMember 2019-12-31 0001159036 halo:DevelopmentFeesMember halo:JanssenMember 2019-12-31 0001159036 halo:BMSMember 2019-01-01 2019-12-31 0001159036 halo:UpfrontfeesMember halo:RocheMember 2019-12-31 0001159036 halo:DevelopmentFeesMember halo:PfizerMember 2019-12-31 0001159036 halo:UpfrontfeesMember halo:AbbVieMember 2019-12-31 0001159036 halo:BaxaltaMember 2019-01-01 2019-12-31 0001159036 halo:AlexionMember 2019-01-01 2019-12-31 0001159036 halo:ArgenxMember 2019-01-01 2019-12-31 0001159036 halo:DevelopmentFeesMember halo:RocheMember 2019-12-31 0001159036 us-gaap:ProductMember us-gaap:ProductMember 2019-12-31 0001159036 halo:LicenseFeesAndEventBasedMember 2018-12-31 0001159036 halo:LicenseFeesAndEventBasedMember 2019-12-31 0001159036 us-gaap:ProductMember us-gaap:ProductMember 2018-12-31 0001159036 us-gaap:LeaseholdImprovementsMember 2019-12-31 0001159036 halo:ManufacturingEquipmentMember 2019-12-31 0001159036 halo:ResearchEquipmentMember 2019-12-31 0001159036 halo:ComputerAndOfficeEquipmentMember 2019-12-31 0001159036 halo:ResearchEquipmentMember 2018-12-31 0001159036 halo:ManufacturingEquipmentMember 2018-12-31 0001159036 halo:ComputerAndOfficeEquipmentMember 2018-12-31 0001159036 us-gaap:LeaseholdImprovementsMember 2018-12-31 0001159036 halo:A1.25ConvertibleSeniorNotesdue2024Member us-gaap:DebtInstrumentRedemptionPeriodOneMember us-gaap:ConvertibleDebtMember 2019-11-01 2019-11-30 0001159036 us-gaap:AcceleratedShareRepurchasesDateDomain 2019-11-01 2019-11-30 0001159036 us-gaap:SeniorLoansMember 2019-12-31 0001159036 halo:A2019QuarterlyMaximumPaymentMember halo:RoyaltybackedLoanMember 2019-01-01 2019-12-31 0001159036 halo:A1.25ConvertibleSeniorNotesdue2024Member us-gaap:ConvertibleDebtMember 2019-12-31 0001159036 us-gaap:SeniorLoansMember 2019-01-01 2019-12-31 0001159036 halo:A2016Member halo:RoyaltybackedLoanMember 2019-01-01 2019-12-31 0001159036 halo:RoyaltybackedLoanMember 2019-12-31 0001159036 halo:SharesacquiredinprivatelynegotiatedtransactionsDomain 2019-11-01 2019-11-30 0001159036 halo:RoyaltybackedLoanMember 2018-01-01 2018-12-31 0001159036 halo:A1.25ConvertibleSeniorNotesdue2024Member us-gaap:DebtInstrumentRedemptionPeriodTwoMember us-gaap:ConvertibleDebtMember 2019-11-01 2019-11-30 0001159036 halo:RoyaltybackedLoanMember 2019-01-01 2019-12-31 0001159036 halo:A2018QuarterlyMaximumPaymentMember halo:RoyaltybackedLoanMember 2019-01-01 2019-12-31 0001159036 us-gaap:SeniorLoansMember 2018-01-01 2018-12-31 0001159036 2019-11-01 2019-11-30 0001159036 halo:A1.25ConvertibleSeniorNotesdue2024Member us-gaap:ConvertibleDebtMember 2019-11-01 2019-11-30 0001159036 srt:MinimumMember halo:RoyaltybackedLoanMember 2019-01-01 2019-12-31 0001159036 srt:MaximumMember halo:RoyaltybackedLoanMember 2019-01-01 2019-12-31 0001159036 2019-11-30 0001159036 halo:A2017QuarterlyMaximumPaymentMember halo:RoyaltybackedLoanMember 2019-01-01 2019-12-31 0001159036 us-gaap:SecuredDebtMember 2018-12-31 0001159036 halo:RoyaltybackedLoanMember 2017-01-01 2017-12-31 0001159036 halo:A2017Member halo:RoyaltybackedLoanMember 2019-01-01 2019-12-31 0001159036 us-gaap:SeniorLoansMember 2017-01-01 2017-12-31 0001159036 halo:A2020QuarterlyMaximumPaymentMember halo:RoyaltybackedLoanMember 2019-01-01 2019-12-31 0001159036 halo:A2018andthereafterMember halo:RoyaltybackedLoanMember 2019-01-01 2019-12-31 0001159036 us-gaap:RestrictedStockMember 2019-12-31 0001159036 us-gaap:RestrictedStockUnitsRSUMember 2019-01-01 2019-12-31 0001159036 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-12-31 0001159036 us-gaap:RestrictedStockUnitsRSUMember 2019-12-31 0001159036 us-gaap:RestrictedStockMember 2019-01-01 2019-12-31 0001159036 us-gaap:EmployeeStockOptionMember 2019-12-31 0001159036 us-gaap:RestrictedStockUnitsRSUMember 2018-12-31 0001159036 us-gaap:RestrictedStockMember 2018-12-31 0001159036 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2017-01-01 2017-12-31 0001159036 us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-12-31 0001159036 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2018-01-01 2018-12-31 0001159036 us-gaap:ResearchAndDevelopmentExpenseMember 2017-01-01 2017-12-31 0001159036 us-gaap:ResearchAndDevelopmentExpenseMember 2018-01-01 2018-12-31 0001159036 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2019-01-01 2019-12-31 0001159036 halo:AmendedandRestated2011StockPlanMember 2019-12-31 0001159036 us-gaap:RestrictedStockMember 2018-01-01 2018-12-31 0001159036 halo:OutstandingAwardsMember 2019-12-31 0001159036 us-gaap:RestrictedStockUnitsRSUMember 2017-01-01 2017-12-31 0001159036 us-gaap:RestrictedStockUnitsRSUMember 2018-01-01 2018-12-31 0001159036 us-gaap:RestrictedStockMember 2017-01-01 2017-12-31 0001159036 halo:RSURSAandPRSUawardsMember 2018-01-01 2018-12-31 0001159036 halo:RSURSAandPRSUawardsMember 2017-01-01 2017-12-31 0001159036 halo:RSURSAandPRSUawardsMember 2019-01-01 2019-12-31 0001159036 us-gaap:EmployeeStockOptionMember 2017-01-01 2017-12-31 0001159036 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-12-31 0001159036 srt:MaximumMember 2018-01-01 2018-12-31 0001159036 srt:MinimumMember 2017-01-01 2017-12-31 0001159036 srt:MaximumMember 2017-01-01 2017-12-31 0001159036 srt:MinimumMember 2018-01-01 2018-12-31 0001159036 halo:CliffVestingFirstAnniversaryMember 2019-01-01 2019-12-31 0001159036 us-gaap:RestrictedStockMember halo:PercentageVestingMember 2019-01-01 2019-12-31 0001159036 halo:MonthlyVestingAfterOneYearMember 2019-01-01 2019-12-31 0001159036 us-gaap:RestrictedStockUnitsRSUMember halo:PercentageVestingMember 2019-01-01 2019-12-31 0001159036 halo:A2019ShareRepurchaseProgramBankofAmericaMember 2019-11-01 2019-11-30 0001159036 halo:StockOptionsAndRestrictedStockUnitsMember 2017-12-31 0001159036 us-gaap:AcceleratedShareRepurchasesDateDomain 2019-11-30 0001159036 2017-05-01 2017-05-31 0001159036 halo:StockOptionsAndRestrictedStockUnitsMember 2019-12-31 0001159036 us-gaap:SubsequentEventMember 2020-02-01 2020-02-29 0001159036 halo:StockOptionsAndRestrictedStockUnitsMember 2018-12-31 0001159036 halo:OfficeAndResearchFacilityMember 2019-01-01 2019-12-31 0001159036 halo:SatelliteofficeMember 2019-01-01 2019-12-31 0001159036 halo:PatheonMember 2019-12-31 0001159036 halo:AvidCommercialSupplyAgreementMember 2019-12-31 0001159036 halo:OtherstatetaxMember 2019-12-31 0001159036 us-gaap:InternalRevenueServiceIRSMember us-gaap:GeneralBusinessMember 2019-12-31 0001159036 us-gaap:InternalRevenueServiceIRSMember us-gaap:ResearchMember 2019-12-31 0001159036 halo:CaliforniaMember 2019-12-31 0001159036 us-gaap:InternalRevenueServiceIRSMember 2019-12-31 0001159036 us-gaap:StateAndLocalJurisdictionMember us-gaap:ResearchMember 2019-12-31 0001159036 us-gaap:InternalRevenueServiceIRSMember halo:A2018expirationMember 2019-12-31 0001159036 us-gaap:StateAndLocalJurisdictionMember halo:A2018expirationMember 2019-12-31 0001159036 us-gaap:InternalRevenueServiceIRSMember halo:A2021andbeyondexpirationMember 2019-12-31 0001159036 us-gaap:StateAndLocalJurisdictionMember halo:A2021andbeyondexpirationMember 2019-12-31 0001159036 us-gaap:StateAndLocalJurisdictionMember halo:A2028andbeyondexpirationMember 2019-12-31 0001159036 us-gaap:InternalRevenueServiceIRSMember halo:A2028andbeyondexpirationMember 2019-12-31 0001159036 us-gaap:StateAndLocalJurisdictionMember 2019-12-31 0001159036 halo:ArgenxMember 2019-01-01 2019-03-31 0001159036 halo:RocheMember 2018-10-01 2018-12-31 0001159036 2019-10-01 2019-12-31 0001159036 2018-10-01 2018-12-31 0001159036 2019-07-01 2019-09-30 0001159036 2019-01-01 2019-03-31 0001159036 2019-04-01 2019-06-30 0001159036 2018-01-01 2018-03-31 0001159036 2018-04-01 2018-06-30 0001159036 2018-07-01 2018-09-30 0001159036 us-gaap:ContractTerminationMember 2019-10-01 2019-12-31 0001159036 2019-11-04 2019-11-04 0001159036 us-gaap:OneTimeTerminationBenefitsMember 2019-10-01 2019-12-31 iso4217:USD xbrli:pure iso4217:USD xbrli:shares halo:trading_day xbrli:shares halo:segment halo:security utreg:sqft


 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-K
☒
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended December 31, 2019
OR
☐
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from           to             
Commission File Number 001-32335
___________________________
HALOZYME THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
___________________________
Delaware
 
88-0488686
(State or other jurisdiction of incorporation or organization)
 
(I.R.S. Employer Identification No.)
 
 
11388 Sorrento Valley Road
 
92121
San Diego
 
(Zip Code)
CA
 
 
(Address of principal executive offices)
 
 
(858) 794-8889
(Registrant’s telephone number, including area code)
Securities registered under Section 12(b) of the Act:
Title of Each Class
Trading Symbol(s)
Name of Each Exchange on Which Registered
Common Stock, $0.001 Par Value
HALO
The NASDAQ Stock Market, LLC
Securities registered under Section 12(g) of the Act:
None
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.    ☒  Yes        ☐  No
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act.    ☐  Yes        ☒  No
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    ☒  Yes        ☐  No
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    ☒  Yes        ☐  No




Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
 
Large accelerated filer
Accelerated filer
  
Non-accelerated filer
Smaller reporting company
Emerging growth company
☒
☐
 
☐
☐
☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    ☐  Yes        ☒    No
The aggregate market value of the voting and non-voting common equity held by non-affiliates of the registrant as of June 30, 2019 was approximately $2.5 billion based on the closing price on the NASDAQ Global Select Market reported for such date. Shares of common stock held by each officer and director and by each person who is known to own 10% or more of the outstanding common stock have been excluded in that such persons may be deemed to be affiliates of the registrant. This determination of affiliate status is not necessarily a conclusive determination for other purposes.
The number of outstanding shares of the registrant’s common stock, par value $0.001 per share, was 138,226,070 as of February 14, 2020.
DOCUMENTS INCORPORATED BY REFERENCE
Portions of the registrant’s definitive Proxy Statement to be filed subsequent to the date hereof with the Securities and Exchange Commission pursuant to Regulation 14A in connection with the registrant’s 2020 Annual Meeting of Stockholders are incorporated by reference into Part III of this Annual Report.
 



HALOZYME THERAPEUTICS, INC.
INDEX
 
 
 
 
Page
Item 1.
 
Item 1A.
 
Item 1B.
 
Item 2.
 
Item 3.
 
Item 4.
 
 
 
 
 
Item 5.
 
Item 6.
 
Item 7.
 
Item 7A.
 
Item 8.
 
Item 9.
 
Item 9A.
 
Item 9B.
 
 
 
 
 
Item 10.
 
Item 11.
 
Item 12.
 
Item 13.
 
Item 14.
 
 
 
 
 
Item 15.
 
Item 16.
 
 



This Annual Report on Form 10-K contains “forward-looking statements” within the meaning of the “safe harbor” provisions of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. All statements, other than statements of historical fact, included herein, including without limitation those regarding our future product development and regulatory events and goals, product collaborations, our business intentions and financial estimates and anticipated results, are, or may be deemed to be, forward-looking statements. Words such as “expect,” “anticipate,” “intend,” “plan,” “believe,” “seek,” “estimate,” “think,” “may,” “could,” “will,” “would,” “should,” “continue,” “potential,” “likely,” “opportunity,” “project” and similar expressions or variations of such words are intended to identify forward-looking statements, but are not the exclusive means of identifying forward-looking statements in this Annual Report. Additionally, statements concerning future matters such as the development or regulatory approval of new partner products, enhancements of existing products or technologies, timing and success of launch of new products by our collaborators, third party performance under key collaboration agreements, revenue, expense and cash burn levels, anticipated profitability and expected trends, expected repayment of the Royalty backed Loan and trends and other statements regarding matters that are not historical are forward-looking statements.
Although forward-looking statements in this Annual Report reflect the good faith judgment of our management, such statements can only be based on facts and factors currently known by us. Consequently, forward-looking statements are inherently subject to risks and uncertainties and actual results and outcomes may differ materially from the results and outcomes discussed in or anticipated by the forward-looking statements. Factors that could cause or contribute to such differences in results and outcomes include without limitation those discussed under the heading “Risk Factors” in Part I, Item 1A below, as well as those discussed elsewhere in this Annual Report. Readers are urged not to place undue reliance on these forward-looking statements, which speak only as of the date of this Annual Report. We undertake no obligation to revise or update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this Annual Report. Readers are urged to carefully review and consider the various disclosures made in this Annual Report, which attempt to advise interested parties of the risks and factors that may affect our business, financial condition, results of operations and prospects.
References to “Halozyme,” “the Company,” “we,” “us,” and “our” refer to Halozyme Therapeutics, Inc. and its wholly owned subsidiary, Halozyme, Inc., and Halozyme, Inc.’s wholly owned subsidiaries, Halozyme Holdings Ltd., Halozyme Royalty LLC, Halozyme Switzerland GmbH and Halozyme Switzerland Holdings GmbH. References to “Notes” refer to the Notes to Consolidated Financial Statements included herein (refer to Part II, Item 8).
PART I

1


Item 1.
Business
Overview
Halozyme Therapeutics Inc. is a biopharma technology platform company that provides innovative and disruptive solutions with the goal of improving patient experience and outcomes. Our proprietary enzyme rHUPH20 is used to facilitate the delivery of injected drugs and fluids. We license our technology to biopharmaceutical companies to collaboratively develop products that combine our ENHANZE® drug delivery technology with the collaborators’ proprietary compounds. 
Our approved product and our collaborators’ approved products and product candidates are based on rHuPH20, our patented recombinant human hyaluronidase enzyme. rHuPH20 is the active ingredient in our first commercially approved product, Hylenex® recombinant (hyaluronidase human injection) (Hylenex), and it works by breaking down hyaluronan (or HA), a naturally occurring carbohydrate that is a major component of the extracellular matrix in tissues throughout the body such as skin and cartilage. This temporarily increases dispersion and absorption allowing for improved subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other large therapeutic molecules, as well as small molecules and fluids. We refer to the application of rHuPH20 to facilitate the delivery of other drugs or fluids as our ENHANZE® Drug Delivery Technology (ENHANZE). We license the ENHANZE technology to form collaborations with biopharmaceutical companies that develop or market drugs requiring or benefiting from injection via the subcutaneous route of administration. In the development of proprietary intravenous (IV) drugs combined with our ENHANZE technology, data have been generated supporting the potential for ENHANZE to reduce treatment burden, as a result of shorter duration of subcutaneous (SC) administration. ENHANZE may enable fixed-dose SC dosing compared to weight-based dosing required for IV administration, and potentially allow for lower rates of infusion related reactions. Lastly, certain proprietary drugs co-formulated with ENHANZE have been granted additional exclusivity, extending the patent life of the product beyond the one of the proprietary IV drug.
We currently have ENHANZE collaborations with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc. (Roche), Baxalta US Inc. and Baxalta GmbH (now members of the Takeda group of companies, following the acquisition of Shire plc by Takeda Pharmaceutical Company Limited in January 2019) (Baxalta), Pfizer Inc. (Pfizer), Janssen Biotech, Inc. (Janssen), AbbVie, Inc. (AbbVie), Eli Lilly and Company (Lilly), Bristol-Myers Squibb Company (BMS), Alexion Pharma Holding (Alexion) and ARGENX BVBA (argenx). We receive royalties from two of these collaborations, including royalties from sales of one product from the Baxalta collaboration and two products from the Roche collaboration. Future potential revenues from the sales and/or royalties of our approved products, product candidates, and ENHANZE collaborations will depend on the ability of Halozyme and our collaborators to develop, manufacture, secure and maintain regulatory approvals for approved products and product candidates and commercialize product candidates.
On November 4, 2019, we announced that our HALO-301 Phase 3 clinical study evaluating PEGylated recombinant human hyaluronidase (PEGPH20) in combination with ABRAXANE® (nab-paclitaxel) and gemcitabine as a first-line therapy for treatment of patients with metastatic pancreatic cancer failed to reach the primary endpoint of overall survival. The study failed to demonstrate an improvement in overall survival compared to gemcitabine and nab-paclitaxel alone (11.2 months median overall survival compared to 11.5 months, HR=1.00, p=0.9692). Due to the results of the study, we halted development activities for PEGPH20, closed our oncology operations and implemented an organizational restructuring to focus our operations on ENHANZE.
We closed all ongoing oncology clinical studies including the Phase 3 clinical testing for PEGPH20 with ABRAXANE and gemcitabine in stage IV pancreatic ductal adenocarcinoma (“PDA”) (HALO-301) and the Phase 1b/2 clinical testing for PEGPH20 with Tecentriq in patients with cholangiocarcinoma and gall bladder cancer (HALO 110-101/MATRIX). The Roche -Genentech sponsored MORPHEUS PDA and gastric cancer studies closed the arms containing PEGPH20 to enrollment. All patients who were treated in PEGPH20 arms are off PEGPH20 treatment and are in follow up, per study protocol.
Our principal offices and research facilities are located at 11388 Sorrento Valley Road, San Diego, California 92121. Our telephone number is (858) 794-8889 and our e-mail address is info@halozyme.com. Our website address is www.halozyme.com. Information found on, or accessible through, our website is not a part of, and is not incorporated into, this Annual Report on Form 10-K. Our periodic and current reports that we filed with the SEC are available on our website at www.halozyme.com, free of charge, as soon as reasonably practicable after we have electronically filed such material with, or furnished them to, the SEC, including our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and any amendments to those reports.

2


Technology
rHuPH20 can be applied as a drug delivery platform to increase dispersion and absorption of other injected drugs and fluids potentially reducing treatment burden. For example, rHuPH20 has been used to convert drugs that must be delivered intravenously into subcutaneous injections or to reduce the number of subcutaneous injections needed for effective therapy. When ENHANZE technology is applied subcutaneously, the rHuPH20 acts locally and transiently, with a tissue half-life of less than 15 minutes. HA at the local site reconstitutes its normal density within a few days and, therefore, the effect of rHuPH20 on the architecture of the subcutaneous space is temporary.
Strategy
We currently have nine collaborations with three current product approvals and additional product candidates in development using our ENHANZE technology. We intend to work with our existing collaborators to expand our collaborations to add new targets and develop targets and product candidates under the terms of the operative collaboration agreements. We will also continue our efforts to enter into new collaborations to further derive additional value from our proprietary technology.
Product and Product Candidates
We currently have one marketed proprietary product and three marketed partnered products. The following table summarizes our proprietary product, marketed partnered products and product candidates under development with our collaborators:
slide1b04.jpg

3


slide2a93.jpg
Proprietary Product
Hylenex Recombinant (hyaluronidase human injection)
Hylenex recombinant is a formulation of rHuPH20 that facilitates subcutaneous fluid administration for achieving hydration, to increase the dispersion and absorption of other injected drugs and, in subcutaneous urography, to improve resorption of radiopaque agents. Hylenex recombinant is currently the number one prescribed branded hyaluronidase.
ENHANZE Collaborations
Roche Collaboration
In December 2006, we and Roche entered into a collaboration and license agreement under which Roche obtained a worldwide license to develop and commercialize product combinations of rHuPH20 and up to thirteen Roche target compounds (the Roche Collaboration). Under this agreement, Roche elected a total of eight targets, two of which are exclusive.
In September 2013, Roche launched a subcutaneous (SC) formulation of Herceptin (trastuzumab) (Herceptin SC) in Europe for the treatment of patients with HER2-positive breast cancer followed by launches in additional countries. This formulation utilizes our ENHANZE technology and is administered in two to five minutes, compared to 30 to 90 minutes with the standard intravenous form. In September 2018, we announced that Roche received approval from Health Canada for Herceptin SC for the treatment of patients with HER2-positive breast cancer. In February 2019, we announced that Roche received approval from the FDA for Herceptin SC under the brand name Herceptin Hylecta™ (trastuzumab and hyaluronidase-oysk). In April 2019, Roche made Herceptin Hylecta available in the U.S.

4


Directed at the same target, Roche initiated a Phase 1 study of Perjeta® (pertuzumab) and Herceptin (trastuzumab) using ENHANZE technology in patients with early breast cancer in March 2016. In June 2018, Roche initiated a global Phase 3 study of a fixed-dose combination of Perjeta and Herceptin using ENHANZE technology in patients with HER2-positive early breast cancer. In August 2019, the global phase 3 study met its primary endpoint. The study results demonstrated non-inferior levels of Perjeta in the blood (pharmacokinetics) compared to standard intravenous (IV) infusion of Perjeta plus Herceptin and chemotherapy in patients with HER2-positive early breast cancer. The study also demonstrated that the safety profile of the fixed dose subcutaneous combination of Perjeta and Herceptin was consistent with the safety profile of Perjeta and Herceptin administered intravenously. In December 2019, the full data from the study was presented at the San Antonio Breast Cancer Symposium. Based on the results of this study, BLA and MAA submissions are expected to be completed in the first quarter of 2020.
In June 2014, Roche launched MabThera SC in Europe for the treatment of patients with common forms of non-Hodgkin lymphoma (NHL) followed by launches in additional countries. This formulation utilizes our ENHANZE technology and is administered in approximately five minutes compared to the approximately 1.5 to 4 hour intravenous infusion. In May 2016, Roche announced that the EMA approved Mabthera SC to treat patients with chronic lymphocytic leukemia (CLL). In June 2017, the FDA approved Genentech’s RITUXAN HYCELA™, a combination of rituximab and rHuPH20 (approved and marketed under the MabThera SC brand in countries outside the U.S. and Canada), for CLL and two types of NHL, follicular lymphoma and diffuse large B-cell lymphoma. In March 2018, Health Canada approved a combination of rituximab and rHuPH20 (approved and marketed under the brand name RITUXAN® SC) for patients with CLL.
In September 2017, we and Roche entered into an agreement providing Roche the right to develop and commercialize one additional exclusive target using ENHANZE technology. The upfront license payment may be followed by event-based payments subject to Roche’s achievement of specified development, regulatory and sales-based milestones. In addition, Roche will pay royalties to us if products under the collaboration are commercialized.
In October 2018, we entered into an agreement with Roche for the right to develop and commercialize one additional exclusive target and an option to select two additional targets within four years using our ENHANZE technology. The upfront license payment may be followed by event-based payments subject to Roche’s achievement of specified development, regulatory and sales-based milestones. In addition, Roche will pay royalties to us if products under the collaboration are commercialized.
In December 2018, Roche initiated a Phase 1b/2 study in patients with non-small cell lung cancer for Tecentriq (atezolizumab) using ENHANZE technology. In August 2019, Roche initiated a Phase 1 study evaluating OCREVUS (ocrelizumab) with ENHANZE Technology in subjects with multiple sclerosis. In October 2019, Roche nominated a new undisclosed target to be studied using ENHANZE technology, triggering a $10 million milestone payment.
Baxalta Collaboration
In September 2007, we and Baxalta entered into a collaboration and license agreement under which Baxalta obtained a worldwide, exclusive license to develop and commercialize product combinations of rHuPH20 with GAMMAGARD LIQUID (HYQVIA) (the Baxalta Collaboration). HYQVIA is indicated for the treatment of primary immunodeficiency disorders associated with defects in the immune system.
In May 2013, the European Commission granted Baxalta marketing authorization in all EU Member States for the use of HYQVIA (solution for subcutaneous use) as replacement therapy for adult patients with primary and secondary immunodeficiencies. Baxalta launched HYQVIA in the first EU country in July 2013 and has continued to launch in additional countries.
In September 2014, HYQVIA was approved by the FDA for treatment of adult patients with primary immunodeficiency in the U.S. HYQVIA is the first subcutaneous immune globulin (IG) treatment approved for adult primary immunodeficiency patients with a dosing regimen requiring only one infusion up to once per month (every three to four weeks) and one injection site per infusion in most patients, to deliver a full therapeutic dose of IG. The FDA’s approval of HYQVIA was a significant milestone for us as it represented the first U.S. approved BLA which utilizes our rHuPH20 platform.
In May 2016, Baxalta announced that HYQVIA received a marketing authorization from the European Commission for a pediatric indication, which was launched in Europe to treat primary and certain secondary immunodeficiencies.

5


Pfizer Collaboration
In December 2012, we and Pfizer entered into a collaboration and license agreement, under which Pfizer has the worldwide license to develop and commercialize products combining our rHuPH20 enzyme with Pfizer proprietary biologics directed to up to six targets in primary care and specialty care indications. Targets may be selected on an exclusive or non-exclusive basis. Pfizer has elected five targets and has returned two targets.
Janssen Collaboration
In December 2014, we and Janssen entered into a collaboration and license agreement, under which Janssen has the worldwide license to develop and commercialize products combining our rHuPH20 enzyme with Janssen proprietary biologics directed to up to five targets. Targets may be selected on an exclusive basis. Janssen has elected CD38 as the first target on an exclusive basis. In October 2017, Janssen initiated its first Phase 3 study of subcutaneous delivery of DARZALEX® (daratumumab), directed at CD38, using ENHANZE technology, in multiple myeloma patients. Janssen has initiated seven Phase 3 studies, two Phase 2 study and one Phase 1 study of daratumumab using ENHANZE technology in patients with amyloidosis, smoldering myeloma and multiple myeloma.
In February 2019, Janssen’s development partner, Genmab, announced positive Phase 3 trial results from the COLUMBA study evaluating subcutaneous DARZALEX in comparison to DARZALEX IV in patients with relapsed or refractory multiple myeloma. DARZALEX SC (utilizing ENHANZE technology) was found to be non-inferior to Darzalex IV with regard the co-primary endpoints of Overall Response Rate and Maximum Trough concentration. In July 2019, Janssen submitted a BLA to the FDA and an extension application to the EMA for the subcutaneous delivery of DARZALEX for patients with multiple myeloma.
In December 2019, Janssen elected targets EGFR and cMET on an exclusive basis as part of the bispecific antibody (JNJ-61186372), which is being studied in solid tumors.
AbbVie Collaboration
In June 2015, we and AbbVie entered into a collaboration and license agreement, under which AbbVie has the worldwide license to develop and commercialize products combining our rHuPH20 enzyme with AbbVie proprietary biologics directed to up to nine targets. Targets may be selected on an exclusive basis. AbbVie elected one target on an exclusive basis, TNF alpha, for which it has discontinued development and returned the target.
Lilly Collaboration
In December 2015, we and Lilly entered into a collaboration and license agreement, under which Lilly has the worldwide license to develop and commercialize products combining our rHuPH20 enzyme with Lilly proprietary biologics directed to up to five targets. Targets may be selected on an exclusive basis. Lilly has elected two targets on an exclusive basis and one target on a semi-exclusive basis. In August 2017, Lilly initiated a Phase 1 study of an investigational therapy in combination with rHuPH20.
BMS Collaboration
In September 2017, we and BMS entered into a collaboration and license agreement, which became effective in November 2017, under which BMS has the worldwide license to develop and commercialize products combining our rHuPH20 enzyme with BMS immuno-oncology targets directed at up to eleven targets. Targets may be selected on an exclusive basis, with the exception of one co-exclusive target. BMS has designated multiple immuno-oncology targets including programmed death 1 (PD-1) and has an option to select additional targets within five years from the effective date. In October 2018, BMS dosed the first patient in a Phase 1/2a study evaluating the safety, pharmacokinetics and pharmacodynamics of BMS-986179, an investigational anti-CD-73 antibody alone and in combination with nivolumab, using ENHANZE technology. BMS is also conducting a Phase 1/2 study of nivolumab using ENHANZE technology in patients with solid tumors. In October 2019, BMS initiated a Phase 1 study for Relatlimab in combination with nivolumab and ENHANZE technology.
Alexion Collaboration
In December 2017, we and Alexion entered into a collaboration and license agreement, under which Alexion has the worldwide license to develop and commercialize products combining our rHuPH20 enzyme with Alexion’s portfolio of products directed at up to four targets. Targets may be selected on an exclusive basis. Alexion elected two targets on an exclusive basis, including a

6


C5 complement inhibitor and has an option to select two additional targets within five years from the effective date. In August 2018, Alexion announced that it initiated a Phase 1 trial to study a next-generation subcutaneous formulation of ALXN1210 using ENHANZE technology. Alexion believes this next-generation subcutaneous formulation, called ALXN1810, has the potential to extend the dosing interval from once a week to greater than two weeks between doses. In January 2020, Alexion announced plans to conduct a phase 2 basket trial in renal indications for ALXN1810.
argenx Collaboration
In February 2019, we entered into an agreement with argenx for the right to develop and commercialize one exclusive target, the human neonatal Fc receptor FcRn, which includes argenx's lead asset efgartigimod (ARGX-113), and an option to select two additional targets using ENHANZE technology. In May 2019, argenx nominated a second target to be studied using ENHANZE technology, a human complement factor C2 associated with the product candidate ARGX-117, which is being developed to treat severe autoimmune diseases.
In July 2019, argenx dosed the first subject in a phase 1 clinical trial evaluating the safety, pharmacokinetics and pharmacodynamics of efgartigimod (ARGX-113), using ENHANZE technology. In December 2019, argenx reported that based on data from the phase 1 study and internal company analysis, a one minute injection administered every 2 weeks may be possible.
NIH CRADA
In June 2019, we announced a Cooperative Research and Development Agreement (CRADA) with the National Institute of Allergy and Infectious Diseases’ Vaccine Research Center (VRC), part of National Institute of Health (NIH), enabling the VRC’s use of ENHANZE technology to develop subcutaneous formulations of broadly neutralizing antibodies (bnAbs) against HIV for HIV treatment.
For a further discussion of the collaboration agreements, refer to Note 2, Summary of Significant Accounting Policies - Revenues under Collaborative Agreements.
Customers
The following table indicates the percentage of total revenues in excess of 10% with any single customer:
 
Year Ended December 31,
 
2019
 
2018
 
2017
Roche
40
%
 
72
%
 
38
%
argenx
23
%
 
—
%
 
—
%
Janssen
18
%
 
2
%
 
6
%
BMS
1
%
 
4
%
 
32
%
Alexion
1
%
 
3
%
 
13
%
For additional information regarding our revenues from customers, refer to Note 2, Summary of Significant Accounting Policies — Concentrations of Credit Risk, Sources of Supply and Significant Customers, to our consolidated financial statements.
Patents and Proprietary Rights
Patents and other proprietary rights are essential to our business. Our success will depend in part on our ability to obtain patent protection for our inventions, to preserve our trade secrets and to operate without infringing the proprietary rights of third parties. Our strategy is to actively pursue patent protection in the U.S. and certain foreign jurisdictions for technology that we believe to be proprietary to us and that offers us a potential competitive advantage. Our patent portfolio includes 43 issued patents in the U.S., more than 520 issued patents in Europe and other countries in the world and more than 70 pending patent applications. In general, patents have a term of 20 years from the application filing date or earlier claimed priority date. Our issued patents will expire between 2023 and 2035. We have multiple patents and patent applications throughout the world pertaining to our recombinant human hyaluronidase and methods of use and manufacture, including an issued U.S. patent which expires in 2027 and an issued European patent which expires in 2024, which we believe cover the products and product candidates under our existing

7


collaborations and Hylenex recombinant . In addition, we have, under prosecution throughout the world, multiple patent applications that relate specifically to individual product candidates under development, the expiration of which can only be definitely determined upon maturation into our issued patents. We believe our patent filings represent a barrier to entry for potential competitors looking to utilize these hyaluronidases.
In addition to patents, we rely on unpatented trade secrets, proprietary know-how and continuing technological innovation. We seek protection of these trade secrets, proprietary know-how and innovation, in part, through confidentiality and proprietary information agreements. Our policy is to require our employees, directors, consultants, advisors, collaborators, outside scientific collaborators and sponsored researchers, other advisors and other individuals and entities to execute confidentiality agreements upon the start of employment, consulting or other contractual relationships with us. These agreements provide that all confidential information developed or made known to the individual or entity during the course of the relationship is to be kept confidential and not disclosed to third parties except in specific circumstances. In the case of employees and some other parties, the agreements provide that all inventions conceived by the individual will be our exclusive property. Despite the use of these agreements and our efforts to protect our intellectual property, there will always be a risk of unauthorized use or disclosure of information. Furthermore, our trade secrets may otherwise become known to, or be independently developed by, our competitors.
We also file trademark applications to protect the names of our products and product candidates. These applications may not mature to registration and may be challenged by third parties. We are pursuing trademark protection in a number of different countries around the world. There can be no assurances that our registered or unregistered trademarks or trade names will not infringe on rights of third parties or will be acceptable to regulatory agencies.
Research and Development Activities
Our research and development expenses consist primarily of costs associated with the product development, quality and regulatory work required to maintain the ENHANZE platform, development and manufacturing of product candidates performed on behalf of our partners, compensation and other expenses for research and development personnel, supplies and materials, facility costs and amortization and depreciation. We charge all research and development expenses to operations as they are incurred. Prior to our November 2019 restructuring, our research and development activities were primarily focused on the development of PEGPH20.
Manufacturing
We do not have our own manufacturing facility for our product and our partners’ products and product candidates, or the capability to package our products. We have engaged third parties to manufacture bulk rHuPH20 and Hylenex.
We have existing supply agreements with contract manufacturing organizations Avid Bioservices, Inc. (Avid) and Catalent Indiana LLC (formerly Cook Pharmica LLC) (Catalent) to produce supplies of bulk rHuPH20. These manufacturers each produce bulk rHuPH20 under current Good Manufacturing Practices (cGMP) for clinical and commercial uses. Catalent currently produces bulk rHuPH20 for use in Hylenex and collaboration product candidates. Avid currently produces bulk rHuPH20 for use in collaboration products. We rely on their ability to successfully manufacture these batches according to product specifications. It is important for our business for Catalent and Avid to (i) retain their status as cGMP-approved manufacturing facilities; (ii) successfully scale up bulk rHuPH20 production; and/or (iii) manufacture the bulk rHuPH20 required by us and our collaborators for use in our proprietary and collaboration products and product candidates. In addition to supply obligations, Avid and Catalent will also provide support for data and information used in the chemistry, manufacturing and controls sections for FDA and other regulatory filings.
We have a commercial manufacturing and supply agreement with Patheon Manufacturing Services, LLC (Patheon) under which Patheon will provide the final fill and finishing steps in the production process of Hylenex recombinant. Under our commercial services agreement with Patheon, Patheon has agreed to fill and finish Hylenex recombinant product for us until December 31, 2021, subject to further extensions in accordance with the terms of the agreement.

8


Sales, Marketing and Distribution
Hylenex Recombinant
Our commercial activities currently focus on Hylenex recombinant. We have a team of sales specialists that provide hospital and surgery center customers with the information about Hylenex recombinant and information needed to obtain formulary approval for, and support utilization of, Hylenex recombinant. Our commercial activities also include marketing and related services and commercial support services such as commercial operations, managed markets and commercial analytics. We also employ third-party vendors, such as advertising agencies, market research firms and suppliers of marketing and other sales support related services to assist with our commercial activities.
We sell Hylenex recombinant in the U.S. to wholesale pharmaceutical distributors, who sell the product to hospitals and other end-user customers. We engage Integrated Commercialization Solutions (ICS), a division of AmerisourceBergen Specialty Group, a subsidiary of AmerisourceBergen, to act as our exclusive distributor for commercial shipment and distribution of Hylenex recombinant to our customers in the United States. In addition to distribution services, ICS provides us with other key services related to logistics, warehousing, returns and inventory management, contract administration and chargebacks processing and accounts receivable management. In addition, we utilize third parties to perform various other services for us relating to regulatory monitoring, including call center management, adverse event reporting, safety database management and other product maintenance services.
Competition
The pharmaceutical industry is characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary therapeutics. We face competition from a number of sources, some of which may target the same indications as our product or product candidates, including large pharmaceutical companies, smaller pharmaceutical companies, biotechnology companies, academic institutions, government agencies and private and public research institutions, many of which have greater financial resources, drug development experience, sales and marketing capabilities, including larger, well established sales forces, manufacturing capabilities, experience in obtaining regulatory approvals for product candidates and other resources than us. We face competition not only in the commercialization of Hylenex but also for the out-licensing of our ENHANZE technology. Our ENHANZE technology may face increasing competition from alternate approaches and/or emerging technologies to deliver medicines SC. In addition, our collaborators face competition in the commercialization of the product candidates for which the collaborators seek marketing approval from the FDA or other regulatory authorities.
Hylenex Recombinant
Hylenex recombinant is currently the only FDA approved recombinant human hyaluronidase on the market. The competitors for Hylenex recombinant include, but are not limited to, Valeant Pharmaceuticals International, Inc.’s product, Vitrase®, an ovine (ram) hyaluronidase, and Amphastar Pharmaceuticals, Inc.’s product, Amphadase®, a bovine (bull) hyaluronidase. In addition, some commercial pharmacies compound hyaluronidase preparations for institutions and physicians even though compounded preparations are not FDA approved products.
Government Regulations
The FDA and comparable regulatory agencies in foreign countries regulate the manufacture and sale of the pharmaceutical products that we or our partners have developed or that our partners currently are developing. The FDA has established guidelines and safety standards that are applicable to the laboratory and preclinical evaluation and clinical investigation of therapeutic products and stringent regulations that govern the manufacture and sale of these products. The process of obtaining regulatory approval for a new therapeutic product usually requires a significant amount of time and substantial resources.
Regulatory obligations continue post-approval and include the reporting of adverse events when a drug is utilized in the broader patient population. Promotion and marketing of drugs is also strictly regulated, with penalties imposed for violations of FDA regulations, the Lanham Act and other federal and state laws, including the federal anti-kickback statute.

9


We currently intend to continue to seek, through our collaborators, approval to market products and product candidates in foreign countries, which may have regulatory processes that differ materially from those of the FDA. Our partners may rely upon independent consultants to seek and gain approvals to market our proposed products in foreign countries or may rely on other pharmaceutical or biotechnology companies to license our proposed products. We cannot guarantee that approvals to market any of our partners’ products can be obtained in any country. Approval to market a product in any one foreign country does not necessarily indicate that approval can be obtained in other countries.
From time to time, legislation is drafted and introduced in Congress that could significantly change the statutory provisions governing the approval, manufacturing and marketing of drug products. In addition, FDA regulations and guidance are often revised or reinterpreted by the agency or reviewing courts in ways that may significantly affect our business and development of our partners’ product candidates and any products that we may commercialize. It is impossible to predict whether additional legislative changes will be enacted, or FDA regulations, guidance or interpretations changed, or what the impact of any such changes may be.
Information about our Executive Officers
Information concerning our executive officers, including their names, ages and certain biographical information can be found in Part III, Item 10, Directors, Executive Officers and Corporate Governance. This information is incorporated by reference into Part I of this report.
Employees
As of February 14, 2020, we had 132 full-time employees. None of our employees are unionized and we believe our employee relations to be good.

10


Item 1A.Risk Factors
Risks Related To Our Business
We recently initiated a significant corporate restructuring including a substantial reduction in our workforce to reduce our operating costs. As a result of this initiative, we may experience a disruption to our business operations. In addition, we may not realize all of the expected cost savings from our corporate restructuring which could have an adverse effect on our business or results of operations.
In November 2019, we announced that our HALO-301 Phase 3 clinical study evaluating investigational new drug PEGPH20 as a first-line therapy for treatment of patients with metastatic pancreatic cancer failed to reach the primary endpoint of overall survival. As a result, we have closed all ongoing oncology clinical studies including all development activities for PEGPH20. In connection with this decision, we have initiated a significant restructuring, including a staff reduction of approximately 55 percent of our total workforce. This restructuring and staff reduction is aimed at reducing operating costs and focusing our resources on our ENHANZE technology and Hylenex. Our restructuring initiative and staff reduction may cause disruption to our business operations. For example, the reduction in force has resulted in the loss of a number of long-term employees including some members of the senior management team, the loss of institutional knowledge and expertise and the reallocation and combination of certain roles and responsibilities across the organization, all of which could adversely affect our operations. In addition, we may not be able to effectively realize all the cost savings anticipated by the restructuring initiative and reduction-in-force and we may incur unanticipated charges or make cash payments as a result of our restructuring initiative that were not previously contemplated which could result in an adverse effect on our business or results of operations.
Our inability to attract, hire and retain key management and scientific personnel could negatively affect our business.
Our success depends on the performance of key management and scientific employees with relevant experience. We depend substantially on our ability to hire, train, motivate and retain high quality personnel, especially our scientists and management team which may be adversely affected by our recent restructuring and reduction in force. Particularly in view of the small number of employees on our staff to manage our alliance programs and key functions, if we are unable to retain existing personnel or identify or hire additional personnel, we may not be able to adequately support current and future alliances with strategic collaborators. Our use of domestic and international third-party contractors, consultants and staffing agencies also subjects us to potential co-employment liability claims.
Furthermore, if we were to lose key management personnel, we would likely lose some portion of our institutional knowledge and technical know-how, potentially causing a substantial disruption or delay in one or more of our partnered development programs until adequate replacement personnel could be hired and trained. In addition, we do not have key person life insurance policies on the lives of any of our employees which would help cover the cost of associated with the loss of key employees.
We have generated only limited revenues to date and we have a history of net losses and negative cash flows.
Relative to expenses incurred in our operations, we have generated only limited revenues from product sales, royalties, licensing fees, milestone payments, bulk rHuPH20 supply payments and research reimbursements to date. Through December 31, 2019, we have incurred aggregate net losses of $603.7 million. Although we expect to achieve sustainable profitability beginning the second quarter of 2020, unexpected declines in revenues and increases in expenses could inhibit our ability to achieve and sustain profitability.
If partners’ product candidates do not receive and maintain regulatory approvals, or if approvals are not obtained in a timely manner, such failure or delay would substantially impair our ability to generate revenues.
Approval from the FDA or equivalent health authorities is necessary to manufacture and market pharmaceutical products in the U.S. and the other countries in which we anticipate doing business have similar requirements. The process for obtaining FDA and other regulatory approvals is extensive, time-consuming, risky and costly, and there is no guarantee that the FDA or other regulatory bodies will approve any applications that may be filed with respect to any of our partners’ product candidates, or that the timing of any such approval will be appropriate for the desired product launch schedule for a product candidate. We and our collaborators attempt to provide guidance as to the timing for the filing and acceptance of such regulatory approvals, but such filings and approvals may not occur when we or our collaborators expect, or at all. The FDA or other foreign regulatory agency may refuse or delay approval of our partners’ product candidates for failure to collect sufficient clinical or animal safety data and require our collaborators to conduct additional clinical or animal safety studies which may cause lengthy delays and increased costs to our partners’ development programs. Any such issues associated with rHuPH20 could have an adverse impact on future development of our partners’ products which include rHuPH20, future sales of Hylenex recombinant, or our ability to maintain our existing collaborations or enter into new collaborations.

11


We and our collaborators may not be successful in obtaining approvals for any additional potential products in a timely manner, or at all. Refer to the risk factor titled “Our collaboration product candidates may not receive regulatory approvals or their development may be delayed for a variety of reasons, including delayed or unsuccessful clinical trials, regulatory requirements or safety concerns” for additional information relating to the approval of product candidates.
Additionally, even with respect to products which have been approved for commercialization, in order to continue to manufacture and market pharmaceutical products, we or our collaborators must maintain our regulatory approvals. If we or any of our collaborators are unsuccessful in maintaining our regulatory approvals, our ability to generate revenues would be adversely affected.
Use of Hylenex and the products and product candidates of our partners’ could be associated with side effects or adverse events.
As with most pharmaceutical products, use of Hylenex and the products and product candidates of our collaborators could be associated with side effects or adverse events which can vary in severity (from minor reactions to death) and frequency (infrequent or prevalent). Side effects or adverse events associated with the use of Hylenex and the products or product candidates of our collaborators may be observed at any time, including in clinical trials or when a product is commercialized, and any such side effects or adverse events may negatively affect our or our collaborators’ ability to obtain or maintain regulatory approval or market such products and product candidates. Side effects such as toxicity or other safety issues associated with the use of Hylenex and the products and product candidates of our collaborators could require us or our collaborators to perform additional studies or halt development or commercialization of these products and product candidates or expose us to product liability lawsuits which will harm our business. For example, we experienced a clinical hold on patient enrollment and dosing in our phase 2 study of PEGPH20 in patients with PDA (a discontinued program), which was not resolved until we implemented steps to address an observed possible difference in TE event rates between the arms of the study. We or our collaborators may be required by regulatory agencies to conduct additional animal or human studies regarding the safety and efficacy of our pharmaceutical products or product candidates which we have not planned or anticipated. Furthermore, there can be no assurance that we or our collaborators will resolve any issues related to any product or product candidate side effects or adverse events to the satisfaction of the FDA or any regulatory agency in a timely manner or ever, which could harm our business, prospects and financial condition.
If our contract manufacturers are unable to manufacture and supply to us bulk rHuPH20 or other raw materials in the quantity and quality required by us or our collaborators for use in Hylenex or our partners’ products and product candidates, our partners’ product development and commercialization efforts could be delayed or stopped and our collaborations could be damaged.
We have existing supply agreements with contract manufacturing organizations Avid Bioservices, Inc. (Avid) and Catalent Indiana LLC (Catalent) to produce bulk rHuPH20. These manufacturers each produce bulk rHuPH20 under cGMP for use in Hylenex recombinant, and for use in collaboration products and product candidates.Catalent currently produces bulk rHuPH20 for use in Hylenex recombinant and collaboration product candidates. In addition to supply obligations, Avid and Catalent will also provide support for the chemistry, manufacturing and controls sections for FDA and other regulatory filings. We rely on their ability to successfully manufacture bulk rHuPH20 according to product specifications. If either Avid or Catalent: (i) is unable to retain its status as an FDA approved manufacturing facility; (ii) is unable to otherwise successfully scale up bulk rHuPH20 production to meet corporate or regulatory authority quality standards; or (iii) fails to manufacture and supply bulk rHuPH20 in the quantity and quality required by us or our collaborators for use in Hylenex and collaboration products and product candidates for any other reason, our business will be adversely affected. In addition, a significant change in such parties’ or other third party manufacturers’ business or financial condition could adversely affect their abilities to fulfill their contractual obligations to us. We have not established, and may not be able to establish, favorable arrangements with additional bulk rHuPH20 manufacturers and suppliers of the ingredients necessary to manufacture bulk rHuPH20 should the existing manufacturers and suppliers become unavailable or in the event that our existing manufacturers and suppliers are unable to adequately perform their responsibilities. We have attempted to mitigate the impact of a potential supply interruption through the establishment of excess bulk rHuPH20 inventory where possible, but there can be no assurances that this safety stock will be maintained or that it will be sufficient to address any delays, interruptions or other problems experienced by Avid and/or Catalent. Any delays, interruptions or other problems regarding the ability of Avid and/or Catalent to supply bulk rHuPH20 or the ability of other third party manufacturers, to supply other raw materials or ingredients necessary to produce our products on a timely basis could: (i) cause the delay of our partners’ clinical trials or otherwise delay or prevent the regulatory approval of our partners’ product candidates; (ii) delay or prevent the effective commercialization of Hylenex or collaboration products and product candidates; and/or (iii) cause us to breach contractual obligations to deliver bulk rHuPH20 to our collaborators. Such delays would likely damage our relationship with our collaborators, and they would have a material adverse effect on royalties and thus our business and financial condition. Additionally, we rely on third parties to manufacture, prepare, fill, finish, package, store and ship our product and partners’ product candidates on our behalf. If the third parties we identify fail to perform their obligations, the progress of partners’ clinical trials could be delayed or even suspended and the commercialization of approved product candidates could be delayed or prevented.

12


If we or any party to a key collaboration agreement fail to perform material obligations under such agreement, or if a key collaboration agreement, is terminated for any reason, our business could significantly suffer.
We have entered into multiple collaboration agreements under which we may receive significant future payments in the form of milestone payments, target designation fees, maintenance fees and royalties. We are heavily dependent on our collaborators to develop and commercialize product candidates subject to our collaborations in order for us to realize any financial benefits from these collaborations. Our collaborators may not devote the attention and resources to such efforts that we would ourselves, change their clinical development plans, promotional efforts or simultaneously develop and commercialize products in competition to those products we have licensed to them. Any of these actions could not be visible to us immediately and could negatively impact our ability to forecast and our ability to achieve the benefits and revenue we receive from such collaboration. In addition, in the event that a party fails to perform under a key collaboration agreement, or if a key collaboration agreement is terminated, the reduction in anticipated revenues could negatively impact our operations and our commercialization efforts for Hylenex. In addition, the termination of a key collaboration agreement by one or more of our collaborators could have a material adverse impact our ability to enter into additional collaboration agreements with new collaborators on favorable terms, if at all. In certain circumstances, the termination of a key collaboration agreement would require us to revise our corporate strategy going forward and reevaluate the applications and value of our technology.
Hylenex and our partners’ products and product candidates rely on the rHuPH20 enzyme, and any adverse development regarding rHuPH20 could substantially impact multiple areas of our business, including current and potential collaborations, as well as any proprietary programs.
rHuPH20 is a key technological component of Hylenex and our ENHANZE technology and most of our collaboration products and product candidates, including the current and future products and product candidates under our ENHANZE collaborations. If there is an adverse development for rHuPH20 (e.g., an adverse regulatory determination relating to rHuPH20, if we are unable to obtain sufficient quantities of rHuPH20, if we are unable to obtain or maintain material proprietary rights to rHuPH20 or if we discover negative characteristics of rHuPH20), multiple areas of our business, including current and potential collaborations, as well as proprietary programs would be substantially impacted. For example, elevated anti-rHuPH20 antibody titers were detected in the registration trial for Baxalta’s HYQVIA product as well as in a former collaborator’s product in a Phase 2 clinical trial with rHuPH20, but have not been associated, in either case, with any adverse events. We monitor for antibodies to rHuPH20 in our collaboration and proprietary programs, and although we do not believe at this time that the incidence of non-neutralizing anti-rHuPH20 antibodies in either the HYQVIA program or the former collaborator’s program will have a significant impact on our proprietary product and our partners’ product and product candidates, there can be no assurance that there will not be other such occurrences in the foregoing programs or that concerns regarding these antibodies will not also be raised by the FDA or other health authorities in the future, which could result in delays or discontinuations of our Hylenex commercialization activities, the development or commercialization activities of our partners, or deter our entry into additional collaborations with third parties.
We routinely evaluate, and may modify, our business strategy and our strategic focus to only a few fields or applications of our technology which may increase the risk for potential negative impact from adverse developments.
We routinely evaluate our business strategy, and may modify this strategy in the future in light of our assessment of unmet medical needs, growth potential, resource requirements, regulatory issues, competition, risks and other factors. As a result of these strategic evaluations, we may focus our resources and efforts on one or a few programs or fields and may suspend or reduce our efforts on other programs and fields. For example, in the fourth quarter of 2019, we decided to focus our resources on our ENHANZE technology and our commercial product, Hylenex. By focusing on these areas, we increase the potential impact on us if one of those partner programs does not successfully complete clinical trials, achieve commercial acceptance or meet expectations regarding sales and revenue. Our decision to focus on one or a few programs may also reduce the value of programs that are no longer within our principal strategic focus, which could impair our ability to pursue collaborations or other strategic alternatives for those programs we are not pursuing.
Our collaboration product candidates may not receive regulatory approvals or their development may be delayed for a variety of reasons, including delayed or unsuccessful clinical trials, regulatory requirements or safety concerns.
Clinical testing of pharmaceutical products is a long, expensive and uncertain process, and the failure or delay of a clinical trial can occur at any stage, including the patient enrollment stage. Even if initial results of preclinical and nonclinical studies or clinical trial results are promising, our collaborators may obtain different results in subsequent trials or studies that fail to show the desired levels of dose safety and efficacy, or our collaborators may not, obtain applicable regulatory approval for a variety of other reasons. Preclinical, nonclinical, and clinical trials for collaboration product candidates could be unsuccessful, which would delay or preclude regulatory approval and commercialization of the product candidates. In the U.S. and other jurisdictions, regulatory approval can be delayed, limited or not granted for many reasons, including, among others:
•
during the course of clinical studies, the final data may differ from initial reported data, and clinical results may not meet prescribed endpoints for the studies or otherwise provide sufficient data to support the efficacy of our collaborators’ product candidates;

13


•
clinical and nonclinical test results may reveal inferior pharmacokinetics, side effects, adverse events or unexpected safety issues associated with the use of our collaborators’ product candidates;
•
regulatory review may not find that the data from preclinical testing and clinical trials justifies approval;
•
regulatory authorities may require that our partners change their studies or conduct additional studies which may significantly delay or make continued pursuit of approval commercially unattractive;
•
a regulatory agency may reject partner trial data or disagree with their interpretations of either clinical trial data or applicable regulations;
•
a regulatory agency may require additional safety monitoring and reporting through Risk Evaluation and Mitigation Strategies or conditions to assure safe use programs;
•
a partner may decide to not pursue regulatory approval for such a product;
•
a regulatory agency may not approve our manufacturing processes or facilities, or the processes or facilities of our collaborators, our contract manufacturers or our raw material suppliers;
•
a regulatory agency may identify problems or other deficiencies in our existing manufacturing processes or facilities, or the existing processes or facilities of our collaborators, our contract manufacturers or our raw material suppliers;
•
a regulatory agency may change its formal or informal approval requirements and policies, act contrary to previous guidance, adopt new regulations or raise new issues or concerns late in the approval process; or
•
a partner product candidate may be approved only for indications that are narrow or under conditions that place the product at a competitive disadvantage, which may limit the sales and marketing activities for such product candidate or otherwise adversely impact the commercial potential of a product.
If a collaboration product candidate is not approved in a timely fashion or obtained on commercially viable terms, or if development of any product candidate is terminated due to difficulties or delays encountered in the regulatory approval process, it could have a material adverse impact on our business, and we would become more dependent on the development of other collaboration product candidates and/or our ability to successfully acquire other technologies. There can be no assurances that any collaboration product candidate will receive regulatory approval in a timely manner, or at all. There can be no assurance that partners will be able to gain clarity as to the FDA’s requirements or that the requirements may be satisfied in a commercially feasible way, in which case our ability to enter into collaborations with third parties or explore other strategic alternatives to exploit an opportunity will be limited or may not be possible.
We anticipate that certain collaboration products will be marketed, and perhaps manufactured, in foreign countries. The process of obtaining regulatory approvals in foreign countries is subject to delay and failure for the reasons set forth above, as well as for reasons that vary from jurisdiction to jurisdiction. The approval process varies among countries and jurisdictions and can involve additional testing. The time required to obtain approval may differ from that required to obtain FDA approval. Foreign regulatory agencies may not provide approvals on a timely basis, if at all. Approval by the FDA does not ensure approval by regulatory authorities in other countries or jurisdictions, and approval by one foreign regulatory authority does not ensure approval by regulatory authorities in other foreign countries or jurisdictions or by the FDA.
Our third party collaborators are responsible for providing certain proprietary materials that are essential components of our collaboration products and product candidates, and any failure to supply these materials could delay the development and commercialization efforts for these collaboration products and product candidates and/or damage our collaborations.
Our development and commercialization collaborators are responsible for providing certain proprietary materials that are essential components of our collaboration products and product candidates. For example, Roche is responsible for producing the Herceptin and MabThera required for its subcutaneous products and Baxalta is responsible for producing the GAMMAGARD LIQUID for its product HYQVIA. If a collaborator, or any applicable third party service provider of a collaborator, encounters difficulties in the manufacture, storage, delivery, fill, finish or packaging of the collaboration product or product candidate or component of such product or product candidate, such difficulties could (i) cause the delay of clinical trials or otherwise delay or prevent the regulatory approval of collaboration product candidates; and/or (ii) delay or prevent the effective commercialization of collaboration products. Such delays could have a material adverse effect on our business and financial condition.
If we or our collaborators fail to comply with regulatory requirements applicable to promotion, sale and manufacturing of approved products, regulatory agencies may take action against us or them, which could significantly harm our business.
Any approved products, along with the manufacturing processes, post-approval clinical data, labeling, advertising and promotional activities for these products, are subject to continual requirements and review by the FDA, state and foreign regulatory bodies. Regulatory authorities subject a marketed product, its manufacturer and the manufacturing facilities to continual review and periodic inspections. We, our collaborators and our respective contractors, suppliers and vendors, will be subject to ongoing regulatory requirements, including complying with regulations and laws regarding advertising, promotion and sales of drug products, required submissions of safety and other post-market information and reports, registration requirements, cGMP regulations (including requirements relating to quality control and quality assurance, as well as the corresponding maintenance of records and documentation), and the requirements regarding the distribution of samples to physicians and recordkeeping requirements. Regulatory agencies may change existing requirements or adopt new requirements or policies. We, our collaborators

14


and our respective contractors, suppliers and vendors, may be slow to adapt or may not be able to adapt to these changes or new requirements.
In particular, regulatory requirements applicable to pharmaceutical products make the substitution of suppliers and manufacturers costly and time consuming. We have minimal internal manufacturing capabilities and are, and expect to be in the future, entirely dependent on contract manufacturers and suppliers for the manufacture of our products and for their active and other ingredients. The disqualification of these manufacturers and suppliers through their failure to comply with regulatory requirements could negatively impact our business because the delays and costs in obtaining and qualifying alternate suppliers (if such alternative suppliers are available, which we cannot assure) could delay our partners’ clinical trials or otherwise inhibit our or partners’ ability to bring approved products to market, which would have a material adverse effect on our business and financial condition. Likewise, if we, our collaborators and our respective contractors, suppliers and vendors involved in sales and promotion of our products do not comply with applicable laws and regulations, for example off-label or false or misleading promotion, this could materially harm our business and financial condition.
Failure to comply with regulatory requirements may result in any of the following:
•
restrictions on our or our partners’ products or manufacturing processes;
•
warning letters;
•
withdrawal of our or our partners’ products from the market;
•
voluntary or mandatory recall;
•
fines;
•
suspension or withdrawal of regulatory approvals;
•
suspension or termination of any of our partners’ ongoing clinical trials;
•
refusal to permit the import or export of our or our partners’ products;
•
refusal to approve pending applications or supplements to approved applications that we submit;
•
product seizure;
•
injunctions; or
•
imposition of civil or criminal penalties.
We may need to raise additional capital in the future and there can be no assurance that we will be able to obtain such funds.
We may need to raise additional capital in the future to fund our operations and for general corporate purposes if revenues do not occur as expected. Our current cash reserves and expected revenues may not be sufficient for us to fund general operations and conduct our business at the level desired. In addition, if we engage in acquisitions of companies, products or technologies in order to execute our business strategy, we may need to raise additional capital. We may raise additional capital in the future through one or more financing vehicles that may be available to us including (i) new collaborative agreements; (ii) expansions or revisions to existing collaborative relationships; (iii) private financings; (iv) other equity or debt financings; (v) monetizing assets; and/or (vi) the public offering of securities.
If we are required to raise additional capital in the future, it may not be available on favorable financing terms within the time required, or at all. If additional capital is not available on favorable terms when needed, we will be required to raise capital on adverse terms or significantly reduce operating expenses through the restructuring of our operations or deferral of strategic business initiatives. If we raise additional capital through a public offering of securities or equity, a substantial number of additional shares may be issued, which may negatively affect our stock price and these additional shares will dilute the ownership interest of our current investors.
We currently have significant debt and failure by us to fulfill our obligations under the applicable loan agreements may cause the repayment obligations to accelerate.
The aggregate amount of our consolidated indebtedness, net of debt discount, as of December 31, 2019 was $402.6 million, which includes $460.0 million in aggregate principal amount of 1.25% Convertible Senior Notes due 2024 (Convertible Notes) and an outstanding balance on our Royalty-backed Loan of $19.5 million, net of unamortized debt discount of $77.0 million. We currently estimate that the Royalty-backed Loan will be repaid in the second quarter of 2020. We also may incur additional indebtedness in the future.

Our indebtedness may:
•
make it difficult for us to satisfy our financial obligations, including making scheduled principal and interest payments on our indebtedness;
•
limit our ability to borrow additional funds for working capital, capital expenditures, acquisitions or other general corporate purposes;
•
limit our ability to use our cash flow or obtain additional financing for future working capital, capital expenditures, acquisitions, share repurchases or other general business purposes;
•
require us to use a portion of our cash flow from operations to make debt service payments;

15


•
limit our flexibility to plan for, or react to, changes in our business and industry;
•
place us at a competitive disadvantage compared to our less leveraged competitors; and
increase our vulnerability to the impact of adverse economic and industry conditions.
Our ability to make payments on our debt will depend on our future operating performance and ability to generate cash and may also depend on our ability to obtain additional debt or equity financing. It will also depend on financial, business or other factors affecting our operations, many of which are beyond our control. We will need to use cash to pay principal and interest on our debt, thereby reducing the funds available to fund operations, strategic initiatives and working capital requirements. If we are unable to generate sufficient cash to service our debt obligations, an event of default may occur under any of our debt instruments which could result in an acceleration of such debt upon which we may be required to repay all the amounts outstanding under some or all of our debt instruments. Such an acceleration of our debt obligations could harm our financial condition.
The conditional conversion feature of the Convertible Notes, if triggered, may adversely affect our financial condition and operating results.
In the event the conditional conversion feature of the Convertible Notes is triggered, holders of the Convertible Notes will be entitled to convert the notes at any time during specified periods at their option. If one or more holders elect to convert their notes, unless we elect to satisfy our conversion obligation by delivering solely shares of our common stock (other than paying cash in lieu of delivering any fractional share), we would be required to settle a portion or all of our conversion obligation in cash, which could adversely affect our liquidity. Even if holders of the Convertible Notes do not elect to convert their notes, we could be required under applicable accounting rules to reclassify all or a portion of the outstanding principal of the notes as a current rather than long-term liability, which would result in a material reduction of our net working capital.
Conversion of our Convertible Notes may dilute the ownership interest of existing stockholders or may otherwise depress the price of our common stock.
The conversion of some or all of our Convertible Notes, to the extent we deliver shares upon conversion, will dilute the ownership interests of existing stockholders. Any sales in the public market of the Convertible Notes or our common stock issuable upon conversion of the Convertible Notes could adversely affect prevailing market prices of our common stock. In addition, the existence of the Convertible Notes may encourage short selling by market participants because the conversion of the Convertible Notes could be used to satisfy short positions, or anticipated conversion of the Convertible Notes into shares of our common stock could depress the price of our common stock.
The accounting method for the Convertible Notes could have a material effect on our reported financial results.
Pursuant to Financial Accounting Standards Board Accounting Standards Codification Subtopic 470-20, Debt with Conversion and Other Options (“ASC 470-20”), an entity must separately account for the liability and equity components of convertible debt instruments whose conversion may be settled entirely or partially in cash (such as our Convertible Notes) in a manner that reflects the issuer’s economic interest cost for non-convertible debt. The liability component of our Convertible Notes was initially be valued at the fair value of a similar debt instrument that does not have an associated equity component and was reflected as a liability in our consolidated balance sheet. The equity component of the Convertible Notes was included in the additional paid-in capital section of our stockholders’ equity on our consolidated balance sheet, and the value of the equity component was treated as original issue discount for purposes of accounting for the debt component. This original issue discount will be amortized to non-cash interest expense over the term of the notes, and we will record a greater amount of non-cash interest expense in current periods as a result of this amortization. Accordingly, we will report lower net income in our financial results because ASC 470-20 will require the interest expense associated with the notes to include both the current period’s amortization of the debt discount and the notes’ coupon interest, which could adversely affect our reported or future financial results, the trading price of our common stock and the trading price of the Convertible Notes.
In addition, under certain circumstances, convertible debt instruments (such as the notes) that may be settled entirely or partly in cash are currently accounted for utilizing the treasury stock method, the effect of which is that the shares issuable upon conversion of the notes are not included in the calculation of diluted net income per share except to the extent that the conversion value of the notes exceeds their principal amount. Under the treasury stock method, for diluted earnings per share purposes, the transaction is accounted for as if the number of shares of common stock that would be necessary to settle such excess, if we elected to settle such excess in shares, are issued. We cannot be sure that the accounting standards in the future will continue to permit the use of the treasury stock method. If we are unable or otherwise elect not to use the treasury stock method in accounting for the shares issuable upon conversion of the notes, then our diluted earnings per share would be adversely affected. For example, the FASB recently published an exposure draft proposing to amend these accounting standards to eliminate the treasury stock method for convertible instruments and instead require application of the ‘‘if-converted’’ method. Under that method, if it is adopted, diluted net income (loss) per share would generally be calculated assuming that all the notes were converted solely into shares of common stock at the beginning of the reporting period. The application of the ‘‘if-converted’’ method may reduce our reported diluted net income per share.

16


If collaboration product candidates are approved for marketing but do not gain market acceptance resulting in commercial performance below that which was expected or projected, our business may suffer and we may not be able to fund future operations.
Assuming that existing or future collaboration product candidates obtain the necessary regulatory approvals for commercial sale, a number of factors may affect the market acceptance of these newly-approved products, including, among others:
•
the degree to which the use of these products is restricted by the approved product label;
•
the price of these products relative to other therapies for the same or similar treatments;
•
the extent to which reimbursement for these products and related treatments will be available from third party payors including government insurance programs (Medicare and Medicaid) and private insurers;
•
the introduction of generic or biosimilar competitors to these products;
•
the perception by patients, physicians and other members of the health care community of the effectiveness and safety of these products for their prescribed treatments relative to other therapies for the same or similar treatments;
•
the ability and willingness of our collaborators to fund sales and marketing efforts; and
•
the effectiveness of the sales and marketing efforts of our collaborators.
If these collaboration products do not gain market acceptance resulting in commercial performance below that which was expected or projected, the royalties we expect to receive from these products will be diminished which could harm our ability to fund future operations, including conduct acquisitions, execute our planned share repurchases, or affect our ability to use funds for other general corporate purposes and cause our business to suffer.
In addition, our partners’ product candidates will be restricted to the labels approved by FDA and applicable regulatory bodies, and these restrictions may limit the marketing and promotion of the ultimate products. If the approved labels are restrictive, the sales and marketing efforts for these collaboration products may be negatively affected.
Our ability to license our ENHANZE technology to our collaboration partners depends on the validity of our patents and other proprietary rights.  
Patents and other proprietary rights are essential to our business. Our success will depend in part on our ability to obtain and maintain patent protection for our inventions, to preserve our trade secrets and to operate without infringing the proprietary rights of third parties. We have multiple patents and patent applications throughout the world pertaining to our recombinant human hyaluronidase and methods of use and manufacture, including an issued U.S. patent which expires in 2027 and an issued European patent which expires in 2024, which we believe cover the products and product candidates under our existing collaborations, and Hylenex. Although we believe our patent filings represent a barrier to entry for potential competitors looking to utilize these hyaluronidases, upon expiration of our patents other pharmaceutical companies may (if they do not infringe our other patents) seek to compete with us by developing, manufacturing and selling biosimilars to the active drug ingredient in our ENHANZE technology used by our collaboration partners in combination with their products. Any such loss of patent protection or proprietary rights could lead to a reduction or loss of revenues, incentivize one or more of our key ENHANZE collaboration partners to terminate their relationship with us and impact our ability to enter into new collaboration and license agreements.
Developing and marketing pharmaceutical products for human use involves significant product liability risks for which we currently have limited insurance coverage.
The testing, marketing and sale of pharmaceutical products involves the risk of product liability claims by consumers and other third parties. Although we maintain product liability insurance coverage, product liability claims can be high in the pharmaceutical industry, and our insurance may not sufficiently cover our actual liabilities. If product liability claims were to be made against us, it is possible that the liabilities may exceed the limits of our insurance policy, or our insurance carriers may deny, or attempt to deny, coverage in certain instances. If a lawsuit against us is successful, then the insurance coverage may not be sufficient and could materially and adversely affect our business and financial condition. Furthermore, various distributors of pharmaceutical products require minimum product liability insurance coverage before purchase or acceptance of products for distribution. Failure to satisfy these insurance requirements could impede our ability to achieve broad distribution of our proposed products, and higher insurance requirements could impose additional costs on us. In addition, since many of our collaboration product candidates include the pharmaceutical products of a third party, we run the risk that problems with the third party pharmaceutical product will give rise to liability claims against us.

17


Our operations might be interrupted by the occurrence of a natural disaster or other catastrophic event.
Our operations, including laboratories, offices and other research facilities, are located in multiple buildings in San Diego, California. We depend on our facilities and on our collaborators, contractors and vendors for the continued operation of our business. Natural disasters or other catastrophic events, interruptions in the supply of natural resources, political and governmental changes, wildfires and other fires, floods, explosions, actions of animal rights activists, earthquakes and civil unrest could disrupt our operations or those of our collaborators, contractors and vendors. Even though we believe we carry commercially reasonable business interruption and liability insurance, and our contractors may carry liability insurance that protect us in certain events, we may suffer losses as a result of business interruptions that exceed the coverage available under our and our contractors’ insurance policies or for which we or our contractors do not have coverage. Any natural disaster or catastrophic event could have a significant negative impact on our operations and financial results. Moreover, any such event could delay our partners’ research and development programs.
If our collaborators do not achieve projected development, clinical, or regulatory goals in the timeframes publicly announced or otherwise expected, the commercialization of our collaboration products may be delayed and, as a result, our stock price may decline, and we may face lawsuits relating to such declines.
From time to time, our collaborators may publicly articulate the estimated timing for the accomplishment of certain scientific, clinical, regulatory and other product development goals. The accomplishment of any goal is typically based on numerous assumptions, and the achievement of a particular goal may be delayed for any number of reasons both within and outside of our and our collaborators’ control. If scientific, regulatory, strategic or other factors cause a collaboration partner to not meet a goal, regardless of whether that goal has been publicly articulated or not, our stock price may decline rapidly. Stock price declines may also trigger direct or derivative shareholder lawsuits. As with any litigation proceeding, the eventual outcome of any legal action is difficult to predict. If any such lawsuits occur, we will incur expenses in connection with the defense of these lawsuits, and we may have to pay substantial damages or settlement costs in connection with any resolution thereof. Although we have insurance coverage against which we may claim recovery against some of these expenses and costs, the amount of coverage may not be adequate to cover the full amount or certain expenses and costs may be outside the scope of the policies we maintain. In the event of an adverse outcome or outcomes, our business could be materially harmed from depletion of cash resources, negative impact on our reputation, or restrictions or changes to our governance or other processes that may result from any final disposition of the lawsuit. Moreover, responding to and defending pending litigation significantly diverts management’s attention from our operations.
In addition, the consistent failure to meet publicly announced milestones may erode the credibility of our management team with respect to future milestone estimates.
Future acquisitions could disrupt our business and harm our financial condition.
In order to augment our product pipeline or otherwise strengthen our business, we may decide to acquire additional businesses, products and technologies. As we have limited experience in evaluating and completing acquisitions, our ability as an organization to make such acquisitions is unproven. Acquisitions could require significant capital infusions and could involve many risks, including, but not limited to, the following:
•
we may have to issue additional convertible debt or equity securities to complete an acquisition, which would dilute our stockholders and could adversely affect the market price of our common stock;
•
an acquisition may negatively impact our results of operations because it may require us to amortize or write down amounts related to goodwill and other intangible assets, or incur or assume substantial debt or liabilities, or it may cause adverse tax consequences, substantial depreciation or deferred compensation charges;
•
we may encounter difficulties in assimilating and integrating the business, products, technologies, personnel or operations of companies that we acquire;
•
certain acquisitions may impact our relationship with existing or potential collaborators who are competitive with the acquired business, products or technologies;
•
acquisitions may require significant capital infusions and the acquired businesses, products or technologies may not generate sufficient value to justify acquisition costs;
•
we may take on liabilities from the acquired company such as debt, legal liabilities or business risk which could be significant;
•
an acquisition may disrupt our ongoing business, divert resources, increase our expenses and distract our management;
•
acquisitions may involve the entry into a geographic or business market in which we have little or no prior experience; and
•
key personnel of an acquired company may decide not to work for us.
If any of these risks occurred, it could adversely affect our business, financial condition and operating results. There is no assurance that we will be able to identify or consummate any future acquisitions on acceptable terms, or at all. If we do pursue any acquisitions, it is possible that we may not realize the anticipated benefits from such acquisitions or that the market will not view such acquisitions positively.

18


Cyberattacks, security breaches or system breakdowns may disrupt our operations and harm our operating results and reputation.
We and our partners are subject to increasingly sophisticated attempts to gain unauthorized access to our information technology storage and access systems and are devoting resources to protect against such intrusion. Cyberattacks could render us or our partners unable to utilize key systems or access important data needed to operate our business. The wrongful use, theft, deliberate sabotage or any other type of security breach with respect to any of our or any of our vendors and partners’ information technology storage and access systems could result in the breakdown or other service interruption, or the disruption of our ability to use such systems or disclosure or dissemination of proprietary and confidential information that is electronically stored, including intellectual property, trade secrets, financial information, regulatory information, strategic plans, sales trends and forecasts, litigation materials or personal information belonging to us, our staff, our patients, customers and/or other business partners which could result in a material adverse impact on our business, operating results and financial condition. We continue to invest in monitoring, and other security and data recovery measures to protect our critical and sensitive data and systems.  However, these may not be adequate to prevent or fully recover systems or data from all breakdowns, service interruptions, attacks or breaches of our systems. Furthermore, any physical break-in or trespass of our facilities could result in the misappropriation, theft, sabotage or any other type of security breach with respect to our proprietary and confidential information, including research or clinical data or damage to our research and development equipment and assets. Such adverse effects could be material and irrevocable to our business, operating results, financial condition and reputation.

Risks Related To Ownership of Our Common Stock
Our stock price is subject to significant volatility.
We participate in a highly dynamic industry which often results in significant volatility in the market price of common stock irrespective of company performance. The high and low sales prices of our common stock during the twelve months ended December 31, 2019 were $19.73 and $13.84, respectively. We expect our stock price to continue to be subject to significant volatility and, in addition to the other risks and uncertainties described elsewhere in this Annual Report on Form 10-K and all other risks and uncertainties that are either not known to us at this time or which we deem to be immaterial, any of the following factors may lead to a significant drop in our stock price:
•
the presence of competitive products to those being developed by our partners;
•
failure (actual or perceived) of our collaborators to devote attention or resources to the development or commercialization of products or product candidates licensed to such collaborator;
•
a dispute regarding our failure, or the failure of one of our third party collaborators, to comply with the terms of a collaboration agreement;
•
the termination, for any reason, of any of our collaboration agreements;
•
the sale of common stock by any significant stockholder, including, but not limited to, direct or indirect sales by members of management or our Board of Directors;
•
the resignation, or other departure, of members of management or our Board of Directors;
•
general negative conditions in the healthcare industry;
•
general negative conditions in the financial markets;
•
the cost associated with obtaining regulatory approval for any of our collaboration product candidates;
•
the failure, for any reason, to secure or defend our intellectual property position;
•
the failure or delay of applicable regulatory bodies to approve our partners’ product candidates;
•
identification of safety or tolerability issues;
•
failure of our partners’ clinical trials to meet efficacy endpoints;
•
suspensions or delays in the conduct of our partners’ clinical trials or securing of regulatory approvals;
•
adverse regulatory action with respect to our and our collaborators’ products and product candidates such as loss of regulatory approval to commercialize such products, clinical holds, imposition of onerous requirements for approval or product recalls;
•
our failure, or the failure of our third party collaborators, to successfully commercialize products approved by applicable regulatory bodies such as the FDA;
•
our failure, or the failure of our third party collaborators, to generate product revenues anticipated by investors;
•
disruptions in our clinical or commercial supply chains, including disruptions caused by problems with a bulk rHuPH20 contract manufacturer or a fill and finish manufacturer for any product or product collaboration candidate;
•
the sale of additional debt and/or equity securities by us;
•
our failure to obtain financing on acceptable terms or at all;
•
a restructuring of our operations.
•
an inability to execute our share repurchase program in the time and manner we expect due to market, business, legal or other considerations; or

19


•
a conversion of the Convertible Notes into shares of our common stock.
Future transactions where we raise capital may negatively affect our stock price.
We are currently a “Well-Known Seasoned Issuer” and may file automatic shelf registration statements at any time with the SEC. Sales of substantial amounts of shares of our common stock or other securities under our current or future shelf registration statements could lower the market price of our common stock and impair our ability to raise capital through the sale of equity securities.
Anti-takeover provisions in our charter documents, the Indenture and Delaware law may make an acquisition of us more difficult.
Anti-takeover provisions in our charter documents, the Indenture and Delaware law may make an acquisition of us more difficult. First, our Board of Directors is classified into three classes of directors. Under Delaware law, directors of a corporation with a classified board may be removed only for cause unless the corporation’s certificate of incorporation provides otherwise. Our amended and restated certificate of incorporation, as amended, does not provide otherwise. In addition, our bylaws limit who may call special meetings of stockholders, permitting only stockholders holding at least 50% of our outstanding shares to call a special meeting of stockholders. Our amended and restated certificate of incorporation does not include a provision for cumulative voting for directors. Under cumulative voting, a minority stockholder holding a sufficient percentage of a class of shares may be able to ensure the election of one or more directors. Finally, our bylaws establish procedures, including advance notice procedures, with regard to the nomination of candidates for election as directors and stockholder proposals.
These provisions in our charter documents may discourage potential takeover attempts, discourage bids for our common stock at a premium over market price or adversely affect the market price of, and the voting and other rights of the holders of, our common stock. These provisions could also discourage proxy contests and make it more difficult for stockholders to elect directors other than the candidates nominated by our board of directors.
Further, in connection with our recent Convertible Notes issuance, we entered into an indenture, dated as of November 18, 2019, (“Indenture”) with The Bank of New York Mellon Trust Company, N.A., as trustee. Certain provisions in the Indenture could make it more difficult or more expensive for a third party to acquire us. For example, if a takeover would constitute a fundamental change, holders of the Convertible Notes will have the right to require us to repurchase their Convertible Notes in cash. In addition, if a takeover constitutes a make-whole fundamental change, we may be required to increase the conversion rate for holders who convert their Convertible Notes in connection with such takeover. In either case, and in other cases, our obligations under the Convertible Notes and the Indenture could increase the cost of acquiring us or otherwise discourage a third party from acquiring us or removing incumbent management
In addition, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, which may prohibit large stockholders from consummating a merger with, or acquisition of, us.
These provisions may deter an acquisition of us that might otherwise be attractive to stockholders.

20


Risks Related to Our Industry
Our partners’ products must receive regulatory approval before they can be sold, and compliance with the extensive government regulations is expensive and time consuming and may result in the delay or cancellation of collaboration product sales, introductions or modifications.
Extensive industry regulation has had, and will continue to have, a significant impact on our business. All pharmaceutical companies, including ours, are subject to extensive, complex, costly and evolving regulation by the health regulatory agencies including the FDA (and with respect to controlled drug substances, the U.S. Drug Enforcement Administration (DEA)) and equivalent foreign regulatory agencies and state and local/regional government agencies. The Federal Food, Drug and Cosmetic Act, the Controlled Substances Act and other domestic and foreign statutes and regulations govern or influence the testing, manufacturing, packaging, labeling, storing, recordkeeping, safety, approval, advertising, promotion, sale and distribution of our product and our partners’ products and product candidates. We are dependent on receiving FDA and other governmental approvals, including regulatory approvals in jurisdictions outside the United States, prior to manufacturing, marketing and shipping our products. Consequently, there is always a risk that the FDA or other applicable governmental authorities, including those outside the United States, will not approve our partners’ products or may impose onerous, costly and time-consuming requirements such as additional clinical or animal testing. Regulatory authorities may require that our partners’ change our studies or conduct additional studies, which may significantly delay or make continued pursuit of approval commercially unattractive to our partners. For example, the approval of Baxalta’s HYQVIA BLA was delayed by the FDA until we and Baxalta provided additional preclinical data sufficient to address concerns regarding non-neutralizing antibodies to rHuPH20 that were detected in the registration trial. Although these antibodies have not been associated with any known adverse clinical effects, and the HYQVIA BLA was ultimately approved by the FDA, the FDA or other foreign regulatory agency may, at any time, halt our and our collaborators’ development and commercialization activities due to safety concerns. In addition, even if our product or partners’ products are approved, regulatory agencies may also take post-approval action limiting or revoking our or our partners’ ability to sell these products. Any of these regulatory actions may adversely affect the economic benefit we may derive from our product or our partners’ products and therefore harm our financial condition.
Under certain of these regulations, in addition to our partners, we and our contract suppliers and manufacturers are subject to periodic inspection of our or their respective facilities, procedures and operations and/or the testing of products by the FDA, the DEA and other authorities, which conduct periodic inspections to confirm that we and our contract suppliers and manufacturers are in compliance with all applicable regulations. The FDA also conducts pre-approval and post-approval reviews and plant inspections to determine whether our systems, or our contract suppliers’ and manufacturers’ processes, are in compliance with cGMP and other FDA regulations. If our partners, we, or our contract suppliers, fail these inspections, our partners may not be able to commercialize their products in a timely manner without incurring significant additional costs, or at all.
In addition, the FDA imposes a number of complex regulatory requirements on entities that advertise and promote pharmaceuticals including, but not limited to, standards and regulations for direct-to-consumer advertising, off-label promotion, industry-sponsored scientific and educational activities, and promotional activities involving the Internet.
We may be subject, directly or indirectly, to various broad federal and state healthcare laws. If we are unable to comply, or have not fully complied, with such laws, we could face civil, criminal and administrative penalties, damages, monetary fines, disgorgement, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings and curtailment or restructuring of our operations, any of which could adversely affect our ability to operate.
Our business operations and activities may be directly, or indirectly, subject to various broad federal and state healthcare laws, including without limitation, anti-kickback laws, the Foreign Corrupt Practices Act (FCPA), false claims laws, civil monetary penalty laws, data privacy and security laws, tracing and tracking laws, as well as transparency laws regarding payments or other items of value provided to healthcare providers. These laws may restrict or prohibit a wide range of business activities, including, but not limited to, research, manufacturing, distribution, pricing, discounting, marketing and promotion and other business arrangements. These laws may impact, among other things, our current activities with principal investigators and research subjects, as well as sales, marketing and education programs. Many states have similar healthcare fraud and abuse laws, some of which may be broader in scope and may not be limited to items or services for which payment is made by a government health care program.
Efforts to ensure that our business arrangements will comply with applicable healthcare laws may involve substantial costs. While we have adopted a healthcare corporate compliance program, it is possible that governmental and enforcement authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law interpreting applicable fraud and abuse or other healthcare laws. If our operations or activities are found to be in violation of any of the laws described above or any other governmental regulations that apply to us, we may be subject to, without limitation, civil, criminal and administrative penalties, damages, monetary fines, disgorgement, possible exclusion from participation in Medicare, Medicaid

21


and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings and curtailment or restructuring of our operations, any of which could adversely affect our ability to operate.
In addition, any sales of products outside the U.S. will also likely subject us to the FCPA and foreign equivalents of the healthcare laws mentioned above, among other foreign laws.
We may be required to initiate or defend against legal proceedings related to intellectual property rights, which may result in substantial expense, delay and/or cessation of the development and commercialization of our products.
We primarily rely on patents to protect our intellectual property rights. The strength of this protection, however, is uncertain. For example, it is not certain that:
•
we will be able to obtain patent protection for our products and technologies;
•
the scope of any of our issued patents will be sufficient to provide commercially significant exclusivity for our products and technologies;
•
others will not independently develop similar or alternative technologies or duplicate our technologies and obtain patent protection before we do; and
•
any of our issued patents, or patent pending applications that result in issued patents, will be held valid, enforceable and infringed in the event the patents are asserted against others.
We currently own or license several patents and also have pending patent applications applicable to rHuPH20 and other proprietary materials. There can be no assurance that our existing patents, or any patents issued to us as a result of our pending patent applications, will provide a basis for commercially viable products, will provide us with any competitive advantages, or will not face third party challenges or be the subject of further proceedings limiting their scope or enforceability. Any weaknesses or limitations in our patent portfolio could have a material adverse effect on our business and financial condition. In addition, if any of our pending patent applications do not result in issued patents, or result in issued patents with narrow or limited claims, this could result in us having no or limited protection against generic or biosimilar competition against our product candidates which would have a material adverse effect on our business and financial condition.
We may become involved in interference proceedings in the U.S. Patent and Trademark Office, or other proceedings in other jurisdictions, to determine the priority, validity or enforceability of our patents. In addition, costly litigation could be necessary to protect our patent position.
We also rely on trademarks to protect the names of our products (e.g. Hylenex recombinant). We may not be able to obtain trademark protection for any proposed product names we select. In addition, product names for pharmaceutical products must be approved by health regulatory authorities such as the FDA in addition to meeting the legal standards required for trademark protection and product names we propose may not be timely approved by regulatory agencies which may delay product launch. In addition, our trademarks may be challenged by others. If we enforce our trademarks against third parties, such enforcement proceedings may be expensive.
We also rely on trade secrets, unpatented proprietary know-how and continuing technological innovation that we seek to protect with confidentiality agreements with employees, consultants and others with whom we discuss our business. Disputes may arise concerning the ownership of intellectual property or the applicability or enforceability of these agreements, and we might not be able to resolve these disputes in our favor.
In addition to protecting our own intellectual property rights, third parties may assert patent, trademark or copyright infringement or other intellectual property claims against us. If we become involved in any intellectual property litigation, we may be required to pay substantial damages, including but not limited to treble damages, attorneys’ fees and costs, for past infringement if it is ultimately determined that our products infringe a third party’s intellectual property rights. Even if infringement claims against us are without merit, defending a lawsuit takes significant time, may be expensive and may divert management’s attention from other business concerns. Further, we may be stopped from developing, manufacturing or selling our products until we obtain a license from the owner of the relevant technology or other intellectual property rights. If such a license is available at all, it may require us to pay substantial royalties or other fees.
Patent protection for protein-based therapeutic products and other biotechnology inventions is subject to a great deal of uncertainty, and if patent laws or the interpretation of patent laws change, our competitors may be able to develop and commercialize products based on our discoveries.
Patent protection for protein-based therapeutic products is highly uncertain and involves complex legal and factual questions. In recent years, there have been significant changes in patent law, including the legal standards that govern the scope of protein and biotechnology patents. Standards for patentability of full-length and partial genes, and their corresponding proteins, are changing. Recent court decisions have made it more difficult to obtain patents, by making it more difficult to satisfy the patentable subject matter requirement and the requirement of non-obviousness, have decreased the availability of injunctions against infringers, and have increased the likelihood of challenging the validity of a patent through a declaratory judgment action. Taken together,

22


these decisions could make it more difficult and costly for us to obtain, license and enforce our patents. In addition, the Leahy-Smith America Invents Act (HR 1249) was signed into law in September 2011, which among other changes to the U.S. patent laws, changes patent priority from “first to invent” to “first to file,” implements a post-grant opposition system for patents and provides for a prior user defense to infringement. These judicial and legislative changes have introduced significant uncertainty in the patent law landscape and may potentially negatively impact our ability to procure, maintain and enforce patents to provide exclusivity for our products.
There also have been, and continue to be, policy discussions concerning the scope of patent protection awarded to biotechnology inventions. Social and political opposition to biotechnology patents may lead to narrower patent protection within the biotechnology industry. Social and political opposition to patents on genes and proteins and recent court decisions concerning patentability of isolated genes may lead to narrower patent protection, or narrower claim interpretation, for isolated genes, their corresponding proteins and inventions related to their use, formulation and manufacture. Patent protection relating to biotechnology products is also subject to a great deal of uncertainty outside the U.S., and patent laws are evolving and undergoing revision in many countries. Changes in, or different interpretations of, patent laws worldwide may result in our inability to obtain or enforce patents, and may allow others to use our discoveries to develop and commercialize competitive products, which would impair our business.
If third party reimbursement and customer contracts are not available, Hylenex and our partners’ products may not be accepted in the market resulting in commercial performance below that which was expected or projected.
Our ability to earn sufficient returns on Hylenex and our partners’ ability to earn sufficient returns on their products will depend in part on the extent to which reimbursement for these products and related treatments will be available from government health administration authorities, private health insurers, managed care organizations and other healthcare providers.
Third-party payors are increasingly attempting to limit both the coverage and the level of reimbursement of new drug products to contain costs. Consequently, significant uncertainty exists as to the reimbursement status of newly approved healthcare products. Third party payors may not establish adequate levels of reimbursement for the products that we and our partners commercialize, which could limit their market acceptance and result in a material adverse effect on our revenues and financial condition.
Customer contracts, such as with group purchasing organizations and hospital formularies, will often not offer contract or formulary status without either the lowest price or substantial proven clinical differentiation. If, for example, Hylenex is compared to animal-derived hyaluronidases by these entities, it is possible that neither of these conditions will be met, which could limit market acceptance and result in a material adverse effect on our revenues and financial condition.
The rising cost of healthcare and related pharmaceutical product pricing has led to cost containment pressures as well as changes in federal coverage and reimbursement policies and practices that could cause us and our partners to sell our products at lower prices, and impact access to our and our partners’ products, resulting in less revenue to us.
Any of our proprietary or collaboration products that have been, or in the future are, approved by the FDA may be purchased or reimbursed by state and federal government authorities, private health insurers and other organizations, such as health maintenance organizations and managed care organizations. Such third party payors increasingly challenge pharmaceutical product pricing. The trend toward managed healthcare in the U.S., the growth of such organizations, and various legislative proposals and enactments to reform healthcare and government insurance programs, including the Medicare Prescription Drug Modernization Act of 2003, could significantly influence the manner in which pharmaceutical products are prescribed and purchased, resulting in lower prices and/or a reduction in demand. Such cost containment measures and healthcare reforms could adversely affect our ability to sell our product and our partners’ ability to sell their products.
In the U.S., our business may be impacted by changes in federal reimbursement policy resulting from executive actions, federal regulations, or federal demonstration projects. For example, in May 2018, the U.S. presidential administration released a drug pricing “blueprint” and requested public comment on an array of policy ideas intended to increase competition, improve the negotiating power of the federal government, reduce drug prices and lower patient out-of-pocket costs. This blueprint includes a number of policy ideas with the potential to significantly impact, whether individually or collectively, our industry. Such proposals include moving coverage and reimbursement for Medicare Part B drugs into Medicare Part D, and instituting a competitive acquisition program for Part B drugs in which competing third-party vendors take on the financial risk of acquiring drugs and billing Medicare.
Since that time, the federal administration and/or agencies, such as CMS, have announced a number of demonstration projects, recommendations and proposals to implement various elements described in the drug pricing blueprint. CMS, the federal agency responsible for administering Medicare and overseeing state Medicaid programs and Health Insurance Marketplaces, has substantial power to implement policy changes or demonstration projects that can quickly and significantly affect how drugs, including our products, are covered and reimbursed. For example, in October 2018, President Trump announced that CMS was evaluating a pilot program proposed to initially cover fifty percent of spending on Part B single-source drugs referred to as the “International

23


Price Index” that would, among other things, set the Medicare payment amount for such single-source drugs to more closely align with international drug prices.
In this dynamic environment, we are unable to predict which or how many federal policy, legislative or regulatory changes may ultimately be enacted, to the extent federal government initiatives decrease or modify the coverage or reimbursement available for our or our partners’ products, limit or impact our decisions regarding the pricing of biopharmaceutical products or otherwise reduce the use of our or our partners’ U.S. products, such actions could have a material adverse effect on our business and results of operations.
Furthermore, individual states are considering proposed legislation and have become increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access, importation from other countries and bulk purchasing. Legally mandated price controls on payment amounts by third party payors or other restrictions could negatively and materially impact our revenues and financial condition. We anticipate that we will encounter similar regulatory and legislative issues in most other countries outside the U.S.
We also face risks relating to the reporting of pricing data that affects the reimbursement of and discounts provided for our products. Government price reporting regulations are complex and may require a manufacturer to update certain previously submitted data. If our submitted pricing data are incorrect, we may become subject to substantial fines and penalties or other government enforcement actions, which could have a material adverse effect on our business and results of operations. In addition, as a result of restating previously reported price data, we also may be required to pay additional rebates and provide additional discounts.
We face intense competition and rapid technological change that could result in the development of products by others that are competitive with or superior to our proprietary and collaboration products, including those under development.
Our proprietary and collaboration products have numerous competitors in the U.S. and abroad including, among others, major pharmaceutical and specialized biotechnology firms, universities and other research institutions that have developed competing products. Many of these competitors have substantially more resources and product development, manufacturing and marketing experience and capabilities than we do. The competitors for Hylenex recombinant include, but are not limited to, Valeant Pharmaceuticals International, Inc.’s FDA-approved product, Vitrase®, an ovine (ram) hyaluronidase, and Amphastar Pharmaceuticals, Inc.’s product, Amphadase®, a bovine (bull) hyaluronidase. For our ENHANZE technology, such competitors may include major pharmaceutical and specialized biotechnology firms. These competitors may develop technologies and products that are more effective, safer, or less costly than our current or future proprietary and collaboration products and product candidates or that could render our and our partners’ products, technologies and product candidates obsolete or noncompetitive.
Item 1B.
Unresolved Staff Comments
None.
Item 2.
Properties
Our administrative offices and research facilities are currently located in San Diego, California. During 2019 we leased an aggregate of approximately 80,000 square feet of office and research space, which we plan to reduce to approximately 48,000 square feet subsequent to our November 2019 restructuring. We believe our facilities are adequate for our current and near-term needs.
Item 3.
Legal Proceedings
From time to time, we may be involved in disputes, including litigation, relating to claims arising out of operations in the normal course of our business. Any of these claims could subject us to costly legal expenses and, while we generally believe that we have adequate insurance to cover many different types of liabilities, our insurance carriers may deny coverage or our policy limits may be inadequate to fully satisfy any damage awards or settlements. If this were to happen, the payment of any such awards could have a material adverse effect on our consolidated results of operations and financial position. Additionally, any such claims, whether or not successful, could damage our reputation and business. We currently are not a party to any legal proceedings, the adverse outcome of which, in management’s opinion, individually or in the aggregate, would have a material adverse effect on our consolidated results of operations or financial position.
Item 4.
Mine Safety Disclosures
Not applicable.

24


PART II
Item 5.
Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
Market Information
Our common stock is listed on the NASDAQ Global Select Market under the symbol “HALO.” As of February 14, 2020, we had approximately 19,877 stockholders of record and beneficial owners of our common stock.
Dividends
We have never declared or paid any dividends on our common stock. We currently intend to retain available cash for funding operations and stock repurchases; therefore, we do not expect to pay any dividends on our common stock in the foreseeable future. In addition, the provisions of our borrowing arrangements limit, among other things, our ability to pay dividends and make certain other payments. Any future determination to pay dividends on our common stock will be at the discretion of our board of directors and will depend upon, among other factors, our results of operations, financial condition, capital requirements, contract restrictions, business prospects and other factors our board of directors may deem relevant.
Purchase of Equity Securities by the Issuer
In November, 2019, we announced that the Board of Directors authorized the initiation of a capital return program to repurchase up to $550.0 million of outstanding common stock a three-year period.
In November 2019, we repurchased approximately 8.1 million shares of common stock concurrently with the Convertible Note in privately negotiated transactions for $143.1 million and 0.4 million shares of common stock in open market purchases for $6.9 million. Also in November 2019, we entered into an Accelerated Share Repurchase (ASR) agreement with Bank of America to repurchase $50.0 million of common stock. At inception, pursuant to the agreement, we took an initial delivery of 2.1 million shares. In February 2020, we finalized the transaction and received an additional 0.5 million shares.

Period
 
Total Number of Shares Purchased
 
Weighted-Average Price paid per share
 
Total Number of Shares Purchased as Part of Publicly Announced Programs
 
Approximate Dollar Value of Shares That May Yet Be purchased under the Programs
October 1, 2019 through October 31, 2019
 
—

 
$
—

 
—

 
$
—

November 1, 2019 through November 30, 2019
 
8,464,093

 
$
17.72

 
8,464.093

 
$
400,002

December 1, 2019 through December 31, 2019
 
—

 
$
—

 
—

 
$
—

 
 
 
 
 
 
 
 
 
Accelerated share repurchases
 
2,629,754

 
$
19.01

 
2,629,754

 
$
350,002

 
 
 
 
 
 
 
 
 
Total
 
11,093,847

 

 
11,093.847

 


25


Stock Performance Graph and Cumulative Total Return
Notwithstanding any statement to the contrary in any of our previous or future filings with the SEC, the following information relating to the price performance of our common stock shall not be deemed to be “filed” with the SEC or to be “soliciting material” under the Securities Exchange Act of 1934, as amended, or the Exchange Act, and it shall not be deemed to be incorporated by reference into any of our filings under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent we specifically incorporate it by reference into such filing.
The graph below compares Halozyme Therapeutics, Inc.’s cumulative five-year total shareholder return on common stock with the cumulative total returns of the NASDAQ Composite Index and the NASDAQ Biotechnology Index. The graph tracks the performance of a $100 investment in our common stock and in each of the indexes (with the reinvestment of all dividends) from December 31, 2014 to December 31, 2019. The historical stock price performance included in this graph is not necessarily indicative of future stock price performance.

perfrormancegraph.jpg

26


 
12/31/2014
12/31/2015
12/31/2016
12/31/2017
12/31/2018
12/31/2019
Halozyme Therapeutics, Inc.
$100
$180
$102
$210
$152
$184
NASDAQ Composite
$100
$107
$116
$151
$147
$200
NASDAQ Biotechnology
$100
$112
$88
$107
$97
$122
Item 6.
Selected Financial Data
The selected consolidated financial data set forth below as of December 31, 2019 and 2018, and for the years ended December 31, 2019, 2018 and 2017, are derived from our audited consolidated financial statements included elsewhere in this report. This information should be read in conjunction with those consolidated financial statements, the notes thereto, and with “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” The selected consolidated financial data set forth below as of December 31, 2017, 2016 and 2015, and for the years ended December 31, 2016 and 2015, are derived from our audited consolidated financial statements that are contained in reports previously filed with the SEC, not included herein.
Summary Financial Information
 
 
Year Ended December 31,
Statement of Operations Data:
 
2019
 
2018
 
2017
 
2016
 
2015
 
 
(in thousands, except for per share amounts)
Total revenues
 
$
195,992

 
$
151,862

 
$
316,613

 
$
146,691

 
$
135,057

Net (loss) income
 
$
(72,240
)
 
$
(80,330
)
 
$
62,971

 
$
(103,023
)
 
$
(32,231
)
Net (loss) income per share, basic
 
$
(0.50
)
 
$
(0.56
)
 
$
0.46

 
$
(0.81
)
 
$
(0.25
)
Net (loss) income per share, diluted
 
$
(0.50
)
 
$
(0.56
)
 
$
0.45

 
$
(0.81
)
 
$
(0.25
)
Shares used in computing net (loss) income per share, basic
 
144,329

 
143,599

 
136,419

 
127,964

 
126,704

Shares used in computing net (loss) income per share, diluted
 
144,329

 
143,599

 
139,068

 
127,964

 
126,704

 
  
 
As of December 31,
Balance Sheet Data:
 
2019
 
2018
 
2017
 
2016
 
2015
 
 
(in thousands)
Cash and cash equivalents and available-for-sale marketable securities
 
$
421,262

 
$
354,526

 
$
469,214

 
$
204,981

 
$
108,339

Working capital
 
$
457,799

 
$
278,488

 
$
379,044

 
$
201,947

 
$
109,315

Total assets
 
$
565,874

 
$
440,248

 
$
519,945

 
$
261,515

 
$
181,789

Deferred revenue
 
$
5,259

 
$
9,255

 
$
60,865

 
$
44,618

 
$
53,223

Long-term debt, net
 
$
383,045

 
$
34,874

 
$
125,140

 
$
199,228

 
$
27,971

Total liabilities
 
$
474,109

 
$
191,361

 
$
311,579

 
$
293,996

 
$
138,790

Stockholders’ equity (deficit)
 
$
91,765

 
$
248,887

 
$
208,366

 
$
(32,481
)
 
$
42,999



27


Item 7.
Management’s Discussion and Analysis of Financial Condition and Results of Operation
In addition to historical information, the following discussion contains forward-looking statements that are subject to risks and uncertainties. Actual results may differ substantially from those referred to herein due to a number of factors, including but not limited to risks described in the Part I, Item 1A, Risks Factors, and elsewhere in this Annual Report. References to “Notes” are Notes included in our Notes to Consolidated Financial Statements.
Overview
Halozyme Therapeutics Inc. is a biopharma technology platform company that provides innovative and disruptive solutions with the goal of improving patient experience and outcomes. Our proprietary enzyme rHUPH20 is used to facilitate the delivery of injected drugs and fluids. We license our technology to biopharmaceutical companies to collaboratively develop products that combine our ENHANZE® drug delivery technology with the collaborators’ proprietary compounds. 
Our approved product and our collaborators’ approved products and product candidates are based on rHuPH20, our patented recombinant human hyaluronidase enzyme. rHuPH20 is the active ingredient in our first commercially approved product, Hylenex® recombinant, and it works by breaking down hyaluronan (or HA), a naturally occurring carbohydrate that is a major component of the extracellular matrix in tissues throughout the body such as skin and cartilage. This temporarily increases dispersion and absorption allowing for improved subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other large therapeutic molecules, as well as small molecules and fluids. We refer to the application of rHuPH20 to facilitate the delivery of other drugs or fluids as our ENHANZE® Drug Delivery Technology (ENHANZE). We license the ENHANZE technology to form collaborations with biopharmaceutical companies that develop or market drugs requiring or benefiting from injection via the subcutaneous route of administration. In the development of proprietary intravenous (IV) drugs combined with our ENHANZE technology, data have been generated supporting the potential for ENHANZE to reduce treatment burden, as a result of shorter duration of subcutaneous (SC) administration. ENHANZE may enable fixed-dose SC dosing compared to weight-based dosing required for IV administration, and potentially allow for lower rates of infusion related reactions. Lastly, certain proprietary drugs co-formulated with ENHANZE have been granted additional exclusivity, extending the patent life of the product beyond the one of the proprietary IV drug.
We currently have ENHANZE collaborations with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc. (Roche), Baxalta US Inc. and Baxalta GmbH (now members of the Takeda group of companies, following the acquisition of Shire plc by Takeda Pharmaceutical Company Limited in January 2019) (Baxalta), Pfizer Inc. (Pfizer), Janssen Biotech, Inc. (Janssen), AbbVie, Inc. (AbbVie), Eli Lilly and Company (Lilly), Bristol-Myers Squibb Company (BMS), Alexion Pharma Holding (Alexion) and ARGENX BVBA (argenx). We receive royalties from two of these collaborations, including royalties from sales of one product from the Baxalta collaboration and two products from the Roche collaboration. Future potential revenues from the sales and/or royalties of our approved products, product candidates, and ENHANZE collaborations will depend on the ability of Halozyme and our collaborators to develop, manufacture, secure and maintain regulatory approvals for approved products and product candidates and commercialize product candidates.
On November 4, 2019, we announced that our HALO-301 Phase 3 clinical study evaluating PEGPH20 in combination with ABRAXANE and gemcitabine as a first-line therapy for treatment of patients with metastatic pancreatic cancer failed to reach the primary endpoint of overall survival. The study failed to demonstrate an improvement in overall survival compared to gemcitabine and nab-paclitaxel alone (11.2 months median overall survival compared to 11.5 months, HR=1.00, p=0.9692). Due to the results of the study, we halted development activities for PEGPH20, closed our oncology operations and implemented an organizational restructuring to focus our operations on ENHANZE.
We closed all ongoing oncology clinical studies including the Phase 3 clinical testing for PEGPH20 with ABRAXANE and gemcitabine in stage IV pancreatic ductal adenocarcinoma (“PDA”) (HALO-301) and the Phase 1b/2 clinical testing for PEGPH20 with Tecentriq in patients with cholangiocarcinoma and gall bladder cancer (HALO 110-101/MATRIX). The Roche -Genentech sponsored MORPHEUS PDA and gastric cancer studies closed the arms containing PEGPH20 to enrollment. All patients who were treated in PEGPH20 arms are off PEGPH20 treatment and are in follow up, per study protocol.


28


Our 2019 and recent key events are as follows:
•
In November 2019, we entered into an Accelerated Share Repurchase (ASR) agreement with Bank of America to repurchase $50.0 million of common stock. At inception we took an initial delivery of 2.1 million shares. In February 2020, we finalized the transaction and received an additional 0.5 million shares.
•
In November 2019, we completed the sale of $460.0 million aggregate principal amount of Convertible Senior Notes due 2024.
•
In November 2019, we announced the initiation of a capital return program, to repurchase up to $550.0 million of our outstanding common stock over a three-year period.
•
In November 2019, following the results of our HALO-301 study, we announced strategic actions to reposition the Company with a focus solely on ENHANZE. Headcount will be reduced by approximately 55% or approximately 160 positions. Upon completion of the restructuring and after recording all related one-time charges, we anticipate becoming a sustainably profitable company, beginning in the second quarter of 2020.
•
In November 2019, we announced that our HALO-301 study, a Phase 3 clinical study evaluating PEGylated recombinant human hyaluronidase (PEGPH20) in combination with ABRAXANE® (nab-paclitaxel) and gemcitabine as a first-line therapy for treatment of patients with metastatic pancreatic cancer failed to reach the primary endpoint of overall survival. The study failed to demonstrate an improvement in overall survival compared to gemcitabine and nab-paclitaxel alone (11.2 months median overall survival compared to 11.5 months, HR=1.00, p=0.9692).
•
In October 2019, Roche nominated a new undisclosed target to be studied using ENHANZE technology, triggering a $10 million milestone payment.
•
In October 2019, BMS initiated a Phase 1 study for Relatlimab in combination with nivolumab and ENHANZE Technology.
•
In September 2019, Roche announced that the global Phase 3 FeDeriCa study met its primary endpoint. The FeDeriCa study investigated a fixed-dose combination of pertuzumab (Perjeta®) and trastuzumab (Herceptin®) for subcutaneous administration using Halozyme's ENHANZE drug delivery technology in combination with intravenous chemotherapy. The study results demonstrated non-inferior levels of Perjeta in the blood (pharmacokinetics) compared to standard intravenous (IV) infusion of Perjeta plus Herceptin and chemotherapy in patients with HER2-positive early breast cancer. The study also demonstrated that the safety profile of the fixed dose subcutaneous combination of Perjeta and Herceptin was consistent with the safety profile of Perjeta and Herceptin administered intravenously.
•
In August 2019, Roche initiated a Phase 1 study evaluating OCREVUS® (ocrelizumab) with ENHANZE Technology in subjects with multiple sclerosis.
•
In July 2019, Janssen announced that it submitted a Biological License Application (BLA) to the U.S. Food and Drug Administration (FDA) and an extension application to the European Medicines Agency (EMA) for the subcutaneous delivery of DARZALEX (daratumumab) for patients with multiple myeloma. Janssen’s regulatory submissions follow the announcement of positive results from its phase 3 COLUMBA study, which investigated subcutaneously administered DARZALEX in comparison to intravenous DARZALEX in patients with relapsed or refractory multiple myeloma.
•
In July 2019, argenx dosed the first subject in a phase 1 clinical trial evaluating the safety, pharmacokinetics and pharmacodynamics of efgartigimod (ARGX-113), using ENHANZE technology, triggering a $5.0 million milestone payment.
•
In June 2019, we announced a Cooperative Research and Development Agreement (CRADA) with the National Institute of Allergy and Infectious Diseases’ Vaccine Research Center (VRC), part of National Institute of Health, enabling the VRC’s use of ENHANZE technology to develop subcutaneous formulations of broadly neutralizing antibodies (bnAbs) against HIV for HIV treatment.
•
In May 2019, argenx nominated a second target to be studied using ENHANZE technology, a human complement factor C2 associated with the product candidate ARGX-117, which is being developed to treat severe autoimmune diseases, triggering a $10.0 million payment.

29


•
In February 2019, we announced that Genentech, a member of the Roche Group, received approval from the FDA for Herceptin Hylecta™ (trastuzumab and hyaluronidase-oysk), a co-formulation of trastuzumab and rHuPH20 marketed as Herceptin SC outside of the U.S. Herceptin Hylecta is approved for the treatment of certain people with HER2-positive early breast cancer and is a ready-to-use formulation that can be administered in two to five minutes, compared to 30 to 90 minutes for intravenous trastuzumab. In April 2019, Roche made Herceptin Hylecta available in the U.S.
•
In February 2019, Janssen’s development partner, Genmab, announced positive Phase 3 trial results from the COLUMBA study evaluating subcutaneous DARZALEX® in comparison to DARZALEX IV in patients with relapsed and refractory multiple myeloma. DARZALEX SC (utilizing ENHANZE technology) was found to be non-inferior to DARZALEX IV with regard the co-primary endpoints of Overall Response Rate and Maximum Trough concentration.
•
In February 2019, we entered into an agreement with argenx for the right to develop and commercialize one exclusive target, the human neonatal Fc receptor FcRn, which includes argenx's lead asset efgartigimod (ARGX-113), and an option to select two additional targets using our ENHANZE technology for an upfront payment of $30.0 million. We will receive payments of $10.0 million per target for future target nominations and potential milestone payments of up to $160.0 million per target, subject to the achievement of specific development, regulatory and sales-based milestones. We will receive mid-single digit royalties on sales of commercialized products.














30


Results of Operations
Comparison of Years Ended December 31, 2019 and 2018
Royalties – Royalty revenue was $69.9 million in 2019 compared to $79.0 million in 2018 . The decrease was mainly driven by lower sales of Herceptin SC by Roche, partially offset by higher sales of RITUXAN HYCELA in the U.S. by Roche and higher sales of HyQvia by Baxalta. In general, we expect royalty revenue to decline in the near term prior to our next ENHANZE partner product launch, primarily attributable to the ongoing impact from biosimilars in Europe.
Product Sales, Net – Product sales, net were as follows (in thousands):
 
 
Year Ended December 31,
 
 
2019
 
2018
 
Dollar Change
Percentage Change
Sales of bulk rHuPH20:
 
 
 
 
 
 
 
Janssen
 
$
31,956

 
$
2,510

 
29,446

1,173
%
Roche
 
6,963

 
6,767

 
196

3
%
Baxalta
 
5,657

 
1,820

 
3,837

211
%
Other
 
3,709

 
1,632

 
2,077

127
%
Sales of ENHANZE drug product
 
768

 
460

 
308

67
%
Sales of Hylenex
 
16,995

 
15,045

 
1,950

13
%
Total product sales, net
 
$
66,048

 
$
28,234

 
$
37,814

134
%
Product sales, net increased $37.8 million in 2019 compared to 2018, primarily due to an increase in the sale of bulk rHuPH20 to Janssen, in addition to an increase in sales of bulk rHuPH20 to Baxalta and an increase in sales of Hylenex. We expect that product sales of bulk rHuPH20 and ENHANZE drug product will fluctuate in future periods based on the needs of our collaborators. We expect that future product sales of Hylenex to be flat as we experience modest market growth offset by competition for market share.
Revenues Under Collaborative Agreements – Revenues under collaborative agreements were as follows (in thousands):
 
 
Year Ended December 31,
 
 
2019
 
2018
 
Dollar Change
Percentage Change
Upfront license fees, license fees for the election of additional targets, event-based payments, license maintenance fees and amortization of deferred upfront and other license fees:
 
 
 
 
 
 
 
argenx
 
$
45,000

 
—

 
$
45,000

100
 %
Roche
 
10,000

 
31,000

 
(21,000
)
(68
)%
Other
 
3,500

 
11,336

 
(7,836
)
(69
)%
Subtotal
 
58,500

 
42,336

 
16,164

38
 %
Reimbursements for research and development services:
 
1,545

 
2,311

 
(766
)
(33
)%
Total revenues under collaborative agreements
 
$
60,045

 
$
44,647

 
$
15,398

34
 %
Revenue from license fees increased $16.2 million in 2019, compared to 2018 mainly due to $45.0 million recognized in connection with the argenx Collaboration in 2019, offset by a reduction of milestones earned from other collaboration agreements. Revenue from upfront licenses fees, license fees for the election of additional targets, license maintenance fees and other license fees and event-based payments vary from period to period based on our ENHANZE collaboration activity. We expect these revenues to continue to fluctuate in future periods based on our collaborators’ ability to meet various clinical and regulatory milestones set forth in such agreements and our abilities to obtain new collaborative agreements.


31


Revenue from reimbursements for research and development services decreased in 2019, compared to the same period in 2018 mainly due to a decrease in services provided to Janssen and Roche. Research and development services rendered by us on behalf of our collaborators are at the request of the collaborators; therefore, the amount and timing of future revenues related to reimbursable research and development services is uncertain.
Cost of Product Sales –Cost of product sales were $45.5 million in 2019 compared to $10.1 million in 2018. The increase of $35.4 million in cost of product sales was mainly due to an increase in sales of bulk rHuPH20 to Janssen. There were $1.5 million of costs of bulk rHuPH20 and ENHANZE drug product sales in 2019 that were previously expensed as research and development.
Research and Development – Research and development expenses consist of external costs, salaries and benefits and allocation of facilities and other overhead expenses related to research manufacturing, clinical trials, preclinical and regulatory activities. Research and development expenses incurred were as follows (in thousands):
 
 
Year Ended December 31,
 
 
 
2019
 
2018
 
Dollar Change
Percentage Change
Programs
 
 
 
 
 
 
 
PEGPH20
 
$
103,150

 
131,064

 
$
(27,914
)
(21
)%
Restructuring
 
17,201

 
—

 
17,201

100
 %
ENHANZE collaborations and rHuPH20 platform
 
18,896

 
17,242

 
1,654

10
 %
Other
 
1,584

 
1,946

 
(362
)
(19
)%
Total research and development expenses
 
$
140,831

 
$
150,252

 
$
(9,421
)
(6
)%
Research and development expenses relating to our PEGPH20 programs for 2019 decreased by 21%, compared to the same period in 2018, primarily due to decreased clinical trial activities resulting from the completion of enrollment of HALO-301 in December 2018 and decreased clinical trial activities related to the close out of the HALO-202 study and the HALO 107-101 study, partially offset by an increase in clinical trial activities in the HALO 110-101/MATRIX study. On November 4, 2019, we announced that the HALO-301 clinical study failed to reach the primary endpoint of overall survival. As a result, we halted development activities for PEGPH20, closed our oncology operations and began the close out process for all our clinical trials. We began to implement an organizational restructuring to focus our operations solely on ENHANZE, which will result in a reduction in research and development expenses in the near term. In the fourth quarter of 2019 we incurred restructuring and other one-time charges of $17.2 million, of which $12.0 million related to personnel costs and $5.2 million related to asset impairments and contract cancellations. Refer to Note 13 to the Financial Statements for further details on the organizational restructuring.
Research and development expenses relating to our ENHANZE collaborations and our rHuPH20 platform for 2019 increased by 10%, compared to 2018, primarily due to increased costs to support new partners and targets related to our ENHANZE collaboration activity, partially offset by a decrease in support for one-time partner research and development projects. We expect research and development expenses relating to our ENHANZE collaborations and our rHuPH20 platform to increase in the near term as the rHuPH20 platform is burdened with a higher allocation of overhead costs. The rHuPH20 platform includes research, development and manufacturing expenses related to our proprietary rHuPH20 enzyme. These expenses were not designated to a specific program at the time the expenses were incurred.
Selling, General and Administrative – Selling, general and administrative (SG&A) expenses were $77.3 million in 2019 compared to $60.8 million in 2018. The increase of $16.5 million, or 27%, was primarily due to an increase in compensation expense, including stock compensation, and an increase in commercial expenses related to market research and educational activities as we prepared for a potential commercial launch of PEGPH20. On November 4, 2019, we announced that the HALO-301 clinical study failed to reach the primary endpoint of overall survival. As a result, we halted development activities for PEGPH20, closed our oncology operations and began to implement an organizational restructuring to focus our operations solely on ENHANZE, which will result in a reduction in commercialization activities and compensation expense in the near term. In the fourth quarter of 2019 we incurred restructuring and other one-time charges of $11.2 million, of which $7.5 million related to personnel costs

32


and $3.7 million related to asset impairments and contract cancellations. Refer to Note 13 to the Financial Statements for further details on the organizational restructuring.
Interest Expense – Interest expense was $11.6 million in 2019 compared to $18.0 million in 2018. The decrease of $6.4 million was primarily due to a decrease in the Royalty-backed Loan principal balance, offset by an increase in $0.7 million of interest expense related to the Convertible Notes.
Income Taxes – Income tax benefit was $11 thousand for 2019, compared to income tax expense of $0.5 million for 2018 due to a decrease in estimated state taxes. The 2018 amount was comprised primarily of state income tax. The U.S. federal AMT was eliminated via the Tax Cuts and Jobs Act that was enacted on December 22, 2017. The AMT credit carryovers will be used to offset regular tax liability for any taxable year beginning after 2017. If not utilized before 2022, any remaining AMT credit carryforward amount is fully refundable. The remaining AMT credit carryforward of $1.7 million was recognized as a deferred tax asset at December 31, 2018 as realization is certain. For the year ended December 31, 2018, we generated taxable income in the U.S., which was offset by utilizing net operating losses carried forward from earlier years.
Comparison of Years Ended December 31, 2018 and 2017
For discussion related to changes in financial condition and the results of operations for fiscal year 2018 compared to fiscal year 2017, refer to Part II - Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2018, which was filed with the SEC on February 21, 2019.
Liquidity and Capital Resources
Our principal sources of liquidity are our existing cash, cash equivalents and available-for-sale marketable securities. As of December 31, 2019, we had cash, cash equivalents and marketable securities of $421.3 million. On November 4, 2019, we announced a significant workforce reduction and our intention to solely focus on ENHANZE. Upon completion of the restructuring and after recording all related one-time charges, we anticipate becoming a sustainably profitable company, beginning in the second quarter of 2020.
We believe that our current cash, cash equivalents and marketable securities will be sufficient to fund our operations for at least the next twelve months. We expect to fund our operations going forward with existing cash resources, anticipated revenues from our existing collaborations and cash that we may raise through future transactions. We may raise cash through any one of the following financing vehicles: (i) new collaborative agreements; (ii) expansions or revisions to existing collaborative relationships; (iii) private financings; (iv) other equity or debt financings; (v) monetizing assets; and/or (vi) the public offering of securities.
In May 2017, we completed an underwritten public offering pursuant to which we sold 11.5 million shares of common stock, generating $134.9 million in net proceeds, after deducting underwriting discounts and commissions and other offering expenses. We may, in the future, offer and sell additional equity, debt securities and warrants to purchase any of such securities, either individually or in units to raise capital to raise funds for additional working capital, capital expenditures, share repurchases, acquisitions or for other general corporate purposes.
Cash Flows
Operating Activities
Net cash used in operations was $85.4 million in 2019 compared to $49.5 million in 2018. The $35.9 million increase in utilization of cash in operations was mainly due to an increase in working capital spend in 2019 compared to the corresponding period in the prior year, offset by an increase in cash received related to the argenx license fees of $40.0 million.


33


Investing Activities
Net cash used in investing activities was $5.5 million in 2019 compared to $2.5 million net cash provided by investing activities in 2018. The increase in net cash used in investing activities was primarily due to an increase in purchase of marketable securities in 2019, offset by a decrease in purchase of property and equipment.
Financing Activities
Net cash provided by financing activities was $153.2 million in 2019, compared to net cash used in financing activities of $63.8 million in 2018, mainly due to the net proceeds from issuance of the Convertible Notes of $447.4 million and a $0.5 million increase in net proceeds from the issuance of common stock under equity incentive plans, offset by an increase in the amount long-term debt repayment of $30.6 million due to the settlement of our loan with Oxford Finance and SVB and the repurchase of shares of $200.0 million in 2019.
Share Repurchases
The Board of Directors approved a share repurchase program, pursuant to which we may repurchase our issued and outstanding shares of common stock from time to time. The Company retired the repurchased shares. See Note 8. Stockholders’ Equity, within the notes to the consolidated financial statements for additional information regarding our share repurchases.
Long-Term Debt
Convertible Notes
In November 2019, we completed the sale of $460.0 million in aggregate principal amount of 1.25% Convertible Senior Notes due in 2024 (Convertible Notes) in a private placement to qualified institutional buyers. We received net proceeds from the offering of approximately $447.4 million. We used $200.0 million of the net proceeds from the offering to repurchase shares of our common stock, including approximately $143.1 million to repurchase approximately 8.1 million shares of common stock concurrently with the offering in privately negotiated transactions, $6.9 million in open market purchases and $50.0 million to repurchase approximately 2.6 million shares of common stock through an accelerated share repurchase agreement.
We used approximately $26.1 million of the net proceeds from the offering to repay all outstanding amounts under our loan agreement with Oxford Finance and Silicon Valley Bank and intend to use the remainder of the net proceeds for general corporate purposes, including additional share repurchases subsequent to the offering, and working capital.
The Convertible Notes will pay interest semi-annually in arrears on June 1st and December 1st of each year, beginning on June 1, 2020, at an annual rate of 1.25% and will be convertible into cash, shares of common stock or a combination of cash and shares of common stock, at our election, based on the applicable conversion rate at such time. The Convertible Notes are general unsecured obligations and will rank senior in right of payment to all indebtedness that is expressly subordinated in right of payment to the Convertible Notes, will rank equally in right of payment with all existing and future liabilities that are not so subordinated, will be effectively junior to any secured indebtedness to the extent of the value of the assets securing such indebtedness and will be structurally subordinated to all indebtedness and other liabilities (including trade payables) of our current or future subsidiaries.
Holders may convert their Convertible Notes at their option only in the following circumstances: (1) during any calendar quarter commencing after the calendar quarter ending on March 31, 2020, if the last reported sale price per share of common stock exceeds 130% of the conversion price for each of at least 20 trading days during the 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter; (2) during the five consecutive business days immediately after any five consecutive trading day period (such five consecutive trading day period, the “measurement period”) in which the trading price per $1,000 principal amount of notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price per share of Company’s common stock on such trading day and the conversion rate on such trading day; (3) upon the occurrence of certain corporate events or distributions on Company’s common stock, as described in the offering memorandum; (4) if we call such notes for redemption; and (5) at any time from, and including, June 1, 2024 until the close of business on the scheduled trading day immediately

34


before the maturity date of December 1, 2024. The Convertible Notes will be convertible, regardless of the foregoing circumstances, at any time from, and including, June 1, 2024 until the close of business on the scheduled trading day immediately preceding the maturity date.
Upon conversion, we will pay or deliver, as applicable, cash, shares of common stock or a combination of cash and shares of common stock, at our election. The initial conversion rate for the Convertible Notes will be 41.9208 shares of common stock per $1,000 in principal amount of Convertible Notes, equivalent to a conversion price of approximately $23.85 per share of our common stock. The conversion rate is subject to adjustment as described in the Indenture.
Royalty-backed Loan
In January 2016, through our wholly-owned subsidiary Halozyme Royalty LLC (Halozyme Royalty), we received a $150 million loan (the Royalty-backed Loan) pursuant to a credit agreement (the Credit Agreement) with BioPharma Credit Investments IV Sub, LP and Athyrium Opportunities II Acquisition LP (the Royalty-backed Lenders). Under the terms of the Credit Agreement, Halozyme Therapeutics, Inc. transferred to Halozyme Royalty the right to receive royalty payments from the commercial sales of ENHANZE products owed under the Roche Collaboration and Baxalta Collaboration (Collaboration Agreements). The royalty payments from the Collaboration Agreements will be used to repay the principal and interest on the loan (the Royalty Payments).  The Royalty-backed Loan bears interest at a per annum rate of 8.75% plus the three-month LIBOR rate. The three-month LIBOR rate is subject to a floor of 0.7% and a cap of 1.5%. The interest rate as of December 31, 2019 was 10.25%. The outstanding balance of the Royalty-backed Loan net of unamortized discount as of December 31, 2019 was $19.5 million.
The Credit Agreement provides that none of the Royalty Payments were required to be applied to the Royalty-backed Loan prior to January 1, 2017, 50% of the Royalty Payments were required to be applied to the Royalty-backed Loan between January 1, 2017 and January 1, 2018 and thereafter all Royalty Payments must be applied to the Royalty-backed Loan. However, the amounts available to repay the Royalty-backed Loan are subject to caps of $13.75 million per quarter in 2017, $18.75 million per quarter in 2018, $21.25 million per quarter in 2019 and $22.5 million per quarter in 2020 and thereafter. Amounts available to repay the Royalty-backed Loan will be applied first, to pay interest and second, to repay principal on the Royalty-backed Loan. Any accrued interest that is not paid on any applicable quarterly payment date, as defined, will be capitalized and added to the principal balance of the Royalty-backed Loan on such date. Halozyme Royalty will be entitled to receive and distribute to Halozyme any Royalty Payments that are not required to be applied to the Royalty-backed Loan or which are in excess of the foregoing caps.
The final maturity date of the Royalty-backed Loan will be the earlier of (i) the date when principal and interest is paid in full, (ii) the termination of Halozyme Royalty’s right to receive royalties under the Collaboration Agreements, and (iii) December 31, 2050. Currently, we estimate that the loan will be repaid in the second quarter of 2020. This estimate could be adversely affected and the repayment period could be extended if future royalty amounts are less than currently expected. Under the terms of the Credit Agreement, at any time after January 1, 2019, Halozyme Royalty may, subject to certain limitations, prepay the outstanding principal of the Royalty-backed Loan in whole or in part, at a price equal to 105% of the outstanding principal on the Royalty-backed Loan, plus accrued but unpaid interest. The Royalty-backed Loan constitutes an obligation of Halozyme Royalty, and is non-recourse to Halozyme. Halozyme Royalty retains its right to the Royalty Payments following repayment of the loan.
Oxford and SVB Loan and Security Agreement
In June 2016, we entered into a Loan and Security Agreement (the Loan Agreement) with Oxford Finance LLC (Oxford) and Silicon Valley Bank (SVB) (collectively, the Lenders), providing a senior secured loan facility of up to an aggregate principal amount of $70.0 million, comprising a $55.0 million draw in June 2016 and an additional $15.0 million tranche, which we had the option to draw during the second quarter of 2017 and did not exercise. The proceeds were partially used to pay the outstanding principal and final payment owed on a previous loan agreement with the Lenders. The remaining proceeds were used for working capital and general business requirements. The Loan Agreement repayment schedule provided for interest only payments for the first 18 months, followed by consecutive equal monthly payments of principal and interest in arrears through the maturity date of January 1, 2021. The Loan Agreement provided for a final payment equal to 5.50% of the initial $55 million principal amount. The final payment was due when the Loan Agreement becomes due or upon the prepayment of the facility. We had the option to prepay the outstanding balance of the Loan Agreement in full and exercised this option in November 2019, at which point we paid

35


the full remaining balance and final payment of $26.1 million satisfying and discharging all obligations under, and terminating, the Loan Agreement.
Off-Balance Sheet Arrangements
As of December 31, 2019, we did not have any relationships with unconsolidated entities or financial partnerships, such as entities often referred to as structured finance or special purpose entities, which would have been established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes. In addition, we did not engage in trading activities involving non-exchange traded contracts. As such, we are not materially exposed to any financing, liquidity, market or credit risk that could arise if we had engaged in such relationships.
Contractual Obligations
As of December 31, 2019, future minimum payments due under our contractual obligations are as follows (in thousands):
 
 
Payments Due by Period
Contractual Obligations
 
Total
 
Less than
1 Year
 
1-3 Years
 
4-5 Years
 
More than
5 Years
Long-term debt, including current portion(1)
 
$
479,560

 
$
19,560

 
$
—

 
$
460,000

 
$
—

Interest on long-term debt(2)
 
29,540

 
6,540

 
11,500

 
11,500

 
—

Operating leases(3)
 
7,244

 
3,355

 
3,819

 
70

 
—

Third-party manufacturing obligations(4)
 
36,333

 
36,333

 
—

 
—

 
—

Purchase obligations
 
622

 
377

 
245

 
—

 
—

Total
 
$
553,299

 
$
66,165

 
$
15,564

 
$
471,570

 
$
—

_______________
(1).
Long-term debt consists of the Royalty-backed Loan and the Convertible Notes. Obligations include future quarterly principal payments for the Royalty-backed Loan based on an estimate of future royalty amounts. This estimate could be adversely affected and the repayment period could be extended if future royalty amounts are less than currently expected.
(2).
Interest on long-term debt includes quarterly interest payments on the Royalty-backed Loan and semi-annual interest payments on the Convertible Note. The Royalty-backed Loan bears interest at a per annum rate of 8.75% plus the three-month LIBOR rate. The three-month LIBOR rate is subject to a floor of 0.7% and a cap of 1.5%. Future interest obligations for the Royalty-backed Loan were estimated using rates in effect as of December 31, 2019. The Convertible Note bears interest at an annual rate of 1.25%.
(3).
Includes minimum lease payments related to leases of our office and research facilities and certain autos under non-cancelable operating leases.
(4).
We have contracted with third-party manufacturers for the supply of bulk rHuPH20 and fill/finish of Hylenex recombinant. Under these agreements, we are required to purchase certain quantities each year during the terms of the agreements. The amounts presented represent our estimates of the minimum required payments under these agreements.
Contractual obligations for purchases of goods or services include agreements that are enforceable and legally binding to us and that specify all significant terms, including fixed or minimum quantities to be purchased; fixed, minimum or variable price provisions; and the approximate timing of the transaction. For obligations with cancellation provisions, the amounts included in the preceding table were limited to the non-cancelable portion of the agreement terms or the minimum cancellation fee.
For certain restricted stock units and performance stock units granted, the number of shares issued on the date the restricted stock units vest is net of the minimum statutory withholding requirements that we pay in cash to the appropriate taxing authorities on behalf of our employees. The obligation to pay the relevant taxing authority is not included in the preceding table, as the amount is contingent upon continued employment. In addition, the amount of the obligation is unknown, as it is based in part on the market price of our common stock when the awards vest.

36


The expected timing of payments of the obligations above is estimated based on current information. Timing of payments and actual amounts paid may be different, depending on the time of receipt of goods or services, or changes to agreed-upon amounts for some obligations.
Our future capital uses and requirements depend on numerous forward-looking factors. These factors may include, but are not limited to, the following:
•
the rate of progress and cost of research and development activities;
•
the number and scope of our research and development activities;
•
the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights;
•
our ability to establish and maintain product discovery and development collaborations, including scale-up manufacturing costs for our collaborators’ product candidates;
•
the amount of royalties and milestones from our collaborators;
•
the amount of product sales for Hylenex recombinant;
•
the costs of obtaining and validating additional manufacturers of rHuPH20;
•
the effect of competing technological and market developments;
•
the terms and timing of any collaborative, licensing and other arrangements that we may establish; and
•
the extent to which we acquire or in-license new products, technologies or businesses.
Critical Accounting Estimates
The discussion and analysis of our financial condition and results of operations are based on our consolidated financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles, or U.S. GAAP. The preparation of our consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosure of contingent assets and liabilities. We review our estimates on an ongoing basis. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results may differ from these estimates under different assumptions or conditions. Our significant accounting policies are outlined in Note 2 to the Consolidated Financial Statements included in the Form 10-K. We believe the following accounting policies to be critical to the judgments and estimates used in the preparation of our consolidated financial statements.


Revenue Recognition
 
 
 
 
Methodology
 
Judgment and Uncertainties
 
Effect if Actual Results Differ From Assumptions
 
 
 
 
 
For collaborative agreements, we are entitled to receive event-based payments subject to the collaboration partner's achievement of specified development and regulatory milestones. We recognize revenue when it is deemed probable that these milestones will be achieved, which could be in a period prior to its actual occurrence. At the end of each reporting period, we re-evaluate the probability of achievement of such milestones, and if necessary, adjust our estimate of the overall transaction price.
 
Revenue is recognized when we determine it is probable a milestone will be achieved. This assessment is based on our past experience with our collaboration partners, market insight and partner communication.
 
A revenue reversal will be required in the event it is determined that achievement of a milestone, previously deemed probable, will not occur. This reversal may be material.

37


For collaborative agreements, royalty revenue is recognized in the period the underlying sales occur, but we do not receive final royalty reports from our collaboration partners until after we complete our financial statements for a prior quarter. Therefore, we recognize revenue based on estimates of the royalty earned, which are based on preliminary reports provided by our collaboration partners.
 
The amount of royalty revenue recognized for the quarter is estimated using our knowledge of past royalty payments, market insight and an estimate made by our collaboration partners provided in a preliminary report.
 
A final royalty report and associated royalty payment is received approximately 60 days after quarter-end. If necessary, a true-up is recorded at that time if there is a difference from the initial estimated royalty revenue recorded. To date, the true-up entries have not been material.
For collaborative arrangements, when necessary, we perform an allocation of the upfront amount based on relative stand-alone selling prices (SSP) of licenses for individual targets. We determine
license SSP using an income-based valuation approach utilizing risk-adjusted discounted cash flow projections.
 
The inputs used in the valuation model to determine SSP are based on estimates utilizing market data and information provided by our collaboration partners.
 
Differences in the allocation of the transaction price between delivered and undelivered performance obligations can impact the timing of revenue recognition but do not change the total revenue recognized under any agreement.

38


Debt Classification
 
 
 
 
Methodology
 
Judgment and Uncertainties
 
Effect if Actual Results Differ From Assumptions
 
 
 
 
 
The short-term and long-term classification of outstanding debt represents our best estimate of the timing of the amounts to be repaid. These estimates are based on contractual obligations, anticipated timing of royalty payments received and changes in LIBOR interest rates.
 
Royalty payments are estimated using partner insight to the marketplace, historical trends and our knowledge of the therapeutic space.
 
The short-term and long-term portion of the debts may change and the repayment term may be shortened or extended depending on the actual level of royalty payments received. The actual repayment period could vary materially from our estimate to the extent that royalty payments from our partners are lower than our current estimates, which could arise due to factors beyond our control, such as competitive factors, decreased market acceptance or a failure by our partners to successfully commercialize in territories where regulatory approval has been received.

Currently, we do not believe that we have significant amount of risk relative to the repayment of the debt. A 10% reduction in the amount of anticipated royalties would not change our expected repayment period at maximum contractual interest rates.
Share-Based Payments
 
 
 
 
Methodology
 
Judgment and Uncertainties
 
Effect if Actual Results Differ From Assumptions
 
 
 
 
 
We maintain a Stock Incentive Plan, which provides for share-based payment awards, including stock options, restricted stock and performance awards. We determine the fair value of our stock option awards and performance awards at the date of grant using a Black-Scholes model. We determine the fair value of our restricted stock awards at the date of grant using the closing market value of our common stock on the date of grant.
 
Option-pricing models and generally accepted valuation techniques require management to make assumptions and to apply judgment to determine the fair value of our awards. These assumptions and judgments include estimating the future volatility of our stock price, expected dividend yield and future employee stock option exercise behaviors. Changes in these assumptions can materially affect the fair value estimate.

Our performance awards require management to make assumptions regarding the likelihood of achieving long-term Company goals.

 
We do not currently believe there is a reasonable likelihood that there will be a material change in estimates or assumptions we use to determine stock-based compensation expense. However, if actual results are not consistent with our estimates or assumptions, we may be exposed to changes in share-based compensation expense that could be material.

If actual results are not consistent with the assumptions used, the share-based compensation expense reported in our financial statements may not be representative of the actual economic cost of the share-based compensation. A 10% change in our share-based compensation expense for the year ended December 31, 2019 would have affected pre-tax earnings by approximately $3.5 million in 2019.
Recent Accounting Pronouncements
Refer to Note 2, Summary of Significant Accounting Policies, of our consolidated financial statements for a discussion of recent accounting pronouncements and their effect, if any, on us.

39


Item 7A.
Quantitative and Qualitative Disclosures About Market Risk
As of December 31, 2019, our cash equivalents and marketable securities consisted of investments in money market funds, asset-backed securities, U.S. Treasury securities, corporate debt obligations and commercial paper. These investments were made in accordance with our investment policy which specifies the categories, allocations, and ratings of securities we may consider for investment. The primary objective of our investment activities is to preserve principal while at the same time maximizing the income we receive without significantly increasing risk. Some of the financial instruments that we invest in could be subject to market risk. This means that a change in prevailing interest rates may cause the value of the instruments to fluctuate. For example, if we purchase a security that was issued with a fixed interest rate and the prevailing interest rate later rises, the value of that security will probably decline. Based on our current investment portfolio as of December 31, 2019, we do not believe that our results of operations would be materially impacted by an immediate change of 10% in interest rates.
We do not hold or issue derivatives, derivative commodity instruments or other financial instruments for speculative trading purposes. Further, we do not believe our cash, cash equivalents and marketable securities have significant risk of default or illiquidity. We made this determination based on discussions with our investment advisors and a review of our holdings. While we believe our cash, cash equivalents and marketable securities do not contain excessive risk, we cannot provide absolute assurance that in the future our investments will not be subject to adverse changes in market value. All of our cash equivalents and marketable securities are recorded at fair market value.
Item 8.
Financial Statements and Supplementary Data
Our financial statements are annexed to this report beginning on page F-1.
Item 9.
Changes In and Disagreements with Accountants on Accounting and Financial Disclosure
None.

40


Item 9A.
Controls and Procedures
Evaluation of Disclosure Controls and Procedures
We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the timelines specified in the Securities and Exchange Commission’s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decision regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can only provide reasonable assurance of achieving the desired control objectives, and in reaching a reasonable level of assurance, management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.
Under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, we conducted an evaluation of our disclosure controls and procedures, as such term is defined under Rule 13a-15(e) promulgated under the Securities Exchange Act of 1934, as amended. Based on this evaluation, our principal executive officer and our principal financial officer concluded that our disclosure controls and procedures were effective as of the end of the period covered by this Annual Report on Form 10-K.
Changes in Internal Control Over Financial Reporting
There have been no significant changes in our internal control over financial reporting that occurred during the quarter ended December 31, 2019 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
Management’s Report on Internal Control Over Financial Reporting
Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting is defined in Rule 13a-15(f) and Rule 15d-15(f) promulgated under the Exchange Act as a process designed by, or under the supervision of, our principal executive and principal financial officers and effected by our board of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles and includes those policies and procedures that:
•
Pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of our assets;
•
Provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures are being made only in accordance with authorizations of our management and directors; and
•
Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on our financial statements.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
Our management assessed the effectiveness of our internal control over financial reporting as of December 31, 2019. In making this assessment, our management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control-Integrated Framework (2013 framework) (the COSO criteria). Based on our assessment, management concluded that, as of December 31, 2019, our internal control over financial reporting is effective based on the COSO criteria. The independent registered public accounting firm that audited the consolidated financial statements that are included in this Annual Report on Form 10-K has issued an audit report on the effectiveness of our internal control over financial reporting as of December 31, 2019. The report appears below.

41


Report of Independent Registered Public Accounting Firm
The Board of Directors and Stockholders
Halozyme Therapeutics, Inc.
Opinion on Internal Control over Financial Reporting
We have audited Halozyme Therapeutics, Inc.’s internal control over financial reporting as of December 31, 2019, based on criteria established in Internal Control - Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria). In our opinion, Halozyme Therapeutics, Inc. (the Company) maintained, in all material respects, effective internal control over financial reporting as of December 31, 2019, based on the COSO criteria.
We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of December 31, 2019 and 2018, and the related consolidated statements of operations, comprehensive (loss) income, cash flows, and stockholders’ equity (deficit) for each of the three years in the period ended December 31, 2019, and the related notes and the financial statement schedule listed in the Index at Item 15(a) and our report dated February 24, 2020 expressed an unqualified opinion thereon.
Basis for Opinion
The Company’s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management’s Report on Internal Control Over Financial Reporting. Our responsibility is to express an opinion on the Company’s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.
Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.
Definition and Limitations of Internal Control Over Financial Reporting
A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
                                                                                                   /s/    Ernst & Young LLP
San Diego, California
February 24, 2020

42


Item 9B.
Other Information
None.
PART III
Item 10.
Directors, Executive Officers and Corporate Governance
The information required by this item regarding directors is incorporated by reference to our definitive Proxy Statement (the Proxy Statement) to be filed with the Securities and Exchange Commission in connection with our 2020 Annual Meeting of Stockholders under the heading “Election of Directors.” The information required by this item regarding compliance with Section 16(a) of the Securities Exchange Act of 1934, as amended, is incorporated by reference to the information under the caption “Compliance with Section 16(a) of the Exchange Act” to be contained in the Proxy Statement. The information required by this item regarding our code of ethics is incorporated by reference to the information under the caption “Code of Conduct and Ethics and Corporate Governance Guidelines” to be contained in the Proxy Statement. The information required by this item regarding our audit committee is incorporated by reference to the information under the caption “Board Meetings and Committees—Audit Committee” to be contained in the Proxy Statement. The information required by this item regarding material changes, if any, to the process by which stockholders may recommend nominees to our board of directors is incorporated by reference to the information under the caption “Board Meetings and Committees—Nominating and Governance Committee” to be contained in the Proxy Statement.
Executive Officers
Helen I. Torley, M.B. Ch. B., M.R.C.P. (57), President, Chief Executive Officer and Director. Dr. Torley joined Halozyme in January 2014 as President and Chief Executive Officer and as a member of Halozyme’s Board of Directors. Throughout her career, Dr. Torley has led several successful product launches, including Kyprolis®, Prolia®, Sensipar®, and Miacalcin®. Prior to joining Halozyme, Dr. Torley served as Executive Vice President and Chief Commercial Officer for Onyx Pharmaceuticals (Onyx) from August 2011 to December 2013 overseeing the collaboration with Bayer on Nexavar® and Stivarga® and the U.S. launch of Kyprolis. She was responsible for the development of Onyx's commercial capabilities in ex-US markets and in particular, in Europe. Prior to Onyx, Dr. Torley spent 10 years in management positions at Amgen Inc., most recently serving as Vice President and General Manager of the US Nephrology Business Unit from 2003 to 2009 and the U.S. Bone Health Business Unit from 2009 to 2011. From 1997 to 2002, she held various senior management positions at Bristol-Myers Squibb, including Regional Vice President of Cardiovascular and Metabolic Sales and Head of Cardiovascular Global Marketing. She began her career at Sandoz/Novartis, where she ultimately served as Vice President of Medical Affairs, developing and conducting post-marketing clinical studies across all therapeutic areas, including oncology. Dr. Torley serves on the board of directors of Quest Diagnostics Incorporated, a diagnostic information services company. Within the past five years, Dr. Torley served on the board of directors of Relypsa, Inc., a biopharmaceutical company. Before joining the industry, Dr. Torley was in medical practice as a senior registrar in rheumatology at the Royal Infirmary in Glasgow, Scotland. Dr. Torley received her Bachelor of Medicine and Bachelor of Surgery degrees (M.B. Ch.B.) from the University of Glasgow and is a Member of the Royal College of Physicians (M.R.C.P).
Laurie D. Stelzer (52), Senior Vice President, Chief Financial Officer. Ms. Stelzer joined Halozyme in June 2015 as Senior Vice President, Chief Financial Officer. Prior to joining Halozyme, Ms. Stelzer served from April 2014 to January 2015 as the Senior Vice President of Finance supporting R&D, Technical Operations and M&A at Shire, Inc., a biopharmaceutical company. Prior to that she was the Division CFO for the Regenerative Medicine Division and the Head of Investor Relations at Shire from March 2012 to April 2014. Prior to Shire, Ms. Stelzer held positions of increasing responsibility for 15 years at Amgen, Inc., a biopharmaceutical company, including Interim Treasurer, Head of Emerging Markets Expansion, Executive Director of Global Commercial Finance and Head of Global Accounting. Early in her career, she held various finance and accounting positions in the real estate and banking industries. Ms. Stelzer serves on the board of directors of Surface Oncology, Inc., an immuno-oncology company. Ms. Stelzer received her MBA from the Anderson School at the University of California, Los Angeles, and a Bachelor of Science in Accounting from Arizona State University.


43


Masaru Matsuda (49), Senior Vice President, General Counsel, Chief Compliance Officer & Secretary. Mr. Matsuda joined Halozyme in August 2018 as Vice President, Associate General Counsel and Chief Compliance Officer and has served as Senior Vice President, General Counsel, Chief Compliance Officer and Secretary since January 2020. Prior to joining Halozyme, Mr. Matsuda held positions of increasing responsibility in the Law Department at Amgen Inc., a biopharmaceutical company, from May 2000 to August 2018, most recently as Vice President, Law, Global Commercial Operations. Prior to joining Amgen, Mr. Matsuda was an associate attorney at Orrick, Herrington & Sutcliffe LLP from June 1998 to April 2000, and at Pillsbury Winthrop Shaw Pittman LLP from June 1996 to June 1998. Mr. Matsuda received his Juris Doctor from the University of California, Hastings College of the Law and his Bachelor of Science Degree in Business Administration from the University of Southern California.
Michael J. LaBarre (56), Senior Vice President, Chief Technical Officer. Dr. LaBarre joined Halozyme in June 2008 as Vice President, Product Development and has served in various officer positions most recently as Senior Vice President, Chief Technical Officer since January 2020. Prior to joining Halozyme, Dr. LaBarre served as Vice President, Product Development at Paramount BioSciences, a pharmaceutical company, from April 2006 to June 2008. Prior to that he served as Director, Analytical and Protein Biochemistry, Discovery Research at Biogen Idec, a pharmaceutical company, from December 2003 to April 2006. He also served in various research and development roles at IDEC Pharmaceuticals Corporation, a pharmaceutical company, from November 1995 to December 2003 most recently as Director, Analytical and Formulation Sciences, R&D. Prior to joining IDEC, Dr. LaBarre held research and development positions at various pharmaceutical companies from July 1992 to November 1995. Dr. LaBarre received his Ph.D. in Chemistry from the University of Arizona and his B.S. in Chemistry from Southampton College of Long Island University.
Item 11.
Executive Compensation
The information required by this item is incorporated by reference to the information under the caption “Executive Compensation” to be contained in the Proxy Statement.
Item 12.
Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
Other than as set forth below, the information required by this item is incorporated by reference to the information under the caption “Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters” to be contained in the Proxy Statement.
Equity Compensation Plan Information
The following table summarizes our compensation plans under which our equity securities are authorized for issuance as of December 31, 2019:
Plan Category
 
 
Number of Shares 
to be Issued upon
Exercise of
Outstanding Options
and Restricted Stock
Units
(a)
 
Weighted Average
Exercise Price
of Outstanding
Options(2)
(b) 
 
Number of Shares
Remaining Available
for Future Issuance
under Equity
Compensation
Plans (Excluding
Shares Reflected
in Column (a))
(c)
Equity compensation plans approved by stockholders (1)
 
13,640,668

 
$14.72
 
9,352,360

Equity compensation plans not approved by stockholders
 
—

 
—
 
—

 
 
13,640,668

 
$14.72
 
9,352,360

_____________________
(1)
Represents stock options, restricted stock units, and performance restricted stock units under the Amended and Restated 2011 Stock Plan, and 2008 Stock Plan.
(2)
This amount does not include restricted stock units and performance restricted stock units as there is no exercise price for such units.

44


Item 13.
Certain Relationships and Related Transactions, and Director Independence
The information required by this item is incorporated by reference to the information under the caption “Certain Relationships and Related Transactions” and “Corporate Governance - Director Independence” to be contained in the Proxy Statement.
Item 14.
Principal Accounting Fees and Services
The information required by this item is incorporated by reference to the information under the caption “Principal Accounting Fees and Services” to be contained in the Proxy Statement.
PART IV
Item 15.
Exhibits and Financial Statement Schedules
(a)
Documents filed as part of this report.
1.   Financial Statements 
  
  
Page
Report of Independent Registered Public Accounting Firm
  
Consolidated Balance Sheets at December 31, 2019 and 2018
  
Consolidated Statements of Operations for Each of the Years Ended December 31, 2019, 2018 and 2017
  
Consolidated Statements of Comprehensive (Loss) Income for Each of the Years Ended December 31, 2019,
     2018 and 2017
 
Consolidated Statements of Cash Flows for Each of the Years Ended December 31, 2019, 2018 and 2017
  
Consolidated Statements of Stockholders’ Equity for Each of the Years Ended December  31, 2019,
     2018 and 2017
  
Notes to the Consolidated Financial Statements
  
2.   List of all Financial Statement schedules.
The following financial statement schedule of Halozyme Therapeutics, Inc. is filed as part of this Annual Report on Form 10-K and should be read in conjunction with the consolidated financial statements of Halozyme Therapeutics, Inc.
 
 
Page
Schedule II: Valuation and Qualifying Accounts
 
All other schedules are omitted because they are not applicable or the required information is shown in the Financial Statements or notes thereto.
3.   List of Exhibits required by Item 601 of Regulation S-K. See part (b) below.

45


(b)
Exhibits.
 
 
 
Incorporated by Reference
Exhibit
 
Filed
 
 
Number
Exhibit Title
Herewith
Form
Date Filed
 
 
 
 
 
3.1
 
8-K
5/3/2019
 
 
 
 
 
3.2
 
8-K
12/19/2016
 
 
 
 
 
4.1

 
8-K
11/18/2019
 
 
 
 
 
4.2
 
8-K
11/18/2019
 
 
 
 
 
4.3
X
 
 
10.1
 
SB-2
4/23/2004
 
 
 
 
 
10.2
 
8-K
1/12/2006
 
 
 
 
 
10.3#
 
8-K
3/19/2008
 
 
 
 
 
10.4#
 
10-Q
8/7/2009
 
 
 
 
 
10.5#
 
10-Q
8/7/2009
 
 
 
 
 
10.6#
 
8-K
4/6/2018
 
 
 
 
 
10.7#
 
8-K
5/6/2011
 
 
 
 
 
10.8#
 
8-K
5/6/2011
 
 
 
 
 
10.9#
 
10-Q
8/10/2015
 
 
 
 
 
10.10#
 
10-Q
8/10/2015
 
 
 
 
 
10.11#
 
8-K
5/6/2011
 
 
 
 
 
10.12#
 
8-K
5/6/2011
 
 
 
 
 
10.13#
 
10-Q
11/9/2015
 
 
 
 
 
10.14#
 
10-Q
11/9/2015
 
 
 
 
 
10.15#
 
10-Q
11/9/2015
 
 
 
 
 
10.16#
 
10-K
2/28/2017
 
 
 
 
 
10.17#
 
8-K
12/20/2007

46


 
 
 
Incorporated by Reference
Exhibit
 
Filed
 
 
Number
Exhibit Title
Herewith
Form
Date Filed
 
 
 
 
 
10.18#
 
8-K
12/13/2018
 
 
 
 
 
10.19#
 
10-Q
11/9/2015
 
 
 
 
 
10.20
 
8-K
6/16/2011
 
 
 
 
 
10.21
 
8-K
7/5/2017
 
 
 
 
 
10.22
 
10-Q
5/10/2018
 
 
 
 
 
10.23
 
8-K
6/16/2011
 
 
 
 
 
10.24
 
8-K
7/5/2017
 
 
 
 
 
10.25
 
10-Q
5/10/2018
 
 
 
 
 
10.26
 
10-K
3/1/2013
 
 
 
 
 
10.27
 
10-Q
5/8/2013
 
 
 
 
 
10.28
 
8-K
7/5/2017
 
 
 
 
 
10.29#
 
DEF-14A
3/23/2016
 
 
 
 
 
 
 
 
 
 
21.1
X
 
 
 
 
 
 
 
23.1
X
 
 
 
 
 
 
 
31.1
X
 
 
 
 
 
 
 
31.2
X
 
 

47


 
 
 
Incorporated by Reference
Exhibit
 
Filed
 
 
Number
Exhibit Title
Herewith
Form
Date Filed
 
 
 
 
 
32
X
 
 
 
 
 
 
 
101.INS
XBRL Instance Document - the instance document does not appear in the interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
X
 
 
 
 
 
 
 
101.SCH
XBRL Taxonomy Extension Schema
X
 
 
 
 
 
 
 
101.CAL
XBRL Taxonomy Extension Calculation Linkbase
X
 
 
 
 
 
 
 
101.DEF
XBRL Taxonomy Extension Definition Linkbase
X
 
 
 
 
 
 
 
101.LAB
XBRL Taxonomy Extension Label Linkbase
X
 
 
 
 
 
 
 
101.PRE
XBRL Taxonomy Presentation Linkbase
X
 
 
 
 
 
 
 
104
Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)
X
 
 
_______________
#
Indicates management contract or compensatory plan or arrangement.
(c)
Financial Statement Schedules.  See Item 15(a) 2 above.
Item 16.
Form 10-K Summary
None.

48


SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 
 
 
 
Halozyme Therapeutics, Inc.,
a Delaware corporation
 
 
 
 
Date:
 
February 24, 2020
 
 
 
By:
 
/s/    Helen I. Torley, M.B. Ch.B., M.R.C.P.
 
 
 
 
 
 
 
 
Helen I. Torley, M.B. Ch.B., M.R.C.P.
 
 
 
 
 
 
 
 
President and Chief Executive Officer

49


POWER OF ATTORNEY
Know all persons by these presents, that each person whose signature appears below constitutes and appoints Helen I. Torley and Laurie D. Stelzer, and each of them, as his/her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him/her and in his/her name, place, and stead, in any and all capacities, to sign any and all amendments to this Annual Report, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he/she might or could do in person, hereby ratifying and confirming that all said attorneys-in-fact and agents, or any of them or their or his/her substitute or substituted, may lawfully do or cause to be done by virtue thereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, this Annual Report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.
Signature
  
Title
 
Date
 
 
 
/s/    Helen I. Torley, M.B. Ch.B., M.R.C.P.
  
President and Chief Executive Officer
 
February 24, 2020
       Helen I. Torley, M.B. Ch.B., M.R.C.P.
 
 (Principal Executive Officer), Director
 
 
 
 
 
 
/s/   Laurie D. Stelzer
  
Senior Vice President and Chief Financial Officer
 
February 24, 2020
       Laurie D. Stelzer
 
(Principal Financial and Accounting Officer)
 
 
 
 
 
 
/s/    Connie L. Matsui
  
Chair of the Board of Directors
 
February 24, 2020
       Connie L. Matsui
 
 
 
 
 
 
 
 
/s/ Jean-Pierre Bizzari
 
Director
 
February 24, 2020
     Jean-Pierre Bizzari
 
 
 
 
 
 
 
 
 
/s/    Bernadette Connaughton
  
Director
 
February 24, 2020
       Bernadette Connaughton
 
 
 
 
 
 
 
 
/s/    James M. Daly
  
Director
 
February 24, 2020
       James M. Daly
 
 
 
 
 
 
 
 
 
/s/    Jeffrey W. Henderson
  
Director
 
February 24, 2020
       Jeffrey W. Henderson
 
 
 
 
 
 
 
 
/s/    Kenneth J. Kelley
  
Director
 
February 24, 2020
       Kenneth J. Kelley
 
 
 
 
 
 
 
 
/s/    Matthew L. Posard
 
Director
 
February 24, 2020
       Matthew L. Posard
 
 
 
 

50


Report of Independent Registered Public Accounting Firm
The Board of Directors and Stockholders
Halozyme Therapeutics, Inc.

Opinion on the Financial Statements
We have audited the accompanying consolidated balance sheets of Halozyme Therapeutics, Inc. (the Company) as of December 31, 2019 and 2018, and the related consolidated statements of operations, comprehensive (loss) income, stockholders’ equity (deficit) and cash flows for each of the three years in the period ended December 31, 2019, and the related notes and the financial statement schedule listed in the Index at Item 15(a) (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements referred to above, present fairly, in all material respects, the financial position of the Company at December 31, 2019 and 2018, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2019, in conformity with U.S. generally accepted accounting principles.
We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company’s internal control over financial reporting as of December 31, 2019, based on criteria established in Internal Control - Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) and our report dated February 24, 2020 expressed an unqualified opinion thereon.
Adoption of ASU No. 2014-09
As discussed in Note 2 to the consolidated financial statements, the Company changed its method for recognizing revenue as a result of the adoption of Accounting Standards Update (ASU) No. 2014-09, Revenue from Contracts with Customers (Topic 606), and the amendments in ASUs 2015-14, 2016-08, 2016-10 and 2016-12 effective January 1, 2018.
Basis for Opinion
These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.
Critical Audit Matters
The critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.




F-1





Estimation of Overall Transaction Price for Collaboration Agreements

 
 
 
 
 
Description of the Matter

 
At December 31, 2019 the Company has nine collaboration agreements. As discussed in Notes 2 and 4 of the financial statements, amounts are included in the transaction price when management determines that it is probable that the amount will not result in a significant reversal of revenue in the future. During 2019, the Company recognized $5.5 million of variable consideration in the transaction price under their collaboration arrangements.

Auditing management’s conclusions related to determining the probability of achievement of milestones is complex and highly judgmental as a result of the uncertainties and limited visibility by the Company into the progression of developing and commercializing the combined targets as completed by the collaboration partners



How We Addressed the Matter in Our Audit

 
We obtained an understanding and evaluated the design and tested the operating effectiveness of controls over the Company’s process to routinely evaluate the probability of achievement of milestones and any related constraint for each collaboration, in addition to the controls over the completeness and accuracy of determining the population of agreements and potential milestone payments.

To test the milestone amounts included, or excluded, from the transaction price, we performed audit procedures that included, among others, observing the quarterly meetings with accounting and Alliance Managers discussing the status of each collaboration. For each milestone, we examined available evidence including correspondence with the collaboration partner and evaluated management’s conclusions on the probabilities of achievement. We reviewed supporting documentation to corroborate that milestones were included in the transaction price when determined to be probable of achievement. We reviewed the collaboration agreements and related amendments to validate the completeness of the list of targets and potential milestone payments that management considered in their analysis. We performed a lookback analysis to validate the company’s accuracy of determining the probability of achieving these milestones.




 
 
 
 
 
Accounting for Convertible Senior Notes

Description of the Matter

 
On November 18, 2019 the Company issued $460 million of Convertible Senior Notes due 2024. As discussed in Note 6 of the financial statements, the Convertible Notes include conversion terms that require the Company to account for the debt and equity components of the Convertible Notes separately including allocating value to the debt component with the remaining value allocated to the equity component reflected as a debt discount to be amortized to interest expense over the terms of the notes.

Auditing management’s conclusions related to the value allocated to the debt portion of the Convertible Note is complex and involves estimation to determine the effective yield that the Company would have received on the debt issuance had it not included in the conversion feature.


F-2


How We Addressed the Matter in Our Audit

 
We obtained an understanding and evaluated the design and tested the operating effectiveness of controls over the Company’s process to determine the valuation allocation between debt and equity components, including the valuation model and assumptions.

To test the value assigned to each component, we performed audit procedures that included, among others, evaluating the Company’s use of independent valuation specialist, and the valuation methodology. In addition, we involved our valuation specialists to assist in testing the concluded effective yield used to determine the value allocated to the debt component by performing an independent credit analysis including comparison to market rates for similarly rated instruments. We also tested the completeness and accuracy of the calculation used to estimate the fair value of the debt component.




/s/    Ernst & Young LLP
We have served as the Company’s auditor since 2006.

San Diego, California
February 24, 2020

F-3


HALOZYME THERAPEUTICS, INC.
CONSOLIDATED BALANCE SHEETS
(In thousands, except per share amounts)
 
 
December 31,
2019
 
December 31,
2018
ASSETS
 
 
 
 
Current assets:
 
 
 
 
Cash and cash equivalents
 
$
120,179

 
$
57,936

Marketable securities, available-for-sale
 
301,083

 
296,590

Accounts receivable, net
 
59,442

 
30,005

Inventories
 
29,359

 
22,625

Prepaid expenses and other assets
 
33,373

 
20,693

Total current assets
 
543,436

 
427,849

Property and equipment, net
 
10,855

 
7,465

Prepaid expenses and other assets
 
11,083

 
4,434

Restricted cash
 
500

 
500

Total assets
 
$
565,874

 
$
440,248

 
 
 
 
 
LIABILITIES AND STOCKHOLDERS’ EQUITY
 
 
 
 
Current liabilities:
 
 
 
 
Accounts payable
 
$
6,434

 
$
4,079

Accrued expenses
 
55,649

 
49,529

Deferred revenue, current portion
 
4,012

 
4,247

Current portion of long-term debt, net
 
19,542

 
91,506

Total current liabilities
 
85,637

 
149,361

Deferred revenue, net of current portion
 
1,247

 
5,008

Long-term debt, net
 
383,045

 
34,874

Other long-term liabilities
 
4,180

 
2,118

Commitments and contingencies (Note 9)
 

 

Stockholders’ equity:
 
 
 
 
Preferred stock - $0.001 par value; 20,000 shares authorized; no shares
     issued and outstanding
 
—

 
—

Common stock - $0.001 par value; 300,000 shares authorized; 136,713 and
    144,725 shares issued and outstanding at December 31, 2019 and 2018,
    respectively
 
137

 
145

Additional paid-in capital
 
695,066

 
780,457

Accumulated other comprehensive loss
 
240

 
(277
)
Accumulated deficit
 
(603,678
)
 
(531,438
)
Total stockholders’ equity
 
91,765

 
248,887

Total liabilities and stockholders’ equity
 
$
565,874

 
$
440,248

See accompanying notes to consolidated financial statements.

F-4


HALOZYME THERAPEUTICS, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share amounts)

 
 
Year Ended December 31,
 
 
2019
 
2018
 
2017
Revenues:
 
 
 
 
 
 
Royalties
 
$
69,899

 
$
78,981

 
$
63,507

Product sales, net
 
66,048

 
28,234

 
50,396

Revenues under collaborative agreements
 
60,045

 
44,647

 
202,710

Total revenues
 
195,992

 
151,862

 
316,613

Operating expenses:
 
 
 
 
 
 
Cost of product sales
 
45,546

 
10,136

 
31,152

Research and development
 
140,804

 
150,252

 
150,643

Selling, general and administrative
 
77,252

 
60,804

 
53,816

Total operating expenses
 
263,602

 
221,192

 
235,611

Operating (loss) income
 
(67,610
)
 
(69,330
)
 
81,002

Other income (expense):
 
 
 
 
 
 
Investment and other income, net
 
6,986

 
7,578

 
2,592

Interest expense
 
(11,627
)
 
(18,041
)
 
(21,984
)
(Loss) income before income taxes
 
(72,251
)
 
(79,793
)
 
61,610

Income tax expense (benefit)
 
(11
)
 
537

 
(1,361
)
Net (loss) income
 
$
(72,240
)
 
$
(80,330
)
 
$
62,971

 
 
 
 
 
 
 
Net (loss) income per share:
 
 
 
 
 
 
Basic
 
$
(0.50
)
 
$
(0.56
)
 
$
0.46

Diluted
 
$
(0.50
)
 
$
(0.56
)
 
$
0.45

 
 
 
 
 
 
 
Shares used in computing net (loss) income per share:
 
 
 
 
 
 
Basic
 
144,329

 
143,599

 
136,419

Diluted
 
144,329

 
143,599

 
139,068

See accompanying notes to consolidated financial statements.

F-5


HALOZYME THERAPEUTICS, INC.
CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME
(In thousands)
 
 
Year Ended December 31,
 
 
2019
 
2018
 
2017
Net (loss) income
 
$
(72,240
)
 
$
(80,330
)
 
$
62,971

Other comprehensive (loss) income:
 
 
 
 
 
 
Unrealized gain (loss) on marketable securities
 
508

 
182

 
(430
)
Foreign currency translation adjustment
 
9

 
(8
)
 
(14
)
Unrealized loss on foreign currency
 
—

 
(1
)
 
—

Total comprehensive (loss) income
 
$
(71,723
)
 
$
(80,157
)
 
$
62,527

See accompanying notes to consolidated financial statements.

F-6


HALOZYME THERAPEUTICS, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)
 
 
Year Ended December 31,
 
 
2019
 
2018
 
2017
Operating activities:
 
 
 
 
 
 
Net (loss) income
 
$
(72,240
)
 
$
(80,330
)
 
$
62,971

Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities:
 
 
 
 
 
 
Share-based compensation
 
34,776

 
35,696

 
30,670

Depreciation and amortization
 
4,068

 
2,388

 
2,161

Amortization of debt discount
 
2,484

 
1,545

 
1,761

(Accretion of discounts) amortization of premiums on marketable securities, net
 
(2,469
)
 
(3,090
)
 
(303
)
Loss on disposal of equipment
 
1,431

 
5

 
46

Deferral of unearned revenue
 
—

 
3,000

 
22,759

Recognition of deferred revenue
 
(3,996
)
 
(2,832
)
 
(6,512
)
Lease payments (deferred) recognized
 
(459
)
 
(7
)
 
13

Loss on impairment of right-of-use asset
 
1,127

 
—

 
—

Recognition of deferred rent
 
—

 
—

 
(185
)
Loss on extinguishment of debt
 
401

 
—

 
—

Other
 
(7
)
 
(9
)
 
(16
)
Changes in operating assets and liabilities:
 
 
 
 
 
 
Accounts receivable, net
 
(29,437
)
 
11,613

 
(6,453
)
Inventories
 
(6,734
)
 
(17,480
)
 
9,477

Prepaid expenses and other assets
 
(19,006
)
 
(5,695
)
 
2,035

Accounts payable and accrued expenses
 
4,638

 
5,696

 
15,629

Net cash (used in) provided by operating activities
 
(85,423
)
 
(49,500
)
 
134,053

Investing activities:
 
 
 
 
 
 
Purchases of marketable securities
 
(389,759
)
 
(311,112
)
 
(398,187
)
Proceeds from maturities of marketable securities
 
388,250

 
318,268

 
235,805

Purchases of property and equipment
 
(4,040
)
 
(4,663
)
 
(1,350
)
Net cash provided by (used in) investing activities
 
(5,549
)
 
2,493

 
(163,732
)
Financing activities:
 
 
 
 
 
 
Proceeds from issuance of common stock, net
 
—

 
—

 
134,874

Proceeds from issuance of long-term debt, net
 
447,350

 
—

 
—

Repayment of long-term debt
 
(108,082
)
 
(77,516
)
 
(15,995
)
Payment of debt issuance cost
 
(279
)
 
—

 
—

Repurchase of common stock
 
(199,998
)
 
—

 
—

Proceeds from issuance of common stock under equity incentive plans, net of taxes paid related to net share settlement
 
14,224

 
13,719

 
12,776

Net cash provided by (used in) financing activities
 
153,215

 
(63,797
)
 
$
131,655

Net increase (decrease) in cash, cash equivalents and restricted cash
 
62,243

 
(110,804
)
 
101,976

Cash, cash equivalents and restricted cash at beginning of period
 
58,436

 
169,240

 
67,264

Cash, cash equivalents and restricted cash at end of period
 
$
120,679

 
$
58,436

 
$
169,240


F-7


 
 
Year Ended December 31,
 
 
2019
 
2018
 
2017
 
 
 
 
 
 
 
Supplemental disclosure of cash flow information:
 
 
 
 
 
 
Interest paid
 
$
9,029

 
$
16,891

 
$
20,295

Income taxes paid
 
$
188

 
$
220

 
$
3,015

Supplemental disclosure of non-cash investing and financing activities:
 
 
 
 
 
 
Amounts accrued for purchases of property and equipment
 
$
61

 
$
542

 
$
189

Debt issuance cost included in accounts payable
 
$
68

 
$
—

 
$
—

Right-of-use assets obtained in exchange for lease obligation
 
$
897

 
$
—

 
$
—

Leasehold improvements paid by lessor
 
$
—

 
$
1,322

 
$
13

See accompanying notes to consolidated financial statements.

F-8


HALOZYME THERAPEUTICS, INC.
CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
(in thousands)
 
 
Common Stock
 
Additional
Paid-In
Capital
 
Accumulated
Other
Comprehensive
Income (Loss)
 
Accumulated
Deficit
 
Total
Stockholders’
Equity (Deficit)
 
 
Shares
 
Amount
 
BALANCE AT JANUARY 1, 2017
 
129,502

 
$
130

 
$
552,737

 
$
(6
)
 
$
(585,342
)
 
$
(32,481
)
Share-based compensation expense
 
—

 
—

 
30,670

 
—

 
—

 
30,670

Issuance of common stock for cash, net
 
11,500

 
11

 
134,863

 
—

 
—

 
134,874

Issuance of common stock pursuant to exercise of stock options and vesting of restricted stock units, net
 
1,796

 
2

 
12,774

 
—

 
—

 
12,776

Cancellation of restricted stock awards, net
 
(9
)
 
—

 
—

 
—

 
—

 
—

Other comprehensive income
 
—

 
—

 
—

 
(444
)
 
—

 
(444
)
Net income
 
—

 
—

 
—

 
—

 
62,971

 
62,971

BALANCE AT DECEMBER 31, 2017
 
142,789

 
143

 
731,044

 
(450
)
 
(522,371
)
 
208,366

Adjustment to beginning retained earnings
 
—

 
—

 
—

 
—

 
71,263

 
71,263

Share-based compensation expense
 
—

 
—

 
35,696

 
—

 
—

 
35,696

Issuance of common stock pursuant to exercise of stock options and vesting of restricted stock units and performance restricted stock units, net
 
1,932

 
2

 
13,717

 
—

 
—

 
13,719

Issuance of restricted stock awards, net
 
4

 
—

 
—

 
—

 
—

 
—

Other comprehensive loss
 
—

 
—

 
—

 
173

 
—

 
173

Net loss
 
—

 
—

 
—

 
—

 
(80,330
)
 
(80,330
)
BALANCE AT DECEMBER 31, 2018
 
144,725

 
145

 
780,457

 
(277
)
 
(531,438
)
 
248,887

Share-based compensation expense
 
—

 
—

 
34,776

 
—

 
—

 
34,776

Issuance of common stock pursuant to exercise of stock options and vesting of restricted stock units and performance restricted stock units, net
 
2,493

 
2

 
14,222

 
—

 
—

 
14,224

Issuance of restricted stock awards, net
 
74

 
—

 
—

 
—

 
—

 
—

Repurchase of common stock
 
(10,579
)
 
(10
)
 
(199,988
)
 
 
 
 
 
(199,998
)
Equity component of convertible notes
 
 
 
 
 
65,599

 
 
 
 
 
65,599

Other comprehensive income
 
—

 
—

 
—

 
517

 
 
 
517

Net loss
 
—

 
—

 
—

 
—

 
(72,240
)
 
(72,240
)
BALANCE AT DECEMBER 31, 2019
 
136,713

 
137

 
695,066

 
240

 
(603,678
)
 
91,765

See accompanying notes to consolidated financial statements.

F-9


Halozyme Therapeutics, Inc.
Notes to Consolidated Financial Statements
1. Organization and Business
Halozyme Therapeutics Inc. is a biopharma technology platform company that provides innovative and disruptive solutions with the goal of improving patient experience and outcomes. Our proprietary enzyme rHUPH20 is used to facilitate the delivery of injected drugs and fluids. We license our technology to biopharmaceutical companies to collaboratively develop products that combine our ENHANZE® drug delivery technology with the collaborators’ proprietary compounds. 
Our approved product and our collaborators’ approved products and product candidates are based on rHuPH20, our patented recombinant human hyaluronidase enzyme. rHuPH20 is the active ingredient in our first commercially approved product, Hylenex® recombinant (“Hylenex”), and it works by breaking down hyaluronan (or “HA”), a naturally occurring carbohydrate that is a major component of the extracellular matrix in tissues throughout the body such as skin and cartilage. This temporarily increases dispersion and absorption allowing for improved subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other large therapeutic molecules, as well as small molecules and fluids. We refer to the application of rHuPH20 to facilitate the delivery of other drugs or fluids as our ENHANZE® Drug Delivery Technology (“ENHANZE”). We license the ENHANZE technology to form collaborations with biopharmaceutical companies that develop or market drugs requiring or benefiting from injection via the subcutaneous route of administration. In the development of proprietary intravenous (IV) drugs combined with our ENHANZE technology, data have been generated supporting the potential for ENHANZE to reduce treatment burden, as a result of shorter duration of subcutaneous (SC) administration. ENHANZE may enable fixed-dose SC dosing compared to weight-based dosing required for IV administration, and potentially allow for lower rates of infusion related reactions. Lastly, certain proprietary drugs co-formulated with ENHANZE have been granted additional exclusivity, extending the patent life of the product beyond the one of the proprietary IV drug.
We currently have ENHANZE collaborations with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc. (“Roche”), Baxalta US Inc. and Baxalta GmbH (now members of the Takeda group of companies, following the acquisition of Shire plc by Takeda Pharmaceutical Company Limited in January 2019) (“Baxalta”), Pfizer Inc. (“Pfizer”), Janssen Biotech, Inc. (“Janssen”), AbbVie, Inc. (“AbbVie”), Eli Lilly and Company (“Lilly”), Bristol-Myers Squibb Company (“BMS”), Alexion Pharma Holding (“Alexion”) and ARGENX BVBA (“argenx”). We receive royalties from two of these collaborations, including royalties from sales of one product from the Baxalta collaboration and two products from the Roche collaboration. Future potential revenues from the sales and/or royalties of our approved products, product candidates, and ENHANZE collaborations will depend on the ability of Halozyme and our collaborators to develop, manufacture, secure and maintain regulatory approvals for approved products and product candidates and commercialize product candidates.
On November 4, 2019, we announced that our HALO-301 Phase 3 clinical study evaluating PEGPH20 in combination with ABRAXANE and gemcitabine as a first-line therapy for treatment of patients with metastatic pancreatic cancer failed to reach the primary endpoint of overall survival. The study failed to demonstrate an improvement in overall survival compared to gemcitabine and nab-paclitaxel alone (11.2 months median overall survival compared to 11.5 months, HR=1.00, p=0.9692). Due to the results of the study, we halted development activities for PEGPH20, closed our oncology operations and implemented an organizational restructuring to focus our operations on ENHANZE.
We closed all ongoing oncology clinical studies including the Phase 3 clinical testing for PEGPH20 with ABRAXANE and gemcitabine in stage IV pancreatic ductal adenocarcinoma (“PDA”) (HALO-301) and the Phase 1b/2 clinical testing for PEGPH20 with Tecentriq in patients with cholangiocarcinoma and gall bladder cancer (HALO 110-101/MATRIX). The Roche -Genentech sponsored MORPHEUS PDA and gastric cancer studies closed the arms containing PEGPH20 to enrollment. All patients who were treated in PEGPH20 arms are off PEGPH20 treatment and are in follow up, per study protocol.
Except where specifically noted or the context otherwise requires, references to “Halozyme,” “the Company,” “we,” “our,” and “us” in these notes to consolidated financial statements refer to Halozyme Therapeutics, Inc. and its wholly owned subsidiary, Halozyme, Inc., and Halozyme, Inc.’s wholly owned subsidiaries, Halozyme Holdings Ltd., Halozyme Royalty LLC, Halozyme Switzerland GmbH and Halozyme Switzerland Holdings GmbH.

F-10
Halozyme Therapeutics, Inc.
Notes to Consolidated Financial Statements — (Continued)


2. Summary of Significant Accounting Policies
Basis of Presentation
The consolidated financial statements include the accounts of Halozyme Therapeutics, Inc. and our wholly owned subsidiary, Halozyme, Inc., and Halozyme, Inc.’s wholly owned subsidiaries, Halozyme Holdings Ltd., Halozyme Royalty LLC, Halozyme Switzerland GmbH and Halozyme Switzerland Holdings GmbH. All intercompany accounts and transactions have been eliminated.
Use of Estimates
The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”) requires management to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes. On an ongoing basis, we evaluate our estimates and judgments, which are based on historical and anticipated results and trends and on various other assumptions that management believes to be reasonable under the circumstances. By their nature, estimates are subject to an inherent degree of uncertainty and, as such, actual results may differ from management’s estimates.
Cash Equivalents and Marketable Securities
Cash equivalents consist of highly liquid investments, readily convertible to cash, that mature within ninety days or less from the date of purchase. As of December 31, 2019, our cash equivalents consisted of money market funds.
Marketable securities are investments with original maturities of more than ninety days from the date of purchase that are specifically identified to fund current operations. Marketable securities are considered available-for-sale. These investments are classified as current assets, even though the stated maturity date may be one year or more beyond the current balance sheet date which reflects management’s intention to use the proceeds from the sale of these investments to fund our operations, as necessary. Such available-for-sale investments are carried at fair value with unrealized gains and losses recorded in other comprehensive income (loss) and included as a separate component of stockholders’ equity (deficit). The cost of marketable securities is adjusted for amortization of premiums or accretion of discounts to maturity, and such amortization or accretion is included in investment and other income, net in the consolidated statements of operations. We use the specific identification method for calculating realized gains and losses on marketable securities sold. Realized gains and losses and declines in value judged to be other-than-temporary on marketable securities, if any, are included in investment and other income, net in the consolidated statements of operations.
Restricted Cash
Under the terms of the leases of our facilities, we are required to maintain letters of credit as security deposits during the terms of such leases. At December 31, 2019 and 2018, restricted cash of $0.5 million was pledged as collateral for the letters of credit.
Fair Value of Financial Instruments
The authoritative guidance for fair value measurements establishes a three tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.
Our financial instruments include cash equivalents, available-for-sale marketable securities, accounts receivable, prepaid expenses and other assets, accounts payable, accrued expenses and long-term debt. Fair value estimates of these instruments are made at a specific point in time, based on relevant market information. These estimates may be subjective in nature and involve uncertainties and matters of significant judgment and therefore cannot be determined with precision. The carrying amount of cash equivalents, accounts receivable, prepaid expenses and other assets, accounts payable and accrued expenses are generally considered to be representative of their respective fair values because of the short-term nature of those instruments. Based on Level 3 inputs and the borrowing rates currently available for loans with similar terms, we believe the fair value of long-term debt approximates its carrying value.

F-11
Halozyme Therapeutics, Inc.
Notes to Consolidated Financial Statements — (Continued)


Available-for-sale marketable securities consist of asset-backed securities, corporate debt securities, U.S. Treasury securities and commercial paper, and are measured at fair value using Level 1 and Level 2 inputs. Level 2 financial instruments are valued using market prices on less active markets and proprietary pricing valuation models with observable inputs, including interest rates, yield curves, maturity dates, issue dates, settlement dates, reported trades, broker-dealer quotes, issue spreads, benchmark securities or other market related data. We obtain the fair value of Level 2 investments from our investment manager, who obtains these fair values from a third-party pricing source. We validate the fair values of Level 2 financial instruments provided by our investment manager by comparing these fair values to a third-party pricing source.
Concentrations of Credit Risk, Sources of Supply and Significant Customers
We are subject to credit risk from our portfolio of cash equivalents and marketable securities. These investments were made in accordance with our investment policy which specifies the categories, allocations, and ratings of securities we may consider for investment. The primary objective of our investment activities is to preserve principal while at the same time maximizing the income we receive without significantly increasing risk. We maintain our cash and cash equivalent balances with one major commercial bank and marketable securities with another financial institution. Deposits held with the financial institutions exceed the amount of insurance provided on such deposits. We are exposed to credit risk in the event of a default by the financial institutions holding our cash, cash equivalents and marketable securities to the extent recorded on the consolidated balance sheets.
We are also subject to credit risk from our accounts receivable related to our product sales and revenues under our license and collaborative agreements. We have license and collaborative agreements with pharmaceutical companies under which we receive payments for royalties, license fees, milestone payments for specific achievements designated in the collaborative agreements, reimbursements of research and development services and supply of bulk formulation of rHuPH20. In addition, we sell Hylenex® recombinant in the United States to a limited number of established wholesale distributors in the pharmaceutical industry. Credit is extended based on an evaluation of the customer’s financial condition, and collateral is not required. Management monitors our exposure to accounts receivable by periodically evaluating the collectibility of the accounts receivable based on a variety of factors including the length of time the receivables are past due, the financial health of the customer and historical experience. Based upon the review of these factors, we recorded no allowance for doubtful accounts at December 31, 2019 and 2018. Approximately 93% of the accounts receivable balance at December 31, 2019 represents amounts due from Janssen, Roche and Baxalta. Approximately 81% of the accounts receivable balance at December 31, 2018 represents amounts due from Roche and Baxalta.
The following table indicates the percentage of total revenues in excess of 10% with any single customer:
 
 
Year Ended December 31,
 
 
2019
 
2018
 
2017
Roche
 
40%
 
72%
 
38%
argenx
 
23%
 
—%
 
—%
Janssen
 
18%
 
2%
 
6%
BMS
 
1%
 
4%
 
32%
Alexion
 
1%
 
3%
 
13%

F-12
Halozyme Therapeutics, Inc.
Notes to Consolidated Financial Statements — (Continued)


We attribute revenues under collaborative agreements, including royalties, to the individual countries where the customer is headquartered. We attribute revenues from product sales to the individual countries to which the product is shipped. Worldwide revenues from external customers are summarized by geographic location in the following table (in thousands):
 
 
Year Ended December 31,
 
 
2019
 
2018
 
2017
United States
 
$
116,083

 
$
40,475

 
$
196,274

Switzerland
 
78,413

 
109,890

 
119,136

All other foreign
 
1,496

 
1,497

 
1,203

Total revenues
 
$
195,992

 
$
151,862

 
$
316,613


We rely on two third-party manufacturers for the supply of bulk rHuPH20 for use in the manufacture of Hylenex recombinant and our other collaboration products and product candidates. Payments due to these suppliers represented 47% and 2% of the accounts payable balance at December 31, 2019 and 2018, respectively. We also rely on a third-party manufacturer for the fill and finish of Hylenex recombinant product under a contract. Payments due to this supplier represented 8% and 0% of the accounts payable balance at December 31, 2019 and 2018, respectively.
Accounts Receivable, Net
Accounts receivable is recorded at the invoiced amount and is non-interest bearing. Accounts receivable is recorded net of allowances for doubtful accounts, cash discounts for prompt payment, distribution fees and chargebacks. We recorded no allowance for doubtful accounts at December 31, 2019 and 2018 as the collectibility of accounts receivable was reasonably assured.
Inventories
Inventories are stated at lower of cost or net realizable value. Cost is determined on a first-in, first-out basis. Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. Inventories are reviewed periodically for potential excess, dated or obsolete status. We evaluate the carrying value of inventories on a regular basis, taking into account such factors as historical and anticipated future sales compared to quantities on hand, the price we expect to obtain for products in their respective markets compared with historical cost and the remaining shelf life of goods on hand.
Bulk rHuPH20 formulations manufactured for partner use prior to our partner receiving marketing approval from the U.S. Food and Drug Administration (“FDA”) or comparable regulatory agencies in foreign countries and with no alternative future use are recorded as research and development expense. All direct manufacturing costs incurred after the partner receives marketing approval are capitalized as inventory. Bulk rHuPH20 formulations manufactured for general partner and internal use, which can potentially be used by any collaboration partner or by us in Hylenex, and ENHANZE drug product used by our partners in clinical trials, is considered to have alternative future use and all manufacturing costs are capitalized as inventory. Inventories used in our clinical trials are expensed at the time the inventories are packaged for the clinical trials.
As of December 31, 2019 and 2018, inventories consisted of $1.4 million and $2.2 million, respectively, of Hylenex recombinant inventory, net, and $28.0 million and $20.4 million, respectively, of bulk rHuPH20.
Leases

The Company has entered into operating leases primarily for real estate and automobiles. These leases have terms which range from 3 years to 6 years. We determine if an arrangement contains a lease at inception. Right of use (“ROU”) assets and liabilities resulting from operating leases are included in property and equipment, accrued expenses and other long-term liabilities on our consolidated balance sheets. Operating lease ROU assets and liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the discount rate to calculate the present value of future payments. The operating lease ROU asset also includes any lease payments made and

F-13
Halozyme Therapeutics, Inc.
Notes to Consolidated Financial Statements — (Continued)


excludes lease incentives and initial direct costs incurred. Our leases often include options to extend or terminate the lease. These options are included in the lease term when it is reasonably certain that we will exercise that option. Short-term leases with an initial term of 12 months or less are not recorded on the balance sheet. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term.
We have lease agreements with lease and non-lease components, which are generally accounted for separately. For certain equipment leases, such as automobiles, we account for the lease and non-lease components as a single lease component.
Property and Equipment, Net
Property and equipment are recorded at cost, less accumulated depreciation and amortization. Equipment is depreciated using the straight-line method over its estimated useful life ranging from three years to ten years and leasehold improvements are amortized using the straight-line method over the estimated useful life of the asset or the lease term, whichever is shorter.
Impairment of Long-Lived Assets
We account for long-lived assets in accordance with authoritative guidance for impairment or disposal of long-lived assets. Long-lived assets are reviewed for events or changes in circumstances, which indicate that their carrying value may not be recoverable.
Comprehensive Income (Loss)
Comprehensive income (loss) is defined as the change in equity during the period from transactions and other events and circumstances from non-owner sources.
Revenue Recognition
We generate revenues from payments received under collaborative agreements and product sales. As of January 1, 2018, we adopted ASC 606, Revenue from Contracts with Customers (ASC 606) which affects how we recognize revenues in these arrangements. We applied the provisions of ASC 606 using the modified retrospective approach, with the cumulative effect of the adoption recognized as of January 1, 2018, to all contracts that had not been completed as of that date. Under ASC 606, we recognize revenue when we transfer promised goods or services to customers in an amount that reflects the consideration to which we expect to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers we perform the following five steps: (i) identify the promised goods or services in the contract; (ii) identify the performance obligations in the contract, including whether they are distinct in the context of the contract; (iii) determine the transaction price, including the constraint on variable consideration; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) we satisfy the performance obligations. Amounts reported in prior periods have not been adjusted to reflect the adoption of ASC 606. Accordingly, the reported revenue amounts for the year ended December 31, 2019 and 2018 and the year ended December 31, 2017 are based on different accounting policies.
Prior to the ASC 606 adoption, revenue was recognized when all of the following criteria were met: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred or services have been rendered; (3) the seller’s price to the buyer is fixed or determinable; and (4) collectibility is reasonably assured. Differences between the revenue recognition policies applicable prior to the adoption and ASC 606 are described in the following sections and in Note 4.
Revenues under Collaborative Agreements - as reported under ASC 606 beginning January 1, 2018
Under these agreements, we grant the collaboration partner a worldwide license to develop and commercialize products using our ENHANZE technology to combine our patented rHuPH20 enzyme with their proprietary biologics directed at up to a specified number of targets. Targets are usually licensed on an exclusive, global basis. Targets selected subsequent to inception of the arrangement require payment of an additional license fee. The collaboration partner is responsible for all development, manufacturing, clinical, regulatory, sales and marketing costs for any products developed under the agreement. We are responsible for supply of bulk rHuPH20 based on the collaboration partner’s purchase orders, and may also be separately engaged to perform research and development services. While these collaboration agreements are similar in that they originate from the same framework, each one is the result of an arms-length negotiation and thus may vary from one to the other.

F-14
Halozyme Therapeutics, Inc.
Notes to Consolidated Financial Statements — (Continued)


We collect an upfront license payment from the collaboration partner, and are also entitled to receive event-based payments subject to the collaboration partner’s achievement of specified development, regulatory and sales-based milestones. In several agreements, collaboration partners pay us annual fees to maintain their exclusive license rights if they are unable to advance product development to specified stages. We earn separate fees for bulk rHuPH20 supplies and research and development services. In addition, the collaboration partner will pay us royalties at an on average mid-single digit percent rate of their sales if products under the collaboration are commercialized. All amounts owed to us are noncancelable after the underlying triggering event occurs, and nonrefundable once paid. Unless terminated earlier in accordance with its terms, the collaboration generally continues in effect until the later of: (i) expiration of the last to expire of the valid claims of our patents covering rHuPH20 or other specified patents developed under the collaboration which valid claim covers a product developed under the collaboration, and (ii) expiration of the last to expire royalty term for a product developed under the collaboration, which is determined separately for each country. In the event such valid claims expire prior to the last to expire royalty term, the royalty rate is reduced for the remaining royalty term following such expiration. The collaboration partner may terminate the agreement prior to expiration for any reason in its entirety or on a target-by-target basis generally upon 90 days prior written notice to us. Upon any such termination, the license granted to the collaboration partner (in total or with respect to the terminated target, as applicable) will terminate provided, however, that in the event of expiration of the agreement, the on-going licenses granted will become perpetual, non-exclusive and fully paid.
Although these agreements are in form structured as collaborative agreements, we concluded for accounting purposes they represent contracts with customers, and are not subject to accounting literature on collaborative arrangements. This is because we grant to collaboration partners licenses to our intellectual property, and provide supply of bulk rHuPH20 and research and development services which are all outputs of our ongoing activities, in exchange for consideration. We do not develop assets jointly with collaboration partners, and do not share in significant risks of their development or commercialization activities. Accordingly, we concluded our collaborative agreements must be accounted for pursuant to ASC Topic 606, Revenue from Contracts with Customers.
Under all of our collaborative agreements, we have identified licenses to use functional intellectual property as the only performance obligation. The intellectual property underlying the license is our proprietary ENHANZE® technology which represents application of rHuPH20 to facilitate delivery of drugs or fluids. The license grants the collaboration partners right to use our intellectual property as it exists on the effective date of the license, because there is no ongoing development of the ENHANZE technology required. Therefore, we recognize revenue from licenses at the point when the license becomes effective and the collaboration partner has received access to our intellectual property, usually at the inception of the agreement.
When collaboration partners can select additional targets to add to the licenses granted, we consider these rights to be options. We evaluate whether such options contain material rights, i.e. have exercise prices that are discounted compared to what we would charge for a similar license to a new collaboration partner. The exercise price of these options includes a combination of the target selection fees, event-based milestone payments and royalties. When these amounts in aggregate are not offered at a discount that exceeds discounts available to other customers, we conclude the option does not contain a material right, and we consider grants of additional licensing rights upon option exercises to be separate contracts (target selection contracts).
We provide standard indemnification and protection of licensed intellectual property for our customers. These provisions are part of assurance that the licenses meet the agreements’ representations and are not obligations to provide goods or services.
We also fulfill purchase orders for supply of bulk rHuPH20 and perform research and development services pursuant to projects authorization forms for our collaboration partners, which represent separate contracts. Additionally, we price our supply of bulk rHuPH20 and research and development services at our regular selling prices, called standalone selling price or SSP. Therefore, our collaboration partners do not have material rights to order these items at prices not reflective of SSP. Refer to the discussion below regarding recognition of revenue for these separate contracts.
Transaction price for a contract represents the amount to which we are entitled in exchange for providing goods and services to the customer. Transaction price does not include amounts subject to uncertainties unless it is probable that there will be no significant reversal of revenue when the uncertainty is resolved. Apart from the upfront license payment (or target selection fees in the target selection contracts), all other fees we may earn under our collaborative agreements are subject to significant uncertainties of product development. Achievement of many of the event-based development and regulatory milestones may not be probable until such milestones are actually achieved. This generally relates to milestones such as obtaining marketing authorization approvals.

F-15
Halozyme Therapeutics, Inc.
Notes to Consolidated Financial Statements — (Continued)


With respect to other development milestones, e.g. dosing of a first patient in a clinical trial, achievement could be considered probable prior to its actual occurrence, based on the progress towards commencement of the trial. We do not include any amounts subject to uncertainties into the transaction price until it is probable that the amount will not result in a significant reversal of revenue in the future. At the end of each reporting period, we re-evaluate the probability of achievement of such milestones and any related constraint, and if necessary, adjust our estimate of the overall transaction price.
When target exchange rights are held by collaboration partners, and the amounts attributed to these rights are not refundable, they are included in the transaction price. However, they are recorded as deferred revenues because we have a potential performance obligation to provide a new target upon an exchange right being exercised. These amounts are recognized in revenue when the right of exchange expires or is exercised.
Because our agreements have one type of performance obligation (licenses) which are typically all transferred at the same time at agreement inception, allocation of transaction price often is not required. However, allocation is required when licenses for some of the individual targets are subject to rights of exchange, because revenue associated with these targets cannot be recognized. We perform an allocation of the upfront amount based on relative SSP of licenses for individual targets. We determine license SSP using income-based valuation approach utilizing risk-adjusted discounted cash flow projections of the estimated return a licensor would receive. When amounts subject to uncertainties, such as milestones and royalties, are included in the transaction price, we attribute them to the specific individual target licenses which generate such milestone or royalty amounts.
We also estimate SSP of bulk rHuPH20 and research and development services, to determine that our collaboration partners do not have material rights to order them at discounted prices. For supplies of bulk rHuPH20, because we effectively act as a contract manufacturer to our collaboration partners, we estimate and charge SSP based on the typical contract manufacturer margins consistently with all of our collaborative partners. We determine SSP of research and development services based on a fully-burdened labor rate. Our rates are comparable to those we observe in other collaborative agreements. We also have a history of charging similar rates to all of our collaboration partners.
Upfront amounts allocated to licenses to individual targets are recognized as revenue when the license is transferred to the collaboration partner, as discussed above, if the license is not subject to exchange rights, or when the exchange right expires or is exercised. Development milestones and other fees are recognized in revenue when they are included in the transaction price, because by that time we have already transferred the related license to the collaboration partner.
Sales-based milestones and royalties cannot be recognized until the underlying sales occur. We do not receive final royalty reports from our collaboration partners until after we complete our financial statements for a prior quarter. Therefore, we recognize revenue based on estimates of the royalty earned, which are based on preliminary reports provided by our collaboration partners. We will record a true-up in the following quarter if necessary, when final royalty reports are received. To date, we have not recorded any material true-ups.
In contracts to provide research and development services, such services represent the only performance obligation. The fees are charged based on hours worked by our employees and the fixed contractual rate per hour, plus third-party pass-through costs, on a monthly basis. We recognize revenues as the related services are performed based on the amounts billed, as the collaboration partner consumes the benefit of research and development work simultaneously as we perform these services, and the amounts billed reflect the value of these services to the customer.
Refer to Note 4 Revenue, for further discussion on our collaborative arrangements.
Prior to the adoption of ASC 606 on January 1, 2018, we recognized upfront amounts received under two of our collaborative agreements straight-line over the contract term in accordance with the accounting standards that were in effect in 2006-2007, when these collaborative agreements were entered into. In addition, we recognized royalty revenue in the period when we received final royalty reports from the collaboration partners, in the quarter following the quarter in which the corresponding sales occurred. There were no other adoption differences in revenue recognized due to the transition from the previously existing authoritative accounting literature to ASC 606.

F-16
Halozyme Therapeutics, Inc.
Notes to Consolidated Financial Statements — (Continued)


Product Sales, Net - as reported under ASC 606 beginning January 1, 2018
Hylenex Recombinant
We sell Hylenex recombinant in the U.S. to wholesale pharmaceutical distributors, who sell the product to hospitals and other end-user customers. Sales to wholesalers are made pursuant to purchase orders subject to the terms of a master agreement, and delivery of individual packages of Hylenex recombinant represent performance obligations under each purchase order. We use a contract manufacturer to produce Hylenex recombinant and a third-party logistics (3PL) vendor to process and fulfill orders. We concluded we are the principal in the sales to wholesalers because we control access to services rendered by both vendors and direct their activities. We have no significant obligations to wholesalers to generate pull-through sales.
Selling prices initially billed to wholesalers are subject to discounts for prompt payment and subsequent chargebacks when wholesalers sell Hylenex recombinant at negotiated discounted prices to members of certain group purchasing organizations (“GPOs”) and government programs. We also pay quarterly distribution fees to certain wholesalers for inventory reporting and chargeback processing, and to GPOs as administrative fees for services and for access to GPO members. We concluded the benefits received in exchange for these fees are not distinct from our sales of Hylenex recombinant, and accordingly we apply these amounts to reduce revenues. Wholesalers also have rights to return unsold product nearing or past the expiration date. Because of the shelf life of Hylenex recombinant and our lengthy return period, there may be a significant period of time between when the product is shipped and when we issue credits on returned product.
We estimate the transaction price when we receive each purchase order taking into account the expected reductions of the selling price initially billed to the wholesaler arising from all of the above factors. We have compiled historical experience and data to estimate future returns and chargebacks of Hylenex recombinant and the impact of the other discounts and fees we pay. When estimating these adjustments to the transaction price, we reduce it sufficiently to be able to assert that it is probable that there will be no significant reversal of revenue when the ultimate adjustment amounts are known.
Each purchase order contains only one type of product, and is usually shipped to the wholesaler in a single shipment. Therefore, allocation of the transaction price to individual packages is not required.
We recognize revenue from Hylenex recombinant product sales and related cost of sales upon product delivery to the wholesaler location. At that time, the wholesalers take control of the product as they take title, bear the risk of loss of ownership, and have an enforceable obligation to pay us. They also have the ability to direct sales of product to their customers on terms and at prices they negotiate. Although wholesalers have product return rights, we do not believe they have a significant incentive to return the product to us.
Upon recognition of revenue from product sales of Hylenex recombinant, the estimated amounts of credit for product returns, chargebacks, distribution fees, prompt payment discounts, and GPO fees are included in sales reserves, accrued liabilities and net of accounts receivable. We monitor actual product returns, chargebacks, discounts and fees subsequent to the sale. If these amounts differ from our estimates, we make adjustments to these allowances, which are applied to increase or reduce product sales revenue and earnings in the period of adjustment.
In connection with the orders placed by wholesalers, we incur costs such as commissions to our sales representatives. However, as revenue from product sales is recognized upon delivery to the wholesaler, which occurs shortly after we receive a purchase order, we do not capitalize these commissions and other costs, based on application of the practical expedient allowed within the applicable guidance.

F-17
Halozyme Therapeutics, Inc.
Notes to Consolidated Financial Statements — (Continued)


Bulk rHuPH20
We sell bulk rHuPH20 to collaboration partners for use in research and development; subsequent to receiving marketing approval, we sell it for use in collaboration commercial products. Sales are made pursuant to purchase orders subject to the terms of the collaborative agreement, and delivery of units of bulk rHuPH20 represent performance obligations under each purchase order. We provide a standard warranty that the product conforms to specifications. We use contract manufacturers to produce bulk rHuPH20 and have concluded we are the principal in the sales to collaboration partners. The transaction price for each purchase order of bulk rHuPH20 is fixed based on the cost of production plus a contractual markup, and is not subject to adjustments. Allocation of the transaction price to individual quantities of the product is usually not required because each order contains only one type of product.
We recognize revenue from the sale of bulk rHuPH20 as product sales and related cost of sales upon transfer of title to our partners. At that time, the partners take control of the product, bear the risk of loss of ownership, and have an enforceable obligation to pay us.
ENHANZE Drug Product
We sell ENHANZE drug product to collaboration partners for use in research and development in early phase clinical studies. Sales are made pursuant to purchase orders subject to the terms of the collaborative agreement, and delivery of units of ENHANZE drug product represent performance obligations under each purchase order. We provide a standard warranty that the product conforms to specifications. We use contract manufacturers to produce ENHANZE drug product and we concluded we are the principal in the sales to collaboration partners. The transaction price for each purchase order of ENHANZE drug product is fixed based on the cost of production plus a contractual markup, and is not subject to adjustments. Allocation of the transaction price to individual quantities of the product is usually not required because each order contains only one type of product.
We recognize revenue from the sale of ENHANZE drug product as product sales and related cost of sales upon transfer of title to our partners. At that time, the partners take control of the product, bear the risk of loss of ownership, and have an enforceable obligation to pay us.
Revenue Presentation
In our statements of operations, we report as revenues under collaborative agreements the upfront payments, event-based development and regulatory milestones and sales milestones. We also include in this category revenues from separate research and development contracts pursuant to project authorization forms. We report royalties received from collaboration partners as a separate line in our statements of operations.
Revenues from sales of Hylenex recombinant, bulk rHuPH20 that has alternative future use and ENHANZE drug product are included in product sales, net.
In the footnotes to our financial statements, we provide disaggregated revenue information by type of arrangement (product sales, net, collaborative agreements and research and development services), and additionally, by type of payment stream received under collaborative agreements (upfront license fees, event-based development and regulatory milestones and other fees, sales milestones and royalties).

F-18
Halozyme Therapeutics, Inc.
Notes to Consolidated Financial Statements — (Continued)


Cost of Product Sales
Cost of product sales consists primarily of raw materials, third-party manufacturing costs, fill and finish costs, freight costs, internal costs and manufacturing overhead associated with the production of Hylenex recombinant and bulk rHuPH20 and ENHANZE drug product that has alternative future use. Cost of product sales also consists of the write-down of excess, dated and obsolete inventories and the write-off of inventories that do not meet certain product specifications, if any. Prior to bulk rHuPH20 and ENHANZE drug product having alternative future use, all costs related to the manufacturing of those products were charged to research and development expenses in the periods such costs were incurred. During the year ended December 31, 2019, sales of bulk rHuPH20 and ENHANZE drug product included $1.5 million of cost of sales that were previously expensed as research and development. Of the bulk rHuPH20 and ENHANZE drug product that has alternative future use on hand as of December 31, 2019, approximately $0.1 million in manufacturing costs were previously recorded as research and development expenses. We expect to sell this inventory by the end of 2020.
Research and Development Expenses
Research and development expenses include salaries and benefits, facilities and other overhead expenses, external clinical trial expenses, research related manufacturing services, contract services and other outside expenses. Research and development expenses are charged to operating expenses as incurred when these expenditures relate to our research and development efforts and have no alternative future uses. When bulk rHuPH20 is manufactured for use in research and development by us or our partners and the product cannot be redirected for alternative use due to formulation and manufacturing specifications, the manufacturing costs are recorded as research and development expense. Bulk rHuPH20 that is manufactured for partner use prior to our partner receiving marketing approval from the FDA or comparable regulatory agencies in foreign countries and meet these specifications is recorded as research and development expenses. Bulk rHuPH20 formulations manufactured for general partner and internal use, which can potentially be used by any collaboration partner or by us in Hylenex, is considered to have alternative future use and all manufacturing costs are capitalized as inventory. Inventories used in our clinical trials were expensed at the time the inventories were packaged for the clinical trials.
We are obligated to make upfront payments upon execution of certain research and development agreements. Advance payments, including nonrefundable amounts, for goods or services that will be used or rendered for future research and development activities are deferred. Such amounts are recognized as expense as the related goods are delivered or the related services are performed or such time when we do not expect the goods to be delivered or services to be performed.
Milestone payments that we make in connection with in-licensed technology for a particular research and development project that have no alternative future uses (in other research and development projects or otherwise) and therefore no separate economic value are expensed as research and development costs at the time the costs are incurred. We currently have no in-licensed technologies that have alternative future uses in research and development projects or otherwise.
Clinical Trial Expenses
We make payments in connection with our clinical trials under contracts with contract research organizations that support conducting and managing clinical trials. The financial terms of these agreements are subject to negotiation and vary from contract to contract and may result in uneven payment flows. Generally, these agreements set forth the scope of work to be performed at a fixed fee, unit price or on a time and materials basis. A portion of our obligation to make payments under these contracts depends on factors such as the successful enrollment or treatment of patients or the completion of other clinical trial milestones.
Expenses related to clinical trials are accrued based on our estimates and/or representations from service providers regarding work performed, including actual level of patient enrollment, completion of patient studies and progress of the clinical trials. Other incidental costs related to patient enrollment or treatment are accrued when reasonably certain. If the amounts we are obligated to pay under our clinical trial agreements are modified (for instance, as a result of changes in the clinical trial protocol or scope of work to be performed), we adjust our accruals accordingly on a prospective basis. Revisions to our contractual payment obligations are charged to expense in the period in which the facts that give rise to the revision become reasonably certain.

F-19
Halozyme Therapeutics, Inc.
Notes to Consolidated Financial Statements — (Continued)


Share-Based Compensation
We record compensation expense associated with stock options, restricted stock awards (“RSAs”), and restricted stock units (“RSUs”) in accordance with the authoritative guidance for stock-based compensation. The cost of employee services received in exchange for an award of an equity instrument is measured at the grant date, based on the estimated fair value of the award, and is recognized as expense on a straight-line basis over the requisite service period of the award. Share-based compensation expense for an award with a performance condition is recognized when the achievement of such performance condition is determined to be probable. If the outcome of such performance condition is not determined to be probable or is not met, no compensation expense is recognized and any previously recognized compensation expense is reversed. Forfeitures are recognized as a reduction of share-based compensation expense as they occur.
Income Taxes
We provide for income taxes using the liability method. Under this method, deferred income tax assets and liabilities are determined based on the differences between the financial statement carrying amounts of existing assets and liabilities at each year end and their respective tax bases and are measured using enacted tax rates in effect for the year in which the differences are expected to affect taxable income. Significant judgment is required by management to determine our provision for income taxes, our deferred tax assets and liabilities, and the valuation allowance to record against our net deferred tax assets, which are based on complex and evolving tax regulations throughout the world. Deferred tax assets and other tax benefits are recorded when it is more likely than not that the position will be sustained upon audit. While we have begun to utilize certain of our net operating losses, we have not yet established a track record of profitability. Accordingly, valuation allowances have been recorded to reduce our net deferred tax assets to zero, with the exception of the alternative minimum tax ("AMT") credit carryover of $1.7 million. Under the Tax Cuts and Jobs Act (the “Act”) enacted in December 2017, the AMT credit carryover will either be utilized, or if unutilized fully refunded in 2022. For all other deferred tax assets, the valuation allowance will reduce the net value to zero until such time as we can demonstrate an ability to realize them.
The 2015 and 2016 federal returns were selected for audit by the IRS. The audit was completed in September 2019 with no material adjustments.
Net (Loss) Income Per Share
Basic net (loss) income per common share is computed by dividing net (loss) income for the period by the weighted average number of common shares outstanding during the period, without consideration for common stock equivalents. Outstanding stock options, unvested RSAs, unvested RSUs and the Convertible Notes are considered common stock equivalents and are only included in the calculation of diluted earnings per common share when net income is reported and their effect is dilutive. For the years ended December 31, 2019, 2018 and 2017, approximately 33.1 million, 13.8 million, and 7.1 million shares, respectively, of outstanding stock options, unvested RSAs, unvested RSUs and Convertible Notes were excluded from the calculation of diluted net (loss) income per common share because their effect was anti-dilutive.
The 19.3 million shares underlying the conversion option of the Convertible Notes will not have an impact on our diluted earnings per share when net income is reported until the average market price of our common stock exceeds the conversion price of $23.85 per share, as we intend and have the ability to settle the principal amount of the Convertible Notes in cash upon conversion. We compute the potentially dilutive impact of the shares of common stock related to the Convertible Notes using the treasury stock method.
A reconciliation of the numerators and the denominators of the basic and diluted net (loss) income per common share computations is as follows (in thousands, except per share amounts):

F-20
Halozyme Therapeutics, Inc.
Notes to Consolidated Financial Statements — (Continued)


 
 
Year Ended December 31,
 
 
2019
 
2018
 
2017
Numerator:
 
 
 
 
 
 
Net (loss) income
 
$
(72,240
)
 
$
(80,330
)
 
$
62,971

Denominator:
 
 
 
 
 
 
Weighted average common shares outstanding for basic
net (loss) income per share
 
144,329

 
143,599

 
136,419

Net effect of dilutive common stock equivalents
 
—

 
—

 
2,649

Weighted average common shares outstanding for diluted
net (loss) income per share
 
144,329

 
143,599

 
139,068

Net (loss) income per share:
 
 
 
 
 
 
Basic
 
$
(0.50
)
 
$
(0.56
)
 
$
0.46

Diluted
 
$
(0.50
)
 
$
(0.56
)
 
$
0.45


Segment Information
We operate our business in one segment, which includes all activities related to the research, development and commercialization of our proprietary enzymes. This segment also includes revenues and expenses related to (i) research and development and bulk rHuPH20 manufacturing activities conducted under our collaborative agreements with third parties and (ii) product sales of Hylenex recombinant. The chief operating decision-maker reviews the operating results on an aggregate basis and manages the operations as a single operating segment. Our long-lived assets located in foreign countries had no book value as of December 31, 2019, 2018 and 2017.

F-21
Halozyme Therapeutics, Inc.
Notes to Consolidated Financial Statements — (Continued)


Adoption and Pending Adoption of Recent Accounting Pronouncements
The following table provides a brief description of recently issued accounting standards, those adopted in the current period and those not yet adopted:
Standard
 
Description
 
Effective Date
 
Effect on the Financial
Statements or Other Significant Matters
 
 
 
 
 
 
 
In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). In July 2018, the FASB issued additional guidance related to Topic 842.
 
The new guidance requires lessees to recognize assets and liabilities for most leases and provides enhanced disclosures.
 
January 1, 2019
 
We implemented the guidance on January 1, 2019 using a modified retrospective transition basis for leases existing as of the period of adoption. In order to adopt the new standard, we used the available practical expedients and newly implemented processes and internal controls for lease accounting. The practical expedients allowed us to carry forward our historical assessment of whether existing agreements are or contain a lease and the classification of our existing lease arrangements. All of our real-estate and automobile operating lease commitments are recognized as lease liabilities with corresponding right-of-use assets, which resulted in an increase in the assets and liabilities of the consolidated balance sheet of $7.2 million, using an assumed weighted average discount rate of 10.0%. The adoption did not have an impact on our consolidated statements of operations and did not require recognition of a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. We elected to continue applying the guidance under ASC 840 for comparative periods, as allowed through ASC 2018-11.
 
 
 
 
 
 
 


F-22
Halozyme Therapeutics, Inc.
Notes to Consolidated Financial Statements — (Continued)


Standard
 
Description
 
Effective Date
 
Effect on the Financial
Statements or Other Significant Matters
In December 2019, the FASB issued ASU 2019-12, Simplifying the Accounting for Income Taxes

 
The new guidance removes certain exceptions to the general principles of ASC 740 in order to simplify the complexities of its application. These changes include eliminations to the exceptions for intraperiod tax allocation, recognizing deferred tax liabilities related to outside basis differences, and year-to-date losses in interim periods among others.

 
January 1, 2019

 
We early adopted the new guidance on January 1, 2019. With the adoption we no longer apply the exception to the general rule for intraperiod tax allocations under the incremental method. During the period, we would have recorded a $14.7 million tax expense to APIC fully offset by a $14.7 million tax benefit in continuing operations.

 
 
 
 
 
 
 
In August 2018, the FASB issued ASU 2018-15, Intangibles-Goodwill and other Internal-Use Software (Subtopic 350-40)

 
The new guidance aligns the requirement for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirement for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license).

 
January 1, 2020

 
We plan to adopt the new guidance on January 1, 2020. We do not anticipate the adoption will have a material impact on our condensed consolidated financial position or results of operations.

 
 
 
 
 
 
 
In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820).
 
The new guidance removes, modifies and adds to certain disclosure requirements on fair value measurements in Topic 820, Fair Value Measurement.


 
January 1, 2020
 
We plan to adopt the new guidance on January 1, 2020. We do not anticipate the adoption will have a material impact on our consolidated financial position or results of operations.
 
 
 
 
 
 
 
In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326), Measurement of Credit Losses on Financial Instruments
 
The standard amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses for most financial assets and certain other instruments that aren’t measured at fair value through net income. For available-for-sale debt securities, entities will be required to recognize an allowance for credit losses rather than a reduction in carrying value of the asset. Entities will no longer be permitted to consider the length of time that fair value has been less than amortized cost when evaluating when credit losses should be recognized.
 
January 1, 2020
 
We plan to adopt the new guidance on January 1, 2020. We do not anticipate the adoption will have a material impact on our consolidated financial position or results of operations.




F-23
Halozyme Therapeutics, Inc.
Notes to Consolidated Financial Statements — (Continued)


3. Fair Value Measurement
Available-for-sale marketable securities consisted of the following (in thousands):
 
 
December 31, 2019
 
 
Amortized Cost
 
Gross Unrealized Gains
 
Gross Unrealized Losses
 
Estimated Fair Value
Asset-backed securities
 
$
30,484

 
$
55

 
$
—

 
$
30,539

Corporate debt securities
 
161,308

 
178

 
(14
)
 
161,472

U.S. Treasury securities
 
75,192

 
40

 
(5
)
 
75,227

Commercial paper
 
33,845

 
—

 
—

 
33,845

 
 
$
300,829

 
$
273

 
$
(19
)
 
$
301,083


 
 
December 31, 2018
 
 
Amortized Cost
 
Gross Unrealized Gains
 
Gross Unrealized Losses
 
Estimated Fair Value
Asset-backed securities
 
$
39,787

 
$
—

 
$
(40
)
 
$
39,747

Corporate debt securities
 
57,860

 
—

 
(127
)
 
57,733

U.S. Treasury securities
 
84,924

 
—

 
(87
)
 
84,837

Commercial paper
 
114,273

 
—

 
—

 
114,273

 
 
$
296,844

 
$
—

 
$
(254
)
 
$
296,590


As of December 31, 2019, 11 available-for-sale marketable securities with a fair market value of $82.9 million were in a gross unrealized loss position of $19 thousand, all of which had been in such position for less than 12 months. Based on our review of these marketable securities, we believe we had no other-than-temporary impairments on these securities as of December 31, 2019, because we do not intend to sell these securities and it is not more-likely-than-not that we will be required to sell these securities before the recovery of their amortized cost basis.
Contractual maturities of available-for-sale debt securities are as follows (in thousands):
 
 
December 31, 2019
 
December 31, 2018
 
 
Estimated Fair Value
Due within one year
 
$
274,805

 
$
296,590

After one but within five years
 
26,278

 
—

 
 
$
301,083

 
$
296,590



F-24
Halozyme Therapeutics, Inc.
Notes to Consolidated Financial Statements — (Continued)


The following table summarizes, by major security type, our cash equivalents and available-for-sale marketable securities that are measured at fair value on a recurring basis and are categorized using the fair value hierarchy (in thousands):
 
 
December 31, 2019
 
December 31, 2018
 
 
Level 1
 
Level 2
 
Total estimated fair value
 
Level 1
 
Level 2
 
Total estimated fair value
Cash equivalents:
 
 
 
 
 
 
 
 
 
 
 
 
Money market funds
 
$
119,949

 
$
—

 
$
119,949

 
$
57,987

 
$
—

 
$
57,987

Available-for-sale marketable
   securities:
 
 
 
 
 
 
 
 
 
 
 
 
Asset-backed securities
 
—

 
30,539

 
30,539

 
—

 
39,747

 
39,747

Corporate debt securities
 
—

 
161,472

 
161,472

 
—

 
57,733

 
57,733

U.S. Treasury securities
 
75,228

 
—

 
75,228

 
84,837

 
—

 
84,837

Commercial paper
 
—

 
33,845

 
33,845

 
—

 
114,273

 
114,273

 
 
$
195,177

 
$
225,856

 
$
421,033

 
$
142,824

 
$
211,753

 
$
354,577


There were no transfers between Level 1 and Level 2 of the fair value hierarchy during the year ended December 31, 2019. We had no instruments that were classified within Level 3 as of December 31, 2019 and 2018.

F-25
Halozyme Therapeutics, Inc.
Notes to Consolidated Financial Statements — (Continued)


4. Revenue
Our disaggregated revenues were as follows (in thousands):
 
 
Year Ended December 31,
 
 
2019
 
2018
 
2017
Royalties
 
$
69,899

 
$
78,981

 
$
63,507

 
 
 
 
 
 
 
Product sales, net
 
 
 
 
 
 
  Sales of bulk rHuPH20
 
$
48,285

 
$
12,729

 
$
35,246

  Sales of ENHANZE drug product
 
768

 
460

 
—

  Sales of Hylenex
 
16,995

 
15,045

 
15,150

Total product sales, net
 
66,048

 
28,234

 
50,396

 
 
 
 
 
 
 
Revenues under collaborative agreements:
 
 
 
 
 
 
  Upfront license and target nomination fees
 
53,000

 
26,336

 
172,806

  Event-based development milestones and regulatory milestone and other fees
 
5,500

 
16,000

 
16,317

  Sales-based milestones
 
—

 
—

 
1,417

  Research and development services
 
1,545

 
2,311

 
12,170

Total revenues under collaborative agreements
 
60,045

 
44,647

 
202,710

 
 
 
 
 
 
 
Total revenue
 
$
195,992

 
$
151,862

 
$
316,613


During the year ended December 31, 2019 we recognized revenue related to licenses granted to collaboration partners in prior periods in the amount of $74.9 million. This amount represents royalties earned in the current period, in addition to $5.0 million of variable consideration in the contracts where uncertainties have been resolved and the development milestones were expected to be achieved or were achieved. We also recognized revenue of $4.0 million during the year ended December 31, 2019 that had been included in deferred revenues at December 31, 2018. We did not recognize any adjustments to reduce sales reserves and allowances liability related to Hylenex recombinant sales in prior periods.
Revenue recognized during the year ended December 31, 2017 was determined in accordance with the accounting rules applicable prior to the adoption of ASC 606 on January 1, 2018.
Upon the adoption of ASC 606, we recognized an adjustment to increase our accounts receivable by $19.4 million, decrease deferred revenues by $51.8 million, and decrease accumulated deficit by $71.2 million. The impact of applying the provisions of ASC 606 in the year ended December 31, 2018 was to decrease revenues by $4.7 million. Under the previously existing authoritative accounting literature, at December 31, 2018 our accounts receivable, net would have been $19.3 million lower, and our deferred revenue $47.4 million higher, than the amounts reported in our consolidated balance sheet. ASC 606 did not have an aggregate impact on our net cash used in operating activities, but resulted in offsetting changes in net loss and certain assets and liabilities within net cash used in operating activities in the consolidated statement of cash flows.
Accounts receivable, net and deferred revenues (contract liabilities) from contracts with customers, including collaboration partners, consisted of the following (in thousands):
 
 
December 31, 2019
 
December 31, 2018
Accounts receivable, net
 
$
59,442

 
$
30,005

Deferred revenues
 
5,259

 
9,255



F-26
Halozyme Therapeutics, Inc.
Notes to Consolidated Financial Statements — (Continued)


As of December 31, 2019, the amounts included in the transaction price of our contracts with customers, including collaboration partners, and allocated to goods and services not yet provided were $12.3 million of which $7.0 million relates to unfulfilled product purchase orders and $5.3 million has been collected and reported as deferred revenues. The unfulfilled product purchase orders are estimated to be delivered in 2020. Of the total deferred revenues of $5.3 million, $4.0 million is expected to be used by our customers within the next 12 months.
There were no contract assets related to collaborative agreements at December 31, 2019. While we may become entitled to receive additional event-based development and regulatory milestones and other fees under our collaborative agreements, which relate to intellectual property licenses granted to collaboration partners in prior periods, no amounts were probable. The following table presents amounts under our collaborative agreements included in the transaction price (i.e. cumulative amounts triggered or probable) as of December 31, 2019 (in thousands):
 
 
Upfront
(1)
 
Development
(2)
 
Sales
(3)
 
 
Total
Collaboration partner and agreement date:
 
 
 
 
 
 
 
 
 
Roche (December 2006, September 2017 and October 2018)
 
$
105,000

 
$
30,000

 
$
22,000

 
 
$
157,000

Baxalta (September 2007)
 
10,000

 
3,000

 
9,000

 
 
22,000

Pfizer (December 2012)
 
14,500

 
2,000

 
—

 
 
16,500

Janssen (December 2014)
 
18,250

 
15,000

 
—

 
 
33,250

AbbVie (June 2015)
 
23,000

 
6,000

 
—

 
 
29,000

Lilly (December 2015)
 
33,000

 
—

 
—

 
 
33,000

BMS (September 2017)
 
105,000

 
5,000

 
—

 
 
110,000

Alexion (December 2017)
 
40,000

 
6,000

 
—

 
 
46,000

argenx (February 2019)
 
40,000

 
5,000

 
 
 
 
45,000

Royalties
 
 
 
 
 
 
 
 
323,285

Total amounts under our collaborative agreements included in the transaction price
 
 
 
 
 
 
 
 
815,035


(1)
Upfront and additional target selection fees
(2)
Event-based development and regulatory milestone amounts and other fees
(3)
Sales-based milestone amounts
Through December 31, 2019, our collaboration partners have completed development, obtained marketing authorization approvals for certain indications and commenced commercialization of the following products:
•
Roche, for Herceptin SC in the European Union (“EU”) in August 2013; and MabThera SC in the EU in March 2014 and its equivalent RITUXAN HYCELA™ in the US in June 2017; Herceptin SC in Canada in September 2018; and Herceptin Hylecta in the US in February 2019.
•
Baxalta, for HYQVIA in the EU and in the US in May 2013.
The remaining targets and products are currently in the process of development by the collaboration partners.


F-27
Halozyme Therapeutics, Inc.
Notes to Consolidated Financial Statements — (Continued)


5. Certain Balance Sheet Items
Accounts receivable, net consisted of the following (in thousands):
 
 
December 31,
2019
 
December 31,
2018
Accounts receivable from product sales to collaborators
 
$
35,649

 
$
3,717

Accounts receivable from revenues under collaborative agreements
 
3,850

 
5,499

Accounts receivable from royalty payments
 
17,149

 
19,199

Accounts receivable from other product sales
 
3,591

 
2,182

     Subtotal
 
60,239

 
30,597

Allowance for distribution fees and discounts
 
(797
)
 
(592
)
     Total accounts receivable, net
 
$
59,442

 
$
30,005


Inventories consisted of the following (in thousands):
 
 
December 31,
2019
 
December 31,
2018
Raw materials
 
$
2,769

 
$
735

Work-in-process
 
15,710

 
11,430

Finished goods
 
10,880

 
10,460

     Total inventories
 
$
29,359

 
$
22,625


Prepaid expenses and other assets consisted of the following (in thousands):
 
 
December 31,
2019
 
December 31,
2018
Prepaid manufacturing expenses
 
$
30,156

 
$
8,230

Prepaid research and development expenses
 
4,964

 
7,922

Other prepaid expenses
 
3,655

 
2,513

Other assets
 
5,681

 
6,462

     Total prepaid expenses and other assets
 
44,456

 
25,127

Less long-term portion
 
11,083

 
4,434

     Total prepaid expenses and other assets, current
 
$
33,373

 
$
20,693


Prepaid manufacturing expenses include raw materials, slot reservation fees and other amounts paid to contract manufacturing organizations. Such amounts are reclassified to work-in-process inventory as materials are used or the CMO services are complete.

F-28
Halozyme Therapeutics, Inc.
Notes to Consolidated Financial Statements — (Continued)


Property and equipment, net consisted of the following (in thousands):
 
 
December 31,
2019
 
December 31,
2018
Research equipment
 
$
7,403

 
$
9,945

Manufacturing equipment
 
3,858

 
3,979

Computer and office equipment
 
4,859

 
5,211

Leasehold improvements
 
1,628

 
4,569

     Subtotal
 
17,748

 
23,704

Accumulated depreciation and amortization
 
(10,742
)
 
(16,239
)
Subtotal
 
$
7,006

 
$
7,465

Right of use of assets
 
$
3,849

 
$
—

     Property and equipment, net
 
$
10,855

 
$
7,465
Depreciation and amortization expense was approximately $4.1 million , $2.4 million, and $2.2 million for the years ended December 31, 2019, 2018 and 2017, respectively. The depreciation and amortization expense for the year ended December 31, 2019 is inclusive of $1.8 million ROU asset amortization. As discussed in Note 9, we have recorded a ROU impairment charge of $1.1 million as a result of the organizational restructuring. We also recorded an impairment charge of $1.4 million related to property and equipment as a result of the organizational restructuring (Refer to Note 13 for further details on the organizational restructuring).
Accrued expenses consisted of the following (in thousands):
 
 
December 31,
2019
 
December 31,
2018
Accrued outsourced research and development expenses
 
$
8,423

 
$
21,921

Accrued compensation and payroll taxes
 
27,888

 
16,604

Accrued outsourced manufacturing expenses
 
9,173

 
3,975

Other accrued expenses
 
7,876

 
7,623

Lease liability
 
6,469

 
—

     Total accrued expenses
 
59,829

 
50,123

Less long-term portion
 
4,180

 
594

     Total accrued expenses, current
 
$
55,649

 
$
49,529


Expense associated with the accretion of the lease liabilities was approximately $0.8 million and zero for the twelve months ended December 31, 2019 and 2018, respectively. Total lease expense for the twelve months ended December 31, 2019 and 2018 $2.6 million and $2.4 million respectively.
Cash paid for amounts related to leases for the twelve months ended December 31, 2019 and 2018 was $3.1 million and $2.4 million respectively.

F-29
Halozyme Therapeutics, Inc.
Notes to Consolidated Financial Statements — (Continued)


Deferred revenue consisted of the following (in thousands):
 
 
December 31,
2019
 
December 31,
2018
Collaborative agreements
 
 
 
 
License fees and event-based payments:
 
2,764

 
2,264

Product sales
 
2,495

 
6,991

Total deferred revenue
 
5,259

 
9,255

Less current portion
 
4,012

 
4,247

Deferred revenue, net of current portion
 
$
1,247

 
$
5,008



F-30
Halozyme Therapeutics, Inc.
Notes to Consolidated Financial Statements — (Continued)


6. Long-Term Debt, Net
Convertible Notes
In November 2019, we completed the sale of $460.0 million in aggregate principal amount of 1.25% Convertible Senior Notes due 2024 (“Convertible Notes”) in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (“Securities Act”). The Convertible Notes were issued under an indenture, dated as of November 18, 2019, (“Indenture”) with The Bank of New York Mellon Trust Company, N.A., as trustee. The offer and sale of the Convertible Notes and the shares of common stock issuable upon conversion of the Convertible Notes have not been registered under the Securities Act, or the securities laws of any other jurisdiction, and the Convertible Notes and such shares may not be offered or sold absent registration or an applicable exemption from registration requirements, or in a transaction not subject to, such registration requirements.
We received net proceeds from the offering of approximately $447.4 million. We used $200.0 million of the net proceeds from the offering to repurchase shares of common stock, including approximately $143.1 million to repurchase approximately 8.1 million shares of common stock concurrently with the offering in privately negotiated transactions, $6.9 million in open market purchases and $50.0 million to repurchase a total of approximately 2.6 million shares of common stock through an accelerated share repurchase agreement.
We used approximately $26.1 million of the net proceeds from the offering to repay all outstanding amounts under its loan agreement with Oxford Finance and Silicon Valley Bank and intend to use the remainder of the net proceeds for general corporate purposes, including additional share repurchases subsequent to the offering and working capital.
The Convertible Notes will pay interest semi-annually in arrears on June 1st and December 1st of each year, beginning on June 1, 2020, at an annual rate of 1.25% and will be convertible into cash, shares of common stock or a combination of cash and shares of common stock, at our election, based on the applicable conversion rate at such time. The Convertible Notes are general unsecured obligations and will rank senior in right of payment to all indebtedness that is expressly subordinated in right of payment to the Convertible Notes, will rank equally in right of payment with all existing and future liabilities that are not so subordinated, will be effectively junior to any secured indebtedness to the extent of the value of the assets securing such indebtedness and will be structurally subordinated to all indebtedness and other liabilities (including trade payables) of the our current or future subsidiaries. The Convertible Notes have a maturity date of December 1, 2024.
Holders may convert their Convertible Notes at their option only in the following circumstances: (1) during any calendar quarter commencing after the calendar quarter ending on March 31, 2020, if the last reported sale price per share of common stock exceeds 130% of the conversion price for each of at least 20 trading days during the 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter; (2) during the five consecutive business days immediately after any five consecutive trading day period (such five consecutive trading day period, the “measurement period”) in which the trading price per $1,000 principal amount of notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price per share of Company’s common stock on such trading day and the conversion rate on such trading day; (3) upon the occurrence of certain corporate events or distributions on Company’s common stock, as described in the offering memorandum; (4) if we call such notes for redemption; and (5) at any time from, and including, June 1, 2024 until the close of business on the scheduled trading day immediately before the maturity date.
Upon conversion, we will pay or deliver, as applicable, cash, shares of common stock or a combination of cash and shares of common stock, at our election. The initial conversion rate for the Convertible Notes will be 41.9208 shares of common stock per $1,000 in principal amount of Convertible Notes, equivalent to a conversion price of approximately $23.85 per share of our common stock. The conversion rate is subject to adjustment as described in the Indenture.
In accordance with accounting guidance for debt with conversion and other options, we accounted for the debt and equity components of the Convertible Notes separately. The estimated fair value of the debt component at the date of issuance was $381.8 million, which was computed based on our non-convertible borrowing rate for similar debt of 5.19%, derived from independent valuation analysis. The equity component was allocated a value of $65.6 million and represents the difference

F-31
Halozyme Therapeutics, Inc.
Notes to Consolidated Financial Statements — (Continued)


between the $447.4 million of net proceeds from the issuance of the Convertible Notes and the $381.8 million estimated fair value of the debt component at the date of issuance.
In connection with the Convertible Notes, we paid the initial purchasers of the Convertible Notes a fee of $12.7 million and incurred additional debt issuance costs totaling $0.3 million, which includes expenses that we paid on behalf of the initial purchasers and expenses incurred directly by us. Debt issuance costs, the initial purchasers’ fee and the equity component is presented as a debt discount as of December 31, 2019 in the amount of $76.9 million, and will be amortized over the remaining estimated term of 5 years using the effective interest method, utilizing an effective interest rate of 5.10%. The net carrying amount of the debt as of December 31, 2019 is $383.1 million. For the year ended December 31, 2019, we recognized interest expense of $2.3 million, including contractual coupon interest of $0.7 million and amortization of the debt discount of $1.6 million.
As of December 31, 2019, we were in compliance with all covenants under the Indenture and there was no material adverse change in our business, operations or financial condition.
Royalty-backed Loan
In January 2016, through our wholly-owned subsidiary Halozyme Royalty LLC (“Halozyme Royalty”), we received a $150 million loan (the “Royalty-backed Loan”) pursuant to a credit agreement (the “Credit Agreement”) with BioPharma Credit Investments IV Sub, LP and Athyrium Opportunities II Acquisition LP (the “Royalty-backed Lenders”). Under the terms of the Credit Agreement, Halozyme Therapeutics, Inc. transferred to Halozyme Royalty the right to receive royalty payments from the commercial sales of ENHANZE products owed under the Roche Collaboration and Baxalta Collaboration (“Collaboration Agreements”). The royalty payments from the Collaboration Agreements will be used to repay the principal and interest on the loan (the “Royalty Payments”).  The Royalty-backed Loan bears interest at a per annum rate of 8.75% plus the three-month LIBOR rate. The three-month LIBOR rate is subject to a floor of 0.7% and a cap of 1.5%. The interest rate as of December 31, 2019 and 2018 was 10.25%.
The Credit Agreement provides that none of the Royalty Payments were required to be applied to the Royalty-backed Loan prior to January 1, 2017, 50% of the Royalty Payments are required to be applied to the Royalty-backed Loan between January 1, 2017 and January 1, 2018 and thereafter all Royalty Payments must be applied to the Royalty-backed Loan. However, the amounts available to repay the Royalty-backed Loan are subject to caps of $13.75 million per quarter in 2017, $18.75 million per quarter in 2018, $21.25 million per quarter in 2019 and $22.5 million per quarter in 2020 and thereafter. Amounts available to repay the Royalty-backed Loan will be applied first to pay interest and second to repay principal on the Royalty-backed Loan. Any accrued interest that is not paid on any applicable quarterly payment date, as defined, will be capitalized and added to the principal balance of the Royalty-backed Loan on such date. Halozyme Royalty will be entitled to receive and distribute to Halozyme any Royalty Payments that are not required to be applied to the Royalty-backed Loan or which are in excess of the foregoing caps.
Because the repayment of the term loan is contingent upon the level of Royalty Payments received, the repayment term may be shortened or extended depending on the actual level of Royalty Payments. The final maturity date of the Royalty-backed Loan will be the earlier of (i) the date when principal and interest is paid in full, (ii) the termination of Halozyme Royalty’s right to receive royalties under the Collaboration Agreements, and (iii) December 31, 2050.  Currently, we estimate that the loan will be repaid in the second quarter of 2020. This estimate could be adversely affected and the repayment period could be extended if future royalty amounts are less than currently expected. Under the terms of the Credit Agreement, at any time after January 1, 2019, Halozyme Royalty may, subject to certain limitations, prepay the outstanding principal of the Royalty-backed Loan in whole or in part, at a price equal to 105% of the outstanding principal on the Royalty-backed Loan, plus accrued but unpaid interest. The Royalty-backed Loan constitutes an obligation of Halozyme Royalty, and is non-recourse to Halozyme. Halozyme Royalty retains its right to the Royalty Payments following repayment of the loan.
As of December 31, 2019, we were in compliance with all covenants under the Royalty-backed Loan and there was no material adverse change in our business, operations or financial condition.
We began making principal and interest payments against the Royalty-backed Loan in the first quarter of 2017 and therefore had zero capitalized interest for the twelve months ended December 31, 2019. In addition, we recorded accrued interest, which is included in accrued expenses, of $0.1 million and $0.4 million as of December 31, 2019 and 2018, respectively.

F-32
Halozyme Therapeutics, Inc.
Notes to Consolidated Financial Statements — (Continued)


In connection with the Royalty-backed Loan, we paid the Royalty-backed Lenders a fee of $1.5 million and incurred additional debt issuance costs totaling $0.4 million, which includes expenses that we paid on behalf of the Royalty-backed Lenders and expenses incurred directly by us. Debt issuance costs and the lender fee have been netted against the debt as of December 31, 2019, and are being amortized over the estimated term of the debt using the effective interest method. For the years ended December 31, 2019, 2018 and 2017, we recognized interest expense, including amortization of the debt discount, related to the Royalty-backed Loan of $6.2 million, $13.1 million and $16.4 million, respectively. The assumptions used in determining the expected repayment term of the debt and amortization period of the issuance costs requires that we make estimates that could impact the short- and long-term classification of these costs, as well as the period over which these costs will be amortized. The outstanding balance of the Royalty-backed Loan as of December 31, 2019 was $19.5 million.
Oxford and SVB Loan and Security Agreement
In June 2016, we entered into a Loan and Security Agreement (the “Loan Agreement”) with Oxford Finance LLC (“Oxford”) and Silicon Valley Bank (“SVB”) (collectively, the “Lenders”), providing a senior secured loan facility of up to an aggregate principal amount of $70.0 million, comprising a $55.0 million draw in June 2016 and an additional $15.0 million tranche, which we had the option to draw during the second quarter of 2017 and did not exercise. The initial proceeds were partially used to pay the outstanding principal and final payment of $4.25 million owed on a previous loan agreement with the Lenders. The remaining proceeds were used for working capital and general business requirements. The senior secured loan facility carried a fixed interest rate of 8.25%. The repayment schedule provided for interest only payments for the first 18 months, followed by consecutive equal monthly payments of principal and interest in arrears through the maturity date of January 1, 2021. The Loan Agreement provided for a final payment equal to 5.50% of the initial $55.0 million principal amount, which was due when the Loan Agreement becomes due or upon the prepayment of the facility. We had the option to prepay the outstanding balance of the Loan Agreement in full and exercised this option in November 2019, at which point we paid the full remaining balance and final payment of $26.1 million.
Interest expense, including amortization of the debt discount, related to the Loan Agreement totaled $3.0 million, $4.9 million and $5.5 million for the years ended December 31, 2019, 2018 and 2017, respectively.
Future maturities and interest payments of long-term debt as of December 31, 2019, are as follows (in thousands):
2020
 
$
26,100

2021
 
5,750

2022
 
5,750

2023
 
5,750

2024
 
465,750

Total minimum payments
 
509,100

Less amount representing interest
 
(29,540
)
Gross balance of long-term debt
 
479,560

Less unamortized debt discount
 
(76,973
)
Present value of long-term debt
 
402,587

Less current portion of long-term debt
 
(19,542
)
Long-term debt, less current portion and unamortized debt discount
 
$
383,045



F-33
Halozyme Therapeutics, Inc.
Notes to Consolidated Financial Statements — (Continued)


7. Share-based Compensation
We currently grant stock options, restricted stock awards and restricted stock units under the Amended and Restated 2011 Stock Plan (“2011 Stock Plan”), which was approved by the stockholders on May 6, 2016 and provides for the grant of up to 44.2 million shares of common stock to selected employees, consultants and non-employee members of our Board of Directors as stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards and performance awards. Awards are subject to terms and conditions established by the Compensation Committee of our Board of Directors. During the year ended December 31, 2019, we granted share-based awards under the 2011 Stock Plan. At December 31, 2019, 13,640,668 shares were subject to outstanding awards and 9,352,360 shares were available for future grants of share-based awards.
Total share-based compensation expense related to share-based awards was comprised of the following (in thousands):
 
 
Year Ended December 31,
 
 
2019
 
2018
 
2017
Research and development
 
$
15,107

 
$
17,220

 
$
13,080

Selling, general and administrative
 
19,669

 
18,476

 
17,590

Share-based compensation expense
 
$
34,776

 
$
35,696

 
$
30,670


Share-based compensation expense by type of share-based award (in thousands):
 
 
Year Ended December 31,
 
 
2019
 
2018
 
2017
Stock options
 
$
17,624

 
$
18,742

 
$
19,583

RSAs and RSUs
 
17,152

 
16,954

 
11,087

 
 
$
34,776

 
$
35,696

 
$
30,670


Total unrecognized estimated compensation cost by type of award and the weighted-average remaining requisite service period over which such expense is expected to be recognized (in thousands, unless otherwise noted):
 
 
December 31, 2019
 
 
Unrecognized
Expense
 
Remaining
Weighted-Average
Recognition Period
(years)
Stock options
 
$
16,524

 
2.59
RSAs
 
$
570

 
0.16
RSUs
 
$
11,600

 
2.32

Stock Options. Options granted under the Plans must have an exercise price equal to at least 100% of the fair market value of our common stock on the date of grant. The options generally have a maximum contractual term of ten years and vest at the rate of one-fourth of the shares on the first anniversary of the date of grant and 1/48 of the shares monthly thereafter. Certain option awards provide for accelerated vesting if there is a change in control (as defined in the Plans).

F-34
Halozyme Therapeutics, Inc.
Notes to Consolidated Financial Statements — (Continued)


A summary of our stock option award activity as of and for the year ended December 31, 2019 is as follows: 
 
 
Shares
Underlying
Stock Options
 
Weighted
Average Exercise
Price per Share
 
Weighted
Average
Remaining
Contractual
Term (years)
 
Aggregate
Intrinsic
Value
Outstanding at December 31, 2018
 
11,012,381

 
$13.81
 
 
 
 
Granted
 
3,056,191

 
$16.46
 
 
 
 
Exercised
 
(1,540,690
)
 
$10.73
 
 
 
 
Canceled/forfeited
 
(979,653
)
 
$16.19
 
 
 
 
Outstanding at December 31, 2019
 
11,548,229

 
$14.72
 
3.98
 

$39.8
 million
Vested and expected to vest at December 31, 2019
 
11,548,229

 
$14.72
 
3.98
 

$39.8
 million
Exercisable at December 31, 2019
 
6,962,972

 
$13.64
 
3.59
 

$32.7
 million

The weighted average grant date fair values of options granted during the years ended December 31, 2019, 2018 and 2017 were $16.46 per share, $10.33 per share and $7.86 per share, respectively. The total intrinsic value of options exercised during the years ended December 31, 2019, 2018 and 2017 was approximately $10.6 million, $11.5 million and $10.0 million, respectively. Cash received from stock option exercises for the years ended December 31, 2019, 2018 and 2017 was approximately $16.5 million, $16.3 million and $14.0 million, respectively.
The exercise price of stock options granted is equal to the closing price of the common stock on the date of grant. The fair value of each option award is estimated on the date of grant using the Black-Scholes-Merton option pricing model (“Black-Scholes model”). Expected volatility is based on historical volatility of our common stock. The expected term of options granted is based on analyses of historical employee termination rates and option exercises. The risk-free interest rate is based on the U.S. Treasury yield for a period consistent with the expected term of the option in effect at the time of the grant. The dividend yield assumption is based on the expectation of no future dividend payments. The assumptions used in the Black-Scholes model were as follows:
 
 
Year Ended December 31,
 
 
2019
 
2018
 
2017
Expected volatility
 
51.56-56.94%
 
57.18-70.06%
 
69.81-71.73%
Average expected term (in years)
 
5.5
 
5.5
 
5.6
Risk-free interest rate
 
1.35-2.56%
 
2.25-2.96%
 
1.73-2.13%
Expected dividend yield
 
—
 
—
 
—


F-35
Halozyme Therapeutics, Inc.
Notes to Consolidated Financial Statements — (Continued)


Restricted Stock Awards. RSAs are grants that entitle the holder to acquire shares of our common stock at zero cost. The shares covered by a RSA cannot be sold, pledged, or otherwise disposed of until the award vests and any unvested shares may be reacquired by us for the original purchase price following the awardee’s termination of service. The RSAs will generally vest at the rate of one-fourth of the shares on each anniversary of the date of grant. Annual grants of RSAs to the Board of Directors typically vest in approximately one year.
The following table summarizes our RSA activity during the year ended December 31, 2019:
 
 
Number of
Shares
 
Weighted
Average
Grant Date
Fair Value
Unvested at December 31, 2018
 
397,389

 
$11.03
Granted
 
85,211

 
$16.43
Vested
 
(260,086
)
 
$12.57
Forfeited
 
(11,391
)
 
$8.11
Unvested at December 31, 2019
 
211,123

 
$11.47

The estimated fair value of the RSAs was based on the closing market value of our common stock on the date of grant. The total grant date fair value of RSAs vested during the years ended December 31, 2019, 2018 and 2017 was approximately $3.3 million, $4.5 million and $5.3 million, respectively. The fair value of RSAs vested during the years ended December 31, 2019, 2018 and 2017, was approximately $4.2 million, $7.2 million and $6.6 million, respectively.
Restricted Stock Units. A RSU is a promise by us to issue a share of our common stock upon vesting of the unit. The RSUs will generally vest at the rate of one-fourth of the shares on each anniversary of the date of grant.
The following table summarizes our RSU activity during the year ended December 31, 2019:
 
 
Number of
Shares
 
Weighted
Average
Grant Date
Fair Value
 
Weighted
Average
Remaining
Contractual
Term (yrs)
 
Aggregate
Intrinsic
Value
Outstanding at December 31, 2018
 
2,388,342

 
$15.12
 
 
 
 
Granted
 
1,151,464

 
$16.55
 
 
 
 
Vested
 
(1,092,648
)
 
$15.35
 
 
 
 
Forfeited
 
(354,719
)
 
$16.22
 
 
 
 
Outstanding at December 31, 2019
 
2,092,439

 
$15.60
 
1.23
 

$37.1
 million

The estimated fair value of the RSUs was based on the closing market value of our common stock on the date of grant. The total grant date fair value of RSUs vested during the years ended December 31, 2019, 2018 and 2017 was approximately $19.1 million, $6.7 million and $4.0 million, respectively. The fair value of RSUs vested during the years ended December 31, 2019, 2018 and 2017 was approximately $18.5 million, $11.0 million and $4.7 million, respectively.


F-36


8. Stockholders’ Equity (Deficit)
In May 2017, we completed an underwritten public offering pursuant to which we sold 11.5 million shares of common stock, including 1.5 million shares sold pursuant to the full exercise of an option to purchase additional shares granted to the underwriters. All of the shares were offered at a public offering price of $12.50 per share, generating $134.9 million in net proceeds, after deducting underwriting discounts and commissions and other offering expenses.
During the years ended December 31, 2019, 2018 and 2017, we issued an aggregate of 1,540,690, 1,489,138 and 1,514,826 shares of common stock, respectively, in connection with the exercises of stock options, for net proceeds of approximately $16.5 million, $16.3 million and $14.0 million, respectively. For the years ended December 31, 2019, 2018 and 2017, we issued 952,182, 442,599 and 281,398 shares of common stock, respectively, upon vesting of certain RSUs for which the RSU holders surrendered 140,466, 139,850 and 97,008 RSUs, respectively, to pay for minimum withholding taxes totaling approximately $7.0 million, $4.2 million and $1.9 million, respectively. Stock options and unvested restricted units totaling approximately 13.6 million, 13.4 million and 13.0 million shares of our common stock were outstanding as of December 31, 2019, 2018 and 2017, respectively.
Share Repurchases
The Board of Directors approved a share repurchase program, pursuant to which we may repurchase issued and outstanding shares of common stock from time to time. We may utilize a variety of methods including open market purchases, privately negotiated transactions, accelerated share repurchase programs or any combination of such methods.
In November 2019, we announced that the Board of Directors has authorized the initiation of a capital return program to repurchase up to $550.0 million of outstanding common stock over a three-year period. The Board will regularly review this capital return program in connection with a balanced capital allocation strategy. In November 2019, we repurchased approximately 8.1 million shares of common stock concurrently with the Convertible Notes issuance in privately negotiated transactions for $143.1 million and 0.4 million shares of common stock in open market purchases for $6.9 million. Also in November 2019, we entered into an Accelerated Share Repurchase (ASR) agreement with Bank of America to repurchase $50.0 million of common stock. At inception, pursuant to the agreement, we paid $50.0 million to Bank of America and took an initial delivery of 2.1 million shares. In February 2020 we finalized the transaction and received an additional 0.5 million shares. We retired the repurchased shares and they resumed the status of authorized and unissued shares.








F-37
Halozyme Therapeutics, Inc.
Notes to Consolidated Financial Statements — (Continued)


9. Commitments and Contingencies
Operating Leases
Our administrative offices and research facilities are located in San Diego, California. We lease an aggregate of approximately 80,000 square feet of office and research space in five buildings. The leases commenced in June 2011, November 2013 and June 2018 and continue through January 2023. The leases are subject to approximately 3.0% annual increases throughout the terms of the leases. We also pay a pro rata share of operating costs, insurance costs, utilities and real property taxes.
We lease approximately 10,000 square feet of office space for a satellite office located in South San Francisco, California. The lease commenced in November 2015 and continues through January 2021. The lease is subject to approximately 3.0% annual increases throughout the term of the lease. We also pay a pro rata share of operating costs, insurance costs, utilities and real property taxes.
As a result of the restructuring we announced on November 4, 2019, we abandoned two of our buildings in San Diego and our satellite office located in San Francisco. As a result, we have reassessed the likelihood of exercising contractual options impacting the term of these leases. These considerations have been reflected in the recognition of impairment charges of $1.1 million in accordance with ASC 360 during the year ended December 31, 2019.
Additionally, we lease certain office equipment under operating leases. Total rent expense was approximately $2.7 million, $2.5 million and $2.3 million for the years ended December 31, 2019, 2018 and 2017, respectively.
Approximate annual future minimum operating lease payments as of December 31, 2019 are as follows (in thousands): 
Year:
 
Operating
Leases
2020
 
$
3,355

2021
 
2,260

2022
 
1,559

2023
 
70

2024
 
—

Total minimum lease payments
 
$
7,244

Less imputed interest
 
(775
)
Total
 
$
6,469


The weighted-average remaining lease term of our operating leases is approximately 2.36 years.
Other Commitments
We have existing supply agreements with contract manufacturing organizations Avid Bioservices, Inc. (“Avid”) and Catalent Indiana LLC (formerly Cook Pharmica LLC) (“Catalent”) to produce supplies of bulk rHuPH20. Under the terms of the agreements, we are committed to certain minimum annual purchases of bulk rHuPH20. At December 31, 2019, we had a $35.7 million minimum purchase obligation in connection with these agreements.
In June 2011, we entered into a services agreement with Patheon for the technology transfer and manufacture of Hylenex recombinant. At December 31, 2019, we had a $0.6 million minimum purchase obligation in connection with this agreement. 


F-38
Halozyme Therapeutics, Inc.
Notes to Consolidated Financial Statements — (Continued)


Legal Contingencies
From time to time, we may be involved in disputes, including litigation, relating to claims arising out of operations in the normal course of our business. Any of these claims could subject us to costly legal expenses and, while we generally believe that we have adequate insurance to cover many different types of liabilities, our insurance carriers may deny coverage or our policy limits may be inadequate to fully satisfy any damage awards or settlements. If this were to happen, the payment of any such awards could have a material adverse effect on our consolidated results of operations and financial position. Additionally, any such claims, whether or not successful, could damage our reputation and business. We currently are not a party to any legal proceedings, the adverse outcome of which, in management’s opinion, individually or in the aggregate, would have a material adverse effect on our consolidated results of operations or financial position.

F-39
Halozyme Therapeutics, Inc.
Notes to Consolidated Financial Statements — (Continued)


10.
Income Taxes
The Tax Cuts and Jobs Act (the “Act”) was enacted in December 2017. The Act reduces the U.S. federal corporate tax rate from 35% to 21%. As of December 31, 2017, the Company remeasured its existing deferred tax balance by recording a provisional benefit of $17.1 million, which was fully offset by a change in the valuation allowance. As of December 31, 2018, upon completing its analysis of the Act, the Company believes that the disclosures in its financial statements as of December 31, 2017 are accurate.
Total (loss) income before income taxes summarized by region were as follows (in thousands):
 
 
Year Ended December 31,
 
 
2019
 
2018
 
2017
United States
 
$
(70,737
)
 
$
(45,819
)
 
$
160,938

Foreign
 
(1,514
)
 
(33,974
)
 
(99,328
)
Net (loss) income before income taxes
 
$
(72,251
)
 
$
(79,793
)
 
$
61,610


Significant components of our net deferred tax assets/(liabilities) were as follows (in thousands).
 
 
December 31,
 
 
2019
 
2018
Deferred tax assets:
 
 
 
 
Net operating loss carryforwards
 
$
39,401

 
$
26,267

Deferred revenue
 
1,069

 
1,395

Research and development and orphan drug credits
 
114,357

 
106,406

Share-based compensation
 
9,972

 
9,541

Alternative minimum tax credit
 
1,683

 
2,959

ASC 842 lease liability
 
1,454

 
—

Interest expense limitation
 
2,163

 
1,750

Other, net
 
3,037

 
2,452

 
 
173,136

 
150,770

Valuation allowance for deferred tax assets
 
(155,100
)
 
(146,953
)
Deferred tax assets, net of valuation
 
18,036

 
3,817

Deferred tax liabilities:
 
 
 
 
Depreciation
 
(865
)
 
(858
)
Convertible note
 
(14,450
)
 
—

ASC 842 right of use asset
 
(865
)
 
—

Other, net
 
(173
)
 
—

Total deferred tax liabilities
 
(16,353
)
 
(858
)
Net deferred tax asset
 
$
1,683

 
$
2,959


A valuation allowance of $155.1 million and $147.0 million has been established to offset the net deferred tax assets as of December 31, 2019 and 2018, respectively, as realization of such assets is uncertain. Under the Act, taxpayers are able to claim a refund of the AMT credit carryover by December 31, 2021. Accordingly, the recognized net deferred tax asset as of December 31, 2019 is the AMT credit carryover that will either be utilized or refunded by December 31, 2021.

F-40
Halozyme Therapeutics, Inc.
Notes to Consolidated Financial Statements — (Continued)


Income tax expense was comprised of the following components (in thousands):
 
 
Year Ended December 31,
 
 
2019
 
2018
 
2017
Current - federal
 
$
114

 
$
82

 
$
4,051

Current - state
 
(40
)
 
519

 
120

Deferred - federal
 
(85
)
 
(64
)
 
(5,532
)
Deferred - state
 
—

 
—

 
—

 
 
$
(11
)
 
$
537

 
$
(1,361
)

The provision for income taxes on earnings subject to income taxes differs from the statutory federal income tax rate due to the following (in thousands):
 
 
Year Ended December 31,
 
 
2019
 
2018
 
2017
Federal income tax expense (benefit) at 21% for 2019 and 2018 and 34% for 2017
 
$
(15,173
)
 
$
(16,754
)
 
$
20,947

State income tax benefit, net of federal income tax impact
 
(1,509
)
 
(4,297
)
 
930

(Decrease) increase in valuation allowance
 
8,147

 
35,731

 
(77,181
)
Enactment of the Tax Cuts and Jobs Act
 
—

 
—

 
17,132

Foreign income subject to tax at other than federal statutory rate
 
318

 
7,106

 
33,674

Shared-based compensation
 
315

 
425

 
525

Non-deductible expenses and other
 
924

 
1,599

 
5,779

Research and development credits, net
 
(1,091
)
 
(5,210
)
 
4,162

Orphan drug credits, net of federal add back
 
(5,718
)
 
(18,063
)
 
(7,329
)
Convertible note discount in APIC
 
$
13,776

 
$
—

 
$
—

 
 
$
(11
)
 
$
537

 
$
(1,361
)

At December 31, 2019, our unrecognized tax benefit and uncertain tax positions were $21.5 million. Of this, $0.2 million of this amount would affect the effective tax rate and $21.5 million would affect the effective tax rate only in the event the valuation allowance was removed. Of the unrecognized tax benefits, we do not expect any significant changes to occur in the next 12 months. Interest and/or penalties related to uncertain income tax positions are recognized by us as a component of income tax expense. For the years ended December 31, 2019, 2018 and 2017, we recognized an immaterial amount of interest and penalties.
The following table summarizes the activity related to our unrecognized tax benefits (in thousands):
 
 
Year Ended December 31,
 
 
2019
 
2018
 
2017
Gross unrecognized tax benefits at beginning of period
 
$
20,028

 
$
14,428

 
$
12,799

Increases in tax positions for prior years
 
69

 
3,083

 
—

Decreases in tax positions for prior years
 
(23
)
 
—

 
(2,518
)
Increases in tax positions for current year
 
1,409

 
2,517

 
4,147

Gross unrecognized tax benefits at end of period
 
$
21,483

 
$
20,028

 
$
14,428


At December 31, 2019, we had federal, California and other state tax net operating loss carryforwards of approximately $118.5 million, $244.3 million and $26.7 million, respectively.

F-41
Halozyme Therapeutics, Inc.
Notes to Consolidated Financial Statements — (Continued)


The following table shows key expiration dates of the federal and California net operating loss carryforwards (in thousands):
 
 
 
 
Expires in:
 
 
Net Operating Loss
 
2020
 
2021 and beyond
 
2028 and beyond
Federal
 
$
118,480

 
$
—

 
$
118,480

 
—

California
 
$
244,337

 
$
—

 
—

 
$
244,337


At December 31, 2019, we had federal and California research and development tax credit carryforwards of approximately $27.9 million and $19.1 million, respectively. The federal research and development tax credits will begin to expire in 2024 unless previously utilized. The California research and development tax credits will carryforward indefinitely until utilized. Additionally, we had Orphan Drug Credit carryforwards of $88.0 million which will begin to expire in 2034.
Pursuant to Internal Revenue Code Section 382, the annual use of the net operating loss carryforwards and research and development tax credits could be limited by any greater than 50% ownership change during any three year testing period. As a result of any such ownership change, portions of our net operating loss carryforwards and research and development tax credits are subject to annual limitations. We completed an updated Section 382 analysis regarding the limitation of the net operating losses and research and development credits as of December 31, 2019. Based upon the analysis, we determined that ownership changes occurred in prior years; however, the annual limitations on net operating loss and research and development tax credit carryforwards will not have a material impact on the future utilization of such carryforwards.
The Company’s 2015 and 2016 federal returns were selected for audit by the IRS. The audit was completed in September 2019 with no material adjustments.
We do not provide for U.S. income taxes on the undistributed earnings of our foreign subsidiary as it is our intention to utilize those earnings in the foreign operations for an indefinite period of time. At December 31, 2019 and 2018, there were no undistributed earnings in foreign subsidiaries.
We are subject to taxation in the U.S. and in various state and foreign jurisdictions. Our tax years for 2004 and forward are subject to examination by the U.S. and California tax authorities due to the carryforward of unutilized net operating losses and research and development credits.
A Swiss subsidiary, Halozyme Switzerland GmbH, was formed during the fourth quarter of 2016 and obtained a tax ruling from Canton of Basel Stadt for its operations in Switzerland. The tax ruling is dated December 21, 2016, and will continue for a period of ten years, not to extend beyond December 31, 2026. The combined income tax burden at the federal, cantonal and communal level will not exceed 10% during the period covered by the ruling. As a result of foreign losses and a full valuation allowance, no net tax benefit was derived for the year ended December 31, 2019 as a result of the tax ruling.

F-42
Halozyme Therapeutics, Inc.
Notes to Consolidated Financial Statements — (Continued)


11.
Employee Savings Plan
We have an employee savings plan pursuant to Section 401(k) of the Internal Revenue Code. All employees are eligible to participate, provided they meet the requirements of the plan. We are not required to make matching contributions under the plan. However, we voluntarily contributed to the plan approximately $2.2 million, $1.3 million and $1.2 million for the years ended December 31, 2019, 2018 and 2017, respectively.

F-43
Halozyme Therapeutics, Inc.
Notes to Consolidated Financial Statements — (Continued)


12.
Summary of Unaudited Quarterly Financial Information
The following is a summary of our unaudited quarterly results for the years ended December 31, 2019 and 2018 (in thousands):
 
 
Quarter Ended
2019 (Unaudited):
 
March 31,
 
June 30,
 
September 30,
 
December 31,
Total revenues (1)
 
$
56,949

 
$
39,148

 
$
46,230

 
$
53,665

Gross profit on product sales
 
$
3,741

 
$
3,883

 
$
6,872

 
$
6,006

Total operating expenses(3)
 
$
53,983

 
$
53,125

 
$
70,767

 
$
85,727

Net Income (loss)
 
$
1,796

 
$
(14,624
)
 
$
(25,015
)
 
$
(34,397
)
Net Income (loss) per share:
 
 
 
 
 
 
 
 
Basic
 
$
0.01

 
$
(0.10
)
 
$
(0.17
)
 
$
(0.24
)
Diluted
 
$
0.01

 
$
(0.10
)
 
$
(0.17
)
 
$
(0.24
)
Shares used in computing net income (loss) per share:
 
 
 
 
 
 
 
 
Basic
 
144,743

 
145,411

 
146,136

 
141,046

Diluted
 
147,474

 
145,411

 
146,136

 
141,046

 
 
Quarter Ended
2018 (Unaudited):
 
March 31,
 
June 30,
 
September 30,
 
December 31,
Total revenues (2)
 
$
30,872

 
$
35,202

 
$
25,556

 
$
60,232

Gross profit on product sales
 
$
3,749

 
$
3,647

 
$
5,643

 
$
5,059

Total operating expenses
 
$
54,584

 
$
55,275

 
$
51,030

 
$
60,303

Net loss
 
$
(27,461
)
 
$
(22,893
)
 
$
(27,850
)
 
$
(2,126
)
Net loss per share:
 
 
 


 


 


Basic
 
$
(0.19
)
 
$
(0.16
)
 
$
(0.19
)
 
$
(0.01
)
Diluted
 
$
(0.19
)
 
$
(0.16
)
 
$
(0.19
)
 
$
(0.01
)
Shares used in computing net loss per share:
 


 


 


 


Basic
 
142,656

 
143,568

 
143,949

 
144,203

Diluted
 
142,656

 
143,568

 
143,949

 
144,203

_______________
(1)
Revenue for the quarter ended March 31, 2019 included $30.0 million in revenue under a collaborative arrangement from argenx.
(2)
Revenues for the quarter ended December 31, 2018 included $30.0 million in revenue under a collaborative arrangement from Roche.
(3)
Total operating expenses for the quarter ended December 31, 2019 included $28.4 million restructuring charges.


F-44
Halozyme Therapeutics, Inc.
Notes to Consolidated Financial Statements — (Continued)


13. Restructuring Charges
On November 4, 2019, we announced that our HALO-301 Phase 3 clinical study evaluating investigational new drug PEGPH20 in combination with ABRAXANE and gemcitabine as a first-line therapy for treatment of patients with metastatic pancreatic cancer failed to reach the primary endpoint of overall survival. Due to the results of the study, we halted development activities for PEGPH20, closed our oncology operations and implemented an organizational restructuring to focus our operations solely on marketing Hylenex and our ENHANZE business. In connection with the restructuring, we reduced our headcount by approximately 55% or approximately 160 positions.
We incurred restructuring charges consisting of one-time severance payments and other employee related costs, including non-cash costs related to the acceleration of equity awards for employees affected by the restructuring, of $19.5 million in the fourth quarter of 2019. The majority of the cash payments for employee related restructuring charges will be paid during the first quarter of 2020. Additionally, we incurred one-time charges related to lease and other contract cancellations and asset impairments of $8.9 million in the fourth quarter of 2019. We may also incur additional costs not currently contemplated due to events that may occur as a result of, or that are associated with, the workforce reduction and the cancellation of our PEGPH20 programs.



F-45
Halozyme Therapeutics, Inc.
Notes to Consolidated Financial Statements — (Continued)



Halozyme Therapeutics, Inc.
Schedule II
Valuation and Qualifying Accounts
(in thousands)
 
 
Balance at Beginning of Period
 
Additions
 
Deductions
 
Balance at End of Period
For the year ended December 31, 2019
 
 
 
 
 
 
 
 
Accounts receivable allowances (1)
 
$
592

 
$
7,327

 
$
(7,122
)
 
$
797

For the year ended December 31, 2018
 
 
 
 
 
 
 
 
Accounts receivable allowances (1)
 
$
559

 
$
5,988

 
$
(5,955
)
 
$
592

For the year ended December 31, 2017
 
 
 
 
 
 
 
 
Accounts receivable allowances (1)
 
$
559

 
$
4,645

 
$
(4,645
)
 
$
559

_______________
(1)
Allowances are for chargebacks, prompt payment discounts and distribution fees related to Hylenex recombinant product sales.

F-46
 EX-4.3 2 ex43halo-descriptionof.htm EXHIBIT 4.3 Exhibit


DESCRIPTION OF THE REGISTRANT’S SECURITIES
REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES
EXCHANGE ACT OF 1934
Halozyme Therapeutics, Inc. (“Halozyme,” “we,” “our,” or “us”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: our common stock.
DESCRIPTION OF CAPITAL STOCK
The following summary of the terms of our capital stock is based upon our Amended and Restated Certificate of Incorporation (the “Certificate of Incorporation”) and our Bylaws, as amended (the “Bylaws”). The summary is not complete, and is qualified by reference to our Certificate of Incorporation and our Bylaws, which are filed as exhibits to our Annual Report on Form 10-K and are incorporated by reference herein. We encourage you to read our Certificate of Incorporation, our Bylaws and the applicable provisions of the Delaware General Corporation Law (the “DGCL”) for additional information.
Authorized Shares of Capital Stock
Our authorized capital stock consists of 300,000,000 (Three Hundred Million) shares of common stock, $0.001 par value, and 20,000,000 (Twenty Million) shares of preferred stock, $0.001 par value. Our Board of Directors is authorized to establish one or more series of preferred stock and to set the powers, preferences and rights, as well as the qualifications, limitations or restrictions, of such series. These rights of the series of preferred stock may include, without limitation, dividend rights, dividend rates, conversion rights, voting rights, rights and terms of redemption (including sinking fund provisions) and liquidation preferences.
Listing
Our common stock is listed and principally traded on The Nasdaq Stock Market LLC (Nasdaq Global Select Market segment) under the symbol “HALO.”
Voting Rights
The holders of common stock are entitled to one vote per share on all matters voted on by the stockholders, including the election of directors. Except as otherwise provided by law, our Certificate of Incorporation or our Bylaws, matters will generally be decided by a majority of the votes cast. Our stockholders do not have the right to vote cumulatively.
Board of Directors
Our Bylaws provide that the authorized number of directors shall be fixed from time to time by a resolution duly adopted by the Board of Directors. Our Board of Directors is classified into three classes, each class to serve for a term of three years and to be as nearly equal in number as possible.
Our Bylaws provide that directors may be removed with or without cause by the affirmative vote of the holders of two-thirds (2/3rds) of the voting power of all of the outstanding shares entitled to vote.
Our Bylaws provide that a vacancy on the Board of Directors resulting from an increase in the number of authorized directors or death, resignation, retirement, disqualification, removal or other causes shall be filled by a majority of the directors then in office.




Dividend Rights
Subject to any preferential dividend rights granted to the holders of any shares of our preferred stock that may at the time be outstanding, holders of our common stock are entitled to receive dividends as may be declared from time to time by our Board of Directors out of funds legally available therefor.
Rights upon Liquidation
Subject to any preferential rights of outstanding shares of preferred stock, upon any liquidation or dissolution of Halozyme, holders of our common stock are entitled to share pro rata in all remaining assets legally available for distribution to stockholders.
Other Rights and Preferences
Our common stock has no sinking fund, redemption provisions, or preemptive, conversion, or exchange rights. There are no restrictions on transfer of our common stock, except as required by law.
Transfer Agent and Registrar
Corporate Stock Transfer Company is the transfer agent and registrar for our common stock.
Certain Anti-Takeover Effects
Certain provisions of our Certificate of Incorporation and Bylaws may be deemed to have an anti-takeover effect.
Business Combinations. Section 203 of the DGCL restricts a wide range of transactions (“business combinations”) between a corporation and an interested stockholder. An “interested stockholder” is, generally, any person who beneficially owns, directly or indirectly, 15% or more of the corporation’s outstanding voting stock. Business combinations are broadly defined to include (i) mergers or consolidations with, (ii) sales or other dispositions of more than 10% of the corporation’s assets to, (iii) certain transactions resulting in the issuance or transfer of any stock of the corporation or any subsidiary to, (iv) certain transactions resulting in an increase in the proportionate share of stock of the corporation or any subsidiary owned by, or (v) receipt of the benefit (other than proportionately as a stockholder) of any loans, advances or other financial benefits by, an interested stockholder. Section 203 provides that an interested stockholder may not engage in a business combination with the corporation for a period of three years from the time of becoming an interested stockholder unless (a) the Board of Directors approved either the business combination or the transaction which resulted in the person becoming an interested stockholder prior to the time that person became an interested stockholder; (b) upon consummation of the transaction which resulted in the person becoming an interested stockholder, that person owned at least 85% of the corporation’s voting stock (excluding, for purposes of determining the voting stock outstanding (but not the outstanding voting stock owned by the interested stockholder) shares owned by persons who are directors and also officers and shares owned by certain employee stock plans); or (c) the business combination is approved by the Board of Directors and authorized by the affirmative vote of at least 66 2/3% of the outstanding voting stock not owned by the interested stockholder. The restrictions on business combinations with interested stockholders contained in Section 203 of the DGCL do not apply to a corporation whose certificate of incorporation or bylaws contains a provision expressly electing not to be governed by the statute. Neither our Certificate of Incorporation nor our Bylaws contains a provision electing to “opt-out” of Section 203.
Advance Notice and Proxy Access Provisions. Our Bylaws require timely advance notice for stockholders seeking to bring business before our annual meeting of stockholders or to nominate candidates for election as directors at our annual meeting of stockholders and specify certain requirements regarding the form and content of a stockholder’s notice. The chair of the annual meeting has the ability to determine and declare at the meeting that business was not properly brought before the meeting in accordance with the provisions of our Bylaws, and, if he or she should so determine, he or she shall so declare at the meeting that any such business not properly brought before the meeting shall not be transacted.




These provisions might preclude our stockholders from bringing matters before our annual meeting of stockholders or from making nominations for directors at our annual meeting of stockholders if the proper procedures are not followed.
Board Classification. Our Bylaws provide that our board of directors is divided into three classes, one class of which is elected each year by our stockholders. The directors in each class serve for a three-year term. Our classified board of directors may tend to discourage a third party from making a tender offer or otherwise attempting to obtain control of us because it generally makes it more difficult for stockholders to replace a majority of the directors.
Special Meetings. Special meetings of stockholders may be called at any time by the Board of Directors, the Chairman of the Board, or the holders of record of not less than 50% of the shares entitled to cast votes at the meeting.
Stockholder Action by Written Consent without a Meeting. Our Certificate of Incorporation provides that no action shall be taken by the stockholders by written consent.
Additional Authorized Shares of Capital Stock. The additional shares of authorized common stock and preferred stock available for issuance under our Certificate of Incorporation could be issued at such times, under such circumstances and with such terms and conditions as to impede a change in control.



 EX-21.1 3 ex211subsidiaries2019.htm EXHIBIT 21.1 Exhibit

EXHIBIT 21.1


SUBSIDIARIES OF HALOZYME THERAPEUTICS, INC.

Name of Subsidiary
 
State or Jurisdiction of
 Incorporation or Organization
 
Percent Owned
Halozyme, Inc.
 
California
 
100%
Halozyme Holdings Ltd., a wholly owned subsidiary of Halozyme Switzerland Holdings GmbH
 
Bermuda
 
100%
Halozyme Royalty LLC, a wholly owned subsidiary of Halozyme, Inc.
 
Delaware
 
100%
Halozyme Switzerland GmbH, a wholly owned subsidiary of Halozyme Switzerland Holdings GmbH
 
Switzerland
 
100%
Halozyme Switzerland Holdings GmbH, a wholly owned subsidiary of Halozyme, Inc.
 
Switzerland
 
100%

 EX-23.1 4 ex231auditorconsent2019.htm EXHIBIT 23.1 Exhibit

EXHIBIT 23.1
Consent of Independent Registered Public Accounting Firm

We consent to the incorporation by reference in the following Registration Statements:

(1) Registration Statement (Form S-3 No. 333-216315) of Halozyme Therapeutics, Inc.,

(2) Registration Statement (Form S-8 No. 333-152914) pertaining to the Halozyme Therapeutics, Inc. 2008 Outside Directors’ Stock Plan and Halozyme Therapeutics, Inc. 2008 Stock Plan of Halozyme Therapeutics, Inc.,

(3) Registration Statement (Form S-8 No. 333-174013) pertaining to the Halozyme Therapeutics, Inc. 2011 Stock Plan of Halozyme Therapeutics, Inc.,

(4) Registration Statement (Form S-8 No. 333-188997) pertaining to the Halozyme Therapeutics, Inc. Amended and Restated 2011 Stock Plan of Halozyme Therapeutics, Inc.;

(5) Registration Statement (Form S-8 No. 333-206279) pertaining to the Halozyme Therapeutics, Inc. Amended and Restated 2011 Stock Plan of Halozyme Therapeutics, Inc.,

(6) Registration Statement (Form S-8 No. 333-211244) pertaining to the Halozyme Therapeutics, Inc. Amended and Restated 2011 Stock Plan of Halozyme Therapeutics, Inc., and

(7) Registration Statement (Form S-8 No. 333-224843) pertaining to the Halozyme Therapeutics, Inc. Amended and Restated 2011 Stock Plan of Halozyme Therapeutics, Inc.


of our reports dated February 24, 2020, with respect to the consolidated financial statements and schedule of Halozyme Therapeutics, Inc. and the effectiveness of internal control over financial reporting of Halozyme Therapeutics, Inc. included in this Annual Report (Form 10-K) of Halozyme Therapeutics, Inc. for the year ended December 31, 2019.


/s/ Ernst & Young LLP


San Diego, California
February 24, 2020


EX-31.1 5 ex31110k2019.htm EXHIBIT 31.1 Exhibit


EXHIBIT 31.1
CERTIFICATION OF CHIEF EXECUTIVE OFFICER
PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Helen I. Torley, M.B. Ch.B., M.R.C.P., Chief Executive Officer of Halozyme Therapeutics, Inc. certify that:
1.
I have reviewed this Annual Report on Form 10-K of Halozyme Therapeutics, Inc.;
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this report;
4.
The Registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Registrant and have:
a)
designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)
designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)
evaluated the effectiveness of the Registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)
disclosed in this report any change in the Registrant’s internal control over financial reporting that occurred during the Registrant’s most recent fiscal quarter (the Registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrant’s internal control over financial reporting; and
5.
The Registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Registrant’s auditors and the audit committee of the Registrant’s board of directors (or persons performing the equivalent functions):
a)
all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant’s ability to record, process, summarize and report financial information; and
b)
any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant’s internal control over financial reporting.
 
 
 
 
 
 
 
 
Dated:
February 24, 2020
 
 
 
 
/s/ Helen I. Torley, M.B. Ch.B., M.R.C.P.
 
 
 
 
 
 
Helen I. Torley, M.B. Ch.B., M.R.C.P
 
 
 
 
 
 
President and Chief Executive Officer


 EX-31.2 6 ex31210k2019.htm EXHIBIT 31.2 Exhibit


EXHIBIT 31.2
CERTIFICATION OF CHIEF FINANCIAL OFFICER
PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Laurie D. Stelzer, Chief Financial Officer of Halozyme Therapeutics, Inc. certify that:
1.
I have reviewed this Annual Report on Form 10-K of Halozyme Therapeutics, Inc.;
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this report;
4.
The Registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Registrant and have:
a)
designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)
designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)
evaluated the effectiveness of the Registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)
disclosed in this report any change in the Registrant’s internal control over financial reporting that occurred during the Registrant’s most recent fiscal quarter (the Registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrant’s internal control over financial reporting; and
5.
The Registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Registrant’s auditors and the audit committee of the Registrant’s board of directors (or persons performing the equivalent functions):
a)
all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant’s ability to record, process, summarize and report financial information; and
b)
any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant’s internal control over financial reporting.

 
 
 
 
 
 
 
 
Dated:
February 24, 2020
 
 
 
 
/s/ Laurie D. Stelzer
 
 
 
 
 
 
Laurie D. Stelzer
 
 
 
 
 
 
Senior Vice President and Chief Financial Officer


 EX-32 7 ex3210k2019.htm EXHIBIT 32 Exhibit


EXHIBIT 32
CERTIFICATION OF
CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER
PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report of Halozyme Therapeutics, Inc. (the “Registrant”) on Form 10-K for the fiscal year ended December 31, 2019, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Helen I. Torley, M.B. Ch.B., M.R.C.P., Chief Executive Officer of the Registrant, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:
(1)
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m); and
(2)
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.
 
 
 
 
 
 
 
Dated:
February 24, 2020
 
 
 
 
/s/ Helen I. Torley, M.B. Ch.B., M.R.C.P.
 
 
 
 
 
 
Helen I. Torley, M.B. Ch.B., M.R.C.P.
 
 
 
 
 
 
President and Chief Executive Officer
In connection with the Annual Report of Halozyme Therapeutics, Inc. (the “Registrant”) on Form 10-K for the fiscal year ended December 31, 2019, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Laurie D. Stelzer, Chief Financial Officer of the Registrant, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:
(1)
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m); and
(2)
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.
 
 
 
 
 
 
 
Dated:
February 24, 2020
 
 
 
 
/s/ Laurie D. Stelzer
 
 
 
 
 
 
Laurie D. Stelzer
 
 
 
 
 
 
Senior Vice President and Chief Financial Officer


 EX-101.SCH 8 halo-20191231.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 2105100 - Disclosure - Certain Balance Sheet Items link:presentationLink link:calculationLink link:definitionLink 2405402 - Disclosure - Certain Balance Sheet Items - Accounts receivable (Details) link:presentationLink link:calculationLink link:definitionLink 2405407 - Disclosure - Certain Balance Sheet Items - Accrued Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 2405408 - Disclosure - Certain Balance Sheet Items - Deferred Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 2405403 - Disclosure - Certain Balance Sheet Items - Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 2405404 - Disclosure - Certain Balance Sheet Items - Prepaid expenses and other assets (Details) link:presentationLink link:calculationLink link:definitionLink 2405405 - Disclosure - Certain Balance Sheet Items - Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 2405406 - Disclosure - Certain Balance Sheet Items - Property and Equipment, Net (Textuals) (Details) link:presentationLink link:calculationLink link:definitionLink 2305301 - Disclosure - Certain Balance Sheet Items (Tables) link:presentationLink link:calculationLink link:definitionLink 2109100 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 2409403 - Disclosure - Commitments and Contingencies Commitments and Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 2409403 - Disclosure - Commitments and Contingencies Commitments and Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 2309301 - Disclosure - Commitments and Contingencies Commitments and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 2409402 - Disclosure - Commitments and Contingencies Operating Lease textual (Details) link:presentationLink link:calculationLink link:definitionLink 2409404 - Disclosure - Commitments and Contingencies Other Commitments (Details) link:presentationLink link:calculationLink link:definitionLink 1001000 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 1001501 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1005000 - Statement - Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 1004000 - Statement - Consolidated Statements of Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 1002000 - Statement - Consolidated Statements of Operations link:presentationLink link:calculationLink link:definitionLink 1006000 - Statement - Consolidated Statements of Stockholders' Equity (Deficit) Statement link:presentationLink link:calculationLink link:definitionLink 0001000 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 2411402 - Disclosure - Employee Savings Plan (Details) link:presentationLink link:calculationLink link:definitionLink 2111100 - Disclosure - Employee Savings Plan (Notes) link:presentationLink link:calculationLink link:definitionLink 2311301 - Disclosure - Employee Savings Plan (Tables) link:presentationLink link:calculationLink link:definitionLink 2403405 - Disclosure - Fair Value Measurement Fair Value Measures (Details) link:presentationLink link:calculationLink link:definitionLink 2403404 - Disclosure - Fair Value Measurement Maturities (Details) link:presentationLink link:calculationLink link:definitionLink 2103100 - Disclosure - Fair Value Measurement (Notes) link:presentationLink link:calculationLink link:definitionLink 2403402 - Disclosure - Fair Value Measurement - Summary (Details) link:presentationLink link:calculationLink link:definitionLink 2303301 - Disclosure - Fair Value Measurement (Tables) link:presentationLink link:calculationLink link:definitionLink 2403403 - Disclosure - Fair Value Measurement Textuals (Details) link:presentationLink link:calculationLink link:definitionLink 2410404 - Disclosure - Income Taxes Components Deferred Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 2410402 - Disclosure - Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 2410405 - Disclosure - Income Taxes Income Tax Expense (Details) link:presentationLink link:calculationLink link:definitionLink 2410403 - Disclosure - Income Taxes Net Income (Loss) By Region (Details) link:presentationLink link:calculationLink link:definitionLink 2110100 - Disclosure - Income Taxes (Notes) link:presentationLink link:calculationLink link:definitionLink 2410408 - Disclosure - Income Taxes Operating Loss Carryforward Expiration (Details) link:presentationLink link:calculationLink link:definitionLink 2410406 - Disclosure - Income Taxes Schedule of Income Tax Reconciliation (Details) link:presentationLink link:calculationLink link:definitionLink 2310301 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 2410409 - Disclosure - Income Taxes Tax textuals (Details) link:presentationLink link:calculationLink link:definitionLink 2410407 - Disclosure - Income Taxes Unrecognized Tax Benefit (Details) link:presentationLink link:calculationLink link:definitionLink 2106100 - Disclosure - Long-Term Debt, Net link:presentationLink link:calculationLink link:definitionLink 2306301 - Disclosure - Long-Term Debt, Net Debt Disclosure (Tables) link:presentationLink link:calculationLink link:definitionLink 2406403 - Disclosure - Long-Term Debt, Net Debt Table (Details) link:presentationLink link:calculationLink link:definitionLink 2406402 - Disclosure - Long-Term Debt, Net Long-Term Debt Textuals (Details) link:presentationLink link:calculationLink link:definitionLink 2101100 - Disclosure - Organization and Business link:presentationLink link:calculationLink link:definitionLink 2113100 - Disclosure - Restructuring Charges link:presentationLink link:calculationLink link:definitionLink 2413401 - Disclosure - Restructuring Charges - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2104100 - Disclosure - Revenue link:presentationLink link:calculationLink link:definitionLink 2404404 - Disclosure - Revenue - Contract with Customer, Asset and Liability (Details) link:presentationLink link:calculationLink link:definitionLink 2404402 - Disclosure - Revenue - Disaggregation of Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 2404405 - Disclosure - Revenue - Revenue Recognition, Multiple-deliverable Arrangements (Details) link:presentationLink link:calculationLink link:definitionLink 2404406 - Disclosure - Revenue - Revenue, Remaining Performance Obligation (Details) link:presentationLink link:calculationLink link:definitionLink 2304301 - Disclosure - Revenue (Tables) link:presentationLink link:calculationLink link:definitionLink 2404403 - Disclosure - Revenue - Textuals (Details) link:presentationLink link:calculationLink link:definitionLink 2114100 - Schedule - Schedule II Valuation and Qualifying Accounts link:presentationLink link:calculationLink link:definitionLink 2414401 - Disclosure - Schedule II Valuation and Qualifying Accounts (Details) link:presentationLink link:calculationLink link:definitionLink 2407403 - Disclosure - Share-based Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 2107100 - Disclosure - Share-based Compensation (Notes) link:presentationLink link:calculationLink link:definitionLink 2407405 - Disclosure - Share-based Compensation Options (Details) link:presentationLink link:calculationLink link:definitionLink 2407407 - Disclosure - Share-based Compensation Restricted Stock Awards (Details) link:presentationLink link:calculationLink link:definitionLink 2407408 - Disclosure - Share-based Compensation Restricted Stock Units (Details) link:presentationLink link:calculationLink link:definitionLink 2307301 - Disclosure - Share-based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 2407402 - Disclosure - Share-based Compensation Textuals (Details) link:presentationLink link:calculationLink link:definitionLink 2407404 - Disclosure - Share-based Compensation Unrecognized Expense (Details) link:presentationLink link:calculationLink link:definitionLink 2407406 - Disclosure - Share-based Compensation Valuation (Details) link:presentationLink link:calculationLink link:definitionLink 2108100 - Disclosure - Stockholders' Equity (Deficit) link:presentationLink link:calculationLink link:definitionLink 2408402 - Disclosure - Stockholders' Equity (Deficit) (Details) link:presentationLink link:calculationLink link:definitionLink 2408401 - Disclosure - Stockholders' Equity (Deficit) Public Offering (Details) link:presentationLink link:calculationLink link:definitionLink 2408403 - Disclosure - Stockholders' Equity (Deficit) Share Repurchases (Details) link:presentationLink link:calculationLink link:definitionLink 2102100 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 2402405 - Disclosure - Summary of Significant Accounting Policies Accounts Receivable (Details) link:presentationLink link:calculationLink link:definitionLink 2402415 - Disclosure - Summary of Significant Accounting Policies Adoption of Recent Accounting Pronouncements (Details) link:presentationLink link:calculationLink link:definitionLink 2402404 - Disclosure - Summary of Significant Accounting Policies Concentrations of Credit Risk (Details) link:presentationLink link:calculationLink link:definitionLink 2402409 - Disclosure - Summary of Significant Accounting Policies Impairment of Long-Lived Assets (Details) link:presentationLink link:calculationLink link:definitionLink 2402412 - Disclosure - Summary of Significant Accounting Policies Income tax (Details) link:presentationLink link:calculationLink link:definitionLink 2402406 - Disclosure - Summary of Significant Accounting Policies Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 2402407 - Disclosure - Summary of Significant Accounting Policies Leases (Details) link:presentationLink link:calculationLink link:definitionLink 2402413 - Disclosure - Summary of Significant Accounting Policies Net Loss Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 2202201 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 2402408 - Disclosure - Summary of Significant Accounting Policies Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 2402411 - Disclosure - Summary of Significant Accounting Policies Research and development (Details) link:presentationLink link:calculationLink link:definitionLink 2402403 - Disclosure - Summary of Significant Accounting Policies Restricted Cash (Details) link:presentationLink link:calculationLink link:definitionLink 2402410 - Disclosure - Summary of Significant Accounting Policies Revenue recognition (Details) link:presentationLink link:calculationLink link:definitionLink 2402414 - Disclosure - Summary of Significant Accounting Policies Segment information (Details) link:presentationLink link:calculationLink link:definitionLink 2302302 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 2112100 - Disclosure - Summary of Unaudited Quarterly Financial Information link:presentationLink link:calculationLink link:definitionLink 2412402 - Disclosure - Summary of Unaudited Quarterly Financial Information - Quarterly Financial Information (Details) link:presentationLink link:calculationLink link:definitionLink 2312301 - Disclosure - Summary of Unaudited Quarterly Financial Information (Tables) link:presentationLink link:calculationLink link:definitionLink 2412403 - Disclosure - Summary of Unaudited Quarterly Financial Information - Textuals (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 9 halo-20191231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 10 halo-20191231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 11 halo-20191231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Statement of Stockholders' Equity [Abstract] Statement [Table] Statement [Table] Equity Components [Axis] Equity Components [Axis] Equity Component [Domain] Equity Component [Domain] Common Stock Common Stock [Member] Additional Paid-in Capital [Member] Additional Paid-in Capital [Member] AOCI Attributable to Parent [Member] AOCI Attributable to Parent [Member] Retained Earnings [Member] Retained Earnings [Member] Statement [Line Items] Statement [Line Items] Shares outstanding Shares, Outstanding Total stockholders' equity (deficit) Stockholders' Equity Attributable to Parent Adjustment to beginning retained earnings Cumulative Effect of New Accounting Principle in Period of Adoption Share-based Compensation APIC, Share-based Payment Arrangement, Increase for Cost Recognition Shares, New Issues Stock Issued During Period, Shares, New Issues Stock Issued During Period, Value, New Issues Stock Issued During Period, Value, New Issues Issuance of common stock pursuant to exercise of stock options and vesting of restricted stock units and performance restricted stock units, net Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture Value, Stock Options Exercised Stock Issued During Period, Value, Stock Options Exercised Shares, Restricted Stock Award Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures Value, Restricted Stock Award Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures Stock Repurchased and Retired During Period, Shares Stock Repurchased and Retired During Period, Shares Stock Repurchased and Retired During Period, Value Stock Repurchased and Retired During Period, Value Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt Other Comprehensive Income (Loss) Other Comprehensive Income (Loss), before Tax Net income (loss) Net Income (Loss) Attributable to Parent Shares outstanding Total stockholders' equity (deficit) Commitments and Contingencies Disclosure [Abstract] Operating Lease, Impairment Loss Operating Lease, Impairment Loss Operating Leases, Rent Expense, Net Operating Leases, Rent Expense, Net 2020 Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months 2021 Lessee, Operating Lease, Liability, Payments, Due Year Two 2022 Lessee, Operating Lease, Liability, Payments, Due Year Three 2023 Lessee, Operating Lease, Liability, Payments, Due Year Four 2024 Lessee, Operating Lease, Liability, Payments, Due Year Five Total minimum lease payments Lessee, Operating Lease, Liability, Payments, Due Less imputed interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Total Operating Lease, Liability Share-based Payment Arrangement [Abstract] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Award Type [Axis] Award Type [Axis] Award Type [Domain] Award Type [Domain] Stock options Share-based Payment Arrangement, Option [Member] RSAs Restricted Stock [Member] RSUs Restricted Stock Units (RSUs) [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Compensation Cost Not yet Recognized, Period for Recognition Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Fair Value Disclosures [Abstract] Due within one year Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, within One Year, Fair Value After one but within five years Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after One Through Five Years, Fair Value Available-for-sale Securities Available-for-sale Securities Schedule of Available-for-sale Securities [Table] Schedule of Available-for-sale Securities [Table] Financial Instrument [Axis] Financial Instrument [Axis] Financial Instruments [Domain] Financial Instruments [Domain] Asset-backed Securities [Member] Asset-backed Securities [Member] Corporate Debt Securities [Member] Corporate Debt Securities [Member] US Treasury Securities [Member] US Treasury Securities [Member] Commercial Paper [Member] Commercial Paper [Member] Schedule of Available-for-sale Securities Debt Securities, Available-for-sale [Line Items] Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value Debt Securities, Available-for-sale, Amortized Cost Debt Securities, Available-for-sale, Amortized Cost Amortized cost Available-for-sale Securities, Amortized Cost Basis Gross Unrealized Gains Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax Gross Unrealized Losses Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax Debt Securities, Available-for-sale Debt Securities, Available-for-sale Estimated fair value Restructuring and Related Activities [Abstract] Schedule of Restructuring and Related Costs [Table] Schedule of Restructuring and Related Costs [Table] Restructuring Type [Axis] Restructuring Type [Axis] Type of Restructuring [Domain] Type of Restructuring [Domain] One-time Termination Benefits One-time Termination Benefits [Member] Contract Termination and Asset Impairments Contract Termination [Member] Restructuring Cost and Reserve [Line Items] Restructuring Cost and Reserve [Line Items] Number of positions eliminated (as a percent) Restructuring and Related Cost, Number of Positions Eliminated, Period Percent Number of positions eliminated Restructuring and Related Cost, Number of Positions Eliminated Restructuring charges Restructuring Charges Inventory Disclosure [Abstract] Inventory, Current [Table] Inventory, Current [Table] Inventory [Axis] Inventory [Axis] Inventory [Domain] Inventory [Domain] Sales of Hylenex Hylenex Recombinant [Member] Hylenex Recombinant [Member] bulk rHuPH20 bulk rHuPH20 [Member] bulk rHuPH20 for use in collaboration products Inventory [Line Items] Inventory [Line Items] Inventory, Net Inventory, Net Income Tax Disclosure [Abstract] Operating Loss Carryforwards [Table] Operating Loss Carryforwards [Table] Income Tax Authority [Axis] Income Tax Authority [Axis] Income Tax Authority [Domain] Income Tax Authority [Domain] Internal Revenue Service (IRS) [Member] Internal Revenue Service (IRS) [Member] State and Local Jurisdiction [Member] State and Local Jurisdiction [Member] California [Member] California [Member] California [Member] Other state tax [Member] Other state tax [Member] Other state tax [Member] Income Tax Authority, Name [Axis] Income Tax Authority, Name [Axis] Income Tax Authority, Name [Domain] Income Tax Authority, Name [Domain] Tax Period [Axis] Tax Period [Axis] Tax Period [Domain] Tax Period [Domain] 2018 expiration [Member] 2018 expiration [Member] 2018 expiration [Member] 2021 and beyond expiration [Member] 2021 and beyond expiration [Member] 2021 and beyond expiration [Member] 2028 and beyond expiration [Member] 2028 and beyond expiration [Member] 2028 and beyond expiration [Member] Operating Loss Carryforwards [Line Items] Operating Loss Carryforwards [Line Items] Operating Loss Carryforwards Operating Loss Carryforwards SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract] Accounts receivable allowance, beginning balance SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount Additions SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense Deductions SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction Accounts receivable allowance, ending balance Long-term Purchase Commitment [Table] Long-term Purchase Commitment [Table] Unrecorded Unconditional Purchase Obligation by Category of Item Purchased [Axis] Unrecorded Unconditional Purchase Obligation by Category of Item Purchased [Axis] Unconditional Purchase Obligation, Category of Goods or Services Acquired [Domain] Unconditional Purchase Obligation, Category of Goods or Services Acquired [Domain] Avid Commercial Supply Agreement [Member] Avid Commercial Supply Agreement [Member] Avid Commercial Supply Agreement [Member] Patheon [Member] Patheon [Member] Patheon [Member] Category of Item Purchased [Axis] Category of Item Purchased [Axis] Long-term Purchase Commitment, Category of Item Purchased [Domain] Long-term Purchase Commitment, Category of Item Purchased [Domain] Long-term Purchase Commitment [Line Items] Long-term Purchase Commitment [Line Items] Purchase Obligation Purchase Obligation Fair Value Disclosures [Text Block] Fair Value Disclosures [Text Block] RSUs Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Nonvested, Number, period start Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Nonvested, Weighted Average Grant Date Fair Value, period start Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Grants in Period Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Grants in Period, Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Vested in Period Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Vested in Period, Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Forfeited in Period Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Forfeitures, Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Nonvested, Number, period end Nonvested, Weighted Average Grant Date Fair Value, period end Outstanding, Weighted Average Remaining Contractual Terms Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms Aggregate Intrinsic Value, Nonvested Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Nonvested Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract] Vested in Period, Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value Aggregate Intrinsic Value, Vested Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested Statement of Financial Position [Abstract] ASSETS Assets [Abstract] Current assets: Assets, Current [Abstract] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Marketable securities, available-for-sale Available-for-sale Securities, Current Accounts receivable, net Accounts Receivable, after Allowance for Credit Loss, Current Inventories Prepaid expenses and other assets Prepaid Expense and Other Assets, Current Total current assets Assets, Current Property and equipment, net Property, Plant and Equipment, Net Prepaid expenses and other assets Prepaid Expense and Other Assets, Noncurrent Restricted cash Restricted Cash and Cash Equivalents, Noncurrent Total assets Assets LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) Liabilities and Equity [Abstract] Current liabilities: Liabilities, Current [Abstract] Accounts payable Accounts Payable, Current Accrued expenses Accrued Liabilities, Current Deferred Credits and Other Liabilities, Current Deferred Credits and Other Liabilities, Current Deferred revenue, current portion Deferred Revenue, Current Current portion of long-term debt, net Long-term Debt, Current Maturities Total current liabilities Liabilities, Current Deferred Credits and Other Liabilities, Noncurrent Deferred Credits and Other Liabilities, Noncurrent Deferred revenue, net of current portion Deferred Revenue, Noncurrent Long-term debt, net Long-term Debt Other long-term liabilities Other Liabilities, Noncurrent Commitments and contingencies (Note 9) Commitments and Contingencies Stockholders' equity (deficit): Stockholders' Equity Attributable to Parent [Abstract] Preferred stock - $0.001 par value; 20,000 shares authorized; no shares issued and outstanding Preferred Stock, Value, Issued Common stock - $0.001 par value; 200,000 shares authorized; 142,789 and 129,502 shares issued and outstanding at December 31, 2017 and 2016, respectively Common Stock, Value, Issued Additional paid-in capital Additional Paid in Capital, Common Stock Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated deficit Retained Earnings (Accumulated Deficit) Total stockholders' equity (deficit) Total liabilities and stockholders' equity (deficit) Liabilities and Equity Debt Disclosure [Abstract] 2018 Long-term Debt, Maturities, Repayments of Principal in Next Twelve Months 2019 Long-term Debt, Maturities, Repayments of Principal in Year Two 2020 Long-term Debt, Maturities, Repayments of Principal in Year Three 2021 Long-term Debt, Maturities, Repayments of Principal in Year Four 2022 Long-term Debt, Maturities, Repayments of Principal in Year Five Total minimum payments Long-term Debt Including Interest, Gross Long-term Debt Including Interest, Gross Less amount representing interest Long-term Debt, Interest, Gross Long-term Debt, Interest, Gross Gross balance of long-term debt Long-term Debt, Gross Less unamortized debt discount Debt Instrument, Unamortized Discount Present value of long-term debt Long-term Debt, Fair Value Less current portion of long-term debt Long-term debt, less current portion and unamortized debt discount Long-term Debt, Excluding Current Maturities Fair Value, by Balance Sheet Grouping [Table] Fair Value, by Balance Sheet Grouping [Table] Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Domain] Cash and Cash Equivalents [Domain] Money Market Funds [Member] Money Market Funds [Member] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 2 [Member] Fair Value, Inputs, Level 2 [Member] Fair Value, Inputs, Level 3 [Member] Fair Value, Inputs, Level 3 [Member] Asset Class [Axis] Asset Class [Axis] Asset Class [Domain] Asset Class [Domain] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Cash Equivalents Cash and Cash Equivalents, Fair Value Disclosure Available-for-sale Securities Fair Value Disclosure Assets, Fair Value Disclosure Fair Value, Assets, Level 1 to Level 2 Transfers, Amount Fair Value, Assets, Level 1 to Level 2 Transfers, Amount Investments, Level 3 Investments, Fair Value Disclosure Share-based Payment Arrangement, Noncash Expense [Abstract] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Income Statement Location [Axis] Income Statement Location [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Research and Development Expense [Member] Research and Development Expense [Member] Selling, General and Administrative Expenses [Member] Selling, General and Administrative Expenses [Member] RSU, RSA, and PRSU awards [Member] RSU, RSA, and PRSU awards [Member] Restricted Stock Unit, Restricted Stock Awards, and Performance Restricted Stock Unit awards [Member] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Share-based Payment Arrangement, Expense Share-based Payment Arrangement, Expense Available-for-sale, Securities in Unrealized Loss Positions, Qualitative Disclosure, Number of Positions Available-for-sale, Securities in Unrealized Loss Positions, Qualitative Disclosure, Number of Positions Available-for-sale Securities, Continuous Unrealized Loss Position, Accumulated Loss Available-for-sale Securities, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss Other than Temporary Impairment Losses, Marketable Securities Other than Temporary Impairment Losses, Investments, Available-for-sale Securities Balance Sheet Related Disclosures [Abstract] Certain Balance Sheet Items Supplemental Balance Sheet Disclosures [Text Block] Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Debt Instrument, Redemption, Period [Axis] Debt Instrument, Redemption, Period [Axis] Debt Instrument, Redemption, Period [Domain] Debt Instrument, Redemption, Period [Domain] Debt Instrument, Redemption, Period One Debt Instrument, Redemption, Period One [Member] Debt Instrument, Redemption, Period Two Debt Instrument, Redemption, Period Two [Member] Share Repurchase Program [Axis] Share Repurchase Program [Axis] Share Repurchase Program [Domain] Share Repurchase Program [Domain] Shares acquired in privately negotiated transactions [Domain] Shares acquired in privately negotiated transactions [Domain] Shares acquired in privately negotiated transactions [Domain] Accelerated Share Repurchases, Date [Domain] Accelerated Share Repurchases, Date [Domain] Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Convertible Senior Notes Convertible Debt [Member] Royalty-backed Loan Royalty-backed Loan [Member] Royalty-backed Loan [Member] Secured Debt Secured Debt [Member] Senior Loans [Member] Senior Loans [Member] Statistical Measurement [Axis] Statistical Measurement [Axis] Statistical Measurement [Domain] Statistical Measurement [Domain] Minimum Minimum [Member] Maximum Maximum [Member] Debt Instrument [Axis] Debt Instrument [Axis] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] 1.25% Convertible Senior Notes due 2024 1.25% Convertible Senior Notes due 2024 [Member] 1.25% Convertible Senior Notes due 2024 [Member] 2016 [Member] 2016 [Member] 2016 [Member] 2017 [Member] 2017 [Member] 2017 [Member] 2018 and thereafter [Member] 2018 and thereafter [Member] 2018 and thereafter [Member] 2017 Quarterly Maximum Payment [Member] 2017 Quarterly Maximum Payment [Member] 2017 Quarterly Maximum Payment [Member] 2018 Quarterly Maximum Payment [Member] 2018 Quarterly Maximum Payment [Member] 2018 Quarterly Maximum Payment [Member] 2019 Quarterly Maximum Payment [Member] 2019 Quarterly Maximum Payment [Member] 2019 Quarterly Maximum Payment [Member] 2020 Quarterly Maximum Payment [Member] 2020 Quarterly Maximum Payment [Member] 2020 Quarterly Maximum Payment [Member] Debt Instrument [Line Items] Debt Instrument [Line Items] Face amount of debt instrument Debt Instrument, Face Amount Stated interest rate (as a percent) Debt Instrument, Interest Rate, Stated Percentage Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger Debt Instrument, Convertible, Threshold Trading Days Debt Instrument, Convertible, Threshold Trading Days Debt Instrument, Convertible, Threshold Consecutive Trading Days Debt Instrument, Convertible, Threshold Consecutive Trading Days Conversion rate (shares) Debt Instrument, Convertible, Conversion Ratio Debt Instrument, Convertible, Conversion Price Debt Instrument, Convertible, Conversion Price Long-term Debt, Fair Value Payments of Debt Issuance Costs Payments of Debt Issuance Costs Long-term Debt Non-Convertible Borrowing Rate for Similar Debt, Percent Non-Convertible Borrowing Rate for Similar Debt, Percent Non-Convertible Borrowing Rate for Similar Debt, Percent Debt Instrument, Convertible, Carrying Amount of Equity Component Debt Instrument, Convertible, Carrying Amount of Equity Component Proceeds from Convertible Debt Proceeds from Convertible Debt Payments for Repurchase of Common Stock Payments for Repurchase of Common Stock Secured debt original draw Secured debt original draw Secured debt original draw Debt Instrument, Description of Variable Rate Basis Debt Instrument, Description of Variable Rate Basis Debt Instrument, Basis Spread on Variable Rate Debt Instrument, Basis Spread on Variable Rate Debt, Interest Rate Debt, Weighted Average Interest Rate Royalty payments to be applied to debt instrument Royalty payments to be applied to debt instrument Royalty payments to be applied to debt instrument Debt Instrument, Periodic Payment Debt Instrument, Periodic Payment Debt Instrument, Maturity Date, Description Debt Instrument, Maturity Date, Description Prepayment fee, percent Debt Instrument, Prepayment Fee, Percent Debt Instrument, Prepayment Fee,Percent Debt instrument, covenant in compliance Debt Instrument, Covenant Compliance Interest Costs Capitalized Interest Costs Capitalized Accrued Interest Debt Instrument, Increase, Accrued Interest Lender Fee Debt Instrument, Fee Amount Debt Issuance Cost Debt Issuance Costs, Gross Interest Expense, debt Interest Expense, Debt Debt Instrument, Periodic Payment, Interest Debt Instrument, Periodic Payment, Interest Amortization of Debt Discount (Premium) Amortization of Debt Discount (Premium) Outstanding loan balance Secured Debt Debt Instrument, Unamortized Discount Debt Instrument, Convertible, Remaining Discount Amortization Period Debt Instrument, Convertible, Remaining Discount Amortization Period Debt Instrument, Interest Rate, Effective Percentage Debt Instrument, Interest Rate, Effective Percentage Maturity date Debt Instrument, Maturity Date Final payment as percent of original principal Final payment as percent of original principal Final payment as percent of original principal Final payment Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid Debt Instrument, Unused Borrowing Capacity, Amount Debt Instrument, Unused Borrowing Capacity, Amount Debt Instrument, interest only period Debt Instrument, Payment Terms Treasury Stock, Value, Acquired, Cost Method Treasury Stock, Value, Acquired, Cost Method Treasury Stock, Shares, Acquired Treasury Stock, Shares, Acquired Repayments of Debt Repayments of Debt Revenue from Contract with Customer [Abstract] Revenue Collaborative Arrangement Disclosure [Text Block] Available-for-sale marketable securities Available-for-sale Securities [Table Text Block] Investments Classified by Contractual Maturity Date [Table Text Block] Investments Classified by Contractual Maturity Date [Table Text Block] Fair Value, Assets Measured on Recurring Basis [Table Text Block] Fair Value, Assets Measured on Recurring Basis [Table Text Block] Revenue Recognition, Multiple-deliverable Arrangements [Table] Revenue Recognition, Multiple-deliverable Arrangements [Table] Product and Service [Axis] Product and Service [Axis] Product and Service [Domain] Product and Service [Domain] Upfront Upfront fees [Member] Upfront fees [Member] Development Development Fees [Member] Development Fees [Member] Sales Sales-based milestone [Member] Sales-based milestone [Member] Royalties Royalty [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Roche Roche [Member] Roche Baxalta Baxalta [Member] Baxalta [Member] Pfizer Pfizer [Member] Pfizer [Member] Janssen Janssen [Member] Janssen Collaboration [Member] AbbVie AbbVie [Member] AbbVie [Member] Lilly Lilly [Member] Lilly [Member] BMS BMS [Member] BMS [Member] Alexion Alexion [Member] Alexion [Member] argenx [Member] argenx [Member] argenx [Member] Revenue Recognition, Multiple-deliverable Arrangements [Line Items] Revenue Recognition, Multiple-deliverable Arrangements [Line Items] Total revenues Revenue from Contract with Customer, Excluding Assessed Tax Contract with Customer, Asset, Allowance for Credit Loss Contract with Customer, Asset, Allowance for Credit Loss Property, Plant and Equipment [Abstract] Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment, Type [Domain] Property, Plant and Equipment, Type [Domain] Research equipment Research Equipment [Member] Research equipment. Manufacturing equipment Manufacturing Equipment [Member] Manufacturing Equipment [Member] Computer and office equipment Computer and Office Equipment [Member] Computer and office equipment. Leasehold improvements Leasehold Improvements [Member] Property, Plant and Equipment, Gross, Excluding Capital Leased Assets Property, Plant and Equipment, Gross, Excluding Capital Leased Assets Property and equipment, gross Property, Plant and Equipment, Gross Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Excluding Capital Leased Assets Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Excluding Capital Leased Assets Property, Plant and Equipment, Net, Excluding Capital Leased Assets Property, Plant and Equipment, Net, Excluding Capital Leased Assets Operating Lease, Right-of-Use Asset Operating Lease, Right-of-Use Asset Property and equipment, net Income Tax Disclosure [Text Block] Income Tax Disclosure [Text Block] 2017 Federal tax rate 2017 Federal tax rate 2017 Federal tax rate 2018 Federal tax rate 2018 Federal tax rate 2018 Federal tax rate Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount Income Statement [Abstract] Product sales, net Product [Member] Revenues under collaborative agreements Collaborative Agreements [Member] Collaborative Agreements [Member] Revenues: Revenues [Abstract] Operating expenses: Costs and Expenses [Abstract] Cost of product sales Cost of Goods and Services Sold Research and development Research and Development Expense Selling, general and administrative Selling, General and Administrative Expense Total operating expenses Costs and Expenses Operating income (loss) Operating Income (Loss) Other income (expense): Other Income and Expenses [Abstract] Investment and other income, net Other Nonoperating Income (Expense) Interest expense Interest Expense Income (loss) before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Income tax (benefit) expense Income Tax Expense (Benefit) Net income (loss) Earnings Per Share, Basic and Diluted Earnings Per Share, Basic and Diluted Net income (loss) per share, Basic Earnings Per Share, Basic Net income (loss) per share, Diluted Earnings Per Share, Diluted Weighted Average Number of Shares Outstanding, Basic and Diluted Weighted Average Number of Shares Outstanding, Basic and Diluted Shares used in computing basic net income (loss) per share Weighted Average Number of Shares Outstanding, Basic Shares used in computing diluted net income (loss) per share Weighted Average Number of Shares Outstanding, Diluted Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount Effective Income Tax Rate Reconciliation, Deduction, Amount Effective Income Tax Rate Reconciliation, Deduction, Amount Effective Income Tax Rate Reconciliation, Convertible Note Discount in APIC Effective Income Tax Rate Reconciliation, Convertible Note Discount in APIC Effective Income Tax Rate Reconciliation, Convertible Note Discount in APIC Income Tax Expense (Benefit), Continuing Operations, Discontinued Operations Income Tax Expense (Benefit), Continuing Operations, Discontinued Operations Equity [Abstract] Stock options Stock Options And Restricted Stock Units [Member] Stock Options And Restricted Stock Units [Member] Stock Options And Restricted Stock Units [Member] Restricted stock awards Stockholders' equity (deficit) (textual) Number of shares of common stock issued as a result of stock option exercises Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Net proceeds from stock options exercised Proceeds from Stock Options Exercised Number of RSUs surrendered to pay for minimum withholding taxes Share-based Payment Arrangement, Shares Withheld for Tax Withholding Obligation Payments for tax withholding for restricted stock units vested, net Payment, Tax Withholding, Share-based Payment Arrangement Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Quarterly Financial Information Disclosure [Abstract] Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Proceeds from Collaborator Proceeds from Collaborators Restructuring Charges Long-term Debt Long-term Debt [Text Block] Revenue Recognition [Abstract] Revenue from External Customers by Products and Services [Table] Revenue from External Customers by Products and Services [Table] Period prior to expiration Period after expiration Bulk rHuPH20 And ENHANZE [Member] Bulk rHuPH20 And ENHANZE [Member] Bulk rHuPH20 And ENHANZE [Member] Collaborative agreements termination notification Revenue from External Customer [Line Items] Cost of Goods and Services Sold Manufacturing Costs Manufacturing Costs Disaggregation of Revenue Disaggregation of Revenue [Table Text Block] Contract with Customer, Asset and Liability Contract with Customer, Asset and Liability [Table Text Block] Revenue Recognition, Multiple-deliverable Arrangements Revenue Recognition, Multiple-deliverable Arrangements [Table Text Block] Revenues Revenues Gross Profit Gross Profit Operating Expenses Operating Expenses Earnings Per Share, Basic Earnings Per Share, Diluted Weighted Average Number of Shares Outstanding, Basic Weighted Average Number of Shares Outstanding, Diluted Stock Issued During Period Shares New Issues To Underwriter Stock Issued During Period Shares New Issues To Underwriter Stock Issued During Period Shares New Issues To Underwriter Sale of Stock, Price Per Share Sale of Stock, Price Per Share Proceeds from issuance of common stock, net Proceeds from Issuance of Common Stock Accounting Policies [Abstract] Schedule of Research and Development Arrangement, Contract to Perform for Others [Table] Schedule of Research and Development Arrangement, Contract to Perform for Others [Table] Research and Development Arrangement, Contract to Perform for Others, Type [Axis] Research and Development Arrangement, Contract to Perform for Others, Type [Axis] Research and Development Arrangement, Contract to Perform for Others, Type [Domain] Research and Development Arrangement, Contract to Perform for Others, Type [Domain] In-license technologies [Member] In-license technologies [Member] In-license technologies [Member] Research and Development Arrangement, Contract to Perform for Others [Line Items] Research and Development Arrangement, Contract to Perform for Others [Line Items] Research and Development, in-line technologies Research and Development Expense, Software (Excluding Acquired in Process Cost) Deferred tax asset excluding amount for AMT Deferred tax asset excluding amount for AMT Deferred tax asset excluding amount for AMT Deferred Tax Assets, Tax Credit Carryforwards Deferred Tax Assets, Tax Credit Carryforwards Quarterly Financial Information [Text Block] Quarterly Financial Information [Text Block] Cover page. Document Type Document Type Document Annual Report Document Annual Report Document Period End Date Document Period End Date Document Transition Report Document Transition Report Entity File Number Entity File Number Entity Registrant Name Entity Registrant Name Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province City Area Code City Area Code Local Phone Number Local Phone Number Title of 12(b) Security Title of 12(b) Security Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Well-known Seasoned Issuer Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Voluntary Filers Entity Current Reporting Status Entity Current Reporting Status Entity Interactive Data Current Entity Interactive Data Current Entity Filer Category Entity Filer Category Entity Small Business Entity Small Business Entity Emerging Growth Company Entity Emerging Growth Company Entity Shell Company Entity Shell Company Entity Public Float Entity Public Float Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Entity Central Index Key Entity Central Index Key Amendment Flag Amendment Flag Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Current Fiscal Year End Date Current Fiscal Year End Date Deferred Revenue Disclosure [Abstract] Deferred Revenue Arrangement, by Type [Table] Deferred Revenue Arrangement, by Type [Table] License Fees And Event-Based [Member] License Fees And Event-Based [Member] License Fees And Event-Based [Member] Deferred Revenue Arrangement Type [Axis] Deferred Revenue Arrangement Type [Axis] Deferred Revenue Arrangement Type [Domain] Deferred Revenue [Domain] License fees and event-based payments Deferred revenue Deferred Revenue Arrangement [Line Items] Total deferred revenue Deferred Revenue Contract with Customer, Liability, Current Contract with Customer, Liability, Current Contract with Customer, Liability Contract with Customer, Liability Less current portion Deferred revenue, net of current portion Retirement Benefits [Abstract] Compensation and Employee Benefit Plans [Text Block] Compensation and Employee Benefit Plans [Text Block] Product [Member] Event-based development milestones and regulatory milestone and other fees Adjustments for New Accounting Pronouncements [Axis] Adjustments for New Accounting Pronouncements [Axis] Type of Adoption [Domain] Type of Adoption [Domain] Accounting Standards Update 2014-09 Accounting Standards Update 2014-09 [Member] Initial Application Period Cumulative Effect Transition [Axis] Initial Application Period Cumulative Effect Transition [Axis] Initial Application Period Cumulative Effect Transition [Domain] Initial Application Period Cumulative Effect Transition [Domain] Difference between Revenue Guidance in Effect before and after Topic 606 Difference between Revenue Guidance in Effect before and after Topic 606 [Member] Collaborative Arrangements and Non-collaborative Arrangements [Axis] Collaborative Arrangements and Non-collaborative Arrangement Transactions [Domain] 2017 Roche 2017 Roche [Member] 2017 Roche [Member] Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Revenue related to licenses granted to collaboration partners Proceeds from Partner of License and Collaborative Agreement Proceeds from partner of license and collaborative agreement. Development milestones Nonrefundable Upfront License Fee Payment Received Under Collaborative Agreement Nonrefundable upfront license fee payment received under collaborative agreement. Revenue recognized Deferred Revenue, Revenue Recognized Accounts receivable Contract with Customer, Asset, after Allowance for Credit Loss Deferred revenues Impact of applying the provisions of ASC 606 New Accounting Pronouncement or Change in Accounting Principle, Cumulative Effect of Change on Equity or Net Assets Deferred revenues Deferred Credits and Other Liabilities Deferred Credits and Other Liabilities Employer Discretionary Contribution Amount Defined Contribution Plan, Employer Discretionary Contribution Amount Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block] Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block] Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Summary of Positions for which Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Table Text Block] Summary of Positions for which Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Table Text Block] Summary of Operating Loss Carryforwards [Table Text Block] Summary of Operating Loss Carryforwards [Table Text Block] Quarterly Financial Information [Table Text Block] Quarterly Financial Information [Table Text Block] Statement of Comprehensive Income [Abstract] Other comprehensive income (loss): Other Comprehensive Income (Loss), Net of Tax [Abstract] Unrealized (loss) gain on marketable securities Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, after Tax Foreign currency translation adjustment Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax Foreign Currency Transaction Gain (Loss), Unrealized Foreign Currency Transaction Gain (Loss), Unrealized Total comprehensive income (loss) Comprehensive Income (Loss), Net of Tax, Attributable to Parent Segment Reporting [Abstract] Number of Operating Segments Number of Operating Segments Accounts Receivable, after Allowance for Credit Loss, Current [Abstract] Accounts receivable from product sales to collaborators Accounts receivable from product sales to collaborators Accounts receivable from product sales to collaborators Accounts receivable from collaborators Accounts receivable from collaborators Amounts due from collaborators, within one year of the balance sheet date (or the normal operating cycle, whichever is longer) for goods or services (including trade receivables) that have been delivered or sold in the normal course of business. Accounts receivable from other product sales Accounts receivable from product sales Accounts receivable from product sales Accounts receivable from royalties Accounts receivable from royalties Amounts due from royalties, within one year of the balance sheet date (or the normal operating cycle, whichever is longer) for goods or services (including trade receivables) that have been delivered or sold in the normal course of business. Accounts receivable, gross Accounts Receivable, before Allowance for Credit Loss, Current Allowance for distribution fees and discounts Allowance for Distribution Fees and Discounts Allowance for Discount and Distribution Fees Total accounts receivable, net Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Unrecognized Tax Benefits that Would Impact Effective Tax Rate Unrecognized Tax Benefits that Would Impact Effective Tax Rate Unrecognized Tax Benefits, beginning of period Unrecognized Tax Benefits Increase Resulting from Prior Period Tax Positions Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions Decrease Resulting from Prior Period Tax Positions Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions Increase Resulting from Current Period Tax Positions Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions Unrecognized Tax Benefits, end of period Unrecognized Tax Benefits that Would Impact Effective Tax Rate, no valuation allowance Unrecognized Tax Benefits that Would Impact Effective Tax Rate, no valuation allowance Unrecognized Tax Benefits that Would Impact Effective Tax Rate, no valuation allowance Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Options, Outstanding, Number, period start Options, Outstanding, Weighted Average Exercise Price, period start Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Options, Grants in Period, Gross Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Options, Grants in Period, Weighted Average Exercise Price Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Options, Exercises in Period Options, Exercises in Period, Weighted Average Exercise Price Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Options, Forfeitures and Expirations in Period Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price Options, Outstanding, Number, period end Options, Outstanding, Weighted Average Exercise Price, period end Options, Outstanding, Weighted Average Remaining Contractual Term Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Options, Outstanding, Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Options, Vested and Expected to Vest, Outstanding, Number Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Options, Vested and Expected to Vest, Exercisable, Number Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract] Options, Grants in Period, Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Options, Exercises in Period, Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value Proceeds from Stock Options Exercised Restructuring Charges Restructuring and Related Activities Disclosure [Text Block] Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization and Business Nature of Operations [Text Block] Restricted stock award holder exercise price Restricted stock award holder exercise price Restricted stock award holder exercise price Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Accounts Receivable, Allowance for Credit Loss, Current Accounts Receivable, Allowance for Credit Loss, Current Earnings Per Share, Diluted [Abstract] Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table] Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table] Convertible Debt [Member] 1.25% Convertible Senior Notes due 2024 [Member] Loss Per Share Disclosure [Line Items] Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items] Shares excluded from calculation of diluted net loss, amount Weighted Average Number Diluted Shares Outstanding Adjustment Net loss per share (Textuals) [Abstract] Net income (loss) per share (Textuals) [Abstract] Net income (loss) per share (Textuals) [Abstract] Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Statement of Cash Flows [Abstract] Operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Net income (loss) Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Share-based compensation Share-based Payment Arrangement, Noncash Expense Depreciation and amortization Depreciation, Depletion and Amortization Non-cash interest expense Amortization of Debt Issuance Costs (Accretion of discounts) amortization of premiums on marketable securities, net Accretion (Amortization) of Discounts and Premiums, Investments Loss on disposal of equipment Gain (Loss) on Disposition of Property Plant Equipment Deferral of unearned revenue Increase (Decrease) in Deferred Revenue Recognition of deferred revenue Recognition of Deferred Revenue Deferred Rent Expense Deferred Rent Expense Deferred Rent Expense Deferral of rent expense Other Noncash Expense Recognition of deferred rent Straight Line Rent Gain (Loss) on Extinguishment of Debt Gain (Loss) on Extinguishment of Debt Other Other Operating Activities, Cash Flow Statement Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Accounts receivable, net Increase (Decrease) in Accounts Receivable Inventories Increase (Decrease) in Inventories Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets Accounts payable and accrued expenses Increase (Decrease) in Accounts Payable and Accrued Liabilities Net cash provided by (used in) operating activities Net Cash Provided by (Used in) Operating Activities Investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Purchases of marketable securities Payments to Acquire Available-for-sale Securities Proceeds from maturities of marketable securities Proceeds from Sale of Available-for-sale Securities Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Net cash (used in) provided by investing activities Net Cash Provided by (Used in) Investing Activities Financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Proceeds from issuance of long-term debt, net Proceeds from Debt, Net of Issuance Costs Repayment of long-term debt Repayments of Secured Debt Payments of Debt Issuance Costs Payments for Repurchase of Common Stock Proceeds from issuance of common stock under equity incentive plans, net of taxes paid related to net share settlement Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Net increase (decrease) in cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash, cash equivalents and restricted cash beginning of period Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Cash, cash equivalents and restricted cash end of period Interest Paid, Including Capitalized Interest, Operating and Investing Activities Interest Paid, Including Capitalized Interest, Operating and Investing Activities Income Taxes Paid Income Taxes Paid Amounts accrued for purchases of property and equipment Capital Expenditures Incurred but Not yet Paid Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Payments for Tenant Improvements Payments for Tenant Improvements Prepaid Expense and Other Assets, Current [Abstract] Prepaid manufacturing expenses Prepaid Expense, Current Prepaid research and development expenses Prepaid research and development Prepaid research and development Other prepaid expenses Other Prepaid Expense, Current Other assets Other Assets Total prepaid expense and other assets Prepaid Expense and Other Assets Less long-term portion Total prepaid expense and other assets, current Deferred Tax Assets, Operating Loss Carryforwards Deferred Tax Assets, Operating Loss Carryforwards Deferred Tax Assets, Deferred Income Deferred Tax Assets, Deferred Income Deferred Tax Assets, Tax Credit Carryforwards, Research Deferred Tax Assets, Tax Credit Carryforwards, Research Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost Deferred Tax Assets, Tax Credit Carryforwards, Alternative Minimum Tax Deferred Tax Assets, Tax Credit Carryforwards, Alternative Minimum Tax Deferred Tax Assets, Lease Liabilities Deferred Tax Assets, Lease Liabilities Deferred Tax Assets, Lease Liabilities Deferred Tax Assets, Interest Expense Limitation Deferred Tax Assets, Interest Expense Limitation Deferred Tax Assets, Interest Expense Limitation Deferred Tax Assets, Other Deferred Tax Assets, Other Deferred Tax Assets, Gross Deferred Tax Assets, Gross Deferred Tax Assets, Valuation Allowance Deferred Tax Assets, Valuation Allowance Deferred Tax Assets, Net of Valuation Allowance Deferred Tax Assets, Net of Valuation Allowance Deferred Tax Liabilities, Property, Plant and Equipment Deferred Tax Liabilities, Property, Plant and Equipment Deferred Tax Liabilities, Convertible Note Deferred Tax Liabilities, Convertible Note Deferred Tax Liabilities, Convertible Note Deferred Tax Liabilities, Right-of-Use Asset Deferred Tax Liabilities, Right-of-Use Asset Deferred Tax Liabilities, Right-of-Use Asset Deferred Tax Liabilities, Other Deferred Tax Liabilities, Other Deferred Tax Liabilities, Net, Noncurrent Deferred Tax Liabilities, Net, Noncurrent Deferred Tax Assets, Net Deferred Tax Assets, Net Tax Credit Carryforward [Table] Tax Credit Carryforward [Table] Tax Credit Carryforward [Axis] Tax Credit Carryforward [Axis] Tax Credit Carryforward, Name [Domain] Tax Credit Carryforward, Name [Domain] Research Tax Credit Carryforward [Member] Research Tax Credit Carryforward [Member] General Business Tax Credit Carryforward [Member] General Business Tax Credit Carryforward [Member] Tax Credit Carryforward [Line Items] Tax Credit Carryforward [Line Items] Deferred Tax Assets, Valuation Allowance Unrecognized Tax Benefits Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense Tax Credit Carryforward, Amount Tax Credit Carryforward, Amount Undistributed Earnings of Foreign Subsidiaries Undistributed Earnings of Foreign Subsidiaries Deferred Foreign Tax Benefit Deferred Foreign Income Tax Expense (Benefit) Schedules of Concentration of Risk, by Risk Factor [Table Text Block] Schedules of Concentration of Risk, by Risk Factor [Table Text Block] Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Share-based Payment Arrangement [Text Block] Share-based Payment Arrangement [Text Block] Leases [Abstract] Lessee, Operating Lease, Term of Contract Lessee, Operating Lease, Term of Contract Sales of bulk rHuPH20 Sales of ENHANZE drug product ENHANZE drug product [Member] [Domain] ENHANZE drug product [Member] [Domain] Upfront license and target nomination fees Sales-based milestones Research and development services Research and Development Services [Member] Research and Development Services [Member] United States Income (Loss) from Continuing Operations before Income Taxes, Domestic Foreign Income (Loss) from Continuing Operations before Income Taxes, Foreign Net Income (Loss) Before Income Taxes Preferred stock, par value Preferred Stock, Par or Stated Value Per Share Preferred stock, shares authorized Preferred Stock, Shares Authorized Preferred stock, shares issued Preferred Stock, Shares Issued Preferred stock, shares outstanding Preferred Stock, Shares Outstanding Common stock, par value Common Stock, Par or Stated Value Per Share Common stock, shares authorized Common Stock, Shares Authorized Common stock, shares issued Common Stock, Shares, Issued Shares, Outstanding Common stock, shares outstanding Common Stock, Shares, Outstanding Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Share-based Payment Arrangement, Cost by Plan [Table Text Block] Share-based Payment Arrangement, Cost by Plan [Table Text Block] Share-based Payment Arrangement, Nonvested Award, Cost [Table Text Block] Share-based Payment Arrangement, Nonvested Award, Cost [Table Text Block] Share-based Payment Arrangement, Option, Activity [Table Text Block] Share-based Payment Arrangement, Option, Activity [Table Text Block] Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block] Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block] Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block] Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block] Impairment of Long-Lived Assets Held-for-use Impairment of Long-Lived Assets Held-for-use Summary of Accounts Receivable Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block] Summary of Inventories Schedule of Inventory, Current [Table Text Block] Summary of Prepaid Expenses and Other Assets Schedule of Other Assets [Table Text Block] Summary of Property and Equipment Property, Plant and Equipment [Table Text Block] Summary of Accrued Expenses Schedule of Accrued Liabilities [Table Text Block] Summary of Deferred Revenue Deferred Revenue, by Arrangement, Disclosure [Table Text Block] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] Revenue, Remaining Performance Obligation, Amount Revenue, Remaining Performance Obligation, Amount Schedule of Share-based Compensation Arrangements Valuation Inputs [Table] Schedule of Share-based Compensation Arrangements Valuation Inputs [Table] Schedule of Share-based Compensation Arrangements Valuation Inputs [Table] Schedule of Share-based Compensation Arrangements Valuation Inputs [Line Items] Schedule of Share-based Compensation Arrangements Valuation Inputs [Line Items] [Line Items] for Schedule of Share-based Compensation Arrangements Valuation Inputs [Table] Fair Value Assumptions, Weighted Average Volatility Rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate Fair Value Assumptions, Weighted Average Expected Term Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Fair Value Assumptions, Expected Dividend Rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Fair Value Assumptions, Risk Free Interest Rate, Minimum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum Fair Value Assumptions, Risk Free Interest Rate, Maximum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum Basis of Presentation Basis of Presentation and Significant Accounting Policies [Text Block] Use of Estimates, Policy [Policy Text Block] Use of Estimates, Policy [Policy Text Block] Cash Equivalents Cash and Cash Equivalents, Policy [Policy Text Block] Marketable Securities Marketable Securities, Policy [Policy Text Block] Restricted Cash Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block] Fair Value of Financial Instruments Fair Value of Financial Instruments, Policy [Policy Text Block] Concentration Risk, Credit Risk, Policy [Policy Text Block] Concentration Risk, Credit Risk, Policy [Policy Text Block] Accounts Receivable [Policy Text Block] Accounts Receivable [Policy Text Block] Inventory, Policy [Policy Text Block] Inventory, Policy [Policy Text Block] Property and Equipment, Policy [Policy Text Block] Property, Plant and Equipment, Policy [Policy Text Block] Impairment of Long-Lived Assets, Policy [Policy Text Block] Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] Comprehensive Income (Loss), Policy [Policy Text Block] Comprehensive Income, Policy [Policy Text Block] Revenue [Policy Text Block] Revenue [Policy Text Block] Cost of Product Sales, Policy [Policy Text Block] Cost of Goods and Service [Policy Text Block] Research and Development Expenses Research and Development Expense, Policy [Policy Text Block] Clinical Trial Expenses Disclosure of Accounting Policy for Clinical Trial Expenses [Policy Text Block] Disclosure of accounting policy for clinical trial expenses. Share-Based Compensation Share-based Payment Arrangement [Policy Text Block] Income Taxes Income Tax, Policy [Policy Text Block] Net Income (Loss) Per Share Earnings Per Share, Policy [Policy Text Block] Segment Information Segment Reporting, Policy [Policy Text Block] Adoption and Pending Adoption of Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Accounts receivable, net Restricted Cash and Investments, Current [Abstract] Schedule of Maturities of Long-term Debt [Table Text Block] Schedule of Maturities of Long-term Debt [Table Text Block] Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Property, Plant and Equipment, Useful Life Property, Plant and Equipment, Useful Life Inventory, Raw Materials Inventory, Raw Materials, Net of Reserves Inventory, Work in Process Inventory, Work in Process, Net of Reserves Inventory, Finished Goods Inventory, Finished Goods, Net of Reserves Summary of Inventories Inventory, Net [Abstract] Total inventories Class of Treasury Stock [Table] Class of Treasury Stock [Table] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Subsequent Event Subsequent Event [Member] 2019 Share Repurchase Program - Bank of America 2019 Share Repurchase Program - Bank of America [Member] 2019 Share Repurchase Program - Bank of America [Member] Equity, Class of Treasury Stock [Line Items] Equity, Class of Treasury Stock [Line Items] Stock Repurchase Program, Period in Force Stock Repurchase Program, Period in Force Authorized repurchase amount Stock Repurchase Program, Authorized Amount Stock repurchased (shares) Value of stock repurchased Concentration Risk [Table] Concentration Risk [Table] Major Supplier [Axis] Major Supplier [Axis] Major Supplier [Axis] Major Supplier [Domain] Major Supplier [Domain] [Domain] for Major Supplier [Axis] Bulk formulation [Member] Bulk formulation [Member] Bulk formulation [Member] Customer [Axis] Customer [Axis] Customer [Domain] Customer [Domain] Roche and Baxalta [Member] Roche and Baxalta [Member] Roche and Baxalta [Member] Geographical [Axis] Geographical [Axis] Geographical [Domain] Geographical [Domain] UNITED STATES UNITED STATES SWITZERLAND SWITZERLAND All other foreign [Member] Geographic Distribution, Foreign [Member] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Accounts Receivable [Member] Accounts Receivable [Member] Sales [Member] Sales [Member] Accounts Payable [Member] Accounts Payable [Member] Concentration Risk Type [Axis] Concentration Risk Type [Axis] Concentration Risk Type [Domain] Concentration Risk Type [Domain] Geographic Concentration Risk [Member] Geographic Concentration Risk [Member] Customer Concentration Risk [Member] Customer Concentration Risk [Member] Supplier Concentration Risk [Member] Supplier Concentration Risk [Member] Concentration Risk [Line Items] Concentration Risk [Line Items] Concentration Risk, Percentage Concentration Risk, Percentage Number of manufacturers Number of manufacturers Number of third-party manufacturers for the supply of bulk rHuPH20. Concentration Risk, Percentage (instant date) Concentration Risk, Percentage (instant date) Concentration Risk, Percentage (instant date) Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block] Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block] Stockholders' Equity (Deficit) Stockholders' Equity Note Disclosure [Text Block] Payables and Accruals [Abstract] Operating Lease, Accretion Of Liability Operating Lease, Accretion Of Liability Operating Lease, Accretion Of Liability Summary of Accrued Expenses Accrued Liabilities, Current [Abstract] Accrued outsourced research and development Accrued Outsourced Research and Development Expenses Current Accrued outsourced research and development expenses current. Accrued compensation and payroll taxes Employee-related Liabilities, Current Accrued outsourced manufacturing expenses Accrued manufacturing expenses Accrued manufacturing expenses Other accrued expenses Other Accrued Liabilities, Current Operating Lease, Liability Total accrued expenses Accrued Liabilities and Other Liabilities Accrued Liabilities, Noncurrent Accrued Liabilities, Noncurrent Accrued Liabilities, Noncurrent Total accrued expenses, current Operating Lease, Cost Operating Lease, Cost Operating Lease, Payments Operating Lease, Payments Current Federal Tax Expense (Benefit) Current Federal Tax Expense (Benefit) Current State Tax Expense Current State and Local Tax Expense (Benefit) Deferred Federal Income Tax Benefit Deferred Federal Income Tax Expense (Benefit) Deferred State Income Tax Expense Deferred State and Local Income Tax Expense (Benefit) New Accounting Pronouncements and Changes in Accounting Principles [Abstract] New Accounting Pronouncement or Change in Accounting Principle, Cumulative Effect of Change on Equity or Net Assets Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Name of Property [Axis] Name of Property [Axis] Name of Property [Domain] Name of Property [Domain] Office and Research Facility [Member] Office and Research Facility [Member] Office and Research Facility [Member] Satellite office [Member] Satellite office [Member] Satellite office [Member] Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Operating Lease, Weighted Average Remaining Lease Term Operating Lease, Weighted Average Remaining Lease Term Operating Leases, Area Leased Operating Leases, Area Leased Operating Leases, Area Leased Operating Leases, Base Rent, Periodic Increase, Percent Operating Leases, Base Rent, Periodic Increase, Percent Operating Leases, Base Rent, Periodic Increase, Percent Number of buildings Number of buildings Number of buildings Plan Name [Axis] Plan Name [Axis] Plan Name [Domain] Plan Name [Domain] Amended and Restated 2011 Stock Plan [Member] Amended and Restated 2011 Stock Plan [Member] Amended and Restated 2011 Stock Plan [Member] Outstanding awards [Member] Outstanding awards [Member] Outstanding awards [Member] Vesting [Axis] Vesting [Axis] Vesting [Domain] Vesting [Domain] Cliff Vesting, First Anniversary [Member] Cliff Vesting, First Anniversary [Member] Cliff Vesting, First Anniversary [Member] Monthly Vesting, after One Year [Member] Monthly Vesting, after One Year [Member] Monthly Vesting, after One Year [Member] Percentage Vesting [Member] Percentage Vesting [Member] Percentage Vesting [Member] Number of Shares Authorized Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized Number of Shares Subject To Outstanding Awards Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Subject To Outstanding Awards Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Subject To Outstanding Awards Common Stock, Capital Shares Reserved for Future Issuance Common Stock, Capital Shares Reserved for Future Issuance Options, Exercise Price, Percent of Share Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercise Price, Percent of Share Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercise Price, Percent of Share Price Options, Outstanding, Initial Contractual Term Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Initial Contractual Term Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Initial Contractual Term Award Vesting Rights, Percentage Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage Schedule II Valuation and Qualifying Accounts SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block] Depreciation and amortization Depreciation, Depletion and Amortization [Abstract] Depreciation and amortization Finance Lease, Right-of-Use Asset, Amortization Finance Lease, Right-of-Use Asset, Amortization EX-101.PRE 12 halo-20191231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 13 perfrormancegraph.jpg begin 644 perfrormancegraph.jpg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�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slide1b04.jpg begin 644 slide1b04.jpg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�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end GRAPHIC 15 slide2a93.jpg begin 644 slide2a93.jpg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end XML 16 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 17 R13.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Long-Term Debt, Net
 12 Months Ended
Dec. 31, 2019
Debt Disclosure [Abstract]  
Long-term Debt Long-Term Debt, Net
Convertible Notes
In November 2019, we completed the sale of $460.0 million in aggregate principal amount of 1.25% Convertible Senior Notes due 2024 (“Convertible Notes”) in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (“Securities Act”). The Convertible Notes were issued under an indenture, dated as of November 18, 2019, (“Indenture”) with The Bank of New York Mellon Trust Company, N.A., as trustee. The offer and sale of the Convertible Notes and the shares of common stock issuable upon conversion of the Convertible Notes have not been registered under the Securities Act, or the securities laws of any other jurisdiction, and the Convertible Notes and such shares may not be offered or sold absent registration or an applicable exemption from registration requirements, or in a transaction not subject to, such registration requirements.
We received net proceeds from the offering of approximately $447.4 million. We used $200.0 million of the net proceeds from the offering to repurchase shares of common stock, including approximately $143.1 million to repurchase approximately 8.1 million shares of common stock concurrently with the offering in privately negotiated transactions, $6.9 million in open market purchases and $50.0 million to repurchase a total of approximately 2.6 million shares of common stock through an accelerated share repurchase agreement.
We used approximately $26.1 million of the net proceeds from the offering to repay all outstanding amounts under its loan agreement with Oxford Finance and Silicon Valley Bank and intend to use the remainder of the net proceeds for general corporate purposes, including additional share repurchases subsequent to the offering and working capital.
The Convertible Notes will pay interest semi-annually in arrears on June 1st and December 1st of each year, beginning on June 1, 2020, at an annual rate of 1.25% and will be convertible into cash, shares of common stock or a combination of cash and shares of common stock, at our election, based on the applicable conversion rate at such time. The Convertible Notes are general unsecured obligations and will rank senior in right of payment to all indebtedness that is expressly subordinated in right of payment to the Convertible Notes, will rank equally in right of payment with all existing and future liabilities that are not so subordinated, will be effectively junior to any secured indebtedness to the extent of the value of the assets securing such indebtedness and will be structurally subordinated to all indebtedness and other liabilities (including trade payables) of the our current or future subsidiaries. The Convertible Notes have a maturity date of December 1, 2024.
Holders may convert their Convertible Notes at their option only in the following circumstances: (1) during any calendar quarter commencing after the calendar quarter ending on March 31, 2020, if the last reported sale price per share of common stock exceeds 130% of the conversion price for each of at least 20 trading days during the 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter; (2) during the five consecutive business days immediately after any five consecutive trading day period (such five consecutive trading day period, the “measurement period”) in which the trading price per $1,000 principal amount of notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price per share of Company’s common stock on such trading day and the conversion rate on such trading day; (3) upon the occurrence of certain corporate events or distributions on Company’s common stock, as described in the offering memorandum; (4) if we call such notes for redemption; and (5) at any time from, and including, June 1, 2024 until the close of business on the scheduled trading day immediately before the maturity date.
Upon conversion, we will pay or deliver, as applicable, cash, shares of common stock or a combination of cash and shares of common stock, at our election. The initial conversion rate for the Convertible Notes will be 41.9208 shares of common stock per $1,000 in principal amount of Convertible Notes, equivalent to a conversion price of approximately $23.85 per share of our common stock. The conversion rate is subject to adjustment as described in the Indenture.
In accordance with accounting guidance for debt with conversion and other options, we accounted for the debt and equity components of the Convertible Notes separately. The estimated fair value of the debt component at the date of issuance was $381.8 million, which was computed based on our non-convertible borrowing rate for similar debt of 5.19%, derived from independent valuation analysis. The equity component was allocated a value of $65.6 million and represents the difference
between the $447.4 million of net proceeds from the issuance of the Convertible Notes and the $381.8 million estimated fair value of the debt component at the date of issuance.
In connection with the Convertible Notes, we paid the initial purchasers of the Convertible Notes a fee of $12.7 million and incurred additional debt issuance costs totaling $0.3 million, which includes expenses that we paid on behalf of the initial purchasers and expenses incurred directly by us. Debt issuance costs, the initial purchasers’ fee and the equity component is presented as a debt discount as of December 31, 2019 in the amount of $76.9 million, and will be amortized over the remaining estimated term of 5 years using the effective interest method, utilizing an effective interest rate of 5.10%. The net carrying amount of the debt as of December 31, 2019 is $383.1 million. For the year ended December 31, 2019, we recognized interest expense of $2.3 million, including contractual coupon interest of $0.7 million and amortization of the debt discount of $1.6 million.
As of December 31, 2019, we were in compliance with all covenants under the Indenture and there was no material adverse change in our business, operations or financial condition.
Royalty-backed Loan
In January 2016, through our wholly-owned subsidiary Halozyme Royalty LLC (“Halozyme Royalty”), we received a $150 million loan (the “Royalty-backed Loan”) pursuant to a credit agreement (the “Credit Agreement”) with BioPharma Credit Investments IV Sub, LP and Athyrium Opportunities II Acquisition LP (the “Royalty-backed Lenders”). Under the terms of the Credit Agreement, Halozyme Therapeutics, Inc. transferred to Halozyme Royalty the right to receive royalty payments from the commercial sales of ENHANZE products owed under the Roche Collaboration and Baxalta Collaboration (“Collaboration Agreements”). The royalty payments from the Collaboration Agreements will be used to repay the principal and interest on the loan (the “Royalty Payments”).  The Royalty-backed Loan bears interest at a per annum rate of 8.75% plus the three-month LIBOR rate. The three-month LIBOR rate is subject to a floor of 0.7% and a cap of 1.5%. The interest rate as of December 31, 2019 and 2018 was 10.25%.
The Credit Agreement provides that none of the Royalty Payments were required to be applied to the Royalty-backed Loan prior to January 1, 2017, 50% of the Royalty Payments are required to be applied to the Royalty-backed Loan between January 1, 2017 and January 1, 2018 and thereafter all Royalty Payments must be applied to the Royalty-backed Loan. However, the amounts available to repay the Royalty-backed Loan are subject to caps of $13.75 million per quarter in 2017, $18.75 million per quarter in 2018, $21.25 million per quarter in 2019 and $22.5 million per quarter in 2020 and thereafter. Amounts available to repay the Royalty-backed Loan will be applied first to pay interest and second to repay principal on the Royalty-backed Loan. Any accrued interest that is not paid on any applicable quarterly payment date, as defined, will be capitalized and added to the principal balance of the Royalty-backed Loan on such date. Halozyme Royalty will be entitled to receive and distribute to Halozyme any Royalty Payments that are not required to be applied to the Royalty-backed Loan or which are in excess of the foregoing caps.
Because the repayment of the term loan is contingent upon the level of Royalty Payments received, the repayment term may be shortened or extended depending on the actual level of Royalty Payments. The final maturity date of the Royalty-backed Loan will be the earlier of (i) the date when principal and interest is paid in full, (ii) the termination of Halozyme Royalty’s right to receive royalties under the Collaboration Agreements, and (iii) December 31, 2050.  Currently, we estimate that the loan will be repaid in the second quarter of 2020. This estimate could be adversely affected and the repayment period could be extended if future royalty amounts are less than currently expected. Under the terms of the Credit Agreement, at any time after January 1, 2019, Halozyme Royalty may, subject to certain limitations, prepay the outstanding principal of the Royalty-backed Loan in whole or in part, at a price equal to 105% of the outstanding principal on the Royalty-backed Loan, plus accrued but unpaid interest. The Royalty-backed Loan constitutes an obligation of Halozyme Royalty, and is non-recourse to Halozyme. Halozyme Royalty retains its right to the Royalty Payments following repayment of the loan.
As of December 31, 2019, we were in compliance with all covenants under the Royalty-backed Loan and there was no material adverse change in our business, operations or financial condition.
We began making principal and interest payments against the Royalty-backed Loan in the first quarter of 2017 and therefore had zero capitalized interest for the twelve months ended December 31, 2019. In addition, we recorded accrued interest, which is included in accrued expenses, of $0.1 million and $0.4 million as of December 31, 2019 and 2018, respectively.
In connection with the Royalty-backed Loan, we paid the Royalty-backed Lenders a fee of $1.5 million and incurred additional debt issuance costs totaling $0.4 million, which includes expenses that we paid on behalf of the Royalty-backed Lenders and expenses incurred directly by us. Debt issuance costs and the lender fee have been netted against the debt as of December 31, 2019, and are being amortized over the estimated term of the debt using the effective interest method. For the years ended December 31, 2019, 2018 and 2017, we recognized interest expense, including amortization of the debt discount, related to the Royalty-backed Loan of $6.2 million, $13.1 million and $16.4 million, respectively. The assumptions used in determining the expected repayment term of the debt and amortization period of the issuance costs requires that we make estimates that could impact the short- and long-term classification of these costs, as well as the period over which these costs will be amortized. The outstanding balance of the Royalty-backed Loan as of December 31, 2019 was $19.5 million.
Oxford and SVB Loan and Security Agreement
In June 2016, we entered into a Loan and Security Agreement (the “Loan Agreement”) with Oxford Finance LLC (“Oxford”) and Silicon Valley Bank (“SVB”) (collectively, the “Lenders”), providing a senior secured loan facility of up to an aggregate principal amount of $70.0 million, comprising a $55.0 million draw in June 2016 and an additional $15.0 million tranche, which we had the option to draw during the second quarter of 2017 and did not exercise. The initial proceeds were partially used to pay the outstanding principal and final payment of $4.25 million owed on a previous loan agreement with the Lenders. The remaining proceeds were used for working capital and general business requirements. The senior secured loan facility carried a fixed interest rate of 8.25%. The repayment schedule provided for interest only payments for the first 18 months, followed by consecutive equal monthly payments of principal and interest in arrears through the maturity date of January 1, 2021. The Loan Agreement provided for a final payment equal to 5.50% of the initial $55.0 million principal amount, which was due when the Loan Agreement becomes due or upon the prepayment of the facility. We had the option to prepay the outstanding balance of the Loan Agreement in full and exercised this option in November 2019, at which point we paid the full remaining balance and final payment of $26.1 million.
Interest expense, including amortization of the debt discount, related to the Loan Agreement totaled $3.0 million, $4.9 million and $5.5 million for the years ended December 31, 2019, 2018 and 2017, respectively.
Future maturities and interest payments of long-term debt as of December 31, 2019, are as follows (in thousands):
2020
 
$
26,100

2021
 
5,750

2022
 
5,750

2023
 
5,750

2024
 
465,750

Total minimum payments
 
509,100

Less amount representing interest
 
(29,540
)
Gross balance of long-term debt
 
479,560

Less unamortized debt discount
 
(76,973
)
Present value of long-term debt
 
402,587

Less current portion of long-term debt
 
(19,542
)
Long-term debt, less current portion and unamortized debt discount
 
$
383,045

XML 18 R17.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Income Taxes (Notes)
 12 Months Ended
Dec. 31, 2019
Income Tax Disclosure [Abstract]  
Income Tax Disclosure [Text Block]
Total (loss) income before income taxes summarized by region were as follows (in thousands):
 
 
Year Ended December 31,
 
 
2019
 
2018
 
2017
United States
 
$
(70,737
)
 
$
(45,819
)
 
$
160,938

Foreign
 
(1,514
)
 
(33,974
)
 
(99,328
)
Net (loss) income before income taxes
 
$
(72,251
)
 
$
(79,793
)
 
$
61,610


Significant components of our net deferred tax assets/(liabilities) were as follows (in thousands).
 
 
December 31,
 
 
2019
 
2018
Deferred tax assets:
 
 
 
 
Net operating loss carryforwards
 
$
39,401

 
$
26,267

Deferred revenue
 
1,069

 
1,395

Research and development and orphan drug credits
 
114,357

 
106,406

Share-based compensation
 
9,972

 
9,541

Alternative minimum tax credit
 
1,683

 
2,959

ASC 842 lease liability
 
1,454

 
—

Interest expense limitation
 
2,163

 
1,750

Other, net
 
3,037

 
2,452

 
 
173,136

 
150,770

Valuation allowance for deferred tax assets
 
(155,100
)
 
(146,953
)
Deferred tax assets, net of valuation
 
18,036

 
3,817

Deferred tax liabilities:
 
 
 
 
Depreciation
 
(865
)
 
(858
)
Convertible note
 
(14,450
)
 
—

ASC 842 right of use asset
 
(865
)
 
—

Other, net
 
(173
)
 
—

Total deferred tax liabilities
 
(16,353
)
 
(858
)
Net deferred tax asset
 
$
1,683

 
$
2,959


A valuation allowance of $155.1 million and $147.0 million has been established to offset the net deferred tax assets as of December 31, 2019 and 2018, respectively, as realization of such assets is uncertain. Under the Act, taxpayers are able to claim a refund of the AMT credit carryover by December 31, 2021. Accordingly, the recognized net deferred tax asset as of December 31, 2019 is the AMT credit carryover that will either be utilized or refunded by December 31, 2021.
Income tax expense was comprised of the following components (in thousands):
 
 
Year Ended December 31,
 
 
2019
 
2018
 
2017
Current - federal
 
$
114

 
$
82

 
$
4,051

Current - state
 
(40
)
 
519

 
120

Deferred - federal
 
(85
)
 
(64
)
 
(5,532
)
Deferred - state
 
—

 
—

 
—

 
 
$
(11
)
 
$
537

 
$
(1,361
)

The provision for income taxes on earnings subject to income taxes differs from the statutory federal income tax rate due to the following (in thousands):
 
 
Year Ended December 31,
 
 
2019
 
2018
 
2017
Federal income tax expense (benefit) at 21% for 2019 and 2018 and 34% for 2017
 
$
(15,173
)
 
$
(16,754
)
 
$
20,947

State income tax benefit, net of federal income tax impact
 
(1,509
)
 
(4,297
)
 
930

(Decrease) increase in valuation allowance
 
8,147

 
35,731

 
(77,181
)
Enactment of the Tax Cuts and Jobs Act
 
—

 
—

 
17,132

Foreign income subject to tax at other than federal statutory rate
 
318

 
7,106

 
33,674

Shared-based compensation
 
315

 
425

 
525

Non-deductible expenses and other
 
924

 
1,599

 
5,779

Research and development credits, net
 
(1,091
)
 
(5,210
)
 
4,162

Orphan drug credits, net of federal add back
 
(5,718
)
 
(18,063
)
 
(7,329
)
Convertible note discount in APIC
 
$
13,776

 
$
—

 
$
—

 
 
$
(11
)
 
$
537

 
$
(1,361
)

At December 31, 2019, our unrecognized tax benefit and uncertain tax positions were $21.5 million. Of this, $0.2 million of this amount would affect the effective tax rate and $21.5 million would affect the effective tax rate only in the event the valuation allowance was removed. Of the unrecognized tax benefits, we do not expect any significant changes to occur in the next 12 months. Interest and/or penalties related to uncertain income tax positions are recognized by us as a component of income tax expense. For the years ended December 31, 2019, 2018 and 2017, we recognized an immaterial amount of interest and penalties.
The following table summarizes the activity related to our unrecognized tax benefits (in thousands):
 
 
Year Ended December 31,
 
 
2019
 
2018
 
2017
Gross unrecognized tax benefits at beginning of period
 
$
20,028

 
$
14,428

 
$
12,799

Increases in tax positions for prior years
 
69

 
3,083

 
—

Decreases in tax positions for prior years
 
(23
)
 
—

 
(2,518
)
Increases in tax positions for current year
 
1,409

 
2,517

 
4,147

Gross unrecognized tax benefits at end of period
 
$
21,483

 
$
20,028

 
$
14,428


At December 31, 2019, we had federal, California and other state tax net operating loss carryforwards of approximately $118.5 million, $244.3 million and $26.7 million, respectively.
The following table shows key expiration dates of the federal and California net operating loss carryforwards (in thousands):
 
 
 
 
Expires in:
 
 
Net Operating Loss
 
2020
 
2021 and beyond
 
2028 and beyond
Federal
 
$
118,480

 
$
—

 
$
118,480

 
—

California
 
$
244,337

 
$
—

 
—

 
$
244,337


At December 31, 2019, we had federal and California research and development tax credit carryforwards of approximately $27.9 million and $19.1 million, respectively. The federal research and development tax credits will begin to expire in 2024 unless previously utilized. The California research and development tax credits will carryforward indefinitely until utilized. Additionally, we had Orphan Drug Credit carryforwards of $88.0 million which will begin to expire in 2034.
Pursuant to Internal Revenue Code Section 382, the annual use of the net operating loss carryforwards and research and development tax credits could be limited by any greater than 50% ownership change during any three year testing period. As a result of any such ownership change, portions of our net operating loss carryforwards and research and development tax credits are subject to annual limitations. We completed an updated Section 382 analysis regarding the limitation of the net operating losses and research and development credits as of December 31, 2019. Based upon the analysis, we determined that ownership changes occurred in prior years; however, the annual limitations on net operating loss and research and development tax credit carryforwards will not have a material impact on the future utilization of such carryforwards.
The Company’s 2015 and 2016 federal returns were selected for audit by the IRS. The audit was completed in September 2019 with no material adjustments.
We do not provide for U.S. income taxes on the undistributed earnings of our foreign subsidiary as it is our intention to utilize those earnings in the foreign operations for an indefinite period of time. At December 31, 2019 and 2018, there were no undistributed earnings in foreign subsidiaries.
We are subject to taxation in the U.S. and in various state and foreign jurisdictions. Our tax years for 2004 and forward are subject to examination by the U.S. and California tax authorities due to the carryforward of unutilized net operating losses and research and development credits.
A Swiss subsidiary, Halozyme Switzerland GmbH, was formed during the fourth quarter of 2016 and obtained a tax ruling from Canton of Basel Stadt for its operations in Switzerland. The tax ruling is dated December 21, 2016, and will continue for a period of ten years, not to extend beyond December 31, 2026. The combined income tax burden at the federal, cantonal and communal level will not exceed 10% during the period covered by the ruling. As a result of foreign losses and a full valuation allowance, no net tax benefit was derived for the year ended December 31, 2019 as a result of the tax ruling.
XML 19 R38.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Summary of Significant Accounting Policies Impairment of Long-Lived Assets (Details)
$ in Thousands
 12 Months Ended
Dec. 31, 2018
USD ($)
Accounting Policies [Abstract]  
Impairment of Long-Lived Assets Held-for-use $ 0
XML 20 R34.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Summary of Significant Accounting Policies Accounts Receivable (Details)
$ in Thousands
Dec. 31, 2019
USD ($)
Accounting Policies [Abstract]  
Accounts Receivable, Allowance for Credit Loss, Current $ 0
XML 21 R30.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Income Taxes (Tables)
 12 Months Ended
Dec. 31, 2019
Income Tax Disclosure [Abstract]  
Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]
Total (loss) income before income taxes summarized by region were as follows (in thousands):
 
 
Year Ended December 31,
 
 
2019
 
2018
 
2017
United States
 
$
(70,737
)
 
$
(45,819
)
 
$
160,938

Foreign
 
(1,514
)
 
(33,974
)
 
(99,328
)
Net (loss) income before income taxes
 
$
(72,251
)
 
$
(79,793
)
 
$
61,610
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]
Significant components of our net deferred tax assets/(liabilities) were as follows (in thousands).
 
 
December 31,
 
 
2019
 
2018
Deferred tax assets:
 
 
 
 
Net operating loss carryforwards
 
$
39,401

 
$
26,267

Deferred revenue
 
1,069

 
1,395

Research and development and orphan drug credits
 
114,357

 
106,406

Share-based compensation
 
9,972

 
9,541

Alternative minimum tax credit
 
1,683

 
2,959

ASC 842 lease liability
 
1,454

 
—

Interest expense limitation
 
2,163

 
1,750

Other, net
 
3,037

 
2,452

 
 
173,136

 
150,770

Valuation allowance for deferred tax assets
 
(155,100
)
 
(146,953
)
Deferred tax assets, net of valuation
 
18,036

 
3,817

Deferred tax liabilities:
 
 
 
 
Depreciation
 
(865
)
 
(858
)
Convertible note
 
(14,450
)
 
—

ASC 842 right of use asset
 
(865
)
 
—

Other, net
 
(173
)
 
—

Total deferred tax liabilities
 
(16,353
)
 
(858
)
Net deferred tax asset
 
$
1,683

 
$
2,959
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]
Income tax expense was comprised of the following components (in thousands):
 
 
Year Ended December 31,
 
 
2019
 
2018
 
2017
Current - federal
 
$
114

 
$
82

 
$
4,051

Current - state
 
(40
)
 
519

 
120

Deferred - federal
 
(85
)
 
(64
)
 
(5,532
)
Deferred - state
 
—

 
—

 
—

 
 
$
(11
)
 
$
537

 
$
(1,361
)
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]
The provision for income taxes on earnings subject to income taxes differs from the statutory federal income tax rate due to the following (in thousands):
 
 
Year Ended December 31,
 
 
2019
 
2018
 
2017
Federal income tax expense (benefit) at 21% for 2019 and 2018 and 34% for 2017
 
$
(15,173
)
 
$
(16,754
)
 
$
20,947

State income tax benefit, net of federal income tax impact
 
(1,509
)
 
(4,297
)
 
930

(Decrease) increase in valuation allowance
 
8,147

 
35,731

 
(77,181
)
Enactment of the Tax Cuts and Jobs Act
 
—

 
—

 
17,132

Foreign income subject to tax at other than federal statutory rate
 
318

 
7,106

 
33,674

Shared-based compensation
 
315

 
425

 
525

Non-deductible expenses and other
 
924

 
1,599

 
5,779

Research and development credits, net
 
(1,091
)
 
(5,210
)
 
4,162

Orphan drug credits, net of federal add back
 
(5,718
)
 
(18,063
)
 
(7,329
)
Convertible note discount in APIC
 
$
13,776

 
$
—

 
$
—

 
 
$
(11
)
 
$
537

 
$
(1,361
)
Summary of Positions for which Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Table Text Block]
The following table summarizes the activity related to our unrecognized tax benefits (in thousands):
 
 
Year Ended December 31,
 
 
2019
 
2018
 
2017
Gross unrecognized tax benefits at beginning of period
 
$
20,028

 
$
14,428

 
$
12,799

Increases in tax positions for prior years
 
69

 
3,083

 
—

Decreases in tax positions for prior years
 
(23
)
 
—

 
(2,518
)
Increases in tax positions for current year
 
1,409

 
2,517

 
4,147

Gross unrecognized tax benefits at end of period
 
$
21,483

 
$
20,028

 
$
14,428
Summary of Operating Loss Carryforwards [Table Text Block]
The following table shows key expiration dates of the federal and California net operating loss carryforwards (in thousands):
 
 
 
 
Expires in:
 
 
Net Operating Loss
 
2020
 
2021 and beyond
 
2028 and beyond
Federal
 
$
118,480

 
$
—

 
$
118,480

 
—

California
 
$
244,337

 
$
—

 
—

 
$
244,337
XML 22 R51.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Revenue - Revenue Recognition, Multiple-deliverable Arrangements (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]      
Total revenues $ 195,992 $ 151,862 $ 316,613
Contract with Customer, Asset, Allowance for Credit Loss 815,035    
Roche      
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]      
Total revenues 157,000    
Baxalta      
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]      
Total revenues 22,000    
Pfizer      
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]      
Total revenues 16,500    
Janssen      
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]      
Total revenues 33,250    
AbbVie      
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]      
Total revenues 29,000    
Lilly      
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]      
Total revenues 33,000    
BMS      
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]      
Total revenues 110,000    
Alexion      
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]      
Total revenues 46,000    
argenx [Member]      
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]      
Total revenues 45,000    
Upfront      
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]      
Total revenues 53,000 26,336 172,806
Upfront | Roche      
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]      
Contract with Customer, Asset, Allowance for Credit Loss 105,000    
Upfront | Baxalta      
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]      
Contract with Customer, Asset, Allowance for Credit Loss 10,000    
Upfront | Pfizer      
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]      
Contract with Customer, Asset, Allowance for Credit Loss 14,500    
Upfront | Janssen      
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]      
Contract with Customer, Asset, Allowance for Credit Loss 18,250    
Upfront | AbbVie      
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]      
Contract with Customer, Asset, Allowance for Credit Loss 23,000    
Upfront | Lilly      
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]      
Contract with Customer, Asset, Allowance for Credit Loss 33,000    
Upfront | BMS      
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]      
Contract with Customer, Asset, Allowance for Credit Loss 105,000    
Upfront | Alexion      
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]      
Contract with Customer, Asset, Allowance for Credit Loss 40,000    
Upfront | argenx [Member]      
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]      
Contract with Customer, Asset, Allowance for Credit Loss 40,000    
Development      
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]      
Total revenues 5,500 16,000 16,317
Development | Roche      
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]      
Contract with Customer, Asset, Allowance for Credit Loss 30,000    
Development | Baxalta      
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]      
Contract with Customer, Asset, Allowance for Credit Loss 3,000    
Development | Pfizer      
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]      
Contract with Customer, Asset, Allowance for Credit Loss 2,000    
Development | Janssen      
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]      
Contract with Customer, Asset, Allowance for Credit Loss 15,000    
Development | AbbVie      
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]      
Contract with Customer, Asset, Allowance for Credit Loss 6,000    
Development | BMS      
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]      
Contract with Customer, Asset, Allowance for Credit Loss 5,000    
Development | Alexion      
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]      
Contract with Customer, Asset, Allowance for Credit Loss 6,000    
Development | argenx [Member]      
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]      
Contract with Customer, Asset, Allowance for Credit Loss 5,000    
Sales      
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]      
Total revenues 0 0 1,417
Sales | Roche      
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]      
Contract with Customer, Asset, Allowance for Credit Loss 22,000    
Sales | Baxalta      
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]      
Contract with Customer, Asset, Allowance for Credit Loss 9,000    
Royalties      
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]      
Total revenues 69,899 $ 78,981 $ 63,507
Contract with Customer, Asset, Allowance for Credit Loss $ 323,285    
XML 23 R55.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Certain Balance Sheet Items - Prepaid expenses and other assets (Details) - USD ($)
$ in Thousands
Dec. 31, 2019
Dec. 31, 2018
Prepaid Expense and Other Assets, Current [Abstract]    
Prepaid manufacturing expenses $ 30,156 $ 8,230
Prepaid research and development expenses 4,964 7,922
Other prepaid expenses 3,655 2,513
Other assets 5,681 6,462
Total prepaid expense and other assets 44,456 25,127
Less long-term portion 11,083 4,434
Total prepaid expense and other assets, current $ 33,373 $ 20,693
XML 24 R59.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Certain Balance Sheet Items - Deferred Revenue (Details) - USD ($)
$ in Thousands
Dec. 31, 2019
Dec. 31, 2018
Deferred revenue    
Total deferred revenue $ 5,259 $ 9,255
Contract with Customer, Liability, Current 4,012 4,247
Less current portion   4,247
Deferred revenue, net of current portion 1,247 5,008
License Fees And Event-Based [Member]    
Deferred revenue    
Contract with Customer, Liability 2,764 2,264
Product sales, net | Product sales, net    
Deferred revenue    
Contract with Customer, Liability $ 2,495 $ 6,991
XML 25 R86.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Restructuring Charges - Narrative (Details) - USD ($)
$ in Millions
 3 Months Ended
Nov. 04, 2019
Dec. 31, 2019
Restructuring Cost and Reserve [Line Items]    
Number of positions eliminated (as a percent) 55.00%  
Number of positions eliminated 160  
Restructuring charges   $ 28.4
One-time Termination Benefits    
Restructuring Cost and Reserve [Line Items]    
Restructuring charges   19.5
Contract Termination and Asset Impairments    
Restructuring Cost and Reserve [Line Items]    
Restructuring charges   $ 8.9
XML 26 R76.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Income Taxes Net Income (Loss) By Region (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Income Tax Disclosure [Abstract]      
United States $ (70,737) $ (45,819) $ 160,938
Foreign (1,514) (33,974) (99,328)
Net Income (Loss) Before Income Taxes $ (72,251) $ (79,793) $ 61,610
XML 27 R72.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Commitments and Contingencies Operating Lease textual (Details)
$ in Thousands
 12 Months Ended
Dec. 31, 2019
USD ($)
ft²
Dec. 31, 2018
USD ($)
Dec. 31, 2017
USD ($)
Lessee, Lease, Description [Line Items]      
Operating Lease, Weighted Average Remaining Lease Term 2 years 4 months 9 days    
Operating Lease, Impairment Loss | $ $ 1,127 $ 0 $ 0
Operating Leases, Rent Expense, Net | $ $ 2,700 $ 2,500 $ 2,300
Office and Research Facility [Member]      
Lessee, Lease, Description [Line Items]      
Operating Leases, Area Leased | ft² 80,000    
Operating Leases, Base Rent, Periodic Increase, Percent 3.00%    
Number of buildings 5    
Satellite office [Member]      
Lessee, Lease, Description [Line Items]      
Operating Leases, Area Leased | ft² 10,000    
Operating Leases, Base Rent, Periodic Increase, Percent 3.00%    
XML 28 R82.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Income Taxes Tax textuals (Details) - USD ($)
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Tax Credit Carryforward [Line Items]        
Deferred Tax Assets, Valuation Allowance $ 155,100,000 $ 146,953,000    
Unrecognized Tax Benefits 21,483,000 20,028,000 $ 14,428,000 $ 12,799,000
Unrecognized Tax Benefits that Would Impact Effective Tax Rate 200,000      
Unrecognized Tax Benefits that Would Impact Effective Tax Rate, no valuation allowance 21,500,000      
Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense   0 $ 0  
Undistributed Earnings of Foreign Subsidiaries 0 $ 0    
Deferred Foreign Tax Benefit 0      
Internal Revenue Service (IRS) [Member]        
Tax Credit Carryforward [Line Items]        
Operating Loss Carryforwards 118,480,000      
Internal Revenue Service (IRS) [Member] | Research Tax Credit Carryforward [Member]        
Tax Credit Carryforward [Line Items]        
Tax Credit Carryforward, Amount 27,900,000      
Internal Revenue Service (IRS) [Member] | General Business Tax Credit Carryforward [Member]        
Tax Credit Carryforward [Line Items]        
Tax Credit Carryforward, Amount 88,000,000.0      
California [Member]        
Tax Credit Carryforward [Line Items]        
Operating Loss Carryforwards 244,300,000      
State and Local Jurisdiction [Member]        
Tax Credit Carryforward [Line Items]        
Operating Loss Carryforwards 244,337,000      
State and Local Jurisdiction [Member] | Research Tax Credit Carryforward [Member]        
Tax Credit Carryforward [Line Items]        
Tax Credit Carryforward, Amount 19,100,000      
Other state tax [Member]        
Tax Credit Carryforward [Line Items]        
Operating Loss Carryforwards $ 26,700,000      
ZIP 29 0001159036-20-000013-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001159036-20-000013-xbrl.zip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�E$@)Z0_HLPT/0BV+83M M=?*B^';6$?^N40!Q4,);*(Q**9>T(IA4(S->Y>0RSDH2.WKAYL#86L!OYXO% M_6GQ/FD2M(WS,9AK1B3U5@%,#YL%,C;'H1I1FM0>A-L>Q/9K]Z^__CD_8RL_ M;1,HLA)K!"W2UE#- )/5Q!CU62\S^*2%FX%BGB,T6][HV;?98G/F,>NKC8/0 M6"F.J=/":FT$HZS:0YC",,>^$I.6=Q=P]AD@^1#E\7!N_TN1WFA\^32_GBU. M1,Z.M@],8,LB(!! #"VGC)G#G"#E$S'!>PB@=05IKS0I[IZ/\&0<[6C[H G1 MS$/,"#88,LBYM@>=QY'*H,G(PBP=R+7L'M%Z+%E7-%D7U_^X*[_^Y\.]@-5] M8@JO_D\B"G]"E/T?AS\^O,**Q[\,PIHX/"6M)!@+!8Q3N!JP(UG!F+%1(%]H M929\ \C;O#DA;_,F,,"]XSZJ/V:$[%*]>&%;Z7A?+ZT^?9ZN_SZ24.]BS.7;.=0U$"(HI4-XR[R.@$O)JQ@(*,['$J-T1X"RS MLG >,(73LV= 9[>]8UT"4HQ2+"PPVEBB),#T,$/-V=0OF[86^,MD35W@.UAJ MD]FB6)]/L/O8*FB)A;#,:@&8L]HQAJI0OY!23?V64E<\:0_IT,KE_>R^D6;Y MKGV@B' NM256I@-[(1FH3#SA(2 >T'[N4;9@!.]@L1>:F=, MFJ]ABNOXOVJ>S/BS%"%2K>L")7H$H()SW#"G.D*!&8UK- M4WI>KU;@CVS"^F.)Z7ZS2'\SN3N;R/M4M0$VU M),1:* A);X#B;*N9:F5S[OO\"&95/K$Z1'?"V6VR(5QHVC?\@?\N=\ M\ZFR#]VWZ\7V9KZ\2YE^XJ^;C[-O)^C5XFLAFA=QBXC;!<72*V:8/Q@&RF(_ M==,KGW7]@][Z.O.[;;+]RMO/L^7V-HYKNXH '[O._&KC(# U)&I<0XU%2!HC MF-^/5 -,IWX1H#T].L.TM?1/J,-?E^O-;+E)95F.T:%>[Z")I=I2Y"RA3D=2 M UL]8]4'ZW7S]_FV])K=8ZV:;K-D1(7,,X$!S)58M[/1AL\L:MZG"J4Q%-7\D 3 M21C9J:2?FX,=X#K4OO%^^U=Y4M\"<]H8(0I2S0D38 MH +53(T&$TDQVY&TR]Z O32%:EVI.]\YH+@!8DM)W 2U(@02Q:M9R[C/3NQF M73<$J,FJUBBWCFQVEMV6<6L9< (*;5/UX6B(H6J\QJB)^3I="K!6OMMF\+:F M0\JTO'JS??\&@?/)K;]K&&BROE,B7B7BF*"03%:[LP22Y=@IC?V0(8I!]D6! M7&2'VF8.$WY;XZ+1R\:!Q#W8B,A>0"SVAB*.#XQ6UDSL55&W5DDVG(.3Y%U1 MR[^+S8*%TA/B@"70 AW=:VEU-1/DP<3LBQQ1'F-%F(&?5N!E?G0]2[NHY;\LQ8!6$"IBGZLULRY9+#B_5-501R3$]EY M6\KJN:1;8=:GK'^;+^>?MY]/2ON[-B%:G5I+#!U74'@-8?12JK$;RB>BVEM+ MK.P&MUYE/OMV7N9/VP0'5'1(X^@)UB(5+$]YE_9CEQ#G7"X9D=O5BJVNEY]TK$YUSF85*8/<1>=5&<) -Y4J2T$91R;:>P? M78B][!G;$?GO[XK-VW*]?E^L/GR*N%[:D7>SU3*.[G$\\\5V4]S4\.S/] PI MA:%A43(<..VL4XW1^:@[TWY^7.Y-(O9>GTV'M#\ M:P&EK$9,\/3T-NI6JR23%3; THDD7.Z<*<\WFMZ1'VPG*I=W40Z?;?'7ID9F MH->:!X#<"/L.65H@.^+KX:[':S./R2.,]G[#EM?8!21,5 MMV2>0LR] 3R:F&1Z.]/+!::*^"7;XFS(1WNVO9?F_1<;+5-AOZ97>IEXT"1 M0D0Y[Z(+B1% 6D!0S8HAF+-'C=&?'G"/R@;[,A1*E7W.[E''NH3H]#E.HH6( MH(Y:FGF/*Q5-L/5Z6GHG1\0GV=(:T=;WJ!3\!Z)/%-^'8CDO5^_*3;&^V19Q M(N1,W;.:_8,G6&LEF);$**PH46 ?EF04R*PR%Z-G2!NQEOV#/)2B.:)SZT2" MSW4-C&A!!=(&.&*0Y1%?5,U8(9WCOX\PE<60^UC'T ]%MG?%9O?T*L7V3C#K MNW8!8^BH\X1I1)D$&C!?J6_&C)C(@7+WHBV[ W4H@OQ9S.\^I:!7U*:SNV*7 MKN/J]@&(]=5VDU(PI+>;>K:>7Y\@4*/O!,(]4EA00JF&S$-EP $+Q'E.N9X1 MVMN]$:Q/T"]*P#U"+R:B;OYON]XD(Z(I%<]_,6##+9180FX4L8A+;7"%C\E+ MG3C"S7-84G8._X7UX['Y-->0Q[X4D-5$ VL9B2N;HR!'FG1I: M1W8$^Z6-KI8W^VDT\!F>]0S/0D9SW/R-,7]4; MS;J%^:*T:DJFP+TE@%D($&0&6LX%/\R-89&387^$.8>'I5!#<"\NPA$ M1$6+A")>&&F0I!P]+@P*D!Y*Y:CE9GZ34)A_ M+3X4U]O5P_O=77+9XF:7?/;SE^U.N"]#@NHA^=0)!=7)]P-4A'H '8@(.@05 M4AY6V+FHO*<1.NN#3,]SI%] ')"TOY$AVO'&MA$=]B^ !_1'>#J]XO=^NTZ):TUC-$H#:)1 MNNOBJ0/[/--1-%#5#9=(9 M")VQQEHDI3>65&BEM'E#[EW?IP+YLIJ7<0.X?_A0/WJC"Q:5%Q/&4#O7'^MT MVKK>S#_/-L6I \7O&P9MC*?: 04%19RKZ(Q4$"I/LVHLC/# IP$YV*W- MV?I39'CZS?UK._\Z6Q2I$F["X+Z.]JK5/R@N'#;&$&NDPM99R'0U=TAHCCTS MPG.:'KC4!\Q#4>RWV>KO8C-[N/93.06[D9_@U?%.$4,$&? "Q=G&)<4ZJ]]D@'(#(L_0HT7LFL0?V MR5H3.:^[1W@(,YA*ZP7]H7CJ9_/5/V>+;=SW?4HI>#V?+1[]S_.$K-4_B*C9 M4PX-A*R&4@$L.*_F#C3.2>?6^.QF"C9_'Z@/^.CF^UH\NVSJZ:=3BN]XK^ $ M=X(8)YG@AB!AF;?5/..?Y'B4(SS.6 M-\DX_))VZOK4JON)P$2<.P20&!_=(IY">H?%)'F6SH+@IU!:/4$]F-YZK&^V MLO/UEW(]6[RH=-9 I[7X7!!<**2X S25UU'$$XHK9%1T?')(.*(#ZCXU7/^P M#V?P?XX"^U0LUW'DNZ1%B?96?[!A0Q=5YS*9"4V@G)JWK2RDB(LE(] M-#X5F((AUS7DP^FT]>;J]L-L430Y>#K:*<0EE"[< LWBRG$,4<"K%:J M1=CXA& *Q.H,Z^$4U[J(_U:*']NX*!;E@\GIOGV)FOA\/*-&[Z"Q@!$U8"&T MWCOOI435O+$2.7>@8>/X_Q0XUCWHK6]&/Q;$N[I]-M-[7ZY,_,+\>K;XN)K/ M%OL!UE!<77TZ6&!@.OE 1$M*):3@<$9G@#%9_L!/=0!P(8D,I02K%RG%33)# MX\!W]VZ_["\U_?H0IHYV:7+-SY]-M?A:4$8):2D'&@)@J-*$5.%N:PG)2JK3 M^##A1V;J<$(8+B"\KR[<)"#\>I>@D066*:J!X-0CE(IV53-T,J_JYL]QM- 1 MM)=ZRE:?0V=Z!NZU1UQZQAE0WC&OI3LL%I%7IV&$-^][H%*W" ^V5Q9WR=S\ MO?A2KA[W__J\JM4_8 TD95HS 96&RD$#*_?;"IJEJ-#/<9S0!\[#)7;Z]Q-$ M5N4R_GA=/+EC4I]N33\5)$GUM8B$!G$G-.4*RPH10EC.&S?T4SX4Z%D"8WIA MM#_!>WIX=^E2 UT_.I+4,<*4H91+8Q 43&B$+)$":.=!K21\/6U,AX1Y1T]2 MZU<5./V)0**9AZ&Q3D../?02"EZA@#":6/7Z+NAPM(I ITBWW* ZKE(8$8F_ M--&*>R@@0="P_9@-5'1BF;F[%^6K]0N;@=H[$6K7+X0*&0Z$9E (PRE2VI/= MN"&,)OU$5$5+61VI7]@,LSYEW;Q^(<>">(F8Y0 PQX'$CE=C)]YG7048H;R; M2NQH_<)FN/4J\\;U"RDGS.,X4HKB>)VEEE6S1TA/)>-G)S+/P.WBUR;?ULAB M?;YSX)9A")$5VDEO)2#(LFK6!M"LV,9XV-*[>= ;XA?GV1_KXG:[>#N_/>6K MU.@=&. LKE+LB"4I$SBBE%;S=MI,S!#MD@AU.=8:[!&%+5Z_3S"UP(7BP!M@ M,04$4TV5H!Y( )#5!D &:IU7]!VX>%T2:K5*N^X^,<_#;#Z6[XO5;;GZ[,O5 MPR.7!@43<_^1X!2C!!HC&$?.0QK1]!62TMB<5^4CU"I=4.IH\&-@65SV4EFM M:>G[&J48._E^P(+&+>#5C+]_@QU=$QK(^NR%S'\ M *JR3@2FB\\'*@4F$E@.,2$V+GH"286<,5EI14<=H_D1;8.V4AO%$XL/Y>WF MWU%(N]R_J6C,];^V\TB-7Y?O5^5UL5ZG)R5MGV#4^WK0"F(D#.1*,4L,$(;C M"C?.9$Z&IFF9!2VHUN3Q1B_B&E>DZ4G*JDM'F%XDT$KI'7;UFM9FNTI4JA%R M:O"5((061GF+#54 40>YA4IZ3AFCQN-:&8,&PN)9,K%WY?)Z-YDF4!S]2)": M1\N$0AH-:T00XY2#/1*,*9]3RW.<&J=[CKQ4+/V /RK]\?S9[N5UR/,1U5(9 MQSJ%E%.20H"C"872N3>DL\ A6^",JL-#5CU#OY1#L:N[Z<6,9QRP]$V**YI00@D-KHVQ#KJC%C MP2>VA5U8[J]>"6PF@?%<"50LCMIZ9A!@B##.#=F7;N?,D:P+("-B3DM9';D2 MV RS<5T)=,9"P*G'$$O"'334^FKLW.&L+!MCBH:VEMG12X'-D!O7I4#+B9(4 M2\@$TX (%7?5:NQ2R4&K0HQ>ZAG(]2GU_<9UM=IO6R<,@]>:!N"D(\I 8K#B M6%&*T6$FU.O)AI$O;2-T((P!:/5TKD%AJU6DNQS07)N M.9C0;?,\D;[D1C:8K<]:]7;Q]^K-]OT;!-)5PG=OU+O_=:?/6D]T"=8*I:G@ M.OX&4+K(R$0U:D:S*L:,DP(YDBM[ 76P; X-U6J=X]+6WPS2,&JQ1E)+"1CV M7!A\P$C+G P0(RQ5-([-;6BI#<7L7=Z\7\KRYBE&'\I'B1Q-;/A:IT"]8IS0 MN#6@]*Y$ 59E">4<232Q$\T!V/!JGL,.H!^*8+_-EMO;V?5FNYHO[]+H3^G$ MEXT#1=IJ@+TQ4CB&*?*VFI6PUKII6?+#$RH;\A$=4^U3KSR![M+'5,^3P=0X MI#K6)4AL.&8.8J*E5AIZC.S#[0.C'5.B5ERCGUF^VR;;[>KVZDN1:LHL[_9S M.+74C_8)*-UCGD&;E;=T?"L^7]S/T[YT!.R(UO6#R3:= M%U$I 2="AE!B% 3 ">_$[AJ1MASZ6EM:OV?-ZZO;[VI$7=VFVE#Z/OW7QRF4 MJUH9QYI_+6#OH1+81EP8112FE\H5-M'-'+1:](43O-0DR9%SXOY '\IR?.+X M/4O8ETI@7Z>+?//%=E/ M2=DO\,/N6'\L9]N;>1SS_VQGJRB5Q?V3THP' _1BF];)43UFE*ZQDS7\4J"8 M2V\MT)+[]#ME9&>XZ*A=3+U+S1? I(X"J?>!8"0B%AA/H>7<*,&2![9'@! W ML1LJO?&C' #\,>J,TX!>V*.]G%XA0DA&B912L.C&&.7]?C/PP.AZ5PA[O8QZ M^G'4KDGPR D.J2:.4^QX'#]3U2PP\A.Y@]2[C%^O*]04WJ%,V5]6Y3IE*;V= MGUH03UH%C"5 ./KJ %%C+#20\/T\8+2')A;V'(HF[1$>BBF'J$U5R.,$7UZT M#1Y[XCSA"E-@L$6(.E3-B3B1DUEAA">#0[$F%^>AN/.NV.RJ)+R-+#\5>GW: M+A"OM.98*JJD)(I0;@[KP,.LU 2-*Y%-AS,Y& ]VJ^$U7_S4C877V@>M.-'4 M>JR5Q!9PR^UA;H"KG+SMC:N,38<_76!]*1[M8SD-F+3O$0#ASBHA,' ""B0P M-_8P/Y&5P[5QV;#I![@6H9-2M66E@DG?$*6%'AH[F9 M6%:ZWMAS]+"S/UF,4LW$N6QGB_7/>T(AN"&I?):7#BN H&8&$4JBP\9(W#Z!>.!)50C8"4V:3KS-9A%]M'Z+_"90UW"AG.#%41]BJN44M/#$Z=2/F MLGM@AR+-DU&FEPSORN7L\4\^QI_6<15%:(XG0VWYI>!]W$XAA\YC+KFGQ@*X MQX,ZAR?R;J\C3I1#8MWZ9:=:W17+;Z>?I-:V0V^[5_T_O;AS/O=JD' 7CO""5$:IFV9.6)]-2)OR$1*10TJ M\;;@ME_FB^);'/29=?ZT49 V.E,B71?5P&CO5'K\L!\91RPGAC;"$_%A%GH& MP*U%_]]Q[%$(IT7_7:.0BB73Z$A;I004&AFDW&%RP.=D_QGAP?8@HL\!N+7H M?R^O/QW/\?6\2;!0>.<9,T!)JJACR%3&,[,U<[W^..?1@XB]/;Q#>1-'W*FW M-?(PG.L:;67*!';,1;O%J-. M!]C6.'C9_T7ZSU^S=?%?__'_4$L#!!0 ( ^"6%"^8MF+?TP# '_6)P 0 M :&%L;S(P,3DM,3!K+FAT;>R]:WNC2)8N^GGVK^!X]IZ3^3RVD[L@JSKW M00A5NB?3=MO.ZN[YT@^20A:5"%1<;*M__5DK@ILDT,V2+21ZSZXJBP BUO5= MEPA^_;\O8Y=[(D'H^-Y?SH1+_HPC7M\?.-[C7\Y^/'0OM+/_^^5__?K_7%S\ MHWWWC>OX_7A,O(@S V)'9, ].]&(^_N A#^Y8>"/N;_[P4_GR;ZX8#=-/G=; M[99DB5*K)5M*QY0,138,J]W5=5XR544\?_FL:*JL:Y*F*YH@#W1!(YJD]L4> MWY,)Z0U)^K#\[?WD[7$(\TQ>SV7#3'\R#9S'4<2)O,BG4V+71Q&L%];LA7\Y M&T71Y/.G3\_/SY?/TJ4?/'X2=%W_]()CSMB@SV%_1 :^SB<7#@]?_'6,!I_ M2BY6W!8NNRTLO\WI7X31(+OMI1>XER'I7S[Z3Y^2BWB;,'=;- F6W)=<3?\_ M/D";?4 _#@(0OND%L+CZ0?.C2A;@$KNQB&8_\V(N"5:(Q.P@?TRI]S-+;2VZCVAE6"%5RL632 MGNWTP_)WT4ME$^Q7V!BX4$9^[ZF"^MY3U826TW!F2,D$PV#VYIQ_094Z4I'% M)RX7ZF3$$L'.ABVW,LF()98F-=B.8U&$'_LG-+V&^OH)/%GE>^/2/[]_N@2-C&U4MLKT^R*;G![T^&%4Z=7EJRMN5K MJO02*SQ$M7*7L/3"!,)Y,^M7SHY?+WO5G[$33 MBK?1:V6Z_U)%0 $,I^U;S*Y )L:*_"C>"ELC4,JBP17BFYH2J@ M*XWAT)$L]3+E\@WPL%?B1Q/DV"NS2F W(0ZL?EE^G5)Z]N91%0U&I23 .53' MI+TRL03@4(U\*F%/1<0T*(N72)4U):76M(C[J]W)[* RXY5@/M_O/R]'A3BB M OY4 Y\R=SNID RX4(K)V.O#>#SRW8I;YP8M06GB6<+VU MG8]/YF.ZA1BE.M?3J_!UO3(GA\FKY8%H/J DPX78;'G\61Q1;=B73F%V3 E] M@W[%DN%"F8VI,C&ELC^<7,3]I9D@>KG,9L<5B2"X4.Y-*SUI&;Z>E#_<+@/C M:%$"XBS!6WBUW!F._3(@F;A#O%@!N^")95FM'!:6Y[46=&4V^,3+/3LDQ3?U MO<'0J?"F^?52B%QQ4]G@+.99'9]5)Q &EN#)R@Q"_E=^+U,GL:^L-AA4G%2Q7!['*;5AQ1ABHJ+,>2!/*2U677RW), M,"MGB;[-9Y%HPKE*8RH,*C56L NE@EHA8DOM?">[ZWAX2%TGO/R(.IA MK\*NLFNE<"?T)Q6&CETK32L-"=H*4DGZ)-[.!F9SK,P)5&8"$LQ0"28JLF45 M(4UV:4G>^H*Y/_U9O:ZG/ROS6"7Q M8I[%*HL7J9M9CLV7X?)E>+P$AU=AL'+L-2+]JK 2+Y6QUN]7(5&X4NH92[P& MB !&%A5F7V[%5 M4Q8O1+4DPEP5O1=F,B?9K*)=":K+(QE2A0I(*23 2FT%E>#*I\6:K6,_5I69 MX$J9S-D5Z6RX4,Z]2JZ5<"MRJI!)>J4LBNV3"F"'5Y9X5H+2?NL[7D5YI7Q< M!0 >S$7>F:]D%S,'5F%]2DL585G-@1J2\FH#VN+EX4)%O790!M*H% S*8RA6 M\U@:G+/K%1J]-%=4GB=Z<K&FC8Q5*3 M6I%^35C]2*I,)KVV+'JL++\61Y0!+?*XHAR?0.G'8AV/5&6K MREPQ58RH5&L4IC71V9?_]1^_CH@]@'__QZ]C$MD_2EY]J\]?S#]\NO >>+" M:.H"BX;PL(NA/7;<'9TQ"[IH\, M\^PQ/I$XGPV8^0!GWW7MQS/. H\+QJ\ MT+:Z7>'B^>?%6@//..8!_W(&+O-SSP?NVM[0=D-8!/W7KY]F)KW%&DR:VXJZ M3MBWW7\2.["\00?$I[ <7NNT1(F7.E)+4:5V2Y5$75%$R6RW55'NZ-ER5@T\ M^W)Q(8@@;:^?=BHW;-ZW<)L_Z,)O86'>LFJ &6J; M\R-5&QVIII)=3MMDV3 MS^:]:N#9E^X_=SUE)/7\A(66WN7;;4/I:()D"H;5[?! /UF$_\EM0

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�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�'RY/K&" M1HF,-@@OT5%_ZJ"C1!_VE^^S_7N">=6;&.:&K6\\4^R6XW=?E MRDTVPWN,Q)0O>0XE[4 H<.<( MP&O(O$JXO-=Q\Y0*XLYC6;N*B442[87.AJV35*FHRM' ;V8RO46&'L/OIDM; MHKL2U-SRM U4)P\G7+_]O"R+;.4=LAP16JE%_RO?[<'E M3B'[V,FO13YU)M9^>P,T)R0\/ZLQ$G+YD^QD$ [A^^S'?4^ZRJ][GR[@G69H^J-[BZ\5;U>7'P]R$X_ MF^^DS"YWHC/#SL*%V6N@B,+WNX;D= \;J!+VI@)&BZ/!R/M\*@U!5CNHWW]Z M,J Y[6J[71$YK22Y"VESY#]4/0WV!]V%,C] A3TH6'O!Y5[K10 P(\8'SI3X M=@.N5L;CON@&LP*<8EUE1PQC1N\U9IDS@?$]$TBX,N4]4^^Q/C][.G\7HW2Q.O:7^@<]5VEG 5EG@_)OV M]B+5EH2:<8%UY,/N)C;_SNO'NRWFW)AW4>XPYKM6[(8&LE9C%M3<058/ZU2Z M7I%WD2S;]K&0)Y^6N_E.7X0^Q9KEV"6]3C+(].BC:=SC#GFE*&AARG#EU>TH MAW4_*G5\1[_;J7SGLE\BQP?BB*.+U:.VC-T9LQ1IYPOA\-*:YD?Q;L1:@T9KH53D< JMH^CP@I])PF'Y@U&1XCDK]-><(* M5BO\MAH,]EV&[.L29(IZJ$S*-U >*6V&"3J, M=%KT=F(\T;[D'$FMEB':I'KAC(%3YC:G0.<^?&RZ]3)VO=6?^[O"#0C6:C^Y MTRDK7*LB]AK#CYI[G<_K _I,J?<1YE@M=+<)FCQPGX;-#!-Y&%&\E>O]4!MY MR?D-JZ0.\S17"LFG'W2'T?2E-7D&V@MY2:9U)F;R&RS^%[+/:Z@E:^PZ^$GN MR+OBSV],^#-ZO9Z/WDQ<9H?EAS4@YL@[G"](;SJ*O)&_R[#U,1W[5#+AM:S; M_8W=Z\IS'$./[^](J8"O>2!RFBAP)+58 30!,$/OY[YA/-[63E*=':*)CK_B M$:FC]6Z)8XR?=HIEM<.X'WL6?7UT!A:T[3:81P /W MR+0%#^?W99T-C@HV?8=:!ART;#"0/RVX?9L$$:)<(/&BVL[](,[QX.5.,)N' MLWE]HP-M\1=KNC9E8SN8"%?Q+9:&LD>J*E.&ZGUF+. - C!S0DN& Z&K4A_7 MJ)1&+1E:!,<:ZS7_A\!M5(*_ENUH\)3]='LVJLE;Q\&CPBX"SM-'ER M4=@E+F(^QT'G)3."LN(T6U6C<7Q/@N^$7R>HZCX&A"( <](XXI#^"E6@>"-: M>P0\9^(D-_ME5XL\0AF41NP5JEO!=-"S>?Y]Q[2!>^LT3T ,=N_ CB>^$ZTE M#;U:*1\3S28\$KY,P">+[RR#7' &6 I_0:^39N,>?.W"2A+U*\N,TSB?'TWH MUG=3-RGTF%'/S^PC])+:V<+MKB;R>$VJB95\?>QU9;0VN$.G6?>UGFFV;Z/C MHO-MVK2VQ;$(=Y^X)36I16/(\@*T'L,V=P^J>QJ*V)];<^:<&J'ZC&R1-6TM M\SL#OGE@88K\ A]7AKR!T.)X"KW@'3[MF;/5;YP^HN>V+K8,/3.P8SXSP1\P MDT(WTLBF>AJSW._/AIW_PC@E1*0D.%38LK;"8+!3UMN(U/+4>5LL+TRK^]!U MJC%N%O:RKP5^9J6)31J.(M>HOGA:V+6#ZU6=K.;E\-/0PY1\5--#QU8N3$VR M7HLRDU?R&FI7M,U&ZA& RTM:$_5JE^Q!E'OK?.#RX>++AN7E5P9R'BY4AM M;G3\\XJ5P7>^N&G7XC2S\Y;\AH6<(T?"'-^#DS(Z/Z5DK.N:?LH_Q;CZV^*[5"'X5LBSI5@]@J$39YJW@.S M>5U%/M,=SX!:Z[X;=S[W^GEJ8R\Z-X'M", E8C]](%3TH1S??2+L"8VJ;^C! MP3[U2AT4^/^TC9=X*?LIV>_[VV5V=74E1-O(T1EO>M)]'5-Q% B;O/W(37)< MWH]OUH!#K4?);:U:Z^ONZF*E1:17OO)JYR0D<_PXS>3DTII!&B>&J15,:1]5 M@LUWETI2>N_HW:]JT.ZS^42KO\WO,N9A*TKE-1ZT7I=8RW\]F2/KS;6OL)$M M79(S/TJO '))<_XB_M\4.+#YGU3F*)Q%Y*7G:O3OV1\[;%KSW\P>C8A9RS8) MD'Y\QE0J^82QL\@^<1!W!QM2[+74.UZM9.FVHYP[Q&AG%@#>2%#8[]/U,E72 M?Y."\M.O*_ZVGDMMS1C7?"_UL *1#7?3.*'%.MGY ^8F:S$L@I+JZX'L3@J& M 1G*TR^M?-"1(G,:TQLG,P0@?)K&)NVNCW $JTZJ$X$@$(&.TD .6\7_HN MXQX,X)35_LF1JG+";K)GG,M#@'$GQ,_=BP,TED M0V4.3G6:90MFEC2[)/"&.E8E%Z5.87V;BJSN3.B^Y"W3%_85N0I&&D7#Q^$L M 2E^KRTNV'Z1R]K 8^"5*J_=14CPW<;6X85>P>MMK$%512QQ^@V32SVUV2ZI MWY87J9FV.1F;$M"-BTUPXK!VO[8VX4IUB$;00NP]DH+0E]QI+:222YPBI\GN M(FS0RX/0\P58U++VD) 3?OAZH[?]8+=T']=9_H&XS\]KI[R,Y^9/PW%*^?>2 M8*'^-['AAM]+&/9FN/7Y18/8EF+N,+,[;AKMSJYK1_#KE>LZ.YU&>HM*B%Y* MY3?4#3/!6\'&U,0]W3$B!I7*&HR[^OH5@ED7J".472."8L@7-R$&O;2Q\T.L MG]'D 6[.P4U,Y=_=!'0<H^9<%-WSJI3UX8V'I#-_OU\];]8J;^PO7M1HF MZ&?8Y >V=-,&Z64W(=\<39](0B^,^-^T;>)A])<;:A#-*IH>W]H[X8$);XC% M);86--Y:U/ #8WAG1V+0N0>&&*T0"3WWTLJ!W-.%5A9NC\74K\ EU;X''L % M .B=-F7*&OY$QDS=1$79K7NEE'*^(<*-2<=%1> M2KCMY5!1T@_3]PW]G+!PI\7)O:\(%8;WLF/OFYPG<](F/WE[/2B3>!Y; ?,: MA/CAYW=A2M_=J7QA(8RV N,XC+I<^TWV$\A#,JI#& M*^O?W2UN" MNO@'LG7#(9<,/-?J?$S7)#B>=+2R:A1GY_SH\+1PO]1#C4DIS&#>H#3/HV)PM7!U!GITOK763'DUZ#7X:S>7RM-.: M\\L+J4=G;Z [ !,VE5TZ?1+X%/?*_5M]FJ>K M^/.GT<\J" "]$3:ZO4EHN %6,'[3UR7_\B*)C%G7QL;8%78GTB@EM_8J5O%L ML[Y'/-FI6PT',N8@AAL&+?P^FAJ[$'5PZRX$]:1W^1X:_#EA*"1.**4*,RG. M9Q95VE)_94>T J^_.EW-T*I^ IX2N$DCM%B6CC_LBSLF@5'N38>#*"I$(M(N M.U*9&1E(ND@P,2X(EMP_\E"AFRR_L(QD'8DS?.E53TF'>M9@[MK#2! MP54#PIX9@"R?D,#L<^"(),6&S".)N>"27JZ!:3%-O8GOFCZ4\QKG2.H-5_XW M M,.ML\A%?NIK:"S391K@U]XVF,L&.JF%*.ROM !I_K8[U$4DI#6M O].,CL1".Y84G8KFI=J")/881P?X0E M,_]=X-7-NT $Z]$<9 RA^]TF#4R&T\.0O][+3\WR9?X651\-[1#TGJ\E.QD5 M+U1D4'V8+VS(N)D]#,]]6" ARLS:FWW#-9\[K'G@XY"C MU;#0O%%NF5%\#_NS^P9/>^_(SR0=N*H.& M/82;F-3WP%I="P76D@*MWGE.C65N+=?R)"-N<;/@)-$T#6#,-@0;=UK%RUI4 M6LT*&9GYHV"( ^J?]HZ@$_O=0<-5K'K?YIYOUPI7RFEQC>BF7[ WM M3[A&[6Q)$AM7ZZCW.D_D>@ZYNH\.,<@K[N9JW/_ MW&:6 '9P)>/S%?HGB6&/Q1V%B6F GEQT]L2F9D8 6SD],?4=F@EU=25 VI'- M;DBWA.+<#8LD8[Z R:;XL^ @V3# "2651,PT6?%X,"_]W$Q_5>H_I=4F=;D+ MZ?H9$OSI4>8SS:']#F,\E>6 &U7(JXX.>=>O1\1^F)*?Z"ZDF@$ MRL_.XR?49J;C3_C!J?Q#<3O M_EB#_$]Y/Q?$:WXNB!. O:?Q9XK^#0'._:/1=/;#%GB*"<#H&@%8E9 M:/($X)CR^[G*_^SC#'^'?U>X.*4\:-3'&E&NW*60I6=L*N20@[HW3\M^(W(? M(-6%R*E8/5][WLUVT>]67H4WJR-_EXIC[W>N2[ZQF4E [5_0EH2U*QJO7!A] MO$,<5915C7/^; #:_R8Q6&1%<*\KIX]/(:>\P96%O,3)V]O$>F(/3>REL] C ME?]XWNZOP//G,:+0X!^>-_VU=:FJJ]YA4?C3*/$IFI((=&X4__,EFDJ'[W]E MD20&?QHE*AT$[A( HP*BJ:T3.P"!.ZQ#?R'AOSO$5T3>.;=V9RYNH.81U-&? M +#EHE^&T6ZTHH_M,S2*EHZ*GO<[]KI4VR_GO/ 9;K_@6:W(-Q0I!RDLG=PB MB<2WUX"C_&6'%%AQ J,X]6Q%Y]MX^*5.>D_['CJ>8_V5/K RI#]!\[?LF&=11XO\!:$K[=U!RA5@$2,6D^LAV!^]JI?Z3XX(,E M1256I;(']V]+/\\Y"D0X&^\B(T"7GZ)%0ARY^A^'ZV,T*V7';>N\98QRG3R; M+D"S(!^2N0!WEG.1-NVHJ9?S(B%IG#6,XIW%/ -KXBU4Z9<4G4 W7RW;"J6Q MN;3+;&MHY\WEC!SBSLSE\]V:=O#GS=BF3WN\-U:% H M>Y_(:_1>GD3K?8G>/45WN8#VNP@#]';HWC:3;6)24XPWQT&J-W,B56B4_M > M&*+MS?QE*>X8DO@[,0T@B'HXSJHPB94PDQ.OQH2 M[.#LZ\SQS>'&$.E9=^HSP-L+M/))4[=DH^1[546D%UV3C((DA>^WZ_JK+_B= M;]!I\*]!\&!"6B&7<1)Q7SRGN -5X^XT[FQ(KMVS#>UH64_*S_"M]*_= MH&?L346Z!HOCT^9)3L\P\?/^#I,FFG5IB0,%$6GDC517G%)&>PC )??S[H6. MU+*4T)N--/SJ>)[V5Z;;I?5LA";:^36\CZ-WW'? Q8ZMM$TWFBD(F>".^T/C. M!==:(9!MM#2V>-;Z$&VOBJ][X8C;-I5X)M?&$O]ZU:WP@8#;LF$V[_G^")@C MRB'^S=0F/7OJQIFA^+3'A[C"-.R;.?7H\S@P1KC>.J9QZD..Z51SW"N=M%L? M/C^FX+;R_@(R!E;R'2*PDO-4TZ&0\SB6N53E6U>&)(M8![5KPH;56F/5*>O) MR.*J!5UB->5&;?[+1X__?DCHA:I@#F+0]9]]"$"X^T1TN1VK4,J[=V*>J/#4 M KER]AL M6"238CX7F>E_YV1XT[=='!5 GZ)38T >77G4(#(#H7.0"J=_9^R4ZN)]Z=OY M>YC6WH\!5^:OV,3L(UC1VVTBX5-2:-AG"!W6N;D)-+2'8# RAF"[YM2# U9+ MNYW9@XHR[:1!'^# 4<@B$*4.T'X45]?YR%DKT?1X3P(XYOOX9;7/QZPY@#%, MHX4EZU>#)@>P9%G_2(^2V;YS@29)UO MO@_)5!D=5O>N3<[/'-4U#A68%^BC M-6*[-4F=B%$BS52M31:[S/6TN']PD>/4K22=]!O[[N=EB?2E)BDI)U((4 AS MFE6O'_M.TJ\Q=9L \/\D^]5;65.B<1TC,=/VI5OG;,^,9R/X3M_Y\]M/LS:1 M8K7:49N-J56%A8J"<2VY[:LD\6GWV[]O;=RZFU*Z#+Z[5I]WQC9K4K7&=33* M1YLTGT\Z"J:B#S3V'<+1R2F/ )"R'?.I)<0I6 M]\H(&L[^L?GA?$R9H>T,-!-9O'WNEQ5F/B>5^&F79;5?,KU^&H3T\S6OX_X: M;=*\G&T.+&?%^3.K\*Y?AD*>HR&,(1:6U7-]N[E!ZR /VS&'>#W%CDZ OZSH MX=+%>(;+*SG.3LI4KCY59_/F,0+UO%?9+7O)>3,+E"PS3T8ZX4E):MW #M7# M!LV"67&7T"'A1?+2I]5S?9OW]X\DK&H<;!>JJL7:'5F5J0M^V'PSD)\/.WR$ MOG +?/?.)5T!)P*P/LA2UL#N+[D(*2< H4W"7J\Z6J,QSLU)(D'.5X:RPE7# ME1I.[O59*ZS73HTYNU:DK33>(!T1OR.34^YDKI"PZ$^.S2_TBCMXC4V>,4GV MY1Z BN>N,AFX_A$AS+&5Z'KC;>*5 NS&OTUUR1@W^?W7/W_RKDZ'XT0#R#5 MY(:-G(4S8#,/WE_TTFH'HX.G5&9OI3D@-L80T*$3TT#K<0K2%/9H+9_CFU&5 MS1TSO@O82>D(ZJKE!S#:G'BN'U.>2<*L]URJV3Q*EF7Z[#>;A_6L9+S%>]MU MO$*;.63B%/Q./Q(],YU^?UILU*XYEEB9YQECZ&_8#,)FV2NK=SO>UT!$'R4L MDW,--.4V]0OB5&:/*GHTR>I+&ZIO:E$'7NU_1TT[Q+JD((.]0+1,2',CK,7' MM H-@;3FT[][UGWQFI+S^X+2E=QTR1\F[9;!DK?U[TBZBU[(9GZ6E3S.,U&: MP'XMU]S9D#%V^,=1QX$-UK][KH_>WK@)X8Y0GQ58;1#*H&J#[,G=;Z[E GF/ MR>8_$7_=H1BVV<1-BVT"G8>MY^02G?+*1G3N9]GHEUL-CD*XJIWBZCFV2(,? M)N6BC])N#0DL*K/=>'%.1=.!:5[E)=1ACO:BEZ(Y6KZ.TMZ8_9U27"O-S:#$ M1ZU0BOC8.WTNJ#I[ WV,DRE*TF%O M=K[,:C2):1,=&(6D<><:;FO1V1YDPS M@7%!>'$ UAFC8HR].WO20S4WC>-"/2BI#=148*^JV0%BOG!:WA3ZR@LW/G F M:\'$.AK8XHA36@JM _$[L["2R&F4_)34<@^;QWZ??ZI#7Q,(2WOP$NLP2R/7 MXJ,'IUD>W-M_&K2%.LU^_*CJ41ZIC.5W?1WSKI35]N>-@R,][JB5",6#?0L# MO64'R9SH78DF05M4>\ALW^L1A:NCR-GKPW'M5>;^^0=_5.Z66?/+5\@94MX[ MF;^]ZEY(A1B/;F52N#+@N%B+-62#Y^STF51_QW-",!4,35-1'LQ&HMO^>^M3MB=3V>$,3V=+Q--\# LG MC=N\'04OM\[2?/98%1:VGQ MC,F!S_6(.CYS=!H/&U_[0@W;K98+:S*5SRA?.B*XDB6PRS9Y>UAS83)Y- M-AF;Z'!D>;MV-BPCB.PMP NXD=1G&Z3DU^BD>$(NF;S('EE.II2T> BGT]12 M01\BO^YIL2GFV('(W9FA?CY);4%-[\KUZKP,N#RZ L0_/9XU2D[07VD%7,,P M\+$EEF>2M_VGVYZL0KU&$J//#W'3\ V0J0F]LHRZ,(-=]J!ZH>3C'*; CDV> M4\B=*831JV9%T]H5E29>:AB ] 8$H(5Q^ MW[Y[C+//^/:YYY8Q[A\S62MCS3EFYGK7?)YGON\[%W[95>5 52GY(GC4@U1. MF+,CLC9@D5PD7]SL\("+R""G9:MWRN;,$-?BM[NJ/9XO;[/.4D\7XZM=V"LN MLWJ*UOUV6-S;VC=D?!YX%RY\RXO@+'T<2]E-#/)D:XG5=\NX0R#'Q+T7CJI[ M?^-=(.*.2UW+U.#$5\4[IGGWG=T/A$S[(@J9J],16+941.O?GEG-LH:%;[+% MFR)R5@7KB!0UYV?&N&[6NE;3N3G6B0?GC3 M=+9@F;9AMB/N;0')$W<&.*%>@?XJ@A="O??BX_@)GMUH.K(W4=IQ19[858)= MFU:L#]V3N70_6.F'60CH J+PS8V$UT]W95+O&;416S.TTPR$X &\HX)NGC^L M@X1NF1N/"\DK&LL)&";41V!0?5OPC-RN2)C_IQSB13PF[Y5A@ILLMT2LD),$/G]J_QQ7X9J5J[77%TKL" M/^[41V$;6SPCT'8F!'.XJQ#,PRCU] 5%-BB&GKA6$H&%IQ66TDXT]]0&<$), MISR8?J2G'GR<]%64R02D&(ZV7[T7SABCNLNRNKP3EJ'6)8*K.RMJ%4S?&0]!24@VB"1&.=W0Q(4(XN4'7+!.4(/Q9 MW=3=ELFQJK"0ZE^$;]IF%YMM],)KO@DL*O9S/HSPJ,- DXF4T6*Z#/@C),=6 M\?A3I6V7H_&^F,JU7P$[G/IZBR/S.::;[/1CUW+,Q_!NO"\)^GB_[K:U"2-6 M<$6O7G7"@FD>RH2XRJ?_N\!7<<+$$#$J&?K &!)")UKY-[77,S5.=S(;\9Y\ MD_C*0V'Z\)$YM%'CY"JHZY^W6_ MT(0]A0ITWB$\QGMT$H').[^=("9OW +SHQ&/V3O'F0MA@"Y^8OZ M5B05(AKS*OR7&(.!+6;4LSO1+!9H29S6CHO+RQSH?.:#^)IWQ0D_LLK,NO17 MI?L,D"A8UG>R QV(4R7RD67. .SDZPVRY1\4C6YTL@^R%02%B!&NE\ ,W6%56N6:+?4O+RR95P[F-/J:0E4S M5'69*X0=S0A>&$N(=P<1'=\E"4YU(IKUP0%;$?XQ6FDROS^5)/>.-+J/S _/-/(R8,[D M& 5$CV^?8N^>#\QGG$KO*>_NKC7UPH:#X&[^NQ6WKV&GQ;X!^$+^Y:\@Q6:) M>.G]6 NY;V< ']B\OC%IBL#4NU ]P&)YE^A;3!SI<$R]8U,\9?TI(52FCQXK M/ZZN^EA-U8#'MC?];Y(%R>^#$^6[Z"7B2!%OJL6,!I/(97[;Q1TF1?7;NR-: M.XS7:Q/Y7R5UXXWH"$5'8:=OH'Y0&N< (QHB/*GEQ;L#F2_?R8XLTX4.$\E'(0BA&JH$!QY@PFOZ9Y"Q,).E,A@@E\21/NC)QJB3>R,REG\)5@P M[-::%0UB*(ML:E>4>$3#+8U-"8] &6*3S^6>PLF]A*D3:#\$NF2D<@9PCRGJ MA288*<%P %(^T;._U4.&V*PU[O/.Z1?!0,\CB^G@S=%57=__Z/ [9WR>/X>0WF. M->#%,\#]3-KTIO#7>27/V)B^ M-3+7]5%"\X2B\,#,.J07D&7%>>MB9U!MD )FRRJ.K)C%]=K44O/S4-/FO7BOTG8O=1=B!P&R/*K",9=%!/Z,L1'O=LBJU2G@/^].*<:JQJ=2.T0 M6>'D"BKZ1&,9HD!\/1(:&KH7:K4&4Z>FMHA5FN8^'L-_P< M9X >8!R?52AB(0N5UJ(B]/PK\>.*^&?!-R]@A]]6_ KYPXU_F FO=4YA=E-K M2: C[],/&E^@3D82LTJ:[G%"K^_6.'R^_ZZ?YB/MPY$KYNMTAC%S52@,;*%^ M< :B#SI7$*F(&!M;>J+/2L$CS0(WK]$3'=GE2GYA5?&#?+->]'Q0?QDKA9;\ M@* YA@35;<:I=,XH*T:ZMJ_ZY>]HI7%^#7_LX];1=,6&Q-*C084B\YVFDB6( M3%C'9 ,KHMJQ$S$U$]1P= YH7\_@TV_0\*JES-1^VT#F.1?<81O0"FWR; M"$?[6];Y+IT93N;KB18L;=H12Q:\3F]":88__\0D91X#AD_3XMA)EMCJ;AAC MX(K0)+0)3K9ZN[&07:>RX%NTPT>[; '1_W3;OIJM8[R2]C+OC9ZX&SN M-*C^RG%Q1$UA\'Q>2/P[U_?:$L>6WND56;UII$TL;9K:S)98,U_/B6;_FDL0V7$IB9]U.]Z*TO4%$O%G, ?*96!,RDR(/-L/./0LU< S [&51 MV!"R8NR_B$)?C *\L^PV!21R;3JY0NAH+J32^/'?8],C59PPDL2P;+U(/C , M2*<_DOE]SXZZO2(/^S&^'%3+5%&\Z0@#T\K*Y8^%PT\]JZ/[IG<"1+&LR3:0O36G-A1/-/AQI"A58;D!8##H,5H*.0BB0\?2X?C_4(TP:'2 M-.#LD*LSS:3F9R$0($A:SS?_09Y&UW5:ZU*K2:W]76V_[.=48Q"Z+AA&;A#& M#^% 2D[U13%H9T $#&"MF@T%7SL;!;!QX^KJ\F.0=BJ\\#J$A@0>/SL<@ */VOV>+0 MSW+)!A:5*X4MLSO##%[-KV_Q?4KLQ)F+M%%D[](D%!^I,(/U;Q*BGC8CF3>T MPA;]BT->/>:=?0.I912_<6=K/\%83)0L<9I#5CFY0];_WB5/?OQY^IP<9 SP M3FP>'2E]<%O86%!4!Q 77?IH:ILO\S [Y3EQ1G^MB6,A"W20),ZI[@5!;H]+ MT^=Z/-I(U-WZKC$_8_VA,9=FYO>"V-)H@+7449Y$=ARK8_ M$Q5ZS@#-_6C>3BA^6$S0,]"#O\C\BY-DD'?SB^4;T@\7NKG\$==-_[P\;FJ0 MB9:--TC%^&V75% F/#1(<[%$A3O3A^/43I#KLSN_QVE[HI5>Y[P:$71]GZD( MD]I/CV]E5XA<3MCV;-I+U-AC(%\GS1.4+X'V*$(;K7K!"X^+:CPM]9U=T:YC M^0MF"JHYUPUR[H9^VPL6/=S\9U&L][4GUJH,]F!F-WC7TY.8_1XGY.4CU6;Y MY"6U*;R=CQ6PRISPH]B BU#M0$#O,!"U45':O-:5X#+K2:5@;-K2DNGL>YV< MH:IK\9"9Q91@S+I(MU'P:1+0YPR0$L=&>DD,ZO]KEM*%JB(>*C707MX)0&BA_STB'&:P?(#?:Z3:Q.B02Q;6F= 8(G-5TM@D%*Y$%K M+0'VBG<_)8HN]WNSFX(UU\7^Z;6(%_9V-?'VND-[0YLU#WCPH%_KVC\.)3M #Y%-J"3@0%P@#^0QTC'+= #2/1+#\;- MWGNZ6>10J*>A7I.G\,3\_J,%'@$JI;8FY=CQSY1QX,5#8'*<*'&W!,?P:.IN2\:MVX;"X@E:.G,HZ0B*>)Z-%<_>O9#5L0PPA'@$$89$8G4QW$ M@/.K[,M*\K7$@QU!Q=!MM%]*4/!++SL4Z.40@'7^#3.4R:2.S#=GI 9A;R?R MEN/&&19)HB NTF.\XZO1Z'?=.'_IQCR["$E:>]7\Q-K<<=^XF)H<3.$A MJY#J<)X(< F.[^A61,#?[/)8U8Q;+>#,,->K@##.M[W&7^TLU;5,C45?$_:. M?.8@0&S9LQA41N<=LSMTOB(5PT" MN"]21U 2M(9\B22%\:0+G')9"HSAA055+XUZCWSOS!WD2>>U?] NS/GFA!$ M.WI*.&>0D#L$D\$%LP30[3+K\NP_O%A12?V)0 M3UX"_&W".13A7OOUN!14)QY^!K*27LY8E9;7.,?6T]SK+@ ?*YL ''7_1/G1 M\1MQ8,02@0*0^\3:WG.!0M'8*F4P)63RA?EW6">$[,[J>K=?%1H.4_J*[O6F M'[S[NAHA+ECVZ4 !HDQT,K7[BH=QU%)-:Q\]1Y69) )5;2%*N:Y'8Z=O>$3B MK(3Z)-K'&-(/ +!W0&!5Q-^B;E"V)QTY%K?CB &E0;@BL#">3;L@[5+A:"'K6Z8=SZK0GL@UJAZUL MN114(>?KO#CZ)1-7Z,\ ZZ\"62O(&J@SM*1 M6)A''"D&)N.GJQNG-!8CVY]3_^R>:,YOVO/-_4&P-Z:Z&..72&:+.!&G3(C2 M$%226W9,;$CV^%_PNIU.W5IWS2E_Q]9/FKTM'[.CZ$6H[%)U[K'>!J]1F"G# MR.;J[>'S.VD]$2<*/N[^NZK^4K:+<)Q9_KEP:.BPTVUYLE&8?QU!D 8UB.(U+BQ\@];*SQECEV?OANP@=Y;^E4''!W- ML5P8OMR]N>_V^?JNS^*TC.RN-)X L80'=#$43Y07]? A M8+'5 UH8NR>/7Q:;.T&P\=)&/\>T&'&'\/D]W'HO4 ,I@U7=;=%*]#)-%N/*D>S\"M,_!=$#SH5R8\G/EI1(C7@3]6. M\-LA 4%8%7H7"U#%HKI:TWSKB%,DF,LO;#8KB:1W2_Y3--M,] +$B2MAYO=PQY @)OQKS M\>G[B^'5->('OS_666*T42I)%$/BXUJ">O\*8SL!E7YX2;-DG(6TS]0@6O9$ MG#8ZI*KUS[/,'( S[W0F,@WRY9Z;4M:Y M*>UX<9A*_<^FM%;V8_THEN1.*.KW%.X2WUCAO;))H2;Z-KS;N%-U.BSTA'Y' M$B2M\,U^3&1P_6(7Z,O&=[+X.?:JGMR!Z'ZGR$/^ WM3_Q-[EUTV%C34LHB+ M"WTT-=SGV&LA_>E!M/1NF(FVUEV?D%<:6AZ M_< (NW5@E*7H6C #8(%5=S6'U1&#[BF!)XH1;"3*;^!>6_?'\>5C?T[_E:EO M"@\-?=1VNSQ4=&XTN*F_+J\D^UKKRN-= U3W^+RVV>G;S@!B_0G.H?K]5BGM M)U):W>)&*4OBOJN^A.X+#<0=?F=1LY\\5,'B#EN?J>?.>>$PDK-3[.26%3$( M13%H(%8=56'3'F7,),JV6EID3=N9L7RDTLIX=!WTLNR)/J=C7M ,TN\,D*R' M["T!B@[4+LTO=2'Q(G?ZM0:_F3TL/%:CS?(,5Q:F&A*@;M"@6BVCWKU_6GK> MH\5N/;>.K..$3HYW 7\I6>\\EK\^.K(=#=$?#N#.XX7*"]VSM]!17NDD9V%# MS'K00LU/0$*0(!+?R56(,S'TD]$RS]'+\F6SBA\#$FAA%__$3=759(74X"+= M4!+\^[E]D,6F'\%@9=R0@)JOUVMV> M$O^6*8]A!/2>/JIC(.- G> M^YC"YWD.PNN.96.=4_?R+,3SOEDPC#S[^&$B/Y%/JG0E^82E$;F=1"AXGDB7 MNI-*IR-^CZ([ZDRB/@%NEK$>LG& D2@/&5%M4@$N,MWPCH-KV,6/O,0+DDTM M3V.''".X2MVSU]:KGX.C,&([(@36L;US'DE']L2P6&,GVHI#E%6$%CW. /[^ M#<-2NHFR20IJ[\--;H9;\U^(5P"K7";TK./AE '&)F: I(]\29&=T0H];]CJ<&PO:L#* M"^N^DA_A!1)+AG@&X)@FHJ7>YZW(_W1P:JWP^9IS3VNB9]6&KH34U^W"=]XO MF%CC7K*!NL_IRS<;GHNSLX^[(H9_FBJJ\4$R1Y;RI_/'799.2Z1-2=@3"]F? MREV*38KMZW26+=12FRR/SP <<;R!*\JD.4+9(&^4UL.-4J[\.T]^O8OB,E<. MN2XO266N$_KYY4,]OZKH\7YX_!G@G)T1DUS/U1RP?T6PJ8NH]*53\)PX0P(N M]@4@U+J3)3NRS=E>"B=<^6S,N)078&L0K?.IF(>EL89"]PX61PEEUFK*("?.!4.JG+)^^K=50K<#^W@+4[=TY@ M[4L&1J4;*?0+R-ZRER[&0S:K B?A6.NJ!RI-@K GT1)3&B78ENU09$D5=5LH3DHDDNF"&U1^8ZYT)T5AA>ADA/B M!7;R.66YQN( _7OT0&\H_581S M:UJH6^P?6]?[D M8$XY"Z1\371QQTV@&C1)/.C ;"LE&OH/9TAEH27F/SQ : MF%6LBU\4AOY:__9BL*W/2)M' !#F#MQ&GJB1$!AH_QD@K>LRT3&S",47IY9Z M*R_$[B[[V+&-(@ZT=)DF75PZR\L^JO?]1O<;MDK__\&17/??N.YYE*O.ST[@ M?U?10],N8N2$8.#6"O"4QN;BYK]9RV&?O0O=UW2#SCV'_E6[.?-?'/S_O>/[ M?PX4=OXOD94U@']>$/P_%2J%RVB*:2WZ[W[2&<#4RJ6E /1/\,#>:?35,T"% M['\3/'#3Y2;@*P%.C@^!8CS_"CE\\08[4HRUD/_L$U_K\6]7IS@;F\4.B^&G M<4A*8DNMLPO;WU%'"M+S?&1< +/_IF/_C\L_;T#F+([S:-[<5UF(PJW!"3 L MI028$A(,@KC"@PI%Q2;J#N57+'W;VU\H>]_U>5#+GTNZ?^Q//:=M0Q^X#Q*& MW)V%7"(N8H$)F)3!$/V!QW\[BXXY32GAFI4<%F+Y!]BK:EJ8GK9N_LU8-_8O M7^*Y :?-)?Y+.NOPF]KI *UB^D7+COR']P< _*.R"_OH!$_N0\\TA!C'G#VB M"2$J1(P\2@@XTGCHC4AX(#\9ZCO\>B?O"AL_-?+]GFASO-;)!.+5Y*Y(@';V MI?B0/8OFM>=70LMR?TQJDA3)'6O%U=_J MZ%)6@!.(#$+*?-PFG:Y:?HD2=94.E0($Z\H8&][3\G^WNS@]]R)N"LT=:9UX M!@"0 _ AG"N36_83P5U3-'J)^MT[7QQ9>9[GIACRV]#5[-(6UBY\\TZY) 1H MO/ D@F)E]:_@G5WN\H2U?Z*AIA5H-XRI="HT\E3O2C/GCBG\X[X83X]!#"+C M*5S$KL\77]>_K[VJF#]075')Z!#-?I%UN^^IP+!HQ&^ :-T-;:A;HL[O"O#A M&SI;JZ5+47Y5 "7N9;S.ABG6F/5M2:<-OY;J/P<=63UMHP!E_[&@$:1_R!,< M+(4B6H)\:B0X:6"/0[=>*[LW6P]Y!DDJ4^U!\RL:>3#!:4K-&6/I+ IWW;4F M]K#9*W_*30RNM*Y::&5]JUNB?B4(:+NM-]%1/"(4KQ9S3K*BX2F'Z+1C,6'( MG:HM4<%))2.^Q0V"Q=NMQ\>N\-#Z$E!QGAGRI^T!?M6SP\AWZ7%\3 CWN2_)(NG(UD1LP?*./2. -D;HB65%G6DBP' M!+,3WB["7])$20J!2]D,A[4$2J\)/*?*O ]>_T"Z6 \Q)]+UN0JA,T1%IPQ4 M\6:%5\/>;7"EO3'OXQ"@L1#_ZF'.BDXUIOKU^XX)[<9A!1@/_VG,6BG'71*_ M-1!=O2-!9.H78XQC)L$&/02;FJ9!C_B+;-J:NK+F99NSII<^%$0NBJ>.7+:0 M$O?F,!9]\5&H2LEV0C/(FCU RZ7JZ7"$UY,+;CUZC_*T;;[U_4AD\?BWH3C_ MNX5&CELA=,/D$;P,Z@?B"#+B(!40I;!RZ9'N)HY?)D% !!D(_>#V9>3817/1 MY^ZWU:8_7&GWI7]3 7#Q1HGG=6DW/'7CYCVY6^J$S CP/C::E24GLC$)5I,E M.;@_9M6TT>K%$@VI9+^:K8A)I%?*"6_9UD.D&6@3HKHSH#A/]H$J_QBKYC#+ M#UM%\P\^7'B?Y\RZ_A@5[OSB6#9>;^'FGW_($<%&9?X8570\ZZ+=7\)0OXW) MPV+;FCM: SBXF_YX!%NNLW] !3]YD="MN1B$;D;T 5E(03T4\9E.1] [_U*E MUJ!108^)#A#>ML^CY;$K % MU2NVP&17=IO E[7=,GJ36\TPZ89FW=>K,X67)D2>>_O$BWO'S$7[$9F,D<2U M*LR02F:IS-3'>]/U'R$OZ8I ZAVF)]^V=?U?W>,T7_M%P6;?)X)W_,F>D00^8[& M2$J$(A2!I#" 9-=8%NIO#%X.N'QSBY;,!WZZICL<6)'ED_ M'Z\'<8:RF,CU]H(Z%[U!5+[F3 M@<2X,IPFHJ>4WO)&!,!0T%R:29(Z*?$;50_*Q(TN"=ZRQQOW'=ALG0+%RDS_ M/O%_="HHHHE_,:2!*/T6,MDC]),'<7^<7\8TPECL&AP>$PE!G^B3C0GCY]QT M_@S06U1\!A@8O8,S+7N_I5*Q0$*Z-+2;E>Y:%B7?S]'Q2[N>VWQ_+:0=-4(M M#Z_PL,]R_K%S0T QAFK+F.UM&Y*%[$/PRS 2*1,-^'O:1GCH[$U9^.+0C)@7 M:C0H><>P'WHG]:1NFI-><\V#Y11YSKC%P(U %G\TE\97S6CI_0?9^P+;N(*# M9DDKC0"A!@/ 1TNN07_J7X(*J:1<(N+,]J[*CWBBKHUBQN%G^_E1 X:79X& M-C8KJ?)4?[YBH5WH/JOQ1\K!JRC2@RX./ J(G!]5@EPZ ]#,D:HJ(4ZIMG,@ M(U5P'PK($?K1 ]\ORC_S\_E&C'-0X?[*K#HC2F !T!_:MV; FK0 \3F)HXQ3 M ,2G*WRS%)F-[T%7+%9'>;Y\&1BQ&6*X*.I?X3^30,/NQ)$=9BQVU=8-],SH M"EB[#\B\:R3A&70TBFE3W'LUH'G;:F'S_TCS=]&_*SN6MTU5!'!W#H*SP_M.;AT$6*OF*#L3Q2&XUZL0\*V:0<# ;C3HS^]5!%L"3 M->SI)1/?+G_2$UPM.@TMUJ6[$:.=%5I%.$6E- MH6)[J$=Q=YTM>J*A'!C+X M[YN;+='ROUT7M]^;7T>)"I(<3U1Z<%!.\H//Q.-419F.()@0./U22&5X$1N7 M6:/=9%[CI:R[A;XZ3*]JWK"]K8&KDA1.;D'43M\JPNOC1$FM<_W7^A,B+MQ0 MY&-/FB@6L)5F?/AP\>'#A^!Z]7XD8JY;C!X,O3$;"7IVI#4;TV_Z1&=RP/3Y0_4OV\LDN1+S>X!"!GJ::&IPD351^860=]Z\96%R MP^L\B3[3'^M!\0_/_W.XIP R"/X4V+16#KJ/1PO-^Q=G;K4KVEVJW[V ERB6 MYUCF/E($&-90_Y"O5\>"!JUIR,$$S%PG$\Z5C2O@2:O!K)U/>;"?=\U#8JON M D:8/]T'5SIQI@SP&6B)6SQ#B8+.:!%BM#NMU)6X:M#S0N.W7A^K6E= MU*)M?C5-&_)9>SUJ.)/H_/U7XSQEOG%<>V YW+&3T/,Y"5N[:'%$C['@Y/W, MF?1S]X > U-7C+X, (C^%=)H6143. ,$63_U;%H^;2F"D4$^Y8%\3%WZ/.E! MM3G5%-^9>'$V*\R@47I M8.K!'^O,5#UTY?_ $N$,(!2WZ$G3)?QCQ1V<@6HM#EP(+-+3^-12US=^5/N8 M2>_C)8'<&8%XM@6S M;HU0Z@NVW??HA];B];8G073%0OI!!VS]I5K$X@U1:6([:1DO!(3QQJD5&4]U M\?<]3+4L&/AAKC18@E#A6E3[NKY>+K*B>-T!Z__K/ 89):D(-#>5IQV0J/)OX[0M:L[/_D^UQYJ")LI]$ON])T9) ME+] \1^5-:L2$'T.:*_0>"GZW#O&YL):YJ1WC&WNAC%3L;I%[H:I6=4YM?W/ MR[B-N F9&!2J'?E=(3<;S M:?CF2TUFPFX"W":*;\%NJAG*4T68!IQ_#?U^<_'?7#;\7Y5A;?'7">3Y#ZM> MIYK_[!0Y\]]4^U^WKODOK6CUGUJQ[K;AO\1DR8K.B? _*:B V?^AR=#*I?/J M**PQ[::V[8"P#55'UG28&3<@M")2V'8 (%2S;,8=]D]R'I H\1_II[XM" ?' MY+;O=0GGMGH&N*99.R 8_U\O_S=MV:D*Q>#BN=MX"MZT2L\ _R-'%?X*&C"^ ML.F9W/&5@$Q^D[CGEL6S"U>F\J^+8G[*2+]$DFC7 617O@+#^N"+)8-&8K,( M<*&0>\3-MJ+8W@'&'C5OP$V>7F+\P[Y77E)U3YZ'N[G'&*TP6??_^?:'PL3F MN;D?<_PK[EET_/H/W.N.)@/]>B=2Q8V&F>;%Y,^?OB3[)?J,"?!?8 -ZO.YP MR)M+V2VY]9>_1;HX2N0&MXW-_Q>O4_E7QG%7Q.E;7JL[1YFG)1I1&2.->KOO MWP]IWZ-#3'GOC['9"=[Z.S>1-=D5?%KS' S%FVWC<1L%%PN*,OPFJG*S+VB> M/O\^:&VX)/\WUUBX>B<9:WB.ID)M CJO1'P)^\-FZQ!8O MC7UJH!O._<[MK%<>VY>C4$)*.]$@W3FZ3CPGS,_$&,7L"RAW=S>!+,@5'4U M\/Q6UT];U7XX(.QA0W\WWDL?H8;Q$J@Z+>_BV43S:GC2N03P\3KL^Z\H349N MP1#Z;SMY$1!Q%/8>Z-M]G< MJ WK(Q+R9O&SGSKIX-7]*EEH'B.M%3.EN60RG4\DUI,%5;"H?O5EI/Z+\5N= MSW)JLQD'@QPIC R@B^O=%Q,GGTE[WX>,_EB_ M%S>SY4E#X=@HHXUC!_MU.S )SQ9;);J,RHXPO34DR M91905MXXQ?.GJ@G'Y&IS MH5[";7&(6,-8]76,2DZ#"KLBWS =N??/HF*=AM75YAV' YR7B0]4E+]'(0@1 MF)=0AGW :AA_# \G91'*3$]A1EPK;$\WPNX3J7&T+55@7RA?D..=33ZEB##5 MC)W\Z,SNCM2"3^5WFU3H (Y>..2\LBLPOHPY3A"L1?GA2C+I%[Q=JS1;)U7K MA@)%K+L!A^I.OO)_INH>]A*/\&@B-F$H6<0I;#T#0L2\CZ+H M>["ELMN_-C_J"]\CF+]ANYA/8:@@Y&^K>;3L90CAJ.OW2-;H_BCHPAG '\_E M!RWXK(,?1O%OC4;[#4"?>2@3U\E M,!1K4. !& (KO0 ^ZBJCA[P+9LULB+VYZ?+22 M_>5E06,[*'2Y84?'!"%7!\0[9JI0)./&D(UG@/1(M>H[LYT^F--KJX-MM,XW M/^=4O)$NO1CK@Q^EQ0^(TA)Y,P*)J,B:C3FMAYW]3]FD;Z4[Q9L+&&!$%7HC MT?/5_7^KNST31!G23RS<';MC$*F@0]W2 $A:Q2=[+GJVHO:7#?N[=\?#FZF2 MB?I]4>CFXYU+]9 K,P9F'_RA+)UB%@0NF&8]F\X,0CEDJ1<*3Y>@C,/Z9 M#ZW:Z/@-J:_08)4?![UH*J@O4&@+2K^G":1U,O/E5EC_\*"!XA,.*VF?=MBX2S$$%Z%R6I^XZ?2/D26H@IG8#+VH@N0.- M6 B4\K?+8%B_2PI,'M'5V9*,2]$W]QGS8MWG7&7><7NTQ,9 K*4P'TJ'T M$)]ZLD3;3)?0.;VVZ"BUW IYL(ECN:G*]*=U+LQ:H0(EN2L X'D@]"K$:)VX M=13=1:J2>TJVP(*X+3!ESR@M4U/N?]$Y^>:L<-+<6HUXD M<585T0C;T%W"6P,V5_1/T\\ ?E<69+_@]E*/!#T*(G!H9M*#*"LSNT;*N/U5 M0:E++QWL,BL12SZ?3D)P8A=[<&S,_JT+ M'K7W<9:6+W^?7L4GZAQ7]=_P,4[FCV5QI^[Z[L^::J#:X+/GY;KKF@\?*4_& M:YOIZGD2-PX M%TF[OQB8U@P5G7?^%?,LZ<:TD=1&B$^MQX_.P"$Y?'"C*>6! '=>W_V02ES[ M#A!;MA- P%LA"&5/.Z,(^ $/_J:K(#\X^-NW/Y%M;\;8=>)?^#QR8]E)_!G^ M0WJN$\)+@L+)N@27 ,HEXNLS QRP[ ?$;4P^CN(/EJDJ9'?\6>*##^3($'W ML!NP&TI['UJ^XUGJV7 &V [ 6B^P'?D0WC41 V.M!UJKE.]_;_:9]FMJG%2: M7/-ASNW=Z/(%J6;FA6(+C'OG?D$R.K1LEQYT(H[<28ZU$"X2"Q9(LU6D%153 MG\_<8*U5)M7)[!(M+63YH0&+LA=>BS=R2XGULCQ-/6=H-($+RWMI$@3-L7;L MCK;=C,Q!:&63I=-:L@^$9>1M2/L1@!F@L&/];\$%2!4W'OYC RCTR)/G:T#L M6_(U(LOAWP$OA3U7A0QSZ3-*;Y?G41/2M>[=+=O-$S $T1 M\59AIN#C6>4117IQ!%FZ+NGW&)#Q-TSD?%(TX*LB*\U!0J"U))@-:>I^U6@M MF]CKP)\J?#;94O+^>$<.:=<>FP2UFH>L#X,FXR0H7QN_G@BR)1HQ=+4ZUV&: MTIEV?,VNO\1WIJ\%2,O77PUOU (8?!+1A8<34:FA!E88%7;_QW#N*)>4EV$^ M7"/F-Z(EO>WZ+X05"G3++<0;F9+NG,B1(HX0)#,L+ TJM!L)% "/]PN&>[I: MLE:$>854F$G"E/7-)2)O2%QK\&-VW[>FXS&Y2AH]1WIFRL#C5MX5R2"D*# # MC9TMPV5=9W 7.K':QG<^5^WKZ&>3T_6QFU_K>G].*L0V@8QQ]"2^GH7F681@ M:7+%PL:QNK.ZAHIT6/*#Y *G>C,!F]CDZ*)4J/=0"VS^9+",&1(6R9T31!&? MT037_PY8L@B4ZWI2&\#QDH]S\";G%V9S"?T,Y@LH(>5N/ M]<;3E'9;$M/AX.&J:P:S]@;JS)SJTZ5MZS-2!+:=Y'<+\!2E.&F(YI>)@NM, M>/UET>V@#Z\-IH+Y%S7BJ?J$17^7T4.]@=QDU=-2BC;9L(,H4H_\0)H]=FB? M:LD83A-8/7%_]?!CD=^PD-O0Q]%/1M0/G;[3<1#$CJ@(COW(I!5FHM_ DU/0 MX(H.^E\CWS">)^V$3,I NM^ MX7 M3,&4JD>3&[M['*X9&[OL%S:K)61LP)NL:KKBPMID[CN46R@5XG&AXGH>^D>J0<.TS&N]9L4T:#IRH5K_[8C7\#Q2B5 MAB7MB;7X];I[XJNW3_%L%WYI:SD4=S6 A!T. I4W+A04:^O/<_Q@EOA5__=AM'Y86L&(?)=?H1/B&P6;EG.HRUH_9$#HN65A>2[F>!VZI]T@-)*1Q:,9LL, M, 26^1V8'\D$=C3.=BIAK>3]\NW3[\O=)XGRU#AKID C5M)RQ2)X$>_9C5Q@ MPHUG1"8<_8(WC[)N&HH.7F(EX::N\]G"I"^YZ7NW#T<-Q*J>R$+NSG7J&$D& M.!IQDQI\",N7K=U<+^&V[>;:A M-$8"I+E>O=N("*(4RNZ<6[NL]KJ^P"-X_X9DWM?*>.*DV^NEZS5\>+\80&!+ M1C;"4I!!;*D=*OWH;$>7LGX6K_ZCK[7S&W3V[2U3&CJR0GA$:PH#5X&IO6^X M\S.YI1/'WKWYHMLDSRH2O(\=7.TQUR6R58CT3>I=6,8O*[_X6)\O\^4K2//! M(Y\+:G%V50G#@@=TRY M;/!Y@CJ@34X98&!D2]7E,\"6V-K#T?$5C(-9+^R9AR2!C=+*+KW :.$E_HRI<\$]$.P?P&VI*I2"8?R9>GNRZ[!R5,CEIJJ5897YS S #'%0 :C/IDM#U)#E[C> M[AG@Z2G9+.H4?I2MJA7UQ[4IVZ S++MSKA#B2$K&[8E">_3B9.9)&;:I=XE% MR9#K7?QE+NE7WD,UW]4%IT4TY3!=*$F5DH!=4YCAZX:V7G_LU:= %,.6;.CL M ['J^18=E*7],\ Z?-[L[Z7\T[S')W,W\"KS(B% [T7XTW,HRD0/AP5%*=?6 MCYS 0WDI"K4E:)$KX3@1]WW6DG-<&#$X'_* (Y1Q M1-#7S9LZ::H%$.G9D%VE!3^1)\MTO'Y99238F%D8G-\H8PR5X=GAZ8=P$"S) MFB1]#(SA9I3U6__"&$@E0(W86X/*UA4_#4+\OW.#:F+$FF=+(51PL +>ZE6P M4*^V[+"G_]^NU$?7W!KX]9^J_'1[0E\VVQ7_09"2?!^7Q68S<6CIM/=H]-J* MI6MM@*F=T^N;'5=V&?. @H _3$>6;= %RZ-X4O+)-7=>**M+(0&:B,^]C6[H M[ZE7?BY:ZIV:J-L3::CP!+]24$[J.QHB*6'AHF8\ 2% M-4N8E.N[Y]$^-NY[K_-5!_XFCIM\Y3N%!:+_W8 'VU:983H1XC"+'A,?PH2[ M#P'X?&5>Q*LY$12 >+[N,P =)(900S@#9#U*GE&L* @-J;(0%,JPF-L=9:XQ M&<1/"W/TT'#*4R>>MABP851XXD;B=*U%%IS. #X!Q;>.'Q=%O*V==Y?V&P*[ M?FB/30=(/=Y)E7@&U HRHIN@2)+DCAB_MYSH1(I<]J];+Y[]:8)2R:^L_%;/ MQEQ5X?8>D\V*?77"=&[Y!@P?/^:"48-HCBZI!44[F0)8IL'-N:.%B$9NSA[1 M ?=-H9_*PLS421X5?B>:X,#!12RS*GIS,8Y_8/77P+L,=5AC;-&I%$<6^O/Z MZORXH0;HZ;]AGQ4G1PJSOQ;/S92"82TH\7K[JTOC%-EI*Y;U M!C&M*<8&=KS=3O!)>?/6')_N+',2.2T_#-.XF5.> ^F^]VAC%\C3Q;XAQO>1 MK WZZ+:RJ)P =R:E3/\8>N:!FQ\>A+4+J>9% ZBSGSJ(H:SGX3W(9I[2%Y!K M17\?MU3J6U:24DT^!QF:W7X\B&<>GM(1L*/'"'LS Z*U=T[*?Q6#D@SD\*[F MN"92616IR!)!J"\/O+!B98 PSW-YSZ\F==U72>!;CB[/9^RR*=KZG$G%@V=[ M<3?2M^P(M$5A@9G&!W9"BU4Y->,Z:G+K+D#&,\ #)"U9DSB*R#P$LI/Z<)[I MV[9OIUJ@HEM6[T>KI9BOQ(?8VT7_22\4T)&2,U1!@>8S>L7$2FY\F96;U6#C M] _>J225]#GN>+W_ >H.$W[#D4+-[R,>D>D;KU,&X\NU/G&,&W7Q-HO%H8,0 M.X*'3G>L'BF;O=M@=]3%[UTD-1U%$N7ZSP#"&W&\$Q0YB#KQ5MFBA\SW7<:^ MCR[!:9P.3X?>*=30A#71"U=<,+<+#YHT8J!\C>,DR>&L3 8X-BFR1&3F7AT% MI9)&#OC06A&GE$!C7&]O?T?*0-DZW%1UF+1UQ$+P@W5:U:+1X'&<3'W"QV7# ME5K,"9![K$.3G+U8J=:[6,;\T-S1YLJ%9 CX+B,!EQB2:Q.^@UD]X>M^2^T M9/+-6C7YWL_3?(1'?#/C:;?7>'UYRF0J1..$";R]'?+ 7!R1_+C2]D.RO>T/ M $#L)N)_>XLDEK@DA.9^T;9USH5X Q3>,1G"]X:"/@,T[595]055@U$.(1Y6 M#D+&[,LFHJ^OI$1_?^AN:9Z^GL?$G),D&HT]%D^8)&GLWRY\8I[W[H.SV^QOC/ #T+E-+^3_4[SR1+$ MLGZ'+ME\6R)?8J=?"-T\UX 'RXR8U;15N^Z5SG3&#F]6@=NJ@_+4?;_1*9YB MRDA_=*J'$G$$3?U(Z?;*FG557/$^G?J\/RM@,9R+?()9E*86J2,\8W"VT>,(\ED(_ MT!PB'&=#S^_CMKLTFI_Y(-XH]#2/(K !%0#>TR!X-/([!:EM.8Q>AA7S4:8[ M5$?:*=*19J*;"JE=IV\@[D1+S$H:061O91S_KK;."@/GL&;H+RQL[=9(CQ+YUL@ 2\&'CTX:C=B7A?E8CO5OLT049 MI?%A1JI,X7C(P$D$6/ON1.F'M8!@ M&DI IFCM*YUX7ES":;V!R'MWB$HC$9JB5&S- S%"9O0ON/%BDM2,Z=M; 5YI M(0O^1\=#J,!=B#/!]=H_VTQ1P6\>ZT$H#.W%ZY8MGU11H;<*=T+MKO^X/6"* MN>21A.")PIT!^@W5L2J]9P!N\+"+^,:"TM.Y/+/;J(W M8NUK$S5JI]!#4"A6$U?68-U]2&(C<)E-A@;?FVHY=;'0_/)@90F0N[QTOUA& MI%"#HY^N,NYP-\J&J39:XL&UH2H&D8>F.F_8GE)$MUR.4Z&8/#I;0F=^W\<> M[).U]*#PZPUR"[Z<0T^94YR&/TGE&!L='LIU[Z6> =@@V@10WU_MA$?+:M87 MW3<^=\$!00I(KT3%6FB%$50.@)2(D1$ M($ @% &I$1!0D")%0)I(4UKHB/0N1" )O002:H D7'S/WN^W]]GO.?=^XY[[ MW?'=-::/VC79O['7?U JB M019T:4S]I88DX?S*J ZYYWQ]2\'ZG>:GJV&GHGUT3HU[:Y'8]A$3 G6U1 M6JV9%]R1C"^L;W/MQ$ -U\!J19?"-W%HE8LFEX7V'1;N=0&>-.T25= :O)CR MD^#3$2%M>]=GJ@OJ2^\;=5?="1-9%E"GTSX MEC[Q5EMZXM6-D?4XCM>KE=F2W"=\KVGI";S5PT1VACVB3*Q&%3(^8WL<#ZY&**+L=8U YZ9'*7;HE$^0!EM05#N1UF MFN-OV(COKV^BX9$43J(()@88.^$FU&,?Y MU^#1R^%7+T+SM1.5[I7$RG(QAY[=*4_=E2:*EH>D&M=KLITD0Z.(0_;Y/HV) M"!@_UE6RJNA=O.TU=O*DW M4WT;FD2>EB\(P14+'$I<#RL?K?I,R-Z5_*B=PJZM=F<#X&@?Z\A!57@JM>48$,.3F4LP M>HB7;K>E60EB)^9SQ GD3&7&7*NK&"]A,9+NB[A7+/OI]KKZ.YV%7V=%%9: M>(.L,U F _*[G;Z -N-'=[%W;Z\N>..T']BLX>CDJ.@1<2UF(*ED5?M:^DWA M(\X6T*1O&^B4MQ38NF:\X>Z<-/OJH$CU;!3,X9-B;J'^*99[%Q9,:6@_F[R_ MJM_3#94FG*>'6.*O_7LX2KE(K[F RAVYPC Z8V$+N)TYVX MF'EE2J'F;;MB%\^E@E0>S$W9]XYI1VKHR/4)-#)8\?!])E_HWK[E6(;C&$R[ MU$9C([^P+O9*FO/\W)?"!ZN>B7>?(]E #L"SL%N$Y/V8JG)F8A:HET.D@;I+=$,@-1+RM[BG=@N,)Z&-T MV8V3:Y:=:8,7=3H*:/?B^R-[M^9U;EPUQ4SJ/SW-"4*G!YT>4E?#FUL1V/-C M9=8T!0F*I0KD_12:+Z_*12+DI28>E_C1O3_5JRL\40YC(+\E<>-I5E/3@'N9 MU5@-6\A>052#-FQB*H,R6[]X^R?:7\SXF2SC:0@)2 3EP=CPXD3S6W5-=2,= MTV-+Z7#Q*M3&9;\\W@1C ,_-,P!!JO%@3?>&D=VLG[6ZXZSM0=Q#I$"\[-W MZHBQG ?6#K<2L4N]VQ[9"3[6)<_K3K_CTOOT32(MHGSG[V1U-;M(6S[)=WWZZ.>9%1][TRPL\\U M(_YEZC:0'9GSUEB#QAR$>_4":IKT $DP+';'QO2$,_BY2_H:OI[:$)3WE*0[ M9\IEQ1=R9UQ>@[4%CC>6/IUU1IL_HA0+H5\U%Y"I')EXZH5J'R+'KSKRTS76U7QXN72(X[;=K@(UX\F+J'KKGOF7FUK]"7?SY M5O>J3^QBHRTFJS5# O, &?5XV -R%5Y;C1JX8)4^H7O%\WE+GNE4\4N:9XQ& M1?)-_,3[^5!GK&\,R=O=$WI8&X4K<8=<3+FE2,C_]+WB[:B88)9"K5.Z,E<' MP)B<39'4QBO]OI'E+?6Y454JQDK;K3U$OCT\ZAQ?L/4;UI\\!Z'[>P\( \$; M[B 7#>GVS\2NN9+SD-UBRR$V"[,"1T)ADF&U"'SHI61$O=\YH MB&]CF3KX(2V>""GUD[W.E_NYDJ"VL^',ECTFS=;' *M!6M9+K;'!\&NDJ$;OP9XOB0VLR^5BUO.L-?Z@)+]I%\B MGTB?(:D1LV&NZ!9?]+9&J.L$!3ATQWA%-52GWM[/O=>91>?K><(7/GJ^T!N[ M^?<:#5VH_KL5J,<+[O$ %H.$W'CZ4]$9CY?:]LX5K3&C*BTMOC_[HO1AWF? M_V#3B%AQ=*NK "4)I'M1$_[8.&XOY,=1'%+*B4%[Z M@/KG"^#R'P7PZY;-PH5'BXK\WW/%:MSN4QY[$\B4#L=X! W-[AC((X\H("(9 MB*\%N6P>BJ39DH\!0%)04P[)A00N6'N#7&J' [=5@CY84D)%B,"KQX#67^1< MY'***WR?!"<<@OZYGT!MXA!Q:/>'[386A#B(')6 #]Y"4B_,$BVSJGS)+'W2 ME&, @@+2)4D-3*E1HIZD'@/@72=O+"]$\H!X-+\94&"Z)T9?.PR'')Y-1<[ISNQ!7X MP"L*:!%H7'H,N,%"8DK]'W'2Y7!!^H ["*UK;(CER_9AFQM_LTXFQ0X#GWB M8EX6^S' !8*+$@;250U4*]1)B&9J+C\1/ :4[UYN*B.!Q:4/>,I4C@&I8L@= MQS>!SU-)1 3V3RO>'P/^I\SX,T:Y%(XE'/\QX%;E"!G!BUC0/& :U. M0J,I=!*)MX$W:\DT!GA-ZW^)T0[\G\?M,(:02\C]^_@R%9H= [*C@FA[D/_. M.,2_&SE;DR#Y(/E_\W&.8K][?G:'6;KYP/=?;!OZUY%;6Y7N1'0BRNX= [*8 M2?!>S?\45(T4]I4_;%Y#ASRVWRHN1/'_6I$4? P87CP&@/R'[]Q L M@?Z+0S!-.!R8_T;4IAGVGH;(H [5X*J'D00V]_V_0?["/SZ_-%=.9AX@Q<[. MZ9*DL^*1.[J@+3EX7.#-9VI#"6NZXR<=GH3NTF$<_(]'&O^S1_*4M P0_IJU MNK_M9"J<^'-:-06I'@.&^(X!W_LH\O#6 ^+:"9]X=I):$M))+B=N$0@3E%=+%!T(H;RP8E-'8_EP&G@R/.V: MN;9_ %#LQ%2^)B64ZY N!!_6'^5535I<2@P,]#('_5-?X.59.BIRN#MJ\_Z M-YLP=P^J@WLW;^-$/R'J<;7\VIY:*EP#)B0B&;Q;@"UH 9TG/1Z9JR'P1Z;+ MJQQIK-/V? T#3<->[ G&$_O\:MN8?FYB9L-V>^*,UB?2IOLR>H3IBF\GZ@JP MV:V;&AOU!N$UX#R'ZR#FP3BZVQR)PST.6!D^Z5>9EPAIGH$VQP#/*4IO$/]H MPQ6\4JN_1TFB;E!*GT276)M@HFZ":7R[1&'+_./&VV^+:_DC[]P?;SJ3;P16 MN;OKO"+O^DE^3O_%S2%M]G=?_ZL.M,;*62TA3G:&)Q0\M$XI2M+2>&1XD6[4 M]&O*.:%,;HZ'>?J7G+R=7MQ_K7OGA;"YOC9 QC2B3Z5R*B4:L C3QR]=)\!? MJ?E?P[&'9G;(.4TZ8.$9G M+J3/_R]<-I>>VXS(Y"-^'Z1#B M\L!2&R'HN]R[:L5B/YTLGK+?^MXR9>ES5M@N]+K&_'MC+IZ#D69DK7,;\I4- M"-\5(B4)T\^#3EA\_5J3WG:X^&Z/=UHJIU:)%N>IATE^1#4U=!"<>8Y]B0-4 M)?I2DR9H9+:*%QH!1O59FB$'[8<;0+D6)_2X2*_NX9.'@C>20L;BV5BH!#_3 M4.-4)98&(D U$Z&4B]"9@9:IVDB8$WZ@0S58ZN-*D.80[YTD$X#C :V7!#-Y MN#FS>6PS%EE]DA$IC- IX%EXJ\R<-!\Q9AU<./.0**WMKEUU9/:X6*/EUP?3 M9(^76:G" '-!@35MO[T"PEKS%+"5AICU"0S.)U[!L>RX<0[JT_E!XL)^.+% MA,//U7J* LQC?\);;C6HB^80:0T(B!CU*W/2D8>7<[%G21JLQ-H["*.$ M1UA7[1&ANPF0:B[(43N>;9!VL&IBA3CQ8Q9/0%#I<-[/:IYE+6V@;]9K4DMO ME8MC:_6_N[C4.[FYL#15#YSRFKN<5$#I.4D<5Z,^NE'4AA6F+P6 '\%$W:2# MXP-<%7]U1U#9F9RDTK#A8(U?]L_]S_N M[]T=62>(78< VA61J2:+A(ML;[A M#5)H=R&MQ(!ZRULC"V./A/2&+3D3>GTOL'BEHO83(GA=@8ZDV\1N-&*R"S.6 M4HXM-3/@ORK#'OY&6*%O83W?D\]$L,= B"I3XYPH( VP4R>Q6$Y+FUNS!S M;*;$LM1/W'7&G*_ 6"1? S^>M16$3X#VF%(&*A.=:FI"Q:8LT[M1:O:A(CUZ M2[3!JJ?T :PV)A@@:J3%8BE:/H.NG<),V&_MB7L,J71-M='$'[G6U%8R;W7Q MU4_Z*KG_'##,.T6U\W'33>E)$]<)04V&Z86J(2*0C+N@,]#-=DV^,>\CM3Y[ MF)*3D*7;^->O9B,L#^=U B+$RN=C8=G7[*YWC=I6SJ1G+V>=@4DX8Q#T:T$, M@T(G\-<:5+^5*$*.=9I\>5\R?CV/!2H)[9*G6JZ*K@_*D @C]A!Z6F:IU(6. M >IWAIB%7Z:1G<^MN1YUK13);VHAT MH83[,"OB$N8(% NOS&HO9YURRZ0>TGF'C8E:)]UW<9?&54!.23Z_3@>4^4YE M\KRO\9GL=4&@LT>?%&P-O[8W@W>.UQ1::3HWVB S!XFNAS]#[<4'NF@_[VG7I1#5Q+Q!SI$4%H_IJ4M(/1:@TOBP3;\)U2QY6TB%?>="X; M\1F?VBNL41#C&:OOW*'*_=S/GSV7:&F2ATHWRP6-S=(HX((@;$P\5H%-73<1 M=^JU1W23J*WT/!)>0>H>4@-GT,H7=0":B#YZE,Y=V"8!N+=(],-W=65>Q&OC M$*^J$=PKYAPUGZ%PK9'QK2-35UQ'LV*%Q(:3*4A.LYF)6H5] L9.SE-7(LS< MM32H'H;IG^S265T3\FIGN D^:8<>!32RCKI**?KT<568A'CE_G. 8/_AFE6+ M@YX]0Z.(V?-!@+6Z@HA=*;>V%A^+SG+OP #L4>&,BV,$9N[K\Q\^K\)N= I[;9+0A7H'9,]8^IG" 03CF$K^U/=O*TS-.LLY4-[?T5VS5NX\!I^GP M3KV=F]K$ ()!.X6%)FE."M@J9Y#WE";B]>U'5CFOG]\4>/\D6#-/JK84L-CT M@GAPI 4%/R0GD&[,0M'OMR^2[R>_2[4'T39 MHC%U_D^:+",IYR^B)3K==5 MMBP;#?313A"!-@Q=ZA#'Q?V/LDPSZ_P#R1:@ M"H]:>^Q=K;FRTGP;K<*5U-D+967N'KAY)K8AC;@DB5S&\Z]OT/@/T@Y7O3'O M#Y(CUZDS9Q/K[^%G(V#2X7)6-M&@54"-H)BKF#WEDRW?R/XD M4L=>[:9(XUN#A0Y>-F<:.?ZW(C>PP9KO<[X.A,/97V3%S "18SL! 3U@L)39 MOFZ"= )S[WAE%_H@XB6.H31-LW.8D<4S-[&I9M'.-* MYDF]KZ3F#:J3:?SJY5U#1=H489QK?>>BL?[?FYB"]BY343-*?I6>3>!IY_HOT< M20V,&>"S6<:O9OU,A Y/M'WIR2[%>W*'XE*OT,/2J72S/K:6?:P1( MB4BQ49F;' ->!TZ0GT/FW:08X%B#/_4L/XXBYX$G5,8J_8 G1NODOZ0BR0$G M%#D[&O"M)JYJ58RJW@7U6Z;TKWX!B\L< ]C_%)\I=7AD\D_7&L6H[_^;2*G/ M/RJ6^HSKQI#TW='(,+@*1=&2B&8T09V;W?7PAYO'DG9!OS! M=WOQ^<]T+;\X,]^M676M.W>M9^$1E(X8)C)+=3.EYQBP]>(84&U$CMB!DY6B M 8?.]T?=7U@K;AHCOT7W=PZ+9@9$O1?7YBEZXB,:#*!)6I980,&)8OMM9M^J M&AKQLX@J!/6,H6 -@9*/^68_^$32I^A1#V2J5R:)JV4M^I :.Q'\F%B,1W8$ M,61N&)RMQLG.W047IGII+79V-]#'SJETZGA&'TR@05T2THQ78X[422YX,C(< MYNI4T/;1=?:I=JH.0:/J]J5X2WTN=\D'G->^TL@!J%0> [!;;[&;JRK^XJ5 M75[N"L/Z?(-?7W@K#K[^T19Z5C!4 N+NN RE#$T <-!L.%I=H>(Z \JJJWW@ M59UH*PBP-B-#X&^S=*F3RIVQJ@-8?8IGIQ*ZVG4^5SWQM#?],XEYX)3_Y#' M57J*NOD8 ,!,2[_2BRQU?5V]S_TP8(OFY@+>S.,9FK:5H'3LIP+/[<[R!0WXCXU6 M_B+*+J]J\F5B]A7&PY\OH 4S'[8OS#D,\F?;G2\_9,!UO M_'%=T1_'2D4'G9G/EC]Y>(D#)UR2GQLO^OH[BOOYI^9,-/4:0]NA27T![5;Y M&R>BT9$ERB+#GPDAP-$X'KR-Q+!DM3)KYZ7TP[*JBWDS,FKM%#54Q_O#CNZN MSEY .B&C-441=Y):X,PDS@(WG[2R9-42Y.1A?G6E7DEZRR,A48SMP%^\YK1G \:HZV_81[P+E>&(7;\CB.P&YEBL0[8!!\RS4? MQ]6Z<^YM35FW[#].MY.L9QR^=L;PA!Y$RGO/H13PR'"2Y]$M$I2X34AJIK 3 MR)$A,%&,5$ /HOV^B^)A^ \AP:T2^_!0(3&44$,BA^M-G@!W]&[@,.4/^0V M77[+;2J#=E2*YY$& H553GBQ/N@P5ENR:!3)%Z":%S9:^N> A3N2Z55 MDJ_OQ7.0L]19F3K7/0<=]\JE)IIDH$M[ >2T!G[O.>TD+%.GT86>,ZE.^5UL MBJUKIM\D5SQ@^;?TMITN)E=(P;+'FE.\.8[7S",6(WYC*K%[,N-,D 3\$>$6W1Y>N( M6G@KQ L.V=NL.H ['"D49:DI N6"%'>MO)?RH>8O\\GY(-?2,ZC.0UW$#C)$ M@'DT%6=Q-0D8:3]>?07'^W:AWO6G\-.UR%.:(:.Z6H8!IL[B,@/CC8X?H)59-QZ0*^XC+O2W&E0I%KJZ9[V4P-#XQ&A[<- M9E*">?OX?BL_;^O*K]X&?,>7P3__4=>+N]0#+/'/WJ/2,2U?I;]EH">D;QP#+/Z51+:K_22LXF\'&)?]_?Z7\_S\VGK6O M00I;B'61WRA0Y;-;R>/MWL'/X!VOIY M+BR6WGQL7A]VUDL\'W(_QIUR<#QQ];4RC>[E46/R MSB[\+;KF&" 5395"E^GS/@ 2@G1$O(33;S0H>&$@- ^74VWXT@+B5 ,>/6&1 M3+IIG[#P^.#]VVZK'[;\G_V*2-Y'XB1QXCM/+!C!1E3LL83>7S\&?#+Z!&5J M'E>]6B3[!GQP.6T#8XI_()(QG6#T+(]Z5L$<6[!NCC>?1< +[#!ZJQ8TQ2*/*);:R Y##\2Q._ M:-1\NDUM1M,0V-YOPJA(K5_4._N=""!,8Y#" #X/V@^].H8\L1 3G:$1I3LE_E?F!? ^)-2K7:+$ A%-99:.=/:^B]B9-U4+& 3L?Q MOL?G7ZF289MBW,+^U"TKMGK$5$QM9(,]UH@>?-B4M5=JVZ;$,NVJ=,J/=7VX MASM:9ZJ$?2M6A^_:4C"3PD)6M6V$MQ&S#8F#TCMR79K6DLAHQ#Y-C#G9G;Y4P35L%S?^[G#UT^ULSWBTWWR1GN9M(_05COF0QGS70,@P&%!7P"CTFKB[IA^DG] M+ISV@$+17B?^-H3%[ID3[ <%#T"0!MX!M M['F([T\O@WKL7Z^OUAF6EA+HM'S8'76',9R;ZN;YN#S$FU#EKML 8B5VDY2C MVO;MQ"[.6_LX<(+@D1J?O^RK*(ACXSU+N_2(UV)!A1Y&CH%=46?)+,.9; MFY@05Y\_I!7Q$X+V;9%F$WU% N(/NXS&Y[BB]Q87%W9; M6CK!H]7ED6E,K]3M,;/LMC_]#H\!D8FK&K*;_0E!_;5GBZ[]Y 5[F)IL7^E4 M[@! )W ?DO$3K4M6!S$$T;:7[$?-ZC#(U<6OJ<$^U*:O<_R60/'1:"#DWSDS[#!>-W'$C\H;)0V.'73.6B&NC9Z M,W+/PN<;%WELMV^L;ZW5[^!WH,ZB$I4N,S)9 +9GI\[TF(U4 2<-)VR<4RW# MNGB$_<,J(0[/:KS.Z=OYJ;6H;-I:>H5D-B7W07LPY9%!@M90_SF;D?"=&>#H MW/B+SNT\Q/J^9[&X_DO[>BK4PM.B <,SJL;UUZFC 0?.X-$+:PM MO]'IK)>V-T=W^GC_#8RC"%;8E@P=;[='V1]@W$.1&T\,1H$FDSK]=:-F^O) M*LL/427E'UAT?BX'OM(X.^]SJ:$<8[2NA%=#9T4+$3C#*,!)UZE?#OOFM4KF M2N7GEA9C<"SZ"[7"'G?X!*JHEI!58YFE'TF"Y R<]T3B71\@/]%08L]5J=+J MS*E[EL1XTG:6Q20YNT&N@)B^UTI^-V)2';W%"R+J01['FS+FN.#L7&9I8XOM M0]:OJU\XNX_@@RG@-]MC @6 S*YM)@B]4=QN.OOV?$QW?4B,EJ#,ER57T843 MX/ $5> W;Q!H8]75L*4WNW \?P/K]I]@Y1+Z&UA;NK.9V,G5I8^3VHX!YZ]R M4V6BL.:1-E=4Y9W*:A29GA;+9AGK+3988B=>-K@74F;K\OQ!G1+PE_Y-%1BP MIA'$G+ MGOR!,;7(TFT/O*3/F>SM@<$DB35GE/:/)&NTL+\C6*++0S55H) CVJY,G@K" MU;>E3;E" MCUJID)8FH")Z#[O*39-097,KQZ7Y2L1K^^N/N3"? ^4P\9'.)]3_]&GB2+$^ MO7NA!=%6JR;B<>YSW2O)><;^Z+>YHN2A\?K-L*R*V9;-8-6JM/(0=3K[G-4O MIY!3+#T*"^UN.MP.*;Z^LA)>2[JC< P@*S0& MBL^6>@D($L$G^01:V29P>>PWK0<'<:?X5:67J]XZDC/B3+YRLM#LBP*5GWIS MR5.A9ZEA$A\-CL"484VA #V@V4L7Q0O357;=?%)VY9&;]6/7 SA);& M& MYJ=IOV&E*8NS#86&XX^+JI4/3BT5=2]^0T;Y^T2B#7J0,:*M%EW1L/NY*](? MM2&8G8"8E9+Y-!7A"-[ U7C4F.W']E"ZA"5KU+#BI)#.LJ" (%ZO"O^R)?,:>U_L^M?-]W;F'X,Z-+G'UD'.8#W8?I2+NVQOCK>V$FMM3P@)CLX-SJ8' M*'>Q;\\4' -HUL@9WG#6C* YC,^;NI#7>@ZU7[]%C-:2 X1S^."5E6Q40]#R M#AMZ0NUZ&X'S$9Y])@...=B)OC[_];M7OZ&7K1+L MZ;""E"7E7!B^RL*VYEW^U$HFU[?Q[G2)Q*+W.'<:7J2B(QKLC)&M<]Z+W)UYV/;PA,QWQ&NW>JW2."6U2E M7\)X/Q+O&U3HJ8,*'G9]G/KYO4]6Y(M@G-#EFQT1S52_]#5.4D@2YG]H)&GG M@#1=&!!1=/K]$+2:(@EEAIF L5(6VT:#_>]K+61&S:U?$SRQ\E>,QDR6XS8L#KF^CL+9WK1<44SQ M?VH1V%AUX6''>507F,_^L5YS\_6,4R'-U+&>T8"E*L2K3/IO>!I-\1&2=JYT M&,O/VVE?K#M39%H!@'>R[*;TC'I=MP_J*>?:BJ&V-OC9SD"#%A-=II<;34)N M]UR+S],@NJ]9O#:YSFNZ2TT-")FJ5QL@BJ:NXP*PFT2]>:)Y;IQ6[S:L,#]3 M379F+T8P#+A^ -TK?XR7;@,QP!0HJ),-%?@V0M_:C5RM-A\UG6(0QJ/[[4'4 M645MKO/!8JCFM=<,0&Y+-_-,YG'AC;AG=_(.44*QI.8/G)Y ME%\@5A^QDEB)"UCJ,N((AI)5M":%D*5,N:Y_3*<&?-_;Y'X=##C=W0QX<2I8 M/:QE1AX/C .A"WA*FA@;/H]NKE,$^MQ+9UT3A1/TG]>.'YED*+LR*Q;S)6H^ M4"^C-?_]]73H:15RIT])P)0;/:V_>2&(-DZ.'#Y*A.0Q9AD_=X&9Q- M/=IVV=,70)CP']J_^Z(X[![6G.#GM1\@DC"[3-3O0,\,@DA7K4I M:]:T;9L1% &B.:9Z$"9M3WZ75]J^?W-V(!$R=3UB^FT^21\1=0SK>%$=]-O2;1.@H3H4V+)Y2 M2XC9DR,U4-"K=-$EWY%+56-78*;7TNS=TKFJWZR[JT[?J]%#5/[-_?:-<&0^) M4:?%#A"OS'R98FXMM?OU['J#>F'Z@_I8\[E!969*D-;/LRB+MVT+Q-DPL?\;-C>*IJ$1M0G(=8B)M/ MLONI#TFN=23U4H5A^W0?DF-A<@%SB-/08EU"9$M,G\- 4JMY6U GF@L$%&3+) 006A'+W"DQ/>2S^[L8;+38J9J_KEIO6I=* M"MM KB7!A4Q+ACEE3E9CR4 J &-#2 MI$IXDHH&!")0 M*LX48^&GB,[M:>_/8[QNGD!''\"S?JE6S\$TCD/>F/V!#H Z MNRN;C0KK7XMSQT@984!Q, A^@Q<1U=9JSN!>N&(A)F,E=%' ]91Q?K)QY8+6 MF?,WEVB!H*#)8P"P"0#S)Z?L,MMCIX$= F)U49?Q9>D??PB/?Q@[=XHA9>UH M^6T->Y@8.F'%]BG4JZ6.,ZQTHY0$RG&M8^/T9?+U%$AW25F3WXS;^GI=2Y)G"'I.81AU5AY7MSB=*%"W->$ZU&/WJ8R/J>BIMGA M+H=4--6.EJ#KJ]Y=E?(0>O0X[3)]HA!]\2EEP="S98^/6@XYX^8(9U*Q4IR& M$SN=HT*O)]U2BKS..86RE)BT<-.^]NSP=@FY!@!0Q9X'M!##Y]RE,;4AU9OL M:_<.5,UBG!3(/8[47^0EKP^8*3?S=Y]JDB(R'3$21??B\8%='^X*?WP'5-73T%:$TMR,7>2/03+>/ MHI[$,-X ^_EIL$AR45 MIB^MN609C>(2L3/6)=R^.NAB^S?,":/4%M=:4PAYGI^Z>!@^O;KVB?;Z:0#L M(B%LSQIOM*[OC;&-!YTER7GFW<" "<#HJF7IC3(**O?7XRN_)(=5IL])"-*% MM#PYRN4%UBAU?"=1'5T/Z@U2'MY!E;.OV'NCWCD,S6TO)G:LHV6-6!#(+Y>& MT=[G=?V/M,R&2ZK[9#?OCI9*[3*H;EVN_595%^48[?*+W?&%G=85FM]?9+1A M1P0E=&>QU]$M2G_:0#A, PQ!(VGBGJCM5KI(?1B9R^RVKS6-%+^=8IVMDW=5 ME>HZ3VI6K5*SA/39+!901Q:]?L&!)K0FXL!FWT,U,$$_R_=(358MQ(8?;K6K9EV\857W,)4[Y.N ]6"OB-KG-L* MB$ TDA&ZU,X#:4.PK_ PQ,JY4D3K#,YNN)->7K!"=V]=*)#'DDYB<("/$-2&UT@T+Z"/7I:(IFRU.V"6T>GYI5TQ"@. MF[OR^WPN?T)\A.>\.0IWGHW09"+?ZJP%T^'I^ M6)GO5=F78?'GRLU/9DOX3M;9E6LK_HRI#CFNSYR[*T9*$\\Z='>W"IY7V6&C MVH:O!X&P:T$CM 4D\X%C0-[GPV- 5NNW1B!6$7$D0AD%L90$7?S>!,2GML<0 M%?IH.VK].)XLN(]+Q$A$(9BO76E4LO=)^OZ==HT?V&HA'5E6K98AH3NRTU-Z M;P[GNVUAD6?DJPC8=G("?"<"/)Z^I^H#M0MP#\.L"_ M.2T::C)!'W_^\\!C,>KYK"G47B+>N2,KPC^K%1A>-Y-.$.V:40Y>,?,)$JB+ MWZ-3?A^B,-8[E**7&R?[W- K+/:4[K>UV3,[$"Z8TI@FUUI ^8L !#W*9?C' MI.R%G%N/;J@++6^#T<]^,:(E:-_!YOL+R*Q]67D^6Y+V0 MO/3@5U!UOD*6(T!1LPROU@1&FZBOCT, M]DW,&%I+^\010,DG'(/+\T<0Q Y\#/E:H'HH%GH#'F^+&E.'4Y M#+^_AJXMGI(E7.3I];'!G6WS0EQR3,M?Z&F;ISN MF"M)E=/E,G^7?%-"A5KRYJ="T6QCU?-5DUUL5 _=]N!O+K]/-#G2@,IUSE8,M$OQ8K*"%9C".9K4 MJ^L-U*R?;P5$E;%)B)3VQLC'/W[$)N%.&ZYR$''N\!;I--%MYLK)_O(M21W_ M@2":L1=2PL^"PF4Z[Y-PZ?L!2PJ_UG>SF5*. ?JZ%Z;LD.AC&()); M\8H?Y/\47IF!K/N5=64R-IZ)C6KPWLB#FR.%?Q-3RKEOU:5D;AQ#'CT'W\&^DM5F?_;_M\W0^1M"S&J M3U\+_GOWO_ZQQ24-8E.B 6YEC(%%_]G182&&T2IC:L5,?V"I>-FLE^'_\UX) M-]LMIK\LB6WP'^@?L5'Y_V6AG']4-JJ^ZZ3[6WWH[Z='_F. BU*^%.3)BJ6/*77[8].IPPV0]'[ %0'8A[\ MY%L6T\D\G,.6[^.0.WIE:7\-Q(JY-&72H^>QS?(IKS\QW1-P("&3GYI+!!X# M1$YU(0X>9QTR] &\'^7G\=T;_)=K#OH&>B[4P-9[DFGL7\T8JCXKK_MF2CSY M5@XX>3&CT>'!B>$WR_Y:S>7"X;ANY+S9U[%!16L(5_+.CS()JPD5#.* $1I# M:3J9MC>R&1/_)RIN_56CF=:OGXK@>]R@M%=,G"Z',>'[8PJ7.>H"ISMPF-H7 MHY=\C3_0>59/O(]?8F\\+]=N:OJA7J6"ZY6]J^J8HNXWCU-QK4W67XA11T;6 MW4]Q^,VVQU,Z]ZR?W-AZ[W7"V3*3O?;>D_,;M/!R'9G\%2-5?7+&%0UA.$[] M%XE^!2QVGV2_GO=L%K%,RO2,7HVWM?!^("8_?R2_IRR29APN:N':*5%7LS1< M+.AF>\V7JPS<&J0X O-&HT LRR/DG-:MV8%7M0[]#X*734/S? 0GW@3]. 8( M*!P#XL8UA;-LJD?<@7"%\-8Z[UJC'ZH/OXVSE,TMA^EK>M$0=56D<1)MJ!7##MN71^MPG#FDBMK_$2D,]ME^0DU'_X M;OATDZ=VNN[?)7X@H&SQMCAJ=#GUPRG7+RNJPSQ]5:_MSOFP,.(ZZ]V#31WRHSFE[K@V6@ M-U&W-]MM@;3A3M4C< Q+75, K]IR0D>;XNWV=0/7 MK+_T70MF'DE\V'[P_>'\KW5&S& L["?7P5[[KWG6ITH/-@YT0N(]3(73I$L/RH'(/\+7AZ][3=^%9QCP969]_9WIM-_4J95@P/ (J'I1>NC.:AM1;\X!?VQ M9\FI"3O.;Z_ FE7Q$DM,45GL35(D:3PRTMRX$A^W'[5;ZN@ZJ.O /S)U\#3L MB:_JY^<'M(74P(CR5R"7G@CB%

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…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htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Revenue - Disaggregation of Revenue (Details) - USD ($)
    $ in Thousands
    		 12 Months Ended
    Dec. 31, 2019
    Dec. 31, 2018
    Dec. 31, 2017
    Disaggregation of Revenue [Line Items]      
    Total revenues $ 195,992 $ 151,862 $ 316,613
    Royalties      
    Disaggregation of Revenue [Line Items]      
    Total revenues 69,899 78,981 63,507
    Product sales, net      
    Disaggregation of Revenue [Line Items]      
    Total revenues 66,048 28,234 50,396
    Sales of bulk rHuPH20      
    Disaggregation of Revenue [Line Items]      
    Total revenues 48,285 12,729 35,246
    Sales of ENHANZE drug product      
    Disaggregation of Revenue [Line Items]      
    Total revenues 768 460 0
    Sales of Hylenex      
    Disaggregation of Revenue [Line Items]      
    Total revenues 16,995 15,045 15,150
    Revenues under collaborative agreements      
    Disaggregation of Revenue [Line Items]      
    Total revenues 60,045 44,647 202,710
    Upfront license and target nomination fees      
    Disaggregation of Revenue [Line Items]      
    Total revenues 53,000 26,336 172,806
    Event-based development milestones and regulatory milestone and other fees      
    Disaggregation of Revenue [Line Items]      
    Total revenues 5,500 16,000 16,317
    Sales-based milestones      
    Disaggregation of Revenue [Line Items]      
    Total revenues 0 0 1,417
    Research and development services      
    Disaggregation of Revenue [Line Items]      
    Total revenues $ 1,545 $ 2,311 $ 12,170
    XML 31 R44.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Fair Value Measurement - Summary (Details) - USD ($)
    $ in Thousands
    Dec. 31, 2019
    Dec. 31, 2018
    Schedule of Available-for-sale Securities    
    Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value $ 82,900  
    Amortized cost 300,829 $ 296,844
    Gross Unrealized Gains 273 0
    Gross Unrealized Losses (19) (254)
    Estimated fair value 301,083 296,590
    Asset-backed Securities [Member]    
    Schedule of Available-for-sale Securities    
    Debt Securities, Available-for-sale, Amortized Cost 30,484 39,787
    Gross Unrealized Gains 55 0
    Gross Unrealized Losses 0 (40)
    Debt Securities, Available-for-sale 30,539 39,747
    Corporate Debt Securities [Member]    
    Schedule of Available-for-sale Securities    
    Debt Securities, Available-for-sale, Amortized Cost 161,308 57,860
    Gross Unrealized Gains 178 0
    Gross Unrealized Losses (14) (127)
    Estimated fair value 161,472 57,733
    US Treasury Securities [Member]    
    Schedule of Available-for-sale Securities    
    Debt Securities, Available-for-sale, Amortized Cost 75,192 84,924
    Gross Unrealized Gains 40 0
    Gross Unrealized Losses (5) (87)
    Estimated fair value 75,227 84,837
    Commercial Paper [Member]    
    Schedule of Available-for-sale Securities    
    Debt Securities, Available-for-sale, Amortized Cost   114,273
    Amortized cost 33,845  
    Gross Unrealized Gains 0 0
    Gross Unrealized Losses 0 0
    Estimated fair value $ 33,845 $ 114,273
    XML 32 R40.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Summary of Significant Accounting Policies Research and development (Details)
    $ in Thousands
    		 12 Months Ended
    Dec. 31, 2019
    USD ($)
    In-license technologies [Member]  
    Research and Development Arrangement, Contract to Perform for Others [Line Items]  
    Research and Development, in-line technologies $ 0
    XML 33 R63.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Share-based Compensation Expense (Details) - USD ($)
    $ in Thousands
    		 12 Months Ended
    Dec. 31, 2019
    Dec. 31, 2018
    Dec. 31, 2017
    Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]      
    Share-based Payment Arrangement, Expense $ 34,776 $ 35,696 $ 30,670
    Stock options      
    Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]      
    Share-based Payment Arrangement, Expense 17,624 18,742 19,583
    RSU, RSA, and PRSU awards [Member]      
    Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]      
    Share-based Payment Arrangement, Expense 17,152 16,954 11,087
    Research and Development Expense [Member]      
    Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]      
    Share-based Payment Arrangement, Expense 15,107 17,220 13,080
    Selling, General and Administrative Expenses [Member]      
    Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]      
    Share-based Payment Arrangement, Expense $ 19,669 $ 18,476 $ 17,590
    XML 34 R67.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Share-based Compensation Restricted Stock Awards (Details) - USD ($)
    $ / shares in Units, $ in Millions
    		 12 Months Ended
    Dec. 31, 2019
    Dec. 31, 2018
    Dec. 31, 2017
    Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]      
    Restricted stock award holder exercise price $ 0    
    Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period 1 year    
    RSAs      
    Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]      
    Nonvested, Number, period start 397,389    
    Nonvested, Weighted Average Grant Date Fair Value, period start $ 11.03    
    Grants in Period 85,211    
    Grants in Period, Weighted Average Grant Date Fair Value $ 16.43    
    Vested in Period (260,086)    
    Vested in Period, Weighted Average Grant Date Fair Value $ 12.57    
    Forfeited in Period (11,391)    
    Forfeitures, Weighted Average Grant Date Fair Value $ 8.11    
    Nonvested, Number, period end 211,123 397,389  
    Nonvested, Weighted Average Grant Date Fair Value, period end $ 11.47 $ 11.03  
    Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]      
    Vested in Period, Fair Value $ 3.3 $ 4.5 $ 5.3
    Aggregate Intrinsic Value, Vested $ 4.2 $ 7.2 $ 6.6
    XML 35 R21.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Schedule II Valuation and Qualifying Accounts
    		 12 Months Ended
    Dec. 31, 2019
    SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]  
    Schedule II Valuation and Qualifying Accounts
    Valuation and Qualifying Accounts
    (in thousands)
     
     
    Balance at Beginning of Period
     
    Additions
     
    Deductions
     
    Balance at End of Period
    For the year ended December 31, 2019
     
     
     
     
     
     
     
     
    Accounts receivable allowances (1)
     
    $
    592

     
    $
    7,327

     
    $
    (7,122
    )
     
    $
    797

    For the year ended December 31, 2018
     
     
     
     
     
     
     
     
    Accounts receivable allowances (1)
     
    $
    559

     
    $
    5,988

     
    $
    (5,955
    )
     
    $
    592

    For the year ended December 31, 2017
     
     
     
     
     
     
     
     
    Accounts receivable allowances (1)
     
    $
    559

     
    $
    4,645

     
    $
    (4,645
    )
     
    $
    559

    _______________
    (1)
    Allowances are for chargebacks, prompt payment discounts and distribution fees related to Hylenex recombinant product sales.
    XML 36 R3.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Consolidated Balance Sheets (Parenthetical) - $ / shares
    Dec. 31, 2019
    Dec. 31, 2018
    Preferred stock, par value $ 0.001  
    Preferred stock, shares authorized 20,000,000 20,000,000
    Preferred stock, shares issued 0  
    Preferred stock, shares outstanding 0  
    Common stock, par value $ 0.001  
    Common stock, shares authorized 300,000,000 200,000,000
    Common stock, shares issued 136,712,480  
    Common stock, shares outstanding 136,712,480 144,725,164
    Common Stock    
    Shares, Outstanding 136,713,000 144,725,164
    XML 37 R7.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Consolidated Statements of Stockholders' Equity (Deficit) Statement - USD ($)
    $ in Thousands
    Total
    Common Stock
    Additional Paid-in Capital [Member]
    AOCI Attributable to Parent [Member]
    Retained Earnings [Member]
    Shares outstanding at Dec. 31, 2016   129,502,000      
    Total stockholders' equity (deficit) at Dec. 31, 2016 $ (32,481) $ 130 $ 552,737 $ (6) $ (585,342)
    Share-based Compensation 30,670   30,670    
    Shares, New Issues   11,500,000      
    Stock Issued During Period, Value, New Issues 134,874 $ 11 134,863    
    Issuance of common stock pursuant to exercise of stock options and vesting of restricted stock units and performance restricted stock units, net   1,796,000      
    Value, Stock Options Exercised 12,776 $ 2 12,774    
    Shares, Restricted Stock Award   (9,000)      
    Value, Restricted Stock Award 0 $ 0 0    
    Other Comprehensive Income (Loss) (444)     (444)  
    Net income (loss) 62,971        
    Shares outstanding at Dec. 31, 2017   142,789,000      
    Total stockholders' equity (deficit) at Dec. 31, 2017 208,366 $ 143 731,044 (450) (522,371)
    Share-based Compensation 35,696   35,696    
    Issuance of common stock pursuant to exercise of stock options and vesting of restricted stock units and performance restricted stock units, net   1,932,000      
    Value, Stock Options Exercised 13,719 $ 2 13,717    
    Shares, Restricted Stock Award   4,000      
    Value, Restricted Stock Award 0 $ 0 0    
    Other Comprehensive Income (Loss) 173     173  
    Net income (loss) (80,330)       (80,330)
    Shares outstanding at Dec. 31, 2018   144,725,164      
    Total stockholders' equity (deficit) at Dec. 31, 2018 248,887 $ 145 780,457 (277) (531,438)
    Share-based Compensation $ 34,776   34,776    
    Shares, New Issues 11,500,000        
    Issuance of common stock pursuant to exercise of stock options and vesting of restricted stock units and performance restricted stock units, net   2,493,000      
    Value, Stock Options Exercised $ 14,224 $ 2 14,222    
    Shares, Restricted Stock Award   74,000      
    Value, Restricted Stock Award $ 0 $ 0 0    
    Stock Repurchased and Retired During Period, Shares (10,579,000)        
    Stock Repurchased and Retired During Period, Value $ (199,998) $ (10) (199,988)    
    Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt 65,599        
    Other Comprehensive Income (Loss) 517     517  
    Net income (loss) (72,240)       (72,240)
    Shares outstanding at Dec. 31, 2019   136,713,000      
    Total stockholders' equity (deficit) at Dec. 31, 2019 $ 91,765 $ 137 $ 695,066 $ 240 $ (603,678)
    XML 38 R25.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Revenue (Tables)
    		 12 Months Ended
    Dec. 31, 2019
    Revenue from Contract with Customer [Abstract]  
    Disaggregation of Revenue
    Our disaggregated revenues were as follows (in thousands):
     
     
    Year Ended December 31,
     
     
    2019
     
    2018
     
    2017
    Royalties
     
    $
    69,899

     
    $
    78,981

     
    $
    63,507

     
     
     
     
     
     
     
    Product sales, net
     
     
     
     
     
     
      Sales of bulk rHuPH20
     
    $
    48,285

     
    $
    12,729

     
    $
    35,246

      Sales of ENHANZE drug product
     
    768

     
    460

     
    —

      Sales of Hylenex
     
    16,995

     
    15,045

     
    15,150

    Total product sales, net
     
    66,048

     
    28,234

     
    50,396

     
     
     
     
     
     
     
    Revenues under collaborative agreements:
     
     
     
     
     
     
      Upfront license and target nomination fees
     
    53,000

     
    26,336

     
    172,806

      Event-based development milestones and regulatory milestone and other fees
     
    5,500

     
    16,000

     
    16,317

      Sales-based milestones
     
    —

     
    —

     
    1,417

      Research and development services
     
    1,545

     
    2,311

     
    12,170

    Total revenues under collaborative agreements
     
    60,045

     
    44,647

     
    202,710

     
     
     
     
     
     
     
    Total revenue
     
    $
    195,992

     
    $
    151,862

     
    $
    316,613
    Contract with Customer, Asset and Liability
    Accounts receivable, net and deferred revenues (contract liabilities) from contracts with customers, including collaboration partners, consisted of the following (in thousands):
     
     
    December 31, 2019
     
    December 31, 2018
    Accounts receivable, net
     
    $
    59,442

     
    $
    30,005

    Deferred revenues
     
    5,259

     
    9,255
    Revenue Recognition, Multiple-deliverable Arrangements
    There were no contract assets related to collaborative agreements at December 31, 2019. While we may become entitled to receive additional event-based development and regulatory milestones and other fees under our collaborative agreements, which relate to intellectual property licenses granted to collaboration partners in prior periods, no amounts were probable. The following table presents amounts under our collaborative agreements included in the transaction price (i.e. cumulative amounts triggered or probable) as of December 31, 2019 (in thousands):
     
     
    Upfront
    (1)
     
    Development
    (2)
     
    Sales
    (3)
     
     
    Total
    Collaboration partner and agreement date:
     
     
     
     
     
     
     
     
     
    Roche (December 2006, September 2017 and October 2018)
     
    $
    105,000

     
    $
    30,000

     
    $
    22,000

     
     
    $
    157,000

    Baxalta (September 2007)
     
    10,000

     
    3,000

     
    9,000

     
     
    22,000

    Pfizer (December 2012)
     
    14,500

     
    2,000

     
    —

     
     
    16,500

    Janssen (December 2014)
     
    18,250

     
    15,000

     
    —

     
     
    33,250

    AbbVie (June 2015)
     
    23,000

     
    6,000

     
    —

     
     
    29,000

    Lilly (December 2015)
     
    33,000

     
    —

     
    —

     
     
    33,000

    BMS (September 2017)
     
    105,000

     
    5,000

     
    —

     
     
    110,000

    Alexion (December 2017)
     
    40,000

     
    6,000

     
    —

     
     
    46,000

    argenx (February 2019)
     
    40,000

     
    5,000

     
     
     
     
    45,000

    Royalties
     
     
     
     
     
     
     
     
    323,285

    Total amounts under our collaborative agreements included in the transaction price
     
     
     
     
     
     
     
     
    815,035


    (1)
    Upfront and additional target selection fees
    (2)
    Event-based development and regulatory milestone amounts and other fees
    (3)
    Sales-based milestone amounts
    JSON 39 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "halo2019-10k.htm": { "axisCustom": 1, "axisStandard": 34, "contextCount": 301, "dts": { "calculationLink": { "local": [ "halo-20191231_cal.xml" ] }, "definitionLink": { "local": [ "halo-20191231_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml", "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml" ] }, "inline": { "local": [ "halo2019-10k.htm" ] }, "labelLink": { "local": [ "halo-20191231_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml", "http://xbrl.fasb.org/srt/2019/elts/srt-doc-2019-01-31.xml", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "halo-20191231_pre.xml" ] }, "referenceLink": { "remote": [ "http://xbrl.fasb.org/srt/2019/elts/srt-ref-2019-01-31.xml", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-ref-2019-01-31.xml", "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "halo-20191231.xsd" ], "remote": [ "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd", "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd", "http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd", "http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-parts-codification-2019-01-31.xsd" ] } }, "elementCount": 725, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2019-01-31": 45, "http://www.halozyme.com/20191231": 1, "http://xbrl.sec.gov/dei/2019-01-31": 5, "total": 51 }, "keyCustom": 40, "keyStandard": 474, "memberCustom": 53, "memberStandard": 47, "nsprefix": "halo", "nsuri": "http://www.halozyme.com/20191231", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001000 - Document - Cover", "role": "http://www.halozyme.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2103100 - Disclosure - Fair Value Measurement (Notes)", "role": "http://www.halozyme.com/role/FairValueMeasurementNotes", "shortName": "Fair Value Measurement (Notes)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2104100 - Disclosure - Revenue", "role": "http://www.halozyme.com/role/Revenue", "shortName": "Revenue", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2105100 - Disclosure - Certain Balance Sheet Items", "role": "http://www.halozyme.com/role/CertainBalanceSheetItems", "shortName": "Certain Balance Sheet Items", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2106100 - Disclosure - Long-Term Debt, Net", "role": "http://www.halozyme.com/role/LongTermDebtNet", "shortName": "Long-Term Debt, Net", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2107100 - Disclosure - Share-based Compensation (Notes)", "role": "http://www.halozyme.com/role/ShareBasedCompensationNotes", "shortName": "Share-based Compensation (Notes)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2108100 - Disclosure - Stockholders' Equity (Deficit)", "role": "http://www.halozyme.com/role/StockholdersEquityDeficit", "shortName": "Stockholders' Equity (Deficit)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2109100 - Disclosure - Commitments and Contingencies", "role": "http://www.halozyme.com/role/CommitmentsAndContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2110100 - Disclosure - Income Taxes (Notes)", "role": "http://www.halozyme.com/role/IncomeTaxesNotes", "shortName": "Income Taxes (Notes)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2111100 - Disclosure - Employee Savings Plan (Notes)", "role": "http://www.halozyme.com/role/EmployeeSavingsPlanNotes", "shortName": "Employee Savings Plan (Notes)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:QuarterlyFinancialInformationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2112100 - Disclosure - Summary of Unaudited Quarterly Financial Information", "role": "http://www.halozyme.com/role/SummaryOfUnauditedQuarterlyFinancialInformation", "shortName": "Summary of Unaudited Quarterly Financial Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:QuarterlyFinancialInformationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001000 - Statement - Consolidated Balance Sheets", "role": "http://www.halozyme.com/role/ConsolidatedBalanceSheets", "shortName": "Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2113100 - Disclosure - Restructuring Charges", "role": "http://www.halozyme.com/role/RestructuringCharges", "shortName": "Restructuring Charges", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "", "isDefault": "false", "longName": "2114100 - Schedule - Schedule II Valuation and Qualifying Accounts", "role": "http://www.halozyme.com/role/ScheduleIiValuationAndQualifyingAccounts", "shortName": "Schedule II Valuation and Qualifying Accounts", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2202201 - Disclosure - Summary of Significant Accounting Policies (Policies)", "role": "http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "us-gaap:ConcentrationRiskCreditRisk", "ix:continuation", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2302302 - Disclosure - Summary of Significant Accounting Policies (Tables)", "role": "http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesTables", "shortName": "Summary of Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:ConcentrationRiskCreditRisk", "ix:continuation", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleSecuritiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2303301 - Disclosure - Fair Value Measurement (Tables)", "role": "http://www.halozyme.com/role/FairValueMeasurementTables", "shortName": "Fair Value Measurement (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleSecuritiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2304301 - Disclosure - Revenue (Tables)", "role": "http://www.halozyme.com/role/RevenueTables", "shortName": "Revenue (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2305301 - Disclosure - Certain Balance Sheet Items (Tables)", "role": "http://www.halozyme.com/role/CertainBalanceSheetItemsTables", "shortName": "Certain Balance Sheet Items (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2306301 - Disclosure - Long-Term Debt, Net Debt Disclosure (Tables)", "role": "http://www.halozyme.com/role/LongTermDebtNetDebtDisclosureTables", "shortName": "Long-Term Debt, Net Debt Disclosure (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2307301 - Disclosure - Share-based Compensation (Tables)", "role": "http://www.halozyme.com/role/ShareBasedCompensationTables", "shortName": "Share-based Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2309301 - Disclosure - Commitments and Contingencies Commitments and Contingencies (Tables)", "role": "http://www.halozyme.com/role/CommitmentsAndContingenciesCommitmentsAndContingenciesTables", "shortName": "Commitments and Contingencies Commitments and Contingencies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001501 - Statement - Consolidated Balance Sheets (Parenthetical)", "role": "http://www.halozyme.com/role/ConsolidatedBalanceSheetsParenthetical", "shortName": "Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R30": { "firstAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2310301 - Disclosure - Income Taxes (Tables)", "role": "http://www.halozyme.com/role/IncomeTaxesTables", "shortName": "Income Taxes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2312301 - Disclosure - Summary of Unaudited Quarterly Financial Information (Tables)", "role": "http://www.halozyme.com/role/SummaryOfUnauditedQuarterlyFinancialInformationTables", "shortName": "Summary of Unaudited Quarterly Financial Information (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RestrictedCashAndCashEquivalentsNoncurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402403 - Disclosure - Summary of Significant Accounting Policies Restricted Cash (Details)", "role": "http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesRestrictedCashDetails", "shortName": "Summary of Significant Accounting Policies Restricted Cash (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R33": { "firstAnchor": { "ancestors": [ "span", "span", "div", "us-gaap:TradeAndOtherAccountsReceivablePolicy", "ix:continuation", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402404 - Disclosure - Summary of Significant Accounting Policies Concentrations of Credit Risk (Details)", "role": "http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesConcentrationsOfCreditRiskDetails", "shortName": "Summary of Significant Accounting Policies Concentrations of Credit Risk (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FD2019Q4YTD_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_GeographicConcentrationRiskMember", "decimals": "-3", "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "span", "div", "us-gaap:TradeAndOtherAccountsReceivablePolicy", "ix:continuation", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402405 - Disclosure - Summary of Significant Accounting Policies Accounts Receivable (Details)", "role": "http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesAccountsReceivableDetails", "shortName": "Summary of Significant Accounting Policies Accounts Receivable (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R35": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InventoryNet", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402406 - Disclosure - Summary of Significant Accounting Policies Inventories (Details)", "role": "http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesInventoriesDetails", "shortName": "Summary of Significant Accounting Policies Inventories (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "ix:continuation", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FI2019Q4_us-gaap_PublicUtilitiesInventoryAxis_halo_HylenexRecombinantMember", "decimals": "-5", "lang": null, "name": "us-gaap:InventoryNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FI2019Q4_srt_RangeAxis_srt_MinimumMember", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseTermOfContract", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402407 - Disclosure - Summary of Significant Accounting Policies Leases (Details)", "role": "http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesLeasesDetails", "shortName": "Summary of Significant Accounting Policies Leases (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FI2019Q4_srt_RangeAxis_srt_MinimumMember", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseTermOfContract", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "span", "div", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402408 - Disclosure - Summary of Significant Accounting Policies Property and Equipment (Details)", "role": "http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails", "shortName": "Summary of Significant Accounting Policies Property and Equipment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R38": { "firstAnchor": null, "groupType": "disclosure", "isDefault": "false", "longName": "2402409 - Disclosure - Summary of Significant Accounting Policies Impairment of Long-Lived Assets (Details)", "role": "http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesImpairmentOfLongLivedAssetsDetails", "shortName": "Summary of Significant Accounting Policies Impairment of Long-Lived Assets (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R39": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CostOfGoodsAndServicesSold", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402410 - Disclosure - Summary of Significant Accounting Policies Revenue recognition (Details)", "role": "http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails", "shortName": "Summary of Significant Accounting Policies Revenue recognition (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "us-gaap:CostOfSalesPolicyTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FD2019Q4YTD_srt_ProductOrServiceAxis_halo_BulkrHuPH20AndENHANZEMember", "decimals": "-5", "lang": null, "name": "us-gaap:CostOfGoodsAndServicesSold", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002000 - Statement - Consolidated Statements of Operations", "role": "http://www.halozyme.com/role/ConsolidatedStatementsOfOperations", "shortName": "Consolidated Statements of Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "span", "div", "us-gaap:ResearchAndDevelopmentExpensePolicy", "ix:continuation", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FD2019Q4YTD_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_halo_InlicensetechnologiesMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpenseSoftwareExcludingAcquiredInProcessCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402411 - Disclosure - Summary of Significant Accounting Policies Research and development (Details)", "role": "http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesResearchAndDevelopmentDetails", "shortName": "Summary of Significant Accounting Policies Research and development (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "us-gaap:ResearchAndDevelopmentExpensePolicy", "ix:continuation", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FD2019Q4YTD_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_halo_InlicensetechnologiesMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpenseSoftwareExcludingAcquiredInProcessCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "span", "div", "us-gaap:IncomeTaxPolicyTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FI2019Q4", "decimals": "0", "first": true, "lang": null, "name": "halo:DeferredtaxassetexcludingamountforAMT", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402412 - Disclosure - Summary of Significant Accounting Policies Income tax (Details)", "role": "http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesIncomeTaxDetails", "shortName": "Summary of Significant Accounting Policies Income tax (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "us-gaap:IncomeTaxPolicyTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FI2019Q4", "decimals": "0", "first": true, "lang": null, "name": "halo:DeferredtaxassetexcludingamountforAMT", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FD2019Q4QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402413 - Disclosure - Summary of Significant Accounting Policies Net Loss Per Share (Details)", "role": "http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesNetLossPerShareDetails", "shortName": "Summary of Significant Accounting Policies Net Loss Per Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "lang": null, "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "span", "ix:continuation", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FD2019Q4YTD", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402414 - Disclosure - Summary of Significant Accounting Policies Segment information (Details)", "role": "http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesSegmentInformationDetails", "shortName": "Summary of Significant Accounting Policies Segment information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "ix:continuation", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FD2019Q4YTD", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FI2019Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403402 - Disclosure - Fair Value Measurement - Summary (Details)", "role": "http://www.halozyme.com/role/FairValueMeasurementSummaryDetails", "shortName": "Fair Value Measurement - Summary (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:AvailableForSaleSecuritiesTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FI2019Q4", "decimals": "-3", "lang": null, "name": "us-gaap:AvailableForSaleSecuritiesAmortizedCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FI2019Q4", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1", "reportCount": 1, "unique": true, "unitRef": "security", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403403 - Disclosure - Fair Value Measurement Textuals (Details)", "role": "http://www.halozyme.com/role/FairValueMeasurementTextualsDetails", "shortName": "Fair Value Measurement Textuals (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FI2019Q4", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1", "reportCount": 1, "unique": true, "unitRef": "security", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403404 - Disclosure - Fair Value Measurement Maturities (Details)", "role": "http://www.halozyme.com/role/FairValueMeasurementMaturitiesDetails", "shortName": "Fair Value Measurement Maturities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:AvailableForSaleSecuritiesTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleSecurities", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403405 - Disclosure - Fair Value Measurement Fair Value Measures (Details)", "role": "http://www.halozyme.com/role/FairValueMeasurementFairValueMeasuresDetails", "shortName": "Fair Value Measurement Fair Value Measures (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FI2019Q4", "decimals": "-3", "lang": null, "name": "us-gaap:AssetsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2404402 - Disclosure - Revenue - Disaggregation of Revenue (Details)", "role": "http://www.halozyme.com/role/RevenueDisaggregationOfRevenueDetails", "shortName": "Revenue - Disaggregation of Revenue (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FD2019Q4YTD_srt_ProductOrServiceAxis_halo_BulkrHuPH20Member", "decimals": "-3", "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FD2019Q4YTD", "decimals": "-5", "first": true, "lang": null, "name": "halo:ProceedsFromPartnerOfLicenseAndCollaborativeAgreement", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2404403 - Disclosure - Revenue - Textuals (Details)", "role": "http://www.halozyme.com/role/RevenueTextualsDetails", "shortName": "Revenue - Textuals (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FD2019Q4YTD", "decimals": "-5", "first": true, "lang": null, "name": "halo:ProceedsFromPartnerOfLicenseAndCollaborativeAgreement", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004000 - Statement - Consolidated Statements of Comprehensive Loss", "role": "http://www.halozyme.com/role/ConsolidatedStatementsOfComprehensiveLoss", "shortName": "Consolidated Statements of Comprehensive Loss", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "lang": null, "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FI2019Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DeferredCreditsAndOtherLiabilities", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2404404 - Disclosure - Revenue - Contract with Customer, Asset and Liability (Details)", "role": "http://www.halozyme.com/role/RevenueContractWithCustomerAssetAndLiabilityDetails", "shortName": "Revenue - Contract with Customer, Asset and Liability (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R51": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2404405 - Disclosure - Revenue - Revenue Recognition, Multiple-deliverable Arrangements (Details)", "role": "http://www.halozyme.com/role/RevenueRevenueRecognitionMultipleDeliverableArrangementsDetails", "shortName": "Revenue - Revenue Recognition, Multiple-deliverable Arrangements (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:RevenueRecognitionMultipleDeliverableArrangementsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FI2019Q4", "decimals": "-3", "lang": null, "name": "us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredRevenue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2404406 - Disclosure - Revenue - Revenue, Remaining Performance Obligation (Details)", "role": "http://www.halozyme.com/role/RevenueRevenueRemainingPerformanceObligationDetails", "shortName": "Revenue - Revenue, Remaining Performance Obligation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FI2019Q4_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain_2019-07-01", "decimals": "-5", "lang": null, "name": "us-gaap:RevenueRemainingPerformanceObligation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "halo:Accountsreceivablefromproductsalestocollaborators", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2405402 - Disclosure - Certain Balance Sheet Items - Accounts receivable (Details)", "role": "http://www.halozyme.com/role/CertainBalanceSheetItemsAccountsReceivableDetails", "shortName": "Certain Balance Sheet Items - Accounts receivable (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "halo:Accountsreceivablefromproductsalestocollaborators", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2405403 - Disclosure - Certain Balance Sheet Items - Inventories (Details)", "role": "http://www.halozyme.com/role/CertainBalanceSheetItemsInventoriesDetails", "shortName": "Certain Balance Sheet Items - Inventories (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfOtherAssetsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PrepaidExpenseCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2405404 - Disclosure - Certain Balance Sheet Items - Prepaid expenses and other assets (Details)", "role": "http://www.halozyme.com/role/CertainBalanceSheetItemsPrepaidExpensesAndOtherAssetsDetails", "shortName": "Certain Balance Sheet Items - Prepaid expenses and other assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfOtherAssetsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PrepaidExpenseCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2405405 - Disclosure - Certain Balance Sheet Items - Property and Equipment (Details)", "role": "http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyAndEquipmentDetails", "shortName": "Certain Balance Sheet Items - Property and Equipment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseImpairmentLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2405406 - Disclosure - Certain Balance Sheet Items - Property and Equipment, Net (Textuals) (Details)", "role": "http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyAndEquipmentNetTextualsDetails", "shortName": "Certain Balance Sheet Items - Property and Equipment, Net (Textuals) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FD2019Q4YTD", "decimals": "-5", "lang": null, "name": "us-gaap:FinanceLeaseRightOfUseAssetAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FD2019Q4YTD", "decimals": "-5", "first": true, "lang": null, "name": "halo:OperatingLeaseAccretionOfLiability", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2405407 - Disclosure - Certain Balance Sheet Items - Accrued Expenses (Details)", "role": "http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails", "shortName": "Certain Balance Sheet Items - Accrued Expenses (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FD2019Q4YTD", "decimals": "-5", "first": true, "lang": null, "name": "halo:OperatingLeaseAccretionOfLiability", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredRevenue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2405408 - Disclosure - Certain Balance Sheet Items - Deferred Revenue (Details)", "role": "http://www.halozyme.com/role/CertainBalanceSheetItemsDeferredRevenueDetails", "shortName": "Certain Balance Sheet Items - Deferred Revenue (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "us-gaap:DeferredRevenueByArrangementDisclosureTextBlock", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FI2019Q4", "decimals": "-3", "lang": null, "name": "us-gaap:ContractWithCustomerLiabilityCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005000 - Statement - Consolidated Statements of Cash Flows", "role": "http://www.halozyme.com/role/ConsolidatedStatementsOfCashFlows", "shortName": "Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "lang": null, "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LongTermDebtFairValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406402 - Disclosure - Long-Term Debt, Net Long-Term Debt Textuals (Details)", "role": "http://www.halozyme.com/role/LongTermDebtNetLongTermDebtTextualsDetails", "shortName": "Long-Term Debt, Net Long-Term Debt Textuals (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "D2019Q4Nov01-Nov30", "decimals": "4", "lang": null, "name": "halo:NonConvertibleBorrowingRateforSimilarDebtPercent", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406403 - Disclosure - Long-Term Debt, Net Debt Table (Details)", "role": "http://www.halozyme.com/role/LongTermDebtNetDebtTableDetails", "shortName": "Long-Term Debt, Net Debt Table (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FI2019Q4", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407402 - Disclosure - Share-based Compensation Textuals (Details)", "role": "http://www.halozyme.com/role/ShareBasedCompensationTextualsDetails", "shortName": "Share-based Compensation Textuals (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FI2019Q4", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407403 - Disclosure - Share-based Compensation Expense (Details)", "role": "http://www.halozyme.com/role/ShareBasedCompensationExpenseDetails", "shortName": "Share-based Compensation Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407404 - Disclosure - Share-based Compensation Unrecognized Expense (Details)", "role": "http://www.halozyme.com/role/ShareBasedCompensationUnrecognizedExpenseDetails", "shortName": "Share-based Compensation Unrecognized Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FI2018Q4", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407405 - Disclosure - Share-based Compensation Options (Details)", "role": "http://www.halozyme.com/role/ShareBasedCompensationOptionsDetails", "shortName": "Share-based Compensation Options (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FD2019Q4YTD", "decimals": "0", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407406 - Disclosure - Share-based Compensation Valuation (Details)", "role": "http://www.halozyme.com/role/ShareBasedCompensationValuationDetails", "shortName": "Share-based Compensation Valuation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FD2019Q4YTD", "decimals": "0", "first": true, "lang": null, "name": "halo:Restrictedstockawardholderexerciseprice", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407407 - Disclosure - Share-based Compensation Restricted Stock Awards (Details)", "role": "http://www.halozyme.com/role/ShareBasedCompensationRestrictedStockAwardsDetails", "shortName": "Share-based Compensation Restricted Stock Awards (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FD2019Q4YTD", "decimals": "0", "first": true, "lang": null, "name": "halo:Restrictedstockawardholderexerciseprice", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407408 - Disclosure - Share-based Compensation Restricted Stock Units (Details)", "role": "http://www.halozyme.com/role/ShareBasedCompensationRestrictedStockUnitsDetails", "shortName": "Share-based Compensation Restricted Stock Units (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember", "decimals": "0", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FD2019Q4YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408401 - Disclosure - Stockholders' Equity (Deficit) Public Offering (Details)", "role": "http://www.halozyme.com/role/StockholdersEquityDeficitPublicOfferingDetails", "shortName": "Stockholders' Equity (Deficit) Public Offering (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FD2019Q4YTD", "decimals": "-5", "lang": null, "name": "halo:StockIssuedDuringPeriodSharesNewIssuesToUnderwriter", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1006000 - Statement - Consolidated Statements of Stockholders' Equity (Deficit) Statement", "role": "http://www.halozyme.com/role/ConsolidatedStatementsOfStockholdersEquityDeficitStatement", "shortName": "Consolidated Statements of Stockholders' Equity (Deficit) Statement", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R70": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FD2019Q4YTD", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408402 - Disclosure - Stockholders' Equity (Deficit) (Details)", "role": "http://www.halozyme.com/role/StockholdersEquityDeficitDetails", "shortName": "Stockholders' Equity (Deficit) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember", "decimals": "INF", "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R71": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "I2019Q4Nov30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408403 - Disclosure - Stockholders' Equity (Deficit) Share Repurchases (Details)", "role": "http://www.halozyme.com/role/StockholdersEquityDeficitShareRepurchasesDetails", "shortName": "Stockholders' Equity (Deficit) Share Repurchases (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "I2019Q4Nov30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R72": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FI2019Q4", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409402 - Disclosure - Commitments and Contingencies Operating Lease textual (Details)", "role": "http://www.halozyme.com/role/CommitmentsAndContingenciesOperatingLeaseTextualDetails", "shortName": "Commitments and Contingencies Operating Lease textual (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FI2019Q4", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R73": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseImpairmentLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409403 - Disclosure - Commitments and Contingencies Commitments and Contingencies (Details)", "role": "http://www.halozyme.com/role/CommitmentsAndContingenciesCommitmentsAndContingenciesDetails", "shortName": "Commitments and Contingencies Commitments and Contingencies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FI2019Q4", "decimals": "-3", "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R74": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FI2019Q4_us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_halo_AvidCommercialSupplyAgreementMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:PurchaseObligation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409404 - Disclosure - Commitments and Contingencies Other Commitments (Details)", "role": "http://www.halozyme.com/role/CommitmentsAndContingenciesOtherCommitmentsDetails", "shortName": "Commitments and Contingencies Other Commitments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FI2019Q4_us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_halo_AvidCommercialSupplyAgreementMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:PurchaseObligation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R75": { "firstAnchor": { "ancestors": [ "span", "span", "div", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FD2019Q4YTD", "decimals": "INF", "first": true, "lang": null, "name": "halo:A2017Federaltaxrate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2410402 - Disclosure - Income Taxes (Details)", "role": "http://www.halozyme.com/role/IncomeTaxesDetails", "shortName": "Income Taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FD2019Q4YTD", "decimals": "INF", "first": true, "lang": null, "name": "halo:A2017Federaltaxrate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R76": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2410403 - Disclosure - Income Taxes Net Income (Loss) By Region (Details)", "role": "http://www.halozyme.com/role/IncomeTaxesNetIncomeLossByRegionDetails", "shortName": "Income Taxes Net Income (Loss) By Region (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R77": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2410404 - Disclosure - Income Taxes Components Deferred Taxes (Details)", "role": "http://www.halozyme.com/role/IncomeTaxesComponentsDeferredTaxesDetails", "shortName": "Income Taxes Components Deferred Taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R78": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2410405 - Disclosure - Income Taxes Income Tax Expense (Details)", "role": "http://www.halozyme.com/role/IncomeTaxesIncomeTaxExpenseDetails", "shortName": "Income Taxes Income Tax Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R79": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2410406 - Disclosure - Income Taxes Schedule of Income Tax Reconciliation (Details)", "role": "http://www.halozyme.com/role/IncomeTaxesScheduleOfIncomeTaxReconciliationDetails", "shortName": "Income Taxes Schedule of Income Tax Reconciliation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2101100 - Disclosure - Organization and Business", "role": "http://www.halozyme.com/role/OrganizationAndBusiness", "shortName": "Organization and Business", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R80": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FI2019Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2410407 - Disclosure - Income Taxes Unrecognized Tax Benefit (Details)", "role": "http://www.halozyme.com/role/IncomeTaxesUnrecognizedTaxBenefitDetails", "shortName": "Income Taxes Unrecognized Tax Benefit (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "lang": null, "name": "us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R81": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FI2019Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_InternalRevenueServiceIRSMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLossCarryforwards", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2410408 - Disclosure - Income Taxes Operating Loss Carryforward Expiration (Details)", "role": "http://www.halozyme.com/role/IncomeTaxesOperatingLossCarryforwardExpirationDetails", "shortName": "Income Taxes Operating Loss Carryforward Expiration (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FI2019Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_InternalRevenueServiceIRSMember_us-gaap_TaxPeriodAxis_halo_A2018expirationMember", "decimals": "-3", "lang": null, "name": "us-gaap:OperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R82": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsValuationAllowance", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2410409 - Disclosure - Income Taxes Tax textuals (Details)", "role": "http://www.halozyme.com/role/IncomeTaxesTaxTextualsDetails", "shortName": "Income Taxes Tax textuals (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FI2019Q4", "decimals": "-5", "lang": null, "name": "us-gaap:UndistributedEarningsOfForeignSubsidiaries", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R83": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FD2019Q4YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2411402 - Disclosure - Employee Savings Plan (Details)", "role": "http://www.halozyme.com/role/EmployeeSavingsPlanDetails", "shortName": "Employee Savings Plan (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FD2019Q4YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R84": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FD2019Q4QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2412402 - Disclosure - Summary of Unaudited Quarterly Financial Information - Quarterly Financial Information (Details)", "role": "http://www.halozyme.com/role/SummaryOfUnauditedQuarterlyFinancialInformationQuarterlyFinancialInformationDetails", "shortName": "Summary of Unaudited Quarterly Financial Information - Quarterly Financial Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FD2019Q4QTD", "decimals": "-3", "lang": null, "name": "us-gaap:GrossProfit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R85": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "ix:continuation", "td", "tr", "table", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FD2019Q4QTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:RestructuringCharges", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2412403 - Disclosure - Summary of Unaudited Quarterly Financial Information - Textuals (Details)", "role": "http://www.halozyme.com/role/SummaryOfUnauditedQuarterlyFinancialInformationTextualsDetails", "shortName": "Summary of Unaudited Quarterly Financial Information - Textuals (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "ix:continuation", "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FD2019Q1QTD_us-gaap_TypeOfArrangementAxis_halo_ArgenxMember", "decimals": "-5", "lang": null, "name": "us-gaap:ProceedsFromCollaborators", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R86": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "D2019Q4SubEvent", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2413401 - Disclosure - Restructuring Charges - Narrative (Details)", "role": "http://www.halozyme.com/role/RestructuringChargesNarrativeDetails", "shortName": "Restructuring Charges - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "D2019Q4SubEvent", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R87": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FI2018Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ValuationAllowancesAndReservesBalance", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2414401 - Disclosure - Schedule II Valuation and Qualifying Accounts (Details)", "role": "http://www.halozyme.com/role/ScheduleIiValuationAndQualifyingAccountsDetails", "shortName": "Schedule II Valuation and Qualifying Accounts (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FI2016Q4", "decimals": "-3", "lang": null, "name": "us-gaap:ValuationAllowancesAndReservesBalance", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2102100 - Disclosure - Summary of Significant Accounting Policies", "role": "http://www.halozyme.com/role/SummaryOfSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9999": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "halo2019-10k.htm", "contextRef": "I2018Q1SD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "", "isDefault": "false", "longName": "Uncategorized Items - halo2019-10k.htm", "role": "http://xbrl.sec.gov/role/uncategorizedFacts", "shortName": "Uncategorized Items - halo2019-10k.htm", "subGroupType": "", "uniqueAnchor": null } }, "segmentCount": 113, "tag": { "country_CH": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "SWITZERLAND", "terseLabel": "SWITZERLAND" } } }, "localname": "CH", "nsuri": "http://xbrl.sec.gov/country/2017-01-31", "presentation": [ "http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesConcentrationsOfCreditRiskDetails" ], "xbrltype": "domainItemType" }, "country_US": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "UNITED STATES", "terseLabel": "UNITED STATES" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2017-01-31", "presentation": [ "http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesConcentrationsOfCreditRiskDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.halozyme.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.halozyme.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.halozyme.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r476" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report", "terseLabel": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.halozyme.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.halozyme.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.halozyme.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.halozyme.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r475" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.halozyme.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.halozyme.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.halozyme.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.halozyme.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.halozyme.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.halozyme.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r477" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.halozyme.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.halozyme.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.halozyme.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r477" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.halozyme.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.halozyme.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r477" ], "lang": { "en-US": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.halozyme.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.halozyme.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r478" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.halozyme.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float", "terseLabel": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.halozyme.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r477" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.halozyme.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r477" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.halozyme.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r477" ], "lang": { "en-US": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.halozyme.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r477" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.halozyme.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers", "terseLabel": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.halozyme.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer", "terseLabel": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.halozyme.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.halozyme.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r473" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.halozyme.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r474" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.halozyme.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.halozyme.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "halo_A1.25ConvertibleSeniorNotesdue2024Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "1.25% Convertible Senior Notes due 2024 [Member]", "label": "1.25% Convertible Senior Notes due 2024 [Member]", "terseLabel": "1.25% Convertible Senior Notes due 2024 [Member]", "verboseLabel": "1.25% Convertible Senior Notes due 2024" } } }, "localname": "A1.25ConvertibleSeniorNotesdue2024Member", "nsuri": "http://www.halozyme.com/20191231", "presentation": [ "http://www.halozyme.com/role/LongTermDebtNetLongTermDebtTextualsDetails", "http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesNetLossPerShareDetails" ], "xbrltype": "domainItemType" }, "halo_A2016Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "2016 [Member]", "label": "2016 [Member]", "terseLabel": "2016 [Member]" } } }, "localname": "A2016Member", "nsuri": "http://www.halozyme.com/20191231", "presentation": [ "http://www.halozyme.com/role/LongTermDebtNetLongTermDebtTextualsDetails" ], "xbrltype": "domainItemType" }, "halo_A2017Federaltaxrate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "2017 Federal tax rate", "label": "2017 Federal tax rate", "terseLabel": "2017 Federal tax rate" } } }, "localname": "A2017Federaltaxrate", "nsuri": "http://www.halozyme.com/20191231", "presentation": [ "http://www.halozyme.com/role/IncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "halo_A2017Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "2017 [Member]", "label": "2017 [Member]", "terseLabel": "2017 [Member]" } } }, "localname": "A2017Member", "nsuri": "http://www.halozyme.com/20191231", "presentation": [ "http://www.halozyme.com/role/LongTermDebtNetLongTermDebtTextualsDetails" ], "xbrltype": "domainItemType" }, "halo_A2017QuarterlyMaximumPaymentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "2017 Quarterly Maximum Payment [Member]", "label": "2017 Quarterly Maximum Payment [Member]", "terseLabel": "2017 Quarterly Maximum Payment [Member]" } } }, "localname": "A2017QuarterlyMaximumPaymentMember", "nsuri": "http://www.halozyme.com/20191231", "presentation": [ "http://www.halozyme.com/role/LongTermDebtNetLongTermDebtTextualsDetails" ], "xbrltype": "domainItemType" }, "halo_A2017RocheMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "2017 Roche [Member]", "label": "2017 Roche [Member]", "terseLabel": "2017 Roche" } } }, "localname": "A2017RocheMember", "nsuri": "http://www.halozyme.com/20191231", "presentation": [ "http://www.halozyme.com/role/RevenueTextualsDetails" ], "xbrltype": "domainItemType" }, "halo_A2018Federaltaxrate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "2018 Federal tax rate", "label": "2018 Federal tax rate", "terseLabel": "2018 Federal tax rate" } } }, "localname": "A2018Federaltaxrate", "nsuri": "http://www.halozyme.com/20191231", "presentation": [ "http://www.halozyme.com/role/IncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "halo_A2018QuarterlyMaximumPaymentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "2018 Quarterly Maximum Payment [Member]", "label": "2018 Quarterly Maximum Payment [Member]", "terseLabel": "2018 Quarterly Maximum Payment [Member]" } } }, "localname": "A2018QuarterlyMaximumPaymentMember", "nsuri": "http://www.halozyme.com/20191231", "presentation": [ "http://www.halozyme.com/role/LongTermDebtNetLongTermDebtTextualsDetails" ], "xbrltype": "domainItemType" }, "halo_A2018andthereafterMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "2018 and thereafter [Member]", "label": "2018 and thereafter [Member]", "terseLabel": "2018 and thereafter [Member]" } } }, "localname": "A2018andthereafterMember", "nsuri": "http://www.halozyme.com/20191231", "presentation": [ "http://www.halozyme.com/role/LongTermDebtNetLongTermDebtTextualsDetails" ], "xbrltype": "domainItemType" }, "halo_A2018expirationMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "2018 expiration [Member]", "label": "2018 expiration [Member]", "terseLabel": "2018 expiration [Member]" } } }, "localname": "A2018expirationMember", "nsuri": "http://www.halozyme.com/20191231", "presentation": [ "http://www.halozyme.com/role/IncomeTaxesOperatingLossCarryforwardExpirationDetails" ], "xbrltype": "domainItemType" }, "halo_A2019QuarterlyMaximumPaymentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "2019 Quarterly Maximum Payment [Member]", "label": "2019 Quarterly Maximum Payment [Member]", "terseLabel": "2019 Quarterly Maximum Payment [Member]" } } }, "localname": "A2019QuarterlyMaximumPaymentMember", "nsuri": "http://www.halozyme.com/20191231", "presentation": [ "http://www.halozyme.com/role/LongTermDebtNetLongTermDebtTextualsDetails" ], "xbrltype": "domainItemType" }, "halo_A2019ShareRepurchaseProgramBankofAmericaMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "2019 Share Repurchase Program - Bank of America [Member]", "label": "2019 Share Repurchase Program - Bank of America [Member]", "terseLabel": "2019 Share Repurchase Program - Bank of America" } } }, "localname": "A2019ShareRepurchaseProgramBankofAmericaMember", "nsuri": "http://www.halozyme.com/20191231", "presentation": [ "http://www.halozyme.com/role/StockholdersEquityDeficitShareRepurchasesDetails" ], "xbrltype": "domainItemType" }, "halo_A2020QuarterlyMaximumPaymentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "2020 Quarterly Maximum Payment [Member]", "label": "2020 Quarterly Maximum Payment [Member]", "terseLabel": "2020 Quarterly Maximum Payment [Member]" } } }, "localname": "A2020QuarterlyMaximumPaymentMember", "nsuri": "http://www.halozyme.com/20191231", "presentation": [ "http://www.halozyme.com/role/LongTermDebtNetLongTermDebtTextualsDetails" ], "xbrltype": "domainItemType" }, "halo_A2021andbeyondexpirationMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "2021 and beyond expiration [Member]", "label": "2021 and beyond expiration [Member]", "terseLabel": "2021 and beyond expiration [Member]" } } }, "localname": "A2021andbeyondexpirationMember", "nsuri": "http://www.halozyme.com/20191231", "presentation": [ "http://www.halozyme.com/role/IncomeTaxesOperatingLossCarryforwardExpirationDetails" ], "xbrltype": "domainItemType" }, "halo_A2028andbeyondexpirationMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "2028 and beyond expiration [Member]", "label": "2028 and beyond expiration [Member]", "terseLabel": "2028 and beyond expiration [Member]" } } }, "localname": "A2028andbeyondexpirationMember", "nsuri": "http://www.halozyme.com/20191231", "presentation": [ "http://www.halozyme.com/role/IncomeTaxesOperatingLossCarryforwardExpirationDetails" ], "xbrltype": "domainItemType" }, "halo_AbbVieMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "AbbVie [Member]", "label": "AbbVie [Member]", "terseLabel": "AbbVie" } } }, "localname": "AbbVieMember", "nsuri": "http://www.halozyme.com/20191231", "presentation": [ "http://www.halozyme.com/role/RevenueRevenueRecognitionMultipleDeliverableArrangementsDetails", "http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesConcentrationsOfCreditRiskDetails" ], "xbrltype": "domainItemType" }, "halo_Accountsreceivablefromcollaborators": { "auth_ref": [], "calculation": { "http://www.halozyme.com/role/CertainBalanceSheetItemsAccountsReceivableDetails": { "order": 2.0, "parentTag": "us-gaap_AccountsReceivableGrossCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amounts due from collaborators, within one year of the balance sheet date (or the normal operating cycle, whichever is longer) for goods or services (including trade receivables) that have been delivered or sold in the normal course of business.", "label": "Accounts receivable from collaborators", "terseLabel": "Accounts receivable from collaborators" } } }, "localname": "Accountsreceivablefromcollaborators", "nsuri": "http://www.halozyme.com/20191231", "presentation": [ "http://www.halozyme.com/role/CertainBalanceSheetItemsAccountsReceivableDetails" ], "xbrltype": "monetaryItemType" }, "halo_Accountsreceivablefromproductsales": { "auth_ref": [], "calculation": { "http://www.halozyme.com/role/CertainBalanceSheetItemsAccountsReceivableDetails": { "order": 4.0, "parentTag": "us-gaap_AccountsReceivableGrossCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Accounts receivable from product sales", "label": "Accounts receivable from product sales", "terseLabel": "Accounts receivable from other product sales" } } }, "localname": "Accountsreceivablefromproductsales", "nsuri": "http://www.halozyme.com/20191231", "presentation": [ "http://www.halozyme.com/role/CertainBalanceSheetItemsAccountsReceivableDetails" ], "xbrltype": "monetaryItemType" }, "halo_Accountsreceivablefromproductsalestocollaborators": { "auth_ref": [], "calculation": { "http://www.halozyme.com/role/CertainBalanceSheetItemsAccountsReceivableDetails": { "order": 1.0, "parentTag": "us-gaap_AccountsReceivableGrossCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Accounts receivable from product sales to collaborators", "label": "Accounts receivable from product sales to collaborators", "terseLabel": "Accounts receivable from product sales to collaborators" } } }, "localname": "Accountsreceivablefromproductsalestocollaborators", "nsuri": "http://www.halozyme.com/20191231", "presentation": [ "http://www.halozyme.com/role/CertainBalanceSheetItemsAccountsReceivableDetails" ], "xbrltype": "monetaryItemType" }, "halo_Accountsreceivablefromroyalties": { "auth_ref": [], "calculation": { "http://www.halozyme.com/role/CertainBalanceSheetItemsAccountsReceivableDetails": { "order": 3.0, "parentTag": "us-gaap_AccountsReceivableGrossCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amounts due from royalties, within one year of the balance sheet date (or the normal operating cycle, whichever is longer) for goods or services (including trade receivables) that have been delivered or sold in the normal course of business.", "label": "Accounts receivable from royalties", "terseLabel": "Accounts receivable from royalties" } } }, "localname": "Accountsreceivablefromroyalties", "nsuri": "http://www.halozyme.com/20191231", "presentation": [ "http://www.halozyme.com/role/CertainBalanceSheetItemsAccountsReceivableDetails" ], "xbrltype": "monetaryItemType" }, "halo_AccruedLiabilitiesNoncurrent": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accrued Liabilities, Noncurrent", "label": "Accrued Liabilities, Noncurrent", "terseLabel": "Accrued Liabilities, Noncurrent" } } }, "localname": "AccruedLiabilitiesNoncurrent", "nsuri": "http://www.halozyme.com/20191231", "presentation": [ "http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "halo_AccruedOutsourcedResearchAndDevelopmentExpensesCurrent": { "auth_ref": [], "calculation": { "http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails": { "order": 2.0, "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accrued outsourced research and development expenses current.", "label": "Accrued Outsourced Research and Development Expenses Current", "terseLabel": "Accrued outsourced research and development" } } }, "localname": "AccruedOutsourcedResearchAndDevelopmentExpensesCurrent", "nsuri": "http://www.halozyme.com/20191231", "presentation": [ "http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "halo_Accruedmanufacturingexpenses": { "auth_ref": [], "calculation": { "http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails": { "order": 3.0, "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accrued manufacturing expenses", "label": "Accrued manufacturing expenses", "terseLabel": "Accrued outsourced manufacturing expenses" } } }, "localname": "Accruedmanufacturingexpenses", "nsuri": "http://www.halozyme.com/20191231", "presentation": [ "http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "halo_AlexionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Alexion [Member]", "label": "Alexion [Member]", "terseLabel": "Alexion" } } }, "localname": "AlexionMember", "nsuri": "http://www.halozyme.com/20191231", "presentation": [ "http://www.halozyme.com/role/RevenueRevenueRecognitionMultipleDeliverableArrangementsDetails", "http://www.halozyme.com/role/RevenueTextualsDetails", "http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesConcentrationsOfCreditRiskDetails", "http://www.halozyme.com/role/SummaryOfUnauditedQuarterlyFinancialInformationTextualsDetails" ], "xbrltype": "domainItemType" }, "halo_AllowanceforDistributionFeesandDiscounts": { "auth_ref": [], "calculation": { "http://www.halozyme.com/role/CertainBalanceSheetItemsAccountsReceivableDetails": { "order": 2.0, "parentTag": "us-gaap_AccountsReceivableNetCurrent", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Allowance for Discount and Distribution Fees", "label": "Allowance for Distribution Fees and Discounts", "negatedTerseLabel": "Allowance for distribution fees and discounts" } } }, "localname": "AllowanceforDistributionFeesandDiscounts", "nsuri": "http://www.halozyme.com/20191231", "presentation": [ "http://www.halozyme.com/role/CertainBalanceSheetItemsAccountsReceivableDetails" ], "xbrltype": "monetaryItemType" }, "halo_AmendedandRestated2011StockPlanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Amended and Restated 2011 Stock Plan [Member]", "label": "Amended and Restated 2011 Stock Plan [Member]", "terseLabel": "Amended and Restated 2011 Stock Plan [Member]" } } }, "localname": "AmendedandRestated2011StockPlanMember", "nsuri": "http://www.halozyme.com/20191231", "presentation": [ "http://www.halozyme.com/role/ShareBasedCompensationTextualsDetails" ], "xbrltype": "domainItemType" }, "halo_ArgenxMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "argenx [Member]", "label": "argenx [Member]", "terseLabel": "argenx [Member]" } } }, "localname": "ArgenxMember", "nsuri": "http://www.halozyme.com/20191231", "presentation": [ "http://www.halozyme.com/role/RevenueRevenueRecognitionMultipleDeliverableArrangementsDetails", "http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesConcentrationsOfCreditRiskDetails", "http://www.halozyme.com/role/SummaryOfUnauditedQuarterlyFinancialInformationTextualsDetails" ], "xbrltype": "domainItemType" }, "halo_AvidCommercialSupplyAgreementMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Avid Commercial Supply Agreement [Member]", "label": "Avid Commercial Supply Agreement [Member]", "terseLabel": "Avid Commercial Supply Agreement [Member]" } } }, "localname": "AvidCommercialSupplyAgreementMember", "nsuri": "http://www.halozyme.com/20191231", "presentation": [ "http://www.halozyme.com/role/CommitmentsAndContingenciesOtherCommitmentsDetails" ], "xbrltype": "domainItemType" }, "halo_BMSMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "BMS [Member]", "label": "BMS [Member]", "terseLabel": "BMS" } } }, "localname": "BMSMember", "nsuri": "http://www.halozyme.com/20191231", "presentation": [ "http://www.halozyme.com/role/RevenueRevenueRecognitionMultipleDeliverableArrangementsDetails", "http://www.halozyme.com/role/RevenueTextualsDetails", "http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesConcentrationsOfCreditRiskDetails", "http://www.halozyme.com/role/SummaryOfUnauditedQuarterlyFinancialInformationTextualsDetails" ], "xbrltype": "domainItemType" }, "halo_BaxaltaMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Baxalta [Member]", "label": "Baxalta [Member]", "terseLabel": "Baxalta" } } }, "localname": "BaxaltaMember", "nsuri": "http://www.halozyme.com/20191231", "presentation": [ "http://www.halozyme.com/role/RevenueRevenueRecognitionMultipleDeliverableArrangementsDetails", "http://www.halozyme.com/role/RevenueTextualsDetails" ], "xbrltype": "domainItemType" }, "halo_BulkFormulationMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Bulk formulation [Member]", "label": "Bulk formulation [Member]", "terseLabel": "Bulk formulation [Member]" } } }, "localname": "BulkFormulationMember", "nsuri": "http://www.halozyme.com/20191231", "presentation": [ "http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesConcentrationsOfCreditRiskDetails" ], "xbrltype": "domainItemType" }, "halo_BulkrHuPH20AndENHANZEMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Bulk rHuPH20 And ENHANZE [Member]", "label": "Bulk rHuPH20 And ENHANZE [Member]", "terseLabel": "Bulk rHuPH20 And ENHANZE [Member]" } } }, "localname": "BulkrHuPH20AndENHANZEMember", "nsuri": "http://www.halozyme.com/20191231", "presentation": [ "http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "halo_BulkrHuPH20Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "bulk rHuPH20 for use in collaboration products", "label": "bulk rHuPH20 [Member]", "terseLabel": "Sales of bulk rHuPH20", "verboseLabel": "bulk rHuPH20" } } }, "localname": "BulkrHuPH20Member", "nsuri": "http://www.halozyme.com/20191231", "presentation": [ "http://www.halozyme.com/role/RevenueDisaggregationOfRevenueDetails", "http://www.halozyme.com/role/RevenueRevenueRemainingPerformanceObligationDetails", "http://www.halozyme.com/role/RevenueTextualsDetails", "http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesInventoriesDetails" ], "xbrltype": "domainItemType" }, "halo_CaliforniaMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "California [Member]", "label": "California [Member]", "terseLabel": "California [Member]" } } }, "localname": "CaliforniaMember", "nsuri": "http://www.halozyme.com/20191231", "presentation": [ "http://www.halozyme.com/role/IncomeTaxesOperatingLossCarryforwardExpirationDetails", "http://www.halozyme.com/role/IncomeTaxesTaxTextualsDetails" ], "xbrltype": "domainItemType" }, "halo_CliffVestingFirstAnniversaryMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cliff Vesting, First Anniversary [Member]", "label": "Cliff Vesting, First Anniversary [Member]", "terseLabel": "Cliff Vesting, First Anniversary [Member]" } } }, "localname": "CliffVestingFirstAnniversaryMember", "nsuri": "http://www.halozyme.com/20191231", "presentation": [ "http://www.halozyme.com/role/ShareBasedCompensationTextualsDetails" ], "xbrltype": "domainItemType" }, "halo_CollaborativeAgreementsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Collaborative Agreements [Member]", "label": "Collaborative Agreements [Member]", "terseLabel": "Revenues under collaborative agreements" } } }, "localname": "CollaborativeAgreementsMember", "nsuri": "http://www.halozyme.com/20191231", "presentation": [ "http://www.halozyme.com/role/ConsolidatedStatementsOfOperations", "http://www.halozyme.com/role/RevenueDisaggregationOfRevenueDetails" ], "xbrltype": "domainItemType" }, "halo_ComputerAndOfficeEquipmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Computer and office equipment.", "label": "Computer and Office Equipment [Member]", "terseLabel": "Computer and office equipment" } } }, "localname": "ComputerAndOfficeEquipmentMember", "nsuri": "http://www.halozyme.com/20191231", "presentation": [ "http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "halo_ConcentrationRiskPercentageInstantDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Concentration Risk, Percentage (instant date)", "label": "Concentration Risk, Percentage (instant date)", "terseLabel": "Concentration Risk, Percentage (instant date)" } } }, "localname": "ConcentrationRiskPercentageInstantDate", "nsuri": "http://www.halozyme.com/20191231", "presentation": [ "http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesConcentrationsOfCreditRiskDetails" ], "xbrltype": "percentItemType" }, "halo_DebtInstrumentPrepaymentFeePercent": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt Instrument, Prepayment Fee,Percent", "label": "Debt Instrument, Prepayment Fee, Percent", "terseLabel": "Prepayment fee, percent" } } }, "localname": "DebtInstrumentPrepaymentFeePercent", "nsuri": "http://www.halozyme.com/20191231", "presentation": [ "http://www.halozyme.com/role/LongTermDebtNetLongTermDebtTextualsDetails" ], "xbrltype": "percentItemType" }, "halo_DeferredRentExpense": { "auth_ref": [], "calculation": { "http://www.halozyme.com/role/ConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Deferred Rent Expense", "label": "Deferred Rent Expense", "terseLabel": "Deferred Rent Expense" } } }, "localname": "DeferredRentExpense", "nsuri": "http://www.halozyme.com/20191231", "presentation": [ "http://www.halozyme.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "halo_DeferredTaxAssetsInterestExpenseLimitation": { "auth_ref": [], "calculation": { "http://www.halozyme.com/role/IncomeTaxesComponentsDeferredTaxesDetails": { "order": 7.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Deferred Tax Assets, Interest Expense Limitation", "label": "Deferred Tax Assets, Interest Expense Limitation", "terseLabel": "Deferred Tax Assets, Interest Expense Limitation" } } }, "localname": "DeferredTaxAssetsInterestExpenseLimitation", "nsuri": "http://www.halozyme.com/20191231", "presentation": [ "http://www.halozyme.com/role/IncomeTaxesComponentsDeferredTaxesDetails" ], "xbrltype": "monetaryItemType" }, "halo_DeferredTaxAssetsLeaseLiabilities": { "auth_ref": [], "calculation": { "http://www.halozyme.com/role/IncomeTaxesComponentsDeferredTaxesDetails": { "order": 8.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Deferred Tax Assets, Lease Liabilities", "label": "Deferred Tax Assets, Lease Liabilities", "terseLabel": "Deferred Tax Assets, Lease Liabilities" } } }, "localname": "DeferredTaxAssetsLeaseLiabilities", "nsuri": "http://www.halozyme.com/20191231", "presentation": [ "http://www.halozyme.com/role/IncomeTaxesComponentsDeferredTaxesDetails" ], "xbrltype": "monetaryItemType" }, "halo_DeferredTaxLiabilitiesConvertibleNote": { "auth_ref": [], "calculation": { "http://www.halozyme.com/role/IncomeTaxesComponentsDeferredTaxesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxLiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Deferred Tax Liabilities, Convertible Note", "label": "Deferred Tax Liabilities, Convertible Note", "negatedTerseLabel": "Deferred Tax Liabilities, Convertible Note" } } }, "localname": "DeferredTaxLiabilitiesConvertibleNote", "nsuri": "http://www.halozyme.com/20191231", "presentation": [ "http://www.halozyme.com/role/IncomeTaxesComponentsDeferredTaxesDetails" ], "xbrltype": "monetaryItemType" }, "halo_DeferredTaxLiabilitiesRightofUseAsset": { "auth_ref": [], "calculation": { "http://www.halozyme.com/role/IncomeTaxesComponentsDeferredTaxesDetails": { "order": 3.0, "parentTag": "us-gaap_DeferredTaxLiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Deferred Tax Liabilities, Right-of-Use Asset", "label": "Deferred Tax Liabilities, Right-of-Use Asset", "negatedTerseLabel": "Deferred Tax Liabilities, Right-of-Use Asset" } } }, "localname": "DeferredTaxLiabilitiesRightofUseAsset", "nsuri": "http://www.halozyme.com/20191231", "presentation": [ "http://www.halozyme.com/role/IncomeTaxesComponentsDeferredTaxesDetails" ], "xbrltype": "monetaryItemType" }, "halo_DeferredtaxassetexcludingamountforAMT": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Deferred tax asset excluding amount for AMT", "label": "Deferred tax asset excluding amount for AMT", "terseLabel": "Deferred tax asset excluding amount for AMT" } } }, "localname": "DeferredtaxassetexcludingamountforAMT", "nsuri": "http://www.halozyme.com/20191231", "presentation": [ "http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesIncomeTaxDetails" ], "xbrltype": "monetaryItemType" }, "halo_DevelopmentFeesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Development Fees [Member]", "label": "Development Fees [Member]", "terseLabel": "Event-based development milestones and regulatory milestone and other fees", "verboseLabel": "Development" } } }, "localname": "DevelopmentFeesMember", "nsuri": "http://www.halozyme.com/20191231", "presentation": [ "http://www.halozyme.com/role/RevenueDisaggregationOfRevenueDetails", "http://www.halozyme.com/role/RevenueRevenueRecognitionMultipleDeliverableArrangementsDetails", "http://www.halozyme.com/role/RevenueTextualsDetails" ], "xbrltype": "domainItemType" }, "halo_DisclosureOfAccountingPolicyForClinicalTrialExpensesPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for clinical trial expenses.", "label": "Disclosure of Accounting Policy for Clinical Trial Expenses [Policy Text Block]", "verboseLabel": "Clinical Trial Expenses" } } }, "localname": "DisclosureOfAccountingPolicyForClinicalTrialExpensesPolicyTextBlock", "nsuri": "http://www.halozyme.com/20191231", "presentation": [ "http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "halo_ENHANZEdrugproductMemberDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "ENHANZE drug product [Member] [Domain]", "label": "ENHANZE drug product [Member] [Domain]", "terseLabel": "Sales of ENHANZE drug product" } } }, "localname": "ENHANZEdrugproductMemberDomain", "nsuri": "http://www.halozyme.com/20191231", "presentation": [ "http://www.halozyme.com/role/RevenueDisaggregationOfRevenueDetails" ], "xbrltype": "domainItemType" }, "halo_EffectiveIncomeTaxRateReconciliationConvertibleNoteDiscountinAPIC": { "auth_ref": [], "calculation": { "http://www.halozyme.com/role/IncomeTaxesScheduleOfIncomeTaxReconciliationDetails": { "order": 10.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsDiscontinuedOperationsExtraordinaryItems", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Effective Income Tax Rate Reconciliation, Convertible Note Discount in APIC", "label": "Effective Income Tax Rate Reconciliation, Convertible Note Discount in APIC", "terseLabel": "Effective Income Tax Rate Reconciliation, Convertible Note Discount in APIC" } } }, "localname": "EffectiveIncomeTaxRateReconciliationConvertibleNoteDiscountinAPIC", "nsuri": "http://www.halozyme.com/20191231", "presentation": [ "http://www.halozyme.com/role/IncomeTaxesScheduleOfIncomeTaxReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "halo_Finalpaymentaspercentoforiginalprincipal": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Final payment as percent of original principal", "label": "Final payment as percent of original principal", "terseLabel": "Final payment as percent of original principal" } } }, "localname": "Finalpaymentaspercentoforiginalprincipal", "nsuri": "http://www.halozyme.com/20191231", "presentation": [ "http://www.halozyme.com/role/LongTermDebtNetLongTermDebtTextualsDetails" ], "xbrltype": "percentItemType" }, "halo_HylenexRecombinantMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Hylenex Recombinant [Member]", "label": "Hylenex Recombinant [Member]", "terseLabel": "Sales of Hylenex" } } }, "localname": "HylenexRecombinantMember", "nsuri": "http://www.halozyme.com/20191231", "presentation": [ "http://www.halozyme.com/role/RevenueDisaggregationOfRevenueDetails", "http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesConcentrationsOfCreditRiskDetails", "http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesInventoriesDetails" ], "xbrltype": "domainItemType" }, "halo_InlicensetechnologiesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "In-license technologies [Member]", "label": "In-license technologies [Member]", "terseLabel": "License fees and event-based payments", "verboseLabel": "In-license technologies [Member]" } } }, "localname": "InlicensetechnologiesMember", "nsuri": "http://www.halozyme.com/20191231", "presentation": [ "http://www.halozyme.com/role/CertainBalanceSheetItemsDeferredRevenueDetails", "http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesResearchAndDevelopmentDetails" ], "xbrltype": "domainItemType" }, "halo_JanssenMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Janssen Collaboration [Member]", "label": "Janssen [Member]", "terseLabel": "Janssen" } } }, "localname": "JanssenMember", "nsuri": "http://www.halozyme.com/20191231", "presentation": [ "http://www.halozyme.com/role/RevenueRevenueRecognitionMultipleDeliverableArrangementsDetails", "http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesConcentrationsOfCreditRiskDetails", "http://www.halozyme.com/role/SummaryOfUnauditedQuarterlyFinancialInformationTextualsDetails" ], "xbrltype": "domainItemType" }, "halo_LicenseFeesAndEventBasedMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "License Fees And Event-Based [Member]", "label": "License Fees And Event-Based [Member]", "terseLabel": "License Fees And Event-Based [Member]" } } }, "localname": "LicenseFeesAndEventBasedMember", "nsuri": "http://www.halozyme.com/20191231", "presentation": [ "http://www.halozyme.com/role/CertainBalanceSheetItemsDeferredRevenueDetails" ], "xbrltype": "domainItemType" }, "halo_LillyMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Lilly [Member]", "label": "Lilly [Member]", "terseLabel": "Lilly" } } }, "localname": "LillyMember", "nsuri": "http://www.halozyme.com/20191231", "presentation": [ "http://www.halozyme.com/role/RevenueRevenueRecognitionMultipleDeliverableArrangementsDetails", "http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesConcentrationsOfCreditRiskDetails" ], "xbrltype": "domainItemType" }, "halo_LongTermDebtIncludingInterestGross": { "auth_ref": [], "calculation": { "http://www.halozyme.com/role/LongTermDebtNetDebtTableDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Long-term Debt Including Interest, Gross", "label": "Long-term Debt Including Interest, Gross", "totalLabel": "Total minimum payments" } } }, "localname": "LongTermDebtIncludingInterestGross", "nsuri": "http://www.halozyme.com/20191231", "presentation": [ "http://www.halozyme.com/role/LongTermDebtNetDebtTableDetails" ], "xbrltype": "monetaryItemType" }, "halo_LongTermDebtInterestGross": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Long-term Debt, Interest, Gross", "label": "Long-term Debt, Interest, Gross", "negatedTerseLabel": "Less amount representing interest" } } }, "localname": "LongTermDebtInterestGross", "nsuri": "http://www.halozyme.com/20191231", "presentation": [ "http://www.halozyme.com/role/LongTermDebtNetDebtTableDetails" ], "xbrltype": "monetaryItemType" }, "halo_MajorSupplierAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Major Supplier [Axis]", "label": "Major Supplier [Axis]", "terseLabel": "Major Supplier [Axis]" } } }, "localname": "MajorSupplierAxis", "nsuri": "http://www.halozyme.com/20191231", "presentation": [ "http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesConcentrationsOfCreditRiskDetails" ], "xbrltype": "stringItemType" }, "halo_MajorSupplierDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "[Domain] for Major Supplier [Axis]", "label": "Major Supplier [Domain]", "terseLabel": "Major Supplier [Domain]" } } }, "localname": "MajorSupplierDomain", "nsuri": "http://www.halozyme.com/20191231", "presentation": [ "http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesConcentrationsOfCreditRiskDetails" ], "xbrltype": "domainItemType" }, "halo_ManufacturingEquipmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Manufacturing Equipment [Member]", "label": "Manufacturing Equipment [Member]", "terseLabel": "Manufacturing equipment" } } }, "localname": "ManufacturingEquipmentMember", "nsuri": "http://www.halozyme.com/20191231", "presentation": [ "http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "halo_MonthlyVestingAfterOneYearMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Monthly Vesting, after One Year [Member]", "label": "Monthly Vesting, after One Year [Member]", "terseLabel": "Monthly Vesting, after One Year [Member]" } } }, "localname": "MonthlyVestingAfterOneYearMember", "nsuri": "http://www.halozyme.com/20191231", "presentation": [ "http://www.halozyme.com/role/ShareBasedCompensationTextualsDetails" ], "xbrltype": "domainItemType" }, "halo_NetincomelosspershareTextualsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Net income (loss) per share (Textuals) [Abstract]", "label": "Net income (loss) per share (Textuals) [Abstract]", "terseLabel": "Net loss per share (Textuals) [Abstract]" } } }, "localname": "NetincomelosspershareTextualsAbstract", "nsuri": "http://www.halozyme.com/20191231", "presentation": [ "http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesNetLossPerShareDetails" ], "xbrltype": "stringItemType" }, "halo_NonConvertibleBorrowingRateforSimilarDebtPercent": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Non-Convertible Borrowing Rate for Similar Debt, Percent", "label": "Non-Convertible Borrowing Rate for Similar Debt, Percent", "terseLabel": "Non-Convertible Borrowing Rate for Similar Debt, Percent" } } }, "localname": "NonConvertibleBorrowingRateforSimilarDebtPercent", "nsuri": "http://www.halozyme.com/20191231", "presentation": [ "http://www.halozyme.com/role/LongTermDebtNetLongTermDebtTextualsDetails" ], "xbrltype": "percentItemType" }, "halo_NonrefundableUpfrontLicenseFeePaymentReceivedUnderCollaborativeAgreement": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Nonrefundable upfront license fee payment received under collaborative agreement.", "label": "Nonrefundable Upfront License Fee Payment Received Under Collaborative Agreement", "terseLabel": "Development milestones" } } }, "localname": "NonrefundableUpfrontLicenseFeePaymentReceivedUnderCollaborativeAgreement", "nsuri": "http://www.halozyme.com/20191231", "presentation": [ "http://www.halozyme.com/role/RevenueTextualsDetails" ], "xbrltype": "monetaryItemType" }, "halo_Numberofbuildings": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of buildings", "label": "Number of buildings", "terseLabel": "Number of buildings" } } }, "localname": "Numberofbuildings", "nsuri": "http://www.halozyme.com/20191231", "presentation": [ "http://www.halozyme.com/role/CommitmentsAndContingenciesOperatingLeaseTextualDetails" ], "xbrltype": "integerItemType" }, "halo_Numberofmanufacturers": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of third-party manufacturers for the supply of bulk rHuPH20.", "label": "Number of manufacturers", "terseLabel": "Number of manufacturers" } } }, "localname": "Numberofmanufacturers", "nsuri": "http://www.halozyme.com/20191231", "presentation": [ "http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesConcentrationsOfCreditRiskDetails" ], "xbrltype": "integerItemType" }, "halo_OfficeAndResearchFacilityMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Office and Research Facility [Member]", "label": "Office and Research Facility [Member]", "terseLabel": "Office and Research Facility [Member]" } } }, "localname": "OfficeAndResearchFacilityMember", "nsuri": "http://www.halozyme.com/20191231", "presentation": [ "http://www.halozyme.com/role/CommitmentsAndContingenciesOperatingLeaseTextualDetails" ], "xbrltype": "domainItemType" }, "halo_OperatingLeaseAccretionOfLiability": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Operating Lease, Accretion Of Liability", "label": "Operating Lease, Accretion Of Liability", "terseLabel": "Operating Lease, Accretion Of Liability" } } }, "localname": "OperatingLeaseAccretionOfLiability", "nsuri": "http://www.halozyme.com/20191231", "presentation": [ "http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "halo_OperatingLeasesAreaLeased": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Operating Leases, Area Leased", "label": "Operating Leases, Area Leased", "terseLabel": "Operating Leases, Area Leased" } } }, "localname": "OperatingLeasesAreaLeased", "nsuri": "http://www.halozyme.com/20191231", "presentation": [ "http://www.halozyme.com/role/CommitmentsAndContingenciesOperatingLeaseTextualDetails" ], "xbrltype": "areaItemType" }, "halo_OperatingLeasesBaseRentPeriodicIncreasePercent": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Operating Leases, Base Rent, Periodic Increase, Percent", "label": "Operating Leases, Base Rent, Periodic Increase, Percent", "terseLabel": "Operating Leases, Base Rent, Periodic Increase, Percent" } } }, "localname": "OperatingLeasesBaseRentPeriodicIncreasePercent", "nsuri": "http://www.halozyme.com/20191231", "presentation": [ "http://www.halozyme.com/role/CommitmentsAndContingenciesOperatingLeaseTextualDetails" ], "xbrltype": "percentItemType" }, "halo_OtherstatetaxMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Other state tax [Member]", "label": "Other state tax [Member]", "terseLabel": "Other state tax [Member]" } } }, "localname": "OtherstatetaxMember", "nsuri": "http://www.halozyme.com/20191231", "presentation": [ "http://www.halozyme.com/role/IncomeTaxesOperatingLossCarryforwardExpirationDetails", "http://www.halozyme.com/role/IncomeTaxesTaxTextualsDetails" ], "xbrltype": "domainItemType" }, "halo_OutstandingAwardsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Outstanding awards [Member]", "label": "Outstanding awards [Member]", "terseLabel": "Outstanding awards [Member]" } } }, "localname": "OutstandingAwardsMember", "nsuri": "http://www.halozyme.com/20191231", "presentation": [ "http://www.halozyme.com/role/ShareBasedCompensationTextualsDetails" ], "xbrltype": "domainItemType" }, "halo_PatheonMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Patheon [Member]", "label": "Patheon [Member]", "terseLabel": "Patheon [Member]" } } }, "localname": "PatheonMember", "nsuri": "http://www.halozyme.com/20191231", "presentation": [ "http://www.halozyme.com/role/CommitmentsAndContingenciesOtherCommitmentsDetails" ], "xbrltype": "domainItemType" }, "halo_PercentageVestingMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Percentage Vesting [Member]", "label": "Percentage Vesting [Member]", "terseLabel": "Percentage Vesting [Member]" } } }, "localname": "PercentageVestingMember", "nsuri": "http://www.halozyme.com/20191231", "presentation": [ "http://www.halozyme.com/role/ShareBasedCompensationTextualsDetails" ], "xbrltype": "domainItemType" }, "halo_PfizerMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Pfizer [Member]", "label": "Pfizer [Member]", "terseLabel": "Pfizer" } } }, "localname": "PfizerMember", "nsuri": "http://www.halozyme.com/20191231", "presentation": [ "http://www.halozyme.com/role/RevenueRevenueRecognitionMultipleDeliverableArrangementsDetails" ], "xbrltype": "domainItemType" }, "halo_Prepaidresearchanddevelopment": { "auth_ref": [], "calculation": { "http://www.halozyme.com/role/CertainBalanceSheetItemsPrepaidExpensesAndOtherAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Prepaid research and development", "label": "Prepaid research and development", "terseLabel": "Prepaid research and development expenses" } } }, "localname": "Prepaidresearchanddevelopment", "nsuri": "http://www.halozyme.com/20191231", "presentation": [ "http://www.halozyme.com/role/CertainBalanceSheetItemsPrepaidExpensesAndOtherAssetsDetails" ], "xbrltype": "monetaryItemType" }, "halo_ProceedsFromPartnerOfLicenseAndCollaborativeAgreement": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Proceeds from partner of license and collaborative agreement.", "label": "Proceeds from Partner of License and Collaborative Agreement", "terseLabel": "Revenue related to licenses granted to collaboration partners" } } }, "localname": "ProceedsFromPartnerOfLicenseAndCollaborativeAgreement", "nsuri": "http://www.halozyme.com/20191231", "presentation": [ "http://www.halozyme.com/role/RevenueTextualsDetails" ], "xbrltype": "monetaryItemType" }, "halo_RSURSAandPRSUawardsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Restricted Stock Unit, Restricted Stock Awards, and Performance Restricted Stock Unit awards [Member]", "label": "RSU, RSA, and PRSU awards [Member]", "terseLabel": "RSU, RSA, and PRSU awards [Member]" } } }, "localname": "RSURSAandPRSUawardsMember", "nsuri": "http://www.halozyme.com/20191231", "presentation": [ "http://www.halozyme.com/role/ShareBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "halo_ResearchEquipmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Research equipment.", "label": "Research Equipment [Member]", "terseLabel": "Research equipment" } } }, "localname": "ResearchEquipmentMember", "nsuri": "http://www.halozyme.com/20191231", "presentation": [ "http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "halo_ResearchandDevelopmentServicesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Research and Development Services [Member]", "label": "Research and Development Services [Member]", "terseLabel": "Research and development services" } } }, "localname": "ResearchandDevelopmentServicesMember", "nsuri": "http://www.halozyme.com/20191231", "presentation": [ "http://www.halozyme.com/role/RevenueDisaggregationOfRevenueDetails" ], "xbrltype": "domainItemType" }, "halo_Restrictedstockawardholderexerciseprice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Restricted stock award holder exercise price", "label": "Restricted stock award holder exercise price", "terseLabel": "Restricted stock award holder exercise price" } } }, "localname": "Restrictedstockawardholderexerciseprice", "nsuri": "http://www.halozyme.com/20191231", "presentation": [ "http://www.halozyme.com/role/ShareBasedCompensationRestrictedStockAwardsDetails" ], "xbrltype": "perShareItemType" }, "halo_RocheMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Roche", "label": "Roche [Member]", "terseLabel": "Roche" } } }, "localname": "RocheMember", "nsuri": "http://www.halozyme.com/20191231", "presentation": [ "http://www.halozyme.com/role/CertainBalanceSheetItemsDeferredRevenueDetails", "http://www.halozyme.com/role/RevenueRevenueRecognitionMultipleDeliverableArrangementsDetails", "http://www.halozyme.com/role/RevenueTextualsDetails", "http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesConcentrationsOfCreditRiskDetails", "http://www.halozyme.com/role/SummaryOfUnauditedQuarterlyFinancialInformationTextualsDetails" ], "xbrltype": "domainItemType" }, "halo_RocheandBaxaltaMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Roche and Baxalta [Member]", "label": "Roche and Baxalta [Member]", "terseLabel": "Roche and Baxalta [Member]" } } }, "localname": "RocheandBaxaltaMember", "nsuri": "http://www.halozyme.com/20191231", "presentation": [ "http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesConcentrationsOfCreditRiskDetails" ], "xbrltype": "domainItemType" }, "halo_RoyaltybackedLoanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Royalty-backed Loan [Member]", "label": "Royalty-backed Loan [Member]", "terseLabel": "Royalty-backed Loan" } } }, "localname": "RoyaltybackedLoanMember", "nsuri": "http://www.halozyme.com/20191231", "presentation": [ "http://www.halozyme.com/role/LongTermDebtNetLongTermDebtTextualsDetails" ], "xbrltype": "domainItemType" }, "halo_Royaltypaymentstobeappliedtodebtinstrument": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Royalty payments to be applied to debt instrument", "label": "Royalty payments to be applied to debt instrument", "terseLabel": "Royalty payments to be applied to debt instrument" } } }, "localname": "Royaltypaymentstobeappliedtodebtinstrument", "nsuri": "http://www.halozyme.com/20191231", "presentation": [ "http://www.halozyme.com/role/LongTermDebtNetLongTermDebtTextualsDetails" ], "xbrltype": "percentItemType" }, "halo_SalesbasedmilestoneMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Sales-based milestone [Member]", "label": "Sales-based milestone [Member]", "terseLabel": "Sales-based milestones", "verboseLabel": "Sales" } } }, "localname": "SalesbasedmilestoneMember", "nsuri": "http://www.halozyme.com/20191231", "presentation": [ "http://www.halozyme.com/role/RevenueDisaggregationOfRevenueDetails", "http://www.halozyme.com/role/RevenueRevenueRecognitionMultipleDeliverableArrangementsDetails" ], "xbrltype": "domainItemType" }, "halo_SatelliteofficeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Satellite office [Member]", "label": "Satellite office [Member]", "terseLabel": "Satellite office [Member]" } } }, "localname": "SatelliteofficeMember", "nsuri": "http://www.halozyme.com/20191231", "presentation": [ "http://www.halozyme.com/role/CommitmentsAndContingenciesOperatingLeaseTextualDetails" ], "xbrltype": "domainItemType" }, "halo_ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "[Line Items] for Schedule of Share-based Compensation Arrangements Valuation Inputs [Table]", "label": "Schedule of Share-based Compensation Arrangements Valuation Inputs [Line Items]", "terseLabel": "Schedule of Share-based Compensation Arrangements Valuation Inputs [Line Items]" } } }, "localname": "ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems", "nsuri": "http://www.halozyme.com/20191231", "presentation": [ "http://www.halozyme.com/role/ShareBasedCompensationValuationDetails" ], "xbrltype": "stringItemType" }, "halo_ScheduleofSharebasedCompensationArrangementsValuationInputsTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule of Share-based Compensation Arrangements Valuation Inputs [Table]", "label": "Schedule of Share-based Compensation Arrangements Valuation Inputs [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements Valuation Inputs [Table]" } } }, "localname": "ScheduleofSharebasedCompensationArrangementsValuationInputsTable", "nsuri": "http://www.halozyme.com/20191231", "presentation": [ "http://www.halozyme.com/role/ShareBasedCompensationValuationDetails" ], "xbrltype": "stringItemType" }, "halo_Secureddebtoriginaldraw": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Secured debt original draw", "label": "Secured debt original draw", "terseLabel": "Secured debt original draw" } } }, "localname": "Secureddebtoriginaldraw", "nsuri": "http://www.halozyme.com/20191231", "presentation": [ "http://www.halozyme.com/role/LongTermDebtNetLongTermDebtTextualsDetails" ], "xbrltype": "monetaryItemType" }, "halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesSubjectToOutstandingAwards": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Subject To Outstanding Awards", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Subject To Outstanding Awards", "terseLabel": "Number of Shares Subject To Outstanding Awards" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesSubjectToOutstandingAwards", "nsuri": "http://www.halozyme.com/20191231", "presentation": [ "http://www.halozyme.com/role/ShareBasedCompensationTextualsDetails" ], "xbrltype": "sharesItemType" }, "halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePricePercentOfSharePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercise Price, Percent of Share Price", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercise Price, Percent of Share Price", "terseLabel": "Options, Exercise Price, Percent of Share Price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePricePercentOfSharePrice", "nsuri": "http://www.halozyme.com/20191231", "presentation": [ "http://www.halozyme.com/role/ShareBasedCompensationTextualsDetails" ], "xbrltype": "percentItemType" }, "halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingInitialContractualTerm": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Initial Contractual Term", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Initial Contractual Term", "terseLabel": "Options, Outstanding, Initial Contractual Term" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingInitialContractualTerm", "nsuri": "http://www.halozyme.com/20191231", "presentation": [ "http://www.halozyme.com/role/ShareBasedCompensationTextualsDetails" ], "xbrltype": "durationItemType" }, "halo_SharesacquiredinprivatelynegotiatedtransactionsDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Shares acquired in privately negotiated transactions [Domain]", "label": "Shares acquired in privately negotiated transactions [Domain]", "terseLabel": "Shares acquired in privately negotiated transactions [Domain]" } } }, "localname": "SharesacquiredinprivatelynegotiatedtransactionsDomain", "nsuri": "http://www.halozyme.com/20191231", "presentation": [ "http://www.halozyme.com/role/LongTermDebtNetLongTermDebtTextualsDetails", "http://www.halozyme.com/role/StockholdersEquityDeficitShareRepurchasesDetails" ], "xbrltype": "domainItemType" }, "halo_StockIssuedDuringPeriodSharesNewIssuesToUnderwriter": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stock Issued During Period Shares New Issues To Underwriter", "label": "Stock Issued During Period Shares New Issues To Underwriter", "terseLabel": "Stock Issued During Period Shares New Issues To Underwriter" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssuesToUnderwriter", "nsuri": "http://www.halozyme.com/20191231", "presentation": [ "http://www.halozyme.com/role/StockholdersEquityDeficitPublicOfferingDetails" ], "xbrltype": "sharesItemType" }, "halo_StockOptionsAndRestrictedStockUnitsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stock Options And Restricted Stock Units [Member]", "label": "Stock Options And Restricted Stock Units [Member]", "terseLabel": "Stock Options And Restricted Stock Units [Member]" } } }, "localname": "StockOptionsAndRestrictedStockUnitsMember", "nsuri": "http://www.halozyme.com/20191231", "presentation": [ "http://www.halozyme.com/role/StockholdersEquityDeficitDetails" ], "xbrltype": "domainItemType" }, "halo_UnrecognizedTaxBenefitsthatWouldImpactEffectiveTaxRatenovaluationallowance": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate, no valuation allowance", "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate, no valuation allowance", "terseLabel": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate, no valuation allowance" } } }, "localname": "UnrecognizedTaxBenefitsthatWouldImpactEffectiveTaxRatenovaluationallowance", "nsuri": "http://www.halozyme.com/20191231", "presentation": [ "http://www.halozyme.com/role/IncomeTaxesTaxTextualsDetails", "http://www.halozyme.com/role/IncomeTaxesUnrecognizedTaxBenefitDetails" ], "xbrltype": "monetaryItemType" }, "halo_UpfrontfeesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Upfront fees [Member]", "label": "Upfront fees [Member]", "terseLabel": "Upfront license and target nomination fees", "verboseLabel": "Upfront" } } }, "localname": "UpfrontfeesMember", "nsuri": "http://www.halozyme.com/20191231", "presentation": [ "http://www.halozyme.com/role/RevenueDisaggregationOfRevenueDetails", "http://www.halozyme.com/role/RevenueRevenueRecognitionMultipleDeliverableArrangementsDetails" ], "xbrltype": "domainItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r169", "r274", "r278", "r461" ], "lang": { "en-US": { "role": { "documentation": "Information by name or description of a single external customer or a group of external customers.", "label": "Customer [Axis]", "terseLabel": "Customer [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesConcentrationsOfCreditRiskDetails" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Upper limit of the provided range.", "label": "Maximum [Member]", "terseLabel": "Maximum", "verboseLabel": "Period after expiration" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.halozyme.com/role/LongTermDebtNetLongTermDebtTextualsDetails", "http://www.halozyme.com/role/ShareBasedCompensationValuationDetails", "http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesLeasesDetails", "http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails", "http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Lower limit of the provided range.", "label": "Minimum [Member]", "terseLabel": "Minimum", "verboseLabel": "Period prior to expiration" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.halozyme.com/role/LongTermDebtNetLongTermDebtTextualsDetails", "http://www.halozyme.com/role/ShareBasedCompensationValuationDetails", "http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesLeasesDetails", "http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails", "http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Single external customer or group of external customers.", "label": "Customer [Domain]", "terseLabel": "Customer [Domain]" } } }, "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesConcentrationsOfCreditRiskDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r167", "r274", "r276", "r458", "r459" ], "lang": { "en-US": { "role": { "documentation": "Information by product and service, or group of similar products and similar services.", "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.halozyme.com/role/CertainBalanceSheetItemsDeferredRevenueDetails", "http://www.halozyme.com/role/ConsolidatedStatementsOfOperations", "http://www.halozyme.com/role/RevenueContractWithCustomerAssetAndLiabilityDetails", "http://www.halozyme.com/role/RevenueDisaggregationOfRevenueDetails", "http://www.halozyme.com/role/RevenueRevenueRecognitionMultipleDeliverableArrangementsDetails", "http://www.halozyme.com/role/RevenueRevenueRemainingPerformanceObligationDetails", "http://www.halozyme.com/role/RevenueTextualsDetails", "http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Product or service, or a group of similar products or similar services.", "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.halozyme.com/role/CertainBalanceSheetItemsDeferredRevenueDetails", "http://www.halozyme.com/role/ConsolidatedStatementsOfOperations", "http://www.halozyme.com/role/RevenueContractWithCustomerAssetAndLiabilityDetails", "http://www.halozyme.com/role/RevenueDisaggregationOfRevenueDetails", "http://www.halozyme.com/role/RevenueRevenueRecognitionMultipleDeliverableArrangementsDetails", "http://www.halozyme.com/role/RevenueRevenueRemainingPerformanceObligationDetails", "http://www.halozyme.com/role/RevenueTextualsDetails", "http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.", "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.halozyme.com/role/LongTermDebtNetLongTermDebtTextualsDetails", "http://www.halozyme.com/role/ShareBasedCompensationValuationDetails", "http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesLeasesDetails", "http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails", "http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.", "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.halozyme.com/role/LongTermDebtNetLongTermDebtTextualsDetails", "http://www.halozyme.com/role/ShareBasedCompensationValuationDetails", "http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesLeasesDetails", "http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails", "http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis": { "auth_ref": [ "r470", "r482", "r483" ], "lang": { "en-US": { "role": { "documentation": "Information by name of property.", "label": "Name of Property [Axis]", "terseLabel": "Name of Property [Axis]" } } }, "localname": "RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.halozyme.com/role/CommitmentsAndContingenciesOperatingLeaseTextualDetails" ], "xbrltype": "stringItemType" }, "srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the property, for example, but not limited to, ABC Shopping Center.", "label": "Name of Property [Domain]", "terseLabel": "Name of Property [Domain]" } } }, "localname": "RealEstateAndAccumulatedDepreciationNameOfPropertyDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.halozyme.com/role/CommitmentsAndContingenciesOperatingLeaseTextualDetails" ], "xbrltype": "domainItemType" }, "srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock": { "auth_ref": [ "r123", "r481" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]", "terseLabel": "Schedule II Valuation and Qualifying Accounts" } } }, "localname": "ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ScheduleIiValuationAndQualifyingAccounts" ], "xbrltype": "textBlockItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Geographical area.", "label": "Geographical [Domain]", "terseLabel": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesConcentrationsOfCreditRiskDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r168", "r274", "r277", "r460", "r465", "r469", "r479", "r480" ], "lang": { "en-US": { "role": { "documentation": "Information by geographical components.", "label": "Geographical [Axis]", "terseLabel": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesConcentrationsOfCreditRiskDetails" ], "xbrltype": "stringItemType" }, "srt_ValuationAndQualifyingAccountsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]" } } }, "localname": "ValuationAndQualifyingAccountsAbstract", "nsuri": "http://fasb.org/srt/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_AcceleratedShareRepurchasesDateDomain": { "auth_ref": [ "r261" ], "lang": { "en-US": { "role": { "documentation": "Date upon which the accelerated share repurchase agreement was executed.", "label": "Accelerated Share Repurchases, Date [Domain]", "terseLabel": "Accelerated Share Repurchases, Date [Domain]" } } }, "localname": "AcceleratedShareRepurchasesDateDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/LongTermDebtNetLongTermDebtTextualsDetails", "http://www.halozyme.com/role/StockholdersEquityDeficitShareRepurchasesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountingStandardsUpdate201409Member": { "auth_ref": [ "r280" ], "lang": { "en-US": { "role": { "documentation": "Accounting Standards Update 2014-09 Revenue from Contracts with Customers (Topic 606).", "label": "Accounting Standards Update 2014-09 [Member]", "terseLabel": "Accounting Standards Update 2014-09" } } }, "localname": "AccountingStandardsUpdate201409Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/RevenueTextualsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r43" ], "calculation": { "http://www.halozyme.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "verboseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableMember": { "auth_ref": [ "r13" ], "lang": { "en-US": { "role": { "documentation": "Obligations incurred and payable to vendors for goods and services received.", "label": "Accounts Payable [Member]", "terseLabel": "Accounts Payable [Member]" } } }, "localname": "AccountsPayableMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesConcentrationsOfCreditRiskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsReceivableGrossCurrent": { "auth_ref": [ "r170", "r171" ], "calculation": { "http://www.halozyme.com/role/CertainBalanceSheetItemsAccountsReceivableDetails": { "order": 1.0, "parentTag": "us-gaap_AccountsReceivableNetCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, before Allowance for Credit Loss, Current", "totalLabel": "Accounts receivable, gross" } } }, "localname": "AccountsReceivableGrossCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/CertainBalanceSheetItemsAccountsReceivableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Due from customers or clients for goods or services that have been delivered or sold.", "label": "Accounts Receivable [Member]", "terseLabel": "Accounts Receivable [Member]" } } }, "localname": "AccountsReceivableMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesConcentrationsOfCreditRiskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r2", "r23", "r170", "r171", "r275" ], "calculation": { "http://www.halozyme.com/role/CertainBalanceSheetItemsAccountsReceivableDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.halozyme.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable, net", "totalLabel": "Total accounts receivable, net", "verboseLabel": "Accounts receivable, net" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/CertainBalanceSheetItemsAccountsReceivableDetails", "http://www.halozyme.com/role/ConsolidatedBalanceSheets", "http://www.halozyme.com/role/RevenueContractWithCustomerAssetAndLiabilityDetails", "http://www.halozyme.com/role/RevenueTextualsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Accounts Receivable, after Allowance for Credit Loss, Current [Abstract]" } } }, "localname": "AccountsReceivableNetCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": { "auth_ref": [ "r105" ], "calculation": { "http://www.halozyme.com/role/ConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Accretion (Amortization) of Discounts and Premiums, Investments", "negatedLabel": "(Accretion of discounts) amortization of premiums on marketable securities, net" } } }, "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesAndOtherLiabilities": { "auth_ref": [], "calculation": { "http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.", "label": "Accrued Liabilities and Other Liabilities", "totalLabel": "Total accrued expenses" } } }, "localname": "AccruedLiabilitiesAndOtherLiabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r45" ], "calculation": { "http://www.halozyme.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "terseLabel": "Total accrued expenses, current", "verboseLabel": "Accrued expenses" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails", "http://www.halozyme.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Accrued Liabilities, Current [Abstract]", "verboseLabel": "Summary of Accrued Expenses" } } }, "localname": "AccruedLiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentExcludingCapitalLeasedAssets": { "auth_ref": [ "r42", "r220" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Cumulative amount of depreciation, depletion and amortization (related to property, plant and equipment, but not including land or leased assets).", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Excluding Capital Leased Assets", "negatedLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Excluding Capital Leased Assets" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentExcludingCapitalLeasedAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r65", "r67", "r68" ], "calculation": { "http://www.halozyme.com/role/ConsolidatedBalanceSheets": { "order": 10.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r64", "r68", "r69", "r375" ], "lang": { "en-US": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "AOCI Attributable to Parent [Member]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ConsolidatedStatementsOfStockholdersEquityDeficitStatement" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r24" ], "calculation": { "http://www.halozyme.com/role/ConsolidatedBalanceSheets": { "order": 9.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional Paid in Capital, Common Stock", "verboseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ConsolidatedStatementsOfStockholdersEquityDeficitStatement" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "auth_ref": [ "r126" ], "lang": { "en-US": { "role": { "documentation": "Information by new accounting pronouncement.", "label": "Adjustments for New Accounting Pronouncements [Axis]", "terseLabel": "Adjustments for New Accounting Pronouncements [Axis]" } } }, "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/RevenueTextualsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt": { "auth_ref": [ "r243" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Adjustment to additional paid in capital resulting from the recognition of convertible debt instruments as two separate components - a debt component and an equity component. This bifurcation may result in a basis difference associated with the liability component that represents a temporary difference for purposes of applying accounting for income taxes. The initial recognition of deferred taxes for the tax effect of that temporary difference is as an adjustment to additional paid in capital.", "label": "Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt", "terseLabel": "Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ConsolidatedStatementsOfStockholdersEquityDeficitStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r288", "r290", "r324", "r325" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Share-based Compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ConsolidatedStatementsOfStockholdersEquityDeficitStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "verboseLabel": "Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r290", "r318", "r323" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-based Payment Arrangement, Expense", "terseLabel": "Share-based Payment Arrangement, Expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ShareBasedCompensationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "auth_ref": [ "r29", "r176", "r198" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.", "label": "Accounts Receivable, Allowance for Credit Loss, Current", "terseLabel": "Accounts Receivable, Allowance for Credit Loss, Current" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesAccountsReceivableDetails", "http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesConcentrationsOfCreditRiskDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfDebtDiscountPremium": { "auth_ref": [ "r88", "r104", "r397" ], "calculation": { "http://www.halozyme.com/role/ConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.", "label": "Amortization of Debt Discount (Premium)", "terseLabel": "Amortization of Debt Discount (Premium)" } } }, "localname": "AmortizationOfDebtDiscountPremium", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ConsolidatedStatementsOfCashFlows", "http://www.halozyme.com/role/LongTermDebtNetLongTermDebtTextualsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCosts": { "auth_ref": [ "r81", "r104", "r399" ], "calculation": { "http://www.halozyme.com/role/ConsolidatedStatementsOfCashFlows": { "order": 18.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense attributable to debt issuance costs.", "label": "Amortization of Debt Issuance Costs", "terseLabel": "Non-cash interest expense" } } }, "localname": "AmortizationOfFinancingCosts", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r137" ], "lang": { "en-US": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesNetLossPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "verboseLabel": "Collaborative Arrangements and Non-collaborative Arrangement Transactions [Domain]" } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/RevenueRevenueRecognitionMultipleDeliverableArrangementsDetails", "http://www.halozyme.com/role/RevenueTextualsDetails", "http://www.halozyme.com/role/SummaryOfUnauditedQuarterlyFinancialInformationTextualsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AssetBackedSecuritiesMember": { "auth_ref": [ "r191", "r284" ], "lang": { "en-US": { "role": { "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans.", "label": "Asset-backed Securities [Member]", "terseLabel": "Asset-backed Securities [Member]" } } }, "localname": "AssetBackedSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/FairValueMeasurementFairValueMeasuresDetails", "http://www.halozyme.com/role/FairValueMeasurementSummaryDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r165", "r426", "r449" ], "calculation": { "http://www.halozyme.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets [Abstract]", "verboseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r4", "r6", "r60" ], "calculation": { "http://www.halozyme.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets, Current [Abstract]", "verboseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r377" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure", "terseLabel": "Fair Value Disclosure" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/FairValueMeasurementFairValueMeasuresDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "auth_ref": [ "r184" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax", "terseLabel": "Gross Unrealized Gains" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/FairValueMeasurementSummaryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [ "r185" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax", "negatedLabel": "Gross Unrealized Losses" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/FairValueMeasurementSummaryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "auth_ref": [ "r182", "r207" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Amortized Cost", "terseLabel": "Debt Securities, Available-for-sale, Amortized Cost" } } }, "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/FairValueMeasurementFairValueMeasuresDetails", "http://www.halozyme.com/role/FairValueMeasurementSummaryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecurities": { "auth_ref": [], "calculation": { "http://www.halozyme.com/role/FairValueMeasurementMaturitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.", "label": "Available-for-sale Securities", "terseLabel": "Available-for-sale Securities", "totalLabel": "Available-for-sale Securities", "verboseLabel": "Estimated fair value" } } }, "localname": "AvailableForSaleSecurities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/FairValueMeasurementFairValueMeasuresDetails", "http://www.halozyme.com/role/FairValueMeasurementMaturitiesDetails", "http://www.halozyme.com/role/FairValueMeasurementSummaryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesAmortizedCost": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "This item represents the cost of debt and equity securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.", "label": "Available-for-sale Securities, Amortized Cost Basis", "terseLabel": "Amortized cost" } } }, "localname": "AvailableForSaleSecuritiesAmortizedCost", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/FairValueMeasurementSummaryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "This item represents the aggregate fair value of investments in debt and equity securities in an unrealized loss position which are categorized neither as held-to-maturity nor trading securities.", "label": "Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value", "terseLabel": "Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value" } } }, "localname": "AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/FairValueMeasurementSummaryDetails", "http://www.halozyme.com/role/FairValueMeasurementTextualsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of accumulated unrealized loss on investments in debt and equity securities classified as available-for-sale that have been in a continuous loss position for less than twelve months.", "label": "Available-for-sale Securities, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss", "negatedTerseLabel": "Available-for-sale Securities, Continuous Unrealized Loss Position, Accumulated Loss" } } }, "localname": "AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/FairValueMeasurementTextualsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesCurrent": { "auth_ref": [], "calculation": { "http://www.halozyme.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in debt and equity securities categorized neither as trading securities nor held-to-maturity securities and intended be sold or mature one year or operating cycle, if longer.", "label": "Available-for-sale Securities, Current", "terseLabel": "Marketable securities, available-for-sale" } } }, "localname": "AvailableForSaleSecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": { "auth_ref": [ "r186", "r189", "r438" ], "calculation": { "http://www.halozyme.com/role/FairValueMeasurementMaturitiesDetails": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleSecurities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.", "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after One Through Five Years, Fair Value", "terseLabel": "After one but within five years" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/FairValueMeasurementMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": { "auth_ref": [ "r186", "r188", "r437" ], "calculation": { "http://www.halozyme.com/role/FairValueMeasurementMaturitiesDetails": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleSecurities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), maturing in next fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.", "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, within One Year, Fair Value", "terseLabel": "Due within one year" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/FairValueMeasurementMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r180", "r183", "r207" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale", "terseLabel": "Debt Securities, Available-for-sale" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/FairValueMeasurementFairValueMeasuresDetails", "http://www.halozyme.com/role/FairValueMeasurementSummaryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.", "label": "Available-for-sale Securities [Table Text Block]", "terseLabel": "Available-for-sale marketable securities" } } }, "localname": "AvailableForSaleSecuritiesTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/FairValueMeasurementTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1": { "auth_ref": [ "r192" ], "lang": { "en-US": { "role": { "documentation": "Number of investment positions in available-for-sale investments in a continuous unrealized loss position for which an other-than-temporary impairment (OTTI) has not been recognized in the income statement.", "label": "Available-for-sale, Securities in Unrealized Loss Positions, Qualitative Disclosure, Number of Positions", "terseLabel": "Available-for-sale, Securities in Unrealized Loss Positions, Qualitative Disclosure, Number of Positions" } } }, "localname": "AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/FairValueMeasurementTextualsDetails" ], "xbrltype": "integerItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r291", "r320" ], "lang": { "en-US": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ShareBasedCompensationExpenseDetails", "http://www.halozyme.com/role/ShareBasedCompensationOptionsDetails", "http://www.halozyme.com/role/ShareBasedCompensationRestrictedStockAwardsDetails", "http://www.halozyme.com/role/ShareBasedCompensationRestrictedStockUnitsDetails", "http://www.halozyme.com/role/ShareBasedCompensationTextualsDetails", "http://www.halozyme.com/role/ShareBasedCompensationUnrecognizedExpenseDetails", "http://www.halozyme.com/role/StockholdersEquityDeficitDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetRelatedDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Balance Sheet Related Disclosures [Abstract]" } } }, "localname": "BalanceSheetRelatedDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r124" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.", "label": "Basis of Presentation and Significant Accounting Policies [Text Block]", "verboseLabel": "Basis of Presentation" } } }, "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "auth_ref": [ "r109", "r110", "r111" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.", "label": "Capital Expenditures Incurred but Not yet Paid", "terseLabel": "Amounts accrued for purchases of property and equipment" } } }, "localname": "CapitalExpendituresIncurredButNotYetPaid", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r0", "r39", "r106" ], "calculation": { "http://www.halozyme.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "verboseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of cash and cash equivalent balance.", "label": "Cash and Cash Equivalents [Axis]", "terseLabel": "Cash and Cash Equivalents [Axis]" } } }, "localname": "CashAndCashEquivalentsAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/FairValueMeasurementFairValueMeasuresDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "terseLabel": "Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/FairValueMeasurementFairValueMeasuresDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r14", "r107", "r113" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": { "auth_ref": [ "r14", "r107", "r113", "r424" ], "lang": { "en-US": { "role": { "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.", "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Restricted Cash" } } }, "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r99", "r106", "r112" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash, cash equivalents and restricted cash end of period", "periodStartLabel": "Cash, cash equivalents and restricted cash beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r99", "r394" ], "calculation": { "http://www.halozyme.com/role/ConsolidatedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net increase (decrease) in cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfTreasuryStockTable": { "auth_ref": [ "r262", "r263", "r264", "r265" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.", "label": "Class of Treasury Stock [Table]", "terseLabel": "Class of Treasury Stock [Table]" } } }, "localname": "ClassOfTreasuryStockTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/StockholdersEquityDeficitShareRepurchasesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CollaborativeArrangementDisclosureTextBlock": { "auth_ref": [ "r371", "r372", "r374" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.", "label": "Collaborative Arrangement Disclosure [Text Block]", "terseLabel": "Revenue" } } }, "localname": "CollaborativeArrangementDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/Revenue" ], "xbrltype": "textBlockItemType" }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "terseLabel": "Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]" } } }, "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/RevenueTextualsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommercialPaperMember": { "auth_ref": [ "r239" ], "lang": { "en-US": { "role": { "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.", "label": "Commercial Paper [Member]", "terseLabel": "Commercial Paper [Member]" } } }, "localname": "CommercialPaperMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/FairValueMeasurementFairValueMeasuresDetails", "http://www.halozyme.com/role/FairValueMeasurementSummaryDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r54", "r237", "r431", "r454" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "verboseLabel": "Commitments and contingencies (Note 9)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r236", "r238" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "verboseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/CommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r55" ], "lang": { "en-US": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Common Stock, Capital Shares Reserved for Future Issuance", "terseLabel": "Common Stock, Capital Shares Reserved for Future Issuance" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ShareBasedCompensationTextualsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.halozyme.com/role/ConsolidatedStatementsOfStockholdersEquityDeficitStatement" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r22" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "verboseLabel": "Common stock, par value" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r22" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "verboseLabel": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r22" ], "lang": { "en-US": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "verboseLabel": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r22", "r254" ], "lang": { "en-US": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "verboseLabel": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r22" ], "calculation": { "http://www.halozyme.com/role/ConsolidatedBalanceSheets": { "order": 8.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "verboseLabel": "Common stock - $0.001 par value; 200,000 shares authorized; 142,789 and 129,502 shares issued and outstanding at December 31, 2017 and 2016, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": { "auth_ref": [ "r282", "r283", "r287", "r326" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.", "label": "Compensation and Employee Benefit Plans [Text Block]", "terseLabel": "Compensation and Employee Benefit Plans [Text Block]" } } }, "localname": "CompensationAndEmployeeBenefitPlansTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/EmployeeSavingsPlanNotes" ], "xbrltype": "textBlockItemType" }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Retirement Benefits [Abstract]" } } }, "localname": "CompensationAndRetirementDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r71", "r73", "r74" ], "calculation": { "http://www.halozyme.com/role/ConsolidatedStatementsOfComprehensiveLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Total comprehensive income (loss)" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ConsolidatedStatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for comprehensive income.", "label": "Comprehensive Income, Policy [Policy Text Block]", "terseLabel": "Comprehensive Income (Loss), Policy [Policy Text Block]" } } }, "localname": "ComprehensiveIncomePolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r153", "r154", "r388", "r389" ], "lang": { "en-US": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]", "terseLabel": "Concentration Risk Benchmark [Domain]" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesConcentrationsOfCreditRiskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r153", "r154", "r388", "r389", "r464" ], "lang": { "en-US": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]", "terseLabel": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesConcentrationsOfCreditRiskDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r153", "r154", "r388", "r389", "r464" ], "lang": { "en-US": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]", "terseLabel": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesConcentrationsOfCreditRiskDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r147", "r446" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "terseLabel": "Concentration Risk, Credit Risk, Policy [Policy Text Block]" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Concentration Risk [Line Items]", "terseLabel": "Concentration Risk [Line Items]" } } }, "localname": "ConcentrationRiskLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesConcentrationsOfCreditRiskDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r153", "r154", "r388", "r389" ], "lang": { "en-US": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration Risk, Percentage", "terseLabel": "Concentration Risk, Percentage" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesConcentrationsOfCreditRiskDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTable": { "auth_ref": [ "r150", "r153", "r154", "r155", "r388", "r390" ], "lang": { "en-US": { "role": { "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.", "label": "Concentration Risk [Table]", "terseLabel": "Concentration Risk [Table]" } } }, "localname": "ConcentrationRiskTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesConcentrationsOfCreditRiskDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r153", "r154", "r388", "r389" ], "lang": { "en-US": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]", "terseLabel": "Concentration Risk Type [Domain]" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesConcentrationsOfCreditRiskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ContractTerminationMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Termination of a contract associated with exit from or disposal of business activities or restructurings pursuant to a plan.", "label": "Contract Termination [Member]", "terseLabel": "Contract Termination and Asset Impairments" } } }, "localname": "ContractTerminationMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/RestructuringChargesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss": { "auth_ref": [ "r198", "r200", "r201", "r269" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of accumulated credit loss for right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.", "label": "Contract with Customer, Asset, Allowance for Credit Loss", "terseLabel": "Contract with Customer, Asset, Allowance for Credit Loss" } } }, "localname": "ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/RevenueRevenueRecognitionMultipleDeliverableArrangementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": { "auth_ref": [ "r270" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of contract balances and changes in contract balances.", "label": "Contract with Customer, Asset and Liability [Table Text Block]", "terseLabel": "Contract with Customer, Asset and Liability" } } }, "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/RevenueTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerAssetNet": { "auth_ref": [ "r267", "r269", "r275" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.", "label": "Contract with Customer, Asset, after Allowance for Credit Loss", "terseLabel": "Accounts receivable" } } }, "localname": "ContractWithCustomerAssetNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/RevenueTextualsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiability": { "auth_ref": [ "r267", "r268", "r275" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Contract with Customer, Liability", "terseLabel": "Deferred revenues", "verboseLabel": "Contract with Customer, Liability" } } }, "localname": "ContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/CertainBalanceSheetItemsDeferredRevenueDetails", "http://www.halozyme.com/role/RevenueTextualsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "auth_ref": [ "r267", "r268", "r275" ], "calculation": { "http://www.halozyme.com/role/CertainBalanceSheetItemsDeferredRevenueDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredRevenue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.", "label": "Contract with Customer, Liability, Current", "terseLabel": "Contract with Customer, Liability, Current" } } }, "localname": "ContractWithCustomerLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/CertainBalanceSheetItemsDeferredRevenueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleDebtMember": { "auth_ref": [ "r242" ], "lang": { "en-US": { "role": { "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.", "label": "Convertible Debt [Member]", "terseLabel": "Convertible Debt [Member]", "verboseLabel": "Convertible Senior Notes" } } }, "localname": "ConvertibleDebtMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/LongTermDebtNetLongTermDebtTextualsDetails", "http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesNetLossPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CorporateDebtSecuritiesMember": { "auth_ref": [ "r284", "r286", "r463" ], "lang": { "en-US": { "role": { "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.", "label": "Corporate Debt Securities [Member]", "terseLabel": "Corporate Debt Securities [Member]" } } }, "localname": "CorporateDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/FairValueMeasurementFairValueMeasuresDetails", "http://www.halozyme.com/role/FairValueMeasurementSummaryDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r85" ], "calculation": { "http://www.halozyme.com/role/ConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "terseLabel": "Cost of Goods and Services Sold", "verboseLabel": "Cost of product sales" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ConsolidatedStatementsOfOperations", "http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfSalesPolicyTextBlock": { "auth_ref": [ "r281" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for cost of product sold and service rendered.", "label": "Cost of Goods and Service [Policy Text Block]", "verboseLabel": "Cost of Product Sales, Policy [Policy Text Block]" } } }, "localname": "CostOfSalesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r82" ], "calculation": { "http://www.halozyme.com/role/ConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "Costs and Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpensesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Costs and Expenses [Abstract]", "verboseLabel": "Operating expenses:" } } }, "localname": "CostsAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) to equity or (increase) decrease to net assets, resulting from the cumulative effect adjustment of a new accounting principle applied in the period of adoption.", "label": "Cumulative Effect of New Accounting Principle in Period of Adoption", "terseLabel": "Adjustment to beginning retained earnings" } } }, "localname": "CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ConsolidatedStatementsOfStockholdersEquityDeficitStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentFederalTaxExpenseBenefit": { "auth_ref": [ "r118", "r361", "r365" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current Federal Tax Expense (Benefit)", "terseLabel": "Current Federal Tax Expense (Benefit)" } } }, "localname": "CurrentFederalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/IncomeTaxesIncomeTaxExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": { "auth_ref": [ "r118", "r361", "r365" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current State and Local Tax Expense (Benefit)", "terseLabel": "Current State Tax Expense" } } }, "localname": "CurrentStateAndLocalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/IncomeTaxesIncomeTaxExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r151" ], "lang": { "en-US": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer Concentration Risk [Member]", "terseLabel": "Customer Concentration Risk [Member]" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesConcentrationsOfCreditRiskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r18", "r19", "r20", "r427", "r428", "r447" ], "lang": { "en-US": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/LongTermDebtNetLongTermDebtTextualsDetails", "http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesNetLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.", "label": "Debt Instrument, Basis Spread on Variable Rate", "terseLabel": "Debt Instrument, Basis Spread on Variable Rate" } } }, "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/LongTermDebtNetLongTermDebtTextualsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentCarryingAmount": { "auth_ref": [ "r20", "r245", "r428", "r447" ], "calculation": { "http://www.halozyme.com/role/LongTermDebtNetDebtTableDetails": { "order": 1.0, "parentTag": "us-gaap_LongTermDebtFairValue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.", "label": "Long-term Debt, Gross", "terseLabel": "Gross balance of long-term debt" } } }, "localname": "DebtInstrumentCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/LongTermDebtNetDebtTableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent": { "auth_ref": [ "r244" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The carrying amount of the equity component of convertible debt which may be settled in cash upon conversion.", "label": "Debt Instrument, Convertible, Carrying Amount of Equity Component", "terseLabel": "Debt Instrument, Convertible, Carrying Amount of Equity Component" } } }, "localname": "DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/LongTermDebtNetLongTermDebtTextualsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentConvertibleConversionPrice1": { "auth_ref": [ "r248" ], "lang": { "en-US": { "role": { "documentation": "The price per share of the conversion feature embedded in the debt instrument.", "label": "Debt Instrument, Convertible, Conversion Price", "terseLabel": "Debt Instrument, Convertible, Conversion Price" } } }, "localname": "DebtInstrumentConvertibleConversionPrice1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/LongTermDebtNetLongTermDebtTextualsDetails", "http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesNetLossPerShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_DebtInstrumentConvertibleConversionRatio1": { "auth_ref": [ "r50", "r255", "r256", "r258" ], "lang": { "en-US": { "role": { "documentation": "Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.", "label": "Debt Instrument, Convertible, Conversion Ratio", "terseLabel": "Conversion rate (shares)" } } }, "localname": "DebtInstrumentConvertibleConversionRatio1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/LongTermDebtNetLongTermDebtTextualsDetails" ], "xbrltype": "pureItemType" }, "us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1": { "auth_ref": [ "r247" ], "lang": { "en-US": { "role": { "documentation": "Remaining amortization period for discount on the liability component of convertible debt which may be settled in cash upon conversion, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Debt Instrument, Convertible, Remaining Discount Amortization Period", "terseLabel": "Debt Instrument, Convertible, Remaining Discount Amortization Period" } } }, "localname": "DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/LongTermDebtNetLongTermDebtTextualsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.", "label": "Debt Instrument, Convertible, Threshold Consecutive Trading Days", "terseLabel": "Debt Instrument, Convertible, Threshold Consecutive Trading Days" } } }, "localname": "DebtInstrumentConvertibleThresholdConsecutiveTradingDays1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/LongTermDebtNetLongTermDebtTextualsDetails" ], "xbrltype": "integerItemType" }, "us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.", "label": "Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger", "terseLabel": "Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger" } } }, "localname": "DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/LongTermDebtNetLongTermDebtTextualsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentConvertibleThresholdTradingDays": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.", "label": "Debt Instrument, Convertible, Threshold Trading Days", "terseLabel": "Debt Instrument, Convertible, Threshold Trading Days" } } }, "localname": "DebtInstrumentConvertibleThresholdTradingDays", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/LongTermDebtNetLongTermDebtTextualsDetails" ], "xbrltype": "integerItemType" }, "us-gaap_DebtInstrumentCovenantCompliance": { "auth_ref": [ "r20", "r442" ], "lang": { "en-US": { "role": { "documentation": "States whether the entity was in compliance with the debt covenants throughout the reporting period, and describes facts and circumstances of any compliance failure.", "label": "Debt Instrument, Covenant Compliance", "terseLabel": "Debt instrument, covenant in compliance" } } }, "localname": "DebtInstrumentCovenantCompliance", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/LongTermDebtNetLongTermDebtTextualsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentDescriptionOfVariableRateBasis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The reference rate for the variable rate of the debt instrument, such as LIBOR or the US Treasury rate and the maturity of the reference rate used, such as three months or six months LIBOR.", "label": "Debt Instrument, Description of Variable Rate Basis", "terseLabel": "Debt Instrument, Description of Variable Rate Basis" } } }, "localname": "DebtInstrumentDescriptionOfVariableRateBasis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/LongTermDebtNetLongTermDebtTextualsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r398", "r400" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "terseLabel": "Face amount of debt instrument" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/LongTermDebtNetLongTermDebtTextualsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentFeeAmount": { "auth_ref": [ "r51" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the fee that accompanies borrowing money under the debt instrument.", "label": "Debt Instrument, Fee Amount", "terseLabel": "Lender Fee" } } }, "localname": "DebtInstrumentFeeAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/LongTermDebtNetLongTermDebtTextualsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentIncreaseAccruedInterest": { "auth_ref": [ "r120" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Increase for accrued, but unpaid interest on the debt instrument for the period.", "label": "Debt Instrument, Increase, Accrued Interest", "terseLabel": "Accrued Interest" } } }, "localname": "DebtInstrumentIncreaseAccruedInterest", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/LongTermDebtNetLongTermDebtTextualsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "auth_ref": [ "r47", "r249", "r398" ], "lang": { "en-US": { "role": { "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.", "label": "Debt Instrument, Interest Rate, Effective Percentage", "terseLabel": "Debt Instrument, Interest Rate, Effective Percentage" } } }, "localname": "DebtInstrumentInterestRateEffectivePercentage", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/LongTermDebtNetLongTermDebtTextualsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r47" ], "lang": { "en-US": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Stated interest rate (as a percent)" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/LongTermDebtNetLongTermDebtTextualsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/LongTermDebtNetLongTermDebtTextualsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentMaturityDate": { "auth_ref": [ "r48", "r380" ], "lang": { "en-US": { "role": { "documentation": "Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.", "label": "Debt Instrument, Maturity Date", "terseLabel": "Maturity date" } } }, "localname": "DebtInstrumentMaturityDate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/LongTermDebtNetLongTermDebtTextualsDetails" ], "xbrltype": "dateItemType" }, "us-gaap_DebtInstrumentMaturityDateDescription": { "auth_ref": [ "r48" ], "lang": { "en-US": { "role": { "documentation": "Description of the maturity date of the debt instrument including whether the debt matures serially and, if so, a brief description of the serial maturities.", "label": "Debt Instrument, Maturity Date, Description", "terseLabel": "Debt Instrument, Maturity Date, Description" } } }, "localname": "DebtInstrumentMaturityDateDescription", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/LongTermDebtNetLongTermDebtTextualsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r52" ], "lang": { "en-US": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/LongTermDebtNetLongTermDebtTextualsDetails", "http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesNetLossPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentPaymentTerms": { "auth_ref": [ "r49", "r441" ], "lang": { "en-US": { "role": { "documentation": "Description of the payment terms of the debt instrument (for example, whether periodic payments include principal and frequency of payments) and discussion about any contingencies associated with the payment.", "label": "Debt Instrument, Payment Terms", "terseLabel": "Debt Instrument, interest only period" } } }, "localname": "DebtInstrumentPaymentTerms", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/LongTermDebtNetLongTermDebtTextualsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentPeriodicPayment": { "auth_ref": [ "r52", "r441" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the required periodic payments including both interest and principal payments.", "label": "Debt Instrument, Periodic Payment", "terseLabel": "Debt Instrument, Periodic Payment" } } }, "localname": "DebtInstrumentPeriodicPayment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/LongTermDebtNetLongTermDebtTextualsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentPeriodicPaymentInterest": { "auth_ref": [ "r52" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the required periodic payments applied to interest.", "label": "Debt Instrument, Periodic Payment, Interest", "terseLabel": "Debt Instrument, Periodic Payment, Interest" } } }, "localname": "DebtInstrumentPeriodicPaymentInterest", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/LongTermDebtNetLongTermDebtTextualsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of payment greater than the preceding installment payments to be paid at final maturity date of debt.", "label": "Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid", "terseLabel": "Final payment" } } }, "localname": "DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/LongTermDebtNetLongTermDebtTextualsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentRedemptionPeriodAxis": { "auth_ref": [ "r443" ], "lang": { "en-US": { "role": { "documentation": "Information about timing of debt redemption features under terms of the debt agreement.", "label": "Debt Instrument, Redemption, Period [Axis]", "terseLabel": "Debt Instrument, Redemption, Period [Axis]" } } }, "localname": "DebtInstrumentRedemptionPeriodAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/LongTermDebtNetLongTermDebtTextualsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentRedemptionPeriodDomain": { "auth_ref": [ "r443" ], "lang": { "en-US": { "role": { "documentation": "Period as defined under terms of the debt agreement for debt redemption features.", "label": "Debt Instrument, Redemption, Period [Domain]", "terseLabel": "Debt Instrument, Redemption, Period [Domain]" } } }, "localname": "DebtInstrumentRedemptionPeriodDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/LongTermDebtNetLongTermDebtTextualsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentRedemptionPeriodOneMember": { "auth_ref": [ "r443" ], "lang": { "en-US": { "role": { "documentation": "Period one representing most current period of debt redemption features under terms of the debt agreement.", "label": "Debt Instrument, Redemption, Period One [Member]", "terseLabel": "Debt Instrument, Redemption, Period One" } } }, "localname": "DebtInstrumentRedemptionPeriodOneMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/LongTermDebtNetLongTermDebtTextualsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentRedemptionPeriodTwoMember": { "auth_ref": [ "r443" ], "lang": { "en-US": { "role": { "documentation": "Period two representing second most current period of debt redemption features under terms of the debt agreement.", "label": "Debt Instrument, Redemption, Period Two [Member]", "terseLabel": "Debt Instrument, Redemption, Period Two" } } }, "localname": "DebtInstrumentRedemptionPeriodTwoMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/LongTermDebtNetLongTermDebtTextualsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r52", "r119", "r255", "r257", "r258", "r259", "r397", "r398", "r400", "r444" ], "lang": { "en-US": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-term Debt Instruments [Table]", "terseLabel": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/LongTermDebtNetLongTermDebtTextualsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "auth_ref": [ "r397", "r400" ], "calculation": { "http://www.halozyme.com/role/LongTermDebtNetDebtTableDetails": { "order": 2.0, "parentTag": "us-gaap_LongTermDebtFairValue", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after accumulated amortization, of debt discount.", "label": "Debt Instrument, Unamortized Discount", "negatedTerseLabel": "Less unamortized debt discount", "terseLabel": "Debt Instrument, Unamortized Discount" } } }, "localname": "DebtInstrumentUnamortizedDiscount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/LongTermDebtNetDebtTableDetails", "http://www.halozyme.com/role/LongTermDebtNetLongTermDebtTextualsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount": { "auth_ref": [ "r51" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of unused borrowing capacity under the long-term financing arrangement that is available to the entity as of the balance sheet date.", "label": "Debt Instrument, Unused Borrowing Capacity, Amount", "terseLabel": "Debt Instrument, Unused Borrowing Capacity, Amount" } } }, "localname": "DebtInstrumentUnusedBorrowingCapacityAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/LongTermDebtNetLongTermDebtTextualsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction": { "auth_ref": [ "r109", "r110", "r111" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of debt issuance costs that were incurred during a noncash or partial noncash transaction.", "label": "Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction", "terseLabel": "Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction" } } }, "localname": "DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtWeightedAverageInterestRate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average interest rate of debt outstanding.", "label": "Debt, Weighted Average Interest Rate", "terseLabel": "Debt, Interest Rate" } } }, "localname": "DebtWeightedAverageInterestRate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/LongTermDebtNetLongTermDebtTextualsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DeferredCreditsAndOtherLiabilities": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total carrying amount as of the balance sheet date of unearned revenue or income, not otherwise specified in the taxonomy, which is expected to be taken into income in future periods and obligations not separately disclosed in the balance sheet (other liabilities).", "label": "Deferred Credits and Other Liabilities", "terseLabel": "Deferred Credits and Other Liabilities" } } }, "localname": "DeferredCreditsAndOtherLiabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/RevenueContractWithCustomerAssetAndLiabilityDetails", "http://www.halozyme.com/role/RevenueRevenueRemainingPerformanceObligationDetails", "http://www.halozyme.com/role/RevenueTextualsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent": { "auth_ref": [], "calculation": { "http://www.halozyme.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying amount as of the balance sheet date of unearned revenue or income, not otherwise specified in the taxonomy, which is expected to be taken into income during the current period and current obligations not separately disclosed in the balance sheet (other liabilities, current).", "label": "Deferred Credits and Other Liabilities, Current", "terseLabel": "Deferred Credits and Other Liabilities, Current" } } }, "localname": "DeferredCreditsAndOtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ConsolidatedBalanceSheets", "http://www.halozyme.com/role/RevenueContractWithCustomerAssetAndLiabilityDetails", "http://www.halozyme.com/role/RevenueRevenueRemainingPerformanceObligationDetails", "http://www.halozyme.com/role/RevenueTextualsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent": { "auth_ref": [], "calculation": { "http://www.halozyme.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying amount as of the balance sheet date of unearned revenue or income, not otherwise specified in the taxonomy, which is expected to be taken into income after one year or beyond the normal operating cycle, if longer and noncurrent obligations not separately disclosed in the balance sheet (other liabilities, noncurrent).", "label": "Deferred Credits and Other Liabilities, Noncurrent", "terseLabel": "Deferred Credits and Other Liabilities, Noncurrent" } } }, "localname": "DeferredCreditsAndOtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": { "auth_ref": [ "r118", "r362", "r365" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Federal Income Tax Expense (Benefit)", "terseLabel": "Deferred Federal Income Tax Benefit" } } }, "localname": "DeferredFederalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/IncomeTaxesIncomeTaxExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFinanceCostsGross": { "auth_ref": [ "r399" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Gross", "terseLabel": "Debt Issuance Cost" } } }, "localname": "DeferredFinanceCostsGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/LongTermDebtNetLongTermDebtTextualsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": { "auth_ref": [ "r118", "r362", "r365" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Foreign Income Tax Expense (Benefit)", "terseLabel": "Deferred Foreign Tax Benefit" } } }, "localname": "DeferredForeignIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/IncomeTaxesTaxTextualsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRevenue": { "auth_ref": [ "r30" ], "calculation": { "http://www.halozyme.com/role/CertainBalanceSheetItemsDeferredRevenueDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.", "label": "Deferred Revenue", "terseLabel": "Deferred revenues", "totalLabel": "Total deferred revenue" } } }, "localname": "DeferredRevenue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/CertainBalanceSheetItemsDeferredRevenueDetails", "http://www.halozyme.com/role/RevenueContractWithCustomerAssetAndLiabilityDetails", "http://www.halozyme.com/role/RevenueRevenueRemainingPerformanceObligationDetails", "http://www.halozyme.com/role/RevenueTextualsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRevenueArrangementByTypeTable": { "auth_ref": [ "r9" ], "lang": { "en-US": { "role": { "documentation": "Schedule of deferred revenue disclosure which includes the type of arrangements and the corresponding amount that comprise the current and noncurrent balance of deferred revenue as of the balance sheet date.", "label": "Deferred Revenue Arrangement, by Type [Table]", "terseLabel": "Deferred Revenue Arrangement, by Type [Table]" } } }, "localname": "DeferredRevenueArrangementByTypeTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/CertainBalanceSheetItemsDeferredRevenueDetails", "http://www.halozyme.com/role/RevenueTextualsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredRevenueArrangementLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Deferred Revenue Arrangement [Line Items]", "terseLabel": "Deferred revenue" } } }, "localname": "DeferredRevenueArrangementLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/CertainBalanceSheetItemsDeferredRevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredRevenueArrangementTypeAxis": { "auth_ref": [ "r9" ], "lang": { "en-US": { "role": { "documentation": "Information by type of deferred revenue arrangement.", "label": "Deferred Revenue Arrangement Type [Axis]", "terseLabel": "Deferred Revenue Arrangement Type [Axis]" } } }, "localname": "DeferredRevenueArrangementTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/CertainBalanceSheetItemsDeferredRevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredRevenueArrangementTypeDomain": { "auth_ref": [ "r9" ], "lang": { "en-US": { "role": { "documentation": "Category of obligation arising when an entity receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized.", "label": "Deferred Revenue [Domain]", "terseLabel": "Deferred Revenue Arrangement Type [Domain]" } } }, "localname": "DeferredRevenueArrangementTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/CertainBalanceSheetItemsDeferredRevenueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DeferredRevenueByArrangementDisclosureTextBlock": { "auth_ref": [ "r9" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the type of arrangements and the corresponding amounts that comprise the current and noncurrent balance of deferred revenue as of the balance sheet date.", "label": "Deferred Revenue, by Arrangement, Disclosure [Table Text Block]", "verboseLabel": "Summary of Deferred Revenue" } } }, "localname": "DeferredRevenueByArrangementDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/CertainBalanceSheetItemsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DeferredRevenueCurrent": { "auth_ref": [ "r30" ], "calculation": { "http://www.halozyme.com/role/CertainBalanceSheetItemsDeferredRevenueDetails": { "order": 3.0, "parentTag": "us-gaap_DeferredRevenue", "weight": 1.0 }, "http://www.halozyme.com/role/ConsolidatedBalanceSheets": { "order": 12.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.", "label": "Deferred Revenue, Current", "terseLabel": "Less current portion", "verboseLabel": "Deferred revenue, current portion" } } }, "localname": "DeferredRevenueCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/CertainBalanceSheetItemsDeferredRevenueDetails", "http://www.halozyme.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRevenueDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Deferred Revenue Disclosure [Abstract]" } } }, "localname": "DeferredRevenueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_DeferredRevenueNoncurrent": { "auth_ref": [ "r30" ], "calculation": { "http://www.halozyme.com/role/CertainBalanceSheetItemsDeferredRevenueDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredRevenue", "weight": 1.0 }, "http://www.halozyme.com/role/ConsolidatedBalanceSheets": { "order": 13.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.", "label": "Deferred Revenue, Noncurrent", "terseLabel": "Deferred revenue, net of current portion", "verboseLabel": "Deferred revenue, net of current portion" } } }, "localname": "DeferredRevenueNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/CertainBalanceSheetItemsDeferredRevenueDetails", "http://www.halozyme.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRevenueRevenueRecognized1": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of revenue recognized that was previously reported as deferred or unearned revenue.", "label": "Deferred Revenue, Revenue Recognized", "negatedTerseLabel": "Revenue recognized" } } }, "localname": "DeferredRevenueRevenueRecognized1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/RevenueTextualsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": { "auth_ref": [ "r118", "r362", "r365" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred State and Local Income Tax Expense (Benefit)", "terseLabel": "Deferred State Income Tax Expense" } } }, "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/IncomeTaxesIncomeTaxExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsDeferredIncome": { "auth_ref": [ "r331", "r359", "r360" ], "calculation": { "http://www.halozyme.com/role/IncomeTaxesComponentsDeferredTaxesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.", "label": "Deferred Tax Assets, Deferred Income", "terseLabel": "Deferred Tax Assets, Deferred Income" } } }, "localname": "DeferredTaxAssetsDeferredIncome", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/IncomeTaxesComponentsDeferredTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGross": { "auth_ref": [ "r352" ], "calculation": { "http://www.halozyme.com/role/IncomeTaxesComponentsDeferredTaxesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Gross", "totalLabel": "Deferred Tax Assets, Gross" } } }, "localname": "DeferredTaxAssetsGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/IncomeTaxesComponentsDeferredTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsLiabilitiesNet": { "auth_ref": [ "r355" ], "calculation": { "http://www.halozyme.com/role/IncomeTaxesComponentsDeferredTaxesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.", "label": "Deferred Tax Assets, Net", "totalLabel": "Deferred Tax Assets, Net" } } }, "localname": "DeferredTaxAssetsLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/IncomeTaxesComponentsDeferredTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNet": { "auth_ref": [ "r353" ], "calculation": { "http://www.halozyme.com/role/IncomeTaxesComponentsDeferredTaxesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Net of Valuation Allowance", "totalLabel": "Deferred Tax Assets, Net of Valuation Allowance" } } }, "localname": "DeferredTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/IncomeTaxesComponentsDeferredTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "auth_ref": [ "r330", "r359", "r360" ], "calculation": { "http://www.halozyme.com/role/IncomeTaxesComponentsDeferredTaxesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.", "label": "Deferred Tax Assets, Operating Loss Carryforwards", "terseLabel": "Deferred Tax Assets, Operating Loss Carryforwards" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/IncomeTaxesComponentsDeferredTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOther": { "auth_ref": [ "r331", "r359", "r360" ], "calculation": { "http://www.halozyme.com/role/IncomeTaxesComponentsDeferredTaxesDetails": { "order": 6.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.", "label": "Deferred Tax Assets, Other", "terseLabel": "Deferred Tax Assets, Other" } } }, "localname": "DeferredTaxAssetsOther", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/IncomeTaxesComponentsDeferredTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": { "auth_ref": [ "r357", "r359", "r360" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.", "label": "Deferred Tax Assets, Tax Credit Carryforwards", "terseLabel": "Deferred Tax Assets, Tax Credit Carryforwards" } } }, "localname": "DeferredTaxAssetsTaxCreditCarryforwards", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesIncomeTaxDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax": { "auth_ref": [ "r357", "r359", "r360" ], "calculation": { "http://www.halozyme.com/role/IncomeTaxesComponentsDeferredTaxesDetails": { "order": 5.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible alternative minimum tax credit carryforwards.", "label": "Deferred Tax Assets, Tax Credit Carryforwards, Alternative Minimum Tax", "terseLabel": "Deferred Tax Assets, Tax Credit Carryforwards, Alternative Minimum Tax" } } }, "localname": "DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/IncomeTaxesComponentsDeferredTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": { "auth_ref": [ "r357", "r359", "r360" ], "calculation": { "http://www.halozyme.com/role/IncomeTaxesComponentsDeferredTaxesDetails": { "order": 3.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.", "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research", "terseLabel": "Deferred Tax Assets, Tax Credit Carryforwards, Research" } } }, "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/IncomeTaxesComponentsDeferredTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": { "auth_ref": [ "r330", "r359", "r360" ], "calculation": { "http://www.halozyme.com/role/IncomeTaxesComponentsDeferredTaxesDetails": { "order": 4.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.", "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost", "terseLabel": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/IncomeTaxesComponentsDeferredTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r354" ], "calculation": { "http://www.halozyme.com/role/IncomeTaxesComponentsDeferredTaxesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "Deferred Tax Assets, Valuation Allowance", "negatedTerseLabel": "Deferred Tax Assets, Valuation Allowance", "terseLabel": "Deferred Tax Assets, Valuation Allowance" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/IncomeTaxesComponentsDeferredTaxesDetails", "http://www.halozyme.com/role/IncomeTaxesTaxTextualsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesNoncurrent": { "auth_ref": [ "r338", "r339", "r340" ], "calculation": { "http://www.halozyme.com/role/IncomeTaxesComponentsDeferredTaxesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences, with jurisdictional netting and classified as noncurrent.", "label": "Deferred Tax Liabilities, Net, Noncurrent", "negatedTotalLabel": "Deferred Tax Liabilities, Net, Noncurrent" } } }, "localname": "DeferredTaxLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/IncomeTaxesComponentsDeferredTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesOther": { "auth_ref": [ "r331", "r359", "r360" ], "calculation": { "http://www.halozyme.com/role/IncomeTaxesComponentsDeferredTaxesDetails": { "order": 4.0, "parentTag": "us-gaap_DeferredTaxLiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other.", "label": "Deferred Tax Liabilities, Other", "negatedTerseLabel": "Deferred Tax Liabilities, Other" } } }, "localname": "DeferredTaxLiabilitiesOther", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/IncomeTaxesComponentsDeferredTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": { "auth_ref": [ "r331", "r359", "r360" ], "calculation": { "http://www.halozyme.com/role/IncomeTaxesComponentsDeferredTaxesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxLiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.", "label": "Deferred Tax Liabilities, Property, Plant and Equipment", "negatedTerseLabel": "Deferred Tax Liabilities, Property, Plant and Equipment" } } }, "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/IncomeTaxesComponentsDeferredTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan.", "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount", "terseLabel": "Employer Discretionary Contribution Amount" } } }, "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/EmployeeSavingsPlanDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationAndAmortizationAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Depreciation, Depletion and Amortization [Abstract]", "verboseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationAndAmortizationAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyAndEquipmentNetTextualsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r104", "r163" ], "calculation": { "http://www.halozyme.com/role/ConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization", "verboseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyAndEquipmentNetTextualsDetails", "http://www.halozyme.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member": { "auth_ref": [ "r279" ], "lang": { "en-US": { "role": { "documentation": "Effect in current period from application of guidance for revenue from contract with customer compared with guidance for revenue recognition applicable prior to change when using transition method for cumulative effect in period including initial date of application.", "label": "Difference between Revenue Guidance in Effect before and after Topic 606 [Member]", "terseLabel": "Difference between Revenue Guidance in Effect before and after Topic 606" } } }, "localname": "DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/RevenueTextualsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisaggregationOfRevenueLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Disaggregation of Revenue [Line Items]", "terseLabel": "Disaggregation of Revenue [Line Items]" } } }, "localname": "DisaggregationOfRevenueLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/RevenueDisaggregationOfRevenueDetails", "http://www.halozyme.com/role/SummaryOfUnauditedQuarterlyFinancialInformationTextualsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table]", "terseLabel": "Disaggregation of Revenue [Table]" } } }, "localname": "DisaggregationOfRevenueTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/RevenueDisaggregationOfRevenueDetails", "http://www.halozyme.com/role/SummaryOfUnauditedQuarterlyFinancialInformationTextualsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r274" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table Text Block]", "terseLabel": "Disaggregation of Revenue" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/RevenueTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r326" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-based Payment Arrangement [Text Block]", "terseLabel": "Share-based Payment Arrangement [Text Block]" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ShareBasedCompensationNotes" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Share-based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r80", "r127", "r131", "r134", "r135", "r136", "r140", "r434", "r456" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Earnings Per Share, Basic", "verboseLabel": "Net income (loss) per share, Basic" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ConsolidatedStatementsOfOperations", "http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesNetLossPerShareDetails", "http://www.halozyme.com/role/SummaryOfUnauditedQuarterlyFinancialInformationQuarterlyFinancialInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicAndDiluted": { "auth_ref": [ "r135" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Basic and Diluted", "terseLabel": "Earnings Per Share, Basic and Diluted" } } }, "localname": "EarningsPerShareBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ConsolidatedStatementsOfOperations", "http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesNetLossPerShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r80", "r127", "r131", "r134", "r135", "r136", "r140", "r434", "r456" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Earnings Per Share, Diluted", "verboseLabel": "Net income (loss) per share, Diluted" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ConsolidatedStatementsOfOperations", "http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesNetLossPerShareDetails", "http://www.halozyme.com/role/SummaryOfUnauditedQuarterlyFinancialInformationQuarterlyFinancialInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDilutedAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Earnings Per Share, Diluted [Abstract]" } } }, "localname": "EarningsPerShareDilutedAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareDilutedLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]", "terseLabel": "Loss Per Share Disclosure [Line Items]" } } }, "localname": "EarningsPerShareDilutedLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesNetLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r113", "r137", "r138", "r139" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Net Income (Loss) Per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r341", "r342", "r364" ], "lang": { "en-US": { "role": { "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).", "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent", "terseLabel": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/IncomeTaxesScheduleOfIncomeTaxReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r45" ], "calculation": { "http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails": { "order": 1.0, "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Accrued compensation and payroll taxes" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ShareBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r319" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "terseLabel": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ShareBasedCompensationUnrecognizedExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r319" ], "lang": { "en-US": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Compensation Cost Not yet Recognized, Period for Recognition" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ShareBasedCompensationUnrecognizedExpenseDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r316" ], "lang": { "en-US": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-based Payment Arrangement, Option [Member]", "terseLabel": "Stock options", "verboseLabel": "Stock options" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ShareBasedCompensationExpenseDetails", "http://www.halozyme.com/role/ShareBasedCompensationUnrecognizedExpenseDetails", "http://www.halozyme.com/role/StockholdersEquityDeficitDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Revenue from External Customer [Line Items]", "terseLabel": "Collaborative agreements termination notification" } } }, "localname": "EntityWideInformationRevenueFromExternalCustomerLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityClassOfTreasuryStockLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Equity, Class of Treasury Stock [Line Items]", "terseLabel": "Equity, Class of Treasury Stock [Line Items]" } } }, "localname": "EquityClassOfTreasuryStockLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/StockholdersEquityDeficitShareRepurchasesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r254" ], "lang": { "en-US": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.halozyme.com/role/ConsolidatedStatementsOfStockholdersEquityDeficitStatement" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount": { "auth_ref": [ "r379" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of transfers of assets measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.", "label": "Fair Value, Assets, Level 1 to Level 2 Transfers, Amount", "terseLabel": "Fair Value, Assets, Level 1 to Level 2 Transfers, Amount" } } }, "localname": "FairValueAssetsLevel1ToLevel2TransfersAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/FairValueMeasurementFairValueMeasuresDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": { "auth_ref": [ "r377", "r378" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]", "terseLabel": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/FairValueMeasurementTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": { "auth_ref": [ "r381" ], "lang": { "en-US": { "role": { "documentation": "Class of asset.", "label": "Asset Class [Domain]", "terseLabel": "Asset Class [Domain]" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/FairValueMeasurementFairValueMeasuresDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]", "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]" } } }, "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/FairValueMeasurementFairValueMeasuresDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByAssetClassAxis": { "auth_ref": [ "r377", "r383" ], "lang": { "en-US": { "role": { "documentation": "Information by class of asset.", "label": "Asset Class [Axis]", "terseLabel": "Asset Class [Axis]" } } }, "localname": "FairValueByAssetClassAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/FairValueMeasurementFairValueMeasuresDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByBalanceSheetGroupingTable": { "auth_ref": [ "r377", "r386", "r387" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.", "label": "Fair Value, by Balance Sheet Grouping [Table]", "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]" } } }, "localname": "FairValueByBalanceSheetGroupingTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/FairValueMeasurementFairValueMeasuresDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r284", "r285", "r286", "r378", "r418" ], "lang": { "en-US": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/FairValueMeasurementFairValueMeasuresDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r382" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value Disclosures [Text Block]" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/FairValueMeasurementNotes" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r284", "r285", "r286", "r378", "r419" ], "lang": { "en-US": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Fair Value, Inputs, Level 1 [Member]" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/FairValueMeasurementFairValueMeasuresDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r284", "r285", "r286", "r378", "r420" ], "lang": { "en-US": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Fair Value, Inputs, Level 2 [Member]" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/FairValueMeasurementFairValueMeasuresDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r284", "r285", "r286", "r378", "r421" ], "lang": { "en-US": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Fair Value, Inputs, Level 3 [Member]" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/FairValueMeasurementFairValueMeasuresDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/FairValueMeasurementFairValueMeasuresDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r113", "r384", "r385" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "verboseLabel": "Fair Value of Financial Instruments" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FinanceLeaseRightOfUseAssetAmortization": { "auth_ref": [ "r406", "r410", "r416" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.", "label": "Finance Lease, Right-of-Use Asset, Amortization", "terseLabel": "Finance Lease, Right-of-Use Asset, Amortization" } } }, "localname": "FinanceLeaseRightOfUseAssetAmortization", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyAndEquipmentNetTextualsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r199", "r202", "r203", "r204", "r205", "r208", "r209", "r210", "r211" ], "lang": { "en-US": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]", "terseLabel": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/FairValueMeasurementFairValueMeasuresDetails", "http://www.halozyme.com/role/FairValueMeasurementSummaryDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ForeignCurrencyTransactionGainLossUnrealized": { "auth_ref": [ "r105", "r391", "r392", "r393" ], "calculation": { "http://www.halozyme.com/role/ConsolidatedStatementsOfComprehensiveLoss": { "order": 4.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before tax of foreign currency transaction unrealized gain (loss) recognized in the income statement.", "label": "Foreign Currency Transaction Gain (Loss), Unrealized", "terseLabel": "Foreign Currency Transaction Gain (Loss), Unrealized" } } }, "localname": "ForeignCurrencyTransactionGainLossUnrealized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ConsolidatedStatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": { "auth_ref": [ "r104" ], "calculation": { "http://www.halozyme.com/role/ConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.", "label": "Gain (Loss) on Disposition of Property Plant Equipment", "negatedTerseLabel": "Loss on disposal of equipment" } } }, "localname": "GainLossOnSaleOfPropertyPlantEquipment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyAndEquipmentNetTextualsDetails", "http://www.halozyme.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "auth_ref": [ "r104", "r251", "r252" ], "calculation": { "http://www.halozyme.com/role/ConsolidatedStatementsOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.", "label": "Gain (Loss) on Extinguishment of Debt", "negatedTerseLabel": "Gain (Loss) on Extinguishment of Debt" } } }, "localname": "GainsLossesOnExtinguishmentOfDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralBusinessMember": { "auth_ref": [ "r358" ], "lang": { "en-US": { "role": { "documentation": "Tax credit carryforwards which include, but are not limited to, investment, alcohol fuels, low income housing, alternative fuels, alternative motor vehicles, hurricane relief, disabled access, renewable resources electricity production, employer social security, orphan drug, new markets, employer provided child care facilities and services, biodiesel fuels, low sulfur diesel fuel production, distilled spirits and the advanced nuclear power facilities credit.", "label": "General Business Tax Credit Carryforward [Member]", "terseLabel": "General Business Tax Credit Carryforward [Member]" } } }, "localname": "GeneralBusinessMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/IncomeTaxesTaxTextualsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GeographicConcentrationRiskMember": { "auth_ref": [ "r152" ], "lang": { "en-US": { "role": { "documentation": "Reflects the percentage that a specified dollar value on the balance sheet or income statement in the period from one or more specified geographic areas is to a corresponding consolidated, segment, or product line amount. Risk is the materially adverse effects of economic decline or antagonistic political actions resulting in loss of assets, sales volume, labor supply, or source of materials and supplies in a US state or a specified country, continent, or region such as EMEA (Europe, Middle East, Africa).", "label": "Geographic Concentration Risk [Member]", "terseLabel": "Geographic Concentration Risk [Member]" } } }, "localname": "GeographicConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesConcentrationsOfCreditRiskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GeographicDistributionForeignMember": { "auth_ref": [ "r206" ], "lang": { "en-US": { "role": { "documentation": "Allocation of business activity identified as foreign.", "label": "Geographic Distribution, Foreign [Member]", "terseLabel": "All other foreign [Member]" } } }, "localname": "GeographicDistributionForeignMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesConcentrationsOfCreditRiskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r83" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "terseLabel": "Gross Profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/SummaryOfUnauditedQuarterlyFinancialInformationQuarterlyFinancialInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": { "auth_ref": [ "r104", "r219", "r222", "r468" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).", "label": "Impairment of Long-Lived Assets Held-for-use", "terseLabel": "Impairment of Long-Lived Assets Held-for-use" } } }, "localname": "ImpairmentOfLongLivedAssetsHeldForUse", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesImpairmentOfLongLivedAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "auth_ref": [ "r113", "r218", "r224" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.", "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]", "terseLabel": "Impairment of Long-Lived Assets, Policy [Policy Text Block]" } } }, "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": { "auth_ref": [ "r121" ], "calculation": { "http://www.halozyme.com/role/IncomeTaxesNetIncomeLossByRegionDetails": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic", "terseLabel": "United States" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/IncomeTaxesNetIncomeLossByRegionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r78", "r127", "r423", "r432", "r457" ], "calculation": { "http://www.halozyme.com/role/IncomeTaxesNetIncomeLossByRegionDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "terseLabel": "Income (loss) before income taxes", "totalLabel": "Net Income (Loss) Before Income Taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ConsolidatedStatementsOfOperations", "http://www.halozyme.com/role/IncomeTaxesNetIncomeLossByRegionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": { "auth_ref": [ "r121" ], "calculation": { "http://www.halozyme.com/role/IncomeTaxesNetIncomeLossByRegionDetails": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign", "terseLabel": "Foreign" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/IncomeTaxesNetIncomeLossByRegionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r223" ], "lang": { "en-US": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ShareBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ShareBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityAxis": { "auth_ref": [ "r345" ], "lang": { "en-US": { "role": { "documentation": "Information by tax jurisdiction.", "label": "Income Tax Authority [Axis]", "terseLabel": "Income Tax Authority [Axis]" } } }, "localname": "IncomeTaxAuthorityAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/IncomeTaxesOperatingLossCarryforwardExpirationDetails", "http://www.halozyme.com/role/IncomeTaxesTaxTextualsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority [Domain]", "terseLabel": "Income Tax Authority [Domain]" } } }, "localname": "IncomeTaxAuthorityDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/IncomeTaxesOperatingLossCarryforwardExpirationDetails", "http://www.halozyme.com/role/IncomeTaxesTaxTextualsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityNameAxis": { "auth_ref": [ "r345" ], "lang": { "en-US": { "role": { "documentation": "Information by name of taxing authority.", "label": "Income Tax Authority, Name [Axis]", "terseLabel": "Income Tax Authority, Name [Axis]" } } }, "localname": "IncomeTaxAuthorityNameAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/IncomeTaxesOperatingLossCarryforwardExpirationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority, Name [Domain]", "terseLabel": "Income Tax Authority, Name [Domain]" } } }, "localname": "IncomeTaxAuthorityNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/IncomeTaxesOperatingLossCarryforwardExpirationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r370" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Tax Disclosure [Text Block]" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/IncomeTaxesNotes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r118", "r164", "r366" ], "calculation": { "http://www.halozyme.com/role/ConsolidatedStatementsOfOperations": { "order": 4.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "terseLabel": "Income tax (benefit) expense" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ConsolidatedStatementsOfOperations", "http://www.halozyme.com/role/IncomeTaxesIncomeTaxExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsDiscontinuedOperationsExtraordinaryItems": { "auth_ref": [ "r367" ], "calculation": { "http://www.halozyme.com/role/IncomeTaxesScheduleOfIncomeTaxReconciliationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current tax expense (benefit) and deferred tax expense (benefit) pertaining to income (loss) from continuing operations and income (loss) from discontinued operations.", "label": "Income Tax Expense (Benefit), Continuing Operations, Discontinued Operations", "totalLabel": "Income Tax Expense (Benefit), Continuing Operations, Discontinued Operations" } } }, "localname": "IncomeTaxExpenseBenefitContinuingOperationsDiscontinuedOperationsExtraordinaryItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/IncomeTaxesScheduleOfIncomeTaxReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r75", "r113", "r336", "r337", "r350", "r351", "r356", "r368", "r467" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r335", "r341", "r342" ], "calculation": { "http://www.halozyme.com/role/IncomeTaxesScheduleOfIncomeTaxReconciliationDetails": { "order": 3.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsDiscontinuedOperationsExtraordinaryItems", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.", "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount", "terseLabel": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount" } } }, "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/IncomeTaxesScheduleOfIncomeTaxReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate": { "auth_ref": [ "r334", "r341", "r342" ], "calculation": { "http://www.halozyme.com/role/IncomeTaxesScheduleOfIncomeTaxReconciliationDetails": { "order": 4.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsDiscontinuedOperationsExtraordinaryItems", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.", "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount", "terseLabel": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount" } } }, "localname": "IncomeTaxReconciliationChangeInEnactedTaxRate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/IncomeTaxesDetails", "http://www.halozyme.com/role/IncomeTaxesScheduleOfIncomeTaxReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationDeductions": { "auth_ref": [ "r341", "r342" ], "calculation": { "http://www.halozyme.com/role/IncomeTaxesScheduleOfIncomeTaxReconciliationDetails": { "order": 9.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsDiscontinuedOperationsExtraordinaryItems", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to deductions. Including, but not limited to, extraterritorial income exclusion deduction, qualified production activity deduction, dividend deduction, deduction for dividend paid to employee stock ownership plan, Medicare prescription drug benefit subsidy deduction, and other deductions.", "label": "Effective Income Tax Rate Reconciliation, Deduction, Amount", "negatedTerseLabel": "Effective Income Tax Rate Reconciliation, Deduction, Amount" } } }, "localname": "IncomeTaxReconciliationDeductions", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/IncomeTaxesScheduleOfIncomeTaxReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential": { "auth_ref": [ "r116", "r341", "r342" ], "calculation": { "http://www.halozyme.com/role/IncomeTaxesScheduleOfIncomeTaxReconciliationDetails": { "order": 5.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsDiscontinuedOperationsExtraordinaryItems", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).", "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount", "terseLabel": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount" } } }, "localname": "IncomeTaxReconciliationForeignIncomeTaxRateDifferential", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/IncomeTaxesScheduleOfIncomeTaxReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r117", "r341", "r342" ], "calculation": { "http://www.halozyme.com/role/IncomeTaxesScheduleOfIncomeTaxReconciliationDetails": { "order": 1.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsDiscontinuedOperationsExtraordinaryItems", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount", "terseLabel": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount" } } }, "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/IncomeTaxesScheduleOfIncomeTaxReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther": { "auth_ref": [ "r341", "r342" ], "calculation": { "http://www.halozyme.com/role/IncomeTaxesScheduleOfIncomeTaxReconciliationDetails": { "order": 7.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsDiscontinuedOperationsExtraordinaryItems", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount", "terseLabel": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount" } } }, "localname": "IncomeTaxReconciliationNondeductibleExpenseOther", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/IncomeTaxesScheduleOfIncomeTaxReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": { "auth_ref": [ "r341", "r342" ], "calculation": { "http://www.halozyme.com/role/IncomeTaxesScheduleOfIncomeTaxReconciliationDetails": { "order": 6.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsDiscontinuedOperationsExtraordinaryItems", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount", "terseLabel": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount" } } }, "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/IncomeTaxesScheduleOfIncomeTaxReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": { "auth_ref": [ "r117", "r341", "r342" ], "calculation": { "http://www.halozyme.com/role/IncomeTaxesScheduleOfIncomeTaxReconciliationDetails": { "order": 2.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsDiscontinuedOperationsExtraordinaryItems", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).", "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount", "terseLabel": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount" } } }, "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/IncomeTaxesScheduleOfIncomeTaxReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": { "auth_ref": [ "r341", "r342" ], "calculation": { "http://www.halozyme.com/role/IncomeTaxesScheduleOfIncomeTaxReconciliationDetails": { "order": 8.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsDiscontinuedOperationsExtraordinaryItems", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.", "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount", "negatedTerseLabel": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount" } } }, "localname": "IncomeTaxReconciliationTaxCreditsResearch", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/IncomeTaxesScheduleOfIncomeTaxReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesPaid": { "auth_ref": [ "r101", "r108" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.", "label": "Income Taxes Paid", "terseLabel": "Income Taxes Paid" } } }, "localname": "IncomeTaxesPaid", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r103" ], "calculation": { "http://www.halozyme.com/role/ConsolidatedStatementsOfCashFlows": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "verboseLabel": "Accounts payable and accrued expenses" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r103" ], "calculation": { "http://www.halozyme.com/role/ConsolidatedStatementsOfCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable, net" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDeferredRevenue": { "auth_ref": [ "r103" ], "calculation": { "http://www.halozyme.com/role/ConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.", "label": "Increase (Decrease) in Deferred Revenue", "terseLabel": "Deferral of unearned revenue" } } }, "localname": "IncreaseDecreaseInDeferredRevenue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r103" ], "calculation": { "http://www.halozyme.com/role/ConsolidatedStatementsOfCashFlows": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventories" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "verboseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r103" ], "calculation": { "http://www.halozyme.com/role/ConsolidatedStatementsOfCashFlows": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis": { "auth_ref": [ "r279" ], "lang": { "en-US": { "role": { "documentation": "Information about effect of transition method for cumulative effect in initial period of application.", "label": "Initial Application Period Cumulative Effect Transition [Axis]", "terseLabel": "Initial Application Period Cumulative Effect Transition [Axis]" } } }, "localname": "InitialApplicationPeriodCumulativeEffectTransitionAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/RevenueTextualsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Effect of transition method for cumulative effect in initial period of application.", "label": "Initial Application Period Cumulative Effect Transition [Domain]", "terseLabel": "Initial Application Period Cumulative Effect Transition [Domain]" } } }, "localname": "InitialApplicationPeriodCumulativeEffectTransitionDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/RevenueTextualsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InterestCostsCapitalized": { "auth_ref": [ "r396" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of interest capitalized during the period.", "label": "Interest Costs Capitalized", "terseLabel": "Interest Costs Capitalized" } } }, "localname": "InterestCostsCapitalized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/LongTermDebtNetLongTermDebtTextualsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r76", "r162", "r395", "r399", "r435" ], "calculation": { "http://www.halozyme.com/role/ConsolidatedStatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedTerseLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseDebt": { "auth_ref": [ "r88", "r250" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.", "label": "Interest Expense, Debt", "terseLabel": "Interest Expense, debt" } } }, "localname": "InterestExpenseDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/LongTermDebtNetLongTermDebtTextualsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaid": { "auth_ref": [ "r108" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities.", "label": "Interest Paid, Including Capitalized Interest, Operating and Investing Activities", "terseLabel": "Interest Paid, Including Capitalized Interest, Operating and Investing Activities" } } }, "localname": "InterestPaid", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InternalRevenueServiceIRSMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Designated tax department of the United States of America government entitled to levy and collect income taxes from the entity.", "label": "Internal Revenue Service (IRS) [Member]", "terseLabel": "Internal Revenue Service (IRS) [Member]" } } }, "localname": "InternalRevenueServiceIRSMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/IncomeTaxesOperatingLossCarryforwardExpirationDetails", "http://www.halozyme.com/role/IncomeTaxesTaxTextualsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InventoryCurrentTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about inventory expected to be sold or consumed within one year or operating cycle, if longer.", "label": "Inventory, Current [Table]", "terseLabel": "Inventory, Current [Table]" } } }, "localname": "InventoryCurrentTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesInventoriesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InventoryDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Inventory Disclosure [Abstract]" } } }, "localname": "InventoryDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "auth_ref": [ "r31", "r216" ], "calculation": { "http://www.halozyme.com/role/CertainBalanceSheetItemsInventoriesDetails": { "order": 3.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.", "label": "Inventory, Finished Goods, Net of Reserves", "terseLabel": "Inventory, Finished Goods" } } }, "localname": "InventoryFinishedGoodsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/CertainBalanceSheetItemsInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Inventory [Line Items]", "terseLabel": "Inventory [Line Items]" } } }, "localname": "InventoryLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesInventoriesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r1", "r58", "r213" ], "calculation": { "http://www.halozyme.com/role/CertainBalanceSheetItemsInventoriesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.halozyme.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventory, Net", "totalLabel": "Total inventories", "verboseLabel": "Inventories" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/CertainBalanceSheetItemsInventoriesDetails", "http://www.halozyme.com/role/ConsolidatedBalanceSheets", "http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNetAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Inventory, Net [Abstract]", "verboseLabel": "Summary of Inventories" } } }, "localname": "InventoryNetAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/CertainBalanceSheetItemsInventoriesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InventoryPolicyTextBlock": { "auth_ref": [ "r12", "r59", "r113", "r141", "r214", "r215" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.", "label": "Inventory, Policy [Policy Text Block]", "verboseLabel": "Inventory, Policy [Policy Text Block]" } } }, "localname": "InventoryPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryRawMaterialsNetOfReserves": { "auth_ref": [ "r33", "r216" ], "calculation": { "http://www.halozyme.com/role/CertainBalanceSheetItemsInventoriesDetails": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.", "label": "Inventory, Raw Materials, Net of Reserves", "terseLabel": "Inventory, Raw Materials" } } }, "localname": "InventoryRawMaterialsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/CertainBalanceSheetItemsInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "auth_ref": [ "r32", "r216" ], "calculation": { "http://www.halozyme.com/role/CertainBalanceSheetItemsInventoriesDetails": { "order": 2.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.", "label": "Inventory, Work in Process, Net of Reserves", "terseLabel": "Inventory, Work in Process" } } }, "localname": "InventoryWorkInProcessNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/CertainBalanceSheetItemsInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.", "label": "Investments Classified by Contractual Maturity Date [Table Text Block]", "terseLabel": "Investments Classified by Contractual Maturity Date [Table Text Block]" } } }, "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/FairValueMeasurementTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_InvestmentsFairValueDisclosure": { "auth_ref": [ "r377" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.", "label": "Investments, Fair Value Disclosure", "terseLabel": "Investments, Level 3" } } }, "localname": "InvestmentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/FairValueMeasurementFairValueMeasuresDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r220" ], "lang": { "en-US": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]", "terseLabel": "Leasehold improvements" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Lessee, Lease, Description [Line Items]", "terseLabel": "Lessee, Lease, Description [Line Items]" } } }, "localname": "LesseeLeaseDescriptionLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/CommitmentsAndContingenciesOperatingLeaseTextualDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionTable": { "auth_ref": [ "r409" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about lessee's leases.", "label": "Lessee, Lease, Description [Table]", "terseLabel": "Lessee, Lease, Description [Table]" } } }, "localname": "LesseeLeaseDescriptionTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/CommitmentsAndContingenciesOperatingLeaseTextualDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r415" ], "calculation": { "http://www.halozyme.com/role/CommitmentsAndContingenciesCommitmentsAndContingenciesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.halozyme.com/role/CommitmentsAndContingenciesCommitmentsAndContingenciesDetailsCalc2": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Payments, Due", "totalLabel": "Total minimum lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/CommitmentsAndContingenciesCommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r415" ], "calculation": { "http://www.halozyme.com/role/CommitmentsAndContingenciesCommitmentsAndContingenciesDetails": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in next fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months", "terseLabel": "2020" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/CommitmentsAndContingenciesCommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r415" ], "calculation": { "http://www.halozyme.com/role/CommitmentsAndContingenciesCommitmentsAndContingenciesDetails": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Five", "terseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/CommitmentsAndContingenciesCommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r415" ], "calculation": { "http://www.halozyme.com/role/CommitmentsAndContingenciesCommitmentsAndContingenciesDetails": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Four", "terseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/CommitmentsAndContingenciesCommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r415" ], "calculation": { "http://www.halozyme.com/role/CommitmentsAndContingenciesCommitmentsAndContingenciesDetails": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Three", "terseLabel": "2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/CommitmentsAndContingenciesCommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r415" ], "calculation": { "http://www.halozyme.com/role/CommitmentsAndContingenciesCommitmentsAndContingenciesDetails": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Two", "terseLabel": "2021" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/CommitmentsAndContingenciesCommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r415" ], "calculation": { "http://www.halozyme.com/role/CommitmentsAndContingenciesCommitmentsAndContingenciesDetailsCalc2": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedTerseLabel": "Less imputed interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/CommitmentsAndContingenciesCommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "auth_ref": [ "r408" ], "lang": { "en-US": { "role": { "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Term of Contract", "terseLabel": "Lessee, Operating Lease, Term of Contract" } } }, "localname": "LesseeOperatingLeaseTermOfContract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesLeasesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r28", "r429", "r452" ], "calculation": { "http://www.halozyme.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders' equity (deficit)" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities and Equity [Abstract]", "verboseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r46" ], "calculation": { "http://www.halozyme.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities, Current [Abstract]", "verboseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r20", "r246", "r428", "r450" ], "calculation": { "http://www.halozyme.com/role/ConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt", "terseLabel": "Long-term debt, net", "verboseLabel": "Long-term Debt" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ConsolidatedBalanceSheets", "http://www.halozyme.com/role/LongTermDebtNetLongTermDebtTextualsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtCurrent": { "auth_ref": [ "r44" ], "calculation": { "http://www.halozyme.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt, Current Maturities", "negatedLabel": "Less current portion of long-term debt", "terseLabel": "Current portion of long-term debt, net" } } }, "localname": "LongTermDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ConsolidatedBalanceSheets", "http://www.halozyme.com/role/LongTermDebtNetDebtTableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtFairValue": { "auth_ref": [], "calculation": { "http://www.halozyme.com/role/LongTermDebtNetDebtTableDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.", "label": "Long-term Debt, Fair Value", "terseLabel": "Long-term Debt, Fair Value", "totalLabel": "Present value of long-term debt" } } }, "localname": "LongTermDebtFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/LongTermDebtNetDebtTableDetails", "http://www.halozyme.com/role/LongTermDebtNetLongTermDebtTextualsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "auth_ref": [ "r122", "r240" ], "calculation": { "http://www.halozyme.com/role/LongTermDebtNetDebtTableDetails": { "order": 1.0, "parentTag": "halo_LongTermDebtIncludingInterestGross", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Long-term Debt, Maturities, Repayments of Principal in Next Twelve Months", "terseLabel": "2018" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/LongTermDebtNetDebtTableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": { "auth_ref": [ "r122", "r240" ], "calculation": { "http://www.halozyme.com/role/LongTermDebtNetDebtTableDetails": { "order": 5.0, "parentTag": "halo_LongTermDebtIncludingInterestGross", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Long-term Debt, Maturities, Repayments of Principal in Year Five", "terseLabel": "2022" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/LongTermDebtNetDebtTableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": { "auth_ref": [ "r122", "r240" ], "calculation": { "http://www.halozyme.com/role/LongTermDebtNetDebtTableDetails": { "order": 4.0, "parentTag": "halo_LongTermDebtIncludingInterestGross", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Long-term Debt, Maturities, Repayments of Principal in Year Four", "terseLabel": "2021" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/LongTermDebtNetDebtTableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "auth_ref": [ "r122", "r240" ], "calculation": { "http://www.halozyme.com/role/LongTermDebtNetDebtTableDetails": { "order": 3.0, "parentTag": "halo_LongTermDebtIncludingInterestGross", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Long-term Debt, Maturities, Repayments of Principal in Year Three", "terseLabel": "2020" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/LongTermDebtNetDebtTableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "auth_ref": [ "r122", "r240" ], "calculation": { "http://www.halozyme.com/role/LongTermDebtNetDebtTableDetails": { "order": 2.0, "parentTag": "halo_LongTermDebtIncludingInterestGross", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Long-term Debt, Maturities, Repayments of Principal in Year Two", "terseLabel": "2019" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/LongTermDebtNetDebtTableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtNoncurrent": { "auth_ref": [ "r52" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt, Excluding Current Maturities", "terseLabel": "Long-term debt, less current portion and unamortized debt discount" } } }, "localname": "LongTermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/LongTermDebtNetDebtTableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtTextBlock": { "auth_ref": [ "r253" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for long-term debt.", "label": "Long-term Debt [Text Block]", "terseLabel": "Long-term Debt" } } }, "localname": "LongTermDebtTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/LongTermDebtNet" ], "xbrltype": "textBlockItemType" }, "us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by category of items purchased under a long-term purchase commitment.", "label": "Category of Item Purchased [Axis]", "terseLabel": "Category of Item Purchased [Axis]" } } }, "localname": "LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/CommitmentsAndContingenciesOtherCommitmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "General description of the goods or services to be purchased from the counterparty to the long-term purchase commitment.", "label": "Long-term Purchase Commitment, Category of Item Purchased [Domain]", "terseLabel": "Long-term Purchase Commitment, Category of Item Purchased [Domain]" } } }, "localname": "LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/CommitmentsAndContingenciesOtherCommitmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermPurchaseCommitmentLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Long-term Purchase Commitment [Line Items]", "terseLabel": "Long-term Purchase Commitment [Line Items]" } } }, "localname": "LongTermPurchaseCommitmentLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/CommitmentsAndContingenciesOtherCommitmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongTermPurchaseCommitmentTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule setting forth key provisions of an arrangement under which the entity has agreed to purchase goods or services over a period of time greater than one year or the normal operating cycle, if longer, including the item for which expenditures will be made, minimum quantities, milestones, time period and committed amount.", "label": "Long-term Purchase Commitment [Table]", "terseLabel": "Long-term Purchase Commitment [Table]" } } }, "localname": "LongTermPurchaseCommitmentTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/CommitmentsAndContingenciesOtherCommitmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r52" ], "lang": { "en-US": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/LongTermDebtNetLongTermDebtTextualsDetails", "http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesNetLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r52", "r241" ], "lang": { "en-US": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/LongTermDebtNetLongTermDebtTextualsDetails", "http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesNetLossPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ManufacturingCosts": { "auth_ref": [ "r84" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate costs incurred in the production of goods for sale.", "label": "Manufacturing Costs", "terseLabel": "Manufacturing Costs" } } }, "localname": "ManufacturingCosts", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MarketableSecuritiesPolicy": { "auth_ref": [ "r440" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for investment classified as marketable security.", "label": "Marketable Securities, Policy [Policy Text Block]", "terseLabel": "Marketable Securities" } } }, "localname": "MarketableSecuritiesPolicy", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r284" ], "lang": { "en-US": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]", "terseLabel": "Money Market Funds [Member]" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/FairValueMeasurementFairValueMeasuresDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NatureOfOperations": { "auth_ref": [ "r144", "r159" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.", "label": "Nature of Operations [Text Block]", "verboseLabel": "Organization and Business" } } }, "localname": "NatureOfOperations", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/OrganizationAndBusiness" ], "xbrltype": "textBlockItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r99" ], "calculation": { "http://www.halozyme.com/role/ConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "verboseLabel": "Financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r99" ], "calculation": { "http://www.halozyme.com/role/ConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash (used in) provided by investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "verboseLabel": "Investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r99", "r102", "r105" ], "calculation": { "http://www.halozyme.com/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash provided by (used in) operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "verboseLabel": "Operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r70", "r72", "r79", "r105", "r138", "r433", "r455" ], "calculation": { "http://www.halozyme.com/role/ConsolidatedStatementsOfCashFlows": { "order": 17.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.halozyme.com/role/ConsolidatedStatementsOfComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://www.halozyme.com/role/ConsolidatedStatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net income (loss)", "totalLabel": "Net income (loss)", "verboseLabel": "Net income (loss)" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ConsolidatedStatementsOfCashFlows", "http://www.halozyme.com/role/ConsolidatedStatementsOfComprehensiveLoss", "http://www.halozyme.com/role/ConsolidatedStatementsOfOperations", "http://www.halozyme.com/role/ConsolidatedStatementsOfStockholdersEquityDeficitStatement", "http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesNetLossPerShareDetails", "http://www.halozyme.com/role/SummaryOfUnauditedQuarterlyFinancialInformationQuarterlyFinancialInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleCumulativeEffectOfChangeOnEquityOrNetAssets1": { "auth_ref": [ "r125", "r128" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cumulative effect of the change in accounting principle or new accounting pronouncement on retained earnings or other components of equity or net assets in the statement of financial position as of the beginning of the earliest period presented.", "label": "New Accounting Pronouncement or Change in Accounting Principle, Cumulative Effect of Change on Equity or Net Assets", "terseLabel": "New Accounting Pronouncement or Change in Accounting Principle, Cumulative Effect of Change on Equity or Net Assets", "verboseLabel": "Impact of applying the provisions of ASC 606" } } }, "localname": "NewAccountingPronouncementOrChangeInAccountingPrincipleCumulativeEffectOfChangeOnEquityOrNetAssets1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/RevenueTextualsDetails", "http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesAdoptionOfRecentAccountingPronouncementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "New Accounting Pronouncements and Changes in Accounting Principles [Abstract]" } } }, "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "verboseLabel": "Adoption and Pending Adoption of Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "Number of Operating Segments", "terseLabel": "Number of Operating Segments" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesSegmentInformationDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OneTimeTerminationBenefitsMember": { "auth_ref": [ "r225" ], "lang": { "en-US": { "role": { "documentation": "A lump sum payment to an involuntarily terminated employee in conjunction with exit or disposal activities.", "label": "One-time Termination Benefits [Member]", "terseLabel": "One-time Termination Benefits" } } }, "localname": "OneTimeTerminationBenefitsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/RestructuringChargesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "terseLabel": "Operating Expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/SummaryOfUnauditedQuarterlyFinancialInformationQuarterlyFinancialInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [], "calculation": { "http://www.halozyme.com/role/ConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Operating income (loss)" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r411", "r416" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease, Cost", "terseLabel": "Operating Lease, Cost" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseImpairmentLoss": { "auth_ref": [ "r403" ], "calculation": { "http://www.halozyme.com/role/ConsolidatedStatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of loss from impairment of right-of-use asset from operating lease.", "label": "Operating Lease, Impairment Loss", "terseLabel": "Operating Lease, Impairment Loss" } } }, "localname": "OperatingLeaseImpairmentLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyAndEquipmentNetTextualsDetails", "http://www.halozyme.com/role/CommitmentsAndContingenciesCommitmentsAndContingenciesDetails", "http://www.halozyme.com/role/CommitmentsAndContingenciesOperatingLeaseTextualDetails", "http://www.halozyme.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r405" ], "calculation": { "http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails": { "order": 5.0, "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities", "weight": 1.0 }, "http://www.halozyme.com/role/CommitmentsAndContingenciesCommitmentsAndContingenciesDetailsCalc2": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "terseLabel": "Total", "verboseLabel": "Operating Lease, Liability" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails", "http://www.halozyme.com/role/CommitmentsAndContingenciesCommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r407", "r412" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "terseLabel": "Operating Lease, Payments" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r404" ], "calculation": { "http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyAndEquipmentDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating Lease, Right-of-Use Asset" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r414", "r416" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Operating Lease, Weighted Average Remaining Lease Term" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/CommitmentsAndContingenciesOperatingLeaseTextualDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingLeasesRentExpenseNet": { "auth_ref": [ "r401" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.", "label": "Operating Leases, Rent Expense, Net", "terseLabel": "Operating Leases, Rent Expense, Net" } } }, "localname": "OperatingLeasesRentExpenseNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/CommitmentsAndContingenciesCommitmentsAndContingenciesDetails", "http://www.halozyme.com/role/CommitmentsAndContingenciesOperatingLeaseTextualDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLossCarryforwards": { "auth_ref": [ "r357" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Operating Loss Carryforwards", "terseLabel": "Operating Loss Carryforwards" } } }, "localname": "OperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/IncomeTaxesOperatingLossCarryforwardExpirationDetails", "http://www.halozyme.com/role/IncomeTaxesTaxTextualsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLossCarryforwardsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Operating Loss Carryforwards [Line Items]", "terseLabel": "Operating Loss Carryforwards [Line Items]" } } }, "localname": "OperatingLossCarryforwardsLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/IncomeTaxesOperatingLossCarryforwardExpirationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLossCarryforwardsTable": { "auth_ref": [ "r358" ], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.", "label": "Operating Loss Carryforwards [Table]", "terseLabel": "Operating Loss Carryforwards [Table]" } } }, "localname": "OperatingLossCarryforwardsTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/IncomeTaxesOperatingLossCarryforwardExpirationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r8", "r10", "r11", "r45" ], "calculation": { "http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails": { "order": 4.0, "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities, Current", "terseLabel": "Other accrued expenses" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssets": { "auth_ref": [ "r17", "r425", "r448" ], "calculation": { "http://www.halozyme.com/role/CertainBalanceSheetItemsPrepaidExpensesAndOtherAssetsDetails": { "order": 4.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of assets classified as other.", "label": "Other Assets", "terseLabel": "Other assets" } } }, "localname": "OtherAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/CertainBalanceSheetItemsPrepaidExpensesAndOtherAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossBeforeTax": { "auth_ref": [ "r197" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before tax, after reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), before Tax", "terseLabel": "Other Comprehensive Income (Loss)" } } }, "localname": "OtherComprehensiveIncomeLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ConsolidatedStatementsOfStockholdersEquityDeficitStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax": { "auth_ref": [ "r62", "r66" ], "calculation": { "http://www.halozyme.com/role/ConsolidatedStatementsOfComprehensiveLoss": { "order": 3.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax", "negatedTerseLabel": "Foreign currency translation adjustment" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ConsolidatedStatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]", "terseLabel": "Other comprehensive income (loss):" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ConsolidatedStatementsOfComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": { "auth_ref": [ "r63", "r65" ], "calculation": { "http://www.halozyme.com/role/ConsolidatedStatementsOfComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.", "label": "Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, after Tax", "terseLabel": "Unrealized (loss) gain on marketable securities" } } }, "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ConsolidatedStatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherIncomeAndExpensesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Other Income and Expenses [Abstract]", "terseLabel": "Other income (expense):" } } }, "localname": "OtherIncomeAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r53" ], "calculation": { "http://www.halozyme.com/role/ConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other long-term liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncashExpense": { "auth_ref": [ "r105" ], "calculation": { "http://www.halozyme.com/role/ConsolidatedStatementsOfCashFlows": { "order": 19.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense or loss included in net income that result in no cash flow, classified as other.", "label": "Other Noncash Expense", "terseLabel": "Deferral of rent expense" } } }, "localname": "OtherNoncashExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r89" ], "calculation": { "http://www.halozyme.com/role/ConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "verboseLabel": "Investment and other income, net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherOperatingActivitiesCashFlowStatement": { "auth_ref": [], "calculation": { "http://www.halozyme.com/role/ConsolidatedStatementsOfCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).", "label": "Other Operating Activities, Cash Flow Statement", "terseLabel": "Other" } } }, "localname": "OtherOperatingActivitiesCashFlowStatement", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherPrepaidExpenseCurrent": { "auth_ref": [ "r3", "r5" ], "calculation": { "http://www.halozyme.com/role/CertainBalanceSheetItemsPrepaidExpensesAndOtherAssetsDetails": { "order": 3.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Other Prepaid Expense, Current", "terseLabel": "Other prepaid expenses" } } }, "localname": "OtherPrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/CertainBalanceSheetItemsPrepaidExpensesAndOtherAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount by which the fair value of an investment in debt and equity securities categorized as Available-for-sale is less than the amortized cost basis or carrying amount of that investment at the balance sheet date and the decline in fair value is deemed to be other than temporary, before considering whether or not such amount is recognized in earnings or other comprehensive income.", "label": "Other than Temporary Impairment Losses, Investments, Available-for-sale Securities", "terseLabel": "Other than Temporary Impairment Losses, Marketable Securities" } } }, "localname": "OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/FairValueMeasurementTextualsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PayablesAndAccrualsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Payables and Accruals [Abstract]" } } }, "localname": "PayablesAndAccrualsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "auth_ref": [ "r96" ], "calculation": { "http://www.halozyme.com/role/ConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow to reacquire common stock during the period.", "label": "Payments for Repurchase of Common Stock", "negatedTerseLabel": "Payments for Repurchase of Common Stock", "terseLabel": "Payments for Repurchase of Common Stock" } } }, "localname": "PaymentsForRepurchaseOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ConsolidatedStatementsOfCashFlows", "http://www.halozyme.com/role/LongTermDebtNetLongTermDebtTextualsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForTenantImprovements": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow for the allowance granted to lessee and/or direct costs incurred by lessor used to prepare the leased premises for tenant's occupancy.", "label": "Payments for Tenant Improvements", "terseLabel": "Payments for Tenant Improvements" } } }, "localname": "PaymentsForTenantImprovements", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "auth_ref": [ "r98" ], "calculation": { "http://www.halozyme.com/role/ConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.", "label": "Payments of Debt Issuance Costs", "negatedTerseLabel": "Payments of Debt Issuance Costs", "terseLabel": "Payments of Debt Issuance Costs" } } }, "localname": "PaymentsOfDebtIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ConsolidatedStatementsOfCashFlows", "http://www.halozyme.com/role/LongTermDebtNetLongTermDebtTextualsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [ "r96" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Payment, Tax Withholding, Share-based Payment Arrangement", "terseLabel": "Payments for tax withholding for restricted stock units vested, net" } } }, "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/StockholdersEquityDeficitDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireAvailableForSaleSecurities": { "auth_ref": [ "r92", "r181" ], "calculation": { "http://www.halozyme.com/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow to acquire debt and equity securities not classified as either held-to-maturity securities or trading securities which would be classified as available-for-sale securities and reported at fair value, with unrealized gains and losses excluded from earnings and reported in a separate component of shareholders' equity.", "label": "Payments to Acquire Available-for-sale Securities", "negatedTerseLabel": "Purchases of marketable securities" } } }, "localname": "PaymentsToAcquireAvailableForSaleSecurities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r93" ], "calculation": { "http://www.halozyme.com/role/ConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r291", "r320" ], "lang": { "en-US": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ShareBasedCompensationTextualsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ShareBasedCompensationTextualsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r21" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "verboseLabel": "Preferred stock, par value" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r21" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "verboseLabel": "Preferred stock, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r21" ], "lang": { "en-US": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "verboseLabel": "Preferred stock, shares issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r21" ], "lang": { "en-US": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "verboseLabel": "Preferred stock, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r21" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "verboseLabel": "Preferred stock - $0.001 par value; 20,000 shares authorized; no shares issued and outstanding" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssets": { "auth_ref": [], "calculation": { "http://www.halozyme.com/role/CertainBalanceSheetItemsPrepaidExpensesAndOtherAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.", "label": "Prepaid Expense and Other Assets", "totalLabel": "Total prepaid expense and other assets" } } }, "localname": "PrepaidExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/CertainBalanceSheetItemsPrepaidExpensesAndOtherAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r4", "r37", "r38" ], "calculation": { "http://www.halozyme.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Total prepaid expense and other assets, current", "verboseLabel": "Prepaid expenses and other assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/CertainBalanceSheetItemsPrepaidExpensesAndOtherAssetsDetails", "http://www.halozyme.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Prepaid Expense and Other Assets, Current [Abstract]" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent": { "auth_ref": [ "r17", "r425", "r448" ], "calculation": { "http://www.halozyme.com/role/ConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed after one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Noncurrent", "terseLabel": "Less long-term portion", "verboseLabel": "Prepaid expenses and other assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/CertainBalanceSheetItemsPrepaidExpensesAndOtherAssetsDetails", "http://www.halozyme.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseCurrent": { "auth_ref": [ "r3", "r5", "r217" ], "calculation": { "http://www.halozyme.com/role/CertainBalanceSheetItemsPrepaidExpensesAndOtherAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Expense, Current", "terseLabel": "Prepaid manufacturing expenses" } } }, "localname": "PrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/CertainBalanceSheetItemsPrepaidExpensesAndOtherAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromCollaborators": { "auth_ref": [ "r100" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Cash received from collaborators during the current period.", "label": "Proceeds from Collaborators", "terseLabel": "Proceeds from Collaborator" } } }, "localname": "ProceedsFromCollaborators", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/SummaryOfUnauditedQuarterlyFinancialInformationTextualsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromConvertibleDebt": { "auth_ref": [ "r95" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.", "label": "Proceeds from Convertible Debt", "terseLabel": "Proceeds from Convertible Debt" } } }, "localname": "ProceedsFromConvertibleDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/LongTermDebtNetLongTermDebtTextualsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromDebtNetOfIssuanceCosts": { "auth_ref": [ "r95" ], "calculation": { "http://www.halozyme.com/role/ConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.", "label": "Proceeds from Debt, Net of Issuance Costs", "terseLabel": "Proceeds from issuance of long-term debt, net" } } }, "localname": "ProceedsFromDebtNetOfIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r94" ], "calculation": { "http://www.halozyme.com/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Proceeds from issuance of common stock, net" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ConsolidatedStatementsOfCashFlows", "http://www.halozyme.com/role/StockholdersEquityDeficitPublicOfferingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": { "auth_ref": [ "r94", "r321" ], "calculation": { "http://www.halozyme.com/role/ConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.", "label": "Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised", "verboseLabel": "Proceeds from issuance of common stock under equity incentive plans, net of taxes paid related to net share settlement" } } }, "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities": { "auth_ref": [ "r91", "r181" ], "calculation": { "http://www.halozyme.com/role/ConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow associated with the sale of debt and equity securities classified as available-for-sale securities.", "label": "Proceeds from Sale of Available-for-sale Securities", "terseLabel": "Proceeds from maturities of marketable securities" } } }, "localname": "ProceedsFromSaleOfAvailableForSaleSecurities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r94", "r321" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from Stock Options Exercised", "verboseLabel": "Net proceeds from stock options exercised" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ShareBasedCompensationOptionsDetails", "http://www.halozyme.com/role/StockholdersEquityDeficitDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductMember": { "auth_ref": [ "r276" ], "lang": { "en-US": { "role": { "documentation": "Article or substance produced by nature, labor or machinery.", "label": "Product [Member]", "terseLabel": "Product sales, net", "verboseLabel": "Product [Member]" } } }, "localname": "ProductMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/CertainBalanceSheetItemsDeferredRevenueDetails", "http://www.halozyme.com/role/ConsolidatedStatementsOfOperations", "http://www.halozyme.com/role/RevenueContractWithCustomerAssetAndLiabilityDetails", "http://www.halozyme.com/role/RevenueDisaggregationOfRevenueDetails", "http://www.halozyme.com/role/RevenueRevenueRemainingPerformanceObligationDetails", "http://www.halozyme.com/role/RevenueTextualsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r42", "r221" ], "lang": { "en-US": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Property, Plant and Equipment, Type [Axis]", "terseLabel": "Property, Plant and Equipment, Type [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r41", "r220" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "terseLabel": "Property and equipment, gross" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentGrossExcludingCapitalLeasedAssets": { "auth_ref": [ "r41", "r220" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Gross amount of long-lived physical assets excluding assets held under lease agreements used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property, Plant and Equipment, Gross, Excluding Capital Leased Assets", "terseLabel": "Property, Plant and Equipment, Gross, Excluding Capital Leased Assets" } } }, "localname": "PropertyPlantAndEquipmentGrossExcludingCapitalLeasedAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r15", "r16", "r221", "r453" ], "calculation": { "http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyAndEquipmentDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.halozyme.com/role/ConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "totalLabel": "Property and equipment, net", "verboseLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyAndEquipmentDetails", "http://www.halozyme.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNetExcludingCapitalLeasedAssets": { "auth_ref": [ "r41", "r220" ], "calculation": { "http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyAndEquipmentDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, net of accumulated depreciation, depletion and amortization, of long-lived physical assets excluding assets held under lease agreements used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property, Plant and Equipment, Net, Excluding Capital Leased Assets", "terseLabel": "Property, Plant and Equipment, Net, Excluding Capital Leased Assets" } } }, "localname": "PropertyPlantAndEquipmentNetExcludingCapitalLeasedAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r40", "r113", "r221" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "terseLabel": "Property and Equipment, Policy [Policy Text Block]" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r15", "r221" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Summary of Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/CertainBalanceSheetItemsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r15", "r220" ], "lang": { "en-US": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Property, Plant and Equipment, Type [Domain]", "terseLabel": "Property, Plant and Equipment, Type [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property, Plant and Equipment, Useful Life", "terseLabel": "Property, Plant and Equipment, Useful Life" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" ], "xbrltype": "durationItemType" }, "us-gaap_PublicUtilitiesInventoryAxis": { "auth_ref": [ "r34" ], "lang": { "en-US": { "role": { "documentation": "Information by type of inventory held.", "label": "Inventory [Axis]", "terseLabel": "Inventory [Axis]" } } }, "localname": "PublicUtilitiesInventoryAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesInventoriesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PublicUtilitiesInventoryTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tangible personal property that is held for sale in the ordinary course of business, in process of production for such sale or is to be currently consumed in the production of goods or services to be available for sale.", "label": "Inventory [Domain]", "terseLabel": "Inventory [Domain]" } } }, "localname": "PublicUtilitiesInventoryTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesInventoriesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PurchaseObligation": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.", "label": "Purchase Obligation", "terseLabel": "Purchase Obligation" } } }, "localname": "PurchaseObligation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/CommitmentsAndContingenciesOtherCommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_QuarterlyFinancialInformationDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Quarterly Financial Information Disclosure [Abstract]" } } }, "localname": "QuarterlyFinancialInformationDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_QuarterlyFinancialInformationTextBlock": { "auth_ref": [ "r143" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.", "label": "Quarterly Financial Information [Text Block]", "terseLabel": "Quarterly Financial Information [Text Block]" } } }, "localname": "QuarterlyFinancialInformationTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/SummaryOfUnauditedQuarterlyFinancialInformation" ], "xbrltype": "textBlockItemType" }, "us-gaap_RecognitionOfDeferredRevenue": { "auth_ref": [ "r105" ], "calculation": { "http://www.halozyme.com/role/ConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The amount of previously reported deferred or unearned revenue that was recognized as revenue during the period. For cash flows, this element primarily pertains to amortization of deferred credits on long-term arrangements. As a noncash item, it is deducted from net income when calculating cash provided by or used in operations using the indirect method.", "label": "Recognition of Deferred Revenue", "negatedTerseLabel": "Recognition of deferred revenue" } } }, "localname": "RecognitionOfDeferredRevenue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfDebt": { "auth_ref": [ "r97" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.", "label": "Repayments of Debt", "terseLabel": "Repayments of Debt" } } }, "localname": "RepaymentsOfDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/LongTermDebtNetLongTermDebtTextualsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfSecuredDebt": { "auth_ref": [ "r97" ], "calculation": { "http://www.halozyme.com/role/ConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow to repay long-term debt that is wholly or partially secured by collateral. Excludes repayments of tax exempt secured debt.", "label": "Repayments of Secured Debt", "negatedLabel": "Repayment of long-term debt" } } }, "localname": "RepaymentsOfSecuredDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": { "auth_ref": [ "r328", "r329" ], "lang": { "en-US": { "role": { "documentation": "Information by form of arrangement related to research and development.", "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]", "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]" } } }, "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesResearchAndDevelopmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Research and Development Arrangement, Contract to Perform for Others [Line Items]", "terseLabel": "Research and Development Arrangement, Contract to Perform for Others [Line Items]" } } }, "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesResearchAndDevelopmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": { "auth_ref": [ "r328", "r329" ], "lang": { "en-US": { "role": { "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.", "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]", "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]" } } }, "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesResearchAndDevelopmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r327", "r472" ], "calculation": { "http://www.halozyme.com/role/ConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "verboseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]", "terseLabel": "Research and Development Expense [Member]" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ShareBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r113", "r327" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research and Development Expense, Policy [Policy Text Block]", "verboseLabel": "Research and Development Expenses" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchAndDevelopmentExpenseSoftwareExcludingAcquiredInProcessCost": { "auth_ref": [ "r471" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Research and development expense during the period related to the costs of developing and achieving technological feasibility of a computer software product to be sold, leased, or otherwise marketed.", "label": "Research and Development Expense, Software (Excluding Acquired in Process Cost)", "terseLabel": "Research and Development, in-line technologies" } } }, "localname": "ResearchAndDevelopmentExpenseSoftwareExcludingAcquiredInProcessCost", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesResearchAndDevelopmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchMember": { "auth_ref": [ "r358" ], "lang": { "en-US": { "role": { "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes.", "label": "Research Tax Credit Carryforward [Member]", "terseLabel": "Research Tax Credit Carryforward [Member]" } } }, "localname": "ResearchMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/IncomeTaxesTaxTextualsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents [Domain]", "terseLabel": "Cash and Cash Equivalents [Domain]" } } }, "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/FairValueMeasurementFairValueMeasuresDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsNoncurrent": { "auth_ref": [ "r7", "r17", "r106", "r112", "r466" ], "calculation": { "http://www.halozyme.com/role/ConsolidatedBalanceSheets": { "order": 8.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Restricted Cash and Cash Equivalents, Noncurrent", "terseLabel": "Restricted cash" } } }, "localname": "RestrictedCashAndCashEquivalentsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ConsolidatedBalanceSheets", "http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesRestrictedCashDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashAndInvestmentsCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Restricted Cash and Investments, Current [Abstract]" } } }, "localname": "RestrictedCashAndInvestmentsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r137" ], "lang": { "en-US": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]", "terseLabel": "Restricted stock awards", "verboseLabel": "RSAs" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ShareBasedCompensationRestrictedStockAwardsDetails", "http://www.halozyme.com/role/ShareBasedCompensationTextualsDetails", "http://www.halozyme.com/role/ShareBasedCompensationUnrecognizedExpenseDetails", "http://www.halozyme.com/role/StockholdersEquityDeficitDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "RSUs", "verboseLabel": "RSUs" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ShareBasedCompensationRestrictedStockUnitsDetails", "http://www.halozyme.com/role/ShareBasedCompensationTextualsDetails", "http://www.halozyme.com/role/ShareBasedCompensationUnrecognizedExpenseDetails", "http://www.halozyme.com/role/StockholdersEquityDeficitDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestructuringAndRelatedActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Restructuring and Related Activities [Abstract]" } } }, "localname": "RestructuringAndRelatedActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": { "auth_ref": [ "r232" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.", "label": "Restructuring and Related Activities Disclosure [Text Block]", "terseLabel": "Restructuring Charges" } } }, "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/RestructuringCharges" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The number of positions eliminated during the period as a result of restructuring activities.", "label": "Restructuring and Related Cost, Number of Positions Eliminated", "terseLabel": "Number of positions eliminated" } } }, "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminated", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/RestructuringChargesNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s).", "label": "Restructuring and Related Cost, Number of Positions Eliminated, Period Percent", "terseLabel": "Number of positions eliminated (as a percent)" } } }, "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/RestructuringChargesNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_RestructuringCharges": { "auth_ref": [ "r104", "r226", "r229", "r231" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.", "label": "Restructuring Charges", "terseLabel": "Restructuring Charges", "verboseLabel": "Restructuring charges" } } }, "localname": "RestructuringCharges", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/RestructuringChargesNarrativeDetails", "http://www.halozyme.com/role/SummaryOfUnauditedQuarterlyFinancialInformationTextualsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringCostAndReserveAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of restructuring cost.", "label": "Restructuring Type [Axis]", "terseLabel": "Restructuring Type [Axis]" } } }, "localname": "RestructuringCostAndReserveAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/RestructuringChargesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringCostAndReserveLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Restructuring Cost and Reserve [Line Items]", "terseLabel": "Restructuring Cost and Reserve [Line Items]" } } }, "localname": "RestructuringCostAndReserveLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/RestructuringChargesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r25", "r260", "r451" ], "calculation": { "http://www.halozyme.com/role/ConsolidatedBalanceSheets": { "order": 11.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "verboseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ConsolidatedStatementsOfStockholdersEquityDeficitStatement" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Revenue from Contract with Customer [Abstract]" } } }, "localname": "RevenueFromContractWithCustomerAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r273", "r274" ], "calculation": { "http://www.halozyme.com/role/ConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Total revenues" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ConsolidatedStatementsOfOperations", "http://www.halozyme.com/role/RevenueDisaggregationOfRevenueDetails", "http://www.halozyme.com/role/RevenueRevenueRecognitionMultipleDeliverableArrangementsDetails", "http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesConcentrationsOfCreditRiskDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueRecognitionAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Revenue Recognition [Abstract]" } } }, "localname": "RevenueRecognitionAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Revenue Recognition, Multiple-deliverable Arrangements [Line Items]", "terseLabel": "Revenue Recognition, Multiple-deliverable Arrangements [Line Items]" } } }, "localname": "RevenueRecognitionMultipleDeliverableArrangementsLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/RevenueRevenueRecognitionMultipleDeliverableArrangementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Summarization of information required and determined to be disclosed concerning the recognition of revenue arrangements under which the entity does or will perform multiple revenue-generating activities, categorized by type of arrangement, including certain revenue arrangements that include software elements. This item does not include multiple-deliverable arrangements for industries that prepare disclosures under specific requirements (for instance, construction-type and production-type contracts) otherwise provided for in the taxonomy.", "label": "Revenue Recognition, Multiple-deliverable Arrangements [Table]", "terseLabel": "Revenue Recognition, Multiple-deliverable Arrangements [Table]" } } }, "localname": "RevenueRecognitionMultipleDeliverableArrangementsTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/RevenueRevenueRecognitionMultipleDeliverableArrangementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the recognition of revenue arrangements under which the entity does or will perform multiple revenue-generating activities, categorized by type of arrangement. This item includes certain revenue arrangements that include software elements. This item does not include multiple-deliverable arrangements for industries that prepare disclosures under specific requirements (for instance, construction-type and production-type contracts) otherwise provided for in the taxonomy.", "label": "Revenue Recognition, Multiple-deliverable Arrangements [Table Text Block]", "terseLabel": "Revenue Recognition, Multiple-deliverable Arrangements" } } }, "localname": "RevenueRecognitionMultipleDeliverableArrangementsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/RevenueTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "auth_ref": [ "r114", "r115" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.", "label": "Revenue [Policy Text Block]", "verboseLabel": "Revenue [Policy Text Block]" } } }, "localname": "RevenueRecognitionPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueRemainingPerformanceObligation": { "auth_ref": [ "r271" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.", "label": "Revenue, Remaining Performance Obligation, Amount", "terseLabel": "Revenue, Remaining Performance Obligation, Amount" } } }, "localname": "RevenueRemainingPerformanceObligation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/RevenueRevenueRemainingPerformanceObligationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]", "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]" } } }, "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/RevenueRevenueRemainingPerformanceObligationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": { "auth_ref": [ "r272" ], "lang": { "en-US": { "role": { "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in CCYY-MM-DD format.", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]", "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]" } } }, "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/RevenueRevenueRemainingPerformanceObligationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about expected timing for satisfying remaining performance obligation.", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]", "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]" } } }, "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/RevenueRevenueRemainingPerformanceObligationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r77", "r160", "r161", "r166" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues", "terseLabel": "Revenues" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/RevenueTextualsDetails", "http://www.halozyme.com/role/SummaryOfUnauditedQuarterlyFinancialInformationQuarterlyFinancialInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Revenues [Abstract]", "verboseLabel": "Revenues:" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r413", "r416" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RoyaltyMember": { "auth_ref": [ "r276" ], "lang": { "en-US": { "role": { "documentation": "Money for usage-based right to asset.", "label": "Royalty [Member]", "terseLabel": "Royalties" } } }, "localname": "RoyaltyMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ConsolidatedStatementsOfOperations", "http://www.halozyme.com/role/RevenueDisaggregationOfRevenueDetails", "http://www.halozyme.com/role/RevenueRevenueRecognitionMultipleDeliverableArrangementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockPricePerShare": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.", "label": "Sale of Stock, Price Per Share", "terseLabel": "Sale of Stock, Price Per Share" } } }, "localname": "SaleOfStockPricePerShare", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/StockholdersEquityDeficitPublicOfferingDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SalesMember": { "auth_ref": [ "r376" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing revenue from sale of goods and services rendered in the normal course of business.", "label": "Sales [Member]", "terseLabel": "Sales [Member]" } } }, "localname": "SalesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesConcentrationsOfCreditRiskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": { "auth_ref": [ "r57" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.", "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]", "terseLabel": "Summary of Accounts Receivable" } } }, "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/CertainBalanceSheetItemsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule of Accrued Liabilities [Table Text Block]", "terseLabel": "Summary of Accrued Expenses" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/CertainBalanceSheetItemsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Securities, Available-for-sale [Line Items]", "terseLabel": "Schedule of Available-for-sale Securities" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/FairValueMeasurementSummaryDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesTable": { "auth_ref": [ "r187", "r190", "r193", "r194", "r195", "r196", "r436", "r439" ], "lang": { "en-US": { "role": { "documentation": "Schedule of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.", "label": "Schedule of Available-for-sale Securities [Table]", "terseLabel": "Schedule of Available-for-sale Securities [Table]" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/FairValueMeasurementSummaryDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": { "auth_ref": [ "r317" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.", "label": "Share-based Payment Arrangement, Cost by Plan [Table Text Block]", "terseLabel": "Share-based Payment Arrangement, Cost by Plan [Table Text Block]" } } }, "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ShareBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "auth_ref": [ "r363" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.", "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]", "terseLabel": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]" } } }, "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r355" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]", "terseLabel": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r138" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable": { "auth_ref": [ "r86", "r131", "r132", "r133", "r136", "r140" ], "lang": { "en-US": { "role": { "documentation": "Complete disclosure pertaining to an entity's diluted earnings per share.", "label": "Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table]", "terseLabel": "Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table]" } } }, "localname": "ScheduleOfEarningsPerShareDilutedByCommonClassTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesNetLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r341" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "terseLabel": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "auth_ref": [ "r290", "r317", "r323" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ShareBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r290", "r317", "r323" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ShareBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable": { "auth_ref": [ "r167" ], "lang": { "en-US": { "role": { "documentation": "Tabular presentation of the description and amount of revenues from a product or service, or a group of similar products or similar services, reported from external customers during the period, if the information is not provided as part of the reportable operating segment information.", "label": "Revenue from External Customers by Products and Services [Table]", "terseLabel": "Revenue from External Customers by Products and Services [Table]" } } }, "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock": { "auth_ref": [ "r402" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.", "label": "Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]", "terseLabel": "Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]" } } }, "localname": "ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/CommitmentsAndContingenciesCommitmentsAndContingenciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": { "auth_ref": [ "r121" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.", "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]", "terseLabel": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]" } } }, "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r12", "r34", "r35", "r36" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventory, Current [Table Text Block]", "verboseLabel": "Summary of Inventories" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/CertainBalanceSheetItemsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "auth_ref": [ "r240" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the combined aggregate amount of maturities and sinking fund requirements for all long-term borrowings for each of the five years following the date of the latest balance sheet date presented.", "label": "Schedule of Maturities of Long-term Debt [Table Text Block]", "terseLabel": "Schedule of Maturities of Long-term Debt [Table Text Block]" } } }, "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/LongTermDebtNetDebtDisclosureTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfOtherAssetsTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the carrying amounts of other assets. This disclosure includes other current assets and other noncurrent assets.", "label": "Schedule of Other Assets [Table Text Block]", "terseLabel": "Summary of Prepaid Expenses and Other Assets" } } }, "localname": "ScheduleOfOtherAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/CertainBalanceSheetItemsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r42", "r221" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]", "terseLabel": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyAndEquipmentDetails", "http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock": { "auth_ref": [ "r142" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.", "label": "Quarterly Financial Information [Table Text Block]", "terseLabel": "Quarterly Financial Information [Table Text Block]" } } }, "localname": "ScheduleOfQuarterlyFinancialInformationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/SummaryOfUnauditedQuarterlyFinancialInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable": { "auth_ref": [ "r328", "r329" ], "lang": { "en-US": { "role": { "documentation": "A schedule reflecting the terms of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others (including royalty arrangements, purchase provisions, license agreements, and commitments to provide additional funding), aggregated by similar arrangements or individually if necessary to understand the effects on the financial statements.", "label": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]", "terseLabel": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]" } } }, "localname": "ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesResearchAndDevelopmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "auth_ref": [ "r227", "r228", "r230" ], "lang": { "en-US": { "role": { "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.", "label": "Schedule of Restructuring and Related Costs [Table]", "terseLabel": "Schedule of Restructuring and Related Costs [Table]" } } }, "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/RestructuringChargesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r291", "r320" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ShareBasedCompensationOptionsDetails", "http://www.halozyme.com/role/ShareBasedCompensationRestrictedStockAwardsDetails", "http://www.halozyme.com/role/ShareBasedCompensationRestrictedStockUnitsDetails", "http://www.halozyme.com/role/ShareBasedCompensationTextualsDetails", "http://www.halozyme.com/role/ShareBasedCompensationUnrecognizedExpenseDetails", "http://www.halozyme.com/role/StockholdersEquityDeficitDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": { "auth_ref": [ "r296" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.", "label": "Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]", "terseLabel": "Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]" } } }, "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ShareBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r296", "r306", "r309" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Share-based Payment Arrangement, Option, Activity [Table Text Block]" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ShareBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r312" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ShareBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.", "label": "Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]", "terseLabel": "Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]" } } }, "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ShareBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock": { "auth_ref": [ "r319" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of cost not yet recognized and weighted-average period over which cost is expected to be recognized for nonvested award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost [Table Text Block]", "terseLabel": "Share-based Payment Arrangement, Nonvested Award, Cost [Table Text Block]" } } }, "localname": "ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ShareBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": { "auth_ref": [ "r150", "r153", "r154", "r155", "r388", "r390" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.", "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]", "terseLabel": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]" } } }, "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SecuredDebt": { "auth_ref": [ "r20", "r428", "r450" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date, including the current and noncurrent portions, of collateralized debt obligations (with maturities initially due after one year or beyond the operating cycle, if longer). Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower.", "label": "Secured Debt", "terseLabel": "Outstanding loan balance" } } }, "localname": "SecuredDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/LongTermDebtNetLongTermDebtTextualsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SecuredDebtMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets.", "label": "Secured Debt [Member]", "terseLabel": "Secured Debt" } } }, "localname": "SecuredDebtMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/LongTermDebtNetLongTermDebtTextualsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Segment Reporting [Abstract]" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "auth_ref": [ "r113" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for segment reporting.", "label": "Segment Reporting, Policy [Policy Text Block]", "terseLabel": "Segment Information" } } }, "localname": "SegmentReportingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r87", "r212" ], "calculation": { "http://www.halozyme.com/role/ConsolidatedStatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "verboseLabel": "Selling, general and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "auth_ref": [ "r90" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.", "label": "Selling, General and Administrative Expenses [Member]", "terseLabel": "Selling, General and Administrative Expenses [Member]" } } }, "localname": "SellingGeneralAndAdministrativeExpensesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ShareBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SeniorLoansMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A senior loan takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for [must receive] repayment [prior] relative to junior and unsecured (general) creditors.", "label": "Senior Loans [Member]", "terseLabel": "Senior Loans [Member]" } } }, "localname": "SeniorLoansMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/LongTermDebtNetLongTermDebtTextualsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r103" ], "calculation": { "http://www.halozyme.com/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "verboseLabel": "Share-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Share-based Payment Arrangement, Noncash Expense [Abstract]" } } }, "localname": "ShareBasedCompensationAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r292" ], "lang": { "en-US": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ShareBasedCompensationRestrictedStockAwardsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ShareBasedCompensationRestrictedStockAwardsDetails", "http://www.halozyme.com/role/ShareBasedCompensationRestrictedStockUnitsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r300" ], "lang": { "en-US": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedTerseLabel": "Forfeited in Period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ShareBasedCompensationRestrictedStockAwardsDetails", "http://www.halozyme.com/role/ShareBasedCompensationRestrictedStockUnitsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r305" ], "lang": { "en-US": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Forfeitures, Weighted Average Grant Date Fair Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ShareBasedCompensationRestrictedStockAwardsDetails", "http://www.halozyme.com/role/ShareBasedCompensationRestrictedStockUnitsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r303" ], "lang": { "en-US": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Grants in Period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ShareBasedCompensationRestrictedStockAwardsDetails", "http://www.halozyme.com/role/ShareBasedCompensationRestrictedStockUnitsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r303" ], "lang": { "en-US": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Grants in Period, Weighted Average Grant Date Fair Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ShareBasedCompensationRestrictedStockAwardsDetails", "http://www.halozyme.com/role/ShareBasedCompensationRestrictedStockUnitsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r302" ], "lang": { "en-US": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Nonvested, Number, period end", "periodStartLabel": "Nonvested, Number, period start" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ShareBasedCompensationRestrictedStockAwardsDetails", "http://www.halozyme.com/role/ShareBasedCompensationRestrictedStockUnitsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ShareBasedCompensationRestrictedStockAwardsDetails", "http://www.halozyme.com/role/ShareBasedCompensationRestrictedStockUnitsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r302" ], "lang": { "en-US": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Nonvested, Weighted Average Grant Date Fair Value, period end", "periodStartLabel": "Nonvested, Weighted Average Grant Date Fair Value, period start" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ShareBasedCompensationRestrictedStockAwardsDetails", "http://www.halozyme.com/role/ShareBasedCompensationRestrictedStockUnitsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": { "auth_ref": [ "r310" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms", "terseLabel": "Outstanding, Weighted Average Remaining Contractual Terms" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ShareBasedCompensationRestrictedStockUnitsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r304" ], "lang": { "en-US": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedTerseLabel": "Vested in Period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ShareBasedCompensationRestrictedStockAwardsDetails", "http://www.halozyme.com/role/ShareBasedCompensationRestrictedStockUnitsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": { "auth_ref": [ "r308" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value", "terseLabel": "Vested in Period, Fair Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ShareBasedCompensationRestrictedStockAwardsDetails", "http://www.halozyme.com/role/ShareBasedCompensationRestrictedStockUnitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r304" ], "lang": { "en-US": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Vested in Period, Weighted Average Grant Date Fair Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ShareBasedCompensationRestrictedStockAwardsDetails", "http://www.halozyme.com/role/ShareBasedCompensationRestrictedStockUnitsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r315" ], "lang": { "en-US": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Fair Value Assumptions, Expected Dividend Rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ShareBasedCompensationValuationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum", "terseLabel": "Fair Value Assumptions, Risk Free Interest Rate, Maximum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ShareBasedCompensationValuationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum", "terseLabel": "Fair Value Assumptions, Risk Free Interest Rate, Minimum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ShareBasedCompensationValuationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate": { "auth_ref": [ "r314" ], "lang": { "en-US": { "role": { "documentation": "Rate of weighted-average expected volatility for award under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate", "terseLabel": "Fair Value Assumptions, Weighted Average Volatility Rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ShareBasedCompensationValuationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ShareBasedCompensationOptionsDetails", "http://www.halozyme.com/role/ShareBasedCompensationRestrictedStockAwardsDetails", "http://www.halozyme.com/role/ShareBasedCompensationRestrictedStockUnitsDetails", "http://www.halozyme.com/role/ShareBasedCompensationTextualsDetails", "http://www.halozyme.com/role/ShareBasedCompensationUnrecognizedExpenseDetails", "http://www.halozyme.com/role/StockholdersEquityDeficitDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r293" ], "lang": { "en-US": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized", "terseLabel": "Number of Shares Authorized" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ShareBasedCompensationTextualsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ShareBasedCompensationOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "auth_ref": [ "r308" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value", "terseLabel": "Options, Exercises in Period, Intrinsic Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ShareBasedCompensationOptionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "auth_ref": [ "r301" ], "lang": { "en-US": { "role": { "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period", "negatedTerseLabel": "Options, Forfeitures and Expirations in Period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ShareBasedCompensationOptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r301" ], "lang": { "en-US": { "role": { "documentation": "Weighted average price of options that were either forfeited or expired.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price", "terseLabel": "Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ShareBasedCompensationOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Options, Grants in Period, Gross" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ShareBasedCompensationOptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r307" ], "lang": { "en-US": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Options, Grants in Period, Weighted Average Grant Date Fair Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ShareBasedCompensationOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r320" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value", "terseLabel": "Options, Outstanding, Intrinsic Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ShareBasedCompensationOptionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r298", "r320" ], "lang": { "en-US": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Options, Outstanding, Number, period end", "periodStartLabel": "Options, Outstanding, Number, period start", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ShareBasedCompensationOptionsDetails", "http://www.halozyme.com/role/StockholdersEquityDeficitDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ShareBasedCompensationOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r297" ], "lang": { "en-US": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Options, Outstanding, Weighted Average Exercise Price, period end", "periodStartLabel": "Options, Outstanding, Weighted Average Exercise Price, period start" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ShareBasedCompensationOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": { "auth_ref": [ "r311" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value", "terseLabel": "Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ShareBasedCompensationOptionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": { "auth_ref": [ "r311" ], "lang": { "en-US": { "role": { "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number", "terseLabel": "Options, Vested and Expected to Vest, Exercisable, Number" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ShareBasedCompensationOptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r311" ], "lang": { "en-US": { "role": { "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price", "terseLabel": "Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ShareBasedCompensationOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "auth_ref": [ "r309" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value", "terseLabel": "Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ShareBasedCompensationOptionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "auth_ref": [ "r310" ], "lang": { "en-US": { "role": { "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "terseLabel": "Options, Vested and Expected to Vest, Outstanding, Number" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ShareBasedCompensationOptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r310" ], "lang": { "en-US": { "role": { "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "terseLabel": "Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ShareBasedCompensationOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r289", "r294" ], "lang": { "en-US": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ShareBasedCompensationExpenseDetails", "http://www.halozyme.com/role/ShareBasedCompensationOptionsDetails", "http://www.halozyme.com/role/ShareBasedCompensationRestrictedStockAwardsDetails", "http://www.halozyme.com/role/ShareBasedCompensationRestrictedStockUnitsDetails", "http://www.halozyme.com/role/ShareBasedCompensationTextualsDetails", "http://www.halozyme.com/role/ShareBasedCompensationUnrecognizedExpenseDetails", "http://www.halozyme.com/role/StockholdersEquityDeficitDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Options, Exercises in Period, Weighted Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ShareBasedCompensationOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Options, Grants in Period, Weighted Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ShareBasedCompensationOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r113", "r291", "r295" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share-based Payment Arrangement [Policy Text Block]", "verboseLabel": "Share-Based Compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareRepurchaseProgramAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by share repurchase program.", "label": "Share Repurchase Program [Axis]", "terseLabel": "Share Repurchase Program [Axis]" } } }, "localname": "ShareRepurchaseProgramAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/LongTermDebtNetLongTermDebtTextualsDetails", "http://www.halozyme.com/role/StockholdersEquityDeficitShareRepurchasesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareRepurchaseProgramDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the share repurchase program.", "label": "Share Repurchase Program [Domain]", "terseLabel": "Share Repurchase Program [Domain]" } } }, "localname": "ShareRepurchaseProgramDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/LongTermDebtNetLongTermDebtTextualsDetails", "http://www.halozyme.com/role/StockholdersEquityDeficitShareRepurchasesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": { "auth_ref": [ "r292" ], "lang": { "en-US": { "role": { "documentation": "Percentage of vesting of award under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage", "terseLabel": "Award Vesting Rights, Percentage" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ShareBasedCompensationTextualsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Intrinsic value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Nonvested", "terseLabel": "Aggregate Intrinsic Value, Nonvested" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ShareBasedCompensationRestrictedStockUnitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested", "terseLabel": "Aggregate Intrinsic Value, Vested" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ShareBasedCompensationRestrictedStockAwardsDetails", "http://www.halozyme.com/role/ShareBasedCompensationRestrictedStockUnitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r313", "r322" ], "lang": { "en-US": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Fair Value Assumptions, Weighted Average Expected Term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ShareBasedCompensationValuationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r310" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Options, Outstanding, Weighted Average Remaining Contractual Term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ShareBasedCompensationOptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r311" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ShareBasedCompensationOptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r310" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ShareBasedCompensationOptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Shares outstanding", "periodStartLabel": "Shares outstanding", "terseLabel": "Shares, Outstanding" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.halozyme.com/role/ConsolidatedStatementsOfStockholdersEquityDeficitStatement" ], "xbrltype": "sharesItemType" }, "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Shares Withheld for Tax Withholding Obligation", "verboseLabel": "Number of RSUs surrendered to pay for minimum withholding taxes" } } }, "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/StockholdersEquityDeficitDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r124" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "verboseLabel": "Summary of Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/SummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StateAndLocalJurisdictionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.", "label": "State and Local Jurisdiction [Member]", "terseLabel": "State and Local Jurisdiction [Member]" } } }, "localname": "StateAndLocalJurisdictionMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/IncomeTaxesOperatingLossCarryforwardExpirationDetails", "http://www.halozyme.com/role/IncomeTaxesTaxTextualsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r56", "r254" ], "lang": { "en-US": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.halozyme.com/role/ConsolidatedStatementsOfStockholdersEquityDeficitStatement" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyAndEquipmentDetails", "http://www.halozyme.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.halozyme.com/role/ConsolidatedStatementsOfOperations", "http://www.halozyme.com/role/ConsolidatedStatementsOfStockholdersEquityDeficitStatement", "http://www.halozyme.com/role/RevenueContractWithCustomerAssetAndLiabilityDetails", "http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesLeasesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.halozyme.com/role/ConsolidatedStatementsOfOperations", "http://www.halozyme.com/role/ConsolidatedStatementsOfStockholdersEquityDeficitStatement", "http://www.halozyme.com/role/RevenueContractWithCustomerAssetAndLiabilityDetails", "http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesLeasesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r21", "r22", "r254", "r260" ], "lang": { "en-US": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Shares, New Issues" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ConsolidatedStatementsOfStockholdersEquityDeficitStatement", "http://www.halozyme.com/role/StockholdersEquityDeficitPublicOfferingDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": { "auth_ref": [ "r21", "r22", "r254", "r260" ], "lang": { "en-US": { "role": { "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures", "terseLabel": "Shares, Restricted Stock Award" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ConsolidatedStatementsOfStockholdersEquityDeficitStatement", "http://www.halozyme.com/role/StockholdersEquityDeficitDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "auth_ref": [ "r21", "r22", "r254", "r260" ], "lang": { "en-US": { "role": { "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).", "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture", "terseLabel": "Issuance of common stock pursuant to exercise of stock options and vesting of restricted stock units and performance restricted stock units, net" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ConsolidatedStatementsOfStockholdersEquityDeficitStatement" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r21", "r22", "r254", "r260", "r299" ], "lang": { "en-US": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "negatedTerseLabel": "Options, Exercises in Period", "verboseLabel": "Number of shares of common stock issued as a result of stock option exercises" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ShareBasedCompensationOptionsDetails", "http://www.halozyme.com/role/StockholdersEquityDeficitDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r21", "r22", "r254", "r260" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Stock Issued During Period, Value, New Issues" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ConsolidatedStatementsOfStockholdersEquityDeficitStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": { "auth_ref": [ "r254", "r260" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.", "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures", "terseLabel": "Value, Restricted Stock Award" } } }, "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ConsolidatedStatementsOfStockholdersEquityDeficitStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r56", "r254", "r260" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Value, Stock Options Exercised" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ConsolidatedStatementsOfStockholdersEquityDeficitStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramAuthorizedAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of stock repurchase plan authorized.", "label": "Stock Repurchase Program, Authorized Amount", "terseLabel": "Authorized repurchase amount" } } }, "localname": "StockRepurchaseProgramAuthorizedAmount1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/StockholdersEquityDeficitShareRepurchasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramPeriodInForce1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Period which shares may be purchased under a stock repurchase plan authorized by an entity's Board of Directors, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Stock Repurchase Program, Period in Force", "terseLabel": "Stock Repurchase Program, Period in Force" } } }, "localname": "StockRepurchaseProgramPeriodInForce1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/StockholdersEquityDeficitShareRepurchasesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_StockRepurchasedAndRetiredDuringPeriodShares": { "auth_ref": [ "r21", "r22", "r254", "r260" ], "lang": { "en-US": { "role": { "documentation": "Number of shares that have been repurchased and retired during the period.", "label": "Stock Repurchased and Retired During Period, Shares", "negatedTerseLabel": "Stock Repurchased and Retired During Period, Shares" } } }, "localname": "StockRepurchasedAndRetiredDuringPeriodShares", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ConsolidatedStatementsOfStockholdersEquityDeficitStatement" ], "xbrltype": "sharesItemType" }, "us-gaap_StockRepurchasedAndRetiredDuringPeriodValue": { "auth_ref": [ "r21", "r22", "r254", "r260" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital).", "label": "Stock Repurchased and Retired During Period, Value", "negatedTerseLabel": "Stock Repurchased and Retired During Period, Value" } } }, "localname": "StockRepurchasedAndRetiredDuringPeriodValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ConsolidatedStatementsOfStockholdersEquityDeficitStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r22", "r26", "r27", "r178" ], "calculation": { "http://www.halozyme.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Total stockholders' equity (deficit)", "periodStartLabel": "Total stockholders' equity (deficit)", "totalLabel": "Total stockholders' equity (deficit)" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ConsolidatedBalanceSheets", "http://www.halozyme.com/role/ConsolidatedStatementsOfStockholdersEquityDeficitStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders' equity (deficit) (textual)", "verboseLabel": "Stockholders' equity (deficit):" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ConsolidatedBalanceSheets", "http://www.halozyme.com/role/StockholdersEquityDeficitDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r266" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "verboseLabel": "Stockholders' Equity (Deficit)" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/StockholdersEquityDeficit" ], "xbrltype": "textBlockItemType" }, "us-gaap_StraightLineRent": { "auth_ref": [ "r103" ], "calculation": { "http://www.halozyme.com/role/ConsolidatedStatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Difference between actual rental income due and rental income recognized on a straight-line basis.", "label": "Straight Line Rent", "negatedTerseLabel": "Recognition of deferred rent" } } }, "localname": "StraightLineRent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/StockholdersEquityDeficitShareRepurchasesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r417" ], "lang": { "en-US": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/StockholdersEquityDeficitShareRepurchasesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r417" ], "lang": { "en-US": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/StockholdersEquityDeficitShareRepurchasesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock": { "auth_ref": [ "r358" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.", "label": "Summary of Operating Loss Carryforwards [Table Text Block]", "terseLabel": "Summary of Operating Loss Carryforwards [Table Text Block]" } } }, "localname": "SummaryOfOperatingLossCarryforwardsTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock": { "auth_ref": [ "r344" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of unrecognized tax benefits for which a material change is reasonably possible in the next twelve months, typically including the nature of the uncertainty, the event(s) that could cause a material change, and an estimate of the range of the reasonably possible change or a statement that an estimate of the range cannot be made. An unrecognized tax benefit is the difference between a tax position taken in a tax return and the amounts recognized in the financial statements for which it is more likely than not, based on the technical merits of the position, that the tax position will not be sustained upon examination.", "label": "Summary of Positions for which Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Table Text Block]", "terseLabel": "Summary of Positions for which Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Table Text Block]" } } }, "localname": "SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": { "auth_ref": [ "r61" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.", "label": "Supplemental Balance Sheet Disclosures [Text Block]", "terseLabel": "Certain Balance Sheet Items" } } }, "localname": "SupplementalBalanceSheetDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/CertainBalanceSheetItems" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplierConcentrationRiskMember": { "auth_ref": [ "r151" ], "lang": { "en-US": { "role": { "documentation": "Reflects the percentage that purchases in the period from one or more significant suppliers is to cost of goods or services, as defined by the entity, such as total cost of sales or services, product line cost of sales or services, segment cost of sales or services. Risk is the materially adverse effects of loss of a material supplier or a supplier of critically needed goods or services.", "label": "Supplier Concentration Risk [Member]", "terseLabel": "Supplier Concentration Risk [Member]" } } }, "localname": "SupplierConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesConcentrationsOfCreditRiskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TaxCreditCarryforwardAmount": { "auth_ref": [ "r357" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Tax Credit Carryforward, Amount", "terseLabel": "Tax Credit Carryforward, Amount" } } }, "localname": "TaxCreditCarryforwardAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/IncomeTaxesTaxTextualsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TaxCreditCarryforwardAxis": { "auth_ref": [ "r358" ], "lang": { "en-US": { "role": { "documentation": "Information by specific tax credit related to an unused tax credit.", "label": "Tax Credit Carryforward [Axis]", "terseLabel": "Tax Credit Carryforward [Axis]" } } }, "localname": "TaxCreditCarryforwardAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/IncomeTaxesTaxTextualsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TaxCreditCarryforwardLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Tax Credit Carryforward [Line Items]", "terseLabel": "Tax Credit Carryforward [Line Items]" } } }, "localname": "TaxCreditCarryforwardLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/IncomeTaxesTaxTextualsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TaxCreditCarryforwardNameDomain": { "auth_ref": [ "r358" ], "lang": { "en-US": { "role": { "documentation": "The name of the tax credit carryforward.", "label": "Tax Credit Carryforward, Name [Domain]", "terseLabel": "Tax Credit Carryforward, Name [Domain]" } } }, "localname": "TaxCreditCarryforwardNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/IncomeTaxesTaxTextualsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TaxCreditCarryforwardTable": { "auth_ref": [ "r358" ], "lang": { "en-US": { "role": { "documentation": "A listing of tax credit carryforwards available to reduce future taxable income including descriptions, amounts, expiration dates, limitations on use and the related deferred tax assets and valuation allowances.", "label": "Tax Credit Carryforward [Table]", "terseLabel": "Tax Credit Carryforward [Table]" } } }, "localname": "TaxCreditCarryforwardTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/IncomeTaxesTaxTextualsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TaxPeriodAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information about the period subject to enacted tax laws.", "label": "Tax Period [Axis]", "terseLabel": "Tax Period [Axis]" } } }, "localname": "TaxPeriodAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/IncomeTaxesOperatingLossCarryforwardExpirationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TaxPeriodDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identified tax period.", "label": "Tax Period [Domain]", "terseLabel": "Tax Period [Domain]" } } }, "localname": "TaxPeriodDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/IncomeTaxesOperatingLossCarryforwardExpirationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TradeAndOtherAccountsReceivablePolicy": { "auth_ref": [ "r172", "r173", "r174", "r175", "r177", "r179" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for accounts receivable.", "label": "Accounts Receivable [Policy Text Block]", "terseLabel": "Accounts Receivable [Policy Text Block]" } } }, "localname": "TradeAndOtherAccountsReceivablePolicy", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r422" ], "lang": { "en-US": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]", "terseLabel": "Financial Instruments [Domain]" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/FairValueMeasurementFairValueMeasuresDetails", "http://www.halozyme.com/role/FairValueMeasurementSummaryDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockSharesAcquired": { "auth_ref": [ "r22", "r254", "r260" ], "lang": { "en-US": { "role": { "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.", "label": "Treasury Stock, Shares, Acquired", "terseLabel": "Treasury Stock, Shares, Acquired", "verboseLabel": "Stock repurchased (shares)" } } }, "localname": "TreasuryStockSharesAcquired", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/LongTermDebtNetLongTermDebtTextualsDetails", "http://www.halozyme.com/role/StockholdersEquityDeficitShareRepurchasesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockValueAcquiredCostMethod": { "auth_ref": [ "r254", "r260", "r262" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.", "label": "Treasury Stock, Value, Acquired, Cost Method", "terseLabel": "Treasury Stock, Value, Acquired, Cost Method", "verboseLabel": "Value of stock repurchased" } } }, "localname": "TreasuryStockValueAcquiredCostMethod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/LongTermDebtNetLongTermDebtTextualsDetails", "http://www.halozyme.com/role/StockholdersEquityDeficitShareRepurchasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TypeOfAdoptionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Adoption and early adoption of sources of change to generally accepted accounting principles (GAAP) in the United States. The FASB released the FASB Accounting Standards Codification as the authoritative source of literature effective for interim and annual periods ending after September 15, 2009. As part of the Codification process, the FASB issues Accounting Standards Updates to amend the Codification but otherwise the Accounting Standards Updates are not authoritative in their own right. All previous accounting standards (such as FASB Statements of Financial Accounting Standards, FASB Interpretations, FASB Staff Positions, Emerging Issues Task Force Consensuses, other pronouncements of the FASB or other designated bodies, or other forms of GAAP are considered accounting pronouncements) were superseded upon the adoption of the Codification. For an interim period, references to the superseded standards are included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.", "label": "Type of Adoption [Domain]", "terseLabel": "Type of Adoption [Domain]" } } }, "localname": "TypeOfAdoptionMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/RevenueTextualsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r373" ], "lang": { "en-US": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "verboseLabel": "Collaborative Arrangements and Non-collaborative Arrangements [Axis]" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/RevenueRevenueRecognitionMultipleDeliverableArrangementsDetails", "http://www.halozyme.com/role/RevenueTextualsDetails", "http://www.halozyme.com/role/SummaryOfUnauditedQuarterlyFinancialInformationTextualsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TypeOfRestructuringDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identification of the types of restructuring costs.", "label": "Type of Restructuring [Domain]", "terseLabel": "Type of Restructuring [Domain]" } } }, "localname": "TypeOfRestructuringDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/RestructuringChargesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_USTreasurySecuritiesMember": { "auth_ref": [ "r284", "r286", "r430" ], "lang": { "en-US": { "role": { "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).", "label": "US Treasury Securities [Member]", "terseLabel": "US Treasury Securities [Member]" } } }, "localname": "USTreasurySecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/FairValueMeasurementFairValueMeasuresDetails", "http://www.halozyme.com/role/FairValueMeasurementSummaryDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain": { "auth_ref": [ "r235" ], "lang": { "en-US": { "role": { "documentation": "General description of the goods or services to be purchased from the counterparty to the unconditional purchase arrangement.", "label": "Unconditional Purchase Obligation, Category of Goods or Services Acquired [Domain]", "terseLabel": "Unconditional Purchase Obligation, Category of Goods or Services Acquired [Domain]" } } }, "localname": "UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/CommitmentsAndContingenciesOtherCommitmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UndistributedEarningsOfForeignSubsidiaries": { "auth_ref": [ "r332", "r369", "r445", "r462" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of undistributed earnings of foreign subsidiaries intended to be permanently reinvested outside the country of domicile.", "label": "Undistributed Earnings of Foreign Subsidiaries", "terseLabel": "Undistributed Earnings of Foreign Subsidiaries" } } }, "localname": "UndistributedEarningsOfForeignSubsidiaries", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/IncomeTaxesTaxTextualsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefits": { "auth_ref": [ "r333", "r346" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of unrecognized tax benefits.", "label": "Unrecognized Tax Benefits", "periodEndLabel": "Unrecognized Tax Benefits, end of period", "periodStartLabel": "Unrecognized Tax Benefits, beginning of period", "terseLabel": "Unrecognized Tax Benefits" } } }, "localname": "UnrecognizedTaxBenefits", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/IncomeTaxesTaxTextualsDetails", "http://www.halozyme.com/role/IncomeTaxesUnrecognizedTaxBenefitDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": { "auth_ref": [ "r347" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.", "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions", "negatedTerseLabel": "Decrease Resulting from Prior Period Tax Positions" } } }, "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/IncomeTaxesUnrecognizedTaxBenefitDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": { "auth_ref": [ "r343" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.", "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense", "terseLabel": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense" } } }, "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/IncomeTaxesTaxTextualsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": { "auth_ref": [ "r348" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.", "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions", "terseLabel": "Increase Resulting from Current Period Tax Positions" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/IncomeTaxesUnrecognizedTaxBenefitDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": { "auth_ref": [ "r347" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.", "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions", "terseLabel": "Increase Resulting from Prior Period Tax Positions" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/IncomeTaxesUnrecognizedTaxBenefitDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": { "auth_ref": [ "r349" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.", "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate", "terseLabel": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate" } } }, "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/IncomeTaxesTaxTextualsDetails", "http://www.halozyme.com/role/IncomeTaxesUnrecognizedTaxBenefitDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis": { "auth_ref": [ "r233", "r234" ], "lang": { "en-US": { "role": { "documentation": "Pertinent information about unrecorded unconditional purchase arrangements to acquire goods or services, by category of goods or services. arrangements to acquire goods or services, by category of goods or services.", "label": "Unrecorded Unconditional Purchase Obligation by Category of Item Purchased [Axis]", "terseLabel": "Unrecorded Unconditional Purchase Obligation by Category of Item Purchased [Axis]" } } }, "localname": "UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/CommitmentsAndContingenciesOtherCommitmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r145", "r146", "r148", "r149", "r156", "r157", "r158" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates, Policy [Policy Text Block]" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": { "auth_ref": [ "r335" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.", "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount", "terseLabel": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount" } } }, "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationAllowancesAndReservesBalance": { "auth_ref": [ "r123" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount", "periodEndLabel": "Accounts receivable allowance, ending balance", "periodStartLabel": "Accounts receivable allowance, beginning balance" } } }, "localname": "ValuationAllowancesAndReservesBalance", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ScheduleIiValuationAndQualifyingAccountsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense": { "auth_ref": [ "r123" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in valuation and qualifying accounts and reserves from charge to cost and expense.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense", "terseLabel": "Additions" } } }, "localname": "ValuationAllowancesAndReservesChargedToCostAndExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ScheduleIiValuationAndQualifyingAccountsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationAllowancesAndReservesDeductions": { "auth_ref": [ "r123" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of decrease in valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction", "negatedTerseLabel": "Deductions" } } }, "localname": "ValuationAllowancesAndReservesDeductions", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ScheduleIiValuationAndQualifyingAccountsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_VestingAxis": { "auth_ref": [ "r320" ], "lang": { "en-US": { "role": { "documentation": "Information by vesting schedule of award under share-based payment arrangement.", "label": "Vesting [Axis]", "terseLabel": "Vesting [Axis]" } } }, "localname": "VestingAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ShareBasedCompensationTextualsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VestingDomain": { "auth_ref": [ "r320" ], "lang": { "en-US": { "role": { "documentation": "Vesting schedule of award under share-based payment arrangement.", "label": "Vesting [Domain]", "terseLabel": "Vesting [Domain]" } } }, "localname": "VestingDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ShareBasedCompensationTextualsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": { "auth_ref": [ "r136" ], "lang": { "en-US": { "role": { "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.", "label": "Weighted Average Number Diluted Shares Outstanding Adjustment", "terseLabel": "Shares excluded from calculation of diluted net loss, amount" } } }, "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesNetLossPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r130", "r136" ], "lang": { "en-US": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted Average Number of Shares Outstanding, Diluted", "verboseLabel": "Shares used in computing diluted net income (loss) per share" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ConsolidatedStatementsOfOperations", "http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesNetLossPerShareDetails", "http://www.halozyme.com/role/SummaryOfUnauditedQuarterlyFinancialInformationQuarterlyFinancialInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).", "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted", "terseLabel": "Weighted Average Number of Shares Outstanding, Basic and Diluted" } } }, "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r129", "r136" ], "lang": { "en-US": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted Average Number of Shares Outstanding, Basic", "verboseLabel": "Shares used in computing basic net income (loss) per share" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.halozyme.com/role/ConsolidatedStatementsOfOperations", "http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesNetLossPerShareDetails", "http://www.halozyme.com/role/SummaryOfUnauditedQuarterlyFinancialInformationQuarterlyFinancialInformationDetails" ], "xbrltype": "sharesItemType" } }, "unitCount": 8 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6935-107765" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4273-108586" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4297-108586" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e7018-107765" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(e),(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h)(1)(i))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04.(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24092-122690" }, "r124": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1448-109256" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(19)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1505-109256" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1278-109256" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1311-109256" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117327953&loc=d3e4984-109258" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=116846552&loc=d3e543-108305" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=118952077&loc=d3e1280-108306" }, "r143": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "270", "URI": "http://asc.fasb.org/topic&trid=2126967" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r159": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9031-108599" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9038-108599" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9054-108599" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4428-111522" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4531-111522" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118936363&loc=d3e4975-111524" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "11B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118936363&loc=SL6953423-111524" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118936363&loc=d3e5212-111524" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118936363&loc=d3e5033-111524" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118936363&loc=d3e5074-111524" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118936363&loc=d3e5093-111524" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26610-111562" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26853-111562" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27198-111563" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27198-111563" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27198-111563" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27232-111563" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27290-111563" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27290-111563" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27337-111563" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27340-111563" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)-(d)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27357-111563" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33775-111570" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=118955202&loc=SL82895884-210446" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919244-210447" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919249-210447" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919249-210447" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919249-210447" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919253-210447" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919258-210447" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919230-210447" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(e)(2)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=118955255&loc=SL82921835-210448" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=118942338&loc=SL82898722-210454" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922888-210455" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922895-210455" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922900-210455" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=118942371&loc=SL82922954-210456" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=68048583&loc=d3e3636-108311" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116846819&loc=d3e3927-108312" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.BB)", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2420-110228" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.CC)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.3)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.3)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.4)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r232": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "420", "URI": "http://asc.fasb.org/topic&trid=2175745" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=77896938&loc=d3e25287-109308" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=77896938&loc=d3e25336-109308" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=77896938&loc=d3e25383-109308" }, "r236": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14326-108349" }, "r238": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109126253&loc=d3e4852-112606" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=51819886&loc=SL6014347-161799" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031898-161870" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031898-161870" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6036836-161870" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6036836-161870" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12317-112629" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12355-112629" }, "r253": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405686&loc=d3e22802-112653" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23309-112656" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656" }, "r266": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944033&loc=SL49130531-203044" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944033&loc=SL49130532-203044" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944033&loc=SL49130533-203044" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130551-203045" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130556-203045" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130556-203045" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130543-203045" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(i)(1)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048" }, "r281": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "705", "URI": "http://asc.fasb.org/topic&trid=2122478" }, "r282": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "710", "URI": "http://asc.fasb.org/topic&trid=2127225" }, "r283": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "712", "URI": "http://asc.fasb.org/topic&trid=2197446" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921" }, "r287": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "715", "URI": "http://asc.fasb.org/topic&trid=2235017" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116855982&loc=d3e4534-113899" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(5))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)-(4)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=SL79508275-113901" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11149-113907" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11178-113907" }, "r326": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=117330534&loc=d3e28680-109314" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=117330534&loc=d3e28680-109314" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=117330534&loc=d3e28200-109314" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "10B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=SL37586934-109318" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e32059-109318" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e32123-109318" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e32247-109318" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e32280-109318" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e31917-109318" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e31931-109318" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e31958-109318" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38976-109324" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "05", "SubTopic": "30", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=65884525&loc=d3e40913-109327" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r374": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "808", "URI": "http://asc.fasb.org/topic&trid=5833765" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13279-108611" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13467-108611" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13476-108611" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13531-108611" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13537-108611" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13537-108611" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30690-110894" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30700-110894" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=77902758&loc=d3e41499-112717" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888369&loc=SL77918431-209957" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918638-209977" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6)(a)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62557-112803" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(a)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62586-112803" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62586-112803" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62586-112803" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62652-112803" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "(c)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "(g)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "e", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "740", "Subparagraph": "(b)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6479915&loc=d3e66715-112838" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(10))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "740", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6487024&loc=d3e29054-158556" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=117420044&loc=d3e19393-158473" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=6589523&loc=d3e617274-123014" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=116631420&loc=SL116631458-115580" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "740", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Subparagraph": "(a)", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=114873921&loc=SL114875236-224282" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=6590653&loc=d3e638233-123024" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28)", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=6590653&loc=d3e638233-123024" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r473": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r474": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r475": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1-" }, "r476": { "Name": "Forms 10-K, 20-F, 40-F", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d-1" }, "r477": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r478": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r479": { "Footnote": "2", "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r480": { "Footnote": "4", "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "12", "Subsection": "29" }, "r481": { "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "12", "Subsection": "09" }, "r482": { "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r483": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "c", "Publisher": "SEC", "Section": "5", "Subparagraph": "Schedule III", "Subsection": "04" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6787-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(5))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.3,4)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6801-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r61": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "210", "URI": "http://asc.fasb.org/topic&trid=2122208" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e637-108580" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e640-108580" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e681-108580" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669686-108580" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "17B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL34724394-108580" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6812-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e557-108580" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6911-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(8))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.21)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6935-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a),(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a),(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585" } }, "version": "2.1" } XML 40 R29.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Commitments and Contingencies Commitments and Contingencies (Tables)
    		 12 Months Ended
    Dec. 31, 2019
    Commitments and Contingencies Disclosure [Abstract]  
    Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]
    Approximate annual future minimum operating lease payments as of December 31, 2019 are as follows (in thousands): 
    Year:
     
    Operating
    Leases
    2020
     
    $
    3,355

    2021
     
    2,260

    2022
     
    1,559

    2023
     
    70

    2024
     
    —

    Total minimum lease payments
     
    $
    7,244

    Less imputed interest
     
    (775
    )
    Total
     
    $
    6,469
    XML 41 R9999.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Label Element Value
    Cumulative Effect of New Accounting Principle in Period of Adoption us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption $ 71,263,000
    Retained Earnings [Member]  
    Cumulative Effect of New Accounting Principle in Period of Adoption us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption $ 71,263,000
    XML 42 R45.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Fair Value Measurement Textuals (Details)
    $ in Thousands
    		 12 Months Ended
    Dec. 31, 2019
    USD ($)
    security
    Fair Value Disclosures [Abstract]  
    Available-for-sale, Securities in Unrealized Loss Positions, Qualitative Disclosure, Number of Positions | security 11
    Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value $ 82,900
    Available-for-sale Securities, Continuous Unrealized Loss Position, Accumulated Loss (19)
    Other than Temporary Impairment Losses, Marketable Securities $ 0
    XML 43 R41.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Summary of Significant Accounting Policies Income tax (Details)
    Dec. 31, 2019
    USD ($)
    Income Tax Disclosure [Abstract]  
    Deferred tax asset excluding amount for AMT $ 0
    Deferred Tax Assets, Tax Credit Carryforwards $ 1,700,000
    XML 44 R49.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Revenue - Textuals (Details) - USD ($)
    $ in Thousands
    		 3 Months Ended 12 Months Ended
    Dec. 31, 2019
    Sep. 30, 2019
    Jun. 30, 2019
    Mar. 31, 2019
    Dec. 31, 2018
    Sep. 30, 2018
    Jun. 30, 2018
    Mar. 31, 2018
    Dec. 31, 2019
    Dec. 31, 2018
    Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
    Revenue related to licenses granted to collaboration partners                 $ 74,900  
    Revenue recognized                 (4,000)  
    Accounts receivable $ 0               0  
    Revenues 53,665 $ 46,230 $ 39,148 $ 56,949 $ 60,232 $ 25,556 $ 35,202 $ 30,872    
    Accounts receivable, net 59,442       30,005       59,442 $ 30,005
    Deferred revenues 5,259       9,255       5,259 9,255
    Deferred Credits and Other Liabilities, Current 4,012               4,012  
    Deferred Credits and Other Liabilities 5,300               5,300  
    2017 Roche                    
    Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
    Development milestones                 5,000  
    Difference between Revenue Guidance in Effect before and after Topic 606                    
    Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
    Accounts receivable         19,400         19,400
    Deferred revenues         51,800         51,800
    Impact of applying the provisions of ASC 606         71,200         71,200
    Accounting Standards Update 2014-09 | Difference between Revenue Guidance in Effect before and after Topic 606                    
    Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
    Revenues                   4,700
    Accounts receivable, net         19,300         19,300
    Deferred revenues         $ (47,400)         $ (47,400)
    Product [Member]                    
    Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
    Deferred Credits and Other Liabilities, Current 7,000               7,000  
    Deferred Credits and Other Liabilities $ 12,300               $ 12,300  
    XML 45 R62.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Share-based Compensation Textuals (Details)
    		 12 Months Ended
    Dec. 31, 2019
    shares
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
    Common Stock, Capital Shares Reserved for Future Issuance 9,352,360
    Options, Exercise Price, Percent of Share Price 100.00%
    Options, Outstanding, Initial Contractual Term 10 years
    Cliff Vesting, First Anniversary [Member]  
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
    Award Vesting Rights, Percentage 25.00%
    Monthly Vesting, after One Year [Member]  
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
    Award Vesting Rights, Percentage 2.08%
    RSUs | Percentage Vesting [Member]  
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
    Award Vesting Rights, Percentage 25.00%
    Outstanding awards [Member]  
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
    Number of Shares Subject To Outstanding Awards 13,640,668
    RSAs | Percentage Vesting [Member]  
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
    Award Vesting Rights, Percentage 25.00%
    Amended and Restated 2011 Stock Plan [Member]  
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
    Number of Shares Authorized 44,200,000
    XML 46 R66.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Share-based Compensation Valuation (Details)
    		 12 Months Ended
    Dec. 31, 2019
    Dec. 31, 2018
    Dec. 31, 2017
    Schedule of Share-based Compensation Arrangements Valuation Inputs [Line Items]      
    Fair Value Assumptions, Weighted Average Expected Term 5 years 6 months 5 years 6 months 5 years 7 months 6 days
    Fair Value Assumptions, Expected Dividend Rate 0.00% 0.00% 0.00%
    Fair Value Assumptions, Risk Free Interest Rate, Minimum 1.32% 2.25% 1.73%
    Fair Value Assumptions, Risk Free Interest Rate, Maximum 2.56% 2.96% 2.13%
    Minimum      
    Schedule of Share-based Compensation Arrangements Valuation Inputs [Line Items]      
    Fair Value Assumptions, Weighted Average Volatility Rate 51.56% 57.18% 69.81%
    Fair Value Assumptions, Weighted Average Expected Term 5 years 6 months    
    Maximum      
    Schedule of Share-based Compensation Arrangements Valuation Inputs [Line Items]      
    Fair Value Assumptions, Weighted Average Volatility Rate 56.94% 70.06% 71.73%
    Fair Value Assumptions, Weighted Average Expected Term 5 years 6 months    
    XML 47 R28.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Share-based Compensation (Tables)
    		 12 Months Ended
    Dec. 31, 2019
    Share-based Payment Arrangement, Noncash Expense [Abstract]  
    Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]
    Total share-based compensation expense related to share-based awards was comprised of the following (in thousands):
     
     
    Year Ended December 31,
     
     
    2019
     
    2018
     
    2017
    Research and development
     
    $
    15,107

     
    $
    17,220

     
    $
    13,080

    Selling, general and administrative
     
    19,669

     
    18,476

     
    17,590

    Share-based compensation expense
     
    $
    34,776

     
    $
    35,696

     
    $
    30,670
    Share-based Payment Arrangement, Cost by Plan [Table Text Block]
    Share-based compensation expense by type of share-based award (in thousands):
     
     
    Year Ended December 31,
     
     
    2019
     
    2018
     
    2017
    Stock options
     
    $
    17,624

     
    $
    18,742

     
    $
    19,583

    RSAs and RSUs
     
    17,152

     
    16,954

     
    11,087

     
     
    $
    34,776

     
    $
    35,696

     
    $
    30,670
    Share-based Payment Arrangement, Nonvested Award, Cost [Table Text Block]
    Total unrecognized estimated compensation cost by type of award and the weighted-average remaining requisite service period over which such expense is expected to be recognized (in thousands, unless otherwise noted):
     
     
    December 31, 2019
     
     
    Unrecognized
    Expense
     
    Remaining
    Weighted-Average
    Recognition Period
    (years)
    Stock options
     
    $
    16,524

     
    2.59
    RSAs
     
    $
    570

     
    0.16
    RSUs
     
    $
    11,600

     
    2.32
    Share-based Payment Arrangement, Option, Activity [Table Text Block]
    A summary of our stock option award activity as of and for the year ended December 31, 2019 is as follows: 
     
     
    Shares
    Underlying
    Stock Options
     
    Weighted
    Average Exercise
    Price per Share
     
    Weighted
    Average
    Remaining
    Contractual
    Term (years)
     
    Aggregate
    Intrinsic
    Value
    Outstanding at December 31, 2018
     
    11,012,381

     
    $13.81
     
     
     
     
    Granted
     
    3,056,191

     
    $16.46
     
     
     
     
    Exercised
     
    (1,540,690
    )
     
    $10.73
     
     
     
     
    Canceled/forfeited
     
    (979,653
    )
     
    $16.19
     
     
     
     
    Outstanding at December 31, 2019
     
    11,548,229

     
    $14.72
     
    3.98
     

    $39.8
     million
    Vested and expected to vest at December 31, 2019
     
    11,548,229

     
    $14.72
     
    3.98
     

    $39.8
     million
    Exercisable at December 31, 2019
     
    6,962,972

     
    $13.64
     
    3.59
     

    $32.7
     million
    Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] The assumptions used in the Black-Scholes model were as follows:
     
     
    Year Ended December 31,
     
     
    2019
     
    2018
     
    2017
    Expected volatility
     
    51.56-56.94%
     
    57.18-70.06%
     
    69.81-71.73%
    Average expected term (in years)
     
    5.5
     
    5.5
     
    5.6
    Risk-free interest rate
     
    1.35-2.56%
     
    2.25-2.96%
     
    1.73-2.13%
    Expected dividend yield
     
    —
     
    —
     
    —
    Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]
    The following table summarizes our RSA activity during the year ended December 31, 2019:
     
     
    Number of
    Shares
     
    Weighted
    Average
    Grant Date
    Fair Value
    Unvested at December 31, 2018
     
    397,389

     
    $11.03
    Granted
     
    85,211

     
    $16.43
    Vested
     
    (260,086
    )
     
    $12.57
    Forfeited
     
    (11,391
    )
     
    $8.11
    Unvested at December 31, 2019
     
    211,123

     
    $11.47
    Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]
    The following table summarizes our RSU activity during the year ended December 31, 2019:
     
     
    Number of
    Shares
     
    Weighted
    Average
    Grant Date
    Fair Value
     
    Weighted
    Average
    Remaining
    Contractual
    Term (yrs)
     
    Aggregate
    Intrinsic
    Value
    Outstanding at December 31, 2018
     
    2,388,342

     
    $15.12
     
     
     
     
    Granted
     
    1,151,464

     
    $16.55
     
     
     
     
    Vested
     
    (1,092,648
    )
     
    $15.35
     
     
     
     
    Forfeited
     
    (354,719
    )
     
    $16.22
     
     
     
     
    Outstanding at December 31, 2019
     
    2,092,439

     
    $15.60
     
    1.23
     

    $37.1
     million
    XML 48 R20.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Restructuring Charges
    		 12 Months Ended
    Dec. 31, 2019
    Restructuring and Related Activities [Abstract]  
    Restructuring Charges Restructuring Charges
    On November 4, 2019, we announced that our HALO-301 Phase 3 clinical study evaluating investigational new drug PEGPH20 in combination with ABRAXANE and gemcitabine as a first-line therapy for treatment of patients with metastatic pancreatic cancer failed to reach the primary endpoint of overall survival. Due to the results of the study, we halted development activities for PEGPH20, closed our oncology operations and implemented an organizational restructuring to focus our operations solely on marketing Hylenex and our ENHANZE business. In connection with the restructuring, we reduced our headcount by approximately 55% or approximately 160 positions.
    We incurred restructuring charges consisting of one-time severance payments and other employee related costs, including non-cash costs related to the acceleration of equity awards for employees affected by the restructuring, of $19.5 million in the fourth quarter of 2019. The majority of the cash payments for employee related restructuring charges will be paid during the first quarter of 2020. Additionally, we incurred one-time charges related to lease and other contract cancellations and asset impairments of $8.9 million in the fourth quarter of 2019. We may also incur additional costs not currently contemplated due to events that may occur as a result of, or that are associated with, the workforce reduction and the cancellation of our PEGPH20 programs.
    XML 49 R2.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Consolidated Balance Sheets - USD ($)
    $ in Thousands
    Dec. 31, 2019
    Dec. 31, 2018
    Current assets:    
    Cash and cash equivalents $ 120,179 $ 57,936
    Marketable securities, available-for-sale 301,083 296,590
    Accounts receivable, net 59,442 30,005
    Inventories 29,359 22,625
    Prepaid expenses and other assets 33,373 20,693
    Total current assets 543,436 427,849
    Property and equipment, net 10,855 7,465
    Prepaid expenses and other assets 11,083 4,434
    Restricted cash 500 500
    Total assets 565,874 440,248
    Current liabilities:    
    Accounts payable 6,434 4,079
    Accrued expenses 55,649 49,529
    Deferred Credits and Other Liabilities, Current 4,012  
    Deferred revenue, current portion   4,247
    Current portion of long-term debt, net 19,542 91,506
    Total current liabilities 85,637 149,361
    Deferred Credits and Other Liabilities, Noncurrent 1,247  
    Deferred revenue, net of current portion 1,247 5,008
    Long-term debt, net 383,045 34,874
    Other long-term liabilities 4,180 2,118
    Commitments and contingencies (Note 9)
    Stockholders' equity (deficit):    
    Preferred stock - $0.001 par value; 20,000 shares authorized; no shares issued and outstanding 0 0
    Common stock - $0.001 par value; 200,000 shares authorized; 142,789 and 129,502 shares issued and outstanding at December 31, 2017 and 2016, respectively 137 145
    Additional paid-in capital 695,066 780,457
    Accumulated other comprehensive loss 240 (277)
    Accumulated deficit (603,678) (531,438)
    Total stockholders' equity (deficit) 91,765 248,887
    Total liabilities and stockholders' equity (deficit) $ 565,874 $ 440,248
    XML 50 R6.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Consolidated Statements of Cash Flows - USD ($)
    $ in Thousands
    		 12 Months Ended
    Dec. 31, 2019
    Dec. 31, 2018
    Dec. 31, 2017
    Operating activities:      
    Net income (loss) $ (72,240) $ (80,330) $ 62,971
    Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:      
    Share-based compensation 34,776 35,696 30,670
    Depreciation and amortization 4,068 2,388 2,161
    Amortization of Debt Discount (Premium) 2,484 1,545  
    Non-cash interest expense     1,761
    (Accretion of discounts) amortization of premiums on marketable securities, net (2,469) (3,090) (303)
    Loss on disposal of equipment 1,431 5 46
    Deferral of unearned revenue 0 3,000 22,759
    Recognition of deferred revenue (3,996) (2,832) (6,512)
    Deferred Rent Expense (459) (7)  
    Deferral of rent expense     13
    Operating Lease, Impairment Loss 1,127 0 0
    Recognition of deferred rent 0 0 (185)
    Gain (Loss) on Extinguishment of Debt 401 0 0
    Other (7) (9) (16)
    Changes in operating assets and liabilities:      
    Accounts receivable, net (29,437) 11,613 (6,453)
    Inventories (6,734) (17,480) 9,477
    Prepaid expenses and other assets (19,006) (5,695) 2,035
    Accounts payable and accrued expenses 4,638 5,696 15,629
    Net cash provided by (used in) operating activities (85,423) (49,500) 134,053
    Investing activities:      
    Purchases of marketable securities (389,759) (311,112) (398,187)
    Proceeds from maturities of marketable securities 388,250 318,268 235,805
    Purchases of property and equipment (4,040) (4,663) (1,350)
    Net cash (used in) provided by investing activities (5,549) 2,493 (163,732)
    Financing activities:      
    Proceeds from issuance of common stock, net 0 0 134,874
    Proceeds from issuance of long-term debt, net 447,350 0 0
    Repayment of long-term debt (108,082) (77,516) (15,995)
    Payments of Debt Issuance Costs (279) 0 0
    Payments for Repurchase of Common Stock (199,998) 0 0
    Proceeds from issuance of common stock under equity incentive plans, net of taxes paid related to net share settlement 14,224 13,719 12,776
    Net cash provided by financing activities 153,215 (63,797) 131,655
    Net increase (decrease) in cash, cash equivalents and restricted cash 62,243 (110,804) 101,976
    Cash, cash equivalents and restricted cash beginning of period 58,436 169,240 67,264
    Cash, cash equivalents and restricted cash end of period 120,679 58,436 169,240
    Interest Paid, Including Capitalized Interest, Operating and Investing Activities 9,029 16,891 20,295
    Income Taxes Paid 188 220 3,015
    Amounts accrued for purchases of property and equipment 61 542 189
    Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction 68 0 0
    Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 897 0 0
    Payments for Tenant Improvements $ 0 $ 1,322 $ 13
    XML 51 R24.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Fair Value Measurement (Tables)
    		 12 Months Ended
    Dec. 31, 2019
    Fair Value Disclosures [Abstract]  
    Available-for-sale marketable securities
    Available-for-sale marketable securities consisted of the following (in thousands):
     
     
    December 31, 2019
     
     
    Amortized Cost
     
    Gross Unrealized Gains
     
    Gross Unrealized Losses
     
    Estimated Fair Value
    Asset-backed securities
     
    $
    30,484

     
    $
    55

     
    $
    —

     
    $
    30,539

    Corporate debt securities
     
    161,308

     
    178

     
    (14
    )
     
    161,472

    U.S. Treasury securities
     
    75,192

     
    40

     
    (5
    )
     
    75,227

    Commercial paper
     
    33,845

     
    —

     
    —

     
    33,845

     
     
    $
    300,829

     
    $
    273

     
    $
    (19
    )
     
    $
    301,083


     
     
    December 31, 2018
     
     
    Amortized Cost
     
    Gross Unrealized Gains
     
    Gross Unrealized Losses
     
    Estimated Fair Value
    Asset-backed securities
     
    $
    39,787

     
    $
    —

     
    $
    (40
    )
     
    $
    39,747

    Corporate debt securities
     
    57,860

     
    —

     
    (127
    )
     
    57,733

    U.S. Treasury securities
     
    84,924

     
    —

     
    (87
    )
     
    84,837

    Commercial paper
     
    114,273

     
    —

     
    —

     
    114,273

     
     
    $
    296,844

     
    $
    —

     
    $
    (254
    )
     
    $
    296,590
    Investments Classified by Contractual Maturity Date [Table Text Block]
    Contractual maturities of available-for-sale debt securities are as follows (in thousands):
     
     
    December 31, 2019
     
    December 31, 2018
     
     
    Estimated Fair Value
    Due within one year
     
    $
    274,805

     
    $
    296,590

    After one but within five years
     
    26,278

     
    —

     
     
    $
    301,083

     
    $
    296,590
    Fair Value, Assets Measured on Recurring Basis [Table Text Block]
    The following table summarizes, by major security type, our cash equivalents and available-for-sale marketable securities that are measured at fair value on a recurring basis and are categorized using the fair value hierarchy (in thousands):
     
     
    December 31, 2019
     
    December 31, 2018
     
     
    Level 1
     
    Level 2
     
    Total estimated fair value
     
    Level 1
     
    Level 2
     
    Total estimated fair value
    Cash equivalents:
     
     
     
     
     
     
     
     
     
     
     
     
    Money market funds
     
    $
    119,949

     
    $
    —

     
    $
    119,949

     
    $
    57,987

     
    $
    —

     
    $
    57,987

    Available-for-sale marketable
       securities:
     
     
     
     
     
     
     
     
     
     
     
     
    Asset-backed securities
     
    —

     
    30,539

     
    30,539

     
    —

     
    39,747

     
    39,747

    Corporate debt securities
     
    —

     
    161,472

     
    161,472

     
    —

     
    57,733

     
    57,733

    U.S. Treasury securities
     
    75,228

     
    —

     
    75,228

     
    84,837

     
    —

     
    84,837

    Commercial paper
     
    —

     
    33,845

     
    33,845

     
    —

     
    114,273

     
    114,273

     
     
    $
    195,177

     
    $
    225,856

     
    $
    421,033

     
    $
    142,824

     
    $
    211,753

     
    $
    354,577
    XML 52 R12.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Certain Balance Sheet Items
    		 12 Months Ended
    Dec. 31, 2019
    Balance Sheet Related Disclosures [Abstract]  
    Certain Balance Sheet Items Certain Balance Sheet Items
    Accounts receivable, net consisted of the following (in thousands):
     
     
    December 31,
    2019
     
    December 31,
    2018
    Accounts receivable from product sales to collaborators
     
    $
    35,649

     
    $
    3,717

    Accounts receivable from revenues under collaborative agreements
     
    3,850

     
    5,499

    Accounts receivable from royalty payments
     
    17,149

     
    19,199

    Accounts receivable from other product sales
     
    3,591

     
    2,182

         Subtotal
     
    60,239

     
    30,597

    Allowance for distribution fees and discounts
     
    (797
    )
     
    (592
    )
         Total accounts receivable, net
     
    $
    59,442

     
    $
    30,005


    Inventories consisted of the following (in thousands):
     
     
    December 31,
    2019
     
    December 31,
    2018
    Raw materials
     
    $
    2,769

     
    $
    735

    Work-in-process
     
    15,710

     
    11,430

    Finished goods
     
    10,880

     
    10,460

         Total inventories
     
    $
    29,359

     
    $
    22,625


    Prepaid expenses and other assets consisted of the following (in thousands):
     
     
    December 31,
    2019
     
    December 31,
    2018
    Prepaid manufacturing expenses
     
    $
    30,156

     
    $
    8,230

    Prepaid research and development expenses
     
    4,964

     
    7,922

    Other prepaid expenses
     
    3,655

     
    2,513

    Other assets
     
    5,681

     
    6,462

         Total prepaid expenses and other assets
     
    44,456

     
    25,127

    Less long-term portion
     
    11,083

     
    4,434

         Total prepaid expenses and other assets, current
     
    $
    33,373

     
    $
    20,693


    Prepaid manufacturing expenses include raw materials, slot reservation fees and other amounts paid to contract manufacturing organizations. Such amounts are reclassified to work-in-process inventory as materials are used or the CMO services are complete.
    Property and equipment, net consisted of the following (in thousands):
     
     
    December 31,
    2019
     
    December 31,
    2018
    Research equipment
     
    $
    7,403

     
    $
    9,945

    Manufacturing equipment
     
    3,858

     
    3,979

    Computer and office equipment
     
    4,859

     
    5,211

    Leasehold improvements
     
    1,628

     
    4,569

         Subtotal
     
    17,748

     
    23,704

    Accumulated depreciation and amortization
     
    (10,742
    )
     
    (16,239
    )
    Subtotal
     
    $
    7,006

     
    $
    7,465

    Right of use of assets
     
    $
    3,849

     
    $
    —

         Property and equipment, net
     
    $
    10,855

     
    $
    7,465

    Depreciation and amortization expense was approximately $4.1 million , $2.4 million, and $2.2 million for the years ended December 31, 2019, 2018 and 2017, respectively. The depreciation and amortization expense for the year ended December 31, 2019 is inclusive of $1.8 million ROU asset amortization. As discussed in Note 9, we have recorded a ROU impairment charge of $1.1 million as a result of the organizational restructuring. We also recorded an impairment charge of $1.4 million related to property and equipment as a result of the organizational restructuring (Refer to Note 13 for further details on the organizational restructuring).
    Accrued expenses consisted of the following (in thousands):
     
     
    December 31,
    2019
     
    December 31,
    2018
    Accrued outsourced research and development expenses
     
    $
    8,423

     
    $
    21,921

    Accrued compensation and payroll taxes
     
    27,888

     
    16,604

    Accrued outsourced manufacturing expenses
     
    9,173

     
    3,975

    Other accrued expenses
     
    7,876

     
    7,623

    Lease liability
     
    6,469

     
    —

         Total accrued expenses
     
    59,829

     
    50,123

    Less long-term portion
     
    4,180

     
    594

         Total accrued expenses, current
     
    $
    55,649

     
    $
    49,529


    Expense associated with the accretion of the lease liabilities was approximately $0.8 million and zero for the twelve months ended December 31, 2019 and 2018, respectively. Total lease expense for the twelve months ended December 31, 2019 and 2018 $2.6 million and $2.4 million respectively.
    Cash paid for amounts related to leases for the twelve months ended December 31, 2019 and 2018 was $3.1 million and $2.4 million respectively.
    Deferred revenue consisted of the following (in thousands):
     
     
    December 31,
    2019
     
    December 31,
    2018
    Collaborative agreements
     
     
     
     
    License fees and event-based payments:
     
    2,764

     
    2,264

    Product sales
     
    2,495

     
    6,991

    Total deferred revenue
     
    5,259

     
    9,255

    Less current portion
     
    4,012

     
    4,247

    Deferred revenue, net of current portion
     
    $
    1,247

     
    $
    5,008
    XML 53 R16.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Commitments and Contingencies
    		 12 Months Ended
    Dec. 31, 2019
    Commitments and Contingencies Disclosure [Abstract]  
    Commitments and Contingencies Commitments and Contingencies
    Operating Leases
    Our administrative offices and research facilities are located in San Diego, California. We lease an aggregate of approximately 80,000 square feet of office and research space in five buildings. The leases commenced in June 2011, November 2013 and June 2018 and continue through January 2023. The leases are subject to approximately 3.0% annual increases throughout the terms of the leases. We also pay a pro rata share of operating costs, insurance costs, utilities and real property taxes.
    We lease approximately 10,000 square feet of office space for a satellite office located in South San Francisco, California. The lease commenced in November 2015 and continues through January 2021. The lease is subject to approximately 3.0% annual increases throughout the term of the lease. We also pay a pro rata share of operating costs, insurance costs, utilities and real property taxes.
    As a result of the restructuring we announced on November 4, 2019, we abandoned two of our buildings in San Diego and our satellite office located in San Francisco. As a result, we have reassessed the likelihood of exercising contractual options impacting the term of these leases. These considerations have been reflected in the recognition of impairment charges of $1.1 million in accordance with ASC 360 during the year ended December 31, 2019.
    Additionally, we lease certain office equipment under operating leases. Total rent expense was approximately $2.7 million, $2.5 million and $2.3 million for the years ended December 31, 2019, 2018 and 2017, respectively.
    Approximate annual future minimum operating lease payments as of December 31, 2019 are as follows (in thousands): 
    Year:
     
    Operating
    Leases
    2020
     
    $
    3,355

    2021
     
    2,260

    2022
     
    1,559

    2023
     
    70

    2024
     
    —

    Total minimum lease payments
     
    $
    7,244

    Less imputed interest
     
    (775
    )
    Total
     
    $
    6,469


    The weighted-average remaining lease term of our operating leases is approximately 2.36 years.
    Other Commitments
    We have existing supply agreements with contract manufacturing organizations Avid Bioservices, Inc. (“Avid”) and Catalent Indiana LLC (formerly Cook Pharmica LLC) (“Catalent”) to produce supplies of bulk rHuPH20. Under the terms of the agreements, we are committed to certain minimum annual purchases of bulk rHuPH20. At December 31, 2019, we had a $35.7 million minimum purchase obligation in connection with these agreements.
    In June 2011, we entered into a services agreement with Patheon for the technology transfer and manufacture of Hylenex recombinant. At December 31, 2019, we had a $0.6 million minimum purchase obligation in connection with this agreement. 

    Legal Contingencies
    From time to time, we may be involved in disputes, including litigation, relating to claims arising out of operations in the normal course of our business. Any of these claims could subject us to costly legal expenses and, while we generally believe that we have adequate insurance to cover many different types of liabilities, our insurance carriers may deny coverage or our policy limits may be inadequate to fully satisfy any damage awards or settlements. If this were to happen, the payment of any such awards could have a material adverse effect on our consolidated results of operations and financial position. Additionally, any such claims, whether or not successful, could damage our reputation and business. We currently are not a party to any legal proceedings, the adverse outcome of which, in management’s opinion, individually or in the aggregate, would have a material adverse effect on our consolidated results of operations or financial position.
    XML 54 R35.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Summary of Significant Accounting Policies Inventories (Details) - USD ($)
    $ in Thousands
    Dec. 31, 2019
    Dec. 31, 2018
    Inventory [Line Items]    
    Inventory, Net $ 29,359 $ 22,625
    Sales of Hylenex    
    Inventory [Line Items]    
    Inventory, Net 1,400 2,200
    bulk rHuPH20    
    Inventory [Line Items]    
    Inventory, Net $ 28,000 $ 20,400
    XML 55 halo2019-10k_htm.xml IDEA: XBRL DOCUMENT 0001159036 2019-01-01 2019-12-31 0001159036 2020-02-14 0001159036 2019-06-30 0001159036 2019-12-31 0001159036 2018-12-31 0001159036 us-gaap:CommonStockMember 2018-12-31 0001159036 2018-01-01 2018-12-31 0001159036 2017-01-01 2017-12-31 0001159036 us-gaap:ProductMember 2018-01-01 2018-12-31 0001159036 us-gaap:ProductMember 2017-01-01 2017-12-31 0001159036 us-gaap:RoyaltyMember 2019-01-01 2019-12-31 0001159036 halo:CollaborativeAgreementsMember 2017-01-01 2017-12-31 0001159036 us-gaap:RoyaltyMember 2018-01-01 2018-12-31 0001159036 halo:CollaborativeAgreementsMember 2019-01-01 2019-12-31 0001159036 us-gaap:RoyaltyMember 2017-01-01 2017-12-31 0001159036 us-gaap:ProductMember 2019-01-01 2019-12-31 0001159036 halo:CollaborativeAgreementsMember 2018-01-01 2018-12-31 0001159036 2017-12-31 0001159036 2016-12-31 0001159036 us-gaap:RetainedEarningsMember 2018-01-01 2018-12-31 0001159036 us-gaap:CommonStockMember 2018-01-01 2018-12-31 0001159036 us-gaap:RetainedEarningsMember 2016-12-31 0001159036 us-gaap:CommonStockMember 2019-01-01 2019-12-31 0001159036 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0001159036 us-gaap:RetainedEarningsMember 2018-12-31 0001159036 us-gaap:AdditionalPaidInCapitalMember 2016-12-31 0001159036 us-gaap:CommonStockMember 2017-12-31 0001159036 us-gaap:CommonStockMember 2019-12-31 0001159036 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-12-31 0001159036 us-gaap:CommonStockMember 2017-01-01 2017-12-31 0001159036 us-gaap:RetainedEarningsMember 2019-01-01 2019-12-31 0001159036 us-gaap:AdditionalPaidInCapitalMember 2017-01-01 2017-12-31 0001159036 us-gaap:CommonStockMember 2016-12-31 0001159036 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001159036 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001159036 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001159036 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-12-31 0001159036 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-12-31 0001159036 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-12-31 0001159036 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-12-31 0001159036 us-gaap:RetainedEarningsMember 2019-12-31 0001159036 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-01-01 2017-12-31 0001159036 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0001159036 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-12-31 0001159036 us-gaap:RetainedEarningsMember 2017-12-31 0001159036 us-gaap:RetainedEarningsMember 2018-01-01 0001159036 2018-01-01 0001159036 halo:ArgenxMember us-gaap:SalesMember us-gaap:CustomerConcentrationRiskMember 2018-01-01 2018-12-31 0001159036 halo:RocheMember us-gaap:SalesMember us-gaap:CustomerConcentrationRiskMember 2017-01-01 2017-12-31 0001159036 halo:JanssenMember us-gaap:SalesMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-12-31 0001159036 halo:JanssenMember us-gaap:SalesMember us-gaap:CustomerConcentrationRiskMember 2017-01-01 2017-12-31 0001159036 halo:BMSMember us-gaap:SalesMember us-gaap:CustomerConcentrationRiskMember 2018-01-01 2018-12-31 0001159036 halo:BMSMember us-gaap:SalesMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-12-31 0001159036 halo:RocheMember us-gaap:SalesMember us-gaap:CustomerConcentrationRiskMember 2018-01-01 2018-12-31 0001159036 halo:AlexionMember us-gaap:SalesMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-12-31 0001159036 halo:JanssenMember us-gaap:SalesMember us-gaap:CustomerConcentrationRiskMember 2018-01-01 2018-12-31 0001159036 halo:ArgenxMember us-gaap:SalesMember us-gaap:CustomerConcentrationRiskMember 2017-01-01 2017-12-31 0001159036 halo:RocheMember us-gaap:SalesMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-12-31 0001159036 halo:AlexionMember us-gaap:SalesMember us-gaap:CustomerConcentrationRiskMember 2017-01-01 2017-12-31 0001159036 halo:ArgenxMember us-gaap:SalesMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-12-31 0001159036 halo:AlexionMember us-gaap:SalesMember us-gaap:CustomerConcentrationRiskMember 2018-01-01 2018-12-31 0001159036 halo:BMSMember us-gaap:SalesMember us-gaap:CustomerConcentrationRiskMember 2017-01-01 2017-12-31 0001159036 us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember halo:HylenexRecombinantMember 2019-12-31 0001159036 halo:RocheandBaxaltaMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2019-12-31 0001159036 srt:MaximumMember 2019-12-31 0001159036 halo:A1.25ConvertibleSeniorNotesdue2024Member us-gaap:ConvertibleDebtMember 2019-11-30 0001159036 srt:MinimumMember 2019-12-31 0001159036 us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember halo:BulkFormulationMember 2018-12-31 0001159036 srt:MinimumMember 2019-01-01 2019-12-31 0001159036 srt:MaximumMember 2019-01-01 2019-12-31 0001159036 us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember halo:BulkFormulationMember 2019-01-01 2019-12-31 0001159036 halo:HylenexRecombinantMember 2018-12-31 0001159036 halo:BulkrHuPH20Member 2019-12-31 0001159036 halo:A1.25ConvertibleSeniorNotesdue2024Member us-gaap:ConvertibleDebtMember 2019-01-01 2019-12-31 0001159036 halo:HylenexRecombinantMember 2019-12-31 0001159036 halo:BulkrHuPH20Member 2018-12-31 0001159036 halo:InlicensetechnologiesMember 2019-01-01 2019-12-31 0001159036 halo:BulkrHuPH20AndENHANZEMember 2019-01-01 2019-12-31 0001159036 halo:RocheandBaxaltaMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2018-12-31 0001159036 halo:BulkrHuPH20AndENHANZEMember 2019-10-01 2019-12-31 0001159036 us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember halo:BulkFormulationMember 2019-12-31 0001159036 us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember halo:HylenexRecombinantMember 2018-12-31 0001159036 us-gaap:SalesMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-12-31 0001159036 us-gaap:GeographicConcentrationRiskMember 2018-01-01 2018-12-31 0001159036 country:CH us-gaap:GeographicConcentrationRiskMember 2018-01-01 2018-12-31 0001159036 country:US us-gaap:GeographicConcentrationRiskMember 2017-01-01 2017-12-31 0001159036 us-gaap:GeographicDistributionForeignMember us-gaap:GeographicConcentrationRiskMember 2017-01-01 2017-12-31 0001159036 us-gaap:GeographicConcentrationRiskMember 2019-01-01 2019-12-31 0001159036 us-gaap:GeographicDistributionForeignMember us-gaap:GeographicConcentrationRiskMember 2019-01-01 2019-12-31 0001159036 country:CH us-gaap:GeographicConcentrationRiskMember 2017-01-01 2017-12-31 0001159036 country:US us-gaap:GeographicConcentrationRiskMember 2018-01-01 2018-12-31 0001159036 country:US us-gaap:GeographicConcentrationRiskMember 2019-01-01 2019-12-31 0001159036 us-gaap:GeographicDistributionForeignMember us-gaap:GeographicConcentrationRiskMember 2018-01-01 2018-12-31 0001159036 country:CH us-gaap:GeographicConcentrationRiskMember 2019-01-01 2019-12-31 0001159036 us-gaap:GeographicConcentrationRiskMember 2017-01-01 2017-12-31 0001159036 us-gaap:FairValueInputsLevel3Member 2018-12-31 0001159036 us-gaap:USTreasurySecuritiesMember 2019-12-31 0001159036 us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0001159036 us-gaap:AssetBackedSecuritiesMember 2019-12-31 0001159036 us-gaap:CommercialPaperMember 2019-12-31 0001159036 us-gaap:USTreasurySecuritiesMember 2018-12-31 0001159036 us-gaap:AssetBackedSecuritiesMember 2018-12-31 0001159036 us-gaap:CorporateDebtSecuritiesMember 2018-12-31 0001159036 us-gaap:CommercialPaperMember 2018-12-31 0001159036 us-gaap:FairValueInputsLevel3Member 2019-12-31 0001159036 us-gaap:FairValueInputsLevel2Member 2018-12-31 0001159036 us-gaap:FairValueInputsLevel1Member 2019-12-31 0001159036 us-gaap:FairValueInputsLevel1Member us-gaap:CorporateDebtSecuritiesMember 2018-12-31 0001159036 us-gaap:MoneyMarketFundsMember 2019-12-31 0001159036 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:USTreasurySecuritiesMember 2019-12-31 0001159036 us-gaap:CommercialPaperMember 2019-12-31 0001159036 us-gaap:USTreasurySecuritiesMember 2018-12-31 0001159036 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:USTreasurySecuritiesMember 2018-12-31 0001159036 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member 2019-12-31 0001159036 us-gaap:MoneyMarketFundsMember us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2018-12-31 0001159036 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:CorporateDebtSecuritiesMember 2018-12-31 0001159036 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member 2018-12-31 0001159036 us-gaap:FairValueInputsLevel1Member us-gaap:AssetBackedSecuritiesMember 2018-12-31 0001159036 us-gaap:USTreasurySecuritiesMember 2019-12-31 0001159036 us-gaap:FairValueInputsLevel2Member us-gaap:USTreasurySecuritiesMember 2018-12-31 0001159036 us-gaap:CorporateDebtSecuritiesMember 2018-12-31 0001159036 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0001159036 us-gaap:CommercialPaperMember 2018-12-31 0001159036 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel2Member us-gaap:CommercialPaperMember 2018-12-31 0001159036 us-gaap:FairValueInputsLevel2Member us-gaap:AssetBackedSecuritiesMember 2018-12-31 0001159036 us-gaap:FairValueInputsLevel1Member us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0001159036 us-gaap:FairValueInputsLevel1Member us-gaap:AssetBackedSecuritiesMember 2019-12-31 0001159036 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel2Member 2019-12-31 0001159036 us-gaap:MoneyMarketFundsMember 2018-12-31 0001159036 us-gaap:FairValueInputsLevel1Member us-gaap:CommercialPaperMember 2019-12-31 0001159036 us-gaap:FairValueInputsLevel1Member us-gaap:CommercialPaperMember 2018-12-31 0001159036 us-gaap:FairValueInputsLevel2Member us-gaap:AssetBackedSecuritiesMember 2019-12-31 0001159036 us-gaap:FairValueInputsLevel2Member 2019-12-31 0001159036 us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0001159036 us-gaap:FairValueInputsLevel2Member us-gaap:USTreasurySecuritiesMember 2019-12-31 0001159036 us-gaap:FairValueInputsLevel1Member 2018-12-31 0001159036 us-gaap:MoneyMarketFundsMember us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2019-12-31 0001159036 halo:ENHANZEdrugproductMemberDomain 2019-01-01 2019-12-31 0001159036 halo:DevelopmentFeesMember 2018-01-01 2018-12-31 0001159036 halo:BulkrHuPH20Member 2017-01-01 2017-12-31 0001159036 halo:ResearchandDevelopmentServicesMember 2017-01-01 2017-12-31 0001159036 halo:HylenexRecombinantMember 2017-01-01 2017-12-31 0001159036 halo:ENHANZEdrugproductMemberDomain 2018-01-01 2018-12-31 0001159036 halo:DevelopmentFeesMember 2019-01-01 2019-12-31 0001159036 halo:SalesbasedmilestoneMember 2017-01-01 2017-12-31 0001159036 halo:ResearchandDevelopmentServicesMember 2019-01-01 2019-12-31 0001159036 halo:HylenexRecombinantMember 2018-01-01 2018-12-31 0001159036 halo:ENHANZEdrugproductMemberDomain 2017-01-01 2017-12-31 0001159036 halo:ResearchandDevelopmentServicesMember 2018-01-01 2018-12-31 0001159036 halo:HylenexRecombinantMember 2019-01-01 2019-12-31 0001159036 halo:SalesbasedmilestoneMember 2019-01-01 2019-12-31 0001159036 halo:BulkrHuPH20Member 2019-01-01 2019-12-31 0001159036 halo:UpfrontfeesMember 2019-01-01 2019-12-31 0001159036 halo:BulkrHuPH20Member 2018-01-01 2018-12-31 0001159036 halo:UpfrontfeesMember 2017-01-01 2017-12-31 0001159036 halo:SalesbasedmilestoneMember 2018-01-01 2018-12-31 0001159036 halo:UpfrontfeesMember 2018-01-01 2018-12-31 0001159036 halo:DevelopmentFeesMember 2017-01-01 2017-12-31 0001159036 us-gaap:AccountingStandardsUpdate201409Member us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member 2018-01-01 2018-12-31 0001159036 halo:A2017RocheMember 2019-01-01 2019-12-31 0001159036 us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member 2018-12-31 0001159036 us-gaap:AccountingStandardsUpdate201409Member us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member 2018-12-31 0001159036 2019-07-01 2019-12-31 0001159036 us-gaap:ProductMember 2019-12-31 0001159036 halo:DevelopmentFeesMember halo:BMSMember 2019-12-31 0001159036 halo:UpfrontfeesMember halo:LillyMember 2019-12-31 0001159036 halo:JanssenMember 2019-01-01 2019-12-31 0001159036 halo:DevelopmentFeesMember halo:AlexionMember 2019-12-31 0001159036 halo:DevelopmentFeesMember halo:AbbVieMember 2019-12-31 0001159036 halo:UpfrontfeesMember halo:PfizerMember 2019-12-31 0001159036 halo:AbbVieMember 2019-01-01 2019-12-31 0001159036 halo:DevelopmentFeesMember halo:BaxaltaMember 2019-12-31 0001159036 halo:PfizerMember 2019-01-01 2019-12-31 0001159036 halo:DevelopmentFeesMember halo:ArgenxMember 2019-12-31 0001159036 us-gaap:RoyaltyMember 2019-12-31 0001159036 halo:RocheMember 2019-01-01 2019-12-31 0001159036 halo:UpfrontfeesMember halo:AlexionMember 2019-12-31 0001159036 halo:UpfrontfeesMember halo:JanssenMember 2019-12-31 0001159036 halo:UpfrontfeesMember halo:ArgenxMember 2019-12-31 0001159036 halo:SalesbasedmilestoneMember halo:RocheMember 2019-12-31 0001159036 halo:UpfrontfeesMember halo:BaxaltaMember 2019-12-31 0001159036 halo:LillyMember 2019-01-01 2019-12-31 0001159036 halo:SalesbasedmilestoneMember halo:BaxaltaMember 2019-12-31 0001159036 halo:UpfrontfeesMember halo:BMSMember 2019-12-31 0001159036 halo:DevelopmentFeesMember halo:JanssenMember 2019-12-31 0001159036 halo:BMSMember 2019-01-01 2019-12-31 0001159036 halo:UpfrontfeesMember halo:RocheMember 2019-12-31 0001159036 halo:DevelopmentFeesMember halo:PfizerMember 2019-12-31 0001159036 halo:UpfrontfeesMember halo:AbbVieMember 2019-12-31 0001159036 halo:BaxaltaMember 2019-01-01 2019-12-31 0001159036 halo:AlexionMember 2019-01-01 2019-12-31 0001159036 halo:ArgenxMember 2019-01-01 2019-12-31 0001159036 halo:DevelopmentFeesMember halo:RocheMember 2019-12-31 0001159036 us-gaap:ProductMember us-gaap:ProductMember 2019-12-31 0001159036 halo:LicenseFeesAndEventBasedMember 2018-12-31 0001159036 halo:LicenseFeesAndEventBasedMember 2019-12-31 0001159036 us-gaap:ProductMember us-gaap:ProductMember 2018-12-31 0001159036 us-gaap:LeaseholdImprovementsMember 2019-12-31 0001159036 halo:ManufacturingEquipmentMember 2019-12-31 0001159036 halo:ResearchEquipmentMember 2019-12-31 0001159036 halo:ComputerAndOfficeEquipmentMember 2019-12-31 0001159036 halo:ResearchEquipmentMember 2018-12-31 0001159036 halo:ManufacturingEquipmentMember 2018-12-31 0001159036 halo:ComputerAndOfficeEquipmentMember 2018-12-31 0001159036 us-gaap:LeaseholdImprovementsMember 2018-12-31 0001159036 halo:A1.25ConvertibleSeniorNotesdue2024Member us-gaap:DebtInstrumentRedemptionPeriodOneMember us-gaap:ConvertibleDebtMember 2019-11-01 2019-11-30 0001159036 us-gaap:AcceleratedShareRepurchasesDateDomain 2019-11-01 2019-11-30 0001159036 us-gaap:SeniorLoansMember 2019-12-31 0001159036 halo:A2019QuarterlyMaximumPaymentMember halo:RoyaltybackedLoanMember 2019-01-01 2019-12-31 0001159036 halo:A1.25ConvertibleSeniorNotesdue2024Member us-gaap:ConvertibleDebtMember 2019-12-31 0001159036 us-gaap:SeniorLoansMember 2019-01-01 2019-12-31 0001159036 halo:A2016Member halo:RoyaltybackedLoanMember 2019-01-01 2019-12-31 0001159036 halo:RoyaltybackedLoanMember 2019-12-31 0001159036 halo:SharesacquiredinprivatelynegotiatedtransactionsDomain 2019-11-01 2019-11-30 0001159036 halo:RoyaltybackedLoanMember 2018-01-01 2018-12-31 0001159036 halo:A1.25ConvertibleSeniorNotesdue2024Member us-gaap:DebtInstrumentRedemptionPeriodTwoMember us-gaap:ConvertibleDebtMember 2019-11-01 2019-11-30 0001159036 halo:RoyaltybackedLoanMember 2019-01-01 2019-12-31 0001159036 halo:A2018QuarterlyMaximumPaymentMember halo:RoyaltybackedLoanMember 2019-01-01 2019-12-31 0001159036 us-gaap:SeniorLoansMember 2018-01-01 2018-12-31 0001159036 2019-11-01 2019-11-30 0001159036 halo:A1.25ConvertibleSeniorNotesdue2024Member us-gaap:ConvertibleDebtMember 2019-11-01 2019-11-30 0001159036 srt:MinimumMember halo:RoyaltybackedLoanMember 2019-01-01 2019-12-31 0001159036 srt:MaximumMember halo:RoyaltybackedLoanMember 2019-01-01 2019-12-31 0001159036 2019-11-30 0001159036 halo:A2017QuarterlyMaximumPaymentMember halo:RoyaltybackedLoanMember 2019-01-01 2019-12-31 0001159036 us-gaap:SecuredDebtMember 2018-12-31 0001159036 halo:RoyaltybackedLoanMember 2017-01-01 2017-12-31 0001159036 halo:A2017Member halo:RoyaltybackedLoanMember 2019-01-01 2019-12-31 0001159036 us-gaap:SeniorLoansMember 2017-01-01 2017-12-31 0001159036 halo:A2020QuarterlyMaximumPaymentMember halo:RoyaltybackedLoanMember 2019-01-01 2019-12-31 0001159036 halo:A2018andthereafterMember halo:RoyaltybackedLoanMember 2019-01-01 2019-12-31 0001159036 us-gaap:RestrictedStockMember 2019-12-31 0001159036 us-gaap:RestrictedStockUnitsRSUMember 2019-01-01 2019-12-31 0001159036 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-12-31 0001159036 us-gaap:RestrictedStockUnitsRSUMember 2019-12-31 0001159036 us-gaap:RestrictedStockMember 2019-01-01 2019-12-31 0001159036 us-gaap:EmployeeStockOptionMember 2019-12-31 0001159036 us-gaap:RestrictedStockUnitsRSUMember 2018-12-31 0001159036 us-gaap:RestrictedStockMember 2018-12-31 0001159036 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2017-01-01 2017-12-31 0001159036 us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-12-31 0001159036 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2018-01-01 2018-12-31 0001159036 us-gaap:ResearchAndDevelopmentExpenseMember 2017-01-01 2017-12-31 0001159036 us-gaap:ResearchAndDevelopmentExpenseMember 2018-01-01 2018-12-31 0001159036 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2019-01-01 2019-12-31 0001159036 halo:AmendedandRestated2011StockPlanMember 2019-12-31 0001159036 us-gaap:RestrictedStockMember 2018-01-01 2018-12-31 0001159036 halo:OutstandingAwardsMember 2019-12-31 0001159036 us-gaap:RestrictedStockUnitsRSUMember 2017-01-01 2017-12-31 0001159036 us-gaap:RestrictedStockUnitsRSUMember 2018-01-01 2018-12-31 0001159036 us-gaap:RestrictedStockMember 2017-01-01 2017-12-31 0001159036 halo:RSURSAandPRSUawardsMember 2018-01-01 2018-12-31 0001159036 halo:RSURSAandPRSUawardsMember 2017-01-01 2017-12-31 0001159036 halo:RSURSAandPRSUawardsMember 2019-01-01 2019-12-31 0001159036 us-gaap:EmployeeStockOptionMember 2017-01-01 2017-12-31 0001159036 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-12-31 0001159036 srt:MaximumMember 2018-01-01 2018-12-31 0001159036 srt:MinimumMember 2017-01-01 2017-12-31 0001159036 srt:MaximumMember 2017-01-01 2017-12-31 0001159036 srt:MinimumMember 2018-01-01 2018-12-31 0001159036 halo:CliffVestingFirstAnniversaryMember 2019-01-01 2019-12-31 0001159036 us-gaap:RestrictedStockMember halo:PercentageVestingMember 2019-01-01 2019-12-31 0001159036 halo:MonthlyVestingAfterOneYearMember 2019-01-01 2019-12-31 0001159036 us-gaap:RestrictedStockUnitsRSUMember halo:PercentageVestingMember 2019-01-01 2019-12-31 0001159036 halo:A2019ShareRepurchaseProgramBankofAmericaMember 2019-11-01 2019-11-30 0001159036 halo:StockOptionsAndRestrictedStockUnitsMember 2017-12-31 0001159036 us-gaap:AcceleratedShareRepurchasesDateDomain 2019-11-30 0001159036 2017-05-01 2017-05-31 0001159036 halo:StockOptionsAndRestrictedStockUnitsMember 2019-12-31 0001159036 us-gaap:SubsequentEventMember 2020-02-01 2020-02-29 0001159036 halo:StockOptionsAndRestrictedStockUnitsMember 2018-12-31 0001159036 halo:OfficeAndResearchFacilityMember 2019-01-01 2019-12-31 0001159036 halo:SatelliteofficeMember 2019-01-01 2019-12-31 0001159036 halo:PatheonMember 2019-12-31 0001159036 halo:AvidCommercialSupplyAgreementMember 2019-12-31 0001159036 halo:OtherstatetaxMember 2019-12-31 0001159036 us-gaap:InternalRevenueServiceIRSMember us-gaap:GeneralBusinessMember 2019-12-31 0001159036 us-gaap:InternalRevenueServiceIRSMember us-gaap:ResearchMember 2019-12-31 0001159036 halo:CaliforniaMember 2019-12-31 0001159036 us-gaap:InternalRevenueServiceIRSMember 2019-12-31 0001159036 us-gaap:StateAndLocalJurisdictionMember us-gaap:ResearchMember 2019-12-31 0001159036 us-gaap:InternalRevenueServiceIRSMember halo:A2018expirationMember 2019-12-31 0001159036 us-gaap:StateAndLocalJurisdictionMember halo:A2018expirationMember 2019-12-31 0001159036 us-gaap:InternalRevenueServiceIRSMember halo:A2021andbeyondexpirationMember 2019-12-31 0001159036 us-gaap:StateAndLocalJurisdictionMember halo:A2021andbeyondexpirationMember 2019-12-31 0001159036 us-gaap:StateAndLocalJurisdictionMember halo:A2028andbeyondexpirationMember 2019-12-31 0001159036 us-gaap:InternalRevenueServiceIRSMember halo:A2028andbeyondexpirationMember 2019-12-31 0001159036 us-gaap:StateAndLocalJurisdictionMember 2019-12-31 0001159036 halo:ArgenxMember 2019-01-01 2019-03-31 0001159036 halo:RocheMember 2018-10-01 2018-12-31 0001159036 2019-10-01 2019-12-31 0001159036 2018-10-01 2018-12-31 0001159036 2019-07-01 2019-09-30 0001159036 2019-01-01 2019-03-31 0001159036 2019-04-01 2019-06-30 0001159036 2018-01-01 2018-03-31 0001159036 2018-04-01 2018-06-30 0001159036 2018-07-01 2018-09-30 0001159036 us-gaap:ContractTerminationMember 2019-10-01 2019-12-31 0001159036 2019-11-04 2019-11-04 0001159036 us-gaap:OneTimeTerminationBenefitsMember 2019-10-01 2019-12-31 iso4217:USD pure iso4217:USD shares halo:trading_day shares halo:segment halo:security utreg:sqft false --12-31 FY 2019 0001159036 1 0.001 0.001 200000000 300000000 136712480 144725164 136712480 2050-12-31 0.34 0.21 0.21 0 0 0 0 0.001 0.001 20000000 20000000 0 0 0 0.0213 0.0296 0.0256 0.0173 0.0225 0.0132 0.7173 0.6981 0.7006 0.5718 0.5694 0.5156 0.25 0.25 0.25 0.0208 P5Y6M0D P5Y6M0D 144725164 P3Y 0 0 0 10-K true 2019-12-31 false 001-32335 HALOZYME THERAPEUTICS, INC. DE 88-0488686 11388 Sorrento Valley Road 92121 San Diego CA 858 794-8889 Common Stock, $0.001 Par Value HALO NASDAQ Yes No Yes Yes Large Accelerated Filer false false false 2500000000 138226070 120179000 57936000 301083000 296590000 59442000 30005000 29359000 22625000 33373000 20693000 543436000 427849000 10855000 7465000 11083000 4434000 500000 500000 565874000 440248000 6434000 4079000 55649000 49529000 4012000 4247000 19542000 91506000 85637000 149361000 1247000 5008000 383045000 34874000 4180000 2118000 0 0 137000 145000 695066000 780457000 240000 -277000 -603678000 -531438000 91765000 248887000 565874000 440248000 69899000 78981000 63507000 66048000 28234000 50396000 60045000 44647000 202710000 195992000 151862000 316613000 45546000 10136000 31152000 140804000 150252000 150643000 77252000 60804000 53816000 263602000 221192000 235611000 -67610000 -69330000 81002000 6986000 7578000 2592000 11627000 18041000 21984000 -72251000 -79793000 61610000 -11000 537000 -1361000 -72240000 -80330000 62971000 -0.50 -0.56 0.46 -0.50 -0.56 0.45 144329000 143599000 136419000 144329000 143599000 139068000 -72240000 -80330000 62971000 508000 182000 -430000 -9000 8000 14000 0 -1000 0 -71723000 -80157000 62527000 -72240000 -80330000 62971000 34776000 35696000 30670000 4068000 2388000 2161000 2484000 1545000 1761000 2469000 3090000 303000 -1431000 -5000 -46000 0 3000000 22759000 3996000 2832000 6512000 -459000 -7000 13000 1127000 0 0 0 0 185000 -401000 0 0 -7000 -9000 -16000 29437000 -11613000 6453000 6734000 17480000 -9477000 19006000 5695000 -2035000 4638000 5696000 15629000 -85423000 -49500000 134053000 389759000 311112000 398187000 388250000 318268000 235805000 4040000 4663000 1350000 -5549000 2493000 -163732000 0 0 134874000 447350000 0 0 108082000 77516000 15995000 279000 0 0 199998000 0 0 14224000 13719000 12776000 153215000 -63797000 131655000 62243000 -110804000 101976000 58436000 169240000 67264000 120679000 58436000 169240000 9029000 16891000 20295000 188000 220000 3015000 61000 542000 189000 68000 0 0 897000 0 0 0 1322000 13000 129502000 130000 552737000 -6000 -585342000 -32481000 30670000 30670000 11500000 11000 134863000 134874000 1796000 2000 12774000 12776000 -9000 0 0 0 -444000 -444000 62971000 62971000 142789000 143000 731044000 -450000 -522371000 208366000 71263000 71263000 35696000 35696000 1932000 2000 13717000 13719000 4000 0 0 0 173000 173000 -80330000 -80330000 144725000 145000 780457000 -277000 -531438000 248887000 34776000 34776000 2493000 2000 14222000 14224000 74000 0 0 0 10579000 10000 199988000 199998000 65599000 65599000 517000 517000 -72240000 -72240000 136713000 137000 695066000 240000 -603678000 91765000 Organization and Business <div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Halozyme Therapeutics Inc. is a biopharma technology platform company that provides innovative and disruptive solutions with the goal of improving patient experience and outcomes. Our proprietary enzyme rHUPH20 is used to facilitate the delivery of injected drugs and fluids. We license our technology to biopharmaceutical companies to collaboratively develop products that combine our ENHANZE® drug delivery technology with the collaborators’ proprietary compounds. </span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our approved product and our collaborators’ approved products and product candidates are based on rHuPH20, our patented recombinant human hyaluronidase enzyme. rHuPH20 is the active ingredient in our first commercially approved product, Hylenex</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></span><span style="font-family:inherit;font-size:10pt;"> recombinant (“Hylenex”), and it works by breaking down hyaluronan (or “HA”), a naturally occurring carbohydrate that is a major component of the extracellular matrix in tissues throughout the body such as skin and cartilage. This temporarily increases dispersion and absorption allowing for improved subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other large therapeutic molecules, as well as small molecules and fluids. We refer to the application of rHuPH20 to facilitate the delivery of other drugs or fluids as our ENHANZE</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></span><span style="font-family:inherit;font-size:10pt;"> Drug Delivery Technology (“ENHANZE”). We license the ENHANZE technology to form collaborations with biopharmaceutical companies that develop or market drugs requiring or benefiting from injection via the subcutaneous route of administration. In the development of proprietary intravenous (IV) drugs combined with our ENHANZE technology, data have been generated supporting the potential for ENHANZE to reduce treatment burden, as a result of shorter duration of subcutaneous (SC) administration. ENHANZE may enable fixed-dose SC dosing compared to weight-based dosing required for IV administration, and potentially allow for lower rates of infusion related reactions. Lastly, certain proprietary drugs co-formulated with ENHANZE have been granted additional exclusivity, extending the patent life of the product beyond the one of the proprietary IV drug.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We currently have ENHANZE collaborations with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc. (“Roche”), Baxalta US Inc. and Baxalta GmbH (now members of the Takeda group of companies, following the acquisition of Shire plc by Takeda Pharmaceutical Company Limited in January 2019) (“Baxalta”), Pfizer Inc. (“Pfizer”), Janssen Biotech, Inc. (“Janssen”), AbbVie, Inc. (“AbbVie”), Eli Lilly and Company (“Lilly”), Bristol-Myers Squibb Company (“BMS”), Alexion Pharma Holding (“Alexion”) and ARGENX BVBA (“argenx”). We receive royalties from two of these collaborations, including royalties from sales of one product from the Baxalta collaboration and two products from the Roche collaboration. Future potential revenues from the sales and/or royalties of our approved products, product candidates, and ENHANZE collaborations will depend on the ability of Halozyme and our collaborators to develop, manufacture, secure and maintain regulatory approvals for approved products and product candidates and commercialize product candidates.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On November 4, 2019, we announced that our HALO-301 Phase 3 clinical study evaluating PEGPH20 in combination with ABRAXANE and gemcitabine as a first-line therapy for treatment of patients with metastatic pancreatic cancer failed to reach the primary endpoint of overall survival. The study failed to demonstrate an improvement in overall survival compared to gemcitabine and nab-paclitaxel alone (11.2 months median overall survival compared to 11.5 months, HR=1.00, p=0.9692). Due to the results of the study, we halted development activities for PEGPH20, closed our oncology operations and implemented an organizational restructuring to focus our operations on ENHANZE.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We closed all ongoing oncology clinical studies including the Phase 3 clinical testing for PEGPH20 with ABRAXANE and gemcitabine in stage IV pancreatic ductal adenocarcinoma (“PDA”) (HALO-301) and the Phase 1b/2 clinical testing for PEGPH20 with Tecentriq in patients with cholangiocarcinoma and gall bladder cancer (HALO 110-101/MATRIX). The Roche -Genentech sponsored MORPHEUS PDA and gastric cancer studies closed the arms containing PEGPH20 to enrollment. All patients who were treated in PEGPH20 arms are off PEGPH20 treatment and are in follow up, per study protocol.</span></div>Except where specifically noted or the context otherwise requires, references to “Halozyme,” “the Company,” “we,” “our,” and “us” in these notes to consolidated financial statements refer to Halozyme Therapeutics, Inc. and its wholly owned subsidiary, Halozyme, Inc., and Halozyme, Inc.’s wholly owned subsidiaries, Halozyme Holdings Ltd., Halozyme Royalty LLC, Halozyme Switzerland GmbH and Halozyme Switzerland Holdings GmbH. Summary of Significant Accounting Policies<div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Basis of Presentation</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The consolidated financial statements include the accounts of Halozyme Therapeutics, Inc. and our wholly owned subsidiary, Halozyme, Inc., and Halozyme, Inc.’s wholly owned subsidiaries, Halozyme Holdings Ltd., Halozyme Royalty LLC, Halozyme Switzerland GmbH and Halozyme Switzerland Holdings GmbH. All intercompany accounts and transactions have been eliminated. </span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”) requires management to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes. On an ongoing basis, we evaluate our estimates and judgments, which are based on historical and anticipated results and trends and on various other assumptions that management believes to be reasonable under the circumstances. By their nature, estimates are subject to an inherent degree of uncertainty and, as such, actual results may differ from management’s estimates.</span></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cash Equivalents and Marketable Securities </span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash equivalents consist of highly liquid investments, readily convertible to cash, that mature within ninety days or less from the date of purchase. As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, our cash equivalents consisted of money market funds.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Marketable securities are investments with original maturities of more than ninety days from the date of purchase that are specifically identified to fund current operations. Marketable securities are considered available-for-sale. These investments are classified as current assets, even though the stated maturity date may be one year or more beyond the current balance sheet date which reflects management’s intention to use the proceeds from the sale of these investments to fund our operations, as necessary. Such available-for-sale investments are carried at fair value with unrealized gains and losses recorded in other comprehensive income (loss) and included as a separate component of stockholders’ equity (deficit). The cost of marketable securities is adjusted for amortization of premiums or accretion of discounts to maturity, and such amortization or accretion is included in investment and other income, net in the consolidated statements of operations. We use the specific identification method for calculating realized gains and losses on marketable securities sold. Realized gains and losses and declines in value judged to be other-than-temporary on marketable securities, if any, are included in investment and other income, net in the consolidated statements of operations.</span></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Restricted Cash</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Under the terms of the leases of our facilities, we are required to maintain letters of credit as security deposits during the terms of such leases. At </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019 and 2018</span><span style="font-family:inherit;font-size:10pt;">, restricted cash of </span><span style="font-family:inherit;font-size:10pt;"><span>$0.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> was pledged as collateral for the letters of credit.</span></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Fair Value of Financial Instruments</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The authoritative guidance for fair value measurements establishes a three tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions. </span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our financial instruments include cash equivalents, available-for-sale marketable securities, accounts receivable, prepaid expenses and other assets, accounts payable, accrued expenses and long-term debt. Fair value estimates of these instruments are made at a specific point in time, based on relevant market information. These estimates may be subjective in nature and involve uncertainties and matters of significant judgment and therefore cannot be determined with precision. The carrying amount of cash equivalents, accounts receivable, prepaid expenses and other assets, accounts payable and accrued expenses are generally considered to be representative of their respective fair values because of the short-term nature of those instruments. Based on Level 3 inputs and the borrowing rates currently available for loans with similar terms, we believe the fair value of long-term debt approximates its carrying value.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Available-for-sale marketable securities consist of asset-backed securities, corporate debt securities, U.S. Treasury securities and commercial paper, and are measured at fair value using Level 1 and Level 2 inputs. Level 2 financial instruments are valued using market prices on less active markets and proprietary pricing valuation models with observable inputs, including interest rates, yield curves, maturity dates, issue dates, settlement dates, reported trades, broker-dealer quotes, issue spreads, benchmark securities or other market related data. We obtain the fair value of Level 2 investments from our investment manager, who obtains these fair values from a third-party pricing source. We validate the fair values of Level 2 financial instruments provided by our investment manager by comparing these fair values to a third-party pricing source.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentrations of Credit Risk, Sources of Supply and Significant Customers</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are subject to credit risk from our portfolio of cash equivalents and marketable securities. These investments were made in accordance with our investment policy which specifies the categories, allocations, and ratings of securities we may consider for investment. The primary objective of our investment activities is to preserve principal while at the same time maximizing the income we receive without significantly increasing risk. We maintain our cash and cash equivalent balances with one major commercial bank and marketable securities with another financial institution. Deposits held with the financial institutions exceed the amount of insurance provided on such deposits. We are exposed to credit risk in the event of a default by the financial institutions holding our cash, cash equivalents and marketable securities to the extent recorded on the consolidated balance sheets. </span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are also subject to credit risk from our accounts receivable related to our product sales and revenues under our license and collaborative agreements. We have license and collaborative agreements with pharmaceutical companies under which we receive payments for royalties, license fees, milestone payments for specific achievements designated in the collaborative agreements, reimbursements of research and development services and supply of bulk formulation of rHuPH20. In addition, we sell Hylenex</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></span><span style="font-family:inherit;font-size:10pt;"> recombinant in the United States to a limited number of established wholesale distributors in the pharmaceutical industry. Credit is extended based on an evaluation of the customer’s financial condition, and collateral is not required. Management monitors our exposure to accounts receivable by periodically evaluating the collectibility of the accounts receivable based on a variety of factors including the length of time the receivables are past due, the financial health of the customer and historical experience. Based upon the review of these factors, we recorded </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;"> allowance for doubtful accounts at </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019 and 2018</span><span style="font-family:inherit;font-size:10pt;">. Approximately </span><span style="font-family:inherit;font-size:10pt;"><span>93%</span></span><span style="font-family:inherit;font-size:10pt;"> of the accounts receivable balance at </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> represents amounts due from Janssen, Roche and Baxalta. Approximately </span><span style="font-family:inherit;font-size:10pt;"><span>81%</span></span><span style="font-family:inherit;font-size:10pt;"> of the accounts receivable balance at </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;"> represents amounts due from Roche and Baxalta. </span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table indicates the percentage of total revenues in excess of </span><span style="font-family:inherit;font-size:10pt;"><span>10%</span></span><span style="font-family:inherit;font-size:10pt;"> with any single customer:</span></div><div style="line-height:120%;text-align:center;text-indent:32px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.12670565302143%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:58%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:13%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Roche</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>40%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>72%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>38%</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">argenx</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—%</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Janssen</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6%</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">BMS</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>32%</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Alexion</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13%</span></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We attribute revenues under collaborative agreements, including royalties, to the individual countries where the customer is headquartered. We attribute revenues from product sales to the individual countries to which the product is shipped. Worldwide revenues from external customers are summarized by geographic location in the following table (in thousands):</span></div><div style="line-height:120%;padding-top:8px;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.32163742690058%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:58%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">United States</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>116,083</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>40,475</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>196,274</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Switzerland</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>78,413</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>109,890</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>119,136</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">All other foreign</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,496</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,497</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,203</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>195,992</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>151,862</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>316,613</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We rely on </span><span style="font-family:inherit;font-size:10pt;"><span>two</span></span><span style="font-family:inherit;font-size:10pt;"> third-party manufacturers for the supply of bulk rHuPH20 for use in the manufacture of Hylenex recombinant and our other collaboration products and product candidates. Payments due to these suppliers represented </span><span style="font-family:inherit;font-size:10pt;"><span>47%</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>2%</span></span><span style="font-family:inherit;font-size:10pt;"> of the accounts payable balance at </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019 and 2018</span><span style="font-family:inherit;font-size:10pt;">, respectively. We also rely on a third-party manufacturer for the fill and finish of Hylenex recombinant product under a contract. Payments due to this supplier represented </span><span style="font-family:inherit;font-size:10pt;"><span>8%</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>0%</span></span><span style="font-family:inherit;font-size:10pt;"> of the accounts payable balance at </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019 and 2018</span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Accounts Receivable, Net</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts receivable is recorded at the invoiced amount and is non-interest bearing. Accounts receivable is recorded net of allowances for doubtful accounts, cash discounts for prompt payment, distribution fees and chargebacks. We recorded </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;"> allowance for doubtful accounts at </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019 and 2018</span><span style="font-family:inherit;font-size:10pt;"> as the collectibility of accounts receivable was reasonably assured.</span></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Inventories</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inventories are stated at lower of cost or net realizable value. Cost is determined on a first-in, first-out basis. Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. Inventories are reviewed periodically for potential excess, dated or obsolete status. We evaluate the carrying value of inventories on a regular basis, taking into account such factors as historical and anticipated future sales compared to quantities on hand, the price we expect to obtain for products in their respective markets compared with historical cost and the remaining shelf life of goods on hand.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Bulk rHuPH20 formulations manufactured for partner use prior to our partner receiving marketing approval from the U.S. Food and Drug Administration (“FDA”) or comparable regulatory agencies in foreign countries and with no alternative future use are recorded as research and development expense. All direct manufacturing costs incurred after the partner receives marketing approval are capitalized as inventory. Bulk rHuPH20 formulations manufactured for general partner and internal use, which can potentially be used by any collaboration partner or by us in Hylenex, and ENHANZE drug product used by our partners in clinical trials, is considered to have alternative future use and all manufacturing costs are capitalized as inventory. Inventories used in our clinical trials are expensed at the time the inventories are packaged for the clinical trials. </span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019 and 2018</span><span style="font-family:inherit;font-size:10pt;">, inventories consisted of </span><span style="font-family:inherit;font-size:10pt;"><span>$1.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$2.2 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, of Hylenex recombinant inventory, net, and </span><span style="font-family:inherit;font-size:10pt;"><span>$28.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$20.4 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, of bulk rHuPH20.</span></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Leases</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has entered into operating leases primarily for real estate and automobiles. These leases have terms which range from </span><span style="font-family:inherit;font-size:10pt;"><span>3 years</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>6 years</span></span><span style="font-family:inherit;font-size:10pt;">. We determine if an arrangement contains a lease at inception. Right of use (“ROU”) assets and liabilities resulting from operating leases are included in property and equipment, accrued expenses and other long-term liabilities on our consolidated balance sheets. Operating lease ROU assets and liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the discount rate to calculate the present value of future payments. The operating lease ROU asset also includes any lease payments made and </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">excludes lease incentives and initial direct costs incurred. Our leases often include options to extend or terminate the lease. These options are included in the lease term when it is reasonably certain that we will exercise that option. Short-term leases with an initial term of 12 months or less are not recorded on the balance sheet. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. </span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have lease agreements with lease and non-lease components, which are generally accounted for separately. For certain equipment leases, such as automobiles, we account for the lease and non-lease components as a single lease component. </span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Property and Equipment, Net</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property and equipment are recorded at cost, less accumulated depreciation and amortization. Equipment is depreciated using the straight-line method over its estimated useful life ranging from </span><span style="font-family:inherit;font-size:10pt;"><span>three years</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>ten years</span></span><span style="font-family:inherit;font-size:10pt;"> and leasehold improvements are amortized using the straight-line method over the estimated useful life of the asset or the lease term, whichever is shorter. </span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Impairment of Long-Lived Assets</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We account for long-lived assets in accordance with authoritative guidance for impairment or disposal of long-lived assets. Long-lived assets are reviewed for events or changes in circumstances, which indicate that their carrying value may not be recoverable. </span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Comprehensive Income (Loss)</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Comprehensive income (loss) is defined as the change in equity during the period from transactions and other events and circumstances from non-owner sources.</span></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue Recognition</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We generate revenues from payments received under collaborative agreements and product sales. As of January 1, 2018, we adopted ASC 606, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers</span><span style="font-family:inherit;font-size:10pt;"> (ASC 606) which affects how we recognize revenues in these arrangements. We applied the provisions of ASC 606 using the modified retrospective approach, with the cumulative effect of the adoption recognized as of January 1, 2018, to all contracts that had not been completed as of that date. Under ASC 606, we recognize revenue when we transfer promised goods or services to customers in an amount that reflects the consideration to which we expect to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers we perform the following five steps: (i) identify the promised goods or services in the contract; (ii) identify the performance obligations in the contract, including whether they are distinct in the context of the contract; (iii) determine the transaction price, including the constraint on variable consideration; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) we satisfy the performance obligations. Amounts reported in prior periods have not been adjusted to reflect the adoption of ASC 606. Accordingly, the reported revenue amounts for the year ended December 31, 2019 and 2018 and the year ended December 31, 2017 are based on different accounting policies.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prior to the ASC 606 adoption, revenue was recognized when all of the following criteria were met: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred or services have been rendered; (3) the seller’s price to the buyer is fixed or determinable; and (4) collectibility is reasonably assured. Differences between the revenue recognition policies applicable prior to the adoption and ASC 606 are described in the following sections and in Note 4.</span></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenues under Collaborative Agreements - as reported under ASC 606 beginning January 1, 2018</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Under these agreements, we grant the collaboration partner a worldwide license to develop and commercialize products using our ENHANZE technology to combine our patented rHuPH20 enzyme with their proprietary biologics directed at up to a specified number of targets. Targets are usually licensed on an exclusive, global basis. Targets selected subsequent to inception of the arrangement require payment of an additional license fee. The collaboration partner is responsible for all development, manufacturing, clinical, regulatory, sales and marketing costs for any products developed under the agreement. We are responsible for supply of bulk rHuPH20 based on the collaboration partner’s purchase orders, and may also be separately engaged to perform research and development services. While these collaboration agreements are similar in that they originate from the same framework, each one is the result of an arms-length negotiation and thus may vary from one to the other.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We collect an upfront license payment from the collaboration partner, and are also entitled to receive event-based payments subject to the collaboration partner’s achievement of specified development, regulatory and sales-based milestones. In several agreements, collaboration partners pay us annual fees to maintain their exclusive license rights if they are unable to advance product development to specified stages. We earn separate fees for bulk rHuPH20 supplies and research and development services. In addition, the collaboration partner will pay us royalties at an on average mid-single digit percent rate of their sales if products under the collaboration are commercialized. All amounts owed to us are noncancelable after the underlying triggering event occurs, and nonrefundable once paid. Unless terminated earlier in accordance with its terms, the collaboration generally continues in effect until the later of: (i) expiration of the last to expire of the valid claims of our patents covering rHuPH20 or other specified patents developed under the collaboration which valid claim covers a product developed under the collaboration, and (ii) expiration of the last to expire royalty term for a product developed under the collaboration, which is determined separately for each country. In the event such valid claims expire prior to the last to expire royalty term, the royalty rate is reduced for the remaining royalty term following such expiration. The collaboration partner may terminate the agreement prior to expiration for any reason in its entirety or on a target-by-target basis generally upon 90 days prior written notice to us. Upon any such termination, the license granted to the collaboration partner (in total or with respect to the terminated target, as applicable) will terminate provided, however, that in the event of expiration of the agreement, the on-going licenses granted will become perpetual, non-exclusive and fully paid.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Although these agreements are in form structured as collaborative agreements, we concluded for accounting purposes they represent contracts with customers, and are not subject to accounting literature on collaborative arrangements. This is because we grant to collaboration partners licenses to our intellectual property, and provide supply of bulk rHuPH20 and research and development services which are all outputs of our ongoing activities, in exchange for consideration. We do not develop assets jointly with collaboration partners, and do not share in significant risks of their development or commercialization activities. Accordingly, we concluded our collaborative agreements must be accounted for pursuant to ASC Topic 606, Revenue from Contracts with Customers. </span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Under all of our collaborative agreements, we have identified licenses to use functional intellectual property as the only performance obligation. The intellectual property underlying the license is our proprietary ENHANZE® technology which represents application of rHuPH20 to facilitate delivery of drugs or fluids. The license grants the collaboration partners right to use our intellectual property as it exists on the effective date of the license, because there is no ongoing development of the ENHANZE technology required. Therefore, we recognize revenue from licenses at the point when the license becomes effective and the collaboration partner has received access to our intellectual property, usually at the inception of the agreement.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">When collaboration partners can select additional targets to add to the licenses granted, we consider these rights to be options. We evaluate whether such options contain material rights, i.e. have exercise prices that are discounted compared to what we would charge for a similar license to a new collaboration partner. The exercise price of these options includes a combination of the target selection fees, event-based milestone payments and royalties. When these amounts in aggregate are not offered at a discount that exceeds discounts available to other customers, we conclude the option does not contain a material right, and we consider grants of additional licensing rights upon option exercises to be separate contracts (target selection contracts).</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We provide standard indemnification and protection of licensed intellectual property for our customers. These provisions are part of assurance that the licenses meet the agreements’ representations and are not obligations to provide goods or services.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We also fulfill purchase orders for supply of bulk rHuPH20 and perform research and development services pursuant to projects authorization forms for our collaboration partners, which represent separate contracts. Additionally, we price our supply of bulk rHuPH20 and research and development services at our regular selling prices, called standalone selling price or SSP. Therefore, our collaboration partners do not have material rights to order these items at prices not reflective of SSP. Refer to the discussion below regarding recognition of revenue for these separate contracts.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Transaction price for a contract represents the amount to which we are entitled in exchange for providing goods and services to the customer. Transaction price does not include amounts subject to uncertainties unless it is probable that there will be no significant reversal of revenue when the uncertainty is resolved. Apart from the upfront license payment (or target selection fees in the target selection contracts), all other fees we may earn under our collaborative agreements are subject to significant uncertainties of product development. Achievement of many of the event-based development and regulatory milestones may not be probable until such milestones are actually achieved. This generally relates to milestones such as obtaining marketing authorization approvals. </span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">With respect to other development milestones, e.g. dosing of a first patient in a clinical trial, achievement could be considered probable prior to its actual occurrence, based on the progress towards commencement of the trial. We do not include any amounts subject to uncertainties into the transaction price until it is probable that the amount will not result in a significant reversal of revenue in the future. At the end of each reporting period, we re-evaluate the probability of achievement of such milestones and any related constraint, and if necessary, adjust our estimate of the overall transaction price.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">When target exchange rights are held by collaboration partners, and the amounts attributed to these rights are not refundable, they are included in the transaction price. However, they are recorded as deferred revenues because we have a potential performance obligation to provide a new target upon an exchange right being exercised. These amounts are recognized in revenue when the right of exchange expires or is exercised.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Because our agreements have one type of performance obligation (licenses) which are typically all transferred at the same time at agreement inception, allocation of transaction price often is not required. However, allocation is required when licenses for some of the individual targets are subject to rights of exchange, because revenue associated with these targets cannot be recognized. We perform an allocation of the upfront amount based on relative SSP of licenses for individual targets. We determine license SSP using income-based valuation approach utilizing risk-adjusted discounted cash flow projections of the estimated return a licensor would receive. When amounts subject to uncertainties, such as milestones and royalties, are included in the transaction price, we attribute them to the specific individual target licenses which generate such milestone or royalty amounts.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We also estimate SSP of bulk rHuPH20 and research and development services, to determine that our collaboration partners do not have material rights to order them at discounted prices. For supplies of bulk rHuPH20, because we effectively act as a contract manufacturer to our collaboration partners, we estimate and charge SSP based on the typical contract manufacturer margins consistently with all of our collaborative partners. We determine SSP of research and development services based on a fully-burdened labor rate. Our rates are comparable to those we observe in other collaborative agreements. We also have a history of charging similar rates to all of our collaboration partners.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Upfront amounts allocated to licenses to individual targets are recognized as revenue when the license is transferred to the collaboration partner, as discussed above, if the license is not subject to exchange rights, or when the exchange right expires or is exercised. Development milestones and other fees are recognized in revenue when they are included in the transaction price, because by that time we have already transferred the related license to the collaboration partner.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Sales-based milestones and royalties cannot be recognized until the underlying sales occur. We do not receive final royalty reports from our collaboration partners until after we complete our financial statements for a prior quarter. Therefore, we recognize revenue based on estimates of the royalty earned, which are based on preliminary reports provided by our collaboration partners. We will record a true-up in the following quarter if necessary, when final royalty reports are received. To date, we have not recorded any material true-ups.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In contracts to provide research and development services, such services represent the only performance obligation. The fees are charged based on hours worked by our employees and the fixed contractual rate per hour, plus third-party pass-through costs, on a monthly basis. We recognize revenues as the related services are performed based on the amounts billed, as the collaboration partner consumes the benefit of research and development work simultaneously as we perform these services, and the amounts billed reflect the value of these services to the customer.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Refer to Note 4 Revenue, for further discussion on our collaborative arrangements.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prior to the adoption of ASC 606 on January 1, 2018, we recognized upfront amounts received under two of our collaborative agreements straight-line over the contract term in accordance with the accounting standards that were in effect in 2006-2007, when these collaborative agreements were entered into. In addition, we recognized royalty revenue in the period when we received final royalty reports from the collaboration partners, in the quarter following the quarter in which the corresponding sales occurred. There were no other adoption differences in revenue recognized due to the transition from the previously existing authoritative accounting literature to ASC 606.</span></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Product Sales, Net - as reported under ASC 606 beginning January 1, 2018</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Hylenex</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> Recombinant</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We sell Hylenex recombinant in the U.S. to wholesale pharmaceutical distributors, who sell the product to hospitals and other end-user customers. Sales to wholesalers are made pursuant to purchase orders subject to the terms of a master agreement, and delivery of individual packages of Hylenex recombinant represent performance obligations under each purchase order. We use a contract manufacturer to produce Hylenex recombinant and a third-party logistics (3PL) vendor to process and fulfill orders</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">. </span><span style="font-family:inherit;font-size:10pt;">We concluded we are the principal in the sales to wholesalers because we control access to services rendered by both vendors and direct their activities. We have no significant obligations to wholesalers to generate pull-through sales.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Selling prices initially billed to wholesalers are subject to discounts for prompt payment and subsequent chargebacks when wholesalers sell Hylenex recombinant at negotiated discounted prices to members of certain group purchasing organizations (“GPOs”) and government programs. We also pay quarterly distribution fees to certain wholesalers for inventory reporting and chargeback processing, and to GPOs as administrative fees for services and for access to GPO members. We concluded the benefits received in exchange for these fees are not distinct from our sales of Hylenex</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span><span style="font-family:inherit;font-size:10pt;">recombinant, and accordingly we apply these amounts to reduce revenues. Wholesalers also have rights to return unsold product nearing or past the expiration date. Because of the shelf life of Hylenex recombinant and our lengthy return period, there may be a significant period of time between when the product is shipped and when we issue credits on returned product.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We estimate the transaction price when we receive each purchase order taking into account the expected reductions of the selling price initially billed to the wholesaler arising from all of the above factors. We have compiled historical experience and data to estimate future returns and chargebacks of Hylenex recombinant and the impact of the other discounts and fees we pay. When estimating these adjustments to the transaction price, we reduce it sufficiently to be able to assert that it is probable that there will be no significant reversal of revenue when the ultimate adjustment amounts are known.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Each purchase order contains only one type of product, and is usually shipped to the wholesaler in a single shipment. Therefore, allocation of the transaction price to individual packages is not required.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We recognize revenue from Hylenex recombinant product sales and related cost of sales upon product delivery to the wholesaler location. At that time, the wholesalers take control of the product as they take title, bear the risk of loss of ownership, and have an enforceable obligation to pay us. They also have the ability to direct sales of product to their customers on terms and at prices they negotiate. Although wholesalers have product return rights, we do not believe they have a significant incentive to return the product to us.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Upon recognition of revenue from product sales of Hylenex recombinant, the estimated amounts of credit for product returns, chargebacks, distribution fees, prompt payment discounts, and GPO fees are included in sales reserves, accrued liabilities and net of accounts receivable. We monitor actual product returns, chargebacks, discounts and fees subsequent to the sale. If these amounts differ from our estimates, we make adjustments to these allowances, which are applied to increase or reduce product sales revenue and earnings in the period of adjustment.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In connection with the orders placed by wholesalers, we incur costs such as commissions to our sales representatives. However, as revenue from product sales is recognized upon delivery to the wholesaler, which occurs shortly after we receive a purchase order, we do not capitalize these commissions and other costs, based on application of the practical expedient allowed within the applicable guidance.</span></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Bulk rHuPH20</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We sell bulk rHuPH20 to collaboration partners for use in research and development; subsequent to receiving marketing approval, we sell it for use in collaboration commercial products. Sales are made pursuant to purchase orders subject to the terms of the collaborative agreement, and delivery of units of bulk rHuPH20 represent performance obligations under each purchase order. We provide a standard warranty that the product conforms to specifications. We use contract manufacturers to produce bulk rHuPH20 and have concluded we are the principal in the sales to collaboration partners. The transaction price for each purchase order of bulk rHuPH20 is fixed based on the cost of production plus a contractual markup, and is not subject to adjustments. Allocation of the transaction price to individual quantities of the product is usually not required because each order contains only one type of product.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We recognize revenue from the sale of bulk rHuPH20 as product sales and related cost of sales upon transfer of title to our partners. At that time, the partners take control of the product, bear the risk of loss of ownership, and have an enforceable obligation to pay us.</span></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">ENHANZE Drug Product</span><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We sell ENHANZE drug product to collaboration partners for use in research and development in early phase clinical studies. Sales are made pursuant to purchase orders subject to the terms of the collaborative agreement, and delivery of units of ENHANZE drug product represent performance obligations under each purchase order. We provide a standard warranty that the product conforms to specifications. We use contract manufacturers to produce ENHANZE drug product and we concluded we are the principal in the sales to collaboration partners. The transaction price for each purchase order of ENHANZE drug product is fixed based on the cost of production plus a contractual markup, and is not subject to adjustments. Allocation of the transaction price to individual quantities of the product is usually not required because each order contains only one type of product.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We recognize revenue from the sale of ENHANZE drug product as product sales and related cost of sales upon transfer of title to our partners. At that time, the partners take control of the product, bear the risk of loss of ownership, and have an enforceable obligation to pay us.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue Presentation</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In our statements of operations, we report as revenues under collaborative agreements the upfront payments, event-based development and regulatory milestones and sales milestones. We also include in this category revenues from separate research and development contracts pursuant to project authorization forms. We report royalties received from collaboration partners as a separate line in our statements of operations.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenues from sales of Hylenex recombinant, bulk rHuPH20 that has alternative future use and ENHANZE drug product are included in product sales, net.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In the footnotes to our financial statements, we provide disaggregated revenue information by type of arrangement (product sales, net, collaborative agreements and research and development services), and additionally, by type of payment stream received under collaborative agreements (upfront license fees, event-based development and regulatory milestones and other fees, sales milestones and royalties).</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cost of Product Sales</span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of product sales consists primarily of raw materials, third-party manufacturing costs, fill and finish costs, freight costs, internal costs and manufacturing overhead associated with the production of Hylenex recombinant and bulk rHuPH20 and ENHANZE drug product that has alternative future use. Cost of product sales also consists of the write-down of excess, dated and obsolete inventories and the write-off of inventories that do not meet certain product specifications, if any. Prior to bulk rHuPH20 and ENHANZE drug product having alternative future use, all costs related to the manufacturing of those products were charged to research and development expenses in the periods such costs were incurred. During the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, sales of bulk rHuPH20 and ENHANZE drug product included </span><span style="font-family:inherit;font-size:10pt;"><span>$1.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> of cost of sales that were previously expensed as research and development. Of the bulk rHuPH20 and ENHANZE drug product that has alternative future use on hand as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$0.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> in manufacturing costs were previously recorded as research and development expenses. We expect to sell this inventory by the end of 2020.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Research and Development Expenses</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development expenses include salaries and benefits, facilities and other overhead expenses, external clinical trial expenses, research related manufacturing services, contract services and other outside expenses. Research and development expenses are charged to operating expenses as incurred when these expenditures relate to our research and development efforts and have no alternative future uses.</span><span style="font-family:inherit;font-size:8pt;"> </span><span style="font-family:inherit;font-size:10pt;">When bulk rHuPH20 is manufactured for use in research and development by us or our partners and the product cannot be redirected for alternative use due to formulation and manufacturing specifications, the manufacturing costs are recorded as research and development expense. Bulk rHuPH20 that is manufactured for partner use prior to our partner receiving marketing approval from the FDA or comparable regulatory agencies in foreign countries and meet these specifications is recorded as research and development expenses. Bulk rHuPH20 formulations manufactured for general partner and internal use, which can potentially be used by any collaboration partner or by us in Hylenex, is considered to have alternative future use and all manufacturing costs are capitalized as inventory. Inventories used in our clinical trials were expensed at the time the inventories were packaged for the clinical trials.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are obligated to make upfront payments upon execution of certain research and development agreements. Advance payments, including nonrefundable amounts, for goods or services that will be used or rendered for future research and development activities are deferred. Such amounts are recognized as expense as the related goods are delivered or the related services are performed or such time when we do not expect the goods to be delivered or services to be performed.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Milestone payments that we make in connection with in-licensed technology for a particular research and development project that have no alternative future uses (in other research and development projects or otherwise) and therefore no separate economic value are expensed as research and development costs at the time the costs are incurred. We currently have </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;"> in-licensed technologies that have alternative future uses in research and development projects or otherwise.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Clinical Trial Expenses</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We make payments in connection with our clinical trials under contracts with contract research organizations that support conducting and managing clinical trials. The financial terms of these agreements are subject to negotiation and vary from contract to contract and may result in uneven payment flows. Generally, these agreements set forth the scope of work to be performed at a fixed fee, unit price or on a time and materials basis. A portion of our obligation to make payments under these contracts depends on factors such as the successful enrollment or treatment of patients or the completion of other clinical trial milestones. </span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expenses related to clinical trials are accrued based on our estimates and/or representations from service providers regarding work performed, including actual level of patient enrollment, completion of patient studies and progress of the clinical trials. Other incidental costs related to patient enrollment or treatment are accrued when reasonably certain. If the amounts we are obligated to pay under our clinical trial agreements are modified (for instance, as a result of changes in the clinical trial protocol or scope of work to be performed), we adjust our accruals accordingly on a prospective basis. Revisions to our contractual payment obligations are charged to expense in the period in which the facts that give rise to the revision become reasonably certain. </span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Share-Based Compensation</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We record compensation expense associated with stock options, restricted stock awards (“RSAs”), and restricted stock units (“RSUs”) in accordance with the authoritative guidance for stock-based compensation. The cost of employee services received in exchange for an award of an equity instrument is measured at the grant date, based on the estimated fair value of the award, and is recognized as expense on a straight-line basis over the requisite service period of the award. Share-based compensation expense for an award with a performance condition is recognized when the achievement of such performance condition is determined to be probable. If the outcome of such performance condition is not determined to be probable or is not met, no compensation expense is recognized and any previously recognized compensation expense is reversed. Forfeitures are recognized as a reduction of share-based compensation expense as they occur.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Income Taxes </span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We provide for income taxes using the liability method. Under this method, deferred income tax assets and liabilities are determined based on the differences between the financial statement carrying amounts of existing assets and liabilities at each year end and their respective tax bases and are measured using enacted tax rates in effect for the year in which the differences are expected to affect taxable income. Significant judgment is required by management to determine our provision for income taxes, our deferred tax assets and liabilities, and the valuation allowance to record against our net deferred tax assets, which are based on complex and evolving tax regulations throughout the world. Deferred tax assets and other tax benefits are recorded when it is more likely than not that the position will be sustained upon audit. While we have begun to utilize certain of our net operating losses, we have not yet established a track record of profitability. Accordingly, valuation allowances have been recorded to reduce our net deferred tax assets to </span><span style="font-family:inherit;font-size:10pt;"><span>zero</span></span><span style="font-family:inherit;font-size:10pt;">, with the exception of the alternative minimum tax ("AMT") credit carryover of </span><span style="font-family:inherit;font-size:10pt;"><span>$1.7 million</span></span><span style="font-family:inherit;font-size:10pt;">. Under the Tax Cuts and Jobs Act (the “Act”) enacted in December 2017, the AMT credit carryover will either be utilized, or if unutilized fully refunded in 2022. For all other deferred tax assets, the valuation allowance will reduce the net value to </span><span style="font-family:inherit;font-size:10pt;"><span>zero</span></span><span style="font-family:inherit;font-size:10pt;"> until such time as we can demonstrate an ability to realize them.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The 2015 and 2016 federal returns were selected for audit by the IRS. The audit was completed in September 2019 with no material adjustments.</span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Net (Loss) Income Per Share</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic net (loss) income per common share is computed by dividing net (loss) income for the period by the weighted average number of common shares outstanding during the period, without consideration for common stock equivalents. Outstanding stock options, unvested RSAs, unvested RSUs and the Convertible Notes are considered common stock equivalents and are only included in the calculation of diluted earnings per common share when net income is reported and their effect is dilutive. For the years ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019, 2018 and 2017</span><span style="font-family:inherit;font-size:10pt;">, approximately </span><span style="font-family:inherit;font-size:10pt;"><span>33.1 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>13.8 million</span></span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;"><span>7.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> shares, respectively, of outstanding stock options, unvested RSAs, unvested RSUs and Convertible Notes were excluded from the calculation of diluted net (loss) income per common share because their effect was anti-dilutive.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The </span><span style="font-family:inherit;font-size:10pt;"><span>19.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> shares underlying the conversion option of the Convertible Notes will not have an impact on our diluted earnings per share when net income is reported until the average market price of our common stock exceeds the conversion price of </span><span style="font-family:inherit;font-size:10pt;"><span>$23.85</span></span><span style="font-family:inherit;font-size:10pt;"> per share, as we intend and have the ability to settle the principal amount of the Convertible Notes in cash upon conversion. We compute the potentially dilutive impact of the shares of common stock related to the Convertible Notes using the treasury stock method.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> A reconciliation of the numerators and the denominators of the basic and diluted net (loss) income per common share computations is as follows (in thousands, except per share amounts):</span></div><div style="line-height:120%;padding-top:8px;text-align:center;text-indent:32px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.32163742690058%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:67%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Numerator:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net (loss) income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(72,240</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(80,330</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>62,971</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Denominator:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average common shares outstanding for basic<br/> net (loss) income per share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>144,329</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>143,599</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>136,419</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net effect of dilutive common stock equivalents</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,649</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average common shares outstanding for diluted <br/> net (loss) income per share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>144,329</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>143,599</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>139,068</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net (loss) income per share:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.50</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.56</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.46</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Diluted</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.50</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.56</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.45</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Segment Information</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We operate our business in </span><span style="font-family:inherit;font-size:10pt;"><span>one</span></span><span style="font-family:inherit;font-size:10pt;"> segment, which includes all activities related to the research, development and commercialization of our proprietary enzymes. This segment also includes revenues and expenses related to (i) research and development and bulk rHuPH20 manufacturing activities conducted under our collaborative agreements with third parties and (ii) product sales of Hylenex recombinant. The chief operating decision-maker reviews the operating results on an aggregate basis and manages the operations as a single operating segment. Our long-lived assets located in foreign countries had no book value as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019, 2018 and 2017</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Adoption and Pending Adoption of Recent Accounting Pronouncements</span></div><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides a brief description of recently issued accounting standards, those adopted in the current period and those not yet adopted:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:20%;"/><td style="width:1%;"/><td style="width:39%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:24%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Standard</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Description</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Effective Date</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Effect on the Financial </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Statements or Other Significant Matters</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). In July 2018, the FASB issued additional guidance related to Topic 842.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The new guidance requires lessees to recognize assets and liabilities for most leases and provides enhanced disclosures.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">January 1, 2019 </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We implemented the guidance on January 1, 2019 using a modified retrospective transition basis for leases existing as of the period of adoption. In order to adopt the new standard, we used the available practical expedients and newly implemented processes and internal controls for lease accounting. The practical expedients allowed us to carry forward our historical assessment of whether existing agreements are or contain a lease and the classification of our existing lease arrangements. All of our real-estate and automobile operating lease commitments are recognized as lease liabilities with corresponding right-of-use assets, which resulted in an increase in the assets and liabilities of the consolidated balance sheet of $7.2 million, using an assumed weighted average discount rate of 10.0%. The adoption did not have an impact on our consolidated statements of operations and did not require recognition of a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. We elected to continue applying the guidance under ASC 840 for comparative periods, as allowed through ASC 2018-11.</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:20%;"/><td style="width:1%;"/><td style="width:39%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:24%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Standard</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Description</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Effective Date</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Effect on the Financial </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Statements or Other Significant Matters</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In December 2019, the FASB issued ASU 2019-12, Simplifying the Accounting for Income Taxes</span></div><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The new guidance removes certain exceptions to the general principles of ASC 740 in order to simplify the complexities of its application. These changes include eliminations to the exceptions for intraperiod tax allocation, recognizing deferred tax liabilities related to outside basis differences, and year-to-date losses in interim periods among others. </span></div><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">January 1, 2019</span></div><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We early adopted the new guidance on January 1, 2019. With the adoption we no longer apply the exception to the general rule for intraperiod tax allocations under the incremental method. During the period, we would have recorded a $14.7 million tax expense to APIC fully offset by a $14.7 million tax benefit in continuing operations. </span></div><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In August 2018, the FASB issued ASU 2018-15, Intangibles-Goodwill and other Internal-Use Software (Subtopic 350-40)</span></div><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The new guidance aligns the requirement for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirement for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license).</span></div><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">January 1, 2020</span></div><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We plan to adopt the new guidance on January 1, 2020. We do not anticipate the adoption will have a material impact on our condensed consolidated financial position or results of operations.</span></div><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820).</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The new guidance removes, modifies and adds to certain disclosure requirements on fair value measurements in Topic 820, Fair Value Measurement.</span></div><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">January 1, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We plan to adopt the new guidance on January 1, 2020. We do not anticipate the adoption will have a material impact on our consolidated financial position or results of operations.</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326), Measurement of Credit Losses on Financial Instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The standard amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses for most financial assets and certain other instruments that aren’t measured at fair value through net income. For available-for-sale debt securities, entities will be required to recognize an allowance for credit losses rather than a reduction in carrying value of the asset. Entities will no longer be permitted to consider the length of time that fair value has been less than amortized cost when evaluating when credit losses should be recognized.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">January 1, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We plan to adopt the new guidance on January 1, 2020. We do not anticipate the adoption will have a material impact on our consolidated financial position or results of operations.</span></div><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> <div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Basis of Presentation</span></div>The consolidated financial statements include the accounts of Halozyme Therapeutics, Inc. and our wholly owned subsidiary, Halozyme, Inc., and Halozyme, Inc.’s wholly owned subsidiaries, Halozyme Holdings Ltd., Halozyme Royalty LLC, Halozyme Switzerland GmbH and Halozyme Switzerland Holdings GmbH. All intercompany accounts and transactions have been eliminated. <div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”) requires management to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes. On an ongoing basis, we evaluate our estimates and judgments, which are based on historical and anticipated results and trends and on various other assumptions that management believes to be reasonable under the circumstances. By their nature, estimates are subject to an inherent degree of uncertainty and, as such, actual results may differ from management’s estimates.</span></div> <div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cash Equivalents and Marketable Securities </span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash equivalents consist of highly liquid investments, readily convertible to cash, that mature within ninety days or less from the date of purchase. As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, our cash equivalents consisted of money market funds.</span></div> <div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Marketable securities are investments with original maturities of more than ninety days from the date of purchase that are specifically identified to fund current operations. Marketable securities are considered available-for-sale. These investments are classified as current assets, even though the stated maturity date may be one year or more beyond the current balance sheet date which reflects management’s intention to use the proceeds from the sale of these investments to fund our operations, as necessary. Such available-for-sale investments are carried at fair value with unrealized gains and losses recorded in other comprehensive income (loss) and included as a separate component of stockholders’ equity (deficit). The cost of marketable securities is adjusted for amortization of premiums or accretion of discounts to maturity, and such amortization or accretion is included in investment and other income, net in the consolidated statements of operations. We use the specific identification method for calculating realized gains and losses on marketable securities sold. Realized gains and losses and declines in value judged to be other-than-temporary on marketable securities, if any, are included in investment and other income, net in the consolidated statements of operations.</span></div> <div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Restricted Cash</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Under the terms of the leases of our facilities, we are required to maintain letters of credit as security deposits during the terms of such leases. At </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019 and 2018</span><span style="font-family:inherit;font-size:10pt;">, restricted cash of </span><span style="font-family:inherit;font-size:10pt;"><span>$0.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> was pledged as collateral for the letters of credit.</span></div> 500000 <div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Fair Value of Financial Instruments</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The authoritative guidance for fair value measurements establishes a three tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions. </span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our financial instruments include cash equivalents, available-for-sale marketable securities, accounts receivable, prepaid expenses and other assets, accounts payable, accrued expenses and long-term debt. Fair value estimates of these instruments are made at a specific point in time, based on relevant market information. These estimates may be subjective in nature and involve uncertainties and matters of significant judgment and therefore cannot be determined with precision. The carrying amount of cash equivalents, accounts receivable, prepaid expenses and other assets, accounts payable and accrued expenses are generally considered to be representative of their respective fair values because of the short-term nature of those instruments. Based on Level 3 inputs and the borrowing rates currently available for loans with similar terms, we believe the fair value of long-term debt approximates its carrying value.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Available-for-sale marketable securities consist of asset-backed securities, corporate debt securities, U.S. Treasury securities and commercial paper, and are measured at fair value using Level 1 and Level 2 inputs. Level 2 financial instruments are valued using market prices on less active markets and proprietary pricing valuation models with observable inputs, including interest rates, yield curves, maturity dates, issue dates, settlement dates, reported trades, broker-dealer quotes, issue spreads, benchmark securities or other market related data. We obtain the fair value of Level 2 investments from our investment manager, who obtains these fair values from a third-party pricing source. We validate the fair values of Level 2 financial instruments provided by our investment manager by comparing these fair values to a third-party pricing source.</span></div> <div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentrations of Credit Risk, Sources of Supply and Significant Customers</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are subject to credit risk from our portfolio of cash equivalents and marketable securities. These investments were made in accordance with our investment policy which specifies the categories, allocations, and ratings of securities we may consider for investment. The primary objective of our investment activities is to preserve principal while at the same time maximizing the income we receive without significantly increasing risk. We maintain our cash and cash equivalent balances with one major commercial bank and marketable securities with another financial institution. Deposits held with the financial institutions exceed the amount of insurance provided on such deposits. We are exposed to credit risk in the event of a default by the financial institutions holding our cash, cash equivalents and marketable securities to the extent recorded on the consolidated balance sheets. </span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are also subject to credit risk from our accounts receivable related to our product sales and revenues under our license and collaborative agreements. We have license and collaborative agreements with pharmaceutical companies under which we receive payments for royalties, license fees, milestone payments for specific achievements designated in the collaborative agreements, reimbursements of research and development services and supply of bulk formulation of rHuPH20. In addition, we sell Hylenex</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></span><span style="font-family:inherit;font-size:10pt;"> recombinant in the United States to a limited number of established wholesale distributors in the pharmaceutical industry. Credit is extended based on an evaluation of the customer’s financial condition, and collateral is not required. Management monitors our exposure to accounts receivable by periodically evaluating the collectibility of the accounts receivable based on a variety of factors including the length of time the receivables are past due, the financial health of the customer and historical experience. Based upon the review of these factors, we recorded </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;"> allowance for doubtful accounts at </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019 and 2018</span><span style="font-family:inherit;font-size:10pt;">. Approximately </span><span style="font-family:inherit;font-size:10pt;"><span>93%</span></span><span style="font-family:inherit;font-size:10pt;"> of the accounts receivable balance at </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> represents amounts due from Janssen, Roche and Baxalta. Approximately </span><span style="font-family:inherit;font-size:10pt;"><span>81%</span></span><span style="font-family:inherit;font-size:10pt;"> of the accounts receivable balance at </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;"> represents amounts due from Roche and Baxalta. </span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table indicates the percentage of total revenues in excess of </span><span style="font-family:inherit;font-size:10pt;"><span>10%</span></span><span style="font-family:inherit;font-size:10pt;"> with any single customer:</span></div><div style="line-height:120%;text-align:center;text-indent:32px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.12670565302143%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:58%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:13%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Roche</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>40%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>72%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>38%</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">argenx</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—%</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Janssen</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6%</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">BMS</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>32%</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Alexion</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13%</span></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We attribute revenues under collaborative agreements, including royalties, to the individual countries where the customer is headquartered. We attribute revenues from product sales to the individual countries to which the product is shipped. Worldwide revenues from external customers are summarized by geographic location in the following table (in thousands):</span></div><div style="line-height:120%;padding-top:8px;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.32163742690058%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:58%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">United States</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>116,083</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>40,475</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>196,274</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Switzerland</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>78,413</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>109,890</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>119,136</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">All other foreign</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,496</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,497</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,203</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>195,992</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>151,862</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>316,613</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We rely on </span><span style="font-family:inherit;font-size:10pt;"><span>two</span></span><span style="font-family:inherit;font-size:10pt;"> third-party manufacturers for the supply of bulk rHuPH20 for use in the manufacture of Hylenex recombinant and our other collaboration products and product candidates. Payments due to these suppliers represented </span><span style="font-family:inherit;font-size:10pt;"><span>47%</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>2%</span></span><span style="font-family:inherit;font-size:10pt;"> of the accounts payable balance at </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019 and 2018</span><span style="font-family:inherit;font-size:10pt;">, respectively. We also rely on a third-party manufacturer for the fill and finish of Hylenex recombinant product under a contract. Payments due to this supplier represented </span><span style="font-family:inherit;font-size:10pt;"><span>8%</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>0%</span></span><span style="font-family:inherit;font-size:10pt;"> of the accounts payable balance at </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019 and 2018</span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div> 0 0.93 0.81 <div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table indicates the percentage of total revenues in excess of </span><span style="font-family:inherit;font-size:10pt;"><span>10%</span></span><span style="font-family:inherit;font-size:10pt;"> with any single customer:</span></div><div style="line-height:120%;text-align:center;text-indent:32px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.12670565302143%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:58%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:13%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Roche</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>40%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>72%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>38%</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">argenx</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—%</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Janssen</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6%</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">BMS</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>32%</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Alexion</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13%</span></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We attribute revenues under collaborative agreements, including royalties, to the individual countries where the customer is headquartered. We attribute revenues from product sales to the individual countries to which the product is shipped. Worldwide revenues from external customers are summarized by geographic location in the following table (in thousands):</span></div><div style="line-height:120%;padding-top:8px;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.32163742690058%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:58%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">United States</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>116,083</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>40,475</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>196,274</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Switzerland</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>78,413</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>109,890</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>119,136</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">All other foreign</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,496</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,497</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,203</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>195,992</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>151,862</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>316,613</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 0.10 0.40 0.72 0.38 0.23 0 0 0.18 0.02 0.06 0.01 0.04 0.32 0.01 0.03 0.13 116083000 40475000 196274000 78413000 109890000 119136000 1496000 1497000 1203000 195992000 151862000 316613000 2 0.47 0.02 0.08 0 <div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Accounts Receivable, Net</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts receivable is recorded at the invoiced amount and is non-interest bearing. Accounts receivable is recorded net of allowances for doubtful accounts, cash discounts for prompt payment, distribution fees and chargebacks. We recorded </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;"> allowance for doubtful accounts at </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019 and 2018</span><span style="font-family:inherit;font-size:10pt;"> as the collectibility of accounts receivable was reasonably assured.</span></div> 0 <div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Inventories</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inventories are stated at lower of cost or net realizable value. Cost is determined on a first-in, first-out basis. Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. Inventories are reviewed periodically for potential excess, dated or obsolete status. We evaluate the carrying value of inventories on a regular basis, taking into account such factors as historical and anticipated future sales compared to quantities on hand, the price we expect to obtain for products in their respective markets compared with historical cost and the remaining shelf life of goods on hand.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Bulk rHuPH20 formulations manufactured for partner use prior to our partner receiving marketing approval from the U.S. Food and Drug Administration (“FDA”) or comparable regulatory agencies in foreign countries and with no alternative future use are recorded as research and development expense. All direct manufacturing costs incurred after the partner receives marketing approval are capitalized as inventory. Bulk rHuPH20 formulations manufactured for general partner and internal use, which can potentially be used by any collaboration partner or by us in Hylenex, and ENHANZE drug product used by our partners in clinical trials, is considered to have alternative future use and all manufacturing costs are capitalized as inventory. Inventories used in our clinical trials are expensed at the time the inventories are packaged for the clinical trials. </span></div><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019 and 2018</span><span style="font-family:inherit;font-size:10pt;">, inventories consisted of </span><span style="font-family:inherit;font-size:10pt;"><span>$1.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$2.2 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, of Hylenex recombinant inventory, net, and </span><span style="font-family:inherit;font-size:10pt;"><span>$28.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$20.4 million</span></span>, respectively, of bulk rHuPH20 1400000 2200000 28000000.0 20400000 P3Y P6Y <div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Property and Equipment, Net</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property and equipment are recorded at cost, less accumulated depreciation and amortization. Equipment is depreciated using the straight-line method over its estimated useful life ranging from </span><span style="font-family:inherit;font-size:10pt;"><span>three years</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>ten years</span></span><span style="font-family:inherit;font-size:10pt;"> and leasehold improvements are amortized using the straight-line method over the estimated useful life of the asset or the lease term, whichever is shorter. </span></div> P3Y P10Y <div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Impairment of Long-Lived Assets</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We account for long-lived assets in accordance with authoritative guidance for impairment or disposal of long-lived assets. Long-lived assets are reviewed for events or changes in circumstances, which indicate that their carrying value may not be recoverable. </span></div> <div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Comprehensive Income (Loss)</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Comprehensive income (loss) is defined as the change in equity during the period from transactions and other events and circumstances from non-owner sources.</span></div> <div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue Recognition</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We generate revenues from payments received under collaborative agreements and product sales. As of January 1, 2018, we adopted ASC 606, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers</span><span style="font-family:inherit;font-size:10pt;"> (ASC 606) which affects how we recognize revenues in these arrangements. We applied the provisions of ASC 606 using the modified retrospective approach, with the cumulative effect of the adoption recognized as of January 1, 2018, to all contracts that had not been completed as of that date. Under ASC 606, we recognize revenue when we transfer promised goods or services to customers in an amount that reflects the consideration to which we expect to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers we perform the following five steps: (i) identify the promised goods or services in the contract; (ii) identify the performance obligations in the contract, including whether they are distinct in the context of the contract; (iii) determine the transaction price, including the constraint on variable consideration; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) we satisfy the performance obligations. Amounts reported in prior periods have not been adjusted to reflect the adoption of ASC 606. Accordingly, the reported revenue amounts for the year ended December 31, 2019 and 2018 and the year ended December 31, 2017 are based on different accounting policies.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prior to the ASC 606 adoption, revenue was recognized when all of the following criteria were met: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred or services have been rendered; (3) the seller’s price to the buyer is fixed or determinable; and (4) collectibility is reasonably assured. Differences between the revenue recognition policies applicable prior to the adoption and ASC 606 are described in the following sections and in Note 4.</span></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenues under Collaborative Agreements - as reported under ASC 606 beginning January 1, 2018</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Under these agreements, we grant the collaboration partner a worldwide license to develop and commercialize products using our ENHANZE technology to combine our patented rHuPH20 enzyme with their proprietary biologics directed at up to a specified number of targets. Targets are usually licensed on an exclusive, global basis. Targets selected subsequent to inception of the arrangement require payment of an additional license fee. The collaboration partner is responsible for all development, manufacturing, clinical, regulatory, sales and marketing costs for any products developed under the agreement. We are responsible for supply of bulk rHuPH20 based on the collaboration partner’s purchase orders, and may also be separately engaged to perform research and development services. While these collaboration agreements are similar in that they originate from the same framework, each one is the result of an arms-length negotiation and thus may vary from one to the other.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We collect an upfront license payment from the collaboration partner, and are also entitled to receive event-based payments subject to the collaboration partner’s achievement of specified development, regulatory and sales-based milestones. In several agreements, collaboration partners pay us annual fees to maintain their exclusive license rights if they are unable to advance product development to specified stages. We earn separate fees for bulk rHuPH20 supplies and research and development services. In addition, the collaboration partner will pay us royalties at an on average mid-single digit percent rate of their sales if products under the collaboration are commercialized. All amounts owed to us are noncancelable after the underlying triggering event occurs, and nonrefundable once paid. Unless terminated earlier in accordance with its terms, the collaboration generally continues in effect until the later of: (i) expiration of the last to expire of the valid claims of our patents covering rHuPH20 or other specified patents developed under the collaboration which valid claim covers a product developed under the collaboration, and (ii) expiration of the last to expire royalty term for a product developed under the collaboration, which is determined separately for each country. In the event such valid claims expire prior to the last to expire royalty term, the royalty rate is reduced for the remaining royalty term following such expiration. The collaboration partner may terminate the agreement prior to expiration for any reason in its entirety or on a target-by-target basis generally upon 90 days prior written notice to us. Upon any such termination, the license granted to the collaboration partner (in total or with respect to the terminated target, as applicable) will terminate provided, however, that in the event of expiration of the agreement, the on-going licenses granted will become perpetual, non-exclusive and fully paid.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Although these agreements are in form structured as collaborative agreements, we concluded for accounting purposes they represent contracts with customers, and are not subject to accounting literature on collaborative arrangements. This is because we grant to collaboration partners licenses to our intellectual property, and provide supply of bulk rHuPH20 and research and development services which are all outputs of our ongoing activities, in exchange for consideration. We do not develop assets jointly with collaboration partners, and do not share in significant risks of their development or commercialization activities. Accordingly, we concluded our collaborative agreements must be accounted for pursuant to ASC Topic 606, Revenue from Contracts with Customers. </span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Under all of our collaborative agreements, we have identified licenses to use functional intellectual property as the only performance obligation. The intellectual property underlying the license is our proprietary ENHANZE® technology which represents application of rHuPH20 to facilitate delivery of drugs or fluids. The license grants the collaboration partners right to use our intellectual property as it exists on the effective date of the license, because there is no ongoing development of the ENHANZE technology required. Therefore, we recognize revenue from licenses at the point when the license becomes effective and the collaboration partner has received access to our intellectual property, usually at the inception of the agreement.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">When collaboration partners can select additional targets to add to the licenses granted, we consider these rights to be options. We evaluate whether such options contain material rights, i.e. have exercise prices that are discounted compared to what we would charge for a similar license to a new collaboration partner. The exercise price of these options includes a combination of the target selection fees, event-based milestone payments and royalties. When these amounts in aggregate are not offered at a discount that exceeds discounts available to other customers, we conclude the option does not contain a material right, and we consider grants of additional licensing rights upon option exercises to be separate contracts (target selection contracts).</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We provide standard indemnification and protection of licensed intellectual property for our customers. These provisions are part of assurance that the licenses meet the agreements’ representations and are not obligations to provide goods or services.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We also fulfill purchase orders for supply of bulk rHuPH20 and perform research and development services pursuant to projects authorization forms for our collaboration partners, which represent separate contracts. Additionally, we price our supply of bulk rHuPH20 and research and development services at our regular selling prices, called standalone selling price or SSP. Therefore, our collaboration partners do not have material rights to order these items at prices not reflective of SSP. Refer to the discussion below regarding recognition of revenue for these separate contracts.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Transaction price for a contract represents the amount to which we are entitled in exchange for providing goods and services to the customer. Transaction price does not include amounts subject to uncertainties unless it is probable that there will be no significant reversal of revenue when the uncertainty is resolved. Apart from the upfront license payment (or target selection fees in the target selection contracts), all other fees we may earn under our collaborative agreements are subject to significant uncertainties of product development. Achievement of many of the event-based development and regulatory milestones may not be probable until such milestones are actually achieved. This generally relates to milestones such as obtaining marketing authorization approvals. </span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">With respect to other development milestones, e.g. dosing of a first patient in a clinical trial, achievement could be considered probable prior to its actual occurrence, based on the progress towards commencement of the trial. We do not include any amounts subject to uncertainties into the transaction price until it is probable that the amount will not result in a significant reversal of revenue in the future. At the end of each reporting period, we re-evaluate the probability of achievement of such milestones and any related constraint, and if necessary, adjust our estimate of the overall transaction price.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">When target exchange rights are held by collaboration partners, and the amounts attributed to these rights are not refundable, they are included in the transaction price. However, they are recorded as deferred revenues because we have a potential performance obligation to provide a new target upon an exchange right being exercised. These amounts are recognized in revenue when the right of exchange expires or is exercised.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Because our agreements have one type of performance obligation (licenses) which are typically all transferred at the same time at agreement inception, allocation of transaction price often is not required. However, allocation is required when licenses for some of the individual targets are subject to rights of exchange, because revenue associated with these targets cannot be recognized. We perform an allocation of the upfront amount based on relative SSP of licenses for individual targets. We determine license SSP using income-based valuation approach utilizing risk-adjusted discounted cash flow projections of the estimated return a licensor would receive. When amounts subject to uncertainties, such as milestones and royalties, are included in the transaction price, we attribute them to the specific individual target licenses which generate such milestone or royalty amounts.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We also estimate SSP of bulk rHuPH20 and research and development services, to determine that our collaboration partners do not have material rights to order them at discounted prices. For supplies of bulk rHuPH20, because we effectively act as a contract manufacturer to our collaboration partners, we estimate and charge SSP based on the typical contract manufacturer margins consistently with all of our collaborative partners. We determine SSP of research and development services based on a fully-burdened labor rate. Our rates are comparable to those we observe in other collaborative agreements. We also have a history of charging similar rates to all of our collaboration partners.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Upfront amounts allocated to licenses to individual targets are recognized as revenue when the license is transferred to the collaboration partner, as discussed above, if the license is not subject to exchange rights, or when the exchange right expires or is exercised. Development milestones and other fees are recognized in revenue when they are included in the transaction price, because by that time we have already transferred the related license to the collaboration partner.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Sales-based milestones and royalties cannot be recognized until the underlying sales occur. We do not receive final royalty reports from our collaboration partners until after we complete our financial statements for a prior quarter. Therefore, we recognize revenue based on estimates of the royalty earned, which are based on preliminary reports provided by our collaboration partners. We will record a true-up in the following quarter if necessary, when final royalty reports are received. To date, we have not recorded any material true-ups.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In contracts to provide research and development services, such services represent the only performance obligation. The fees are charged based on hours worked by our employees and the fixed contractual rate per hour, plus third-party pass-through costs, on a monthly basis. We recognize revenues as the related services are performed based on the amounts billed, as the collaboration partner consumes the benefit of research and development work simultaneously as we perform these services, and the amounts billed reflect the value of these services to the customer.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Refer to Note 4 Revenue, for further discussion on our collaborative arrangements.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prior to the adoption of ASC 606 on January 1, 2018, we recognized upfront amounts received under two of our collaborative agreements straight-line over the contract term in accordance with the accounting standards that were in effect in 2006-2007, when these collaborative agreements were entered into. In addition, we recognized royalty revenue in the period when we received final royalty reports from the collaboration partners, in the quarter following the quarter in which the corresponding sales occurred. There were no other adoption differences in revenue recognized due to the transition from the previously existing authoritative accounting literature to ASC 606.</span></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Product Sales, Net - as reported under ASC 606 beginning January 1, 2018</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Hylenex</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> Recombinant</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We sell Hylenex recombinant in the U.S. to wholesale pharmaceutical distributors, who sell the product to hospitals and other end-user customers. Sales to wholesalers are made pursuant to purchase orders subject to the terms of a master agreement, and delivery of individual packages of Hylenex recombinant represent performance obligations under each purchase order. We use a contract manufacturer to produce Hylenex recombinant and a third-party logistics (3PL) vendor to process and fulfill orders</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">. </span><span style="font-family:inherit;font-size:10pt;">We concluded we are the principal in the sales to wholesalers because we control access to services rendered by both vendors and direct their activities. We have no significant obligations to wholesalers to generate pull-through sales.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Selling prices initially billed to wholesalers are subject to discounts for prompt payment and subsequent chargebacks when wholesalers sell Hylenex recombinant at negotiated discounted prices to members of certain group purchasing organizations (“GPOs”) and government programs. We also pay quarterly distribution fees to certain wholesalers for inventory reporting and chargeback processing, and to GPOs as administrative fees for services and for access to GPO members. We concluded the benefits received in exchange for these fees are not distinct from our sales of Hylenex</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span><span style="font-family:inherit;font-size:10pt;">recombinant, and accordingly we apply these amounts to reduce revenues. Wholesalers also have rights to return unsold product nearing or past the expiration date. Because of the shelf life of Hylenex recombinant and our lengthy return period, there may be a significant period of time between when the product is shipped and when we issue credits on returned product.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We estimate the transaction price when we receive each purchase order taking into account the expected reductions of the selling price initially billed to the wholesaler arising from all of the above factors. We have compiled historical experience and data to estimate future returns and chargebacks of Hylenex recombinant and the impact of the other discounts and fees we pay. When estimating these adjustments to the transaction price, we reduce it sufficiently to be able to assert that it is probable that there will be no significant reversal of revenue when the ultimate adjustment amounts are known.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Each purchase order contains only one type of product, and is usually shipped to the wholesaler in a single shipment. Therefore, allocation of the transaction price to individual packages is not required.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We recognize revenue from Hylenex recombinant product sales and related cost of sales upon product delivery to the wholesaler location. At that time, the wholesalers take control of the product as they take title, bear the risk of loss of ownership, and have an enforceable obligation to pay us. They also have the ability to direct sales of product to their customers on terms and at prices they negotiate. Although wholesalers have product return rights, we do not believe they have a significant incentive to return the product to us.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Upon recognition of revenue from product sales of Hylenex recombinant, the estimated amounts of credit for product returns, chargebacks, distribution fees, prompt payment discounts, and GPO fees are included in sales reserves, accrued liabilities and net of accounts receivable. We monitor actual product returns, chargebacks, discounts and fees subsequent to the sale. If these amounts differ from our estimates, we make adjustments to these allowances, which are applied to increase or reduce product sales revenue and earnings in the period of adjustment.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In connection with the orders placed by wholesalers, we incur costs such as commissions to our sales representatives. However, as revenue from product sales is recognized upon delivery to the wholesaler, which occurs shortly after we receive a purchase order, we do not capitalize these commissions and other costs, based on application of the practical expedient allowed within the applicable guidance.</span></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Bulk rHuPH20</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We sell bulk rHuPH20 to collaboration partners for use in research and development; subsequent to receiving marketing approval, we sell it for use in collaboration commercial products. Sales are made pursuant to purchase orders subject to the terms of the collaborative agreement, and delivery of units of bulk rHuPH20 represent performance obligations under each purchase order. We provide a standard warranty that the product conforms to specifications. We use contract manufacturers to produce bulk rHuPH20 and have concluded we are the principal in the sales to collaboration partners. The transaction price for each purchase order of bulk rHuPH20 is fixed based on the cost of production plus a contractual markup, and is not subject to adjustments. Allocation of the transaction price to individual quantities of the product is usually not required because each order contains only one type of product.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We recognize revenue from the sale of bulk rHuPH20 as product sales and related cost of sales upon transfer of title to our partners. At that time, the partners take control of the product, bear the risk of loss of ownership, and have an enforceable obligation to pay us.</span></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">ENHANZE Drug Product</span><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We sell ENHANZE drug product to collaboration partners for use in research and development in early phase clinical studies. Sales are made pursuant to purchase orders subject to the terms of the collaborative agreement, and delivery of units of ENHANZE drug product represent performance obligations under each purchase order. We provide a standard warranty that the product conforms to specifications. We use contract manufacturers to produce ENHANZE drug product and we concluded we are the principal in the sales to collaboration partners. The transaction price for each purchase order of ENHANZE drug product is fixed based on the cost of production plus a contractual markup, and is not subject to adjustments. Allocation of the transaction price to individual quantities of the product is usually not required because each order contains only one type of product.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We recognize revenue from the sale of ENHANZE drug product as product sales and related cost of sales upon transfer of title to our partners. At that time, the partners take control of the product, bear the risk of loss of ownership, and have an enforceable obligation to pay us.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue Presentation</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In our statements of operations, we report as revenues under collaborative agreements the upfront payments, event-based development and regulatory milestones and sales milestones. We also include in this category revenues from separate research and development contracts pursuant to project authorization forms. We report royalties received from collaboration partners as a separate line in our statements of operations.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenues from sales of Hylenex recombinant, bulk rHuPH20 that has alternative future use and ENHANZE drug product are included in product sales, net.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In the footnotes to our financial statements, we provide disaggregated revenue information by type of arrangement (product sales, net, collaborative agreements and research and development services), and additionally, by type of payment stream received under collaborative agreements (upfront license fees, event-based development and regulatory milestones and other fees, sales milestones and royalties).</span></div> <div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cost of Product Sales</span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of product sales consists primarily of raw materials, third-party manufacturing costs, fill and finish costs, freight costs, internal costs and manufacturing overhead associated with the production of Hylenex recombinant and bulk rHuPH20 and ENHANZE drug product that has alternative future use. Cost of product sales also consists of the write-down of excess, dated and obsolete inventories and the write-off of inventories that do not meet certain product specifications, if any. Prior to bulk rHuPH20 and ENHANZE drug product having alternative future use, all costs related to the manufacturing of those products were charged to research and development expenses in the periods such costs were incurred. During the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, sales of bulk rHuPH20 and ENHANZE drug product included </span><span style="font-family:inherit;font-size:10pt;"><span>$1.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> of cost of sales that were previously expensed as research and development. Of the bulk rHuPH20 and ENHANZE drug product that has alternative future use on hand as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$0.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> in manufacturing costs were previously recorded as research and development expenses. We expect to sell this inventory by the end of 2020.</span></div> 1500000 100000 <div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Research and Development Expenses</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development expenses include salaries and benefits, facilities and other overhead expenses, external clinical trial expenses, research related manufacturing services, contract services and other outside expenses. Research and development expenses are charged to operating expenses as incurred when these expenditures relate to our research and development efforts and have no alternative future uses.</span><span style="font-family:inherit;font-size:8pt;"> </span><span style="font-family:inherit;font-size:10pt;">When bulk rHuPH20 is manufactured for use in research and development by us or our partners and the product cannot be redirected for alternative use due to formulation and manufacturing specifications, the manufacturing costs are recorded as research and development expense. Bulk rHuPH20 that is manufactured for partner use prior to our partner receiving marketing approval from the FDA or comparable regulatory agencies in foreign countries and meet these specifications is recorded as research and development expenses. Bulk rHuPH20 formulations manufactured for general partner and internal use, which can potentially be used by any collaboration partner or by us in Hylenex, is considered to have alternative future use and all manufacturing costs are capitalized as inventory. Inventories used in our clinical trials were expensed at the time the inventories were packaged for the clinical trials.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are obligated to make upfront payments upon execution of certain research and development agreements. Advance payments, including nonrefundable amounts, for goods or services that will be used or rendered for future research and development activities are deferred. Such amounts are recognized as expense as the related goods are delivered or the related services are performed or such time when we do not expect the goods to be delivered or services to be performed.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Milestone payments that we make in connection with in-licensed technology for a particular research and development project that have no alternative future uses (in other research and development projects or otherwise) and therefore no separate economic value are expensed as research and development costs at the time the costs are incurred. We currently have </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;"> in-licensed technologies that have alternative future uses in research and development projects or otherwise.</span></div> 0 <div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Clinical Trial Expenses</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We make payments in connection with our clinical trials under contracts with contract research organizations that support conducting and managing clinical trials. The financial terms of these agreements are subject to negotiation and vary from contract to contract and may result in uneven payment flows. Generally, these agreements set forth the scope of work to be performed at a fixed fee, unit price or on a time and materials basis. A portion of our obligation to make payments under these contracts depends on factors such as the successful enrollment or treatment of patients or the completion of other clinical trial milestones. </span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expenses related to clinical trials are accrued based on our estimates and/or representations from service providers regarding work performed, including actual level of patient enrollment, completion of patient studies and progress of the clinical trials. Other incidental costs related to patient enrollment or treatment are accrued when reasonably certain. If the amounts we are obligated to pay under our clinical trial agreements are modified (for instance, as a result of changes in the clinical trial protocol or scope of work to be performed), we adjust our accruals accordingly on a prospective basis. Revisions to our contractual payment obligations are charged to expense in the period in which the facts that give rise to the revision become reasonably certain. </span></div> <div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Share-Based Compensation</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We record compensation expense associated with stock options, restricted stock awards (“RSAs”), and restricted stock units (“RSUs”) in accordance with the authoritative guidance for stock-based compensation. The cost of employee services received in exchange for an award of an equity instrument is measured at the grant date, based on the estimated fair value of the award, and is recognized as expense on a straight-line basis over the requisite service period of the award. Share-based compensation expense for an award with a performance condition is recognized when the achievement of such performance condition is determined to be probable. If the outcome of such performance condition is not determined to be probable or is not met, no compensation expense is recognized and any previously recognized compensation expense is reversed. Forfeitures are recognized as a reduction of share-based compensation expense as they occur.</span></div> <div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Income Taxes </span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We provide for income taxes using the liability method. Under this method, deferred income tax assets and liabilities are determined based on the differences between the financial statement carrying amounts of existing assets and liabilities at each year end and their respective tax bases and are measured using enacted tax rates in effect for the year in which the differences are expected to affect taxable income. Significant judgment is required by management to determine our provision for income taxes, our deferred tax assets and liabilities, and the valuation allowance to record against our net deferred tax assets, which are based on complex and evolving tax regulations throughout the world. Deferred tax assets and other tax benefits are recorded when it is more likely than not that the position will be sustained upon audit. While we have begun to utilize certain of our net operating losses, we have not yet established a track record of profitability. Accordingly, valuation allowances have been recorded to reduce our net deferred tax assets to </span><span style="font-family:inherit;font-size:10pt;"><span>zero</span></span><span style="font-family:inherit;font-size:10pt;">, with the exception of the alternative minimum tax ("AMT") credit carryover of </span><span style="font-family:inherit;font-size:10pt;"><span>$1.7 million</span></span><span style="font-family:inherit;font-size:10pt;">. Under the Tax Cuts and Jobs Act (the “Act”) enacted in December 2017, the AMT credit carryover will either be utilized, or if unutilized fully refunded in 2022. For all other deferred tax assets, the valuation allowance will reduce the net value to </span><span style="font-family:inherit;font-size:10pt;"><span>zero</span></span><span style="font-family:inherit;font-size:10pt;"> until such time as we can demonstrate an ability to realize them.</span></div> 0 1700000 0 <div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Net (Loss) Income Per Share</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic net (loss) income per common share is computed by dividing net (loss) income for the period by the weighted average number of common shares outstanding during the period, without consideration for common stock equivalents. Outstanding stock options, unvested RSAs, unvested RSUs and the Convertible Notes are considered common stock equivalents and are only included in the calculation of diluted earnings per common share when net income is reported and their effect is dilutive. For the years ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019, 2018 and 2017</span><span style="font-family:inherit;font-size:10pt;">, approximately </span><span style="font-family:inherit;font-size:10pt;"><span>33.1 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>13.8 million</span></span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;"><span>7.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> shares, respectively, of outstanding stock options, unvested RSAs, unvested RSUs and Convertible Notes were excluded from the calculation of diluted net (loss) income per common share because their effect was anti-dilutive.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The </span><span style="font-family:inherit;font-size:10pt;"><span>19.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> shares underlying the conversion option of the Convertible Notes will not have an impact on our diluted earnings per share when net income is reported until the average market price of our common stock exceeds the conversion price of </span><span style="font-family:inherit;font-size:10pt;"><span>$23.85</span></span><span style="font-family:inherit;font-size:10pt;"> per share, as we intend and have the ability to settle the principal amount of the Convertible Notes in cash upon conversion. We compute the potentially dilutive impact of the shares of common stock related to the Convertible Notes using the treasury stock method.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> A reconciliation of the numerators and the denominators of the basic and diluted net (loss) income per common share computations is as follows (in thousands, except per share amounts):</span></div> 33100000 13800000 7100000 19300000 23.85 reconciliation of the numerators and the denominators of the basic and diluted net (loss) income per common share computations is as follows (in thousands, except per share amounts):<div style="line-height:120%;padding-top:8px;text-align:center;text-indent:32px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.32163742690058%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:67%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Numerator:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net (loss) income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(72,240</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(80,330</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>62,971</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Denominator:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average common shares outstanding for basic<br/> net (loss) income per share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>144,329</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>143,599</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>136,419</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net effect of dilutive common stock equivalents</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,649</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average common shares outstanding for diluted <br/> net (loss) income per share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>144,329</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>143,599</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>139,068</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net (loss) income per share:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.50</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.56</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.46</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Diluted</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.50</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.56</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.45</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span style="font-family:inherit;font-size:10pt;"> </span> -72240000 -80330000 62971000 144329000 143599000 136419000 0 0 2649000 144329000 143599000 139068000 -0.50 -0.56 0.46 -0.50 -0.56 0.45 <span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Segment Information</span><span style="font-family:inherit;font-size:10pt;">We operate our business in </span><span style="font-family:inherit;font-size:10pt;"><span>one</span></span> segment, which includes all activities related to the research, development and commercialization of our proprietary enzymes. This segment also includes revenues and expenses related to (i) research and development and bulk rHuPH20 manufacturing activities conducted under our collaborative agreements with third parties and (ii) product sales of Hylenex recombinant. The chief operating decision-maker reviews the operating results on an aggregate basis and manages the operations as a single operating segment. 1 <div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Adoption and Pending Adoption of Recent Accounting Pronouncements</span></div><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides a brief description of recently issued accounting standards, those adopted in the current period and those not yet adopted:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:20%;"/><td style="width:1%;"/><td style="width:39%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:24%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Standard</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Description</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Effective Date</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Effect on the Financial </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Statements or Other Significant Matters</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). In July 2018, the FASB issued additional guidance related to Topic 842.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The new guidance requires lessees to recognize assets and liabilities for most leases and provides enhanced disclosures.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">January 1, 2019 </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We implemented the guidance on January 1, 2019 using a modified retrospective transition basis for leases existing as of the period of adoption. In order to adopt the new standard, we used the available practical expedients and newly implemented processes and internal controls for lease accounting. The practical expedients allowed us to carry forward our historical assessment of whether existing agreements are or contain a lease and the classification of our existing lease arrangements. All of our real-estate and automobile operating lease commitments are recognized as lease liabilities with corresponding right-of-use assets, which resulted in an increase in the assets and liabilities of the consolidated balance sheet of $7.2 million, using an assumed weighted average discount rate of 10.0%. The adoption did not have an impact on our consolidated statements of operations and did not require recognition of a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. We elected to continue applying the guidance under ASC 840 for comparative periods, as allowed through ASC 2018-11.</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:20%;"/><td style="width:1%;"/><td style="width:39%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:24%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Standard</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Description</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Effective Date</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Effect on the Financial </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Statements or Other Significant Matters</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In December 2019, the FASB issued ASU 2019-12, Simplifying the Accounting for Income Taxes</span></div><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The new guidance removes certain exceptions to the general principles of ASC 740 in order to simplify the complexities of its application. These changes include eliminations to the exceptions for intraperiod tax allocation, recognizing deferred tax liabilities related to outside basis differences, and year-to-date losses in interim periods among others. </span></div><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">January 1, 2019</span></div><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We early adopted the new guidance on January 1, 2019. With the adoption we no longer apply the exception to the general rule for intraperiod tax allocations under the incremental method. During the period, we would have recorded a $14.7 million tax expense to APIC fully offset by a $14.7 million tax benefit in continuing operations. </span></div><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In August 2018, the FASB issued ASU 2018-15, Intangibles-Goodwill and other Internal-Use Software (Subtopic 350-40)</span></div><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The new guidance aligns the requirement for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirement for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license).</span></div><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">January 1, 2020</span></div><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We plan to adopt the new guidance on January 1, 2020. We do not anticipate the adoption will have a material impact on our condensed consolidated financial position or results of operations.</span></div><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820).</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The new guidance removes, modifies and adds to certain disclosure requirements on fair value measurements in Topic 820, Fair Value Measurement.</span></div><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">January 1, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We plan to adopt the new guidance on January 1, 2020. We do not anticipate the adoption will have a material impact on our consolidated financial position or results of operations.</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326), Measurement of Credit Losses on Financial Instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The standard amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses for most financial assets and certain other instruments that aren’t measured at fair value through net income. For available-for-sale debt securities, entities will be required to recognize an allowance for credit losses rather than a reduction in carrying value of the asset. Entities will no longer be permitted to consider the length of time that fair value has been less than amortized cost when evaluating when credit losses should be recognized.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">January 1, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We plan to adopt the new guidance on January 1, 2020. We do not anticipate the adoption will have a material impact on our consolidated financial position or results of operations.</span></div><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> Fair Value Measurement<div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Available-for-sale marketable securities consisted of the following (in thousands):</span></div><div style="line-height:120%;padding-top:8px;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.51656920077973%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:52%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortized Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross Unrealized Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross Unrealized Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Estimated Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Asset-backed securities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30,484</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>55</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30,539</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>161,308</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>178</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(14</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>161,472</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. Treasury securities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>75,192</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>40</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>75,227</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Commercial paper</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>33,845</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>33,845</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>300,829</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>273</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(19</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>301,083</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.51656920077973%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:52%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortized Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross Unrealized Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross Unrealized Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Estimated Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Asset-backed securities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>39,787</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(40</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>39,747</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>57,860</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(127</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>57,733</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. Treasury securities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>84,924</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(87</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>84,837</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Commercial paper</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>114,273</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>114,273</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>296,844</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(254</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>296,590</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>11</span></span><span style="font-family:inherit;font-size:10pt;"> available-for-sale marketable securities with a fair market value of </span><span style="font-family:inherit;font-size:10pt;"><span>$82.9 million</span></span><span style="font-family:inherit;font-size:10pt;"> were in a gross unrealized loss position of </span><span style="font-family:inherit;font-size:10pt;"><span>$19 thousand</span></span><span style="font-family:inherit;font-size:10pt;">, all of which had been in such position for less than 12 months. Based on our review of these marketable securities, we believe we had </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;"> other-than-temporary impairments on these securities as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, because we do not intend to sell these securities and it is not more-likely-than-not that we will be required to sell these securities before the recovery of their amortized cost basis.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contractual maturities of available-for-sale debt securities are as follows (in thousands):</span></div><div style="line-height:120%;padding-top:8px;text-align:center;padding-left:0px;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.51656920077973%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:68%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Estimated Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Due within one year</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>274,805</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>296,590</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">After one but within five years</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26,278</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>301,083</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>296,590</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes, by major security type, our cash equivalents and available-for-sale marketable securities that are measured at fair value on a recurring basis and are categorized using the fair value hierarchy (in thousands):</span></div><div style="line-height:120%;padding-top:8px;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.51656920077973%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"/></tr><tr><td style="width:32%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:3%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total estimated fair value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total estimated fair value</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash equivalents:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Money market funds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>119,949</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>119,949</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>57,987</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>57,987</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Available-for-sale marketable </span></div><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">   securities:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Asset-backed securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30,539</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30,539</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>39,747</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>39,747</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate debt securities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>161,472</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>161,472</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>57,733</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>57,733</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. Treasury securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>75,228</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>75,228</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>84,837</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>84,837</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Commercial paper</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>33,845</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>33,845</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>114,273</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>114,273</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>195,177</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>225,856</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>421,033</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>142,824</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>211,753</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>354,577</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">There were </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;"> transfers between Level 1 and Level 2 of the fair value hierarchy during the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">. We had </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;"> instruments that were classified within Level 3 as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019 and 2018</span><span style="font-family:inherit;font-size:10pt;">.</span></div> <div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Available-for-sale marketable securities consisted of the following (in thousands):</span></div><div style="line-height:120%;padding-top:8px;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.51656920077973%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:52%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortized Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross Unrealized Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross Unrealized Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Estimated Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Asset-backed securities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30,484</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>55</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30,539</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>161,308</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>178</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(14</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>161,472</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. Treasury securities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>75,192</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>40</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>75,227</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Commercial paper</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>33,845</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>33,845</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>300,829</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>273</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(19</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>301,083</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.51656920077973%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:52%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortized Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross Unrealized Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross Unrealized Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Estimated Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Asset-backed securities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>39,787</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(40</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>39,747</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>57,860</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(127</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>57,733</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. Treasury securities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>84,924</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(87</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>84,837</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Commercial paper</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>114,273</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>114,273</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>296,844</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(254</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>296,590</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 30484000 55000 0 30539000 161308000 178000 14000 161472000 75192000 40000 5000 75227000 33845000 0 0 33845000 300829000 273000 19000 301083000 39787000 0 40000 39747000 57860000 0 127000 57733000 84924000 0 87000 84837000 114273000 0 0 114273000 296844000 0 254000 296590000 11 82900000 19000 0 <div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contractual maturities of available-for-sale debt securities are as follows (in thousands):</span></div><div style="line-height:120%;padding-top:8px;text-align:center;padding-left:0px;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.51656920077973%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:68%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Estimated Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Due within one year</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>274,805</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>296,590</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">After one but within five years</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26,278</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>301,083</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>296,590</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 274805000 296590000 26278000 0 301083000 296590000 <div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes, by major security type, our cash equivalents and available-for-sale marketable securities that are measured at fair value on a recurring basis and are categorized using the fair value hierarchy (in thousands):</span></div><div style="line-height:120%;padding-top:8px;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.51656920077973%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"/></tr><tr><td style="width:32%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:3%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total estimated fair value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total estimated fair value</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash equivalents:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Money market funds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>119,949</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>119,949</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>57,987</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>57,987</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Available-for-sale marketable </span></div><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">   securities:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Asset-backed securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30,539</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30,539</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>39,747</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>39,747</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate debt securities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>161,472</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>161,472</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>57,733</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>57,733</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. Treasury securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>75,228</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>75,228</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>84,837</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>84,837</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Commercial paper</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>33,845</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>33,845</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>114,273</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>114,273</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>195,177</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>225,856</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>421,033</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>142,824</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>211,753</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>354,577</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 119949000 0 119949000 57987000 0 57987000 0 30539000 30539000 0 39747000 39747000 0 161472000 161472000 0 57733000 57733000 75228000 0 75228000 84837000 0 84837000 0 33845000 33845000 0 114273000 114273000 195177000 225856000 421033000 142824000 211753000 354577000 0 0 Revenue<div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our disaggregated revenues were as follows (in thousands):</span></div><div style="line-height:120%;padding-top:8px;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.51656920077973%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:70%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Royalties</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>69,899</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>78,981</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>63,507</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Product sales, net</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">  Sales of bulk rHuPH20</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>48,285</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,729</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>35,246</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">  Sales of ENHANZE drug product</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>768</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>460</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">  Sales of Hylenex</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,995</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15,045</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15,150</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total product sales, net</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>66,048</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28,234</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>50,396</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenues under collaborative agreements:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">  Upfront license and target nomination fees</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>53,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26,336</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>172,806</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">  Event-based development milestones and regulatory milestone and other fees</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,500</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,317</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">  Sales-based milestones</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,417</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">  Research and development services</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,545</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,311</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,170</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total revenues under collaborative agreements</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>60,045</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>44,647</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>202,710</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>195,992</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>151,862</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>316,613</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> we recognized revenue related to licenses granted to collaboration partners in prior periods in the amount of </span><span style="font-family:inherit;font-size:10pt;"><span>$74.9 million</span></span><span style="font-family:inherit;font-size:10pt;">. This amount represents royalties earned in the current period, in addition to </span><span style="font-family:inherit;font-size:10pt;"><span>$5.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> of variable consideration in the contracts where uncertainties have been resolved and the development milestones were expected to be achieved or were achieved. We also recognized revenue of </span><span style="font-family:inherit;font-size:10pt;"><span>$4.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> during the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> that had been included in deferred revenues at </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">. We did not recognize any adjustments to reduce sales reserves and allowances liability related to Hylenex recombinant sales in prior periods.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenue recognized during the year ended December 31, 2017 was determined in accordance with the accounting rules applicable prior to the adoption of ASC 606 on January 1, 2018. </span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Upon the adoption of ASC 606, we recognized an adjustment to increase our accounts receivable by </span><span style="font-family:inherit;font-size:10pt;"><span>$19.4 million</span></span><span style="font-family:inherit;font-size:10pt;">, decrease deferred revenues by </span><span style="font-family:inherit;font-size:10pt;"><span>$51.8 million</span></span><span style="font-family:inherit;font-size:10pt;">, and decrease accumulated deficit by </span><span style="font-family:inherit;font-size:10pt;"><span>$71.2 million</span></span><span style="font-family:inherit;font-size:10pt;">. The impact of applying the provisions of ASC 606 in the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;"> was to decrease revenues by </span><span style="font-family:inherit;font-size:10pt;"><span>$4.7 million</span></span><span style="font-family:inherit;font-size:10pt;">. Under the previously existing authoritative accounting literature, at </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;"> our accounts receivable, net would have been </span><span style="font-family:inherit;font-size:10pt;"><span>$19.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> lower, and our deferred revenue </span><span style="font-family:inherit;font-size:10pt;"><span>$47.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> higher, than the amounts reported in our consolidated balance sheet. ASC 606 did not have an aggregate impact on our net cash used in operating activities, but resulted in offsetting changes in net loss and certain assets and liabilities within net cash used in operating activities in the consolidated statement of cash flows. </span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts receivable, net and deferred revenues (contract liabilities) from contracts with customers, including collaboration partners, consisted of the following (in thousands):</span></div><div style="line-height:120%;padding-top:8px;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.51656920077973%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:78%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts receivable, net</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>59,442</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30,005</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,259</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,255</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the amounts included in the transaction price of our contracts with customers, including collaboration partners, and allocated to goods and services not yet provided were </span><span style="font-family:inherit;font-size:10pt;"><span>$12.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> of which </span><span style="font-family:inherit;font-size:10pt;"><span>$7.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> relates to unfulfilled product purchase orders and </span><span style="font-family:inherit;font-size:10pt;"><span>$5.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> has been collected and reported as deferred revenues. The unfulfilled product purchase orders are estimated to be delivered in 2020. Of the total deferred revenues of </span><span style="font-family:inherit;font-size:10pt;"><span>$5.3 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$4.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> is expected to be used by our customers within the next 12 months.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">There were </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;"> contract assets related to collaborative agreements at </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">. While we may become entitled to receive additional event-based development and regulatory milestones and other fees under our collaborative agreements, which relate to intellectual property licenses granted to collaboration partners in prior periods, no amounts were probable. The following table presents amounts under our collaborative agreements included in the transaction price (i.e. cumulative amounts triggered or probable) as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> (in thousands):</span></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:84.7953216374269%;border-collapse:collapse;text-align:left;"><tr><td colspan="18"/></tr><tr><td style="width:43%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Upfront</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Development</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(2)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Sales</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(3)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Collaboration partner and agreement date:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Roche (December 2006, September 2017 and October 2018)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>105,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>157,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Baxalta (September 2007)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pfizer (December 2012)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14,500</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,500</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Janssen (December 2014)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18,250</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>33,250</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">AbbVie (June 2015)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>29,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Lilly (December 2015)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>33,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>33,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">BMS (September 2017)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>105,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>110,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Alexion (December 2017)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>40,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>46,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">argenx (February 2019)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>40,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>45,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Royalties</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>323,285</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total amounts under our collaborative agreements included in the transaction price</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>815,035</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:inherit;font-size:10pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Upfront and additional target selection fees</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:inherit;font-size:10pt;">(2)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Event-based development and regulatory milestone amounts and other fees</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:inherit;font-size:10pt;">(3)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Sales-based milestone amounts</span></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Through </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, our collaboration partners have completed development, obtained marketing authorization approvals for certain indications and commenced commercialization of the following products:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Roche, for Herceptin SC in the European Union (“EU”) in August 2013; and MabThera SC in the EU in March 2014 and its equivalent RITUXAN HYCELA™ in the US in June 2017; Herceptin SC in Canada in September 2018; and Herceptin Hylecta in the US in February 2019.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Baxalta, for HYQVIA in the EU and in the US in May 2013.</span></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The remaining targets and products are currently in the process of development by the collaboration partners.</span></div> <div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our disaggregated revenues were as follows (in thousands):</span></div><div style="line-height:120%;padding-top:8px;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.51656920077973%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:70%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Royalties</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>69,899</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>78,981</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>63,507</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Product sales, net</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">  Sales of bulk rHuPH20</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>48,285</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,729</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>35,246</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">  Sales of ENHANZE drug product</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>768</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>460</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">  Sales of Hylenex</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,995</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15,045</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15,150</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total product sales, net</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>66,048</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28,234</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>50,396</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenues under collaborative agreements:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">  Upfront license and target nomination fees</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>53,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26,336</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>172,806</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">  Event-based development milestones and regulatory milestone and other fees</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,500</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,317</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">  Sales-based milestones</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,417</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">  Research and development services</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,545</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,311</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,170</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total revenues under collaborative agreements</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>60,045</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>44,647</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>202,710</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>195,992</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>151,862</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>316,613</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 69899000 78981000 63507000 48285000 12729000 35246000 768000 460000 0 16995000 15045000 15150000 66048000 28234000 50396000 53000000 26336000 172806000 5500000 16000000 16317000 0 0 1417000 1545000 2311000 12170000 60045000 44647000 202710000 195992000 151862000 316613000 74900000 5000000.0 4000000.0 19400000 51800000 71200000 4700000 19300000 -47400000 <div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts receivable, net and deferred revenues (contract liabilities) from contracts with customers, including collaboration partners, consisted of the following (in thousands):</span></div><div style="line-height:120%;padding-top:8px;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.51656920077973%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:78%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts receivable, net</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>59,442</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30,005</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,259</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,255</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 59442000 30005000 5259000 9255000 12300000 7000000.0 5300000 5300000 4000000.0 <div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">There were </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;"> contract assets related to collaborative agreements at </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">. While we may become entitled to receive additional event-based development and regulatory milestones and other fees under our collaborative agreements, which relate to intellectual property licenses granted to collaboration partners in prior periods, no amounts were probable. The following table presents amounts under our collaborative agreements included in the transaction price (i.e. cumulative amounts triggered or probable) as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> (in thousands):</span></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:84.7953216374269%;border-collapse:collapse;text-align:left;"><tr><td colspan="18"/></tr><tr><td style="width:43%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Upfront</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Development</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(2)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Sales</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(3)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Collaboration partner and agreement date:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Roche (December 2006, September 2017 and October 2018)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>105,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>157,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Baxalta (September 2007)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pfizer (December 2012)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14,500</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,500</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Janssen (December 2014)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18,250</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>33,250</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">AbbVie (June 2015)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>29,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Lilly (December 2015)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>33,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>33,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">BMS (September 2017)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>105,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>110,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Alexion (December 2017)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>40,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>46,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">argenx (February 2019)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>40,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>45,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Royalties</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>323,285</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total amounts under our collaborative agreements included in the transaction price</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>815,035</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:inherit;font-size:10pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Upfront and additional target selection fees</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:inherit;font-size:10pt;">(2)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Event-based development and regulatory milestone amounts and other fees</span></div></td></tr></table><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:inherit;font-size:10pt;">(3)</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Sales-based milestone amounts</span></div> 0 105000000 30000000 22000000 157000000 10000000 3000000 9000000 22000000 14500000 2000000 16500000 18250000 15000000 33250000 23000000 6000000 29000000 33000000 33000000 105000000 5000000 110000000 40000000 6000000 46000000 40000000 5000000 45000000 323285000 815035000 Certain Balance Sheet Items<div style="line-height:120%;padding-top:16px;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts receivable, net consisted of the following (in thousands):</span></div><div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.12670565302143%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:70%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:3%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, <br/>2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts receivable from product sales to collaborators</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>35,649</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,717</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts receivable from revenues under collaborative agreements</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,850</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,499</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts receivable from royalty payments</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17,149</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19,199</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts receivable from other product sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,591</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,182</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">     Subtotal</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>60,239</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30,597</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Allowance for distribution fees and discounts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(797</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(592</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">     Total accounts receivable, net</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>59,442</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30,005</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:16px;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inventories consisted of the following (in thousands):</span></div><div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.12670565302143%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:70%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:3%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, <br/>2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Raw materials</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,769</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>735</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Work-in-process</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15,710</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,430</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finished goods</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,880</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,460</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">     Total inventories</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>29,359</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22,625</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:16px;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prepaid expenses and other assets consisted of the following (in thousands):</span></div><div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.12670565302143%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:70%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:3%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, <br/>2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prepaid manufacturing expenses</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30,156</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,230</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prepaid research and development expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,964</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,922</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other prepaid expenses</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,655</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,513</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,681</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,462</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">     Total prepaid expenses and other assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>44,456</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25,127</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less long-term portion</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,083</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,434</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">     Total prepaid expenses and other assets, current</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>33,373</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20,693</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prepaid manufacturing expenses include raw materials, slot reservation fees and other amounts paid to contract manufacturing organizations. Such amounts are reclassified to work-in-process inventory as materials are used or the CMO services are complete.</span></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property and equipment, net consisted of the following (in thousands):</span></div><div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.12670565302143%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:70%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:3%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, <br/>2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research equipment</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,403</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,945</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Manufacturing equipment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,858</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,979</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Computer and office equipment</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,859</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,211</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Leasehold improvements</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,628</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,569</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">     Subtotal</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17,748</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23,704</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accumulated depreciation and amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(10,742</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(16,239</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Subtotal</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,006</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,465</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Right of use of assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,849</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">     Property and equipment, net</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,855</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,465</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:9pt;"> </span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Depreciation and amortization expense was approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$4.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> , </span><span style="font-family:inherit;font-size:10pt;"><span>$2.4 million</span></span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;"><span>$2.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> for the years ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019, 2018 and 2017</span><span style="font-family:inherit;font-size:10pt;">, respectively. The depreciation and amortization expense for the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> is inclusive of </span><span style="font-family:inherit;font-size:10pt;"><span>$1.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> ROU asset amortization. As discussed in Note 9, we have recorded a ROU impairment charge of </span><span style="font-family:inherit;font-size:10pt;"><span>$1.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> as a result of the organizational restructuring. We also recorded an impairment charge of </span><span style="font-family:inherit;font-size:10pt;"><span>$1.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> related to property and equipment as a result of the organizational restructuring (Refer to Note 13 for further details on the organizational restructuring).</span></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued expenses consisted of the following (in thousands):</span></div><div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.12670565302143%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:70%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:3%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, <br/>2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued outsourced research and development expenses</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,423</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21,921</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued compensation and payroll taxes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27,888</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,604</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued outsourced manufacturing expenses</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,173</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,975</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other accrued expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,876</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,623</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Lease liability</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,469</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">     Total accrued expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>59,829</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>50,123</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less long-term portion</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,180</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>594</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">     Total accrued expenses, current</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>55,649</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>49,529</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expense associated with the accretion of the lease liabilities was approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$0.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>zero</span></span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">twelve</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, respectively. Total lease expense for the </span><span style="font-family:inherit;font-size:10pt;">twelve</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;"><span>$2.6 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$2.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> respectively. </span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash paid for amounts related to leases for the </span><span style="font-family:inherit;font-size:10pt;">twelve</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> was </span><span style="font-family:inherit;font-size:10pt;"><span>$3.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$2.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> respectively.</span></div><div style="line-height:120%;padding-top:16px;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred revenue consisted of the following (in thousands):</span></div><div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.12670565302143%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:70%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:3%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, <br/>2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Collaborative agreements</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">License fees and event-based payments:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,764</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,264</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Product sales</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,495</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,991</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total deferred revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,259</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,255</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less current portion</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,012</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,247</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred revenue, net of current portion</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,247</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,008</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> <div style="line-height:120%;padding-top:16px;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts receivable, net consisted of the following (in thousands):</span></div><div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.12670565302143%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:70%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:3%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, <br/>2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts receivable from product sales to collaborators</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>35,649</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,717</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts receivable from revenues under collaborative agreements</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,850</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,499</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts receivable from royalty payments</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17,149</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19,199</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts receivable from other product sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,591</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,182</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">     Subtotal</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>60,239</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30,597</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Allowance for distribution fees and discounts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(797</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(592</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">     Total accounts receivable, net</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>59,442</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30,005</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 35649000 3717000 3850000 5499000 17149000 19199000 3591000 2182000 60239000 30597000 797000 592000 59442000 30005000 <div style="line-height:120%;padding-top:16px;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inventories consisted of the following (in thousands):</span></div><div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.12670565302143%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:70%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:3%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, <br/>2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Raw materials</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,769</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>735</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Work-in-process</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15,710</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,430</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finished goods</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,880</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,460</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">     Total inventories</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>29,359</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22,625</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 2769000 735000 15710000 11430000 10880000 10460000 29359000 22625000 <div style="line-height:120%;padding-top:16px;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prepaid expenses and other assets consisted of the following (in thousands):</span></div><div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.12670565302143%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:70%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:3%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, <br/>2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prepaid manufacturing expenses</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30,156</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,230</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prepaid research and development expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,964</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,922</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other prepaid expenses</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,655</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,513</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,681</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,462</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">     Total prepaid expenses and other assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>44,456</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25,127</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less long-term portion</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,083</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,434</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">     Total prepaid expenses and other assets, current</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>33,373</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20,693</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 30156000 8230000 4964000 7922000 3655000 2513000 5681000 6462000 44456000 25127000 11083000 4434000 33373000 20693000 <div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property and equipment, net consisted of the following (in thousands):</span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.12670565302143%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:70%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:3%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, <br/>2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research equipment</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,403</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,945</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Manufacturing equipment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,858</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,979</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Computer and office equipment</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,859</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,211</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Leasehold improvements</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,628</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,569</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">     Subtotal</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17,748</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23,704</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accumulated depreciation and amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(10,742</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(16,239</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Subtotal</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,006</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,465</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Right of use of assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,849</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">     Property and equipment, net</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,855</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,465</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 7403000 9945000 3858000 3979000 4859000 5211000 1628000 4569000 17748000 23704000 10742000 16239000 7006000 7465000 3849000 0 10855000 7465000 4100000 2400000 2200000 1800000 1100000 -1400000 <div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued expenses consisted of the following (in thousands):</span></div><div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.12670565302143%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:70%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:3%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, <br/>2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued outsourced research and development expenses</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,423</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21,921</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued compensation and payroll taxes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27,888</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,604</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued outsourced manufacturing expenses</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,173</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,975</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other accrued expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,876</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,623</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Lease liability</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,469</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">     Total accrued expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>59,829</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>50,123</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less long-term portion</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,180</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>594</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">     Total accrued expenses, current</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>55,649</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>49,529</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 8423000 21921000 27888000 16604000 9173000 3975000 7876000 7623000 6469000 0 59829000 50123000 4180000 594000 55649000 49529000 800000 0 2600000 2400000 3100000 2400000 <div style="line-height:120%;padding-top:16px;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred revenue consisted of the following (in thousands):</span></div><div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.12670565302143%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:70%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:3%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, <br/>2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Collaborative agreements</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">License fees and event-based payments:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,764</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,264</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Product sales</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,495</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,991</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total deferred revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,259</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,255</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less current portion</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,012</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,247</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred revenue, net of current portion</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,247</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,008</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 2764000 2264000 2495000 6991000 5259000 9255000 4012000 4247000 1247000 5008000 Long-Term Debt, Net<div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Convertible Notes</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In November 2019, we completed the sale of </span><span style="font-family:inherit;font-size:10pt;"><span>$460.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> in aggregate principal amount of </span><span style="font-family:inherit;font-size:10pt;"><span>1.25%</span></span><span style="font-family:inherit;font-size:10pt;"> Convertible Senior Notes due 2024 (“Convertible Notes”) in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (“Securities Act”). The Convertible Notes were issued under an indenture, dated as of November 18, 2019, (“Indenture”) with The Bank of New York Mellon Trust Company, N.A., as trustee. The offer and sale of the Convertible Notes and the shares of common stock issuable upon conversion of the Convertible Notes have not been registered under the Securities Act, or the securities laws of any other jurisdiction, and the Convertible Notes and such shares may not be offered or sold absent registration or an applicable exemption from registration requirements, or in a transaction not subject to, such registration requirements.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We received net proceeds from the offering of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$447.4 million</span></span><span style="font-family:inherit;font-size:10pt;">. We used </span><span style="font-family:inherit;font-size:10pt;"><span>$200.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> of the net proceeds from the offering to repurchase shares of common stock, including approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$143.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> to repurchase approximately </span><span style="font-family:inherit;font-size:10pt;"><span>8.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock concurrently with the offering in privately negotiated transactions, </span><span style="font-family:inherit;font-size:10pt;"><span>$6.9 million</span></span><span style="font-family:inherit;font-size:10pt;"> in open market purchases and </span><span style="font-family:inherit;font-size:10pt;"><span>$50.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> to repurchase a total of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>2.6 million</span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock through an accelerated share repurchase agreement.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We used approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$26.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> of the net proceeds from the offering to repay all outstanding amounts under its loan agreement with Oxford Finance and Silicon Valley Bank and intend to use the remainder of the net proceeds for general corporate purposes, including additional share repurchases subsequent to the offering and working capital.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Convertible Notes will pay interest semi-annually in arrears on June 1st and December 1st of each year, beginning on June 1, 2020, at an annual rate of </span><span style="font-family:inherit;font-size:10pt;"><span>1.25%</span></span><span style="font-family:inherit;font-size:10pt;"> and will be convertible into cash, shares of common stock or a combination of cash and shares of common stock, at our election, based on the applicable conversion rate at such time. The Convertible Notes are general unsecured obligations and will rank senior in right of payment to all indebtedness that is expressly subordinated in right of payment to the Convertible Notes, will rank equally in right of payment with all existing and future liabilities that are not so subordinated, will be effectively junior to any secured indebtedness to the extent of the value of the assets securing such indebtedness and will be structurally subordinated to all indebtedness and other liabilities (including trade payables) of the our current or future subsidiaries. The Convertible Notes have a maturity date of December 1, 2024.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Holders may convert their Convertible Notes at their option only in the following circumstances: (1) during any calendar quarter commencing after the calendar quarter ending on March 31, 2020, if the last reported sale price per share of common stock exceeds </span><span style="font-family:inherit;font-size:10pt;"><span>130%</span></span><span style="font-family:inherit;font-size:10pt;"> of the conversion price for each of at least </span><span style="font-family:inherit;font-size:10pt;"><span>20</span></span><span style="font-family:inherit;font-size:10pt;"> trading days during the </span><span style="font-family:inherit;font-size:10pt;"><span>30</span></span><span style="font-family:inherit;font-size:10pt;"> consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter; (2) during the </span><span style="font-family:inherit;font-size:10pt;"><span>five</span></span><span style="font-family:inherit;font-size:10pt;"> consecutive business days immediately after any </span><span style="font-family:inherit;font-size:10pt;"><span>five</span></span><span style="font-family:inherit;font-size:10pt;"> consecutive trading day period (such </span><span style="font-family:inherit;font-size:10pt;"><span>five</span></span><span style="font-family:inherit;font-size:10pt;"> consecutive trading day period, the “measurement period”) in which the trading price per $1,000 principal amount of notes for each trading day of the measurement period was less than </span><span style="font-family:inherit;font-size:10pt;"><span>98%</span></span><span style="font-family:inherit;font-size:10pt;"> of the product of the last reported sale price per share of Company’s common stock on such trading day and the conversion rate on such trading day; (3) upon the occurrence of certain corporate events or distributions on Company’s common stock, as described in the offering memorandum; (4) if we call such notes for redemption; and (5) at any time from, and including, June 1, 2024 until the close of business on the scheduled trading day immediately before the maturity date.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Upon conversion, we will pay or deliver, as applicable, cash, shares of common stock or a combination of cash and shares of common stock, at our election. The initial conversion rate for the Convertible Notes will be </span><span style="font-family:inherit;font-size:10pt;"><span>41.9208</span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock per $1,000 in principal amount of Convertible Notes, equivalent to a conversion price of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$23.85</span></span><span style="font-family:inherit;font-size:10pt;"> per share of our common stock. The conversion rate is subject to adjustment as described in the Indenture.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In accordance with accounting guidance for debt with conversion and other options, we accounted for the debt and equity components of the Convertible Notes separately. The estimated fair value of the debt component at the date of issuance was </span><span style="font-family:inherit;font-size:10pt;"><span>$381.8 million</span></span><span style="font-family:inherit;font-size:10pt;">, which was computed based on our non-convertible borrowing rate for similar debt of </span><span style="font-family:inherit;font-size:10pt;"><span>5.19%</span></span><span style="font-family:inherit;font-size:10pt;">, derived from independent valuation analysis. The equity component was allocated a value of </span><span style="font-family:inherit;font-size:10pt;"><span>$65.6 million</span></span><span style="font-family:inherit;font-size:10pt;"> and represents the difference </span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">between the </span><span style="font-family:inherit;font-size:10pt;"><span>$447.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> of net proceeds from the issuance of the Convertible Notes and the </span><span style="font-family:inherit;font-size:10pt;"><span>$381.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> estimated fair value of the debt component at the date of issuance.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> In connection with the Convertible Notes, we paid the initial purchasers of the Convertible Notes a fee of </span><span style="font-family:inherit;font-size:10pt;"><span>$12.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> and incurred additional debt issuance costs totaling </span><span style="font-family:inherit;font-size:10pt;"><span>$0.3 million</span></span><span style="font-family:inherit;font-size:10pt;">, which includes expenses that we paid on behalf of the initial purchasers and expenses incurred directly by us. Debt issuance costs, the initial purchasers’ fee and the equity component is presented as a debt discount as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> in the amount of </span><span style="font-family:inherit;font-size:10pt;"><span>$76.9 million</span></span><span style="font-family:inherit;font-size:10pt;">, and will be amortized over the remaining estimated term of </span><span style="font-family:inherit;font-size:10pt;"><span>5 years</span></span><span style="font-family:inherit;font-size:10pt;"> using the effective interest method, utilizing an effective interest rate of </span><span style="font-family:inherit;font-size:10pt;"><span>5.10%</span></span><span style="font-family:inherit;font-size:10pt;">. The net carrying amount of the debt as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> is $</span><span style="font-family:inherit;font-size:10pt;"><span>383.1 million</span></span><span style="font-family:inherit;font-size:10pt;">. For the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, we recognized interest expense of </span><span style="font-family:inherit;font-size:10pt;"><span>$2.3 million</span></span><span style="font-family:inherit;font-size:10pt;">, including contractual coupon interest of </span><span style="font-family:inherit;font-size:10pt;"><span>$0.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> and amortization of the debt discount of </span><span style="font-family:inherit;font-size:10pt;"><span>$1.6 million</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, we were </span><span style="font-family:inherit;font-size:10pt;"><span>in compliance</span></span><span style="font-family:inherit;font-size:10pt;"> with all covenants under the Indenture and there was no material adverse change in our business, operations or financial condition.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Royalty-backed Loan</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In </span><span style="font-family:inherit;font-size:10pt;">January 2016</span><span style="font-family:inherit;font-size:10pt;">, through our wholly-owned subsidiary Halozyme Royalty LLC (“Halozyme Royalty”), we received a </span><span style="font-family:inherit;font-size:10pt;"><span>$150 million</span></span><span style="font-family:inherit;font-size:10pt;"> loan (the “Royalty-backed Loan”) pursuant to a credit agreement (the “Credit Agreement”) with BioPharma Credit Investments IV Sub, LP and Athyrium Opportunities II Acquisition LP (the “Royalty-backed Lenders”). Under the terms of the Credit Agreement, Halozyme Therapeutics, Inc. transferred to Halozyme Royalty the right to receive royalty payments from the commercial sales of ENHANZE products owed under the Roche Collaboration and Baxalta Collaboration (“Collaboration Agreements”). The royalty payments from the Collaboration Agreements will be used to repay the principal and interest on the loan (the “Royalty Payments”).  The Royalty-backed Loan bears interest at a per annum rate of </span><span style="font-family:inherit;font-size:10pt;"><span>8.75% plus the three-month LIBOR rate</span></span><span style="font-family:inherit;font-size:10pt;">. The three-month LIBOR rate is subject to a floor of </span><span style="font-family:inherit;font-size:10pt;"><span>0.7%</span></span><span style="font-family:inherit;font-size:10pt;"> and a cap of </span><span style="font-family:inherit;font-size:10pt;"><span>1.5%</span></span><span style="font-family:inherit;font-size:10pt;">. The interest rate as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> was </span><span style="font-family:inherit;font-size:10pt;"><span>10.25%</span></span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Credit Agreement provides that </span><span style="font-family:inherit;font-size:10pt;"><span>none</span></span><span style="font-family:inherit;font-size:10pt;"> of the Royalty Payments were required to be applied to the Royalty-backed Loan prior to January 1, 2017, </span><span style="font-family:inherit;font-size:10pt;"><span>50%</span></span><span style="font-family:inherit;font-size:10pt;"> of the Royalty Payments are required to be applied to the Royalty-backed Loan between January 1, 2017 and January 1, 2018 and thereafter </span><span style="font-family:inherit;font-size:10pt;">all</span><span style="font-family:inherit;font-size:10pt;"> Royalty Payments must be applied to the Royalty-backed Loan. However, the amounts available to repay the Royalty-backed Loan are subject to caps of </span><span style="font-family:inherit;font-size:10pt;"><span>$13.75 million</span></span><span style="font-family:inherit;font-size:10pt;"> per quarter in 2017, </span><span style="font-family:inherit;font-size:10pt;"><span>$18.75 million</span></span><span style="font-family:inherit;font-size:10pt;"> per quarter in 2018, </span><span style="font-family:inherit;font-size:10pt;"><span>$21.25 million</span></span><span style="font-family:inherit;font-size:10pt;"> per quarter in 2019 and </span><span style="font-family:inherit;font-size:10pt;"><span>$22.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> per quarter in 2020 and thereafter. Amounts available to repay the Royalty-backed Loan will be applied first to pay interest and second to repay principal on the Royalty-backed Loan. Any accrued interest that is not paid on any applicable quarterly payment date, as defined, will be capitalized and added to the principal balance of the Royalty-backed Loan on such date. Halozyme Royalty will be entitled to receive and distribute to Halozyme any Royalty Payments that are not required to be applied to the Royalty-backed Loan or which are in excess of the foregoing caps. </span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Because the repayment of the term loan is contingent upon the level of Royalty Payments received, the repayment term may be shortened or extended depending on the actual level of Royalty Payments. The </span><span style="font-family:inherit;font-size:10pt;"><span>final maturity date of the Royalty-backed Loan will be the earlier of (i) the date when principal and interest is paid in full, (ii) the termination of Halozyme Royalty’s right to receive royalties under the Collaboration Agreements, and (iii) December 31, 2050</span></span><span style="font-family:inherit;font-size:10pt;">.  Currently, we estimate that the loan will be repaid in the second quarter of 2020. This estimate could be adversely affected and the repayment period could be extended if future royalty amounts are less than currently expected. Under the terms of the Credit Agreement, at any time after January 1, 2019, Halozyme Royalty may, subject to certain limitations, prepay the outstanding principal of the Royalty-backed Loan in whole or in part, at a price equal to </span><span style="font-family:inherit;font-size:10pt;"><span>105%</span></span><span style="font-family:inherit;font-size:10pt;"> of the outstanding principal on the Royalty-backed Loan, plus accrued but unpaid interest. The Royalty-backed Loan constitutes an obligation of Halozyme Royalty, and is non-recourse to Halozyme. Halozyme Royalty retains its right to the Royalty Payments following repayment of the loan. </span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, we were </span><span style="font-family:inherit;font-size:10pt;"><span>in compliance</span></span><span style="font-family:inherit;font-size:10pt;"> with all covenants under the Royalty-backed Loan and there was no material adverse change in our business, operations or financial condition.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> We began making principal and interest payments against the Royalty-backed Loan in the first quarter of 2017 and therefore had </span><span style="font-family:inherit;font-size:10pt;"><span>zero</span></span><span style="font-family:inherit;font-size:10pt;"> capitalized interest for the </span><span style="font-family:inherit;font-size:10pt;">twelve</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">. In addition, we recorded accrued interest, which is included in accrued expenses, of </span><span style="font-family:inherit;font-size:10pt;"><span>$0.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$0.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019 and 2018</span><span style="font-family:inherit;font-size:10pt;">, respectively. </span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> In connection with the Royalty-backed Loan, we paid the Royalty-backed Lenders a fee of </span><span style="font-family:inherit;font-size:10pt;"><span>$1.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> and incurred additional debt issuance costs totaling </span><span style="font-family:inherit;font-size:10pt;"><span>$0.4 million</span></span><span style="font-family:inherit;font-size:10pt;">, which includes expenses that we paid on behalf of the Royalty-backed Lenders and expenses incurred directly by us. Debt issuance costs and the lender fee have been netted against the debt as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, and are being amortized over the estimated term of the debt using the effective interest method. For the years ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019, 2018 and 2017</span><span style="font-family:inherit;font-size:10pt;">, we recognized interest expense, including amortization of the debt discount, related to the Royalty-backed Loan of </span><span style="font-family:inherit;font-size:10pt;"><span>$6.2 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$13.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$16.4 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively. The assumptions used in determining the expected repayment term of the debt and amortization period of the issuance costs requires that we make estimates that could impact the short- and long-term classification of these costs, as well as the period over which these costs will be amortized. The outstanding balance of the Royalty-backed Loan as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> was </span><span style="font-family:inherit;font-size:10pt;"><span>$19.5 million</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Oxford and SVB Loan and Security Agreement</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In June 2016, we entered into a Loan and Security Agreement (the “Loan Agreement”) with Oxford Finance LLC (“Oxford”) and Silicon Valley Bank (“SVB”) (collectively, the “Lenders”), providing a senior secured loan facility of up to an aggregate principal amount of </span><span style="font-family:inherit;font-size:10pt;"><span>$70.0 million</span></span><span style="font-family:inherit;font-size:10pt;">, comprising a </span><span style="font-family:inherit;font-size:10pt;"><span>$55.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> draw in June 2016 and an additional </span><span style="font-family:inherit;font-size:10pt;"><span>$15.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> tranche, which we had the option to draw during the second quarter of 2017 and did not exercise. The initial proceeds were partially used to pay the outstanding principal and final payment of </span><span style="font-family:inherit;font-size:10pt;"><span>$4.25 million</span></span><span style="font-family:inherit;font-size:10pt;"> owed on a previous loan agreement with the Lenders. The remaining proceeds were used for working capital and general business requirements. The senior secured loan facility carried a fixed interest rate of </span><span style="font-family:inherit;font-size:10pt;"><span>8.25%</span></span><span style="font-family:inherit;font-size:10pt;">. The repayment schedule provided for </span><span style="font-family:inherit;font-size:10pt;"><span>interest only payments for the first 18 months</span></span><span style="font-family:inherit;font-size:10pt;">, followed by consecutive equal monthly payments of principal and interest in arrears through the maturity date of </span><span style="font-family:inherit;font-size:10pt;"><span><span style="white-space:nowrap">January 1, 2021</span></span></span><span style="font-family:inherit;font-size:10pt;">. The Loan Agreement provided for a final payment equal to </span><span style="font-family:inherit;font-size:10pt;"><span>5.50%</span></span><span style="font-family:inherit;font-size:10pt;"> of the initial </span><span style="font-family:inherit;font-size:10pt;"><span>$55.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> principal amount, which was due when the Loan Agreement becomes due or upon the prepayment of the facility. We had the option to prepay the outstanding balance of the Loan Agreement in full and exercised this option in November 2019, at which point we paid the full remaining balance and final payment of </span><span style="font-family:inherit;font-size:10pt;"><span>$26.1 million</span></span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest expense, including amortization of the debt discount, related to the Loan Agreement totaled </span><span style="font-family:inherit;font-size:10pt;"><span>$3.0 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$4.9 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$5.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> for the years ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019, 2018 and 2017</span><span style="font-family:inherit;font-size:10pt;">, respectively. </span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Future maturities and interest payments of long-term debt as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, are as follows (in thousands):</span></div><div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.51656920077973%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:87%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26,100</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,750</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,750</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,750</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2024</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>465,750</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total minimum payments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>509,100</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less amount representing interest</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(29,540</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross balance of long-term debt</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>479,560</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less unamortized debt discount</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(76,973</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Present value of long-term debt</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>402,587</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less current portion of long-term debt</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(19,542</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Long-term debt, less current portion and unamortized debt discount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>383,045</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 460000000.0 0.0125 447400000 200000000.0 143100000 8100000 6900000 50000000.0 2600000 26100000 0.0125 1.30 20 30 5 5 5 0.98 41.9208 23.85 381800000 0.0519 65600000 447400000 381800000 12700000 300000 76900000 P5Y 0.0510 383100000 2300000 700000 1600000 in compliance 150000000 8.75% plus the three-month LIBOR rate 0.007 0.015 0.1025 0 0.50 13750000 18750000 21250000 22500000 final maturity date of the Royalty-backed Loan will be the earlier of (i) the date when principal and interest is paid in full, (ii) the termination of Halozyme Royalty’s right to receive royalties under the Collaboration Agreements, and (iii) December 31, 2050 1.05 in compliance 0 100000 400000 1500000 400000 6200000 13100000 16400000 19500000 70000000.0 55000000.0 15000000.0 4250000 0.0825 interest only payments for the first 18 months 2021-01-01 0.0550 55000000.0 26100000 3000000.0 4900000 5500000 <div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Future maturities and interest payments of long-term debt as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, are as follows (in thousands):</span></div><div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.51656920077973%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:87%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26,100</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,750</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,750</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,750</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2024</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>465,750</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total minimum payments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>509,100</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less amount representing interest</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(29,540</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross balance of long-term debt</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>479,560</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less unamortized debt discount</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(76,973</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Present value of long-term debt</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>402,587</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less current portion of long-term debt</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(19,542</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Long-term debt, less current portion and unamortized debt discount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>383,045</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 26100000 5750000 5750000 5750000 465750000 509100000 29540000 479560000 76973000 402587000 19542000 383045000 Share-based Compensation<div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:11pt;"><span style="font-family:inherit;font-size:10pt;">We currently grant stock options, restricted stock awards and restricted stock units under the Amended and Restated 2011 Stock Plan (“2011 Stock Plan”), which was approved by the stockholders on May 6, 2016 an</span><span style="font-family:inherit;font-size:11pt;">d</span><span style="font-family:inherit;font-size:10pt;"> provides for the grant of up to </span><span style="font-family:inherit;font-size:10pt;"><span>44.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock to selected employees, consultants and non-employee members of our Board of Directors as stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards and performance awards. Awards are subject to terms and conditions established by the Compensation Committee of our Board of Directors. During the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, we granted share-based awards under the 2011 Stock Plan. At </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>13,640,668</span></span><span style="font-family:inherit;font-size:10pt;"> shares were subject to outstanding awards and </span><span style="font-family:inherit;font-size:10pt;"><span>9,352,360</span></span><span style="font-family:inherit;font-size:10pt;"> shares were available for future grants of share-based awards. </span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total share-based compensation expense related to share-based awards was comprised of the following (in thousands):</span></div><div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.51656920077973%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:58%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15,107</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17,220</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,080</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Selling, general and administrative</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19,669</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18,476</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17,590</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Share-based compensation expense</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34,776</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>35,696</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30,670</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Share-based compensation expense by type of share-based award (in thousands):</span></div><div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.51656920077973%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:58%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stock options</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17,624</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18,742</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19,583</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">RSAs and RSUs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17,152</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,954</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,087</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34,776</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>35,696</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30,670</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total unrecognized estimated compensation cost by type of award and the weighted-average remaining requisite service period over which such expense is expected to be recognized (in thousands, unless otherwise noted):</span></div><div style="line-height:120%;text-align:center;text-indent:32px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.32163742690058%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:72%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrecognized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Remaining</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted-Average</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Recognition Period</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(years)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stock options</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,524</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.59</span></span></div></td></tr><tr><td style="vertical-align:top;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">RSAs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>570</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.16</span></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">RSUs</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,600</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.32</span></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Stock Options.</span><span style="font-family:inherit;font-size:10pt;"> Options granted under the Plans must have an exercise price equal to at least </span><span style="font-family:inherit;font-size:10pt;"><span>100%</span></span><span style="font-family:inherit;font-size:10pt;"> of the fair market value of our common stock on the date of grant. The options generally have a maximum contractual term of </span><span style="font-family:inherit;font-size:10pt;"><span>ten years</span></span><span style="font-family:inherit;font-size:10pt;"> and vest at the rate of </span><span style="font-family:inherit;font-size:10pt;">one-fourth</span><span style="font-family:inherit;font-size:10pt;"> of the shares on the first anniversary of the date of grant and </span><span style="font-family:inherit;font-size:10pt;">1/48</span><span style="font-family:inherit;font-size:10pt;"> of the shares monthly thereafter. Certain option awards provide for accelerated vesting if there is a change in control (as defined in the Plans).</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A summary of our stock option award activity as of and for the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> is as follows:</span><span style="font-family:inherit;font-size:9pt;"> </span></div><div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.51656920077973%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:48%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares<br/>Underlying<br/>Stock Options</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted<br/>Average Exercise<br/>Price per Share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term (years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Aggregate<br/>Intrinsic<br/>Value</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding at December 31, 2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,012,381</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$13.81</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,056,191</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$16.46</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exercised</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,540,690</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$10.73</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Canceled/forfeited</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(979,653</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$16.19</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding at December 31, 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,548,229</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$14.72</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.98</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$39.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> million</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested and expected to vest at December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,548,229</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$14.72</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.98</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$39.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> million</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exercisable at December 31, 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,962,972</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$13.64</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.59</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$32.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> million</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The weighted average grant date fair values of options granted during the years ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019, 2018 and 2017</span><span style="font-family:inherit;font-size:10pt;"> were </span><span style="font-family:inherit;font-size:10pt;"><span>$16.46</span></span><span style="font-family:inherit;font-size:10pt;"> per share, </span><span style="font-family:inherit;font-size:10pt;"><span>$10.33</span></span><span style="font-family:inherit;font-size:10pt;"> per share and </span><span style="font-family:inherit;font-size:10pt;"><span>$7.86</span></span><span style="font-family:inherit;font-size:10pt;"> per share, respectively. The total intrinsic value of options exercised during the years ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019, 2018 and 2017</span><span style="font-family:inherit;font-size:10pt;"> was approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$10.6 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$11.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$10.0 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively. Cash received from stock option exercises for the years ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019, 2018 and 2017</span><span style="font-family:inherit;font-size:10pt;"> was approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$16.5 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$16.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$14.0 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The exercise price of stock options granted is equal to the closing price of the common stock on the date of grant. The fair value of each option award is estimated on the date of grant using the Black-Scholes-Merton option pricing model (“Black-Scholes model”). Expected volatility is based on historical volatility of our common stock. The expected term of options granted is based on analyses of historical employee termination rates and option exercises. The risk-free interest rate is based on the U.S. Treasury yield for a period consistent with the expected term of the option in effect at the time of the grant. The dividend yield assumption is based on the expectation of no future dividend payments. The assumptions used in the Black-Scholes model were as follows:</span></div><div style="line-height:120%;text-align:center;text-indent:32px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.32163742690058%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:58%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:13%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected volatility</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">51.56-56.94%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">57.18-70.06%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">69.81-71.73%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Average expected term (in years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.5</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.5</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.6</span></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Risk-free interest rate</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1.35-2.56%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2.25-2.96%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1.73-2.13%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected dividend yield</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Restricted Stock Awards</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">. </span><span style="font-family:inherit;font-size:10pt;">RSAs are grants that entitle the holder to acquire shares of our common stock at </span><span style="font-family:inherit;font-size:10pt;"><span>zero</span></span><span style="font-family:inherit;font-size:10pt;"> cost. The shares covered by a RSA cannot be sold, pledged, or otherwise disposed of until the award vests and any unvested shares may be reacquired by us for the original purchase price following the awardee’s termination of service. The RSAs will generally vest at the rate of </span><span style="font-family:inherit;font-size:10pt;">one-fourth</span><span style="font-family:inherit;font-size:10pt;"> of the shares on each anniversary of the date of grant. Annual grants of RSAs to the Board of Directors typically vest in approximately </span><span style="font-family:inherit;font-size:10pt;"><span>one year</span></span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes our RSA activity during the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.51656920077973%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:77%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Number of<br/>Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted<br/>Average<br/>Grant Date<br/>Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unvested at December 31, 2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>397,389</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$11.03</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>85,211</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$16.43</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(260,086</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$12.57</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(11,391</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$8.11</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unvested at December 31, 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>211,123</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$11.47</span></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The estimated fair value of the RSAs was based on the closing market value of our common stock on the date of grant. The total grant date fair value of RSAs vested during the years ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019, 2018 and 2017</span><span style="font-family:inherit;font-size:10pt;"> was approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$3.3 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$4.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$5.3 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively. The fair value of RSAs vested during the years ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019, 2018 and 2017</span><span style="font-family:inherit;font-size:10pt;">, was approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$4.2 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$7.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$6.6 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively. </span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Restricted Stock Units</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">.</span><span style="font-family:inherit;font-size:10pt;"> A RSU is a promise by us to issue a share of our common stock upon vesting of the unit. The RSUs will generally vest at the rate of </span><span style="font-family:inherit;font-size:10pt;">one-fourth</span><span style="font-family:inherit;font-size:10pt;"> of the shares on each anniversary of the date of grant. </span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes our RSU activity during the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.51656920077973%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:51%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Number of<br/>Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted<br/>Average<br/>Grant Date<br/>Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term (yrs)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Aggregate<br/>Intrinsic<br/>Value</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding at December 31, 2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,388,342</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$15.12</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,151,464</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$16.55</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,092,648</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$15.35</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(354,719</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$16.22</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding at December 31, 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,092,439</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$15.60</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.23</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$37.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> million</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The estimated fair value of the RSUs was based on the closing market value of our common stock on the date of grant. The total grant date fair value of RSUs vested during the years ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019, 2018 and 2017</span><span style="font-family:inherit;font-size:10pt;"> was approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$19.1 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$6.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$4.0 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively. The fair value of RSUs vested during the years ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019, 2018 and 2017</span><span style="font-family:inherit;font-size:10pt;"> was approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$18.5 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$11.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$4.7 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div> 44200000 13640668 9352360 <div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total share-based compensation expense related to share-based awards was comprised of the following (in thousands):</span></div><div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.51656920077973%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:58%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15,107</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17,220</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,080</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Selling, general and administrative</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19,669</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18,476</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17,590</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Share-based compensation expense</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34,776</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>35,696</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30,670</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 15107000 17220000 13080000 19669000 18476000 17590000 34776000 35696000 30670000 <div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Share-based compensation expense by type of share-based award (in thousands):</span></div><div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.51656920077973%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:58%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stock options</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17,624</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18,742</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19,583</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">RSAs and RSUs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17,152</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,954</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,087</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34,776</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>35,696</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30,670</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 17624000 18742000 19583000 17152000 16954000 11087000 34776000 35696000 30670000 <div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total unrecognized estimated compensation cost by type of award and the weighted-average remaining requisite service period over which such expense is expected to be recognized (in thousands, unless otherwise noted):</span></div><div style="line-height:120%;text-align:center;text-indent:32px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.32163742690058%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:72%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrecognized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Remaining</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted-Average</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Recognition Period</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(years)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stock options</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,524</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.59</span></span></div></td></tr><tr><td style="vertical-align:top;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">RSAs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>570</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.16</span></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">RSUs</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,600</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.32</span></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 16524000 P2Y7M2D 570000 P0M4D 11600000 P2Y3M25D 1 P10Y <div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A summary of our stock option award activity as of and for the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> is as follows:</span><span style="font-family:inherit;font-size:9pt;"> </span></div><div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.51656920077973%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:48%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares<br/>Underlying<br/>Stock Options</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted<br/>Average Exercise<br/>Price per Share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term (years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Aggregate<br/>Intrinsic<br/>Value</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding at December 31, 2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,012,381</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$13.81</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,056,191</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$16.46</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exercised</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,540,690</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$10.73</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Canceled/forfeited</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(979,653</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$16.19</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding at December 31, 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,548,229</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$14.72</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.98</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$39.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> million</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested and expected to vest at December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,548,229</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$14.72</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.98</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$39.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> million</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exercisable at December 31, 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,962,972</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$13.64</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.59</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$32.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> million</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 11012381 13.81 3056191 16.46 1540690 10.73 979653 16.19 11548229 14.72 P3Y11M23D 39800000 11548229 14.72 P3Y11M23D 39800000 6962972 13.64 P3Y7M2D 32700000 16.46 10.33 7.86 10600000 11500000 10000000.0 16500000 16300000 14000000.0 The assumptions used in the Black-Scholes model were as follows:<div style="line-height:120%;text-align:center;text-indent:32px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.32163742690058%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:58%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:13%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected volatility</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">51.56-56.94%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">57.18-70.06%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">69.81-71.73%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Average expected term (in years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.5</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.5</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.6</span></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Risk-free interest rate</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1.35-2.56%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2.25-2.96%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1.73-2.13%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected dividend yield</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> P5Y6M P5Y6M P5Y7M6D 0 0 0 0 P1Y <div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes our RSA activity during the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.51656920077973%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:77%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Number of<br/>Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted<br/>Average<br/>Grant Date<br/>Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unvested at December 31, 2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>397,389</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$11.03</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>85,211</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$16.43</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(260,086</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$12.57</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(11,391</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$8.11</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unvested at December 31, 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>211,123</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$11.47</span></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 397389 11.03 85211 16.43 260086 12.57 11391 8.11 211123 11.47 3300000 4500000 5300000 4200000 7200000 6600000 <div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes our RSU activity during the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.51656920077973%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:51%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Number of<br/>Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted<br/>Average<br/>Grant Date<br/>Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term (yrs)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Aggregate<br/>Intrinsic<br/>Value</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding at December 31, 2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,388,342</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$15.12</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,151,464</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$16.55</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,092,648</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$15.35</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(354,719</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$16.22</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding at December 31, 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,092,439</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$15.60</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.23</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$37.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> million</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 2388342 15.12 1151464 16.55 1092648 15.35 354719 16.22 2092439 15.60 P1Y2M23D 37100000 19100000 6700000 4000000.0 18500000 11000000.0 4700000 Stockholders’ Equity (Deficit)<div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In May 2017, we completed an underwritten public offering pursuant to which we sold </span><span style="font-family:inherit;font-size:10pt;"><span>11.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock, including </span><span style="font-family:inherit;font-size:10pt;"><span>1.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> shares sold pursuant to the full exercise of an option to purchase additional shares granted to the underwriters. All of the shares were offered at a public offering price of </span><span style="font-family:inherit;font-size:10pt;"><span>$12.50</span></span><span style="font-family:inherit;font-size:10pt;"> per share, generating </span><span style="font-family:inherit;font-size:10pt;"><span>$134.9 million</span></span><span style="font-family:inherit;font-size:10pt;"> in net proceeds, after deducting underwriting discounts and commissions and other offering expenses. </span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During the years ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019, 2018 and 2017</span><span style="font-family:inherit;font-size:10pt;">, we issued an aggregate of </span><span style="font-family:inherit;font-size:10pt;"><span>1,540,690</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>1,489,138</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>1,514,826</span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock, respectively, in connection with the exercises of stock options, for net proceeds of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$16.5 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$16.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$14.0 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively. For the years ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019, 2018 and 2017</span><span style="font-family:inherit;font-size:10pt;">, we issued </span><span style="font-family:inherit;font-size:10pt;"><span>952,182</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>442,599</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>281,398</span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock, respectively, upon vesting of certain RSUs for which the RSU holders surrendered </span><span style="font-family:inherit;font-size:10pt;"><span>140,466</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>139,850</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>97,008</span></span><span style="font-family:inherit;font-size:10pt;"> RSUs, respectively, to pay for minimum withholding taxes totaling approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$7.0 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$4.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$1.9 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively. Stock options and unvested restricted units totaling approximately </span><span style="font-family:inherit;font-size:10pt;"><span>13.6 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>13.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>13.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> shares of our common stock were outstanding as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019, 2018 and 2017</span><span style="font-family:inherit;font-size:10pt;">, respectively. </span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Share Repurchases</span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Board of Directors approved a share repurchase program, pursuant to which we may repurchase issued and outstanding shares of common stock from time to time. We may utilize a variety of methods including open market purchases, privately negotiated transactions, accelerated share repurchase programs or any combination of such methods. </span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In November 2019, we announced that the Board of Directors has authorized the initiation of a capital return program to repurchase up to </span><span style="font-family:inherit;font-size:10pt;"><span>$550.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> of outstanding common stock over a three-year period. The Board will regularly review this capital return program in connection with a balanced capital allocation strategy. In November </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, we repurchased approximately </span><span style="font-family:inherit;font-size:10pt;"><span>8.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock concurrently with the Convertible Notes issuance in privately negotiated transactions for </span><span style="font-family:inherit;font-size:10pt;"><span>$143.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>0.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock in open market purchases for </span><span style="font-family:inherit;font-size:10pt;"><span>$6.9 million</span></span><span style="font-family:inherit;font-size:10pt;">. Also in November 2019, we entered into an Accelerated Share Repurchase (ASR) agreement with Bank of America to repurchase </span><span style="font-family:inherit;font-size:10pt;"><span>$50.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> of common stock. At inception, pursuant to the agreement, we paid </span><span style="font-family:inherit;font-size:10pt;"><span>$50.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> to Bank of America and took an initial delivery of </span><span style="font-family:inherit;font-size:10pt;"><span>2.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> shares. In February 2020 we finalized the transaction and received an additional </span><span style="font-family:inherit;font-size:10pt;"><span>0.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> shares. We retired the repurchased shares and they resumed the status of authorized and unissued shares.</span></div> 11500000 1500000 12.50 134900000 1540690 1489138 1514826 16500000 16300000 14000000.0 952182 442599 281398 140466 139850 97008 7000000.0 4200000 1900000 13600000 13400000 13000000.0 550000000.0 8100000 143100000 400000 6900000 50000000.0 50000000.0 2100000 500000 Commitments and Contingencies<div style="line-height:120%;padding-top:8px;text-indent:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Operating Leases</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our administrative offices and research facilities are located in San Diego, California. We lease an aggregate of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>80,000</span></span><span style="font-family:inherit;font-size:10pt;"> square feet of office and research space in </span><span style="font-family:inherit;font-size:10pt;"><span>five</span></span><span style="font-family:inherit;font-size:10pt;"> buildings. The leases commenced in June 2011, November 2013 and June 2018 and continue through </span><span style="font-family:inherit;font-size:10pt;">January 2023</span><span style="font-family:inherit;font-size:10pt;">. The leases are subject to approximately </span><span style="font-family:inherit;font-size:10pt;"><span>3.0%</span></span><span style="font-family:inherit;font-size:10pt;"> annual increases throughout the terms of the leases. We also pay a pro rata share of operating costs, insurance costs, utilities and real property taxes. </span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We lease approximately </span><span style="font-family:inherit;font-size:10pt;"><span>10,000</span></span><span style="font-family:inherit;font-size:10pt;"> square feet of office space for a satellite office located in South San Francisco, California. The lease commenced in November 2015 and continues through </span><span style="font-family:inherit;font-size:10pt;">January 2021</span><span style="font-family:inherit;font-size:10pt;">. The lease is subject to approximately </span><span style="font-family:inherit;font-size:10pt;"><span>3.0%</span></span><span style="font-family:inherit;font-size:10pt;"> annual increases throughout the term of the lease. We also pay a pro rata share of operating costs, insurance costs, utilities and real property taxes. </span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As a result of the restructuring we announced on November 4, 2019, we abandoned two of our buildings in San Diego and our satellite office located in San Francisco. As a result, we have reassessed the likelihood of exercising contractual options impacting the term of these leases. These considerations have been reflected in the recognition of impairment charges of </span><span style="font-family:inherit;font-size:10pt;"><span>$1.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> in accordance with ASC 360 during the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Additionally, we lease certain office equipment under operating leases. Total rent expense was approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$2.7 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$2.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$2.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> for the years ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019, 2018 and 2017</span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Approximate annual future minimum operating lease payments as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> are as follows (in thousands):</span><span style="font-family:inherit;font-size:9pt;"> </span></div><div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.51656920077973%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:86%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;">Year:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Operating<br/>Leases</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,355</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,260</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,559</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>70</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2024</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total minimum lease payments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,244</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less imputed interest</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(775</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,469</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The weighted-average remaining lease term of our operating leases is approximately </span><span style="font-family:inherit;font-size:10pt;"><span>2.36</span></span><span style="font-family:inherit;font-size:10pt;"> years. </span></div><div style="line-height:120%;padding-top:8px;text-indent:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Other Commitments </span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have existing supply agreements with contract manufacturing organizations Avid Bioservices, Inc. (“Avid”) and Catalent Indiana LLC (formerly Cook Pharmica LLC) (“Catalent”) to produce supplies of bulk rHuPH20. Under the terms of the agreements, we are committed to certain minimum annual purchases of bulk rHuPH20. At </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, we had a </span><span style="font-family:inherit;font-size:10pt;"><span>$35.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> minimum purchase obligation in connection with these agreements.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In June 2011, we entered into a services agreement with Patheon for the technology transfer and manufacture of Hylenex recombinant. At </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, we had a </span><span style="font-family:inherit;font-size:10pt;"><span>$0.6 million</span></span><span style="font-family:inherit;font-size:10pt;"> minimum purchase obligation in connection with this agreement. </span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;text-indent:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Legal Contingencies</span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">From time to time, we may be involved in disputes, including litigation, relating to claims arising out of operations in the normal course of our business. Any of these claims could subject us to costly legal expenses and, while we generally believe that we have adequate insurance to cover many different types of liabilities, our insurance carriers may deny coverage or our policy limits may be inadequate to fully satisfy any damage awards or settlements. If this were to happen, the payment of any such awards could have a material adverse effect on our consolidated results of operations and financial position. Additionally, any such claims, whether or not successful, could damage our reputation and business. We currently are not a party to any legal proceedings, the adverse outcome of which, in management’s opinion, individually or in the aggregate, would have a material adverse effect on our consolidated results of operations or financial position.</span></div> 80000 5 0.030 10000 0.030 1100000 2700000 2500000 2300000 <div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Approximate annual future minimum operating lease payments as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> are as follows (in thousands):</span><span style="font-family:inherit;font-size:9pt;"> </span></div><div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.51656920077973%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:86%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;">Year:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Operating<br/>Leases</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,355</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,260</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,559</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>70</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2024</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total minimum lease payments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,244</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less imputed interest</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(775</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,469</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 3355000 2260000 1559000 70000 0 7244000 775000 6469000 P2Y4M9D 35700000 600000 0.35 0.21 17100000 <div style="line-height:120%;padding-top:8px;padding-left:30px;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total (loss) income before income taxes summarized by region were as follows (in thousands):</span></div><div style="line-height:120%;text-align:center;text-indent:32px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.32163742690058%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:61%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">United States</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(70,737</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(45,819</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>160,938</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,514</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(33,974</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(99,328</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net (loss) income before income taxes</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(72,251</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(79,793</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>61,610</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Significant components of our net deferred tax assets/(liabilities) were as follows (in thousands). </span></div><div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.51656920077973%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:72%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred tax assets:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net operating loss carryforwards</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>39,401</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26,267</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred revenue</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,069</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,395</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development and orphan drug credits</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>114,357</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>106,406</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Share-based compensation</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,972</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,541</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Alternative minimum tax credit</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,683</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,959</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">ASC 842 lease liability</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,454</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest expense limitation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,163</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,750</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other, net</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,037</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,452</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>173,136</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>150,770</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Valuation allowance for deferred tax assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(155,100</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(146,953</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred tax assets, net of valuation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18,036</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,817</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred tax liabilities:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Depreciation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(865</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(858</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Convertible note</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(14,450</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">ASC 842 right of use asset</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(865</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other, net</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(173</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total deferred tax liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(16,353</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(858</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net deferred tax asset </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,683</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,959</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> A valuation allowance of </span><span style="font-family:inherit;font-size:10pt;"><span>$155.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$147.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> has been established to offset the net deferred tax assets as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019 and 2018</span><span style="font-family:inherit;font-size:10pt;">, respectively, as realization of such assets is uncertain. Under the Act, taxpayers are able to claim a refund of the AMT credit carryover by December 31, 2021. Accordingly, the recognized net deferred tax asset as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> is the AMT credit carryover that will either be utilized or refunded by December 31, 2021. </span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income tax expense was comprised of the following components (in thousands):</span></div><div style="line-height:120%;text-align:center;text-indent:32px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.32163742690058%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:61%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current - federal</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>114</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>82</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,051</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current - state</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(40</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>519</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>120</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred - federal</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(85</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(64</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5,532</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred - state</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(11</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>537</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,361</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The provision for income taxes on earnings subject to income taxes differs from the statutory federal income tax rate due to the following (in thousands):</span></div><div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.51656920077973%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:61%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Federal income tax expense (benefit) at 21% for 2019 and 2018 and 34% for 2017</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(15,173</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(16,754</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20,947</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">State income tax benefit, net of federal income tax impact</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,509</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4,297</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>930</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Decrease) increase in valuation allowance</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,147</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>35,731</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(77,181</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Enactment of the Tax Cuts and Jobs Act</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17,132</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign income subject to tax at other than federal statutory rate</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>318</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,106</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>33,674</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shared-based compensation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>315</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>425</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>525</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-deductible expenses and other</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>924</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,599</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,779</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development credits, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,091</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5,210</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,162</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Orphan drug credits, net of federal add back</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5,718</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(18,063</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(7,329</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Convertible note discount in APIC</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,776</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(11</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>537</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,361</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> At </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, our unrecognized tax benefit and uncertain tax positions were </span><span style="font-family:inherit;font-size:10pt;"><span>$21.5 million</span></span><span style="font-family:inherit;font-size:10pt;">. Of this, </span><span style="font-family:inherit;font-size:10pt;"><span>$0.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> of this amount would affect the effective tax rate and </span><span style="font-family:inherit;font-size:10pt;"><span>$21.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> would affect the effective tax rate only in the event the valuation allowance was removed. Of the unrecognized tax benefits, we do not expect any significant changes to occur in the next 12 months. Interest and/or penalties related to uncertain income tax positions are recognized by us as a component of income tax expense. For the years ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019, 2018 and 2017</span><span style="font-family:inherit;font-size:10pt;">, we recognized an immaterial amount of interest and penalties.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes the activity related to our unrecognized tax benefits (in thousands):</span></div><div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.51656920077973%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:61%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross unrecognized tax benefits at beginning of period</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20,028</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14,428</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,799</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Increases in tax positions for prior years</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>69</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,083</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Decreases in tax positions for prior years</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(23</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,518</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Increases in tax positions for current year </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,409</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,517</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,147</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross unrecognized tax benefits at end of period</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21,483</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20,028</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14,428</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">At </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, we had federal, California and other state tax net operating loss carryforwards of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$118.5 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$244.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$26.7 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively. </span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table shows key expiration dates of the federal and California net operating loss carryforwards (in thousands):</span></div><div style="line-height:120%;text-align:center;text-indent:32px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.32163742690058%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:48%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Expires in:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Net Operating Loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2021 and beyond</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2028 and beyond</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Federal</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>118,480</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>118,480</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">California</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>244,337</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>244,337</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">At </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, we had federal and California research and development tax credit carryforwards of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$27.9 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$19.1 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively. The federal research and development tax credits will begin to expire in </span><span style="font-family:inherit;font-size:10pt;">2024</span><span style="font-family:inherit;font-size:10pt;"> unless previously utilized. The California research and development tax credits will carryforward indefinitely until utilized. Additionally, we had Orphan Drug Credit carryforwards of </span><span style="font-family:inherit;font-size:10pt;"><span>$88.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> which will begin to expire in </span><span style="font-family:inherit;font-size:10pt;">2034</span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pursuant to Internal Revenue Code Section 382, the annual use of the net operating loss carryforwards and research and development tax credits could be limited by any greater than 50% ownership change during any three year testing period. As a result of any such ownership change, portions of our net operating loss carryforwards and research and development tax credits are subject to annual limitations. We completed an updated Section 382 analysis regarding the limitation of the net operating losses and research and development credits as of December 31, 2019. Based upon the analysis, we determined that ownership changes occurred in prior years; however, the annual limitations on net operating loss and research and development tax credit carryforwards will not have a material impact on the future utilization of such carryforwards.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company’s 2015 and 2016 federal returns were selected for audit by the IRS. The audit was completed in September 2019 with no material adjustments.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We do not provide for U.S. income taxes on the undistributed earnings of our foreign subsidiary as it is our intention to utilize those earnings in the foreign operations for an indefinite period of time. At </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019 and 2018</span><span style="font-family:inherit;font-size:10pt;">, there were </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;"> undistributed earnings in foreign subsidiaries.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are subject to taxation in the U.S. and in various state and foreign jurisdictions. Our tax years for 2004 and forward are subject to examination by the U.S. and California tax authorities due to the carryforward of unutilized net operating losses and research and development credits.</span></div><span style="font-family:inherit;font-size:10pt;">A Swiss subsidiary, Halozyme Switzerland GmbH, was formed during the fourth quarter of 2016 and obtained a tax ruling from Canton of Basel Stadt for its operations in Switzerland. The tax ruling is dated December 21, 2016, and will continue for a period of ten years, not to extend beyond December 31, 2026. The combined income tax burden at the federal, cantonal and communal level will not exceed 10% during the period covered by the ruling. As a result of foreign losses and a full valuation allowance, </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;"> net tax benefit was derived for the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span> as a result of the tax ruling. <div style="line-height:120%;padding-top:8px;padding-left:30px;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total (loss) income before income taxes summarized by region were as follows (in thousands):</span></div><div style="line-height:120%;text-align:center;text-indent:32px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.32163742690058%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:61%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">United States</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(70,737</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(45,819</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>160,938</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,514</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(33,974</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(99,328</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net (loss) income before income taxes</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(72,251</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(79,793</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>61,610</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> -70737000 -45819000 160938000 -1514000 -33974000 -99328000 -72251000 -79793000 61610000 <div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Significant components of our net deferred tax assets/(liabilities) were as follows (in thousands). </span></div><div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.51656920077973%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:72%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred tax assets:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net operating loss carryforwards</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>39,401</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26,267</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred revenue</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,069</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,395</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development and orphan drug credits</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>114,357</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>106,406</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Share-based compensation</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,972</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,541</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Alternative minimum tax credit</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,683</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,959</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">ASC 842 lease liability</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,454</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest expense limitation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,163</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,750</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other, net</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,037</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,452</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>173,136</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>150,770</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Valuation allowance for deferred tax assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(155,100</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(146,953</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred tax assets, net of valuation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18,036</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,817</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred tax liabilities:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Depreciation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(865</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(858</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Convertible note</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(14,450</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">ASC 842 right of use asset</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(865</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other, net</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(173</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total deferred tax liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(16,353</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(858</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net deferred tax asset </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,683</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,959</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 39401000 26267000 1069000 1395000 114357000 106406000 9972000 9541000 1683000 2959000 1454000 0 2163000 1750000 3037000 2452000 173136000 150770000 155100000 146953000 18036000 3817000 865000 858000 14450000 0 865000 0 173000 0 16353000 858000 1683000 2959000 155100000 147000000.0 <div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income tax expense was comprised of the following components (in thousands):</span></div><div style="line-height:120%;text-align:center;text-indent:32px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.32163742690058%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:61%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current - federal</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>114</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>82</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,051</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current - state</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(40</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>519</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>120</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred - federal</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(85</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(64</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5,532</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred - state</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(11</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>537</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,361</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 114000 82000 4051000 -40000 519000 120000 -85000 -64000 -5532000 0 0 0 -11000 537000 -1361000 <div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The provision for income taxes on earnings subject to income taxes differs from the statutory federal income tax rate due to the following (in thousands):</span></div><div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.51656920077973%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:61%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Federal income tax expense (benefit) at 21% for 2019 and 2018 and 34% for 2017</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(15,173</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(16,754</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20,947</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">State income tax benefit, net of federal income tax impact</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,509</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4,297</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>930</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Decrease) increase in valuation allowance</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,147</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>35,731</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(77,181</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Enactment of the Tax Cuts and Jobs Act</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17,132</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign income subject to tax at other than federal statutory rate</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>318</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,106</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>33,674</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shared-based compensation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>315</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>425</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>525</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-deductible expenses and other</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>924</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,599</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,779</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development credits, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,091</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5,210</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,162</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Orphan drug credits, net of federal add back</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5,718</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(18,063</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(7,329</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Convertible note discount in APIC</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,776</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(11</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>537</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,361</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> -15173000 -16754000 20947000 -1509000 -4297000 930000 8147000 35731000 -77181000 0 0 17132000 318000 7106000 33674000 315000 425000 525000 924000 1599000 5779000 1091000 5210000 -4162000 5718000 18063000 7329000 13776000 0 0 -11000 537000 -1361000 21500000 200000 21500000 <div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes the activity related to our unrecognized tax benefits (in thousands):</span></div><div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.51656920077973%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:61%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross unrecognized tax benefits at beginning of period</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20,028</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14,428</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,799</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Increases in tax positions for prior years</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>69</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,083</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Decreases in tax positions for prior years</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(23</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,518</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Increases in tax positions for current year </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,409</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,517</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,147</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross unrecognized tax benefits at end of period</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21,483</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20,028</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14,428</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 20028000 14428000 12799000 69000 3083000 0 23000 0 2518000 1409000 2517000 4147000 21483000 20028000 14428000 118500000 244300000 26700000 <div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table shows key expiration dates of the federal and California net operating loss carryforwards (in thousands):</span></div><div style="line-height:120%;text-align:center;text-indent:32px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.32163742690058%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:48%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Expires in:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Net Operating Loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2021 and beyond</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2028 and beyond</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Federal</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>118,480</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>118,480</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">California</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>244,337</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>244,337</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 118480000 0 118480000 0 244337000 0 0 244337000 27900000 19100000 88000000.0 0 0 <div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Employee Savings Plan</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have an employee savings plan pursuant to Section 401(k) of the Internal Revenue Code. All employees are eligible to participate, provided they meet the requirements of the plan. We are not required to make matching contributions under the plan. However, we voluntarily contributed to the plan approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$2.2 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$1.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$1.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> for the years ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019, 2018 and 2017</span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div> 2200000 1300000 1200000 <div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Summary of Unaudited Quarterly Financial Information</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following is a summary of our unaudited quarterly results for the years ended December 31, 2019 and 2018 (in thousands):</span></div><div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.51656920077973%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:48%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Quarter Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019 (Unaudited):</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31,</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total revenues </span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>56,949</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>39,148</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>46,230</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>53,665</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross profit on product sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,741</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,883</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,872</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,006</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total operating expenses</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(3)</sup></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>53,983</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>53,125</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>70,767</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>85,727</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net Income (loss)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,796</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(14,624</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(25,015</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(34,397</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net Income (loss) per share:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.01</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.10</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.17</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.24</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Diluted</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.01</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.10</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.17</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.24</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares used in computing net income (loss) per share:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>144,743</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>145,411</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>146,136</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>141,046</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Diluted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>147,474</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>145,411</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>146,136</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>141,046</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Quarter Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018 (Unaudited):</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31,</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total revenues </span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30,872</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>35,202</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25,556</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>60,232</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross profit on product sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,749</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,647</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,643</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,059</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total operating expenses</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>54,584</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>55,275</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>51,030</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>60,303</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(27,461</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(22,893</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(27,850</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,126</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss per share:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.19</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.16</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.19</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.01</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Diluted</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.19</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.16</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.19</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.01</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares used in computing net loss per share:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>142,656</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>143,568</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>143,949</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>144,203</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Diluted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>142,656</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>143,568</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>143,949</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>144,203</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">_______________</span></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:inherit;font-size:10pt;">(1)</span></div></td><td style="vertical-align:top;padding-left:24px;"><div style="line-height:120%;text-align:justify;font-size:10pt;text-indent:-24px;"><span style="font-family:inherit;font-size:10pt;">Revenue for the quarter ended March 31, 2019 included </span><span style="font-family:inherit;font-size:10pt;"><span>$30.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> in revenue under a collaborative arrangement from argenx.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:inherit;font-size:10pt;">(2)</span></div></td><td style="vertical-align:top;padding-left:24px;"><div style="line-height:120%;text-align:justify;font-size:10pt;text-indent:-24px;"><span style="font-family:inherit;font-size:10pt;">Revenues for the quarter ended December 31, 2018 included </span><span style="font-family:inherit;font-size:10pt;"><span>$30.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> in revenue under a collaborative arrangement from Roche.</span></div></td></tr></table><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:inherit;font-size:10pt;">(3)</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;text-indent:-24px;"><span style="font-family:inherit;font-size:10pt;">Total operating expenses for the quarter ended December 31, 2019 included </span><span style="font-family:inherit;font-size:10pt;text-transform:default;"><span>$28.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> restructuring charges.</span></div> <div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following is a summary of our unaudited quarterly results for the years ended December 31, 2019 and 2018 (in thousands):</span></div><div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.51656920077973%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:48%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Quarter Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019 (Unaudited):</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31,</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total revenues </span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>56,949</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>39,148</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>46,230</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>53,665</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross profit on product sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,741</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,883</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,872</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,006</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total operating expenses</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(3)</sup></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>53,983</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>53,125</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>70,767</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>85,727</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net Income (loss)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,796</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(14,624</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(25,015</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(34,397</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net Income (loss) per share:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.01</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.10</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.17</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.24</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Diluted</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.01</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.10</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.17</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.24</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares used in computing net income (loss) per share:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>144,743</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>145,411</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>146,136</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>141,046</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Diluted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>147,474</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>145,411</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>146,136</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>141,046</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Quarter Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018 (Unaudited):</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31,</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total revenues </span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30,872</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>35,202</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25,556</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>60,232</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross profit on product sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,749</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,647</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,643</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,059</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total operating expenses</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>54,584</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>55,275</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>51,030</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>60,303</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(27,461</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(22,893</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(27,850</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,126</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss per share:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.19</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.16</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.19</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.01</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Diluted</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.19</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.16</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.19</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.01</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares used in computing net loss per share:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>142,656</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>143,568</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>143,949</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>144,203</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Diluted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>142,656</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>143,568</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>143,949</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>144,203</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">_______________</span></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:inherit;font-size:10pt;">(1)</span></div></td><td style="vertical-align:top;padding-left:24px;"><div style="line-height:120%;text-align:justify;font-size:10pt;text-indent:-24px;"><span style="font-family:inherit;font-size:10pt;">Revenue for the quarter ended March 31, 2019 included </span><span style="font-family:inherit;font-size:10pt;"><span>$30.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> in revenue under a collaborative arrangement from argenx.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:inherit;font-size:10pt;">(2)</span></div></td><td style="vertical-align:top;padding-left:24px;"><div style="line-height:120%;text-align:justify;font-size:10pt;text-indent:-24px;"><span style="font-family:inherit;font-size:10pt;">Revenues for the quarter ended December 31, 2018 included </span><span style="font-family:inherit;font-size:10pt;"><span>$30.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> in revenue under a collaborative arrangement from Roche.</span></div></td></tr></table><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:inherit;font-size:10pt;">(3)</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;text-indent:-24px;"><span style="font-family:inherit;font-size:10pt;">Total operating expenses for the quarter ended December 31, 2019 included </span><span style="font-family:inherit;font-size:10pt;text-transform:default;"><span>$28.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> restructuring charges.</span></div> 56949000 39148000 46230000 53665000 3741000 3883000 6872000 6006000 53983000 53125000 70767000 85727000 1796000 -14624000 -25015000 -34397000 0.01 -0.10 -0.17 -0.24 0.01 -0.10 -0.17 -0.24 144743000 145411000 146136000 141046000 147474000 145411000 146136000 141046000 30872000 35202000 25556000 60232000 3749000 3647000 5643000 5059000 54584000 55275000 51030000 60303000 -27461000 -22893000 -27850000 -2126000 -0.19 -0.16 -0.19 -0.01 -0.19 -0.16 -0.19 -0.01 142656000 143568000 143949000 144203000 142656000 143568000 143949000 144203000 30000000.0 30000000.0 28400000 Restructuring Charges<div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On November 4, 2019, we announced that our HALO-301 Phase 3 clinical study evaluating investigational new drug PEGPH20 in combination with ABRAXANE and gemcitabine as a first-line therapy for treatment of patients with metastatic pancreatic cancer failed to reach the primary endpoint of overall survival. Due to the results of the study, we halted development activities for PEGPH20, closed our oncology operations and implemented an organizational restructuring to focus our operations solely on marketing Hylenex and our ENHANZE business. In connection with the restructuring, we reduced our headcount by approximately </span><span style="font-family:inherit;font-size:10pt;"><span>55%</span></span><span style="font-family:inherit;font-size:10pt;"> or approximately </span><span style="font-family:inherit;font-size:10pt;"><span>160</span></span><span style="font-family:inherit;font-size:10pt;"> positions. </span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We incurred restructuring charges consisting of one-time severance payments and other employee related costs, including non-cash costs related to the acceleration of equity awards for employees affected by the restructuring, of </span><span style="font-family:inherit;font-size:10pt;"><span>$19.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> in the fourth quarter of 2019. The majority of the cash payments for employee related restructuring charges will be paid during the first quarter of 2020. Additionally, we incurred one-time charges related to lease and other contract cancellations and asset impairments of </span><span style="font-family:inherit;font-size:10pt;"><span>$8.9 million</span></span><span style="font-family:inherit;font-size:10pt;"> in the fourth quarter of 2019. We may also incur additional costs not currently contemplated due to events that may occur as a result of, or that are associated with, the workforce reduction and the cancellation of our PEGPH20 programs.</span></div> 0.55 160 19500000 8900000 <div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Valuation and Qualifying Accounts</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands)</span></div><div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.51656920077973%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:48%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance at Beginning of Period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Additions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Deductions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance at End of Period</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For the year ended December 31, 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts receivable allowances </span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>592</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,327</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(7,122</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>797</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For the year ended December 31, 2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts receivable allowances </span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>559</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,988</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5,955</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>592</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For the year ended December 31, 2017</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts receivable allowances </span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>559</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,645</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4,645</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>559</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">_______________</span></div><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:inherit;font-size:10pt;">(1)</span></div>Allowances are for chargebacks, prompt payment discounts and distribution fees related to Hylenex recombinant product sales. 592000 7327000 7122000 797000 559000 5988000 5955000 592000 559000 4645000 4645000 559000 XML 56 R31.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Summary of Unaudited Quarterly Financial Information (Tables)
    		 12 Months Ended
    Dec. 31, 2019
    Quarterly Financial Information Disclosure [Abstract]  
    Quarterly Financial Information [Table Text Block]
    The following is a summary of our unaudited quarterly results for the years ended December 31, 2019 and 2018 (in thousands):
     
     
    Quarter Ended
    2019 (Unaudited):
     
    March 31,
     
    June 30,
     
    September 30,
     
    December 31,
    Total revenues (1)
     
    $
    56,949

     
    $
    39,148

     
    $
    46,230

     
    $
    53,665

    Gross profit on product sales
     
    $
    3,741

     
    $
    3,883

     
    $
    6,872

     
    $
    6,006

    Total operating expenses(3)
     
    $
    53,983

     
    $
    53,125

     
    $
    70,767

     
    $
    85,727

    Net Income (loss)
     
    $
    1,796

     
    $
    (14,624
    )
     
    $
    (25,015
    )
     
    $
    (34,397
    )
    Net Income (loss) per share:
     
     
     
     
     
     
     
     
    Basic
     
    $
    0.01

     
    $
    (0.10
    )
     
    $
    (0.17
    )
     
    $
    (0.24
    )
    Diluted
     
    $
    0.01

     
    $
    (0.10
    )
     
    $
    (0.17
    )
     
    $
    (0.24
    )
    Shares used in computing net income (loss) per share:
     
     
     
     
     
     
     
     
    Basic
     
    144,743

     
    145,411

     
    146,136

     
    141,046

    Diluted
     
    147,474

     
    145,411

     
    146,136

     
    141,046

     
     
    Quarter Ended
    2018 (Unaudited):
     
    March 31,
     
    June 30,
     
    September 30,
     
    December 31,
    Total revenues (2)
     
    $
    30,872

     
    $
    35,202

     
    $
    25,556

     
    $
    60,232

    Gross profit on product sales
     
    $
    3,749

     
    $
    3,647

     
    $
    5,643

     
    $
    5,059

    Total operating expenses
     
    $
    54,584

     
    $
    55,275

     
    $
    51,030

     
    $
    60,303

    Net loss
     
    $
    (27,461
    )
     
    $
    (22,893
    )
     
    $
    (27,850
    )
     
    $
    (2,126
    )
    Net loss per share:
     
     
     


     


     


    Basic
     
    $
    (0.19
    )
     
    $
    (0.16
    )
     
    $
    (0.19
    )
     
    $
    (0.01
    )
    Diluted
     
    $
    (0.19
    )
     
    $
    (0.16
    )
     
    $
    (0.19
    )
     
    $
    (0.01
    )
    Shares used in computing net loss per share:
     


     


     


     


    Basic
     
    142,656

     
    143,568

     
    143,949

     
    144,203

    Diluted
     
    142,656

     
    143,568

     
    143,949

     
    144,203

    _______________
    (1)
    Revenue for the quarter ended March 31, 2019 included $30.0 million in revenue under a collaborative arrangement from argenx.
    (2)
    Revenues for the quarter ended December 31, 2018 included $30.0 million in revenue under a collaborative arrangement from Roche.
    (3)
    Total operating expenses for the quarter ended December 31, 2019 included $28.4 million restructuring charges.
    XML 57 R39.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Summary of Significant Accounting Policies Revenue recognition (Details) - USD ($)
    $ in Thousands
    		 3 Months Ended 12 Months Ended
    Dec. 31, 2019
    Dec. 31, 2019
    Dec. 31, 2018
    Dec. 31, 2017
    Collaborative agreements termination notification        
    Cost of Goods and Services Sold   $ 45,546 $ 10,136 $ 31,152
    Bulk rHuPH20 And ENHANZE [Member]        
    Collaborative agreements termination notification        
    Cost of Goods and Services Sold   $ 1,500    
    Manufacturing Costs $ 100      
    XML 58 R58.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Certain Balance Sheet Items - Accrued Expenses (Details) - USD ($)
    		 12 Months Ended
    Dec. 31, 2019
    Dec. 31, 2018
    Payables and Accruals [Abstract]    
    Operating Lease, Accretion Of Liability $ 800,000 $ 0
    Summary of Accrued Expenses    
    Accrued outsourced research and development 8,423,000 21,921,000
    Accrued compensation and payroll taxes 27,888,000 16,604,000
    Accrued outsourced manufacturing expenses 9,173,000 3,975,000
    Other accrued expenses 7,876,000 7,623,000
    Operating Lease, Liability 6,469,000 0
    Total accrued expenses 59,829,000 50,123,000
    Accrued Liabilities, Noncurrent 4,180,000 594,000
    Total accrued expenses, current 55,649,000 49,529,000
    Operating Lease, Cost 2,600,000 2,400,000
    Operating Lease, Payments $ 3,100,000 $ 2,400,000
    XML 59 R50.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Revenue - Contract with Customer, Asset and Liability (Details) - USD ($)
    $ in Thousands
    Dec. 31, 2019
    Dec. 31, 2018
    Deferred Credits and Other Liabilities $ 5,300  
    Accounts receivable, net 59,442 $ 30,005
    Deferred revenues 5,259 $ 9,255
    Deferred Credits and Other Liabilities, Current 4,012  
    Product sales, net    
    Deferred Credits and Other Liabilities 12,300  
    Deferred Credits and Other Liabilities, Current $ 7,000  
    XML 60 R54.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Certain Balance Sheet Items - Inventories (Details) - USD ($)
    $ in Thousands
    Dec. 31, 2019
    Dec. 31, 2018
    Inventory Disclosure [Abstract]    
    Inventory, Raw Materials $ 2,769 $ 735
    Inventory, Work in Process 15,710 11,430
    Inventory, Finished Goods 10,880 10,460
    Summary of Inventories    
    Total inventories $ 29,359 $ 22,625
    XML 61 FilingSummary.xml IDEA: XBRL DOCUMENT 3.19.3.a.u2 html 301 514 1 false 113 0 false 8 false false R1.htm 0001000 - Document - Cover Sheet http://www.halozyme.com/role/Cover Cover Cover 1 false false R2.htm 1001000 - Statement - Consolidated Balance Sheets Sheet http://www.halozyme.com/role/ConsolidatedBalanceSheets Consolidated Balance Sheets Statements 2 false false R3.htm 1001501 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://www.halozyme.com/role/ConsolidatedBalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 1002000 - Statement - Consolidated Statements of Operations Sheet http://www.halozyme.com/role/ConsolidatedStatementsOfOperations Consolidated Statements of Operations Statements 4 false false R5.htm 1004000 - Statement - Consolidated Statements of Comprehensive Loss Sheet http://www.halozyme.com/role/ConsolidatedStatementsOfComprehensiveLoss Consolidated Statements of Comprehensive Loss Statements 5 false false R6.htm 1005000 - Statement - Consolidated Statements of Cash Flows Sheet http://www.halozyme.com/role/ConsolidatedStatementsOfCashFlows Consolidated Statements of Cash Flows Statements 6 false false R7.htm 1006000 - Statement - Consolidated Statements of Stockholders' Equity (Deficit) Statement Sheet http://www.halozyme.com/role/ConsolidatedStatementsOfStockholdersEquityDeficitStatement Consolidated Statements of Stockholders' Equity (Deficit) Statement Statements 7 false false R8.htm 2101100 - Disclosure - Organization and Business Sheet http://www.halozyme.com/role/OrganizationAndBusiness Organization and Business Notes 8 false false R9.htm 2102100 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.halozyme.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 9 false false R10.htm 2103100 - Disclosure - Fair Value Measurement (Notes) Notes http://www.halozyme.com/role/FairValueMeasurementNotes Fair Value Measurement (Notes) Notes 10 false false R11.htm 2104100 - Disclosure - Revenue Sheet http://www.halozyme.com/role/Revenue Revenue Notes 11 false false R12.htm 2105100 - Disclosure - Certain Balance Sheet Items Sheet http://www.halozyme.com/role/CertainBalanceSheetItems Certain Balance Sheet Items Notes 12 false false R13.htm 2106100 - Disclosure - Long-Term Debt, Net Sheet http://www.halozyme.com/role/LongTermDebtNet Long-Term Debt, Net Notes 13 false false R14.htm 2107100 - Disclosure - Share-based Compensation (Notes) Notes http://www.halozyme.com/role/ShareBasedCompensationNotes Share-based Compensation (Notes) Notes 14 false false R15.htm 2108100 - Disclosure - Stockholders' Equity (Deficit) Sheet http://www.halozyme.com/role/StockholdersEquityDeficit Stockholders' Equity (Deficit) Notes 15 false false R16.htm 2109100 - Disclosure - Commitments and Contingencies Sheet http://www.halozyme.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 16 false false R17.htm 2110100 - Disclosure - Income Taxes (Notes) Notes http://www.halozyme.com/role/IncomeTaxesNotes Income Taxes (Notes) Notes 17 false false R18.htm 2111100 - Disclosure - Employee Savings Plan (Notes) Notes http://www.halozyme.com/role/EmployeeSavingsPlanNotes Employee Savings Plan (Notes) Notes 18 false false R19.htm 2112100 - Disclosure - Summary of Unaudited Quarterly Financial Information Sheet http://www.halozyme.com/role/SummaryOfUnauditedQuarterlyFinancialInformation Summary of Unaudited Quarterly Financial Information Notes 19 false false R20.htm 2113100 - Disclosure - Restructuring Charges Sheet http://www.halozyme.com/role/RestructuringCharges Restructuring Charges Notes 20 false false R21.htm 2114100 - Schedule - Schedule II Valuation and Qualifying Accounts Sheet http://www.halozyme.com/role/ScheduleIiValuationAndQualifyingAccounts Schedule II Valuation and Qualifying Accounts Uncategorized 21 false false R22.htm 2202201 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Notes 22 false false R23.htm 2302302 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://www.halozyme.com/role/SummaryOfSignificantAccountingPolicies 23 false false R24.htm 2303301 - Disclosure - Fair Value Measurement (Tables) Sheet http://www.halozyme.com/role/FairValueMeasurementTables Fair Value Measurement (Tables) Tables http://www.halozyme.com/role/FairValueMeasurementNotes 24 false false R25.htm 2304301 - Disclosure - Revenue (Tables) Sheet http://www.halozyme.com/role/RevenueTables Revenue (Tables) Tables http://www.halozyme.com/role/Revenue 25 false false R26.htm 2305301 - Disclosure - Certain Balance Sheet Items (Tables) Sheet http://www.halozyme.com/role/CertainBalanceSheetItemsTables Certain Balance Sheet Items (Tables) Tables http://www.halozyme.com/role/CertainBalanceSheetItems 26 false false R27.htm 2306301 - Disclosure - Long-Term Debt, Net Debt Disclosure (Tables) Sheet http://www.halozyme.com/role/LongTermDebtNetDebtDisclosureTables Long-Term Debt, Net Debt Disclosure (Tables) Tables 27 false false R28.htm 2307301 - Disclosure - Share-based Compensation (Tables) Sheet http://www.halozyme.com/role/ShareBasedCompensationTables Share-based Compensation (Tables) Tables http://www.halozyme.com/role/ShareBasedCompensationNotes 28 false false R29.htm 2309301 - Disclosure - Commitments and Contingencies Commitments and Contingencies (Tables) Sheet http://www.halozyme.com/role/CommitmentsAndContingenciesCommitmentsAndContingenciesTables Commitments and Contingencies Commitments and Contingencies (Tables) Tables 29 false false R30.htm 2310301 - Disclosure - Income Taxes (Tables) Sheet http://www.halozyme.com/role/IncomeTaxesTables Income Taxes (Tables) Tables http://www.halozyme.com/role/IncomeTaxesNotes 30 false false R31.htm 2312301 - Disclosure - Summary of Unaudited Quarterly Financial Information (Tables) Sheet http://www.halozyme.com/role/SummaryOfUnauditedQuarterlyFinancialInformationTables Summary of Unaudited Quarterly Financial Information (Tables) Tables http://www.halozyme.com/role/SummaryOfUnauditedQuarterlyFinancialInformation 31 false false R32.htm 2402403 - Disclosure - Summary of Significant Accounting Policies Restricted Cash (Details) Sheet http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesRestrictedCashDetails Summary of Significant Accounting Policies Restricted Cash (Details) Details 32 false false R33.htm 2402404 - Disclosure - Summary of Significant Accounting Policies Concentrations of Credit Risk (Details) Sheet http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesConcentrationsOfCreditRiskDetails Summary of Significant Accounting Policies Concentrations of Credit Risk (Details) Details 33 false false R34.htm 2402405 - Disclosure - Summary of Significant Accounting Policies Accounts Receivable (Details) Sheet http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesAccountsReceivableDetails Summary of Significant Accounting Policies Accounts Receivable (Details) Details 34 false false R35.htm 2402406 - Disclosure - Summary of Significant Accounting Policies Inventories (Details) Sheet http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesInventoriesDetails Summary of Significant Accounting Policies Inventories (Details) Details 35 false false R36.htm 2402407 - Disclosure - Summary of Significant Accounting Policies Leases (Details) Sheet http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesLeasesDetails Summary of Significant Accounting Policies Leases (Details) Details http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesTables 36 false false R37.htm 2402408 - Disclosure - Summary of Significant Accounting Policies Property and Equipment (Details) Sheet http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails Summary of Significant Accounting Policies Property and Equipment (Details) Details 37 false false R38.htm 2402409 - Disclosure - Summary of Significant Accounting Policies Impairment of Long-Lived Assets (Details) Sheet http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesImpairmentOfLongLivedAssetsDetails Summary of Significant Accounting Policies Impairment of Long-Lived Assets (Details) Details 38 false false R39.htm 2402410 - Disclosure - Summary of Significant Accounting Policies Revenue recognition (Details) Sheet http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails Summary of Significant Accounting Policies Revenue recognition (Details) Details 39 false false R40.htm 2402411 - Disclosure - Summary of Significant Accounting Policies Research and development (Details) Sheet http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesResearchAndDevelopmentDetails Summary of Significant Accounting Policies Research and development (Details) Details 40 false false R41.htm 2402412 - Disclosure - Summary of Significant Accounting Policies Income tax (Details) Sheet http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesIncomeTaxDetails Summary of Significant Accounting Policies Income tax (Details) Details 41 false false R42.htm 2402413 - Disclosure - Summary of Significant Accounting Policies Net Loss Per Share (Details) Sheet http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesNetLossPerShareDetails Summary of Significant Accounting Policies Net Loss Per Share (Details) Details 42 false false R43.htm 2402414 - Disclosure - Summary of Significant Accounting Policies Segment information (Details) Sheet http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesSegmentInformationDetails Summary of Significant Accounting Policies Segment information (Details) Details 43 false false R44.htm 2403402 - Disclosure - Fair Value Measurement - Summary (Details) Sheet http://www.halozyme.com/role/FairValueMeasurementSummaryDetails Fair Value Measurement - Summary (Details) Details 44 false false R45.htm 2403403 - Disclosure - Fair Value Measurement Textuals (Details) Sheet http://www.halozyme.com/role/FairValueMeasurementTextualsDetails Fair Value Measurement Textuals (Details) Details 45 false false R46.htm 2403404 - Disclosure - Fair Value Measurement Maturities (Details) Sheet http://www.halozyme.com/role/FairValueMeasurementMaturitiesDetails Fair Value Measurement Maturities (Details) Details 46 false false R47.htm 2403405 - Disclosure - Fair Value Measurement Fair Value Measures (Details) Sheet http://www.halozyme.com/role/FairValueMeasurementFairValueMeasuresDetails Fair Value Measurement Fair Value Measures (Details) Details 47 false false R48.htm 2404402 - Disclosure - Revenue - Disaggregation of Revenue (Details) Sheet http://www.halozyme.com/role/RevenueDisaggregationOfRevenueDetails Revenue - Disaggregation of Revenue (Details) Details 48 false false R49.htm 2404403 - Disclosure - Revenue - Textuals (Details) Sheet http://www.halozyme.com/role/RevenueTextualsDetails Revenue - Textuals (Details) Details 49 false false R50.htm 2404404 - Disclosure - Revenue - Contract with Customer, Asset and Liability (Details) Sheet http://www.halozyme.com/role/RevenueContractWithCustomerAssetAndLiabilityDetails Revenue - Contract with Customer, Asset and Liability (Details) Details 50 false false R51.htm 2404405 - Disclosure - Revenue - Revenue Recognition, Multiple-deliverable Arrangements (Details) Sheet http://www.halozyme.com/role/RevenueRevenueRecognitionMultipleDeliverableArrangementsDetails Revenue - Revenue Recognition, Multiple-deliverable Arrangements (Details) Details 51 false false R52.htm 2404406 - Disclosure - Revenue - Revenue, Remaining Performance Obligation (Details) Sheet http://www.halozyme.com/role/RevenueRevenueRemainingPerformanceObligationDetails Revenue - Revenue, Remaining Performance Obligation (Details) Details 52 false false R53.htm 2405402 - Disclosure - Certain Balance Sheet Items - Accounts receivable (Details) Sheet http://www.halozyme.com/role/CertainBalanceSheetItemsAccountsReceivableDetails Certain Balance Sheet Items - Accounts receivable (Details) Details 53 false false R54.htm 2405403 - Disclosure - Certain Balance Sheet Items - Inventories (Details) Sheet http://www.halozyme.com/role/CertainBalanceSheetItemsInventoriesDetails Certain Balance Sheet Items - Inventories (Details) Details 54 false false R55.htm 2405404 - Disclosure - Certain Balance Sheet Items - Prepaid expenses and other assets (Details) Sheet http://www.halozyme.com/role/CertainBalanceSheetItemsPrepaidExpensesAndOtherAssetsDetails Certain Balance Sheet Items - Prepaid expenses and other assets (Details) Details 55 false false R56.htm 2405405 - Disclosure - Certain Balance Sheet Items - Property and Equipment (Details) Sheet http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyAndEquipmentDetails Certain Balance Sheet Items - Property and Equipment (Details) Details 56 false false R57.htm 2405406 - Disclosure - Certain Balance Sheet Items - Property and Equipment, Net (Textuals) (Details) Sheet http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyAndEquipmentNetTextualsDetails Certain Balance Sheet Items - Property and Equipment, Net (Textuals) (Details) Details 57 false false R58.htm 2405407 - Disclosure - Certain Balance Sheet Items - Accrued Expenses (Details) Sheet http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails Certain Balance Sheet Items - Accrued Expenses (Details) Details 58 false false R59.htm 2405408 - Disclosure - Certain Balance Sheet Items - Deferred Revenue (Details) Sheet http://www.halozyme.com/role/CertainBalanceSheetItemsDeferredRevenueDetails Certain Balance Sheet Items - Deferred Revenue (Details) Details 59 false false R60.htm 2406402 - Disclosure - Long-Term Debt, Net Long-Term Debt Textuals (Details) Sheet http://www.halozyme.com/role/LongTermDebtNetLongTermDebtTextualsDetails Long-Term Debt, Net Long-Term Debt Textuals (Details) Details 60 false false R61.htm 2406403 - Disclosure - Long-Term Debt, Net Debt Table (Details) Sheet http://www.halozyme.com/role/LongTermDebtNetDebtTableDetails Long-Term Debt, Net Debt Table (Details) Details http://www.halozyme.com/role/LongTermDebtNetDebtDisclosureTables 61 false false R62.htm 2407402 - Disclosure - Share-based Compensation Textuals (Details) Sheet http://www.halozyme.com/role/ShareBasedCompensationTextualsDetails Share-based Compensation Textuals (Details) Details 62 false false R63.htm 2407403 - Disclosure - Share-based Compensation Expense (Details) Sheet http://www.halozyme.com/role/ShareBasedCompensationExpenseDetails Share-based Compensation Expense (Details) Details 63 false false R64.htm 2407404 - Disclosure - Share-based Compensation Unrecognized Expense (Details) Sheet http://www.halozyme.com/role/ShareBasedCompensationUnrecognizedExpenseDetails Share-based Compensation Unrecognized Expense (Details) Details 64 false false R65.htm 2407405 - Disclosure - Share-based Compensation Options (Details) Sheet http://www.halozyme.com/role/ShareBasedCompensationOptionsDetails Share-based Compensation Options (Details) Details 65 false false R66.htm 2407406 - Disclosure - Share-based Compensation Valuation (Details) Sheet http://www.halozyme.com/role/ShareBasedCompensationValuationDetails Share-based Compensation Valuation (Details) Details 66 false false R67.htm 2407407 - Disclosure - Share-based Compensation Restricted Stock Awards (Details) Sheet http://www.halozyme.com/role/ShareBasedCompensationRestrictedStockAwardsDetails Share-based Compensation Restricted Stock Awards (Details) Details 67 false false R68.htm 2407408 - Disclosure - Share-based Compensation Restricted Stock Units (Details) Sheet http://www.halozyme.com/role/ShareBasedCompensationRestrictedStockUnitsDetails Share-based Compensation Restricted Stock Units (Details) Details 68 false false R69.htm 2408401 - Disclosure - Stockholders' Equity (Deficit) Public Offering (Details) Sheet http://www.halozyme.com/role/StockholdersEquityDeficitPublicOfferingDetails Stockholders' Equity (Deficit) Public Offering (Details) Details http://www.halozyme.com/role/StockholdersEquityDeficit 69 false false R70.htm 2408402 - Disclosure - Stockholders' Equity (Deficit) (Details) Sheet http://www.halozyme.com/role/StockholdersEquityDeficitDetails Stockholders' Equity (Deficit) (Details) Details http://www.halozyme.com/role/StockholdersEquityDeficit 70 false false R71.htm 2408403 - Disclosure - Stockholders' Equity (Deficit) Share Repurchases (Details) Sheet http://www.halozyme.com/role/StockholdersEquityDeficitShareRepurchasesDetails Stockholders' Equity (Deficit) Share Repurchases (Details) Details http://www.halozyme.com/role/StockholdersEquityDeficit 71 false false R72.htm 2409402 - Disclosure - Commitments and Contingencies Operating Lease textual (Details) Sheet http://www.halozyme.com/role/CommitmentsAndContingenciesOperatingLeaseTextualDetails Commitments and Contingencies Operating Lease textual (Details) Details 72 false false R73.htm 2409403 - Disclosure - Commitments and Contingencies Commitments and Contingencies (Details) Sheet http://www.halozyme.com/role/CommitmentsAndContingenciesCommitmentsAndContingenciesDetails Commitments and Contingencies Commitments and Contingencies (Details) Details http://www.halozyme.com/role/CommitmentsAndContingenciesCommitmentsAndContingenciesTables 73 false false R74.htm 2409404 - Disclosure - Commitments and Contingencies Other Commitments (Details) Sheet http://www.halozyme.com/role/CommitmentsAndContingenciesOtherCommitmentsDetails Commitments and Contingencies Other Commitments (Details) Details 74 false false R75.htm 2410402 - Disclosure - Income Taxes (Details) Sheet http://www.halozyme.com/role/IncomeTaxesDetails Income Taxes (Details) Details http://www.halozyme.com/role/IncomeTaxesTables 75 false false R76.htm 2410403 - Disclosure - Income Taxes Net Income (Loss) By Region (Details) Sheet http://www.halozyme.com/role/IncomeTaxesNetIncomeLossByRegionDetails Income Taxes Net Income (Loss) By Region (Details) Details 76 false false R77.htm 2410404 - Disclosure - Income Taxes Components Deferred Taxes (Details) Sheet http://www.halozyme.com/role/IncomeTaxesComponentsDeferredTaxesDetails Income Taxes Components Deferred Taxes (Details) Details 77 false false R78.htm 2410405 - Disclosure - Income Taxes Income Tax Expense (Details) Sheet http://www.halozyme.com/role/IncomeTaxesIncomeTaxExpenseDetails Income Taxes Income Tax Expense (Details) Details 78 false false R79.htm 2410406 - Disclosure - Income Taxes Schedule of Income Tax Reconciliation (Details) Sheet http://www.halozyme.com/role/IncomeTaxesScheduleOfIncomeTaxReconciliationDetails Income Taxes Schedule of Income Tax Reconciliation (Details) Details 79 false false R80.htm 2410407 - Disclosure - Income Taxes Unrecognized Tax Benefit (Details) Sheet http://www.halozyme.com/role/IncomeTaxesUnrecognizedTaxBenefitDetails Income Taxes Unrecognized Tax Benefit (Details) Details 80 false false R81.htm 2410408 - Disclosure - Income Taxes Operating Loss Carryforward Expiration (Details) Sheet http://www.halozyme.com/role/IncomeTaxesOperatingLossCarryforwardExpirationDetails Income Taxes Operating Loss Carryforward Expiration (Details) Details 81 false false R82.htm 2410409 - Disclosure - Income Taxes Tax textuals (Details) Sheet http://www.halozyme.com/role/IncomeTaxesTaxTextualsDetails Income Taxes Tax textuals (Details) Details 82 false false R83.htm 2411402 - Disclosure - Employee Savings Plan (Details) Sheet http://www.halozyme.com/role/EmployeeSavingsPlanDetails Employee Savings Plan (Details) Details http://www.halozyme.com/role/EmployeeSavingsPlanNotes 83 false false R84.htm 2412402 - Disclosure - Summary of Unaudited Quarterly Financial Information - Quarterly Financial Information (Details) Sheet http://www.halozyme.com/role/SummaryOfUnauditedQuarterlyFinancialInformationQuarterlyFinancialInformationDetails Summary of Unaudited Quarterly Financial Information - Quarterly Financial Information (Details) Details 84 false false R85.htm 2412403 - Disclosure - Summary of Unaudited Quarterly Financial Information - Textuals (Details) Sheet http://www.halozyme.com/role/SummaryOfUnauditedQuarterlyFinancialInformationTextualsDetails Summary of Unaudited Quarterly Financial Information - Textuals (Details) Details http://www.halozyme.com/role/SummaryOfUnauditedQuarterlyFinancialInformationTables 85 false false R86.htm 2413401 - Disclosure - Restructuring Charges - Narrative (Details) Sheet http://www.halozyme.com/role/RestructuringChargesNarrativeDetails Restructuring Charges - Narrative (Details) Details 86 false false R87.htm 2414401 - Disclosure - Schedule II Valuation and Qualifying Accounts (Details) Sheet http://www.halozyme.com/role/ScheduleIiValuationAndQualifyingAccountsDetails Schedule II Valuation and Qualifying Accounts (Details) Details 87 false false R9999.htm Uncategorized Items - halo2019-10k.htm Sheet http://xbrl.sec.gov/role/uncategorizedFacts Uncategorized Items - halo2019-10k.htm Cover 88 false false All Reports Book All Reports halo2019-10k.htm ex211subsidiaries2019.htm ex231auditorconsent2019.htm ex31110k2019.htm ex31210k2019.htm ex3210k2019.htm ex43halo-descriptionof.htm halo-20191231.xsd halo-20191231_cal.xml halo-20191231_def.xml halo-20191231_lab.xml halo-20191231_pre.xml perfrormancegraph.jpg slide1b04.jpg slide2a93.jpg http://fasb.org/srt/2019-01-31 http://xbrl.sec.gov/country/2017-01-31 http://fasb.org/us-gaap/2019-01-31 http://xbrl.sec.gov/dei/2019-01-31 true true XML 62 R87.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Schedule II Valuation and Qualifying Accounts (Details) - USD ($)
    $ in Thousands
    		 12 Months Ended
    Dec. 31, 2019
    Dec. 31, 2018
    Dec. 31, 2017
    SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]      
    Accounts receivable allowance, beginning balance $ 592 $ 559 $ 559
    Additions 7,327 5,988 4,645
    Deductions (7,122) (5,955) (4,645)
    Accounts receivable allowance, ending balance $ 797 $ 592 $ 559
    XML 63 R77.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Income Taxes Components Deferred Taxes (Details) - USD ($)
    $ in Thousands
    Dec. 31, 2019
    Dec. 31, 2018
    Income Tax Disclosure [Abstract]    
    Deferred Tax Assets, Operating Loss Carryforwards $ 39,401 $ 26,267
    Deferred Tax Assets, Deferred Income 1,069 1,395
    Deferred Tax Assets, Tax Credit Carryforwards, Research 114,357 106,406
    Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost 9,972 9,541
    Deferred Tax Assets, Tax Credit Carryforwards, Alternative Minimum Tax 1,683 2,959
    Deferred Tax Assets, Lease Liabilities 1,454 0
    Deferred Tax Assets, Interest Expense Limitation 2,163 1,750
    Deferred Tax Assets, Other 3,037 2,452
    Deferred Tax Assets, Gross 173,136 150,770
    Deferred Tax Assets, Valuation Allowance (155,100) (146,953)
    Deferred Tax Assets, Net of Valuation Allowance 18,036 3,817
    Deferred Tax Liabilities, Property, Plant and Equipment (865) (858)
    Deferred Tax Liabilities, Convertible Note (14,450) 0
    Deferred Tax Liabilities, Right-of-Use Asset (865) 0
    Deferred Tax Liabilities, Other (173) 0
    Deferred Tax Liabilities, Net, Noncurrent (16,353) (858)
    Deferred Tax Assets, Net $ 1,683 $ 2,959
    XML 64 R73.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Commitments and Contingencies Commitments and Contingencies (Details) - USD ($)
    $ in Thousands
    		 12 Months Ended
    Dec. 31, 2019
    Dec. 31, 2018
    Dec. 31, 2017
    Commitments and Contingencies Disclosure [Abstract]      
    Operating Lease, Impairment Loss $ 1,127 $ 0 $ 0
    Operating Leases, Rent Expense, Net 2,700 2,500 $ 2,300
    2020 3,355    
    2021 2,260    
    2022 1,559    
    2023 70    
    2024 0    
    Total minimum lease payments 7,244    
    Less imputed interest (775)    
    Total $ 6,469 $ 0  
    XML 65 R83.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Employee Savings Plan (Details) - USD ($)
    $ in Millions
    		 12 Months Ended
    Dec. 31, 2019
    Dec. 31, 2018
    Dec. 31, 2017
    Retirement Benefits [Abstract]      
    Employer Discretionary Contribution Amount $ 2.2 $ 1.3 $ 1.2
    XML 66 R60.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Long-Term Debt, Net Long-Term Debt Textuals (Details)
    $ / shares in Units, shares in Millions
    		 1 Months Ended 12 Months Ended
    Nov. 30, 2019
    USD ($)
    trading_day
    $ / shares
    shares
    Dec. 31, 2019
    USD ($)
    Dec. 31, 2018
    USD ($)
    Dec. 31, 2017
    USD ($)
    Debt Instrument [Line Items]        
    Long-term Debt, Fair Value   $ 402,587,000    
    Payments of Debt Issuance Costs   279,000 $ 0 $ 0
    Long-term Debt   383,045,000 34,874,000  
    Non-Convertible Borrowing Rate for Similar Debt, Percent 5.19%      
    Debt Instrument, Convertible, Carrying Amount of Equity Component $ 65,600,000      
    Proceeds from Convertible Debt 447,400,000      
    Payments for Repurchase of Common Stock 200,000,000.0 199,998,000 0 0
    Interest Costs Capitalized   0    
    Amortization of Debt Discount (Premium)   2,484,000 1,545,000  
    Debt Instrument, Unamortized Discount   76,973,000    
    Treasury Stock, Value, Acquired, Cost Method $ 6,900,000      
    Treasury Stock, Shares, Acquired | shares 0.4      
    Repayments of Debt $ 26,100,000      
    Convertible Senior Notes | 1.25% Convertible Senior Notes due 2024        
    Debt Instrument [Line Items]        
    Face amount of debt instrument $ 460,000,000.0      
    Stated interest rate (as a percent) 1.25%      
    Conversion rate (shares) 41.9208      
    Debt Instrument, Convertible, Conversion Price | $ / shares $ 23.85      
    Long-term Debt, Fair Value $ 381,800,000      
    Payments of Debt Issuance Costs 300,000      
    Long-term Debt   383,100,000    
    Lender Fee 12,700,000      
    Interest Expense, debt   2,300,000    
    Debt Instrument, Periodic Payment, Interest   700,000    
    Amortization of Debt Discount (Premium)   1,600,000    
    Debt Instrument, Unamortized Discount   $ 76,900,000    
    Debt Instrument, Convertible, Remaining Discount Amortization Period   5 years    
    Debt Instrument, Interest Rate, Effective Percentage   5.10%    
    Royalty-backed Loan        
    Debt Instrument [Line Items]        
    Face amount of debt instrument   $ 150,000,000    
    Debt Instrument, Description of Variable Rate Basis   8.75% plus the three-month LIBOR rate    
    Debt, Interest Rate   10.25%    
    Debt Instrument, Maturity Date, Description   final maturity date of the Royalty-backed Loan will be the earlier of (i) the date when principal and interest is paid in full, (ii) the termination of Halozyme Royalty’s right to receive royalties under the Collaboration Agreements, and (iii) December 31, 2050    
    Prepayment fee, percent   105.00%    
    Debt instrument, covenant in compliance   in compliance    
    Accrued Interest   $ 100,000 400,000  
    Lender Fee   1,500,000    
    Debt Issuance Cost   400,000    
    Interest Expense, debt   6,200,000 13,100,000 16,400,000
    Outstanding loan balance   $ 19,500,000    
    Maturity date   Dec. 31, 2050    
    Royalty-backed Loan | 2016 [Member]        
    Debt Instrument [Line Items]        
    Royalty payments to be applied to debt instrument   0.00%    
    Royalty-backed Loan | 2017 [Member]        
    Debt Instrument [Line Items]        
    Royalty payments to be applied to debt instrument   50.00%    
    Royalty-backed Loan | 2018 and thereafter [Member]        
    Debt Instrument [Line Items]        
    Royalty payments to be applied to debt instrument   100.00%    
    Royalty-backed Loan | 2017 Quarterly Maximum Payment [Member]        
    Debt Instrument [Line Items]        
    Debt Instrument, Periodic Payment   $ 13,750,000    
    Royalty-backed Loan | 2018 Quarterly Maximum Payment [Member]        
    Debt Instrument [Line Items]        
    Debt Instrument, Periodic Payment   18,750,000    
    Royalty-backed Loan | 2019 Quarterly Maximum Payment [Member]        
    Debt Instrument [Line Items]        
    Debt Instrument, Periodic Payment   21,250,000    
    Royalty-backed Loan | 2020 Quarterly Maximum Payment [Member]        
    Debt Instrument [Line Items]        
    Debt Instrument, Periodic Payment   $ 22,500,000    
    Royalty-backed Loan | Minimum        
    Debt Instrument [Line Items]        
    Debt Instrument, Basis Spread on Variable Rate   0.70%    
    Royalty-backed Loan | Maximum        
    Debt Instrument [Line Items]        
    Debt Instrument, Basis Spread on Variable Rate   1.50%    
    Secured Debt        
    Debt Instrument [Line Items]        
    Final payment     4,250,000  
    Senior Loans [Member]        
    Debt Instrument [Line Items]        
    Face amount of debt instrument   $ 70,000,000.0    
    Stated interest rate (as a percent)   8.25%    
    Secured debt original draw   $ 55,000,000.0    
    Interest Expense, debt   $ 3,000,000.0 $ 4,900,000 $ 5,500,000
    Maturity date   Jan. 01, 2021    
    Final payment as percent of original principal   5.50%    
    Debt Instrument, Unused Borrowing Capacity, Amount   $ 15,000,000.0    
    Debt Instrument, interest only period   interest only payments for the first 18 months    
    Shares acquired in privately negotiated transactions [Domain]        
    Debt Instrument [Line Items]        
    Treasury Stock, Value, Acquired, Cost Method $ 143,100,000      
    Treasury Stock, Shares, Acquired | shares 8.1      
    Accelerated Share Repurchases, Date [Domain]        
    Debt Instrument [Line Items]        
    Treasury Stock, Value, Acquired, Cost Method $ 50,000,000.0      
    Treasury Stock, Shares, Acquired | shares 2.6      
    Debt Instrument, Redemption, Period One | Convertible Senior Notes | 1.25% Convertible Senior Notes due 2024        
    Debt Instrument [Line Items]        
    Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger 130.00%      
    Debt Instrument, Convertible, Threshold Trading Days | trading_day 20      
    Debt Instrument, Convertible, Threshold Consecutive Trading Days | trading_day 30      
    Debt Instrument, Redemption, Period Two | Convertible Senior Notes | 1.25% Convertible Senior Notes due 2024        
    Debt Instrument [Line Items]        
    Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger 98.00%      
    Debt Instrument, Convertible, Threshold Consecutive Trading Days | trading_day 5      
    XML 67 R64.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Share-based Compensation Unrecognized Expense (Details)
    $ in Thousands
    		 12 Months Ended
    Dec. 31, 2019
    USD ($)
    Stock options  
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
    Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount $ 16,524
    Compensation Cost Not yet Recognized, Period for Recognition 2 years 7 months 2 days
    RSAs  
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
    Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount $ 570
    Compensation Cost Not yet Recognized, Period for Recognition 4 days
    RSUs  
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
    Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount $ 11,600
    Compensation Cost Not yet Recognized, Period for Recognition 2 years 3 months 25 days
    XML 68 R68.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Share-based Compensation Restricted Stock Units (Details) - RSUs - USD ($)
    $ / shares in Units, $ in Millions
    		 12 Months Ended
    Dec. 31, 2019
    Dec. 31, 2018
    Dec. 31, 2017
    Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]      
    Nonvested, Number, period start 2,388,342    
    Nonvested, Weighted Average Grant Date Fair Value, period start $ 15.12    
    Grants in Period 1,151,464    
    Grants in Period, Weighted Average Grant Date Fair Value $ 16.55    
    Vested in Period (1,092,648)    
    Vested in Period, Weighted Average Grant Date Fair Value $ 15.35    
    Forfeited in Period (354,719)    
    Forfeitures, Weighted Average Grant Date Fair Value $ 16.22    
    Nonvested, Number, period end 2,092,439 2,388,342  
    Nonvested, Weighted Average Grant Date Fair Value, period end $ 15.60 $ 15.12  
    Outstanding, Weighted Average Remaining Contractual Terms 1 year 2 months 23 days    
    Aggregate Intrinsic Value, Nonvested $ 37.1    
    Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]      
    Vested in Period, Fair Value 19.1 $ 6.7 $ 4.0
    Aggregate Intrinsic Value, Vested $ 18.5 $ 11.0 $ 4.7
    XML 69 R47.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Fair Value Measurement Fair Value Measures (Details) - USD ($)
    $ in Thousands
    Dec. 31, 2019
    Dec. 31, 2018
    Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
    Available-for-sale Securities $ 301,083 $ 296,590
    Fair Value Disclosure 421,033 354,577
    Fair Value, Assets, Level 1 to Level 2 Transfers, Amount 0 0
    Money Market Funds [Member]    
    Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
    Cash Equivalents 119,949 57,987
    Commercial Paper [Member]    
    Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
    Available-for-sale Securities 33,845 114,273
    Corporate Debt Securities [Member]    
    Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
    Available-for-sale Securities 161,472 57,733
    US Treasury Securities [Member]    
    Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
    Available-for-sale Securities 75,228 84,837
    Fair Value, Inputs, Level 1 [Member]    
    Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
    Fair Value Disclosure 195,177 142,824
    Fair Value, Inputs, Level 2 [Member]    
    Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
    Fair Value Disclosure 225,856 211,753
    Fair Value, Inputs, Level 2 [Member] | Commercial Paper [Member]    
    Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
    Available-for-sale Securities 33,845  
    Fair Value, Inputs, Level 3 [Member]    
    Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
    Investments, Level 3 0 0
    Commercial Paper [Member]    
    Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
    Debt Securities, Available-for-sale, Amortized Cost   114,273
    Available-for-sale Securities 33,845 114,273
    Commercial Paper [Member] | Fair Value, Inputs, Level 1 [Member]    
    Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
    Debt Securities, Available-for-sale 0 0
    Commercial Paper [Member] | Fair Value, Inputs, Level 2 [Member] | Commercial Paper [Member]    
    Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
    Debt Securities, Available-for-sale   114,273
    Asset-backed Securities [Member]    
    Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
    Debt Securities, Available-for-sale, Amortized Cost 30,484 39,787
    Debt Securities, Available-for-sale 30,539 39,747
    Asset-backed Securities [Member] | Fair Value, Inputs, Level 1 [Member]    
    Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
    Debt Securities, Available-for-sale 0 0
    Asset-backed Securities [Member] | Fair Value, Inputs, Level 2 [Member]    
    Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
    Debt Securities, Available-for-sale 30,539 39,747
    US Treasury Securities [Member]    
    Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
    Debt Securities, Available-for-sale, Amortized Cost 75,192 84,924
    Available-for-sale Securities 75,227 84,837
    US Treasury Securities [Member] | Fair Value, Inputs, Level 1 [Member] | US Treasury Securities [Member]    
    Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
    Debt Securities, Available-for-sale 75,228 84,837
    US Treasury Securities [Member] | Fair Value, Inputs, Level 2 [Member]    
    Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
    Debt Securities, Available-for-sale 0 0
    Corporate Debt Securities [Member]    
    Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
    Debt Securities, Available-for-sale, Amortized Cost 161,308 57,860
    Available-for-sale Securities 161,472 57,733
    Corporate Debt Securities [Member] | Fair Value, Inputs, Level 1 [Member]    
    Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
    Debt Securities, Available-for-sale 0 0
    Corporate Debt Securities [Member] | Fair Value, Inputs, Level 2 [Member] | Corporate Debt Securities [Member]    
    Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
    Debt Securities, Available-for-sale 161,472 57,733
    Money Market Funds [Member] | Fair Value, Inputs, Level 1 [Member] | Money Market Funds [Member]    
    Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
    Cash Equivalents 119,949 57,987
    Money Market Funds [Member] | Fair Value, Inputs, Level 2 [Member]    
    Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
    Cash Equivalents $ 0 $ 0
    XML 70 R43.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Summary of Significant Accounting Policies Segment information (Details)
    		 12 Months Ended
    Dec. 31, 2019
    segment
    Segment Reporting [Abstract]  
    Number of Operating Segments 1
    XML 71 R8.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Organization and Business
    		 12 Months Ended
    Dec. 31, 2019
    Organization, Consolidation and Presentation of Financial Statements [Abstract]  
    Organization and Business Organization and Business
    Halozyme Therapeutics Inc. is a biopharma technology platform company that provides innovative and disruptive solutions with the goal of improving patient experience and outcomes. Our proprietary enzyme rHUPH20 is used to facilitate the delivery of injected drugs and fluids. We license our technology to biopharmaceutical companies to collaboratively develop products that combine our ENHANZE® drug delivery technology with the collaborators’ proprietary compounds. 
    Our approved product and our collaborators’ approved products and product candidates are based on rHuPH20, our patented recombinant human hyaluronidase enzyme. rHuPH20 is the active ingredient in our first commercially approved product, Hylenex® recombinant (“Hylenex”), and it works by breaking down hyaluronan (or “HA”), a naturally occurring carbohydrate that is a major component of the extracellular matrix in tissues throughout the body such as skin and cartilage. This temporarily increases dispersion and absorption allowing for improved subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other large therapeutic molecules, as well as small molecules and fluids. We refer to the application of rHuPH20 to facilitate the delivery of other drugs or fluids as our ENHANZE® Drug Delivery Technology (“ENHANZE”). We license the ENHANZE technology to form collaborations with biopharmaceutical companies that develop or market drugs requiring or benefiting from injection via the subcutaneous route of administration. In the development of proprietary intravenous (IV) drugs combined with our ENHANZE technology, data have been generated supporting the potential for ENHANZE to reduce treatment burden, as a result of shorter duration of subcutaneous (SC) administration. ENHANZE may enable fixed-dose SC dosing compared to weight-based dosing required for IV administration, and potentially allow for lower rates of infusion related reactions. Lastly, certain proprietary drugs co-formulated with ENHANZE have been granted additional exclusivity, extending the patent life of the product beyond the one of the proprietary IV drug.
    We currently have ENHANZE collaborations with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc. (“Roche”), Baxalta US Inc. and Baxalta GmbH (now members of the Takeda group of companies, following the acquisition of Shire plc by Takeda Pharmaceutical Company Limited in January 2019) (“Baxalta”), Pfizer Inc. (“Pfizer”), Janssen Biotech, Inc. (“Janssen”), AbbVie, Inc. (“AbbVie”), Eli Lilly and Company (“Lilly”), Bristol-Myers Squibb Company (“BMS”), Alexion Pharma Holding (“Alexion”) and ARGENX BVBA (“argenx”). We receive royalties from two of these collaborations, including royalties from sales of one product from the Baxalta collaboration and two products from the Roche collaboration. Future potential revenues from the sales and/or royalties of our approved products, product candidates, and ENHANZE collaborations will depend on the ability of Halozyme and our collaborators to develop, manufacture, secure and maintain regulatory approvals for approved products and product candidates and commercialize product candidates.
    On November 4, 2019, we announced that our HALO-301 Phase 3 clinical study evaluating PEGPH20 in combination with ABRAXANE and gemcitabine as a first-line therapy for treatment of patients with metastatic pancreatic cancer failed to reach the primary endpoint of overall survival. The study failed to demonstrate an improvement in overall survival compared to gemcitabine and nab-paclitaxel alone (11.2 months median overall survival compared to 11.5 months, HR=1.00, p=0.9692). Due to the results of the study, we halted development activities for PEGPH20, closed our oncology operations and implemented an organizational restructuring to focus our operations on ENHANZE.
    We closed all ongoing oncology clinical studies including the Phase 3 clinical testing for PEGPH20 with ABRAXANE and gemcitabine in stage IV pancreatic ductal adenocarcinoma (“PDA”) (HALO-301) and the Phase 1b/2 clinical testing for PEGPH20 with Tecentriq in patients with cholangiocarcinoma and gall bladder cancer (HALO 110-101/MATRIX). The Roche -Genentech sponsored MORPHEUS PDA and gastric cancer studies closed the arms containing PEGPH20 to enrollment. All patients who were treated in PEGPH20 arms are off PEGPH20 treatment and are in follow up, per study protocol.
    Except where specifically noted or the context otherwise requires, references to “Halozyme,” “the Company,” “we,” “our,” and “us” in these notes to consolidated financial statements refer to Halozyme Therapeutics, Inc. and its wholly owned subsidiary, Halozyme, Inc., and Halozyme, Inc.’s wholly owned subsidiaries, Halozyme Holdings Ltd., Halozyme Royalty LLC, Halozyme Switzerland GmbH and Halozyme Switzerland Holdings GmbH.
    XML 72 R22.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Summary of Significant Accounting Policies (Policies)
    		 12 Months Ended
    Dec. 31, 2019
    Accounting Policies [Abstract]  
    Basis of Presentation
    Basis of Presentation
    The consolidated financial statements include the accounts of Halozyme Therapeutics, Inc. and our wholly owned subsidiary, Halozyme, Inc., and Halozyme, Inc.’s wholly owned subsidiaries, Halozyme Holdings Ltd., Halozyme Royalty LLC, Halozyme Switzerland GmbH and Halozyme Switzerland Holdings GmbH. All intercompany accounts and transactions have been eliminated.
    Use of Estimates, Policy [Policy Text Block]
    Use of Estimates
    The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”) requires management to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes. On an ongoing basis, we evaluate our estimates and judgments, which are based on historical and anticipated results and trends and on various other assumptions that management believes to be reasonable under the circumstances. By their nature, estimates are subject to an inherent degree of uncertainty and, as such, actual results may differ from management’s estimates.
    Cash Equivalents
    Cash Equivalents and Marketable Securities
    Cash equivalents consist of highly liquid investments, readily convertible to cash, that mature within ninety days or less from the date of purchase. As of December 31, 2019, our cash equivalents consisted of money market funds.
    Marketable Securities
    Marketable securities are investments with original maturities of more than ninety days from the date of purchase that are specifically identified to fund current operations. Marketable securities are considered available-for-sale. These investments are classified as current assets, even though the stated maturity date may be one year or more beyond the current balance sheet date which reflects management’s intention to use the proceeds from the sale of these investments to fund our operations, as necessary. Such available-for-sale investments are carried at fair value with unrealized gains and losses recorded in other comprehensive income (loss) and included as a separate component of stockholders’ equity (deficit). The cost of marketable securities is adjusted for amortization of premiums or accretion of discounts to maturity, and such amortization or accretion is included in investment and other income, net in the consolidated statements of operations. We use the specific identification method for calculating realized gains and losses on marketable securities sold. Realized gains and losses and declines in value judged to be other-than-temporary on marketable securities, if any, are included in investment and other income, net in the consolidated statements of operations.
    Restricted Cash
    Restricted Cash
    Under the terms of the leases of our facilities, we are required to maintain letters of credit as security deposits during the terms of such leases. At December 31, 2019 and 2018, restricted cash of $0.5 million was pledged as collateral for the letters of credit.
    Fair Value of Financial Instruments
    Fair Value of Financial Instruments
    The authoritative guidance for fair value measurements establishes a three tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.
    Our financial instruments include cash equivalents, available-for-sale marketable securities, accounts receivable, prepaid expenses and other assets, accounts payable, accrued expenses and long-term debt. Fair value estimates of these instruments are made at a specific point in time, based on relevant market information. These estimates may be subjective in nature and involve uncertainties and matters of significant judgment and therefore cannot be determined with precision. The carrying amount of cash equivalents, accounts receivable, prepaid expenses and other assets, accounts payable and accrued expenses are generally considered to be representative of their respective fair values because of the short-term nature of those instruments. Based on Level 3 inputs and the borrowing rates currently available for loans with similar terms, we believe the fair value of long-term debt approximates its carrying value.
    Available-for-sale marketable securities consist of asset-backed securities, corporate debt securities, U.S. Treasury securities and commercial paper, and are measured at fair value using Level 1 and Level 2 inputs. Level 2 financial instruments are valued using market prices on less active markets and proprietary pricing valuation models with observable inputs, including interest rates, yield curves, maturity dates, issue dates, settlement dates, reported trades, broker-dealer quotes, issue spreads, benchmark securities or other market related data. We obtain the fair value of Level 2 investments from our investment manager, who obtains these fair values from a third-party pricing source. We validate the fair values of Level 2 financial instruments provided by our investment manager by comparing these fair values to a third-party pricing source.
    Concentration Risk, Credit Risk, Policy [Policy Text Block]
    Concentrations of Credit Risk, Sources of Supply and Significant Customers
    We are subject to credit risk from our portfolio of cash equivalents and marketable securities. These investments were made in accordance with our investment policy which specifies the categories, allocations, and ratings of securities we may consider for investment. The primary objective of our investment activities is to preserve principal while at the same time maximizing the income we receive without significantly increasing risk. We maintain our cash and cash equivalent balances with one major commercial bank and marketable securities with another financial institution. Deposits held with the financial institutions exceed the amount of insurance provided on such deposits. We are exposed to credit risk in the event of a default by the financial institutions holding our cash, cash equivalents and marketable securities to the extent recorded on the consolidated balance sheets.
    We are also subject to credit risk from our accounts receivable related to our product sales and revenues under our license and collaborative agreements. We have license and collaborative agreements with pharmaceutical companies under which we receive payments for royalties, license fees, milestone payments for specific achievements designated in the collaborative agreements, reimbursements of research and development services and supply of bulk formulation of rHuPH20. In addition, we sell Hylenex® recombinant in the United States to a limited number of established wholesale distributors in the pharmaceutical industry. Credit is extended based on an evaluation of the customer’s financial condition, and collateral is not required. Management monitors our exposure to accounts receivable by periodically evaluating the collectibility of the accounts receivable based on a variety of factors including the length of time the receivables are past due, the financial health of the customer and historical experience. Based upon the review of these factors, we recorded no allowance for doubtful accounts at December 31, 2019 and 2018. Approximately 93% of the accounts receivable balance at December 31, 2019 represents amounts due from Janssen, Roche and Baxalta. Approximately 81% of the accounts receivable balance at December 31, 2018 represents amounts due from Roche and Baxalta.
    The following table indicates the percentage of total revenues in excess of 10% with any single customer:
     
     
    Year Ended December 31,
     
     
    2019
     
    2018
     
    2017
    Roche
     
    40%
     
    72%
     
    38%
    argenx
     
    23%
     
    —%
     
    —%
    Janssen
     
    18%
     
    2%
     
    6%
    BMS
     
    1%
     
    4%
     
    32%
    Alexion
     
    1%
     
    3%
     
    13%
    We attribute revenues under collaborative agreements, including royalties, to the individual countries where the customer is headquartered. We attribute revenues from product sales to the individual countries to which the product is shipped. Worldwide revenues from external customers are summarized by geographic location in the following table (in thousands):
     
     
    Year Ended December 31,
     
     
    2019
     
    2018
     
    2017
    United States
     
    $
    116,083

     
    $
    40,475

     
    $
    196,274

    Switzerland
     
    78,413

     
    109,890

     
    119,136

    All other foreign
     
    1,496

     
    1,497

     
    1,203

    Total revenues
     
    $
    195,992

     
    $
    151,862

     
    $
    316,613


    We rely on two third-party manufacturers for the supply of bulk rHuPH20 for use in the manufacture of Hylenex recombinant and our other collaboration products and product candidates. Payments due to these suppliers represented 47% and 2% of the accounts payable balance at December 31, 2019 and 2018, respectively. We also rely on a third-party manufacturer for the fill and finish of Hylenex recombinant product under a contract. Payments due to this supplier represented 8% and 0% of the accounts payable balance at December 31, 2019 and 2018, respectively.
    Accounts Receivable [Policy Text Block]
    Accounts Receivable, Net
    Accounts receivable is recorded at the invoiced amount and is non-interest bearing. Accounts receivable is recorded net of allowances for doubtful accounts, cash discounts for prompt payment, distribution fees and chargebacks. We recorded no allowance for doubtful accounts at December 31, 2019 and 2018 as the collectibility of accounts receivable was reasonably assured.
    Inventory, Policy [Policy Text Block]
    Inventories
    Inventories are stated at lower of cost or net realizable value. Cost is determined on a first-in, first-out basis. Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. Inventories are reviewed periodically for potential excess, dated or obsolete status. We evaluate the carrying value of inventories on a regular basis, taking into account such factors as historical and anticipated future sales compared to quantities on hand, the price we expect to obtain for products in their respective markets compared with historical cost and the remaining shelf life of goods on hand.
    Bulk rHuPH20 formulations manufactured for partner use prior to our partner receiving marketing approval from the U.S. Food and Drug Administration (“FDA”) or comparable regulatory agencies in foreign countries and with no alternative future use are recorded as research and development expense. All direct manufacturing costs incurred after the partner receives marketing approval are capitalized as inventory. Bulk rHuPH20 formulations manufactured for general partner and internal use, which can potentially be used by any collaboration partner or by us in Hylenex, and ENHANZE drug product used by our partners in clinical trials, is considered to have alternative future use and all manufacturing costs are capitalized as inventory. Inventories used in our clinical trials are expensed at the time the inventories are packaged for the clinical trials.
    As of December 31, 2019 and 2018, inventories consisted of $1.4 million and $2.2 million, respectively, of Hylenex recombinant inventory, net, and $28.0 million and $20.4 million, respectively, of bulk rHuPH20
    Property and Equipment, Policy [Policy Text Block]
    Property and Equipment, Net
    Property and equipment are recorded at cost, less accumulated depreciation and amortization. Equipment is depreciated using the straight-line method over its estimated useful life ranging from three years to ten years and leasehold improvements are amortized using the straight-line method over the estimated useful life of the asset or the lease term, whichever is shorter.
    Impairment of Long-Lived Assets, Policy [Policy Text Block]
    Impairment of Long-Lived Assets
    We account for long-lived assets in accordance with authoritative guidance for impairment or disposal of long-lived assets. Long-lived assets are reviewed for events or changes in circumstances, which indicate that their carrying value may not be recoverable.
    Comprehensive Income (Loss), Policy [Policy Text Block]
    Comprehensive Income (Loss)
    Comprehensive income (loss) is defined as the change in equity during the period from transactions and other events and circumstances from non-owner sources.
    Revenue [Policy Text Block]
    Revenue Recognition
    We generate revenues from payments received under collaborative agreements and product sales. As of January 1, 2018, we adopted ASC 606, Revenue from Contracts with Customers (ASC 606) which affects how we recognize revenues in these arrangements. We applied the provisions of ASC 606 using the modified retrospective approach, with the cumulative effect of the adoption recognized as of January 1, 2018, to all contracts that had not been completed as of that date. Under ASC 606, we recognize revenue when we transfer promised goods or services to customers in an amount that reflects the consideration to which we expect to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers we perform the following five steps: (i) identify the promised goods or services in the contract; (ii) identify the performance obligations in the contract, including whether they are distinct in the context of the contract; (iii) determine the transaction price, including the constraint on variable consideration; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) we satisfy the performance obligations. Amounts reported in prior periods have not been adjusted to reflect the adoption of ASC 606. Accordingly, the reported revenue amounts for the year ended December 31, 2019 and 2018 and the year ended December 31, 2017 are based on different accounting policies.
    Prior to the ASC 606 adoption, revenue was recognized when all of the following criteria were met: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred or services have been rendered; (3) the seller’s price to the buyer is fixed or determinable; and (4) collectibility is reasonably assured. Differences between the revenue recognition policies applicable prior to the adoption and ASC 606 are described in the following sections and in Note 4.
    Revenues under Collaborative Agreements - as reported under ASC 606 beginning January 1, 2018
    Under these agreements, we grant the collaboration partner a worldwide license to develop and commercialize products using our ENHANZE technology to combine our patented rHuPH20 enzyme with their proprietary biologics directed at up to a specified number of targets. Targets are usually licensed on an exclusive, global basis. Targets selected subsequent to inception of the arrangement require payment of an additional license fee. The collaboration partner is responsible for all development, manufacturing, clinical, regulatory, sales and marketing costs for any products developed under the agreement. We are responsible for supply of bulk rHuPH20 based on the collaboration partner’s purchase orders, and may also be separately engaged to perform research and development services. While these collaboration agreements are similar in that they originate from the same framework, each one is the result of an arms-length negotiation and thus may vary from one to the other.
    We collect an upfront license payment from the collaboration partner, and are also entitled to receive event-based payments subject to the collaboration partner’s achievement of specified development, regulatory and sales-based milestones. In several agreements, collaboration partners pay us annual fees to maintain their exclusive license rights if they are unable to advance product development to specified stages. We earn separate fees for bulk rHuPH20 supplies and research and development services. In addition, the collaboration partner will pay us royalties at an on average mid-single digit percent rate of their sales if products under the collaboration are commercialized. All amounts owed to us are noncancelable after the underlying triggering event occurs, and nonrefundable once paid. Unless terminated earlier in accordance with its terms, the collaboration generally continues in effect until the later of: (i) expiration of the last to expire of the valid claims of our patents covering rHuPH20 or other specified patents developed under the collaboration which valid claim covers a product developed under the collaboration, and (ii) expiration of the last to expire royalty term for a product developed under the collaboration, which is determined separately for each country. In the event such valid claims expire prior to the last to expire royalty term, the royalty rate is reduced for the remaining royalty term following such expiration. The collaboration partner may terminate the agreement prior to expiration for any reason in its entirety or on a target-by-target basis generally upon 90 days prior written notice to us. Upon any such termination, the license granted to the collaboration partner (in total or with respect to the terminated target, as applicable) will terminate provided, however, that in the event of expiration of the agreement, the on-going licenses granted will become perpetual, non-exclusive and fully paid.
    Although these agreements are in form structured as collaborative agreements, we concluded for accounting purposes they represent contracts with customers, and are not subject to accounting literature on collaborative arrangements. This is because we grant to collaboration partners licenses to our intellectual property, and provide supply of bulk rHuPH20 and research and development services which are all outputs of our ongoing activities, in exchange for consideration. We do not develop assets jointly with collaboration partners, and do not share in significant risks of their development or commercialization activities. Accordingly, we concluded our collaborative agreements must be accounted for pursuant to ASC Topic 606, Revenue from Contracts with Customers.
    Under all of our collaborative agreements, we have identified licenses to use functional intellectual property as the only performance obligation. The intellectual property underlying the license is our proprietary ENHANZE® technology which represents application of rHuPH20 to facilitate delivery of drugs or fluids. The license grants the collaboration partners right to use our intellectual property as it exists on the effective date of the license, because there is no ongoing development of the ENHANZE technology required. Therefore, we recognize revenue from licenses at the point when the license becomes effective and the collaboration partner has received access to our intellectual property, usually at the inception of the agreement.
    When collaboration partners can select additional targets to add to the licenses granted, we consider these rights to be options. We evaluate whether such options contain material rights, i.e. have exercise prices that are discounted compared to what we would charge for a similar license to a new collaboration partner. The exercise price of these options includes a combination of the target selection fees, event-based milestone payments and royalties. When these amounts in aggregate are not offered at a discount that exceeds discounts available to other customers, we conclude the option does not contain a material right, and we consider grants of additional licensing rights upon option exercises to be separate contracts (target selection contracts).
    We provide standard indemnification and protection of licensed intellectual property for our customers. These provisions are part of assurance that the licenses meet the agreements’ representations and are not obligations to provide goods or services.
    We also fulfill purchase orders for supply of bulk rHuPH20 and perform research and development services pursuant to projects authorization forms for our collaboration partners, which represent separate contracts. Additionally, we price our supply of bulk rHuPH20 and research and development services at our regular selling prices, called standalone selling price or SSP. Therefore, our collaboration partners do not have material rights to order these items at prices not reflective of SSP. Refer to the discussion below regarding recognition of revenue for these separate contracts.
    Transaction price for a contract represents the amount to which we are entitled in exchange for providing goods and services to the customer. Transaction price does not include amounts subject to uncertainties unless it is probable that there will be no significant reversal of revenue when the uncertainty is resolved. Apart from the upfront license payment (or target selection fees in the target selection contracts), all other fees we may earn under our collaborative agreements are subject to significant uncertainties of product development. Achievement of many of the event-based development and regulatory milestones may not be probable until such milestones are actually achieved. This generally relates to milestones such as obtaining marketing authorization approvals.
    With respect to other development milestones, e.g. dosing of a first patient in a clinical trial, achievement could be considered probable prior to its actual occurrence, based on the progress towards commencement of the trial. We do not include any amounts subject to uncertainties into the transaction price until it is probable that the amount will not result in a significant reversal of revenue in the future. At the end of each reporting period, we re-evaluate the probability of achievement of such milestones and any related constraint, and if necessary, adjust our estimate of the overall transaction price.
    When target exchange rights are held by collaboration partners, and the amounts attributed to these rights are not refundable, they are included in the transaction price. However, they are recorded as deferred revenues because we have a potential performance obligation to provide a new target upon an exchange right being exercised. These amounts are recognized in revenue when the right of exchange expires or is exercised.
    Because our agreements have one type of performance obligation (licenses) which are typically all transferred at the same time at agreement inception, allocation of transaction price often is not required. However, allocation is required when licenses for some of the individual targets are subject to rights of exchange, because revenue associated with these targets cannot be recognized. We perform an allocation of the upfront amount based on relative SSP of licenses for individual targets. We determine license SSP using income-based valuation approach utilizing risk-adjusted discounted cash flow projections of the estimated return a licensor would receive. When amounts subject to uncertainties, such as milestones and royalties, are included in the transaction price, we attribute them to the specific individual target licenses which generate such milestone or royalty amounts.
    We also estimate SSP of bulk rHuPH20 and research and development services, to determine that our collaboration partners do not have material rights to order them at discounted prices. For supplies of bulk rHuPH20, because we effectively act as a contract manufacturer to our collaboration partners, we estimate and charge SSP based on the typical contract manufacturer margins consistently with all of our collaborative partners. We determine SSP of research and development services based on a fully-burdened labor rate. Our rates are comparable to those we observe in other collaborative agreements. We also have a history of charging similar rates to all of our collaboration partners.
    Upfront amounts allocated to licenses to individual targets are recognized as revenue when the license is transferred to the collaboration partner, as discussed above, if the license is not subject to exchange rights, or when the exchange right expires or is exercised. Development milestones and other fees are recognized in revenue when they are included in the transaction price, because by that time we have already transferred the related license to the collaboration partner.
    Sales-based milestones and royalties cannot be recognized until the underlying sales occur. We do not receive final royalty reports from our collaboration partners until after we complete our financial statements for a prior quarter. Therefore, we recognize revenue based on estimates of the royalty earned, which are based on preliminary reports provided by our collaboration partners. We will record a true-up in the following quarter if necessary, when final royalty reports are received. To date, we have not recorded any material true-ups.
    In contracts to provide research and development services, such services represent the only performance obligation. The fees are charged based on hours worked by our employees and the fixed contractual rate per hour, plus third-party pass-through costs, on a monthly basis. We recognize revenues as the related services are performed based on the amounts billed, as the collaboration partner consumes the benefit of research and development work simultaneously as we perform these services, and the amounts billed reflect the value of these services to the customer.
    Refer to Note 4 Revenue, for further discussion on our collaborative arrangements.
    Prior to the adoption of ASC 606 on January 1, 2018, we recognized upfront amounts received under two of our collaborative agreements straight-line over the contract term in accordance with the accounting standards that were in effect in 2006-2007, when these collaborative agreements were entered into. In addition, we recognized royalty revenue in the period when we received final royalty reports from the collaboration partners, in the quarter following the quarter in which the corresponding sales occurred. There were no other adoption differences in revenue recognized due to the transition from the previously existing authoritative accounting literature to ASC 606.
    Product Sales, Net - as reported under ASC 606 beginning January 1, 2018
    Hylenex Recombinant
    We sell Hylenex recombinant in the U.S. to wholesale pharmaceutical distributors, who sell the product to hospitals and other end-user customers. Sales to wholesalers are made pursuant to purchase orders subject to the terms of a master agreement, and delivery of individual packages of Hylenex recombinant represent performance obligations under each purchase order. We use a contract manufacturer to produce Hylenex recombinant and a third-party logistics (3PL) vendor to process and fulfill orders. We concluded we are the principal in the sales to wholesalers because we control access to services rendered by both vendors and direct their activities. We have no significant obligations to wholesalers to generate pull-through sales.
    Selling prices initially billed to wholesalers are subject to discounts for prompt payment and subsequent chargebacks when wholesalers sell Hylenex recombinant at negotiated discounted prices to members of certain group purchasing organizations (“GPOs”) and government programs. We also pay quarterly distribution fees to certain wholesalers for inventory reporting and chargeback processing, and to GPOs as administrative fees for services and for access to GPO members. We concluded the benefits received in exchange for these fees are not distinct from our sales of Hylenex recombinant, and accordingly we apply these amounts to reduce revenues. Wholesalers also have rights to return unsold product nearing or past the expiration date. Because of the shelf life of Hylenex recombinant and our lengthy return period, there may be a significant period of time between when the product is shipped and when we issue credits on returned product.
    We estimate the transaction price when we receive each purchase order taking into account the expected reductions of the selling price initially billed to the wholesaler arising from all of the above factors. We have compiled historical experience and data to estimate future returns and chargebacks of Hylenex recombinant and the impact of the other discounts and fees we pay. When estimating these adjustments to the transaction price, we reduce it sufficiently to be able to assert that it is probable that there will be no significant reversal of revenue when the ultimate adjustment amounts are known.
    Each purchase order contains only one type of product, and is usually shipped to the wholesaler in a single shipment. Therefore, allocation of the transaction price to individual packages is not required.
    We recognize revenue from Hylenex recombinant product sales and related cost of sales upon product delivery to the wholesaler location. At that time, the wholesalers take control of the product as they take title, bear the risk of loss of ownership, and have an enforceable obligation to pay us. They also have the ability to direct sales of product to their customers on terms and at prices they negotiate. Although wholesalers have product return rights, we do not believe they have a significant incentive to return the product to us.
    Upon recognition of revenue from product sales of Hylenex recombinant, the estimated amounts of credit for product returns, chargebacks, distribution fees, prompt payment discounts, and GPO fees are included in sales reserves, accrued liabilities and net of accounts receivable. We monitor actual product returns, chargebacks, discounts and fees subsequent to the sale. If these amounts differ from our estimates, we make adjustments to these allowances, which are applied to increase or reduce product sales revenue and earnings in the period of adjustment.
    In connection with the orders placed by wholesalers, we incur costs such as commissions to our sales representatives. However, as revenue from product sales is recognized upon delivery to the wholesaler, which occurs shortly after we receive a purchase order, we do not capitalize these commissions and other costs, based on application of the practical expedient allowed within the applicable guidance.
    Bulk rHuPH20
    We sell bulk rHuPH20 to collaboration partners for use in research and development; subsequent to receiving marketing approval, we sell it for use in collaboration commercial products. Sales are made pursuant to purchase orders subject to the terms of the collaborative agreement, and delivery of units of bulk rHuPH20 represent performance obligations under each purchase order. We provide a standard warranty that the product conforms to specifications. We use contract manufacturers to produce bulk rHuPH20 and have concluded we are the principal in the sales to collaboration partners. The transaction price for each purchase order of bulk rHuPH20 is fixed based on the cost of production plus a contractual markup, and is not subject to adjustments. Allocation of the transaction price to individual quantities of the product is usually not required because each order contains only one type of product.
    We recognize revenue from the sale of bulk rHuPH20 as product sales and related cost of sales upon transfer of title to our partners. At that time, the partners take control of the product, bear the risk of loss of ownership, and have an enforceable obligation to pay us.
    ENHANZE Drug Product
    We sell ENHANZE drug product to collaboration partners for use in research and development in early phase clinical studies. Sales are made pursuant to purchase orders subject to the terms of the collaborative agreement, and delivery of units of ENHANZE drug product represent performance obligations under each purchase order. We provide a standard warranty that the product conforms to specifications. We use contract manufacturers to produce ENHANZE drug product and we concluded we are the principal in the sales to collaboration partners. The transaction price for each purchase order of ENHANZE drug product is fixed based on the cost of production plus a contractual markup, and is not subject to adjustments. Allocation of the transaction price to individual quantities of the product is usually not required because each order contains only one type of product.
    We recognize revenue from the sale of ENHANZE drug product as product sales and related cost of sales upon transfer of title to our partners. At that time, the partners take control of the product, bear the risk of loss of ownership, and have an enforceable obligation to pay us.
    Revenue Presentation
    In our statements of operations, we report as revenues under collaborative agreements the upfront payments, event-based development and regulatory milestones and sales milestones. We also include in this category revenues from separate research and development contracts pursuant to project authorization forms. We report royalties received from collaboration partners as a separate line in our statements of operations.
    Revenues from sales of Hylenex recombinant, bulk rHuPH20 that has alternative future use and ENHANZE drug product are included in product sales, net.
    In the footnotes to our financial statements, we provide disaggregated revenue information by type of arrangement (product sales, net, collaborative agreements and research and development services), and additionally, by type of payment stream received under collaborative agreements (upfront license fees, event-based development and regulatory milestones and other fees, sales milestones and royalties).
    Cost of Product Sales, Policy [Policy Text Block]
    Cost of Product Sales
    Cost of product sales consists primarily of raw materials, third-party manufacturing costs, fill and finish costs, freight costs, internal costs and manufacturing overhead associated with the production of Hylenex recombinant and bulk rHuPH20 and ENHANZE drug product that has alternative future use. Cost of product sales also consists of the write-down of excess, dated and obsolete inventories and the write-off of inventories that do not meet certain product specifications, if any. Prior to bulk rHuPH20 and ENHANZE drug product having alternative future use, all costs related to the manufacturing of those products were charged to research and development expenses in the periods such costs were incurred. During the year ended December 31, 2019, sales of bulk rHuPH20 and ENHANZE drug product included $1.5 million of cost of sales that were previously expensed as research and development. Of the bulk rHuPH20 and ENHANZE drug product that has alternative future use on hand as of December 31, 2019, approximately $0.1 million in manufacturing costs were previously recorded as research and development expenses. We expect to sell this inventory by the end of 2020.
    Research and Development Expenses
    Research and Development Expenses
    Research and development expenses include salaries and benefits, facilities and other overhead expenses, external clinical trial expenses, research related manufacturing services, contract services and other outside expenses. Research and development expenses are charged to operating expenses as incurred when these expenditures relate to our research and development efforts and have no alternative future uses. When bulk rHuPH20 is manufactured for use in research and development by us or our partners and the product cannot be redirected for alternative use due to formulation and manufacturing specifications, the manufacturing costs are recorded as research and development expense. Bulk rHuPH20 that is manufactured for partner use prior to our partner receiving marketing approval from the FDA or comparable regulatory agencies in foreign countries and meet these specifications is recorded as research and development expenses. Bulk rHuPH20 formulations manufactured for general partner and internal use, which can potentially be used by any collaboration partner or by us in Hylenex, is considered to have alternative future use and all manufacturing costs are capitalized as inventory. Inventories used in our clinical trials were expensed at the time the inventories were packaged for the clinical trials.
    We are obligated to make upfront payments upon execution of certain research and development agreements. Advance payments, including nonrefundable amounts, for goods or services that will be used or rendered for future research and development activities are deferred. Such amounts are recognized as expense as the related goods are delivered or the related services are performed or such time when we do not expect the goods to be delivered or services to be performed.
    Milestone payments that we make in connection with in-licensed technology for a particular research and development project that have no alternative future uses (in other research and development projects or otherwise) and therefore no separate economic value are expensed as research and development costs at the time the costs are incurred. We currently have no in-licensed technologies that have alternative future uses in research and development projects or otherwise.
    Clinical Trial Expenses
    Clinical Trial Expenses
    We make payments in connection with our clinical trials under contracts with contract research organizations that support conducting and managing clinical trials. The financial terms of these agreements are subject to negotiation and vary from contract to contract and may result in uneven payment flows. Generally, these agreements set forth the scope of work to be performed at a fixed fee, unit price or on a time and materials basis. A portion of our obligation to make payments under these contracts depends on factors such as the successful enrollment or treatment of patients or the completion of other clinical trial milestones.
    Expenses related to clinical trials are accrued based on our estimates and/or representations from service providers regarding work performed, including actual level of patient enrollment, completion of patient studies and progress of the clinical trials. Other incidental costs related to patient enrollment or treatment are accrued when reasonably certain. If the amounts we are obligated to pay under our clinical trial agreements are modified (for instance, as a result of changes in the clinical trial protocol or scope of work to be performed), we adjust our accruals accordingly on a prospective basis. Revisions to our contractual payment obligations are charged to expense in the period in which the facts that give rise to the revision become reasonably certain.
    Share-Based Compensation
    Share-Based Compensation
    We record compensation expense associated with stock options, restricted stock awards (“RSAs”), and restricted stock units (“RSUs”) in accordance with the authoritative guidance for stock-based compensation. The cost of employee services received in exchange for an award of an equity instrument is measured at the grant date, based on the estimated fair value of the award, and is recognized as expense on a straight-line basis over the requisite service period of the award. Share-based compensation expense for an award with a performance condition is recognized when the achievement of such performance condition is determined to be probable. If the outcome of such performance condition is not determined to be probable or is not met, no compensation expense is recognized and any previously recognized compensation expense is reversed. Forfeitures are recognized as a reduction of share-based compensation expense as they occur.
    Income Taxes
    Income Taxes
    We provide for income taxes using the liability method. Under this method, deferred income tax assets and liabilities are determined based on the differences between the financial statement carrying amounts of existing assets and liabilities at each year end and their respective tax bases and are measured using enacted tax rates in effect for the year in which the differences are expected to affect taxable income. Significant judgment is required by management to determine our provision for income taxes, our deferred tax assets and liabilities, and the valuation allowance to record against our net deferred tax assets, which are based on complex and evolving tax regulations throughout the world. Deferred tax assets and other tax benefits are recorded when it is more likely than not that the position will be sustained upon audit. While we have begun to utilize certain of our net operating losses, we have not yet established a track record of profitability. Accordingly, valuation allowances have been recorded to reduce our net deferred tax assets to zero, with the exception of the alternative minimum tax ("AMT") credit carryover of $1.7 million. Under the Tax Cuts and Jobs Act (the “Act”) enacted in December 2017, the AMT credit carryover will either be utilized, or if unutilized fully refunded in 2022. For all other deferred tax assets, the valuation allowance will reduce the net value to zero until such time as we can demonstrate an ability to realize them.
    Net Income (Loss) Per Share
    Net (Loss) Income Per Share
    Basic net (loss) income per common share is computed by dividing net (loss) income for the period by the weighted average number of common shares outstanding during the period, without consideration for common stock equivalents. Outstanding stock options, unvested RSAs, unvested RSUs and the Convertible Notes are considered common stock equivalents and are only included in the calculation of diluted earnings per common share when net income is reported and their effect is dilutive. For the years ended December 31, 2019, 2018 and 2017, approximately 33.1 million, 13.8 million, and 7.1 million shares, respectively, of outstanding stock options, unvested RSAs, unvested RSUs and Convertible Notes were excluded from the calculation of diluted net (loss) income per common share because their effect was anti-dilutive.
    The 19.3 million shares underlying the conversion option of the Convertible Notes will not have an impact on our diluted earnings per share when net income is reported until the average market price of our common stock exceeds the conversion price of $23.85 per share, as we intend and have the ability to settle the principal amount of the Convertible Notes in cash upon conversion. We compute the potentially dilutive impact of the shares of common stock related to the Convertible Notes using the treasury stock method.
    A reconciliation of the numerators and the denominators of the basic and diluted net (loss) income per common share computations is as follows (in thousands, except per share amounts):
    Segment Information Segment InformationWe operate our business in one segment, which includes all activities related to the research, development and commercialization of our proprietary enzymes. This segment also includes revenues and expenses related to (i) research and development and bulk rHuPH20 manufacturing activities conducted under our collaborative agreements with third parties and (ii) product sales of Hylenex recombinant. The chief operating decision-maker reviews the operating results on an aggregate basis and manages the operations as a single operating segment.
    Adoption and Pending Adoption of Recent Accounting Pronouncements
    Adoption and Pending Adoption of Recent Accounting Pronouncements
    The following table provides a brief description of recently issued accounting standards, those adopted in the current period and those not yet adopted:
    Standard
     
    Description
     
    Effective Date
     
    Effect on the Financial
    Statements or Other Significant Matters
     
     
     
     
     
     
     
    In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). In July 2018, the FASB issued additional guidance related to Topic 842.
     
    The new guidance requires lessees to recognize assets and liabilities for most leases and provides enhanced disclosures.
     
    January 1, 2019
     
    We implemented the guidance on January 1, 2019 using a modified retrospective transition basis for leases existing as of the period of adoption. In order to adopt the new standard, we used the available practical expedients and newly implemented processes and internal controls for lease accounting. The practical expedients allowed us to carry forward our historical assessment of whether existing agreements are or contain a lease and the classification of our existing lease arrangements. All of our real-estate and automobile operating lease commitments are recognized as lease liabilities with corresponding right-of-use assets, which resulted in an increase in the assets and liabilities of the consolidated balance sheet of $7.2 million, using an assumed weighted average discount rate of 10.0%. The adoption did not have an impact on our consolidated statements of operations and did not require recognition of a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. We elected to continue applying the guidance under ASC 840 for comparative periods, as allowed through ASC 2018-11.
     
     
     
     
     
     
     

    Standard
     
    Description
     
    Effective Date
     
    Effect on the Financial
    Statements or Other Significant Matters
    In December 2019, the FASB issued ASU 2019-12, Simplifying the Accounting for Income Taxes

     
    The new guidance removes certain exceptions to the general principles of ASC 740 in order to simplify the complexities of its application. These changes include eliminations to the exceptions for intraperiod tax allocation, recognizing deferred tax liabilities related to outside basis differences, and year-to-date losses in interim periods among others.

     
    January 1, 2019

     
    We early adopted the new guidance on January 1, 2019. With the adoption we no longer apply the exception to the general rule for intraperiod tax allocations under the incremental method. During the period, we would have recorded a $14.7 million tax expense to APIC fully offset by a $14.7 million tax benefit in continuing operations.

     
     
     
     
     
     
     
    In August 2018, the FASB issued ASU 2018-15, Intangibles-Goodwill and other Internal-Use Software (Subtopic 350-40)

     
    The new guidance aligns the requirement for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirement for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license).

     
    January 1, 2020

     
    We plan to adopt the new guidance on January 1, 2020. We do not anticipate the adoption will have a material impact on our condensed consolidated financial position or results of operations.

     
     
     
     
     
     
     
    In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820).
     
    The new guidance removes, modifies and adds to certain disclosure requirements on fair value measurements in Topic 820, Fair Value Measurement.


     
    January 1, 2020
     
    We plan to adopt the new guidance on January 1, 2020. We do not anticipate the adoption will have a material impact on our consolidated financial position or results of operations.
     
     
     
     
     
     
     
    In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326), Measurement of Credit Losses on Financial Instruments
     
    The standard amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses for most financial assets and certain other instruments that aren’t measured at fair value through net income. For available-for-sale debt securities, entities will be required to recognize an allowance for credit losses rather than a reduction in carrying value of the asset. Entities will no longer be permitted to consider the length of time that fair value has been less than amortized cost when evaluating when credit losses should be recognized.
     
    January 1, 2020
     
    We plan to adopt the new guidance on January 1, 2020. We do not anticipate the adoption will have a material impact on our consolidated financial position or results of operations.
    XML 73 R4.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Consolidated Statements of Operations - USD ($)
    shares in Thousands, $ in Thousands
    		 12 Months Ended
    Dec. 31, 2019
    Dec. 31, 2018
    Dec. 31, 2017
    Revenues:      
    Total revenues $ 195,992 $ 151,862 $ 316,613
    Operating expenses:      
    Cost of product sales 45,546 10,136 31,152
    Research and development 140,804 150,252 150,643
    Selling, general and administrative 77,252 60,804 53,816
    Total operating expenses 263,602 221,192 235,611
    Operating income (loss) (67,610) (69,330) 81,002
    Other income (expense):      
    Investment and other income, net 6,986 7,578 2,592
    Interest expense (11,627) (18,041) (21,984)
    Income (loss) before income taxes (72,251) (79,793) 61,610
    Income tax (benefit) expense (11) 537 (1,361)
    Net income (loss) $ (72,240) $ (80,330) $ 62,971
    Earnings Per Share, Basic and Diluted $ (0.50) $ (0.56)  
    Net income (loss) per share, Basic     $ 0.46
    Net income (loss) per share, Diluted $ (0.50) $ (0.56) $ 0.45
    Weighted Average Number of Shares Outstanding, Basic and Diluted 144,329 143,599  
    Shares used in computing basic net income (loss) per share 144,329 143,599 136,419
    Shares used in computing diluted net income (loss) per share 144,329 143,599 139,068
    Royalties      
    Revenues:      
    Total revenues $ 69,899 $ 78,981 $ 63,507
    Product sales, net      
    Revenues:      
    Total revenues 66,048 28,234 50,396
    Revenues under collaborative agreements      
    Revenues:      
    Total revenues $ 60,045 $ 44,647 $ 202,710
    XML 74 R26.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Certain Balance Sheet Items (Tables)
    		 12 Months Ended
    Dec. 31, 2019
    Balance Sheet Related Disclosures [Abstract]  
    Summary of Accounts Receivable
    Accounts receivable, net consisted of the following (in thousands):
     
     
    December 31,
    2019
     
    December 31,
    2018
    Accounts receivable from product sales to collaborators
     
    $
    35,649

     
    $
    3,717

    Accounts receivable from revenues under collaborative agreements
     
    3,850

     
    5,499

    Accounts receivable from royalty payments
     
    17,149

     
    19,199

    Accounts receivable from other product sales
     
    3,591

     
    2,182

         Subtotal
     
    60,239

     
    30,597

    Allowance for distribution fees and discounts
     
    (797
    )
     
    (592
    )
         Total accounts receivable, net
     
    $
    59,442

     
    $
    30,005
    Summary of Inventories
    Inventories consisted of the following (in thousands):
     
     
    December 31,
    2019
     
    December 31,
    2018
    Raw materials
     
    $
    2,769

     
    $
    735

    Work-in-process
     
    15,710

     
    11,430

    Finished goods
     
    10,880

     
    10,460

         Total inventories
     
    $
    29,359

     
    $
    22,625
    Summary of Prepaid Expenses and Other Assets
    Prepaid expenses and other assets consisted of the following (in thousands):
     
     
    December 31,
    2019
     
    December 31,
    2018
    Prepaid manufacturing expenses
     
    $
    30,156

     
    $
    8,230

    Prepaid research and development expenses
     
    4,964

     
    7,922

    Other prepaid expenses
     
    3,655

     
    2,513

    Other assets
     
    5,681

     
    6,462

         Total prepaid expenses and other assets
     
    44,456

     
    25,127

    Less long-term portion
     
    11,083

     
    4,434

         Total prepaid expenses and other assets, current
     
    $
    33,373

     
    $
    20,693
    Summary of Property and Equipment
    Property and equipment, net consisted of the following (in thousands):
     
     
    December 31,
    2019
     
    December 31,
    2018
    Research equipment
     
    $
    7,403

     
    $
    9,945

    Manufacturing equipment
     
    3,858

     
    3,979

    Computer and office equipment
     
    4,859

     
    5,211

    Leasehold improvements
     
    1,628

     
    4,569

         Subtotal
     
    17,748

     
    23,704

    Accumulated depreciation and amortization
     
    (10,742
    )
     
    (16,239
    )
    Subtotal
     
    $
    7,006

     
    $
    7,465

    Right of use of assets
     
    $
    3,849

     
    $
    —

         Property and equipment, net
     
    $
    10,855

     
    $
    7,465
    Summary of Accrued Expenses
    Accrued expenses consisted of the following (in thousands):
     
     
    December 31,
    2019
     
    December 31,
    2018
    Accrued outsourced research and development expenses
     
    $
    8,423

     
    $
    21,921

    Accrued compensation and payroll taxes
     
    27,888

     
    16,604

    Accrued outsourced manufacturing expenses
     
    9,173

     
    3,975

    Other accrued expenses
     
    7,876

     
    7,623

    Lease liability
     
    6,469

     
    —

         Total accrued expenses
     
    59,829

     
    50,123

    Less long-term portion
     
    4,180

     
    594

         Total accrued expenses, current
     
    $
    55,649

     
    $
    49,529
    Summary of Deferred Revenue
    Deferred revenue consisted of the following (in thousands):
     
     
    December 31,
    2019
     
    December 31,
    2018
    Collaborative agreements
     
     
     
     
    License fees and event-based payments:
     
    2,764

     
    2,264

    Product sales
     
    2,495

     
    6,991

    Total deferred revenue
     
    5,259

     
    9,255

    Less current portion
     
    4,012

     
    4,247

    Deferred revenue, net of current portion
     
    $
    1,247

     
    $
    5,008
    XML 76 R37.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Summary of Significant Accounting Policies Property and Equipment (Details)
    		 12 Months Ended
    Dec. 31, 2019
    Minimum  
    Property, Plant and Equipment [Line Items]  
    Property, Plant and Equipment, Useful Life 3 years
    Maximum  
    Property, Plant and Equipment [Line Items]  
    Property, Plant and Equipment, Useful Life 10 years
    XML 77 R33.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Summary of Significant Accounting Policies Concentrations of Credit Risk (Details) - USD ($)
    $ in Thousands
    		 12 Months Ended
    Dec. 31, 2019
    Dec. 31, 2018
    Dec. 31, 2017
    Concentration Risk [Line Items]      
    Accounts Receivable, Allowance for Credit Loss, Current $ 0    
    Total revenues 195,992 $ 151,862 $ 316,613
    Geographic Concentration Risk [Member]      
    Concentration Risk [Line Items]      
    Total revenues $ 195,992 151,862 316,613
    Sales [Member] | Customer Concentration Risk [Member]      
    Concentration Risk [Line Items]      
    Concentration Risk, Percentage 10.00%    
    UNITED STATES | Geographic Concentration Risk [Member]      
    Concentration Risk [Line Items]      
    Total revenues $ 116,083 40,475 196,274
    SWITZERLAND | Geographic Concentration Risk [Member]      
    Concentration Risk [Line Items]      
    Total revenues 78,413 109,890 119,136
    All other foreign [Member] | Geographic Concentration Risk [Member]      
    Concentration Risk [Line Items]      
    Total revenues $ 1,496 $ 1,497 $ 1,203
    Roche | Sales [Member] | Customer Concentration Risk [Member]      
    Concentration Risk [Line Items]      
    Concentration Risk, Percentage 40.00% 72.00% 38.00%
    argenx [Member] | Sales [Member] | Customer Concentration Risk [Member]      
    Concentration Risk [Line Items]      
    Concentration Risk, Percentage 23.00% 0.00% 0.00%
    Janssen | Sales [Member] | Customer Concentration Risk [Member]      
    Concentration Risk [Line Items]      
    Concentration Risk, Percentage 18.00% 2.00% 6.00%
    BMS | Sales [Member] | Customer Concentration Risk [Member]      
    Concentration Risk [Line Items]      
    Concentration Risk, Percentage 1.00% 4.00% 32.00%
    Alexion | Sales [Member] | Customer Concentration Risk [Member]      
    Concentration Risk [Line Items]      
    Concentration Risk, Percentage 1.00% 3.00% 13.00%
    Roche and Baxalta [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]      
    Concentration Risk [Line Items]      
    Concentration Risk, Percentage (instant date) 93.00% 81.00%  
    Bulk formulation [Member] | Accounts Payable [Member] | Supplier Concentration Risk [Member]      
    Concentration Risk [Line Items]      
    Number of manufacturers 2    
    Concentration Risk, Percentage (instant date) 47.00% 2.00%  
    Sales of Hylenex | Accounts Payable [Member] | Supplier Concentration Risk [Member]      
    Concentration Risk [Line Items]      
    Concentration Risk, Percentage (instant date) 8.00% 0.00%  
    XML 79 R10.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Fair Value Measurement (Notes)
    		 12 Months Ended
    Dec. 31, 2019
    Fair Value Disclosures [Abstract]  
    Fair Value Disclosures [Text Block] Fair Value Measurement
    Available-for-sale marketable securities consisted of the following (in thousands):
     
     
    December 31, 2019
     
     
    Amortized Cost
     
    Gross Unrealized Gains
     
    Gross Unrealized Losses
     
    Estimated Fair Value
    Asset-backed securities
     
    $
    30,484

     
    $
    55

     
    $
    —

     
    $
    30,539

    Corporate debt securities
     
    161,308

     
    178

     
    (14
    )
     
    161,472

    U.S. Treasury securities
     
    75,192

     
    40

     
    (5
    )
     
    75,227

    Commercial paper
     
    33,845

     
    —

     
    —

     
    33,845

     
     
    $
    300,829

     
    $
    273

     
    $
    (19
    )
     
    $
    301,083


     
     
    December 31, 2018
     
     
    Amortized Cost
     
    Gross Unrealized Gains
     
    Gross Unrealized Losses
     
    Estimated Fair Value
    Asset-backed securities
     
    $
    39,787

     
    $
    —

     
    $
    (40
    )
     
    $
    39,747

    Corporate debt securities
     
    57,860

     
    —

     
    (127
    )
     
    57,733

    U.S. Treasury securities
     
    84,924

     
    —

     
    (87
    )
     
    84,837

    Commercial paper
     
    114,273

     
    —

     
    —

     
    114,273

     
     
    $
    296,844

     
    $
    —

     
    $
    (254
    )
     
    $
    296,590


    As of December 31, 2019, 11 available-for-sale marketable securities with a fair market value of $82.9 million were in a gross unrealized loss position of $19 thousand, all of which had been in such position for less than 12 months. Based on our review of these marketable securities, we believe we had no other-than-temporary impairments on these securities as of December 31, 2019, because we do not intend to sell these securities and it is not more-likely-than-not that we will be required to sell these securities before the recovery of their amortized cost basis.
    Contractual maturities of available-for-sale debt securities are as follows (in thousands):
     
     
    December 31, 2019
     
    December 31, 2018
     
     
    Estimated Fair Value
    Due within one year
     
    $
    274,805

     
    $
    296,590

    After one but within five years
     
    26,278

     
    —

     
     
    $
    301,083

     
    $
    296,590


    The following table summarizes, by major security type, our cash equivalents and available-for-sale marketable securities that are measured at fair value on a recurring basis and are categorized using the fair value hierarchy (in thousands):
     
     
    December 31, 2019
     
    December 31, 2018
     
     
    Level 1
     
    Level 2
     
    Total estimated fair value
     
    Level 1
     
    Level 2
     
    Total estimated fair value
    Cash equivalents:
     
     
     
     
     
     
     
     
     
     
     
     
    Money market funds
     
    $
    119,949

     
    $
    —

     
    $
    119,949

     
    $
    57,987

     
    $
    —

     
    $
    57,987

    Available-for-sale marketable
       securities:
     
     
     
     
     
     
     
     
     
     
     
     
    Asset-backed securities
     
    —

     
    30,539

     
    30,539

     
    —

     
    39,747

     
    39,747

    Corporate debt securities
     
    —

     
    161,472

     
    161,472

     
    —

     
    57,733

     
    57,733

    U.S. Treasury securities
     
    75,228

     
    —

     
    75,228

     
    84,837

     
    —

     
    84,837

    Commercial paper
     
    —

     
    33,845

     
    33,845

     
    —

     
    114,273

     
    114,273

     
     
    $
    195,177

     
    $
    225,856

     
    $
    421,033

     
    $
    142,824

     
    $
    211,753

     
    $
    354,577


    There were no transfers between Level 1 and Level 2 of the fair value hierarchy during the year ended December 31, 2019. We had no instruments that were classified within Level 3 as of December 31, 2019 and 2018.
    XML 80 R14.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Share-based Compensation (Notes)
    		 12 Months Ended
    Dec. 31, 2019
    Share-based Payment Arrangement, Noncash Expense [Abstract]  
    Share-based Payment Arrangement [Text Block] Share-based Compensation
    We currently grant stock options, restricted stock awards and restricted stock units under the Amended and Restated 2011 Stock Plan (“2011 Stock Plan”), which was approved by the stockholders on May 6, 2016 and provides for the grant of up to 44.2 million shares of common stock to selected employees, consultants and non-employee members of our Board of Directors as stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards and performance awards. Awards are subject to terms and conditions established by the Compensation Committee of our Board of Directors. During the year ended December 31, 2019, we granted share-based awards under the 2011 Stock Plan. At December 31, 2019, 13,640,668 shares were subject to outstanding awards and 9,352,360 shares were available for future grants of share-based awards.
    Total share-based compensation expense related to share-based awards was comprised of the following (in thousands):
     
     
    Year Ended December 31,
     
     
    2019
     
    2018
     
    2017
    Research and development
     
    $
    15,107

     
    $
    17,220

     
    $
    13,080

    Selling, general and administrative
     
    19,669

     
    18,476

     
    17,590

    Share-based compensation expense
     
    $
    34,776

     
    $
    35,696

     
    $
    30,670


    Share-based compensation expense by type of share-based award (in thousands):
     
     
    Year Ended December 31,
     
     
    2019
     
    2018
     
    2017
    Stock options
     
    $
    17,624

     
    $
    18,742

     
    $
    19,583

    RSAs and RSUs
     
    17,152

     
    16,954

     
    11,087

     
     
    $
    34,776

     
    $
    35,696

     
    $
    30,670


    Total unrecognized estimated compensation cost by type of award and the weighted-average remaining requisite service period over which such expense is expected to be recognized (in thousands, unless otherwise noted):
     
     
    December 31, 2019
     
     
    Unrecognized
    Expense
     
    Remaining
    Weighted-Average
    Recognition Period
    (years)
    Stock options
     
    $
    16,524

     
    2.59
    RSAs
     
    $
    570

     
    0.16
    RSUs
     
    $
    11,600

     
    2.32

    Stock Options. Options granted under the Plans must have an exercise price equal to at least 100% of the fair market value of our common stock on the date of grant. The options generally have a maximum contractual term of ten years and vest at the rate of one-fourth of the shares on the first anniversary of the date of grant and 1/48 of the shares monthly thereafter. Certain option awards provide for accelerated vesting if there is a change in control (as defined in the Plans).
    A summary of our stock option award activity as of and for the year ended December 31, 2019 is as follows: 
     
     
    Shares
    Underlying
    Stock Options
     
    Weighted
    Average Exercise
    Price per Share
     
    Weighted
    Average
    Remaining
    Contractual
    Term (years)
     
    Aggregate
    Intrinsic
    Value
    Outstanding at December 31, 2018
     
    11,012,381

     
    $13.81
     
     
     
     
    Granted
     
    3,056,191

     
    $16.46
     
     
     
     
    Exercised
     
    (1,540,690
    )
     
    $10.73
     
     
     
     
    Canceled/forfeited
     
    (979,653
    )
     
    $16.19
     
     
     
     
    Outstanding at December 31, 2019
     
    11,548,229

     
    $14.72
     
    3.98
     

    $39.8
     million
    Vested and expected to vest at December 31, 2019
     
    11,548,229

     
    $14.72
     
    3.98
     

    $39.8
     million
    Exercisable at December 31, 2019
     
    6,962,972

     
    $13.64
     
    3.59
     

    $32.7
     million

    The weighted average grant date fair values of options granted during the years ended December 31, 2019, 2018 and 2017 were $16.46 per share, $10.33 per share and $7.86 per share, respectively. The total intrinsic value of options exercised during the years ended December 31, 2019, 2018 and 2017 was approximately $10.6 million, $11.5 million and $10.0 million, respectively. Cash received from stock option exercises for the years ended December 31, 2019, 2018 and 2017 was approximately $16.5 million, $16.3 million and $14.0 million, respectively.
    The exercise price of stock options granted is equal to the closing price of the common stock on the date of grant. The fair value of each option award is estimated on the date of grant using the Black-Scholes-Merton option pricing model (“Black-Scholes model”). Expected volatility is based on historical volatility of our common stock. The expected term of options granted is based on analyses of historical employee termination rates and option exercises. The risk-free interest rate is based on the U.S. Treasury yield for a period consistent with the expected term of the option in effect at the time of the grant. The dividend yield assumption is based on the expectation of no future dividend payments. The assumptions used in the Black-Scholes model were as follows:
     
     
    Year Ended December 31,
     
     
    2019
     
    2018
     
    2017
    Expected volatility
     
    51.56-56.94%
     
    57.18-70.06%
     
    69.81-71.73%
    Average expected term (in years)
     
    5.5
     
    5.5
     
    5.6
    Risk-free interest rate
     
    1.35-2.56%
     
    2.25-2.96%
     
    1.73-2.13%
    Expected dividend yield
     
    —
     
    —
     
    —

    Restricted Stock Awards. RSAs are grants that entitle the holder to acquire shares of our common stock at zero cost. The shares covered by a RSA cannot be sold, pledged, or otherwise disposed of until the award vests and any unvested shares may be reacquired by us for the original purchase price following the awardee’s termination of service. The RSAs will generally vest at the rate of one-fourth of the shares on each anniversary of the date of grant. Annual grants of RSAs to the Board of Directors typically vest in approximately one year.
    The following table summarizes our RSA activity during the year ended December 31, 2019:
     
     
    Number of
    Shares
     
    Weighted
    Average
    Grant Date
    Fair Value
    Unvested at December 31, 2018
     
    397,389

     
    $11.03
    Granted
     
    85,211

     
    $16.43
    Vested
     
    (260,086
    )
     
    $12.57
    Forfeited
     
    (11,391
    )
     
    $8.11
    Unvested at December 31, 2019
     
    211,123

     
    $11.47

    The estimated fair value of the RSAs was based on the closing market value of our common stock on the date of grant. The total grant date fair value of RSAs vested during the years ended December 31, 2019, 2018 and 2017 was approximately $3.3 million, $4.5 million and $5.3 million, respectively. The fair value of RSAs vested during the years ended December 31, 2019, 2018 and 2017, was approximately $4.2 million, $7.2 million and $6.6 million, respectively.
    Restricted Stock Units. A RSU is a promise by us to issue a share of our common stock upon vesting of the unit. The RSUs will generally vest at the rate of one-fourth of the shares on each anniversary of the date of grant.
    The following table summarizes our RSU activity during the year ended December 31, 2019:
     
     
    Number of
    Shares
     
    Weighted
    Average
    Grant Date
    Fair Value
     
    Weighted
    Average
    Remaining
    Contractual
    Term (yrs)
     
    Aggregate
    Intrinsic
    Value
    Outstanding at December 31, 2018
     
    2,388,342

     
    $15.12
     
     
     
     
    Granted
     
    1,151,464

     
    $16.55
     
     
     
     
    Vested
     
    (1,092,648
    )
     
    $15.35
     
     
     
     
    Forfeited
     
    (354,719
    )
     
    $16.22
     
     
     
     
    Outstanding at December 31, 2019
     
    2,092,439

     
    $15.60
     
    1.23
     

    $37.1
     million

    The estimated fair value of the RSUs was based on the closing market value of our common stock on the date of grant. The total grant date fair value of RSUs vested during the years ended December 31, 2019, 2018 and 2017 was approximately $19.1 million, $6.7 million and $4.0 million, respectively. The fair value of RSUs vested during the years ended December 31, 2019, 2018 and 2017 was approximately $18.5 million, $11.0 million and $4.7 million, respectively.
    XML 81 R18.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Employee Savings Plan (Notes)
    		 12 Months Ended
    Dec. 31, 2019
    Retirement Benefits [Abstract]  
    Compensation and Employee Benefit Plans [Text Block]
    Employee Savings Plan
    We have an employee savings plan pursuant to Section 401(k) of the Internal Revenue Code. All employees are eligible to participate, provided they meet the requirements of the plan. We are not required to make matching contributions under the plan. However, we voluntarily contributed to the plan approximately $2.2 million, $1.3 million and $1.2 million for the years ended December 31, 2019, 2018 and 2017, respectively.
    XML 82 R79.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Income Taxes Schedule of Income Tax Reconciliation (Details) - USD ($)
    $ in Thousands
    		 12 Months Ended
    Dec. 31, 2019
    Dec. 31, 2018
    Dec. 31, 2017
    Income Tax Disclosure [Abstract]      
    Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 21.00% 21.00% 34.00%
    Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount $ (15,173) $ (16,754) $ 20,947
    Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount (1,509) (4,297) 930
    Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount 8,147 35,731 (77,181)
    Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount 0 0 17,132
    Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount 318 7,106 33,674
    Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount 315 425 525
    Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount 924 1,599 5,779
    Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount (1,091) (5,210) 4,162
    Effective Income Tax Rate Reconciliation, Deduction, Amount (5,718) (18,063) (7,329)
    Effective Income Tax Rate Reconciliation, Convertible Note Discount in APIC 13,776 0 0
    Income Tax Expense (Benefit), Continuing Operations, Discontinued Operations $ (11) $ 537 $ (1,361)
    XML 83 R85.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Summary of Unaudited Quarterly Financial Information - Textuals (Details) - USD ($)
    $ in Millions
    		 3 Months Ended
    Dec. 31, 2019
    Mar. 31, 2019
    Dec. 31, 2018
    Disaggregation of Revenue [Line Items]      
    Restructuring Charges $ 28.4    
    argenx [Member]      
    Disaggregation of Revenue [Line Items]      
    Proceeds from Collaborator   $ 30.0  
    Roche      
    Disaggregation of Revenue [Line Items]      
    Proceeds from Collaborator     $ 30.0
    XML 84 R75.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Income Taxes (Details) - USD ($)
    $ in Thousands
    		 12 Months Ended
    Dec. 31, 2019
    Dec. 31, 2018
    Dec. 31, 2017
    Income Tax Disclosure [Abstract]      
    2017 Federal tax rate 35.00%    
    2018 Federal tax rate 21.00%    
    Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount $ 0 $ 0 $ 17,132
    Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount $ 17,100    
    XML 85 R71.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Stockholders' Equity (Deficit) Share Repurchases (Details) - USD ($)
    shares in Millions
    		 1 Months Ended
    Feb. 29, 2020
    Nov. 30, 2019
    Equity, Class of Treasury Stock [Line Items]    
    Stock Repurchase Program, Period in Force   3 years
    Authorized repurchase amount   $ 550,000,000.0
    Stock repurchased (shares)   0.4
    Value of stock repurchased   $ 6,900,000
    Shares acquired in privately negotiated transactions [Domain]    
    Equity, Class of Treasury Stock [Line Items]    
    Stock repurchased (shares)   8.1
    Value of stock repurchased   $ 143,100,000
    2019 Share Repurchase Program - Bank of America    
    Equity, Class of Treasury Stock [Line Items]    
    Stock repurchased (shares)   2.1
    Accelerated Share Repurchases, Date [Domain]    
    Equity, Class of Treasury Stock [Line Items]    
    Authorized repurchase amount   $ 50,000,000.0
    Stock repurchased (shares)   2.6
    Value of stock repurchased   $ 50,000,000.0
    Subsequent Event    
    Equity, Class of Treasury Stock [Line Items]    
    Stock repurchased (shares) 0.5  
    XML 86 R81.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Income Taxes Operating Loss Carryforward Expiration (Details)
    $ in Thousands
    Dec. 31, 2019
    USD ($)
    Internal Revenue Service (IRS) [Member]  
    Operating Loss Carryforwards [Line Items]  
    Operating Loss Carryforwards $ 118,480
    Internal Revenue Service (IRS) [Member] | 2018 expiration [Member]  
    Operating Loss Carryforwards [Line Items]  
    Operating Loss Carryforwards 0
    Internal Revenue Service (IRS) [Member] | 2021 and beyond expiration [Member]  
    Operating Loss Carryforwards [Line Items]  
    Operating Loss Carryforwards 118,480
    Internal Revenue Service (IRS) [Member] | 2028 and beyond expiration [Member]  
    Operating Loss Carryforwards [Line Items]  
    Operating Loss Carryforwards 0
    State and Local Jurisdiction [Member]  
    Operating Loss Carryforwards [Line Items]  
    Operating Loss Carryforwards 244,337
    State and Local Jurisdiction [Member] | 2018 expiration [Member]  
    Operating Loss Carryforwards [Line Items]  
    Operating Loss Carryforwards 0
    State and Local Jurisdiction [Member] | 2021 and beyond expiration [Member]  
    Operating Loss Carryforwards [Line Items]  
    Operating Loss Carryforwards 0
    State and Local Jurisdiction [Member] | 2028 and beyond expiration [Member]  
    Operating Loss Carryforwards [Line Items]  
    Operating Loss Carryforwards 244,337
    California [Member]  
    Operating Loss Carryforwards [Line Items]  
    Operating Loss Carryforwards 244,300
    Other state tax [Member]  
    Operating Loss Carryforwards [Line Items]  
    Operating Loss Carryforwards $ 26,700
    XML 87 R52.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Revenue - Revenue, Remaining Performance Obligation (Details) - USD ($)
    $ in Thousands
    Dec. 31, 2019
    Dec. 31, 2018
    Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]    
    Deferred revenues $ 5,259 $ 9,255
    Deferred Credits and Other Liabilities, Current 4,012  
    Deferred Credits and Other Liabilities 5,300  
    Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-07-01    
    Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]    
    Revenue, Remaining Performance Obligation, Amount 4,000  
    Product [Member]    
    Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]    
    Deferred Credits and Other Liabilities, Current 7,000  
    Deferred Credits and Other Liabilities $ 12,300  
    XML 88 R56.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Certain Balance Sheet Items - Property and Equipment (Details) - USD ($)
    $ in Thousands
    Dec. 31, 2019
    Dec. 31, 2018
    Property and equipment, gross $ 17,748 $ 23,704
    Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Excluding Capital Leased Assets (10,742) (16,239)
    Property, Plant and Equipment, Net, Excluding Capital Leased Assets 7,006 7,465
    Operating Lease, Right-of-Use Asset 3,849 0
    Property and equipment, net 10,855 7,465
    Research equipment    
    Property, Plant and Equipment, Gross, Excluding Capital Leased Assets 7,403 9,945
    Manufacturing equipment    
    Property, Plant and Equipment, Gross, Excluding Capital Leased Assets 3,858 3,979
    Computer and office equipment    
    Property, Plant and Equipment, Gross, Excluding Capital Leased Assets 4,859 5,211
    Leasehold improvements    
    Property, Plant and Equipment, Gross, Excluding Capital Leased Assets $ 1,628 $ 4,569
    XML 89 R36.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Summary of Significant Accounting Policies Leases (Details)
    Dec. 31, 2019
    Minimum  
    Lessee, Operating Lease, Term of Contract 3 years
    Maximum  
    Lessee, Operating Lease, Term of Contract 6 years
    XML 90 R32.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Summary of Significant Accounting Policies Restricted Cash (Details) - USD ($)
    $ in Thousands
    Dec. 31, 2019
    Dec. 31, 2018
    Restricted Cash and Investments, Current [Abstract]    
    Restricted cash $ 500 $ 500
    XML 91 R19.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Summary of Unaudited Quarterly Financial Information
    		 12 Months Ended
    Dec. 31, 2019
    Quarterly Financial Information Disclosure [Abstract]  
    Quarterly Financial Information [Text Block]
    Summary of Unaudited Quarterly Financial Information
    The following is a summary of our unaudited quarterly results for the years ended December 31, 2019 and 2018 (in thousands):
     
     
    Quarter Ended
    2019 (Unaudited):
     
    March 31,
     
    June 30,
     
    September 30,
     
    December 31,
    Total revenues (1)
     
    $
    56,949

     
    $
    39,148

     
    $
    46,230

     
    $
    53,665

    Gross profit on product sales
     
    $
    3,741

     
    $
    3,883

     
    $
    6,872

     
    $
    6,006

    Total operating expenses(3)
     
    $
    53,983

     
    $
    53,125

     
    $
    70,767

     
    $
    85,727

    Net Income (loss)
     
    $
    1,796

     
    $
    (14,624
    )
     
    $
    (25,015
    )
     
    $
    (34,397
    )
    Net Income (loss) per share:
     
     
     
     
     
     
     
     
    Basic
     
    $
    0.01

     
    $
    (0.10
    )
     
    $
    (0.17
    )
     
    $
    (0.24
    )
    Diluted
     
    $
    0.01

     
    $
    (0.10
    )
     
    $
    (0.17
    )
     
    $
    (0.24
    )
    Shares used in computing net income (loss) per share:
     
     
     
     
     
     
     
     
    Basic
     
    144,743

     
    145,411

     
    146,136

     
    141,046

    Diluted
     
    147,474

     
    145,411

     
    146,136

     
    141,046

     
     
    Quarter Ended
    2018 (Unaudited):
     
    March 31,
     
    June 30,
     
    September 30,
     
    December 31,
    Total revenues (2)
     
    $
    30,872

     
    $
    35,202

     
    $
    25,556

     
    $
    60,232

    Gross profit on product sales
     
    $
    3,749

     
    $
    3,647

     
    $
    5,643

     
    $
    5,059

    Total operating expenses
     
    $
    54,584

     
    $
    55,275

     
    $
    51,030

     
    $
    60,303

    Net loss
     
    $
    (27,461
    )
     
    $
    (22,893
    )
     
    $
    (27,850
    )
     
    $
    (2,126
    )
    Net loss per share:
     
     
     


     


     


    Basic
     
    $
    (0.19
    )
     
    $
    (0.16
    )
     
    $
    (0.19
    )
     
    $
    (0.01
    )
    Diluted
     
    $
    (0.19
    )
     
    $
    (0.16
    )
     
    $
    (0.19
    )
     
    $
    (0.01
    )
    Shares used in computing net loss per share:
     


     


     


     


    Basic
     
    142,656

     
    143,568

     
    143,949

     
    144,203

    Diluted
     
    142,656

     
    143,568

     
    143,949

     
    144,203

    _______________
    (1)
    Revenue for the quarter ended March 31, 2019 included $30.0 million in revenue under a collaborative arrangement from argenx.
    (2)
    Revenues for the quarter ended December 31, 2018 included $30.0 million in revenue under a collaborative arrangement from Roche.
    (3)
    Total operating expenses for the quarter ended December 31, 2019 included $28.4 million restructuring charges.
    XML 92 R11.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Revenue
    		 12 Months Ended
    Dec. 31, 2019
    Revenue from Contract with Customer [Abstract]  
    Revenue Revenue
    Our disaggregated revenues were as follows (in thousands):
     
     
    Year Ended December 31,
     
     
    2019
     
    2018
     
    2017
    Royalties
     
    $
    69,899

     
    $
    78,981

     
    $
    63,507

     
     
     
     
     
     
     
    Product sales, net
     
     
     
     
     
     
      Sales of bulk rHuPH20
     
    $
    48,285

     
    $
    12,729

     
    $
    35,246

      Sales of ENHANZE drug product
     
    768

     
    460

     
    —

      Sales of Hylenex
     
    16,995

     
    15,045

     
    15,150

    Total product sales, net
     
    66,048

     
    28,234

     
    50,396

     
     
     
     
     
     
     
    Revenues under collaborative agreements:
     
     
     
     
     
     
      Upfront license and target nomination fees
     
    53,000

     
    26,336

     
    172,806

      Event-based development milestones and regulatory milestone and other fees
     
    5,500

     
    16,000

     
    16,317

      Sales-based milestones
     
    —

     
    —

     
    1,417

      Research and development services
     
    1,545

     
    2,311

     
    12,170

    Total revenues under collaborative agreements
     
    60,045

     
    44,647

     
    202,710

     
     
     
     
     
     
     
    Total revenue
     
    $
    195,992

     
    $
    151,862

     
    $
    316,613


    During the year ended December 31, 2019 we recognized revenue related to licenses granted to collaboration partners in prior periods in the amount of $74.9 million. This amount represents royalties earned in the current period, in addition to $5.0 million of variable consideration in the contracts where uncertainties have been resolved and the development milestones were expected to be achieved or were achieved. We also recognized revenue of $4.0 million during the year ended December 31, 2019 that had been included in deferred revenues at December 31, 2018. We did not recognize any adjustments to reduce sales reserves and allowances liability related to Hylenex recombinant sales in prior periods.
    Revenue recognized during the year ended December 31, 2017 was determined in accordance with the accounting rules applicable prior to the adoption of ASC 606 on January 1, 2018.
    Upon the adoption of ASC 606, we recognized an adjustment to increase our accounts receivable by $19.4 million, decrease deferred revenues by $51.8 million, and decrease accumulated deficit by $71.2 million. The impact of applying the provisions of ASC 606 in the year ended December 31, 2018 was to decrease revenues by $4.7 million. Under the previously existing authoritative accounting literature, at December 31, 2018 our accounts receivable, net would have been $19.3 million lower, and our deferred revenue $47.4 million higher, than the amounts reported in our consolidated balance sheet. ASC 606 did not have an aggregate impact on our net cash used in operating activities, but resulted in offsetting changes in net loss and certain assets and liabilities within net cash used in operating activities in the consolidated statement of cash flows.
    Accounts receivable, net and deferred revenues (contract liabilities) from contracts with customers, including collaboration partners, consisted of the following (in thousands):
     
     
    December 31, 2019
     
    December 31, 2018
    Accounts receivable, net
     
    $
    59,442

     
    $
    30,005

    Deferred revenues
     
    5,259

     
    9,255


    As of December 31, 2019, the amounts included in the transaction price of our contracts with customers, including collaboration partners, and allocated to goods and services not yet provided were $12.3 million of which $7.0 million relates to unfulfilled product purchase orders and $5.3 million has been collected and reported as deferred revenues. The unfulfilled product purchase orders are estimated to be delivered in 2020. Of the total deferred revenues of $5.3 million, $4.0 million is expected to be used by our customers within the next 12 months.
    There were no contract assets related to collaborative agreements at December 31, 2019. While we may become entitled to receive additional event-based development and regulatory milestones and other fees under our collaborative agreements, which relate to intellectual property licenses granted to collaboration partners in prior periods, no amounts were probable. The following table presents amounts under our collaborative agreements included in the transaction price (i.e. cumulative amounts triggered or probable) as of December 31, 2019 (in thousands):
     
     
    Upfront
    (1)
     
    Development
    (2)
     
    Sales
    (3)
     
     
    Total
    Collaboration partner and agreement date:
     
     
     
     
     
     
     
     
     
    Roche (December 2006, September 2017 and October 2018)
     
    $
    105,000

     
    $
    30,000

     
    $
    22,000

     
     
    $
    157,000

    Baxalta (September 2007)
     
    10,000

     
    3,000

     
    9,000

     
     
    22,000

    Pfizer (December 2012)
     
    14,500

     
    2,000

     
    —

     
     
    16,500

    Janssen (December 2014)
     
    18,250

     
    15,000

     
    —

     
     
    33,250

    AbbVie (June 2015)
     
    23,000

     
    6,000

     
    —

     
     
    29,000

    Lilly (December 2015)
     
    33,000

     
    —

     
    —

     
     
    33,000

    BMS (September 2017)
     
    105,000

     
    5,000

     
    —

     
     
    110,000

    Alexion (December 2017)
     
    40,000

     
    6,000

     
    —

     
     
    46,000

    argenx (February 2019)
     
    40,000

     
    5,000

     
     
     
     
    45,000

    Royalties
     
     
     
     
     
     
     
     
    323,285

    Total amounts under our collaborative agreements included in the transaction price
     
     
     
     
     
     
     
     
    815,035


    (1)
    Upfront and additional target selection fees
    (2)
    Event-based development and regulatory milestone amounts and other fees
    (3)
    Sales-based milestone amounts
    Through December 31, 2019, our collaboration partners have completed development, obtained marketing authorization approvals for certain indications and commenced commercialization of the following products:
    •
    Roche, for Herceptin SC in the European Union (“EU”) in August 2013; and MabThera SC in the EU in March 2014 and its equivalent RITUXAN HYCELA™ in the US in June 2017; Herceptin SC in Canada in September 2018; and Herceptin Hylecta in the US in February 2019.
    •
    Baxalta, for HYQVIA in the EU and in the US in May 2013.
    The remaining targets and products are currently in the process of development by the collaboration partners.
    EXCEL 93 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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Ā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

    &PO M=V]R:W-H965T&UL4$L! A0#% @ #H)84/6GZ? 9 @ "@8 !D ( ! M"-0 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% M @ #H)84'03[\Q@ @ C0< !D ( !%MP 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ #H)84 %J!I)=! RQ0 !D M ( !7NT 'AL+W=O&PO=V]R M:W-H965T&UL M4$L! A0#% @ #H)84&'\XNM% @ ZP8 !D ( !E/8 M 'AL+W=O&PO=V]R:W-H965T&UL4$L! M A0#% @ #X)84* 7!E&UL4$L%!@ !A &$ F1H "K5 0 $! end XML 94 R15.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Stockholders' Equity (Deficit)
    		 12 Months Ended
    Dec. 31, 2019
    Equity [Abstract]  
    Stockholders' Equity (Deficit) Stockholders’ Equity (Deficit)
    In May 2017, we completed an underwritten public offering pursuant to which we sold 11.5 million shares of common stock, including 1.5 million shares sold pursuant to the full exercise of an option to purchase additional shares granted to the underwriters. All of the shares were offered at a public offering price of $12.50 per share, generating $134.9 million in net proceeds, after deducting underwriting discounts and commissions and other offering expenses.
    During the years ended December 31, 2019, 2018 and 2017, we issued an aggregate of 1,540,690, 1,489,138 and 1,514,826 shares of common stock, respectively, in connection with the exercises of stock options, for net proceeds of approximately $16.5 million, $16.3 million and $14.0 million, respectively. For the years ended December 31, 2019, 2018 and 2017, we issued 952,182, 442,599 and 281,398 shares of common stock, respectively, upon vesting of certain RSUs for which the RSU holders surrendered 140,466, 139,850 and 97,008 RSUs, respectively, to pay for minimum withholding taxes totaling approximately $7.0 million, $4.2 million and $1.9 million, respectively. Stock options and unvested restricted units totaling approximately 13.6 million, 13.4 million and 13.0 million shares of our common stock were outstanding as of December 31, 2019, 2018 and 2017, respectively.
    Share Repurchases
    The Board of Directors approved a share repurchase program, pursuant to which we may repurchase issued and outstanding shares of common stock from time to time. We may utilize a variety of methods including open market purchases, privately negotiated transactions, accelerated share repurchase programs or any combination of such methods.
    In November 2019, we announced that the Board of Directors has authorized the initiation of a capital return program to repurchase up to $550.0 million of outstanding common stock over a three-year period. The Board will regularly review this capital return program in connection with a balanced capital allocation strategy. In November 2019, we repurchased approximately 8.1 million shares of common stock concurrently with the Convertible Notes issuance in privately negotiated transactions for $143.1 million and 0.4 million shares of common stock in open market purchases for $6.9 million. Also in November 2019, we entered into an Accelerated Share Repurchase (ASR) agreement with Bank of America to repurchase $50.0 million of common stock. At inception, pursuant to the agreement, we paid $50.0 million to Bank of America and took an initial delivery of 2.1 million shares. In February 2020 we finalized the transaction and received an additional 0.5 million shares. We retired the repurchased shares and they resumed the status of authorized and unissued shares.

    XML 95 R84.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Summary of Unaudited Quarterly Financial Information - Quarterly Financial Information (Details) - USD ($)
    $ / shares in Units, shares in Thousands, $ in Thousands
    		 3 Months Ended 12 Months Ended
    Dec. 31, 2019
    Sep. 30, 2019
    Jun. 30, 2019
    Mar. 31, 2019
    Dec. 31, 2018
    Sep. 30, 2018
    Jun. 30, 2018
    Mar. 31, 2018
    Dec. 31, 2019
    Dec. 31, 2018
    Dec. 31, 2017
    Quarterly Financial Information Disclosure [Abstract]                      
    Revenues $ 53,665 $ 46,230 $ 39,148 $ 56,949 $ 60,232 $ 25,556 $ 35,202 $ 30,872      
    Gross Profit 6,006 6,872 3,883 3,741 5,059 5,643 3,647 3,749      
    Operating Expenses 85,727 70,767 53,125 53,983 60,303 51,030 55,275 54,584      
    Net income (loss) $ (34,397) $ (25,015) $ (14,624) $ 1,796 $ (2,126) $ (27,850) $ (22,893) $ (27,461) $ (72,240) $ (80,330) $ 62,971
    Earnings Per Share, Basic $ (0.24) $ (0.17) $ (0.10) $ 0.01 $ (0.01) $ (0.19) $ (0.16) $ (0.19)     $ 0.46
    Earnings Per Share, Diluted $ (0.24) $ (0.17) $ (0.10) $ 0.01 $ (0.01) $ (0.19) $ (0.16) $ (0.19) $ (0.50) $ (0.56) $ 0.45
    Weighted Average Number of Shares Outstanding, Basic 141,046 146,136 145,411 144,743 144,203 143,949 143,568 142,656 144,329 143,599 136,419
    Weighted Average Number of Shares Outstanding, Diluted 141,046 146,136 145,411 147,474 144,203 143,949 143,568 142,656 144,329 143,599 139,068
    XML 96 R74.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Commitments and Contingencies Other Commitments (Details)
    $ in Millions
    Dec. 31, 2019
    USD ($)
    Avid Commercial Supply Agreement [Member]  
    Long-term Purchase Commitment [Line Items]  
    Purchase Obligation $ 35.7
    Patheon [Member]  
    Long-term Purchase Commitment [Line Items]  
    Purchase Obligation $ 0.6
    XML 97 R70.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Stockholders' Equity (Deficit) (Details) - USD ($)
    $ in Millions
    		 12 Months Ended
    Dec. 31, 2019
    Dec. 31, 2018
    Dec. 31, 2017
    Stockholders' equity (deficit) (textual)      
    Number of shares of common stock issued as a result of stock option exercises 1,540,690    
    Net proceeds from stock options exercised $ 16.5 $ 16.3 $ 14.0
    Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number 11,548,229 11,012,381  
    Stock options      
    Stockholders' equity (deficit) (textual)      
    Number of shares of common stock issued as a result of stock option exercises 1,540,690 1,489,138 1,514,826
    Net proceeds from stock options exercised $ 16.5 $ 16.3 $ 14.0
    RSUs      
    Stockholders' equity (deficit) (textual)      
    Shares, Restricted Stock Award 952,182 442,599 281,398
    Number of RSUs surrendered to pay for minimum withholding taxes 140,466 139,850 97,008
    Payments for tax withholding for restricted stock units vested, net $ 7.0 $ 4.2 $ 1.9
    Stock Options And Restricted Stock Units [Member]      
    Stockholders' equity (deficit) (textual)      
    Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number 13,600,000 13,400,000 13,000,000.0
    XML 98 R80.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Income Taxes Unrecognized Tax Benefit (Details) - USD ($)
    $ in Thousands
    		 12 Months Ended
    Dec. 31, 2019
    Dec. 31, 2018
    Dec. 31, 2017
    Income Tax Disclosure [Abstract]      
    Unrecognized Tax Benefits that Would Impact Effective Tax Rate $ 200    
    Unrecognized Tax Benefits, beginning of period 20,028 $ 14,428 $ 12,799
    Increase Resulting from Prior Period Tax Positions 69 3,083 0
    Decrease Resulting from Prior Period Tax Positions (23) 0 (2,518)
    Increase Resulting from Current Period Tax Positions 1,409 2,517 4,147
    Unrecognized Tax Benefits, end of period 21,483 $ 20,028 $ 14,428
    Unrecognized Tax Benefits that Would Impact Effective Tax Rate, no valuation allowance $ 21,500    
    XML 99 R78.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Income Taxes Income Tax Expense (Details) - USD ($)
    $ in Thousands
    		 12 Months Ended
    Dec. 31, 2019
    Dec. 31, 2018
    Dec. 31, 2017
    Income Tax Disclosure [Abstract]      
    Current Federal Tax Expense (Benefit) $ 114 $ 82 $ 4,051
    Current State Tax Expense (40) 519 120
    Deferred Federal Income Tax Benefit (85) (64) (5,532)
    Deferred State Income Tax Expense 0 0 0
    Income tax (benefit) expense $ (11) $ 537 $ (1,361)
    XML 100 R53.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Certain Balance Sheet Items - Accounts receivable (Details) - USD ($)
    $ in Thousands
    Dec. 31, 2019
    Dec. 31, 2018
    Accounts Receivable, after Allowance for Credit Loss, Current [Abstract]    
    Accounts receivable from product sales to collaborators $ 35,649 $ 3,717
    Accounts receivable from collaborators 3,850 5,499
    Accounts receivable from other product sales 3,591 2,182
    Accounts receivable from royalties 17,149 19,199
    Accounts receivable, gross 60,239 30,597
    Allowance for distribution fees and discounts (797) (592)
    Total accounts receivable, net $ 59,442 $ 30,005
    XML 101 R57.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Certain Balance Sheet Items - Property and Equipment, Net (Textuals) (Details) - USD ($)
    $ in Thousands
    		 12 Months Ended
    Dec. 31, 2019
    Dec. 31, 2018
    Dec. 31, 2017
    Property, Plant and Equipment [Abstract]      
    Operating Lease, Impairment Loss $ 1,127 $ 0 $ 0
    Loss on disposal of equipment 1,431 5 46
    Depreciation and amortization      
    Depreciation and amortization 4,068 $ 2,388 $ 2,161
    Finance Lease, Right-of-Use Asset, Amortization $ 1,800    
    XML 102 R69.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Stockholders' Equity (Deficit) Public Offering (Details) - USD ($)
    $ / shares in Units, $ in Thousands, shares in Millions
    		 1 Months Ended 12 Months Ended
    May 31, 2017
    Dec. 31, 2019
    Dec. 31, 2018
    Dec. 31, 2017
    Equity [Abstract]        
    Shares, New Issues   11.5    
    Stock Issued During Period Shares New Issues To Underwriter   1.5    
    Sale of Stock, Price Per Share   $ 12.50    
    Proceeds from issuance of common stock, net $ 134,900 $ 0 $ 0 $ 134,874
    XML 103 R61.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Long-Term Debt, Net Debt Table (Details) - USD ($)
    $ in Thousands
    Dec. 31, 2019
    Dec. 31, 2018
    Debt Disclosure [Abstract]    
    2018 $ 26,100  
    2019 5,750  
    2020 5,750  
    2021 5,750  
    2022 465,750  
    Total minimum payments 509,100  
    Less amount representing interest (29,540)  
    Gross balance of long-term debt 479,560  
    Less unamortized debt discount (76,973)  
    Present value of long-term debt 402,587  
    Less current portion of long-term debt (19,542) $ (91,506)
    Long-term debt, less current portion and unamortized debt discount $ 383,045  
    XML 104 R65.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Share-based Compensation Options (Details) - USD ($)
    $ / shares in Units, $ in Millions
    		 12 Months Ended
    Dec. 31, 2019
    Dec. 31, 2018
    Dec. 31, 2017
    Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]      
    Options, Outstanding, Number, period start 11,012,381    
    Options, Outstanding, Weighted Average Exercise Price, period start $ 13.81    
    Options, Grants in Period, Gross 3,056,191    
    Options, Grants in Period, Weighted Average Exercise Price $ 16.46    
    Options, Exercises in Period (1,540,690)    
    Options, Exercises in Period, Weighted Average Exercise Price $ 10.73    
    Options, Forfeitures and Expirations in Period (979,653)    
    Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price $ 16.19    
    Options, Outstanding, Number, period end 11,548,229 11,012,381  
    Options, Outstanding, Weighted Average Exercise Price, period end $ 14.72 $ 13.81  
    Options, Outstanding, Weighted Average Remaining Contractual Term 3 years 11 months 23 days    
    Options, Outstanding, Intrinsic Value $ 39.8    
    Options, Vested and Expected to Vest, Outstanding, Number 11,548,229    
    Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price $ 14.72    
    Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term 3 years 11 months 23 days    
    Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value $ 39.8    
    Options, Vested and Expected to Vest, Exercisable, Number 6,962,972    
    Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price $ 13.64    
    Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term 3 years 7 months 2 days    
    Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value $ 32.7    
    Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]      
    Options, Grants in Period, Weighted Average Grant Date Fair Value $ 16.46 $ 10.33 $ 7.86
    Options, Exercises in Period, Intrinsic Value $ 10.6 $ 11.5 $ 10.0
    Proceeds from Stock Options Exercised $ 16.5 $ 16.3 $ 14.0
    XML 105 R46.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Fair Value Measurement Maturities (Details) - USD ($)
    $ in Thousands
    Dec. 31, 2019
    Dec. 31, 2018
    Fair Value Disclosures [Abstract]    
    Due within one year $ 274,805 $ 296,590
    After one but within five years 26,278 0
    Available-for-sale Securities $ 301,083 $ 296,590
    XML 106 R42.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Summary of Significant Accounting Policies Net Loss Per Share (Details) - USD ($)
    $ / shares in Units, shares in Thousands, $ in Thousands
    		 3 Months Ended 12 Months Ended
    Dec. 31, 2019
    Sep. 30, 2019
    Jun. 30, 2019
    Mar. 31, 2019
    Dec. 31, 2018
    Sep. 30, 2018
    Jun. 30, 2018
    Mar. 31, 2018
    Dec. 31, 2019
    Dec. 31, 2018
    Dec. 31, 2017
    Nov. 30, 2019
    Loss Per Share Disclosure [Line Items]                        
    Net income (loss) $ (34,397) $ (25,015) $ (14,624) $ 1,796 $ (2,126) $ (27,850) $ (22,893) $ (27,461) $ (72,240) $ (80,330) $ 62,971  
    Weighted Average Number of Shares Outstanding, Basic 141,046 146,136 145,411 144,743 144,203 143,949 143,568 142,656 144,329 143,599 136,419  
    Shares excluded from calculation of diluted net loss, amount                 0 0 2,649  
    Weighted Average Number of Shares Outstanding, Diluted 141,046 146,136 145,411 147,474 144,203 143,949 143,568 142,656 144,329 143,599 139,068  
    Earnings Per Share, Basic and Diluted                 $ (0.50) $ (0.56)    
    Earnings Per Share, Basic $ (0.24) $ (0.17) $ (0.10) $ 0.01 $ (0.01) $ (0.19) $ (0.16) $ (0.19)     $ 0.46  
    Earnings Per Share, Diluted $ (0.24) $ (0.17) $ (0.10) $ 0.01 $ (0.01) $ (0.19) $ (0.16) $ (0.19) $ (0.50) $ (0.56) $ 0.45  
    Net loss per share (Textuals) [Abstract]                        
    Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount                 33,100 13,800 7,100  
    Convertible Debt [Member] | 1.25% Convertible Senior Notes due 2024 [Member]                        
    Net loss per share (Textuals) [Abstract]                        
    Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount                 19,300      
    Debt Instrument, Convertible, Conversion Price                       $ 23.85
    XML 107 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 108 R23.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Summary of Significant Accounting Policies (Tables)
    		 12 Months Ended
    Dec. 31, 2019
    Accounting Policies [Abstract]  
    Schedules of Concentration of Risk, by Risk Factor [Table Text Block]
    The following table indicates the percentage of total revenues in excess of 10% with any single customer:
     
     
    Year Ended December 31,
     
     
    2019
     
    2018
     
    2017
    Roche
     
    40%
     
    72%
     
    38%
    argenx
     
    23%
     
    —%
     
    —%
    Janssen
     
    18%
     
    2%
     
    6%
    BMS
     
    1%
     
    4%
     
    32%
    Alexion
     
    1%
     
    3%
     
    13%
    We attribute revenues under collaborative agreements, including royalties, to the individual countries where the customer is headquartered. We attribute revenues from product sales to the individual countries to which the product is shipped. Worldwide revenues from external customers are summarized by geographic location in the following table (in thousands):
     
     
    Year Ended December 31,
     
     
    2019
     
    2018
     
    2017
    United States
     
    $
    116,083

     
    $
    40,475

     
    $
    196,274

    Switzerland
     
    78,413

     
    109,890

     
    119,136

    All other foreign
     
    1,496

     
    1,497

     
    1,203

    Total revenues
     
    $
    195,992

     
    $
    151,862

     
    $
    316,613
    Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] reconciliation of the numerators and the denominators of the basic and diluted net (loss) income per common share computations is as follows (in thousands, except per share amounts):
     
     
    Year Ended December 31,
     
     
    2019
     
    2018
     
    2017
    Numerator:
     
     
     
     
     
     
    Net (loss) income
     
    $
    (72,240
    )
     
    $
    (80,330
    )
     
    $
    62,971

    Denominator:
     
     
     
     
     
     
    Weighted average common shares outstanding for basic
    net (loss) income per share
     
    144,329

     
    143,599

     
    136,419

    Net effect of dilutive common stock equivalents
     
    —

     
    —

     
    2,649

    Weighted average common shares outstanding for diluted
    net (loss) income per share
     
    144,329

     
    143,599

     
    139,068

    Net (loss) income per share:
     
     
     
     
     
     
    Basic
     
    $
    (0.50
    )
     
    $
    (0.56
    )
     
    $
    0.46

    Diluted
     
    $
    (0.50
    )
     
    $
    (0.56
    )
     
    $
    0.45
    XML 109 R1.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Cover - USD ($)
    $ in Billions
    		 12 Months Ended
    Dec. 31, 2019
    Feb. 14, 2020
    Jun. 30, 2019
    Cover page.      
    Document Type 10-K    
    Document Annual Report true    
    Document Period End Date Dec. 31, 2019    
    Document Transition Report false    
    Entity File Number 001-32335    
    Entity Registrant Name HALOZYME THERAPEUTICS, INC.    
    Entity Incorporation, State or Country Code DE    
    Entity Tax Identification Number 88-0488686    
    Entity Address, Address Line One 11388 Sorrento Valley Road    
    Entity Address, Postal Zip Code 92121    
    Entity Address, City or Town San Diego    
    Entity Address, State or Province CA    
    City Area Code 858    
    Local Phone Number 794-8889    
    Title of 12(b) Security Common Stock, $0.001 Par Value    
    Trading Symbol HALO    
    Security Exchange Name NASDAQ    
    Entity Well-known Seasoned Issuer Yes    
    Entity Voluntary Filers No    
    Entity Current Reporting Status Yes    
    Entity Interactive Data Current Yes    
    Entity Filer Category Large Accelerated Filer    
    Entity Small Business false    
    Entity Emerging Growth Company false    
    Entity Shell Company false    
    Entity Public Float     $ 2.5
    Entity Common Stock, Shares Outstanding   138,226,070  
    Entity Central Index Key 0001159036    
    Amendment Flag false    
    Document Fiscal Year Focus 2019    
    Document Fiscal Period Focus FY    
    Current Fiscal Year End Date --12-31    
    XML 110 R5.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Consolidated Statements of Comprehensive Loss - USD ($)
    $ in Thousands
    		 12 Months Ended
    Dec. 31, 2019
    Dec. 31, 2018
    Dec. 31, 2017
    Statement of Comprehensive Income [Abstract]      
    Net income (loss) $ (72,240) $ (80,330) $ 62,971
    Other comprehensive income (loss):      
    Unrealized (loss) gain on marketable securities 508 182 (430)
    Foreign currency translation adjustment 9 (8) (14)
    Foreign Currency Transaction Gain (Loss), Unrealized 0 (1) 0
    Total comprehensive income (loss) $ (71,723) $ (80,157) $ 62,527
    XML 111 R27.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Long-Term Debt, Net Debt Disclosure (Tables)
    		 12 Months Ended
    Dec. 31, 2019
    Debt Disclosure [Abstract]  
    Schedule of Maturities of Long-term Debt [Table Text Block]
    Future maturities and interest payments of long-term debt as of December 31, 2019, are as follows (in thousands):
    2020
     
    $
    26,100

    2021
     
    5,750

    2022
     
    5,750

    2023
     
    5,750

    2024
     
    465,750

    Total minimum payments
     
    509,100

    Less amount representing interest
     
    (29,540
    )
    Gross balance of long-term debt
     
    479,560

    Less unamortized debt discount
     
    (76,973
    )
    Present value of long-term debt
     
    402,587

    Less current portion of long-term debt
     
    (19,542
    )
    Long-term debt, less current portion and unamortized debt discount
     
    $
    383,045
    XML 112 R9.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Summary of Significant Accounting Policies
    		 12 Months Ended
    Dec. 31, 2019
    Accounting Policies [Abstract]  
    Summary of Significant Accounting Policies Summary of Significant Accounting Policies
    Basis of Presentation
    The consolidated financial statements include the accounts of Halozyme Therapeutics, Inc. and our wholly owned subsidiary, Halozyme, Inc., and Halozyme, Inc.’s wholly owned subsidiaries, Halozyme Holdings Ltd., Halozyme Royalty LLC, Halozyme Switzerland GmbH and Halozyme Switzerland Holdings GmbH. All intercompany accounts and transactions have been eliminated.
    Use of Estimates
    The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”) requires management to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes. On an ongoing basis, we evaluate our estimates and judgments, which are based on historical and anticipated results and trends and on various other assumptions that management believes to be reasonable under the circumstances. By their nature, estimates are subject to an inherent degree of uncertainty and, as such, actual results may differ from management’s estimates.
    Cash Equivalents and Marketable Securities
    Cash equivalents consist of highly liquid investments, readily convertible to cash, that mature within ninety days or less from the date of purchase. As of December 31, 2019, our cash equivalents consisted of money market funds.
    Marketable securities are investments with original maturities of more than ninety days from the date of purchase that are specifically identified to fund current operations. Marketable securities are considered available-for-sale. These investments are classified as current assets, even though the stated maturity date may be one year or more beyond the current balance sheet date which reflects management’s intention to use the proceeds from the sale of these investments to fund our operations, as necessary. Such available-for-sale investments are carried at fair value with unrealized gains and losses recorded in other comprehensive income (loss) and included as a separate component of stockholders’ equity (deficit). The cost of marketable securities is adjusted for amortization of premiums or accretion of discounts to maturity, and such amortization or accretion is included in investment and other income, net in the consolidated statements of operations. We use the specific identification method for calculating realized gains and losses on marketable securities sold. Realized gains and losses and declines in value judged to be other-than-temporary on marketable securities, if any, are included in investment and other income, net in the consolidated statements of operations.
    Restricted Cash
    Under the terms of the leases of our facilities, we are required to maintain letters of credit as security deposits during the terms of such leases. At December 31, 2019 and 2018, restricted cash of $0.5 million was pledged as collateral for the letters of credit.
    Fair Value of Financial Instruments
    The authoritative guidance for fair value measurements establishes a three tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.
    Our financial instruments include cash equivalents, available-for-sale marketable securities, accounts receivable, prepaid expenses and other assets, accounts payable, accrued expenses and long-term debt. Fair value estimates of these instruments are made at a specific point in time, based on relevant market information. These estimates may be subjective in nature and involve uncertainties and matters of significant judgment and therefore cannot be determined with precision. The carrying amount of cash equivalents, accounts receivable, prepaid expenses and other assets, accounts payable and accrued expenses are generally considered to be representative of their respective fair values because of the short-term nature of those instruments. Based on Level 3 inputs and the borrowing rates currently available for loans with similar terms, we believe the fair value of long-term debt approximates its carrying value.
    Available-for-sale marketable securities consist of asset-backed securities, corporate debt securities, U.S. Treasury securities and commercial paper, and are measured at fair value using Level 1 and Level 2 inputs. Level 2 financial instruments are valued using market prices on less active markets and proprietary pricing valuation models with observable inputs, including interest rates, yield curves, maturity dates, issue dates, settlement dates, reported trades, broker-dealer quotes, issue spreads, benchmark securities or other market related data. We obtain the fair value of Level 2 investments from our investment manager, who obtains these fair values from a third-party pricing source. We validate the fair values of Level 2 financial instruments provided by our investment manager by comparing these fair values to a third-party pricing source.
    Concentrations of Credit Risk, Sources of Supply and Significant Customers
    We are subject to credit risk from our portfolio of cash equivalents and marketable securities. These investments were made in accordance with our investment policy which specifies the categories, allocations, and ratings of securities we may consider for investment. The primary objective of our investment activities is to preserve principal while at the same time maximizing the income we receive without significantly increasing risk. We maintain our cash and cash equivalent balances with one major commercial bank and marketable securities with another financial institution. Deposits held with the financial institutions exceed the amount of insurance provided on such deposits. We are exposed to credit risk in the event of a default by the financial institutions holding our cash, cash equivalents and marketable securities to the extent recorded on the consolidated balance sheets.
    We are also subject to credit risk from our accounts receivable related to our product sales and revenues under our license and collaborative agreements. We have license and collaborative agreements with pharmaceutical companies under which we receive payments for royalties, license fees, milestone payments for specific achievements designated in the collaborative agreements, reimbursements of research and development services and supply of bulk formulation of rHuPH20. In addition, we sell Hylenex® recombinant in the United States to a limited number of established wholesale distributors in the pharmaceutical industry. Credit is extended based on an evaluation of the customer’s financial condition, and collateral is not required. Management monitors our exposure to accounts receivable by periodically evaluating the collectibility of the accounts receivable based on a variety of factors including the length of time the receivables are past due, the financial health of the customer and historical experience. Based upon the review of these factors, we recorded no allowance for doubtful accounts at December 31, 2019 and 2018. Approximately 93% of the accounts receivable balance at December 31, 2019 represents amounts due from Janssen, Roche and Baxalta. Approximately 81% of the accounts receivable balance at December 31, 2018 represents amounts due from Roche and Baxalta.
    The following table indicates the percentage of total revenues in excess of 10% with any single customer:
     
     
    Year Ended December 31,
     
     
    2019
     
    2018
     
    2017
    Roche
     
    40%
     
    72%
     
    38%
    argenx
     
    23%
     
    —%
     
    —%
    Janssen
     
    18%
     
    2%
     
    6%
    BMS
     
    1%
     
    4%
     
    32%
    Alexion
     
    1%
     
    3%
     
    13%
    We attribute revenues under collaborative agreements, including royalties, to the individual countries where the customer is headquartered. We attribute revenues from product sales to the individual countries to which the product is shipped. Worldwide revenues from external customers are summarized by geographic location in the following table (in thousands):
     
     
    Year Ended December 31,
     
     
    2019
     
    2018
     
    2017
    United States
     
    $
    116,083

     
    $
    40,475

     
    $
    196,274

    Switzerland
     
    78,413

     
    109,890

     
    119,136

    All other foreign
     
    1,496

     
    1,497

     
    1,203

    Total revenues
     
    $
    195,992

     
    $
    151,862

     
    $
    316,613


    We rely on two third-party manufacturers for the supply of bulk rHuPH20 for use in the manufacture of Hylenex recombinant and our other collaboration products and product candidates. Payments due to these suppliers represented 47% and 2% of the accounts payable balance at December 31, 2019 and 2018, respectively. We also rely on a third-party manufacturer for the fill and finish of Hylenex recombinant product under a contract. Payments due to this supplier represented 8% and 0% of the accounts payable balance at December 31, 2019 and 2018, respectively.
    Accounts Receivable, Net
    Accounts receivable is recorded at the invoiced amount and is non-interest bearing. Accounts receivable is recorded net of allowances for doubtful accounts, cash discounts for prompt payment, distribution fees and chargebacks. We recorded no allowance for doubtful accounts at December 31, 2019 and 2018 as the collectibility of accounts receivable was reasonably assured.
    Inventories
    Inventories are stated at lower of cost or net realizable value. Cost is determined on a first-in, first-out basis. Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. Inventories are reviewed periodically for potential excess, dated or obsolete status. We evaluate the carrying value of inventories on a regular basis, taking into account such factors as historical and anticipated future sales compared to quantities on hand, the price we expect to obtain for products in their respective markets compared with historical cost and the remaining shelf life of goods on hand.
    Bulk rHuPH20 formulations manufactured for partner use prior to our partner receiving marketing approval from the U.S. Food and Drug Administration (“FDA”) or comparable regulatory agencies in foreign countries and with no alternative future use are recorded as research and development expense. All direct manufacturing costs incurred after the partner receives marketing approval are capitalized as inventory. Bulk rHuPH20 formulations manufactured for general partner and internal use, which can potentially be used by any collaboration partner or by us in Hylenex, and ENHANZE drug product used by our partners in clinical trials, is considered to have alternative future use and all manufacturing costs are capitalized as inventory. Inventories used in our clinical trials are expensed at the time the inventories are packaged for the clinical trials.
    As of December 31, 2019 and 2018, inventories consisted of $1.4 million and $2.2 million, respectively, of Hylenex recombinant inventory, net, and $28.0 million and $20.4 million, respectively, of bulk rHuPH20.
    Leases

    The Company has entered into operating leases primarily for real estate and automobiles. These leases have terms which range from 3 years to 6 years. We determine if an arrangement contains a lease at inception. Right of use (“ROU”) assets and liabilities resulting from operating leases are included in property and equipment, accrued expenses and other long-term liabilities on our consolidated balance sheets. Operating lease ROU assets and liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the discount rate to calculate the present value of future payments. The operating lease ROU asset also includes any lease payments made and
    excludes lease incentives and initial direct costs incurred. Our leases often include options to extend or terminate the lease. These options are included in the lease term when it is reasonably certain that we will exercise that option. Short-term leases with an initial term of 12 months or less are not recorded on the balance sheet. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term.
    We have lease agreements with lease and non-lease components, which are generally accounted for separately. For certain equipment leases, such as automobiles, we account for the lease and non-lease components as a single lease component.
    Property and Equipment, Net
    Property and equipment are recorded at cost, less accumulated depreciation and amortization. Equipment is depreciated using the straight-line method over its estimated useful life ranging from three years to ten years and leasehold improvements are amortized using the straight-line method over the estimated useful life of the asset or the lease term, whichever is shorter.
    Impairment of Long-Lived Assets
    We account for long-lived assets in accordance with authoritative guidance for impairment or disposal of long-lived assets. Long-lived assets are reviewed for events or changes in circumstances, which indicate that their carrying value may not be recoverable.
    Comprehensive Income (Loss)
    Comprehensive income (loss) is defined as the change in equity during the period from transactions and other events and circumstances from non-owner sources.
    Revenue Recognition
    We generate revenues from payments received under collaborative agreements and product sales. As of January 1, 2018, we adopted ASC 606, Revenue from Contracts with Customers (ASC 606) which affects how we recognize revenues in these arrangements. We applied the provisions of ASC 606 using the modified retrospective approach, with the cumulative effect of the adoption recognized as of January 1, 2018, to all contracts that had not been completed as of that date. Under ASC 606, we recognize revenue when we transfer promised goods or services to customers in an amount that reflects the consideration to which we expect to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers we perform the following five steps: (i) identify the promised goods or services in the contract; (ii) identify the performance obligations in the contract, including whether they are distinct in the context of the contract; (iii) determine the transaction price, including the constraint on variable consideration; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) we satisfy the performance obligations. Amounts reported in prior periods have not been adjusted to reflect the adoption of ASC 606. Accordingly, the reported revenue amounts for the year ended December 31, 2019 and 2018 and the year ended December 31, 2017 are based on different accounting policies.
    Prior to the ASC 606 adoption, revenue was recognized when all of the following criteria were met: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred or services have been rendered; (3) the seller’s price to the buyer is fixed or determinable; and (4) collectibility is reasonably assured. Differences between the revenue recognition policies applicable prior to the adoption and ASC 606 are described in the following sections and in Note 4.
    Revenues under Collaborative Agreements - as reported under ASC 606 beginning January 1, 2018
    Under these agreements, we grant the collaboration partner a worldwide license to develop and commercialize products using our ENHANZE technology to combine our patented rHuPH20 enzyme with their proprietary biologics directed at up to a specified number of targets. Targets are usually licensed on an exclusive, global basis. Targets selected subsequent to inception of the arrangement require payment of an additional license fee. The collaboration partner is responsible for all development, manufacturing, clinical, regulatory, sales and marketing costs for any products developed under the agreement. We are responsible for supply of bulk rHuPH20 based on the collaboration partner’s purchase orders, and may also be separately engaged to perform research and development services. While these collaboration agreements are similar in that they originate from the same framework, each one is the result of an arms-length negotiation and thus may vary from one to the other.
    We collect an upfront license payment from the collaboration partner, and are also entitled to receive event-based payments subject to the collaboration partner’s achievement of specified development, regulatory and sales-based milestones. In several agreements, collaboration partners pay us annual fees to maintain their exclusive license rights if they are unable to advance product development to specified stages. We earn separate fees for bulk rHuPH20 supplies and research and development services. In addition, the collaboration partner will pay us royalties at an on average mid-single digit percent rate of their sales if products under the collaboration are commercialized. All amounts owed to us are noncancelable after the underlying triggering event occurs, and nonrefundable once paid. Unless terminated earlier in accordance with its terms, the collaboration generally continues in effect until the later of: (i) expiration of the last to expire of the valid claims of our patents covering rHuPH20 or other specified patents developed under the collaboration which valid claim covers a product developed under the collaboration, and (ii) expiration of the last to expire royalty term for a product developed under the collaboration, which is determined separately for each country. In the event such valid claims expire prior to the last to expire royalty term, the royalty rate is reduced for the remaining royalty term following such expiration. The collaboration partner may terminate the agreement prior to expiration for any reason in its entirety or on a target-by-target basis generally upon 90 days prior written notice to us. Upon any such termination, the license granted to the collaboration partner (in total or with respect to the terminated target, as applicable) will terminate provided, however, that in the event of expiration of the agreement, the on-going licenses granted will become perpetual, non-exclusive and fully paid.
    Although these agreements are in form structured as collaborative agreements, we concluded for accounting purposes they represent contracts with customers, and are not subject to accounting literature on collaborative arrangements. This is because we grant to collaboration partners licenses to our intellectual property, and provide supply of bulk rHuPH20 and research and development services which are all outputs of our ongoing activities, in exchange for consideration. We do not develop assets jointly with collaboration partners, and do not share in significant risks of their development or commercialization activities. Accordingly, we concluded our collaborative agreements must be accounted for pursuant to ASC Topic 606, Revenue from Contracts with Customers.
    Under all of our collaborative agreements, we have identified licenses to use functional intellectual property as the only performance obligation. The intellectual property underlying the license is our proprietary ENHANZE® technology which represents application of rHuPH20 to facilitate delivery of drugs or fluids. The license grants the collaboration partners right to use our intellectual property as it exists on the effective date of the license, because there is no ongoing development of the ENHANZE technology required. Therefore, we recognize revenue from licenses at the point when the license becomes effective and the collaboration partner has received access to our intellectual property, usually at the inception of the agreement.
    When collaboration partners can select additional targets to add to the licenses granted, we consider these rights to be options. We evaluate whether such options contain material rights, i.e. have exercise prices that are discounted compared to what we would charge for a similar license to a new collaboration partner. The exercise price of these options includes a combination of the target selection fees, event-based milestone payments and royalties. When these amounts in aggregate are not offered at a discount that exceeds discounts available to other customers, we conclude the option does not contain a material right, and we consider grants of additional licensing rights upon option exercises to be separate contracts (target selection contracts).
    We provide standard indemnification and protection of licensed intellectual property for our customers. These provisions are part of assurance that the licenses meet the agreements’ representations and are not obligations to provide goods or services.
    We also fulfill purchase orders for supply of bulk rHuPH20 and perform research and development services pursuant to projects authorization forms for our collaboration partners, which represent separate contracts. Additionally, we price our supply of bulk rHuPH20 and research and development services at our regular selling prices, called standalone selling price or SSP. Therefore, our collaboration partners do not have material rights to order these items at prices not reflective of SSP. Refer to the discussion below regarding recognition of revenue for these separate contracts.
    Transaction price for a contract represents the amount to which we are entitled in exchange for providing goods and services to the customer. Transaction price does not include amounts subject to uncertainties unless it is probable that there will be no significant reversal of revenue when the uncertainty is resolved. Apart from the upfront license payment (or target selection fees in the target selection contracts), all other fees we may earn under our collaborative agreements are subject to significant uncertainties of product development. Achievement of many of the event-based development and regulatory milestones may not be probable until such milestones are actually achieved. This generally relates to milestones such as obtaining marketing authorization approvals.
    With respect to other development milestones, e.g. dosing of a first patient in a clinical trial, achievement could be considered probable prior to its actual occurrence, based on the progress towards commencement of the trial. We do not include any amounts subject to uncertainties into the transaction price until it is probable that the amount will not result in a significant reversal of revenue in the future. At the end of each reporting period, we re-evaluate the probability of achievement of such milestones and any related constraint, and if necessary, adjust our estimate of the overall transaction price.
    When target exchange rights are held by collaboration partners, and the amounts attributed to these rights are not refundable, they are included in the transaction price. However, they are recorded as deferred revenues because we have a potential performance obligation to provide a new target upon an exchange right being exercised. These amounts are recognized in revenue when the right of exchange expires or is exercised.
    Because our agreements have one type of performance obligation (licenses) which are typically all transferred at the same time at agreement inception, allocation of transaction price often is not required. However, allocation is required when licenses for some of the individual targets are subject to rights of exchange, because revenue associated with these targets cannot be recognized. We perform an allocation of the upfront amount based on relative SSP of licenses for individual targets. We determine license SSP using income-based valuation approach utilizing risk-adjusted discounted cash flow projections of the estimated return a licensor would receive. When amounts subject to uncertainties, such as milestones and royalties, are included in the transaction price, we attribute them to the specific individual target licenses which generate such milestone or royalty amounts.
    We also estimate SSP of bulk rHuPH20 and research and development services, to determine that our collaboration partners do not have material rights to order them at discounted prices. For supplies of bulk rHuPH20, because we effectively act as a contract manufacturer to our collaboration partners, we estimate and charge SSP based on the typical contract manufacturer margins consistently with all of our collaborative partners. We determine SSP of research and development services based on a fully-burdened labor rate. Our rates are comparable to those we observe in other collaborative agreements. We also have a history of charging similar rates to all of our collaboration partners.
    Upfront amounts allocated to licenses to individual targets are recognized as revenue when the license is transferred to the collaboration partner, as discussed above, if the license is not subject to exchange rights, or when the exchange right expires or is exercised. Development milestones and other fees are recognized in revenue when they are included in the transaction price, because by that time we have already transferred the related license to the collaboration partner.
    Sales-based milestones and royalties cannot be recognized until the underlying sales occur. We do not receive final royalty reports from our collaboration partners until after we complete our financial statements for a prior quarter. Therefore, we recognize revenue based on estimates of the royalty earned, which are based on preliminary reports provided by our collaboration partners. We will record a true-up in the following quarter if necessary, when final royalty reports are received. To date, we have not recorded any material true-ups.
    In contracts to provide research and development services, such services represent the only performance obligation. The fees are charged based on hours worked by our employees and the fixed contractual rate per hour, plus third-party pass-through costs, on a monthly basis. We recognize revenues as the related services are performed based on the amounts billed, as the collaboration partner consumes the benefit of research and development work simultaneously as we perform these services, and the amounts billed reflect the value of these services to the customer.
    Refer to Note 4 Revenue, for further discussion on our collaborative arrangements.
    Prior to the adoption of ASC 606 on January 1, 2018, we recognized upfront amounts received under two of our collaborative agreements straight-line over the contract term in accordance with the accounting standards that were in effect in 2006-2007, when these collaborative agreements were entered into. In addition, we recognized royalty revenue in the period when we received final royalty reports from the collaboration partners, in the quarter following the quarter in which the corresponding sales occurred. There were no other adoption differences in revenue recognized due to the transition from the previously existing authoritative accounting literature to ASC 606.
    Product Sales, Net - as reported under ASC 606 beginning January 1, 2018
    Hylenex Recombinant
    We sell Hylenex recombinant in the U.S. to wholesale pharmaceutical distributors, who sell the product to hospitals and other end-user customers. Sales to wholesalers are made pursuant to purchase orders subject to the terms of a master agreement, and delivery of individual packages of Hylenex recombinant represent performance obligations under each purchase order. We use a contract manufacturer to produce Hylenex recombinant and a third-party logistics (3PL) vendor to process and fulfill orders. We concluded we are the principal in the sales to wholesalers because we control access to services rendered by both vendors and direct their activities. We have no significant obligations to wholesalers to generate pull-through sales.
    Selling prices initially billed to wholesalers are subject to discounts for prompt payment and subsequent chargebacks when wholesalers sell Hylenex recombinant at negotiated discounted prices to members of certain group purchasing organizations (“GPOs”) and government programs. We also pay quarterly distribution fees to certain wholesalers for inventory reporting and chargeback processing, and to GPOs as administrative fees for services and for access to GPO members. We concluded the benefits received in exchange for these fees are not distinct from our sales of Hylenex recombinant, and accordingly we apply these amounts to reduce revenues. Wholesalers also have rights to return unsold product nearing or past the expiration date. Because of the shelf life of Hylenex recombinant and our lengthy return period, there may be a significant period of time between when the product is shipped and when we issue credits on returned product.
    We estimate the transaction price when we receive each purchase order taking into account the expected reductions of the selling price initially billed to the wholesaler arising from all of the above factors. We have compiled historical experience and data to estimate future returns and chargebacks of Hylenex recombinant and the impact of the other discounts and fees we pay. When estimating these adjustments to the transaction price, we reduce it sufficiently to be able to assert that it is probable that there will be no significant reversal of revenue when the ultimate adjustment amounts are known.
    Each purchase order contains only one type of product, and is usually shipped to the wholesaler in a single shipment. Therefore, allocation of the transaction price to individual packages is not required.
    We recognize revenue from Hylenex recombinant product sales and related cost of sales upon product delivery to the wholesaler location. At that time, the wholesalers take control of the product as they take title, bear the risk of loss of ownership, and have an enforceable obligation to pay us. They also have the ability to direct sales of product to their customers on terms and at prices they negotiate. Although wholesalers have product return rights, we do not believe they have a significant incentive to return the product to us.
    Upon recognition of revenue from product sales of Hylenex recombinant, the estimated amounts of credit for product returns, chargebacks, distribution fees, prompt payment discounts, and GPO fees are included in sales reserves, accrued liabilities and net of accounts receivable. We monitor actual product returns, chargebacks, discounts and fees subsequent to the sale. If these amounts differ from our estimates, we make adjustments to these allowances, which are applied to increase or reduce product sales revenue and earnings in the period of adjustment.
    In connection with the orders placed by wholesalers, we incur costs such as commissions to our sales representatives. However, as revenue from product sales is recognized upon delivery to the wholesaler, which occurs shortly after we receive a purchase order, we do not capitalize these commissions and other costs, based on application of the practical expedient allowed within the applicable guidance.
    Bulk rHuPH20
    We sell bulk rHuPH20 to collaboration partners for use in research and development; subsequent to receiving marketing approval, we sell it for use in collaboration commercial products. Sales are made pursuant to purchase orders subject to the terms of the collaborative agreement, and delivery of units of bulk rHuPH20 represent performance obligations under each purchase order. We provide a standard warranty that the product conforms to specifications. We use contract manufacturers to produce bulk rHuPH20 and have concluded we are the principal in the sales to collaboration partners. The transaction price for each purchase order of bulk rHuPH20 is fixed based on the cost of production plus a contractual markup, and is not subject to adjustments. Allocation of the transaction price to individual quantities of the product is usually not required because each order contains only one type of product.
    We recognize revenue from the sale of bulk rHuPH20 as product sales and related cost of sales upon transfer of title to our partners. At that time, the partners take control of the product, bear the risk of loss of ownership, and have an enforceable obligation to pay us.
    ENHANZE Drug Product
    We sell ENHANZE drug product to collaboration partners for use in research and development in early phase clinical studies. Sales are made pursuant to purchase orders subject to the terms of the collaborative agreement, and delivery of units of ENHANZE drug product represent performance obligations under each purchase order. We provide a standard warranty that the product conforms to specifications. We use contract manufacturers to produce ENHANZE drug product and we concluded we are the principal in the sales to collaboration partners. The transaction price for each purchase order of ENHANZE drug product is fixed based on the cost of production plus a contractual markup, and is not subject to adjustments. Allocation of the transaction price to individual quantities of the product is usually not required because each order contains only one type of product.
    We recognize revenue from the sale of ENHANZE drug product as product sales and related cost of sales upon transfer of title to our partners. At that time, the partners take control of the product, bear the risk of loss of ownership, and have an enforceable obligation to pay us.
    Revenue Presentation
    In our statements of operations, we report as revenues under collaborative agreements the upfront payments, event-based development and regulatory milestones and sales milestones. We also include in this category revenues from separate research and development contracts pursuant to project authorization forms. We report royalties received from collaboration partners as a separate line in our statements of operations.
    Revenues from sales of Hylenex recombinant, bulk rHuPH20 that has alternative future use and ENHANZE drug product are included in product sales, net.
    In the footnotes to our financial statements, we provide disaggregated revenue information by type of arrangement (product sales, net, collaborative agreements and research and development services), and additionally, by type of payment stream received under collaborative agreements (upfront license fees, event-based development and regulatory milestones and other fees, sales milestones and royalties).
    Cost of Product Sales
    Cost of product sales consists primarily of raw materials, third-party manufacturing costs, fill and finish costs, freight costs, internal costs and manufacturing overhead associated with the production of Hylenex recombinant and bulk rHuPH20 and ENHANZE drug product that has alternative future use. Cost of product sales also consists of the write-down of excess, dated and obsolete inventories and the write-off of inventories that do not meet certain product specifications, if any. Prior to bulk rHuPH20 and ENHANZE drug product having alternative future use, all costs related to the manufacturing of those products were charged to research and development expenses in the periods such costs were incurred. During the year ended December 31, 2019, sales of bulk rHuPH20 and ENHANZE drug product included $1.5 million of cost of sales that were previously expensed as research and development. Of the bulk rHuPH20 and ENHANZE drug product that has alternative future use on hand as of December 31, 2019, approximately $0.1 million in manufacturing costs were previously recorded as research and development expenses. We expect to sell this inventory by the end of 2020.
    Research and Development Expenses
    Research and development expenses include salaries and benefits, facilities and other overhead expenses, external clinical trial expenses, research related manufacturing services, contract services and other outside expenses. Research and development expenses are charged to operating expenses as incurred when these expenditures relate to our research and development efforts and have no alternative future uses. When bulk rHuPH20 is manufactured for use in research and development by us or our partners and the product cannot be redirected for alternative use due to formulation and manufacturing specifications, the manufacturing costs are recorded as research and development expense. Bulk rHuPH20 that is manufactured for partner use prior to our partner receiving marketing approval from the FDA or comparable regulatory agencies in foreign countries and meet these specifications is recorded as research and development expenses. Bulk rHuPH20 formulations manufactured for general partner and internal use, which can potentially be used by any collaboration partner or by us in Hylenex, is considered to have alternative future use and all manufacturing costs are capitalized as inventory. Inventories used in our clinical trials were expensed at the time the inventories were packaged for the clinical trials.
    We are obligated to make upfront payments upon execution of certain research and development agreements. Advance payments, including nonrefundable amounts, for goods or services that will be used or rendered for future research and development activities are deferred. Such amounts are recognized as expense as the related goods are delivered or the related services are performed or such time when we do not expect the goods to be delivered or services to be performed.
    Milestone payments that we make in connection with in-licensed technology for a particular research and development project that have no alternative future uses (in other research and development projects or otherwise) and therefore no separate economic value are expensed as research and development costs at the time the costs are incurred. We currently have no in-licensed technologies that have alternative future uses in research and development projects or otherwise.
    Clinical Trial Expenses
    We make payments in connection with our clinical trials under contracts with contract research organizations that support conducting and managing clinical trials. The financial terms of these agreements are subject to negotiation and vary from contract to contract and may result in uneven payment flows. Generally, these agreements set forth the scope of work to be performed at a fixed fee, unit price or on a time and materials basis. A portion of our obligation to make payments under these contracts depends on factors such as the successful enrollment or treatment of patients or the completion of other clinical trial milestones.
    Expenses related to clinical trials are accrued based on our estimates and/or representations from service providers regarding work performed, including actual level of patient enrollment, completion of patient studies and progress of the clinical trials. Other incidental costs related to patient enrollment or treatment are accrued when reasonably certain. If the amounts we are obligated to pay under our clinical trial agreements are modified (for instance, as a result of changes in the clinical trial protocol or scope of work to be performed), we adjust our accruals accordingly on a prospective basis. Revisions to our contractual payment obligations are charged to expense in the period in which the facts that give rise to the revision become reasonably certain.
    Share-Based Compensation
    We record compensation expense associated with stock options, restricted stock awards (“RSAs”), and restricted stock units (“RSUs”) in accordance with the authoritative guidance for stock-based compensation. The cost of employee services received in exchange for an award of an equity instrument is measured at the grant date, based on the estimated fair value of the award, and is recognized as expense on a straight-line basis over the requisite service period of the award. Share-based compensation expense for an award with a performance condition is recognized when the achievement of such performance condition is determined to be probable. If the outcome of such performance condition is not determined to be probable or is not met, no compensation expense is recognized and any previously recognized compensation expense is reversed. Forfeitures are recognized as a reduction of share-based compensation expense as they occur.
    Income Taxes
    We provide for income taxes using the liability method. Under this method, deferred income tax assets and liabilities are determined based on the differences between the financial statement carrying amounts of existing assets and liabilities at each year end and their respective tax bases and are measured using enacted tax rates in effect for the year in which the differences are expected to affect taxable income. Significant judgment is required by management to determine our provision for income taxes, our deferred tax assets and liabilities, and the valuation allowance to record against our net deferred tax assets, which are based on complex and evolving tax regulations throughout the world. Deferred tax assets and other tax benefits are recorded when it is more likely than not that the position will be sustained upon audit. While we have begun to utilize certain of our net operating losses, we have not yet established a track record of profitability. Accordingly, valuation allowances have been recorded to reduce our net deferred tax assets to zero, with the exception of the alternative minimum tax ("AMT") credit carryover of $1.7 million. Under the Tax Cuts and Jobs Act (the “Act”) enacted in December 2017, the AMT credit carryover will either be utilized, or if unutilized fully refunded in 2022. For all other deferred tax assets, the valuation allowance will reduce the net value to zero until such time as we can demonstrate an ability to realize them.
    The 2015 and 2016 federal returns were selected for audit by the IRS. The audit was completed in September 2019 with no material adjustments.
    Net (Loss) Income Per Share
    Basic net (loss) income per common share is computed by dividing net (loss) income for the period by the weighted average number of common shares outstanding during the period, without consideration for common stock equivalents. Outstanding stock options, unvested RSAs, unvested RSUs and the Convertible Notes are considered common stock equivalents and are only included in the calculation of diluted earnings per common share when net income is reported and their effect is dilutive. For the years ended December 31, 2019, 2018 and 2017, approximately 33.1 million, 13.8 million, and 7.1 million shares, respectively, of outstanding stock options, unvested RSAs, unvested RSUs and Convertible Notes were excluded from the calculation of diluted net (loss) income per common share because their effect was anti-dilutive.
    The 19.3 million shares underlying the conversion option of the Convertible Notes will not have an impact on our diluted earnings per share when net income is reported until the average market price of our common stock exceeds the conversion price of $23.85 per share, as we intend and have the ability to settle the principal amount of the Convertible Notes in cash upon conversion. We compute the potentially dilutive impact of the shares of common stock related to the Convertible Notes using the treasury stock method.
    A reconciliation of the numerators and the denominators of the basic and diluted net (loss) income per common share computations is as follows (in thousands, except per share amounts):
     
     
    Year Ended December 31,
     
     
    2019
     
    2018
     
    2017
    Numerator:
     
     
     
     
     
     
    Net (loss) income
     
    $
    (72,240
    )
     
    $
    (80,330
    )
     
    $
    62,971

    Denominator:
     
     
     
     
     
     
    Weighted average common shares outstanding for basic
    net (loss) income per share
     
    144,329

     
    143,599

     
    136,419

    Net effect of dilutive common stock equivalents
     
    —

     
    —

     
    2,649

    Weighted average common shares outstanding for diluted
    net (loss) income per share
     
    144,329

     
    143,599

     
    139,068

    Net (loss) income per share:
     
     
     
     
     
     
    Basic
     
    $
    (0.50
    )
     
    $
    (0.56
    )
     
    $
    0.46

    Diluted
     
    $
    (0.50
    )
     
    $
    (0.56
    )
     
    $
    0.45


    Segment Information
    We operate our business in one segment, which includes all activities related to the research, development and commercialization of our proprietary enzymes. This segment also includes revenues and expenses related to (i) research and development and bulk rHuPH20 manufacturing activities conducted under our collaborative agreements with third parties and (ii) product sales of Hylenex recombinant. The chief operating decision-maker reviews the operating results on an aggregate basis and manages the operations as a single operating segment. Our long-lived assets located in foreign countries had no book value as of December 31, 2019, 2018 and 2017.
    Adoption and Pending Adoption of Recent Accounting Pronouncements
    The following table provides a brief description of recently issued accounting standards, those adopted in the current period and those not yet adopted:
    Standard
     
    Description
     
    Effective Date
     
    Effect on the Financial
    Statements or Other Significant Matters
     
     
     
     
     
     
     
    In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). In July 2018, the FASB issued additional guidance related to Topic 842.
     
    The new guidance requires lessees to recognize assets and liabilities for most leases and provides enhanced disclosures.
     
    January 1, 2019
     
    We implemented the guidance on January 1, 2019 using a modified retrospective transition basis for leases existing as of the period of adoption. In order to adopt the new standard, we used the available practical expedients and newly implemented processes and internal controls for lease accounting. The practical expedients allowed us to carry forward our historical assessment of whether existing agreements are or contain a lease and the classification of our existing lease arrangements. All of our real-estate and automobile operating lease commitments are recognized as lease liabilities with corresponding right-of-use assets, which resulted in an increase in the assets and liabilities of the consolidated balance sheet of $7.2 million, using an assumed weighted average discount rate of 10.0%. The adoption did not have an impact on our consolidated statements of operations and did not require recognition of a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. We elected to continue applying the guidance under ASC 840 for comparative periods, as allowed through ASC 2018-11.
     
     
     
     
     
     
     

    Standard
     
    Description
     
    Effective Date
     
    Effect on the Financial
    Statements or Other Significant Matters
    In December 2019, the FASB issued ASU 2019-12, Simplifying the Accounting for Income Taxes

     
    The new guidance removes certain exceptions to the general principles of ASC 740 in order to simplify the complexities of its application. These changes include eliminations to the exceptions for intraperiod tax allocation, recognizing deferred tax liabilities related to outside basis differences, and year-to-date losses in interim periods among others.

     
    January 1, 2019

     
    We early adopted the new guidance on January 1, 2019. With the adoption we no longer apply the exception to the general rule for intraperiod tax allocations under the incremental method. During the period, we would have recorded a $14.7 million tax expense to APIC fully offset by a $14.7 million tax benefit in continuing operations.

     
     
     
     
     
     
     
    In August 2018, the FASB issued ASU 2018-15, Intangibles-Goodwill and other Internal-Use Software (Subtopic 350-40)

     
    The new guidance aligns the requirement for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirement for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license).

     
    January 1, 2020

     
    We plan to adopt the new guidance on January 1, 2020. We do not anticipate the adoption will have a material impact on our condensed consolidated financial position or results of operations.

     
     
     
     
     
     
     
    In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820).
     
    The new guidance removes, modifies and adds to certain disclosure requirements on fair value measurements in Topic 820, Fair Value Measurement.


     
    January 1, 2020
     
    We plan to adopt the new guidance on January 1, 2020. We do not anticipate the adoption will have a material impact on our consolidated financial position or results of operations.
     
     
     
     
     
     
     
    In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326), Measurement of Credit Losses on Financial Instruments
     
    The standard amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses for most financial assets and certain other instruments that aren’t measured at fair value through net income. For available-for-sale debt securities, entities will be required to recognize an allowance for credit losses rather than a reduction in carrying value of the asset. Entities will no longer be permitted to consider the length of time that fair value has been less than amortized cost when evaluating when credit losses should be recognized.
     
    January 1, 2020
     
    We plan to adopt the new guidance on January 1, 2020. We do not anticipate the adoption will have a material impact on our consolidated financial position or results of operations.

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